Welcome to ATS 2017

Welcome to Washington, DC for the 2017 American Thoracic Society International Conference. The conference, which is expected to draw more than 15,000 investigators, educators, and clinicians, is truly the destination for pediatric and adult pulmonary, critical care, and sleep medicine professionals at every level of their careers.

The conference is all about learning, networking and connections. Because it engages attendees across many disciplines and continents, the ATS International Conference draws a large, diverse group of participants, a dedicated and collegial community that inspires each of us to make a difference in patients’ lives, now and in the future. By virtue of its size — ATS 2017 features approximately 6,700 original research projects and case reports, 500 sessions, and 800 speakers — participants can attend sessions and special events from early morning to the evening. At ATS 2017 there will be something for everyone.

Don’t miss the following important events:

- **Opening Ceremony** featuring a keynote presentation by Nobel Laureate James Heckman, PhD, MA, from the Center for the Economics of Human Development at the University of Chicago.
- **Ninth Annual ATS Foundation Research Program Benefit** honoring David M. Center, MD, with the Foundation’s Breathing for Life Award on Saturday.
- **ATS Diversity Forum** will feature Eliseo J. Pérez-Stable, MD, Director, National Institute on Minority Health and Health Disparities at the National Institutes of Health.
- **Keynote Series** highlight state of the art lectures on selected topics in an unopposed format to showcase major discoveries in pulmonary, critical care and sleep medicine.
- **Respiratory Health Awards**, which includes the Trudeau Medal, Distinguished Achievement Awards, and Amberson Lecture, given by Peter D. Pare, MD, of the University of British Columbia.
- **ATS Plenary Session** will feature a talk by Marc L. Busch, PhD, the Karl F. Landegger Professor of International Business Diplomacy at the School of Foreign Service, Georgetown University.
- **Assembly Membership Meetings**, which are open to all attendees.

These events create a sense of community among the International Conference attendees, which is precisely what our founders had hoped when they established the world’s first respiratory society.

Finally, we wish to acknowledge the hard work and outstanding efforts of the members of the International Conference Committee, Education Committee, Assembly Program Committees, and ATS staff. The success of our conference depends on the dedication, creativity, and support of these individuals. We welcome you to the International Conference and hope you take advantage of all Washington has to offer.

**INTERNATIONAL CONFERENCE COMMITTEE**

Zeab Borok, MD, Chair 2015-2017  
Jess Mandel, MD, Chair 2017-2019  
JiYeOn Choi, PhD, RN  
Colin R. Cooke, MD  
Sonny K. Danoff, MD, PhD  
Laura C. Feemster, MSc, MD  
Andrew P. Fontenot, MD  
Michelle N. Gong, MS, MD  
David Gozal, MD, MBA  
Tillie-Louise Hackett, BS(Hons), PhD  
Anna Hemnes, MD  
Anastassios C. Koumbourlis, MD, MPH  
Tim Lahm, MD  
Patty Lee, MD  
Tricia D. LeVan, PhD  
Augusto A. Litonjua, MD  
William Man, MD, PhD  
Mark L. Metersky, MD  
Paul E. Moore, MD  
Marc Moss, MD  
Marilyn Moy, MD, MSc  
Robert L. Owens, MD  
Karen M. Ridge, PhD  
Jussi J. Saukkonen, MD  
Frank C. Sciurba, MD  
Gwen S. Skloot, MD  
Christopher G. Slatore, MD  
Anne I. Sperling, PhD  
Renee D. Stapleton, MD, PhD  
Lynn T. Tanoue, MD  
Ersin Tasali, MD  
Judith Tate, PhD, RN  
Atul Malhotra, MD
ATS 2017 INTERNATIONAL CONFERENCE
MAY 19-24
WASHINGTON, D.C.

This year the session portion of the Final Program for the ATS International Conference is available in printed and digital format. This publication contains the programs and speakers for the postgraduate courses, scientific and educational sessions presented at the conference.

You can download this PDF, the Conference APP or access the program via the online program itinerary.

1     Friday Postgraduate Courses
10    Saturday Postgraduate Courses
21    Sunday Conference Sessions
129   Monday Conference Sessions
246   Tuesday Conference Sessions
356   Wednesday Conference Sessions

The information contained in this program is up to date as of March 9, 2017. For the most current session information, please visit the online program itinerary.
In accordance with the ACCME Standards for Commercial Support, and those of the ATS Policy on Management of Conflict of Interest in Official ATS Documents, Projects and Conferences, ATS Policy Governing Relationships Between the Tobacco Industry, ATS Members, and Non-Members Who Participate in ATS Activities, and ATS Policy on Professionalism and Ethical Conduct chairs, moderators, presenters and official planners of the International Conference are required to disclose to ATS any potential conflicts of interest (COI) held by them or their spouse/life partner relevant to their presentation(s) or conference role, including all professional or other financial involvement with tobacco or e-cigarette entities, all relevant financial relationships with commercial interests, and all other relationships that could be perceived as influencing their participation. Conference presenters are also asked to disclose if there will be any discussion in the presentation of “off-label” (unapproved) use of substances/products not approved in the United States for the use under discussion (as per the U.S. Food and Drug Administration Guidance for Industry: Industry-Supported Scientific and Educational Activities).

For the 2017 International Conference, this disclosure information for all individuals in control of content was requested and received by ATS in advance of the Conference, reviewed by appropriate ATS reviewers, and session chairs and others in positions of authority were instructed to manage (resolve) identified conflicts according to procedures overseen by the ATS Ethics and Conflict of Interest Committee.

To access the disclosures made by the faculty of the 2017 International Conference, please go to http://conference.thoracic.org/speakers

### The following members of the Education Committee have disclosed no financial relationships with commercial interests:

- Debra M. Boyer, MD, Chair
- Jason T. Poston, MD, Vice Chair
- Gaetane C. Michaud, MD, Vice Chair
- Mark K. Abe, MD
- Shozab Ahmed, MBBS
- William G. Carlos, MD
- Allison S. Clay, MD
- Walter D. Connell, MD
- Daniel R. Crouch, MD, MS

### The following members of the Education Committee have disclosed the following financial relationships with commercial interests:

- Caralee E. Caplan-Shaw, MD: AristagenMD and Cohera Health (Consultant); Bard Peripheral Vascular, Inc. and Veran Medical Technologies (Food/Beverage Only); Cook Incorporated (Food/Beverage Only, Spouse-CME Speaker); MedImmune, Novartis Pharma and Teva Pharmaceuticals USA (Research Support); Myriad Genetic Laboratories (Spouse-Consultant)
- Colleen L. Channick, MD: Actelion Pharmaceuticals US and Bayer HealthCare Pharmaceuticals (Spouse-Consultant); Medtronic and Olympus Corporation of the Americas (Consultant)
- Charles Dela Cruz, MD, PhD: Compexus (Advisory Committee); Sandif-Aventis U.S. (Consultant)
- Samaan Raufa, MD: Boston Scientific (Consultant, Speaker); Veran Medical (Consultant)
- Mary E. Strek, MD: Boehringer Ingelheim Pharmaceuticals (Data and Safety Monitoring Board, Research Support); Gilead Sciences, InterMune, MedImmune, and Vertex Pharmaceuticals (research support)
- Vishwani S. Naik, MSCR, MD
- Jeremy E. Orr, MD
- Susan Pasnick, MD
- Jessica E. Pittman, MD, MPH
- Allan J. Walkey, MD, MSc
- Tina S. Wang, MD
- Carolyn H. Welsh, MD
- Lisa F. Wolfe, MD

### The following members of the International Conference Committee have disclosed no financial relationships with commercial interests:

- Zee Borok, MD, Chair
- Jess Mandel, MD, Chair Appointee
- Jaffeon Choi, PhD, RN
- Colin R. Cooke, MD
- Sonye K. Danoff, MD, PhD
- Laura C. Feenster, MSc, MD
- Andrew P. Fontenot, MD
- DonAnne M. Doneley, PhD, ANP-BC
- Garth Garrison, MD
- David Gozal, MD, MBA
- Margaret M. Hayes, MD
- Amjad Horani, MD
- Shazia M. Jamil, MD
- Carl A. Kaplan, MD
- Jack Kelly
- Deny P. Kipkpatrick, DNP
- Abigail R. Lara, MD
- Moiseh Liberman, MD, PhD
- Andrew Lukes, MD
- Patrick Lyons, MD
- Samir Makani, MD
- Atul Malhotra, MD
- Jakob I. McSparron, MD
- Paul E. Moore, MD
- Marc Moss, MD
- William Man, MD, PhD
- Paul E. Moore, MD
- Marc Moss, MD
- Marilyn May, MD, MSc
- Robert L. Owens, MD
- Karen M. Ridge, PhD
- Jussi J. Saukkonen, MD
- Gwen S. Skloot, MD
- Christopher G. Slabore, MD
- Anne I. Sperling, PhD
- Renee D. Stapleton, PhD, MD
- Lynn T. Tamoue, MD
- Erea Tassal, MD
- Judith Tate, PhD, RN

### The following members of the International Conference Committee have disclosed the following financial relationships with commercial interests:

- Anna Hennings, MD: Actelion Pharmaceuticals, US and United Therapeutics Corporation (Advisory Committee); Pfizer, Inc. (Expert Testimony)
- Tim Lahn, MD: Bayer Healthcare Pharmaceuticals (Speaker); Gilead Sciences and Pfizer AG (Research Support)
- Augusto A. Litonjua, MD: AstraZeneca Pharmaceuticals (Advisory Committee); Springer Humana Press and UpToDate (author)
- Mark L. Metersky, MD: Aradigm and Bayer (Research Support); EBSCO (Consultant); Grifols (Advisory Committee)
- Frank C. Scurba, MD: Boehringer Ingelheim b.v. (Advisory Committee); BTG and Pulmonx Corporation (Research Support)
PG1A CRITICAL CARE ULTRASOUND AND ECHOCARDIOGRAPHY I

This is part 1 of a two-part course which includes PG1B on Saturday, May 20. Those registering for PG1A will be registered for PG1A and PG1B.

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $900 In-Training Member: $675
Non-Member: $1,200 In-Training Non-Member: $775

Registrants must bring a laptop to the course to view the course material.

Assembly on Critical Care
8:00 a.m. - 4:00 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 145 A (Middle Building, Street Level)

Target Audience
Providers of critical care or emergency medicine

Objectives
At the conclusion of this session, the participant will be able to:
- apply ultrasound at bedside to assess critically ill patients;
- diagnose alternate etiologies of shock in the critically ill patient;
- apply ultrasound to guide common ICU procedures.

This is a 2-day postgraduate course that consists of didactic lectures and hands-on stations. The focus is primarily bedside transthoracic echocardiography, with some diagnostic ultrasound. The topics include basic and intermediate critical care echocardiography (including hemodynamic measures), assessment of fluid status, procedural guidance for vascular access and thoracentesis, venography. The hands-on stations will include both healthy models and simulators that can demonstrate abnormal pathology.

Chairing: M.J. Lanspa, MD, MS, Salt Lake City, UT
X. Monnet, MD, PhD, Paris, France

8:00 Welcome & Introduction to Critical Care Ultrasound: Training and Competency
M.J. Lanspa, MD, MS, Salt Lake City, UT

8:15 Basic Physics, Artifacts, Knobology
Z. Shaman, MD, Cleveland, OH

8:45 Transthoracic Windows and Views
A. Leibowitz, MD, Boston, MA

9:15 Basic Evaluation of LV Systolic Function, Measurement of Cardiac Output
S. Price, MBBS, PhD, EDICM, London, United Kingdom

9:45 Basic Evaluation of RV Size and Function, the RV in Pulmonary Disease
D. Pradhan, MD, New York, NY

10:15 Break

10:30 Practical Skills Sessions: Hands-On Station I

Apical Window
X. Monnet, MD, PhD, Paris, France
T. Brakke, MD, Omaha, NE
Z. Shaman, MD, Cleveland, OH
L. Grecu, MD, Stony Brook, NY

Parasternal Window
P. Mohabir, MD, Stanford, CA
G.B. Allen, MD, Burlington, VT
J. Kasal, MD, St. Louis, MO
S. Price, MBBS, PhD, EDICM, London, United Kingdom
D. Pradhan, MD, New York, NY

Subcostal Window
M. Hunter-Behrend, MD, Tacoma, WA
L. Rapoport, MD, Santa Clara, CA
V.A. Dinh, MD, Loma Linda, CA
E. Teo, MD, Atlanta, GA
J. Pittman, MD, Salt Lake City, UT

12:00 LUNCH

12:30 Lunch and Clinical Cases I
L. Grecu, MD, Stony Brook, NY

12:45 Chest Ultrasound
P. Mohabir, MD, Stanford, CA

1:15 Basic Valvulopathy
T. Brakke, MD, Omaha, NE

1:45 Basic Assessment of Diastolic Function
C.K. Grissom, MD, Murray, UT

2:15 Break

2:30 Practical Skills Sessions: Hands-On Station II

Lung Ultrasound (Model and Management)
P. Mohabir, MD, Stanford, CA
L. Rapoport, MD, Santa Clara, CA
M. Hunter-Behrend, MD, Tacoma, WA
Z. Shaman, MD, Cleveland, OH
D. Pradhan, MD, New York, NY
**Diastolic Measurements**

J. Pittman, MD, Salt Lake City, UT  
T. Brakke, MD, Omaha, NE  
S. Price, MBBS, PhD, EDICM, London, United Kingdom  
X. Monnet, MD, PhD, Paris, France  
A. Leibowitz, MD, Boston, MA

**Cardiac Output**

L. Grecu, MD, Stony Brook, NY  
V.A. Dinh, MD, Loma Linda, CA  
J. Kasal, MD, St. Louis, MO  
E. Teo, MD, Atlanta, GA  
G.B. Allen, MD, Burlington, VT

---

**Basic TRANSLATIONAL POSTGRADUATE COURSE**

CME Credits Available: 6.5

**PG2 HOW TO USE ‘OMICS TO STUDY LUNG DISEASE**

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

| Member: $350 | In-Training Member: $200 |
| Non-Member: $425 | In-Training Non-Member: $300 |

Registrants must bring a laptop to the course to view the course material.

Assemblies on Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology; Respiratory Structure and Function; Thoracic Oncology; Genetics and Genomics Section

8:00 a.m. - 4:00 p.m.  
**WALTER E. WASHINGTON CONVENTION CENTER**  
Room 152 A (Middle Building, Street Level)

**Target Audience**

Lung researchers interested in applying so called ‘omics based approaches, which frequently rely on the deep sequencing revolution, to study all aspects of the lung including disease

**Objectives**

At the conclusion of this session, the participant will be able to:

- gain new findings about how genome wide studies of gene expression enhance the understanding of lung disease;  
- learn practical approaches to using existing genome wide data sets to study lung disease and improve patient care.

The ‘omics revolution continues full speed and is transforming the approach to basic and translational research on lung disease. However, it can be difficult to gain even a working familiarity with many of the key techniques in this rapidly changing field. This course will provide a practical overview of the latest in ‘omics-based techniques and how they can be applied to study lung disease. Topics will include genetics, transcriptomics, single-cell analysis, phenomics, deep sequencing-based methodologies to study gene regulation, including ChIP-seq and Atac-seq, and an overview of statistical approaches and mining of publicly available ‘omics data.

**Chairing:** B.E. Himes, PhD, Philadelphia, PA  
A.N. Gerber, MD, PhD, Denver, CO  
M.M. Wurfel, MD, PhD, Seattle, WA

---

**PG3 LOOK BEFORE YOU LEAP: SKILLS FOR CRITICAL EVALUATION OF CLINICAL RESEARCH**

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

| Member: $400 | In-Training Member: $250 |
| Non-Member: $475 | In-Training Non-Member: $350 |

Registrants must bring a laptop to the course to view the course material.

Assemblies on Behavioral Science and Health Services Research; Allergy, Immunology and Inflammation; Clinical Problems; Critical Care; Environmental, Occupational and Population Health; Nursing; Pediatrics; Pulmonary Circulation; Pulmonary Rehabilitation; Sleep and Respiratory Neurobiology and Thoracic Oncology

8:00 a.m. - 4:00 p.m.  
**WALTER E. WASHINGTON CONVENTION CENTER**  
Room 204 B-C (South Building, Level 2)

**Target Audience**

All health care providers
Objectives
At the conclusion of this session, the participant will be able to:

- learn reasoning behind specific design and analytic approaches most commonly used in quantitative interventional and observational studies, as well as qualitative research;
- better able to identify the strengths and limitations of design choices and subsequent results obtained from clinical studies;
- apply a systematic approach to evaluating and analyzing the quality of clinical studies in the medical literature to guide decisions for uptake of evidence into your practice.

Which studies should change your clinical practice? This session will combine didactics with a workshop to provide a toolkit for clinicians to develop a systematic approach to evaluating the primary clinical research literature. Attendees will interact with clinical researchers and evidence based medicine experts during didactic sessions to learn the elements that characterize quality interventional, observational, and qualitative studies. During two afternoon small group workshops, participants will break out into three rotating small groups with 1-2 faculty members to 1) participate in mini-journal clubs for RCT, observational, and qualitative research “case studies”; and 2) develop a personal strategy to assess the quality of clinical research for adoption into practice.

Each participant should leave the session with a better understanding of both a rigorous approach to evaluating the literature, as well as the internal and external influences that result in their own decisions to change practice.

Chairing: A.J. Walkey, MD, MSc, Boston, MA
H.B. Gershengorn, MD, Bronx, NY

8:00 Introduction
A.J. Walkey, MD, MSc, Boston, MA

8:05 RCT Basics: “Establishing the Gold Standard”
R. Parke, RN, PhD, Auckland, New Zealand

8:35 RCTS: “All that Glitters”
J.A. Krishnan, MD, PhD, Chicago, IL

9:05 General Discussion

9:15 Break

H.B. Gershengorn, MD, Bronx, NY

A.J. Walkey, MD, MSc, Boston, MA

10:20 General Discussion

10:30 Qualitative Research: “The Storytellers Rule Society”
K.A. Riekert, PhD, Baltimore, MD

11:00 General Discussion

11:10 LUNCH

12:00 Meta-Analysis: “Greater than the Sum of Its Parts?”
R. Zarychanski, MD, Winnipeg, Canada

12:25 PRO: Clinical Practice Guidelines, “Maybe Overrated But...Clinicians Still Ask for Guidance”
J. Brozek, MD, PhD, Hamilton, Canada

12:50 CON: Clinical Practice Guidelines, “Genius Abhors a Consensus”
B.P. Kavanagh, MD, Toronto, Canada

1:15 Small Group Discussion I
A.J. Walkey, MD, MSc, Boston, MA
A.B. Mehta, MD, Denver, CO
M. Hua, MD, MSc, New York, NY
H.B. Gershengorn, MD, Bronx, NY
R. Parke, RN, PhD, Auckland, New Zealand
J. Brozek, MD, PhD, Hamilton, Canada
B.P. Kavanagh, MD, Toronto, Canada
R. Zarychanski, MD, Winnipeg, Canada
K.A. Riekert, PhD, Baltimore, MD

3:15 Small Group Discussion II: Putting It All Together
A.J. Walkey, MD, MSc, Boston, MA
A.B. Mehta, MD, Denver, CO
M. Hua, MD, MSc, New York, NY
H.B. Gershengorn, MD, Bronx, NY
R. Parke, RN, PhD, Auckland, New Zealand
J. Brozek, MD, PhD, Hamilton, Canada
B.P. Kavanagh, MD, Toronto, Canada
R. Zarychanski, MD, Winnipeg, Canada
K.A. Riekert, PhD, Baltimore, MD
This course will provide an introduction and update on the diagnosis and management of the heterogeneous group of interstitial lung diseases (ILDs) of unknown etiology as well ILD in the setting of connective tissue diseases, vasculitis, and environmental exposures. Idiopathic pulmonary fibrosis (IPF), alveolar proteinosis, and granulomatous ILD (hypersensitivity pneumonitis and sarcoidosis) are among the diseases that will be discussed. Genetic factors, precision medicine for diagnosis and treatment as well as newer concepts in the pathogenesis of IPF and novel treatment strategies to modulate pulmonary fibrosis will be discussed. Attendees will be updated on evolving enhanced knowledge in the clinical management of patients with ILD. The importance of making an accurate diagnosis will be demonstrated by live interactions with a panel of experts from multiple disciplines confronted with 3-4 cases unknown to them. This will illustrate multidisciplinary diagnosis (MDD) in action. Additional talks will focus on the symptom management of patients with IPF and endpoints to assess treatment response beyond conventionally used pulmonary function tests.

Chairing:
G. Raghu, MD, Seattle, WA
L. Richeldi, MD, PhD, Rome, Italy

8:00 Introduction
G. Raghu, MD, Seattle, WA

8:05 Interstitial Lung Disease: An Overview and Approach to Diagnosis
G. Raghu, MD, Seattle, WA

8:30 Imaging in ILD: Clues to Diagnosis
E.A. Kazerooni, MD, Ann Arbor, MI

9:00 Histopathology Features of ILD, Does Tissue Sampling Matter?: Role of Transbronchial, Cryo, and Thorascopic Biopies
J.L. Myers, MD, Ann Arbor, MI

9:25 Precision Medicine for IPF Diagnosis: Time for Genetic Screening and Intervention?
M. Armanios, MD, Baltimore, MD

T.M. Maher, MD, MSc, PhD, London, United Kingdom

10:15 Break

10:25 Connective Tissue Disease for the Pulmonologist Evaluating Interstitial Lung Disease: A Rheumatologist’s View
A. Fischer, MD, Aurora, CO

10:50 Panel Discussion
L. Ho, MD, Seattle, WA

11:50 LUNCH

12:20 Alveolar Hemorrhage and Pulmonary Vasculitides: What’s New?
U. Specks, MD, Rochester, MN

12:40 Cystic Lung Disease, Making the Correct Diagnosis: Discuss Challenges and Strategies in Diagnosis of Cystic Lung Disease Including LAM, Pulmonary LCH, LIP and Others
M.K. Glassberg, MD, Miami, FL

1:05 Hypersensitivity Pneumonitis: Diagnosis and in Pursuit of the Cause: What and Where is the Antigen and What Does the Antigen Do to Cause Disease?
E. Fernandez Perez, MD, Denver, CO

1:30 Sarcoidosis: Treatment Beyond Prednisone and Methotrexate
M.A. Judson, MD, Albany, NY

1:50 Early Detection and Subclinical ILD: Lessons Learned from the Multi-Ethnic Study of Atherosclerosis (MESA) Database
A.J. Podolanczuk, MD, New York, NY

2:15 Co-Morbidities in Patients with IPF
V. Cottin, MD, PhD, Lyon, France

2:40 Break

2:50 Idiopathic Pulmonary Fibrosis: Precision Medicine and Endpoints for Assessing Treatment Response Beyond Forced Vital Capacity
F.J. Martinez, MD, New York, NY

3:15 Reducing Cough and Other Symptoms and Improving Quality of Life for Patients with IPF: Therapeutic Needs and Palliative Care
M. Wijsenbeek, MD, Rotterdam, Netherlands

3:35 Treatment of IPF: Current Landscape of Treatment and Ongoing/Upcoming Clinical Trials
L. Richeldi, MD, PhD, Rome, Italy

CLINICAL POSTGRADUATE COURSE
CME Credits Available: 6.5

PG5 A PHYSIOLOGIC APPROACH TO THE TREATMENT OF SHOCK
Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.
Member: $400  In-Training Member: $250
Non-Member: $475  In-Training Non-Member: $350
Registrants must bring a laptop to the course to view the course material.

Assemblies on Critical Care; Clinical Problems; Respiratory Structure and Function
8:00 a.m. - 4:00 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 152 B (Middle Building, Street Level)

Target Audience
Clinicians who treat patients with shock. In addition, physiologists and basic scientists who are interested in the scientific basis for medical practice

Objectives
At the conclusion of this session, the participant will be able to:
• apply basic principles in fluid management of shock;
• rationally develop strategy for vasopressor use;
• understand the principles behind and select patients for mechanical support.

This course will use a combination of didactic lectures and small group breakout sessions to describe a ‘first-principles’ approach to the individualized management of shock. The goal of the course is to enable participants to apply fundamental principles at the bedside. Topics include assessment of fluid responsiveness, physiology of right heart failure, choice of...
inotropes/vasopressors, blood pressure targets and assessment of oxygen delivery, as well as cardiogenic shock and the physiology of mechanical support. We will explore controversies in the physiologic literature concerning these issues and critically examine common clinical practice in light of the current physiologic literature.

Chairing:
C.C. Hardin, MD, PhD, Boston, MA
K.A. Hibbert, MD, Boston, MA

8:00 Introduction: A Physiologic Approach to Shock
C.C. Hardin, MD, PhD, Boston, MA

8:20 Meaningful Clinical Targets in Patients with Shock
S. Magder, MD, Montreal, Canada

9:20 Assessing Fluid Responsiveness
V.B. Kerry, MD, Boston, MA

10:05 Break

10:25 Vasopressors and Inotropes
A.J. Goodwin, MD, MSCR, Charleston, SC

11:05 Physiology of Right Heart Failure
R. Naeije, MD, PhD, Brussels, Belgium

12:05 LUNCH

12:50 Mechanical Support for Cardiogenic Shock
G. Lewis, MD, Boston, MA

1:35 Physiology and Treatment of Hemorrhagic Shock
S. Henry, MD, Baltimore, MD

2:20 Break

2:40 Case Examples
K.A. Hibbert, MD, Boston, MA

---

**PG6 LUNG INNATE IMMUNITY: FRONTLINES OF HOST DEFENSE**

- Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.
  - Member: $350
  - In-Training Member: $200
  - Non-Member: $425
  - In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Microbiology, Tuberculosis and Pulmonary Infections; Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology

8:00 a.m. - 4:00 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 145 B (Middle Building, Street Level)

**Target Audience**
Investigators and providers of lung health; postdoctoral fellows in training; students with particular interest in understanding the scientific basis for disease susceptibility to lung infections

**Objectives**
At the conclusion of this session, the participant will be able to:
- apply new findings and information regarding normal host responses to microbial infections in the lung;
- learn new findings about novel strategies and approaches to the management of lung infections;
- improve the life and health status of patients with lung infections.

The course will provide state of the art presentations by experts in the field, updating current knowledge and cutting-edge research in the area of lung innate immunity and host defense. Presentations will provide insights into current understanding of critical components of lung protective mechanisms, in addition to elucidating mechanisms of host susceptibility to serious lung infections.

Chairing:
H. Koziel, MD, Boston, MA
J.P. Mizgerd, ScD, Boston, MA

8:00 Sensing and Signaling Infection Through Pattern Recognition Receptors
J. Imler, PhD, Strasbourg, France

8:30 Cytosolic Immune Receptors and the Inflammasome
Speaker To Be Announced

9:00 Alveolar Macrophage Plasticity and Interplay with Epithelial Cells
R.J. Snelgrove, PhD, London, United Kingdom

9:30 Epithelial Cells in Lung Host Defenses: More than a Barrier
A.S. Prince, MD, New York, NY

10:00 Break

10:15 Lung Dendritic Cells Link Innate and Adaptive Immunity
Speaker To Be Announced

10:45 Systemic Responses to Lung Infection: What Happens in the Lung Does Not Stay in the Lung
L.J. Quinton, PhD, Boston, MA

11:15 Lung Resident Memory Cells: Reshaping Mucosal Innate Immunity
D. Farber, PhD, New York, NY

11:45 LUNCH

12:45 Visualizing Integrated Immune Responses in the Lung
P. Torabi-Parizi, MD, Bethesda, MD

1:15 Role of the Environment on Lung Infection Susceptibility and Pneumonia Pathogenesis
L. Kobzik, MD, Boston, MA

1:45 Airway Microbiome and Innate Immunity
S.V. Lynch, PhD, San Francisco, CA

2:15 Break

2:30 Mutations as Windows into Immunity and Infection in the Lung
S.M. Holland, MD, Bethesda, MD

3:00 Macrophages Determine Injury and Inflammation Resolution in the Infected Lung
S.V. Herold, MD, PhD, Giessen, Germany

3:30 Innate Determinants of Vaccine Responses
K. Mayer, MD, PhD, Bethesda, MD

---

The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.
PG7  PEDIATRIC RESPIRATORY PHYSIOLOGY: WHEN IT’S NORMAL AND WHEN IT’S NOT

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350  In-Training Member: $200
Non-Member: $425  In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Pediatrics; Clinical Problems; Critical Care; Pulmonary Circulation; Respiratory Cell and Molecular Biology; Respiratory Structure and Function; Sleep and Respiratory Neurobiology

8:00 a.m. - 4:00 p.m.  WALTER E. WASHINGTON CONVENTION CENTER
Room 143 B-C (Middle Building, Street Level)

Target Audience
Fellows in training as well as established physicians in the practice of pediatric pulmonology, critical care or neonatal medicine who are interested in reviewing basic physiology principles as they apply to clinical care

Objectives
At the conclusion of this session, the participant will be able to:

· apply several basic respiratory principles to the diagnosis and management of common pediatric respiratory disorders;
· learn how physiologic measurements can be used to change interventions and enhance outcomes;
· identify the rationale for several measurement techniques and determine when these should be used.

The course will consist of a series of paired lectures covering several topics in pediatric respiratory physiology, reviewing first normal physiologic aspects of a topic and then the companion talk will review pathophysiology relating to a particular pediatric respiratory disease that highlights when the normal physiology goes awry. An interactive format, using questions from the speakers will be used to enhance audience participation, and to allow the participant to understand key concepts or to identify areas requiring additional study.

Chairing:
H.B. Panitch, MD, Philadelphia, PA
J.L. Allen, MD, Philadelphia, PA

8:00 Airways and Airway Smooth Muscle
T.H. Shaffer, MSE, PhD, Wilmington, DE

8:35 Wheezing in Infants
T. Guilbert, MD, MS, Cincinnati, OH

9:10 Pulmonary Circulation and Transitional Circulation
S. Lakshminrusimha, MD, Buffalo, NY

9:45 Break

9:55 BPD and Pulmonary Hypertension
S.H. Abman, MD, Aurora, CO

10:30 Neural Control of the Lung
H.B. Panitch, MD, Philadelphia, PA

11:05 The Denervated Lung: Respiratory Responsiveness Following Transplantation
G. Kurland, MD, Pittsburgh, PA

11:40 LUNCH

12:20 Chest Wall and Respiratory Muscle Mechanics
J.L. Allen, MD, Philadelphia, PA

12:55 Weakness and Thoracic Insufficiency Syndrome
G.J. Redding, MD, Seattle, WA

1:30 Control of Breathing
S. Ward, MD, Los Angeles, CA

2:05 Break

2:15 Abnormal Control of Breathing
T.G. Keens, MD, Los Angeles, CA

2:50 Mucociliary Clearance and Pharmacotherapy
J. Clancy, MD, Cincinnati, OH

3:25 Primary Ciliary Dyskinesia
T.W. Ferkol, MD, St. Louis, MO

PG8  PRACTICAL OUTCOME TOOLS IN COPD: FROM CLINICAL CARE TO CLINICAL TRIALS

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350  In-Training Member: $200
Non-Member: $425  In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Pulmonary Rehabilitation; Behavioral Science and Health Services Research; Clinical Problems; Nursing

8:00 a.m. - 4:00 p.m.  WALTER E. WASHINGTON CONVENTION CENTER
Room 201 (South Building, Level 2)

Target Audience
Clinicians involved in the management of patients with COPD; any clinical researcher in COPD

Objectives
At the conclusion of this session, the participant will be able to:

· gain new strategies to manage the care of patients with COPD by being aware of practical outcome tools that can be used to provide holistic assessment;
· assess the response of treatment by improving the means of assessing outcomes in patients with COPD;
· understand what is required for a practical outcome tool to be used in a clinical trial.

COPD is a heterogeneous, multi-system disease, and global assessment of the patient is required to optimize and personalize care in patients with COPD.
There is a need to characterize and phenotype patient population in different settings - clinical and research.

The aims of this course are: To describe the psychometric and prognostic properties of outcome tools commonly used in patients with COPD in different clinical care settings, and whether these can be utilized in clinical trials; disseminate recent ATS/ERS statements on field walking tests, limb muscle dysfunction and pulmonary rehabilitation; disseminate work of the COPD Biomarker Qualification Consortium.

Chairing:
W. Man, MD, PhD, Harefield, United Kingdom
S.J. Singh, PhD, Leicester, United Kingdom

8:00 Six Minute Walk Test
M.A. Spruit, PhD, PT, Horn, Netherlands

8:20 Shuttle Walk Tests
S.J. Singh, PhD, Leicester, United Kingdom

8:40 Cycle Ergometry and Cardiopulmonary Exercise
H.B. Rossiter, PhD, Torrance, CA

9:00 Gerontology Physical Performance Tools and Frailty
M. Maddocks, PhD, London, United Kingdom

9:20 Adapting Test Choice According to the Question Posed
M. Polkey, MD, London, United Kingdom

9:50 Break

10:10 Measuring Muscle Function and Mass in COPD
F. Maltais, MD, Quebec, Canada

10:30 Balance Measures in COPD
D. Brooks, PhD, Toronto, Canada

10:50 Assessing Activities of Daily Living in COPD
S. Lareau, MS, RN, Aurora, CO

11:10 Outcome Tools to Directly Measure Physical Activity in COPD
M.L. Moy, MD, MSc, Boston, MA

11:30 Sleep Disturbance in COPD
X. Soler, MD, PhD, San Diego, CA

11:50 LUNCH

1:00 Measuring Dyspnea in COPD
P.M. Meek, PhD, RN, Denver, CO

1:20 Practical Measures of Health Status in COPD
S. Kon, MD, PhD, Harefield, United Kingdom

1:40 Anxiety, Depression and Pain in COPD
A.M. Yohannes, PhD, Manchester, United Kingdom

2:00 COPD Biomarker Qualification Consortium
R. Tal-Singer, PhD, King of Prussia, PA

2:20 Break

2:40 EXACT-PRO and Measuring Exacerbations in COPD
L. Murray, PhD, MPH, Bethesda, MD

3:00 Hospital Admissions in COPD: How Are They Measured in Clinical Trials of COPD
J. Quint, MSc, PhD, London, United Kingdom

3:20 The Future? Genetics and Genomics in the Global Assessment of the Patient with COPD
E.S. Wan, MD, Boston, MA

3:50 Summary and General Discussion
W. Man, MD, PhD, Harefield, United Kingdom

This session and the International Conference are supported by an educational grant from AstraZeneca LP.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

PG9 MASTER PHYSIOLOGY CLASS: HEMODYNAMICS

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $400     In-Training Member: $250
Non-Member: $475     In-Training Non-Member: $350

Registrants must bring a laptop to the course to view the course material.

Assemblies on Respiratory Structure and Function; Critical Care
8:00 a.m. - 4:00 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 151 A (Middle Building, Street Level)

Target Audience
Practicing clinicians and resident-to-fellow level trainees whose primary clinical focus is critical care medicine

Objectives
At the conclusion of this session, the participant will be able to:

• describe the basic principles of cardiac and pulmonary circulatory physiology;

• understand and describe key features of the cerebral, splanchnic and renal vascular systems and their application to the care of critically ill patients;

• interpret hemodynamic data and describe the physiologic principles underlying the observed patterns and relationships.

Speakers will use a combination of didactic lectures and small group learning to review core principles of hemodynamics including cardiac physiology, the physiology of the major vascular beds, the hemodynamic effects of mechanical ventilation and the bedside assessment of a patient’s hemodynamic status.

Chairing:
A.M. Luks, MD, Seattle, WA
R.W. Glenny, MD, Seattle, WA

8:00 Introduction
A.M. Luks, MD, Seattle, WA

8:10 Physiology of the Pulmonary Circulation
R.W. Glenny, MD, Seattle, WA

8:50 Renovascular Physiology
M. Hoenig, MD, Boston, MA

9:30 Break

9:40 Cerebrovascular Physiology
N. Badjatia, MD, Baltimore, MD
10:20 Small Group Case Review
A.M. Luks, MD, Seattle, WA
R.W. Glenny, MD, Seattle, WA
B. Coruh, MD, Seattle, WA
R. Schwartzstein, MD, Boston, MA
A.S. Clay, MD, Durham, NC
W.G. Carlos, MD, MSCR, Indianapolis, IN
P.G. Carvalho, MD, Boise, ID
J. Petersson, MD, PhD, Stockholm, Sweden
M.M. Hayes, MD, Boston, MA
J.T. Poston, MD, Chicago, IL
J.B. Richards, MD, Charleston, SC

11:35 LUNCH

12:35 Cardiac Physiology for the Intensivist
S. Magder, MD, Montreal, Canada

1:15 The Splanchnic Circulation
A.M. Luks, MD, Seattle, WA

1:55 Break

2:05 Hemodynamics Effects of Mechanical Ventilation
A.S. Clay, MD, Durham, NC

2:45 Small Group Case Review
A.M. Luks, MD, Seattle, WA
R.W. Glenny, MD, Seattle, WA
B. Coruh, MD, Seattle, WA
R. Schwartzstein, MD, Boston, MA
J.T. Poston, MD, Chicago, IL
A.S. Clay, MD, Durham, NC
W.G. Carlos, MD, MSCR, Indianapolis, IN
P.G. Carvalho, MD, Boise, ID
M.M. Hayes, MD, Boston, MA
J. Petersson, MD, PhD, Stockholm, Sweden
J.B. Richards, MD, Charleston, SC

8:00 Introduction
J.E. Metz, DDS, Columbus, OH

8:10 Patient Selection for OAT, Clinical Signs, Screening, Dental Examination and Medical Co-Morbidities Relevant to the Dental Practice
J. Blank, DDS, Springfield, OH

8:40 Hypertension and Type 2 Diabetes Mellitus in OSA and Oral Appliance Therapy
F. Gagnadoux, MD, Angers, France

9:25 Break

10:10 A Current Update on Sleep Bruxism, Orofacial Pain and Research Topics
G. Lavigne, DMD, MSc, PhD, Montreal, Canada

11:20 Drug-Induced Sleep Endoscopy for Evaluation of Oral Appliance Effectiveness and Hypoglossal Nerve Stimulation Surgery
O. Vanderveken, MD, PhD, Antwerp, Belgium

12:20 LUNCH

1:05 Evolving Meaningful Alternatives to CPAP Therapy
D.P. White, MD, Denver, CO

1:55 Types of Oral Appliances for the Treatment of OSA, and How to Recognize a Successful Appliance
F.R. Almeida, DDS, MSc, PhD, Vancouver, Canada

2:25 Break

2:35 Titration Process for Oral Appliance Therapy in the Sleep Laboratory
D. Shrivastava, MD, Sacramento, CA
P. McBride, BA, RDA, CCSH, Suffern, NY
U. Khatwa, MD, Cambridge, MA

3:25 Case Studies of Successful Oral Appliance Therapy Patients with Different Vertical Dimensions
J.E. Metz, DDS, Columbus, OH

Objectives
At the conclusion of this session, the participant will be able to:

- improve how health care providers assess the oral cavity and overall patient for the suspected presence of sleep-disordered breathing;
- apply appliance selection and titration strategies to optimize oral appliance therapy for OSA;
- improve the quality of health/life status of OSA patients by providing successful oral appliance therapy, as a stand-alone treatment or in combination with other modalities.

This course will cover the foundation of knowledge about obstructive sleep apnea and clinical signs in the oral cavity and relevant medical history. How to screen patients for oral appliance therapy, and evaluate effective mandibular advancement devices, including titration processes will be addressed as well as treating sleep apnea patients in an interdisciplinary fashion, with alternative treatment modalities.

Chairing: J.E. Metz, DDS, Columbus, OH
**PG11  LUNG CANCER STATE OF THE ART: 2017**

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

<table>
<thead>
<tr>
<th>Member</th>
<th>In-Training Member</th>
<th>Non-Member</th>
<th>In-Training Non-Member</th>
</tr>
</thead>
<tbody>
<tr>
<td>$350</td>
<td>$200</td>
<td>$425</td>
<td>$300</td>
</tr>
</tbody>
</table>

Assemblies on Thoracic Oncology; Clinical Problems
8:00 a.m. - 4:00 p.m.  WALTER E. WASHINGTON CONVENTION CENTER
Room 144 A-B (Middle Building, Street Level)

**Target Audience**
Clinicians of various specialties (pulmonary medicine, thoracic surgery, medical and radiation oncology, physician extenders) who are involved in the care of patients with lung cancer

**Objectives**
At the conclusion of this session, the participant will be able to:
- Learn strategies for developing and improving screening programs including identifying persons eligible and most likely to benefit from screening, shared decision making aids, and best ways to provide tobacco treatment and cessation support;
- Manage and to diagnose solid and ground glass pulmonary nodules;
- Learn new findings about key developments in clinical research that have impacted lung cancer outcomes and be updated on evolving therapies in NSCLC.

A comprehensive and up-to-date review coupled with interactive tumor boards will cover screening and development of screening programs, tobacco interventions, prognostic factors, and approach to pulmonary nodules (solid and sub-solid) including nodule management guidelines and diagnostic interventions. In addition, we will discuss challenges in SBRT for Stage I when is it clinically indicated without tissue confirmation and a pro con debate on whether all patients need to undergo EBUS for nodal staging, the epidemic of lung cancer in women, advances in personalized medicine and immunotherapy, management of malignant pleural effusions and toxicities due to lung cancer therapies.

**Chairing:** M.P. Rivera, MD, Chapel Hill, NC
D.J. Feller-Kopman, MD, Baltimore, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Introduction</td>
<td>M.P. Rivera, MD, Chapel Hill, NC</td>
<td></td>
</tr>
<tr>
<td>8:05</td>
<td>Smoke Gets in Your Eyes: Tobacco Control and Cessation</td>
<td>A. Vachani, MD, MS, Philadelphia, PA</td>
<td></td>
</tr>
<tr>
<td>8:30</td>
<td>Beyond the NLST: An Update of LDCT Screening and Development of Screening Programs</td>
<td>R.S. Wiener, MD, MPH, Boston, MA</td>
<td></td>
</tr>
<tr>
<td>8:55</td>
<td>If You Have a Hammer Not Everything Is a Nail: Diagnostic Procedures in the Work Up of Lesions Concerning for Lung Cancer</td>
<td>N.T. Tanner, MD, MSCR, Charleston, SC</td>
<td></td>
</tr>
<tr>
<td>9:20</td>
<td>The Solid Pulmonary Nodule: When Is It Cancer</td>
<td>M.K. Gould, MD, MS, Pasadena, CA</td>
<td></td>
</tr>
<tr>
<td>9:45</td>
<td>Ground Glass Nodule: To Treat (or Not) a Fuzzy Spot</td>
<td>J.D. Blasberg, MD, New Haven, CT</td>
<td></td>
</tr>
<tr>
<td>10:10</td>
<td>Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:20</td>
<td>Interactive Tumor Board</td>
<td>M.P. Rivera, MD, Chapel Hill, NC</td>
<td></td>
</tr>
<tr>
<td>10:55</td>
<td>The Holy Grail of Prognostic Factors in Lung Cancer: Searching for Omniscience</td>
<td>F.C. Deterbeck, MD, New Haven, CT</td>
<td></td>
</tr>
<tr>
<td>11:20</td>
<td>The Specter of Gender: Lung Cancer in Women</td>
<td>M.P. Rivera, MD, Chapel Hill, NC</td>
<td></td>
</tr>
<tr>
<td>11:45</td>
<td>LUNCH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>Don't MUSS with My EBUS (Pro-Con Debate): All Patients with Stage I NSCL Undergoing SBRT Need Staging EBUS</td>
<td>J.A. Akulian, MD, MPH, Chapel Hill, NC</td>
<td></td>
</tr>
<tr>
<td>1:10</td>
<td>Is Tissue Always the Issue?: Treating Patients Without Tissue Diagnosis with SBRT</td>
<td>R. Hales, MD, Baltimore, MD</td>
<td></td>
</tr>
<tr>
<td>1:35</td>
<td>How Not to Die Short of Breath: Management of Malignant Pleural Effusions</td>
<td>D.J. Feller-Kopman, MD, Baltimore, MD</td>
<td></td>
</tr>
<tr>
<td>2:00</td>
<td>Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:10</td>
<td>Immunotherapy’s Rook to Lung Cancer’s King: CHECKMATE: Novel Therapies in NSCLC</td>
<td>J. Brahmer, MD, Baltimore, MD</td>
<td></td>
</tr>
<tr>
<td>2:35</td>
<td>Palliative Care in Lung Cancer: It Really Works</td>
<td>G.C. Michaud, MD, New York, NY</td>
<td></td>
</tr>
<tr>
<td>3:00</td>
<td>Pulmonary Complications Associated with Lung Cancer Therapies</td>
<td>P.B. Camus, MD, Dijon, France</td>
<td></td>
</tr>
<tr>
<td>3:25</td>
<td>Interactive Tumor Board</td>
<td>D.J. Feller-Kopman, MD, Baltimore, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>F.C. Deterbeck, MD, New Haven, CT</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>R. Hales, MD, Baltimore, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>J. Brahmer, MD, Baltimore, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>G.C. Michaud, MD, New York, NY</td>
<td></td>
</tr>
</tbody>
</table>

The information contained in this program is up to date as of March 9, 2017. For the most current session information, please visit the online program itinerary.
### Critical Care Ultrasound and Echocardiography II

**Assembly on Critical Care**

*8:00 a.m. - 4:00 p.m.*  
**WALTER E. WASHINGTON CONVENTION CENTER**  
Room 145 A (Middle Building, Street Level)

**Target Audience**

Providers of critical care or emergency medicine

**Objectives**

At the conclusion of this session, the participant will be able to:

- apply ultrasound at bedside to assess critically ill patients;
- diagnose alternate etiologies of shock in the critically ill patient;
- apply ultrasound to guide common ICU procedures.

This is a 2-day postgraduate course that consists of didactic lectures and hands-on stations. The focus is primarily bedside transthoracic echocardiography, with some diagnostic ultrasound. The topics include basic and intermediate critical care echocardiography (including hemodynamic measures), assessment of fluid status, procedural guidance for vascular access and thoracentesis, venography. The hands-on stations will include both healthy models and simulators that can demonstrate abnormal pathology.

**Chairing:** M.J. Lanspa, MD, MS, Salt Lake City, UT  
X. Monnet, MD, PhD, Paris, France

**8:00**  
Vascular Ultrasound: DVT Evaluation  
L. Rapoport, MD, Santa Clara, CA

**8:25**  
Vascular Access  
M. Hunter-Behrend, MD, Tacoma, WA

**8:50**  
Tamponade  
G.B. Allen, MD, Burlington, VT

**9:20**  
Using Ultrasound to Assess Intravascular Volume and Fluid Responsiveness  
X. Monnet, MD, PhD, Paris, France

**9:50**  
Ultrasound for Diuresis and Dialysis  
E. Hirshberg, MD, MS, Salt Lake City, UT

**10:15**  
Break

**10:30**  
Practical Skills Sessions: Hands-On Station III  
*Volume Status*  
X. Monnet, MD, PhD, Paris, France  
P. Mohabir, MD, Stanford, CA  
J. Kasal, MD, St. Louis, MO  
E. Teo, MD, Atlanta, GA  
D. Pradhan, MD, New York, NY

*Tamponade Evaluation*  
V.A. Dinh, MD, Loma Linda, CA  
G.B. Allen, MD, Burlington, VT  
A. Leibowitz, MD, Boston, MA  
S. Price, MBBS, PhD, EDICM, London, United Kingdom  
T. Brakke, MD, Omaha, NE

*Vascular Ultrasound*  
L. Rapoport, MD, Santa Clara, CA  
M. Hunter-Behrend, MD, Tacoma, WA  
Z. Shaman, MD, Cleveland, OH  
L. Grecu, MD, Stony Brook, NY  
J. Pittman, MD, Salt Lake City, UT

**12:00**  
LUNCH

**12:30**  
Lunch and Clinical Cases II  
E. Teo, MD, Atlanta, GA

**12:45**  
Abdominal Ultrasonography  
V.A. Dinh, MD, Loma Linda, CA

**1:15**  
Goal Directed Management of Shock Using Echocardiography  
J. Kasal, MD, St. Louis, MO

**1:45**  
Incorporating Echocardiography into CPR  
M.J. Lanspa, MD, MS, Salt Lake City, UT

**2:15**  
Break

**2:30**  
Practical Skills Sessions: Hands-On Station IV  
*Echo in Shock and CPR*  
P. Mohabir, MD, Stanford, CA  
D. Pradhan, MD, New York, NY  
T. Brakke, MD, Omaha, NE  
S. Price, MBBS, PhD, EDICM, London, United Kingdom  
L. Grecu, MD, Stony Brook, NY

*Abdominal Ultrasound*  
L. Rapoport, MD, Santa Clara, CA  
Z. Shaman, MD, Cleveland, OH  
J. Pittman, MD, Salt Lake City, UT  
G.B. Allen, MD, Burlington, VT  
M. Hunter-Behrend, MD, Tacoma, WA

---

*The information contained in this program is up to date as of March 9, 2017.  
For the most current session information, please visit the [online program itinerary.](#)*
CLINICAL POSTGRADUATE COURSE

CME Credits Available: 6.75

PG12 BRONCH DAY: A COMPREHENSIVE, HANDS-ON GUIDE TO BASIC BRONCHOSCOPY AND EBUS

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $475  In-Training Member: $300
Non-Member: $550  In-Training Non-Member: $400

Registrants must bring a laptop to the course to view the course material.

Assemblies on Clinical Problems; Critical Care; Pediatrics; Thoracic Oncology
8:00 a.m. - 4:00 p.m.  WALTER E. WASHINGTON CONVENTION CENTER
Room 145 B (Middle Building, Street Level)

Target Audience
Adult and pediatric pulmonologists and intensivists, thoracic surgeons, physicians in training, allied health professionals, and anesthesiologists interested in improving their skills in diagnostic and therapeutic flexible bronchoscopy and EBUS

Objectives
At the conclusion of this session, the participant will be able to:

- diagnose and manage adults and children with benign and malignant respiratory diseases;
- improve knowledge of basic flexible bronchoscopy and strengthen procedural skills;
- understand the indications for linear and radial endobronchial ultrasound and the skills necessary to perform these procedures.

This course is designed to provide a comprehensive introduction to diagnostic and therapeutic flexible bronchoscopy. Participants will acquire the knowledge and skills to improve their proficiency in basic bronchoscopic techniques and be introduced to more advanced diagnostic bronchoscopy, including linear and radial endobronchial ultrasound. A series of didactic lectures will be followed by intensive, hands-on training, through the use of physical and virtual reality simulators which will help participants strengthen their procedural skills. This course will be of particular interest to provider seeking to refine their bronchoscopic skills and wish to review the data behind the various bronchoscopic techniques. Audience Response System to be used during lectures.

Chairing:  C.L. Channick, MD, Boston, MA
S. Oh, MD, Los Angeles, CA

8:00 A Quick and Comprehensive Review of Airway Anatomy: The Larynx and Tracheobronchial Tree
L. Frye, MD, Chicago, IL

8:15 Optimizing Basic Bronchoscopy Skills: Bronchoalveolar Lavage, Endobronchial Brushings, and Endobronchial Biopsies
C.M. Kinsey, MD, MPH, Burlington, VT

8:40 Improving Your Technique and Yield for Transbronchial and Needle Aspiration Biopsies
S. Oh, MD, Los Angeles, CA

9:05 Pediatric Flexible Bronchoscopy for the Adult and Pediatric Bronchoscopists
J. Puchalski, MD, New Haven, CT

9:30 Break

9:40 The Role of Flexible Bronchoscopy in the Management of Hemoptysis
C.R. Lamb, MD, Burlington, MA

10:05 Performing Flexible Bronchoscopy in High-Risk Patients: How to Maximize Outcomes
A. Majid, MD, Boston, MA

10:30 The Fundamentals of Linear EBUS: Overview of the Basic Technique and the Data
C.L. Channick, MD, Boston, MA

10:55 Introduction to Radial EBUS: Review of the Evidence
G.C. Michaud, MD, New York, NY

11:20 Bronchial Thermoplasty: Practice and Principles
A. Mahajan, MD, Falls Church, VA

11:45 LUNCH

12:45 Practical Skills Sessions
Bronchoscopy with Brushing, Biopsy, and Needle Aspiration of Endobronchial Lesion
C.M. Kinsey, MD, MPH, Burlington, VT
A. Mahajan, MD, Falls Church, VA
S. Goldfarb, MD, Philadelphia, PA

Bronchoscopic Management of Hemoptysis
A. Majid, MD, Boston, MA
J. Puchalski, MD, New Haven, CT

Management of the Difficult Airway
S. Oh, MD, Los Angeles, CA
I. Susanto, MD, Los Angeles, CA
A. Vicencio, MD, New York, NY

Techniques for Foreign Body Removal Using Flexible Bronchoscopy
C.L. Channick, MD, Boston, MA
B. Husta, MD, New York, NY
C.Y. Spencer, MD, New York, NY

Radial Endobronchial Ultrasound
L. Frye, MD, Chicago, IL
J. Cardenas-Garcia, MD, Hershey, PA

Endobronchial Ultrasound-TBNA
C.R. Lamb, MD, Burlington, MA
G.C. Michaud, MD, New York, NY
PG13  FLOW CYTOMETRY IN HUMAN AND MOUSE LUNGS: FROM EXPERIMENTAL DESIGN TO ANALYSIS

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $400  In-Training Member: $250
Non-Member: $475  In-Training Non-Member: $350

Registrants must bring a laptop to the course to view the course material.

Assemblies on Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology

8:00 a.m. - 4:00 p.m.  WALTER E. WASHINGTON CONVENTION CENTER
Room 204 B-C (South Building, Level 2)

Target Audience
Basic and clinical researchers interested in learning about the techniques to perform high quality flow cytometry in lung samples

Objectives
At the conclusion of this session, the participant will be able to:
• identify the critical components of performing high quality flow cytometry including tissue digestion and handling, performance and data analysis;
• learn about methodologies to identify structural and immune cell populations in the lung and how to link these to bioinformatics and next generation sequencing;
• practically apply the skills learned in this session on cases designed to address routine problems with flow cytometry performance and data analysis.

Flow cytometry is a vital tool to understand the cellular basis and pathological processes in multiple organ systems. However, the implementation of multicolor flow cytometry and cell sorting is technically challenging. This challenge hampers overall reproducibility and cell type generalization across scientific laboratories in the field. This session will assemble a group of experts with the capacity to comprehensively review the technical and interpretive aspects of pulmonary cell isolation and flow cytometric analysis of both non-hematopoietic and hematopoietic cells. Specifically, lectures will focus on strategies for flow cytometric panel design, sample preparation/staining, data analysis, interpretation and presentation.

Chairing:  R.M. Tighe, MD, Durham, NC
          A.V. Misharin, MD, PhD, Chicago, IL
          C. Jakubzick, PhD, Denver, CO

8:00  Introduction, Review of Format for the Day
     R.M. Tighe, MD, Durham, NC

8:10  Programmatic Perspective on Modern Flow Cytometry in Clinical and Basic Research
     P.K. Chattopadhyay, PhD, Bethesda, MD

8:50  Key Steps in Conducting a High Quality Flow Cytometry Study in Research and Clinical Settings
     R.M. Tighe, MD, Durham, NC

9:20  Use of Mass Cytometry (CyTOF) for Analysis of Lung Tissue
     N. McGovern, PhD, Singapore, Singapore

9:50  Break

10:05  Flow Cytometry of Myeloid Cells in the Murine and Human Lung
      C. Jakubzick, PhD, Denver, CO

10:45  Flow Cytometry of Epithelial, Endothelial and Stromal Cells in the Lung
      E.F. Redente, PhD, Denver, CO

11:15  Flow Cytometry Analysis of Experimental Lung Cancers
      K. Politi, PhD, New Haven, CT

11:45  LUNCH

12:30  Flow Cytometry Analysis of Lymphoid Cells in the Lung
      C.M. Lloyd, PhD, London, United Kingdom

1:00  Cell Sorting and Downstream -Omos Applications
     A.V. Misharin, MD, PhD, Chicago, IL

1:30  Bioinformatic Approaches in Flow Cytometry
     R. Brinkman, PhD, Vancouver, Canada

2:00  Break

2:15  Practical Aspects of Compensation in Flow Cytometry
     Y.R. Yu, MD, PhD, Durham, NC

2:35  Errors Commonly Found in Flow Cytometry
     A.V. Misharin, MD, PhD, Chicago, IL

3:00  Practical Workshop on the Performance of Flow Cytometry
     R.M. Tighe, MD, Durham, NC
     A.V. Misharin, MD, PhD, Chicago, IL
     C. Jakubzick, PhD, Denver, CO
     E.F. Redente, PhD, Denver, CO
understand the techniques and tools required to lead efforts in quality measurement and improvement in health care;

identify enablers, barriers, and solutions to facilitate effective implementation;

improve quality at the local level, engaging administrators, mid-level managers, and bedside clinicians to effectively overcome barriers, utilize enablers, and implement programs.

Due to changes in the health care landscape, there is intense pressure to improve the quality of care delivered. The pressure is especially intense in critical care, a venue associated with significant mortality, morbidity, and disproportionate cost. At the same time, despite an ever increasing number of guidelines and an emerging evidence base, knowledge translation is slow and incomplete. Didactic content will include a combination of high level quality overview sessions and a pragmatic set of talks intended for immediate application during the three skills building sessions. Participants will select one of three quality improvement topics for the skills building breakout sessions and work through a simulated quality improvement case study under the guidance of facilitators with deep expertise in the respective topics.

Chairing: D.W. Ford, MD, MSCR, Charleston, SC
A. Amaral, MD, Toronto, Canada
M. Mikkelsen, MD, MSCE, Philadelphia, PA

8:00 Introduction
D.W. Ford, MD, MSCR, Charleston, SC

8:20 Making a Difference: The Science of Quality Improvement
V. Liu, MD, MS, Oakland, CA

8:40 Money Talks: How Financial Incentives (and Disincentives) Impact QI
A. Weinacker, MD, Stanford, CA

9:00 QI Planning: Where Do I Start? Identifying the Problem That Requires a Solution
M. Howell, MD, MPH, Chicago, IL

W.D. Schweickert, MD, Philadelphia, PA

9:40 Break

10:00 QI Implementation: Plan, Do, Study, Act (PDSA) Cycles
C.L. Hough, MD, Seattle, WA

10:20 Breakout Session I
Implementing the ABCDE Bundle
W.D. Schweickert, MD, Philadelphia, PA
D.K. Costa, PhD, RN, Ann Arbor, MI
C.L. Hough, MD, Seattle, WA
A. Amaral, MD, Toronto, Canada

Palliative and End of Life Care
E.K. Kross, MD, Seattle, WA
S.S. Carson, MD, Chapel Hill, NC
D.W. Ford, MD, MSCR, Charleston, SC

Sepsis
V. Liu, MD, MS, Oakland, CA
I.S. Douglas, MD, Denver, CO
M. Howell, MD, MPH, Chicago, IL
M.E. Mikkelsen, MD, MSCE, Philadelphia, PA

11:00 QI Implementation: No One Is an Island: Designing the Initiative with Key Stakeholders (Including Patients and Families) in Mind
D.K. Costa, PhD, RN, Ann Arbor, MI

11:20 QI Evaluation: Show Me the Data! How to Measure Implementation and Patient-Centered Outcomes
A. Amaral, MD, Toronto, Canada

11:40 LUNCH

12:20 Breakout Session II
Implementing the ABCDE Bundle
W.D. Schweickert, MD, Philadelphia, PA
D.K. Costa, PhD, RN, Ann Arbor, MI
C.L. Hough, MD, Seattle, WA
A. Amaral, MD, Toronto, Canada

Palliative and End of Life Care
E.K. Kross, MD, Seattle, WA
S.S. Carson, MD, Chapel Hill, NC
D.W. Ford, MD, MSCR, Charleston, SC

Sepsis
V. Liu, MD, MS, Oakland, CA
I.S. Douglas, MD, Denver, CO
M. Howell, MD, MPH, Chicago, IL
M.E. Mikkelsen, MD, MSCE, Philadelphia, PA

12:40 Breakout Session III
Implementing the ABCDE Bundle
W.D. Schweickert, MD, Philadelphia, PA
D.K. Costa, PhD, RN, Ann Arbor, MI
C.L. Hough, MD, Seattle, WA
A. Amaral, MD, Toronto, Canada

Palliative and End of Life Care
E.K. Kross, MD, Seattle, WA
S.S. Carson, MD, Chapel Hill, NC
D.W. Ford, MD, MSCR, Charleston, SC

Sepsis
V. Liu, MD, MS, Oakland, CA
I.S. Douglas, MD, Denver, CO
M. Howell, MD, MPH, Chicago, IL
M.E. Mikkelsen, MD, MSCE, Philadelphia, PA

3:00 QI Team Reports and Debrief
A. Amaral, MD, Toronto, Canada
D.W. Ford, MD, MSCR, Charleston, SC
M.E. Mikkelsen, MD, MSCE, Philadelphia, PA

The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.
PG15  ADVANCES IN THE DIAGNOSIS AND MANAGEMENT OF SARCOIDOSIS

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350  In-Training Member: $200
Non-Member: $425  In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Clinical Problems; Allergy, Immunology and Inflammation

8:00 a.m. - 4:00 p.m.  WALTER E. WASHINGTON CONVENTION CENTER Room 143 B-C (Middle Building, Street Level)

Target Audience
Clinicians who see sarcoidosis patients; especially on trainees, recent graduates, and individuals interested to establish a sarcoidosis clinic

Objectives
At the conclusion of this session, the participant will be able to:

• understand the changing epidemiology of sarcoidosis and current concepts in the pathogenesis of sarcoidosis;
• diagnose patients with sarcoidosis and identify specific organ involvement, incorporating newer tools;
• provide improved care to patients with sarcoidosis through comprehensive management strategies and an understanding of current and novel therapeutic strategies.

This is an overview of the most recent advances in the diagnosis and management of the whole patient for sarcoidosis. It would be of particular interest to individuals who are establishing a multidisciplinary sarcoidosis clinic, or as a refresher to those trained in some aspects of sarcoidosis. Two panel-based, case-based discussions will summarize and incorporate the decision-making and choices of treating patients with sarcoidosis, with practical information about difficult diagnosis, mimickers, initiating therapy, stopping therapy, how to manage toxicities, how to combine medications, and assessment of other problems like pulmonary hypertension. It is meant to tie together the concepts from the prior speakers.

Chairing:
D.A. Culver, DO, Cleveland, OH
M. Drent, MD, Nieuwegein, Netherlands

8:00  Advances in Untangling the Pathobiology of Sarcoidosis
D.R. Moller, MD, Baltimore, MD

8:30  Evolution of Bronchoscopy for the Diagnosis of Sarcoidosis
R. Trisolini, MD, Bolgna, Italy

8:55  Pitfalls, Challenges, and New Modalities for Diagnosis of Sarcoidosis
L.A. Maier, MD, MSPH, Denver, CO

9:20  Changing Epidemiology of Sarcoidosis
Y. Cozier, DSc, MPH, Boston, MA

9:40  Break

10:00  Assessing Sarcoidosis
J.C. Grutters, MD, PhD, Nieuwegein, Netherlands

10:25  Consequences of Sarcoidosis
M. Drent, MD, Nieuwegein, Netherlands

10:50  Natural History, Prognosis and the Decision to Treat
A.U. Wells, MD, London, United Kingdom

11:15  Case-Based Panel Discussion: Challenging Diagnostic Situations
D.A. Culver, DO, Cleveland, OH
J.P. Kanne, MD, Madison, WI
C. Farver, MD, Cleveland, OH
M.A. Judson, MD, Albany, NY
L.A. Maier, MD, MSPH, Denver, CO
R. Trisolini, MD, Bolgna, Italy

12:00  LUNCH

12:50  Treatment Options from Steroids to the Newest Agents
R.P. Baughman, MD, Cincinnati, OH

1:20  Practical Use of Immunosuppressants
D.A. Culver, DO, Cleveland, OH

1:40  Identifying Health Disparities & How to Adjust Your Management Style to Fit Your Patient
M.A. Judson, MD, Albany, NY

2:00  How to Set up A Successful Sarcoidosis Clinic
L. O’Hare, CRNP, Birmingham, AL

2:20  Break

2:40  Critical Organ Involvement
K.C. Patterson, MD, Philadelphia, PA

3:00  Diagnosis and Management of Other Organ Involvement
W.E. James, MD, Charleston, SC

3:20  Panel Discussion: Challenging Treatment Situations
R.P. Baughman, MD, Cincinnati, OH
J.C. Grutters, MD, PhD, Nieuwegein, Netherlands
A.U. Wells, MD, London, United Kingdom

This session and the International Conference are supported by an educational grant from Mallinckrodt Pharmaceuticals.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
Target Audience
Pulmonologists, critical care physicians, thoracic surgeons, mid-level providers, respiratory therapists, residents, fellows, and students

Objectives
At the conclusion of this session, the participant will be able to:

- formulate a differential diagnosis of respiratory diseases based on diagnostic imaging findings;
- improve strategies for the evaluation of solitary pulmonary nodules and for staging lung cancer;
- state the value of a multidisciplinary approach to diagnosis and management of patients with diffuse lung disease.

This course will review major aspects of thoracic imaging with presentations targeted toward the pulmonologist and critical care physician using a case-based approach and audience participation. Subspecialized thoracic radiologists will give case-based presentations focusing on the practical aspects of chest imaging. Presentations will be image rich and focus on key imaging findings, differential diagnoses, and potential pitfalls. Topics will cover a broad range of chest disease and will be relevant to trainees, generalists, and specialists, alike. At the conclusion of the course, learners will have increased knowledge about thoracic imaging and be able to apply this knowledge to their respective practices.

Chairing:
J.P. Kanne, MD, Madison, WI
C.C. Wu, MD, Houston, TX

8:00 Imaging Diseases of the Small Airways
T.S. Henry, MD, San Francisco, CA

8:30 Imaging Diseases of the Large Airways
S. Rossi, MD, Buenos Aires, Argentina

9:00 Imaging of Pulmonary Vascular Diseases
J.P. Kanne, MD, Madison, WI

9:30 Critical Care Thoracic Imaging
C. Schaefer-Prokop, MD, Nijmegen, Netherlands

10:00 Break

10:15 Imaging of Pleural Diseases
C.C. Wu, MD, Houston, TX

10:45 Imaging of the Solitary Pulmonary Nodule
J.H. Chung, MD, Chicago, IL

11:15 Lung Cancer Imaging
A. Leung, MD, Stanford, CA

11:45 LUNCH

12:45 Imaging of Pulmonary Infections
L. Ketai, MD, Albuquerque, NM

1:15 HRCT of Diffuse Lung Disease
D.A. Lynch, MD, Denver, CO

1:45 Break

2:00 Multidisciplinary Approach to Diffuse Lung Diseases
K.K. Brown, MD, Denver, CO
D.A. Lynch, MD, Denver, CO
S. Groshong, MD, Denver, CO

The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.
10:00 Recruitment and Retention of Minority Populations
M.N. Eakin, PhD, Baltimore, MD

10:45 Respiratory Inhaler Device Technique
N.E. Bracken, MSN, ACNP-BC, Chicago, IL

11:30 Methacholine Challenge
S. Nyenhuis, MD, Chicago, IL

12:15 LUNCH

12:45 General Discussion
Speaker To Be Announced

1:20 CPAP/BiPAP
D. Hart, MSN, Auckland, New Zealand

2:05 Regulatory Management
M. Carno, PhD, MBA, MJ, CHRC, RN, Rochester, NY

2:50 Break

3:05 Impulse Oscillometry
C. Dumonceaux, BSc, RRT, RCPT(P), CCRP, Calgary, Canada

3:50 Wrap Up and Closing Remarks
K.O. Lindell, PhD, RN, Pittsburgh, PA

This course will aid pediatric pulmonologists and care coordinators to develop multidisciplinary programs for children with complex chronic conditions affecting lung health. An integrated team approach to coordinated evaluation and management of children with complex diseases affecting airways and breathing, feeding and swallowing, and development, will be presented. This will focus on the rationale and quality imperative for such programs and strategies to work within and across institutions for program development, expanding provider practices into newer roles and the identification and measurement of outcomes.

Chairing: R.P. Boesch, DO, Rochester, MN
M. Kazachkov, MD, New York, NY

8:00 The Past, Present, and Future of Pediatric Aerodigestive Programs
R.E. Wood, PhD, MD, Cincinnati, OH

8:25 Organization and Knowledge Generation, What Aerodigestive Can Learn from chILD
R.R. Deterding, MD, Aurora, CO

8:50 Building an Aerodigestive Program in Your Hospital
J. Erkman, MSN, CPNP, New York, NY
C. Miller, PhD, MHA, Cincinnati, OH

9:15 Untangling Airway, Lung, Maturational, and GI Disease in the Premature Infant
E.B. Hysinger, MD, Cincinnati, OH

9:40 Aerodigestive Approach to Children with Trisomy 21
E. DeBoer, MD, Aurora, CO

10:00 Break

10:10 Aerodigestive Approach to Tracheoesophageal Fistula and Esophageal Atresia
E. Eber, MD, Graz, Austria

10:30 Is Severe Asthma an Aerodigestive Problem?
M. Kazachkov, MD, New York, NY

10:50 Indications and Methods for Interventional Pulmonology in Complex Pediatric Patients
R.M. Kern, MD, Rochester, MN

11:15 Why Should Pediatricians Do Interventional Pulmonology?
R.P. Boesch, DO, Rochester, MN

11:35 LUNCH

12:20 The Role of the Anesthesia Provider in Aerodigestive Programs
M. Brooks Peterson, MD, Aurora, CO

12:45 The Pulmonologist's Role in Optimization for Airway Surgery and Decannulation
J. Piccione, DO, MS, Philadelphia, PA

1:10 The Multi-Disciplinary Approach to Aspiration
C. Daines, MD, Tucson, AZ

1:35 Feeding Disorders and Swallowing Dysfunction in the Aerodigestive Patient
C. Miller, PhD, Cincinnati, OH

2:00 Break

2:10 Airway and GI Microbiomes. Pure Science or Clinical Application?
M. Kazachkov, MD, New York, NY

2:35 Pediatric Motility Disorders
R. Rosen, MD, Boston, MA

---

PG18 AERODIGESTIVE APPROACH TO COMPLEX CHRONIC PEDIATRIC DISEASES

Target Audience
Pediatric pulmonologists, gastroenterologists, surgeons, fellows, nurses, speech therapists, and health care practitioners providing care coordination to children with chronic multi-system diseases. Faculty representative of major aerodigestive programs, U.S. and international, with gender and discipline diversity and a mix of junior aerodigestive providers and senior program, clinical, and research leaders

Objectives
At the conclusion of this session, the participant will be able to:

• apply successful strategies to develop multi-disciplinary pediatric programs;
• measure relevant outcomes to pediatric populations with complex chronic diseases;
• gain new strategies and methods for pediatric pulmonologists to diagnose and manage complex airway disease.
3:00 Aerodigestive Case Presentations
R.R. Deterding, MD, Aurora, CO
R. Rosen, MD, Boston, MA
C. Miller, PhD, Cincinnati, OH
J. Piccione, DO, MS, Philadelphia, PA

3:45 Where We Are Headed: Maturation of Pediatric Aerodigestive as a Defined Model of Care
R.P. Boesch, DO, Rochester, MN

PG19 CRITICAL CARE OF THE PATIENT WITH PULMONARY VASCULAR DISEASE

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350  In-Training Member: $200
Non-Member: $425  In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Pulmonary Circulation; Critical Care
8:00 a.m. - 4:00 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 202 A (South Building, Level 2)

Target Audience
Pulmonary and cardiology faculty, intensivists of all backgrounds, trainees, allied health professionals

Objectives
At the conclusion of this session, the participant will be able to:
• understand etiology and pathophysiology of RV failure in critically ill patients;
• identify strategies for the diagnosis and treatment of pulmonary vascular disease in critically ill patients;
• interpret common pulmonary artery catheter waveform patterns and learn about the basics of RV echocardiography in critically ill patients with pulmonary vascular disease.

This comprehensive course will provide the learner with a strategy to care for critically ill patients with various diseases of the pulmonary vasculature and right ventricle. Presenters will provide a framework for understanding pathophysiology, hemodynamics, and specific high-risk scenarios using state of the art evidence and clinical expertise. Common pitfalls and knowledge gaps in caring for patients with pulmonary vascular and right heart failure will be addressed. By the session’s conclusion, learners should have a refined approach for the management of these challenging patients.

Chairing:
C.E. Ventetuolo, MD, MS, Providence, RI
T.M. Bull, MD, Aurora, CO
T. Lahm, MD, Indianapolis, IN

8:00 Mechanisms of RV Failure in Critical Illness
R. Naeije, MD, PhD, Brussels, Belgium

8:30 The PA Catheter in Critically Ill Patients with Pulmonary Vascular Disease: The Nuts and Bolts of PAC Waveform Analysis
J.B. Hall, MD, Chicago, IL

9:30 Echo in the ICU: How Can It Help in the Critically Ill Pulmonary Vascular Disease Patient?
A. Viegillard-Baron, MD, PhD, Paris, France

10:00 Break
Management of PAH in ICU

10:45 Supportive Care: Volume, Arrhythmias, Mechanical Ventilation
T. Lahm, MD, Indianapolis, IN

11:15 Pulmonary Vascular Disease in Pregnancy: PH, PAH and Embolism Syndromes
A.R. Hennes, MD, Nashville, TN

11:45 Pulmonary Vasculitis Crises in the ICU
U. Specks, MD, Rochester, MN

12:15 LUNCH

1:15 Post-Cardiotomy RV Dysfunction
J.L. Diaz-Gomez, MD, Jacksonville, FL

1:45 Catheter-Based Therapy and PERT for VTE: Yay or Nay
J.A. Kline, MD, Indianapolis, IN

2:00 Rebuttal
T.M. Bull, MD, Aurora, CO

2:45 Rebuttal
T.M. Bull, MD, Aurora, CO

3:00 Reperfusion Injury and Post-Endarterectomy Care in CTEPH
W. Auger, MD, San Diego, CA

3:30 Mechanical Circulatory Support for the RV
M.M. Hoeper, MD, Hannover, Germany

PG20 THE HALLMARKS OF AGING IN THE LUNG

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350  In-Training Member: $200
Non-Member: $425  In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Respiratory Cell and Molecular Biology; Allergy, Immunology and Inflammation
8:00 a.m. - 4:00 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 152 B (Middle Building, Street Level)

Target Audience
Basic and clinical researchers interested in learning about the hallmarks of the aging lung and new methods of studying lung aging
Objectives
At the conclusion of this session, the participant will be able to:

• recognize the hallmarks of aging in the lung;

• understand and learn the new systems biology approaches to study the aging lung;

• learn about the new tools and techniques for assessment of the aging in the lung.

Aging is one the crucial factors contributing to lung diseases, however, mechanisms of normal aging are not well understood. Moreover, there is no clear consensus about the hallmarks of normal aging in the lung, both in clinical settings and in research. This session will assemble a group of experts with the capacity to comprehensively review the state of the art in aging research. Specifically, lectures will focus on practically oriented, measurable hallmarks of aging which can be used in clinical and basic research.

Chairing: P.J. Lee, MD, New Haven, CT
M. Rojas, MD, Pittsburgh, PA
A.V. Misharin, MD, PhD, Chicago, IL

8:00 General Welcome and Overview of the Hallmarks of Aging in the Lung
P.J. Lee, MD, New Haven, CT

8:15 NIH NIA Programmatic Perspective on Aging-Related Research
R. Kohanski, PhD, Bethesda, MD

8:50 Lung Endothelium in Aging and Age-Related Lung Disease
P.J. Lee, MD, New Haven, CT

9:25 Immune Landscape in the Aging Lung
A.V. Misharin, MD, PhD, Chicago, IL

10:00 Break

10:10 Extracellular Matrix and the Aging Lung
V.J. Thannickal, MD, Birmingham, AL

10:45 Proteostasis and Aging
W. Balch, PhD, La Jolla, CA

11:20 Cellular Senescence
I. Rahman, PhD, Rochester, NY

11:55 LUNCH

12:35 Mitochondrial Dysfunction and Aging
G.S. Budinger, MD, Chicago, IL

1:10 The Long and Short of Telomeres and Telomerase in Lung Disease
M. Armanios, MD, Baltimore, MD

1:45 Break

1:55 Influenza Virus Infection of the Stem Cell Niche - Implications for Lung Regeneration
S. Herold, MD, PhD, Giessen, Germany

2:30 Age-Related Changes in Lung Mesenchymal Cells
M. Rojas, MD, Pittsburgh, PA

3:05 Age-Related Changes in Ubiquitin-Proteosome System
S. Meiners, PhD, Munich, Germany

3:40 Closing Remarks and Open Discussion
M. Rojas, MD, Pittsburgh, PA

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350 In-Training Member: $200
Non-Member: $425 In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Respiratory Structure and Function; Clinical Problems
8:00 a.m. - 4:00 p.m. WALTER E. WASHINGTON CONVENTION CENTER Room 207 B (South Building, Level 2)

Target Audience
Current and future directors of PFT labs, attending physicians, respiratory therapists, trainees, fellows, and other interested health care providers

Objectives
At the conclusion of this session, the participant will be able to:

• gain further understanding of the principles and practice of pulmonary function and exercise physiology diagnostic tests;

• develop greater confidence interpreting pulmonary function and cardiopulmonary exercise test results in clinical practice;

• identify strategies to approach the interpretation of pulmonary function and cardiopulmonary exercise test results in complex patients.

This course will focus on the approach to interpreting pulmonary function and cardiopulmonary exercise tests, moving from the basic physiologic underpinnings to implementation in clinical practice. We will combine didactic lectures with case-based instruction in small group settings, and we will offer participants the opportunity to bring their own complex cases for review by an expert team of clinicians and physiologists. Small group discussion will include pulmonary function and exercise tests, and we will use a team approach to facilitating the group discussions including content experts and pulmonary function laboratory medical directors from around the world.

Chairing: C.E. Berry, MD, Tucson, AZ
M.C. McCormack, MD, MHS, Baltimore, MD
D.A. Kaminsky, MD, Burlington, VT

8:00 Introduction to Pulmonary Function and Cardiopulmonary Exercise Testing: From Physiology to Practice
C.E. Berry, MD, Tucson, AZ

8:15 Take a Deep Breath: Expert Approach to Spirometry Interpretation and Reference Equations
B.H. Culver, MD, Seattle, WA

8:45 Sizing Things Up: Lung Volume Measurement and Interpretation
B. Borg, BAppSc, CRFS, Prahran, Australia

9:15 Confusion with Diffusion: Understanding Diffusing Capacity and KCO
C.E. Berry, MD, Tucson, AZ
9:45 What About the Kids? Special Considerations for Pediatric Pulmonary Function Measurement and Interpretation
D. Weiner, MD, Pittsburgh, PA

10:15 Easing Your Frustration with Bronchoprovocation: Rethinking the Approach to Challenge Testing and Interpretation
T.S. Hallstrand, MD, MPH, Seattle, WA

10:45 Break

11:00 Make the Case: Pulmonary Function Testing
M.C. McCormack, MD, MHS, Baltimore, MD
M. Rosenfeld, MD, MPH, Seattle, WA

12:00 LUNCH

C.D. Mottram, RRT, RPFT, Rochester, MN

1:00 Data Overload: Understanding the Physiology and Evaluating the Data in Cardiopulmonary Exercise Testing
C.G. Irvin, PhD, Burlington, VT

1:30 Abnormal Responses to Exercise: What Happens in Patients with Cardiopulmonary Disease?
D.A. Kaminsky, MD, Burlington, VT

2:15 Break

2:30 Make the Case: Cardiopulmonary Exercise Testing
C.E. Berry, MD, Tucson, AZ
R. Casaburi, MD, PhD, Torrance, CA
N. Maclntyre, MD, Durham, NC

• complete the 2016 ABIM Pulmonary and Critical Care SEP module.

Led by expert faculty, this active learning session is a clinical practice and literature review designed around the most recent ABIM Self-Evaluation Process modules in pulmonary and critical care medicine. Using the ABIM-SEP questions with an audience response system as a launching point, faculty will lead a brief didactic review followed by an engaging discussion of knowledge gaps, controversy, and practice variation. In addition to a valuable review of high-impact medical knowledge and critical thinking, this session will provide a convenient opportunity to fulfill ABIM maintenance of certification requirements while at the ATS international conference.

Chaising: J.T. Poston, MD, Chicago, IL

8:00 Introduction
J.T. Poston, MD, Chicago, IL

8:10 Pulmonary Part 1
J.T. Poston, MD, Chicago, IL

9:50 Break

10:00 Pulmonary Part 2
B. Coruh, MD, Seattle, WA

11:40 LUNCH

12:30 Critical Care Part 1
J.B. Hall, MD, Chicago, IL

2:10 Break

2:20 Critical Care Part 2
P.A. Kritek, MD, Seattle, WA

PG22 PULMONARY AND CRITICAL CARE REVIEWS: BUILT AROUND THE 2016 ABIM-SEP MODULES

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350
Non-Member: $425
In-Training Member: $200
In-Training Non-Member: $300
Registrants must bring a laptop to the course to view the course material.

Education Committee

8:00 a.m. - 4:00 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Room 207 A (South Building, Level 2)

Target Audience
Clinicians practicing pulmonary and/or critical care medicine; clinicians seeking ABIM MOC credit

Objectives
At the conclusion of this session, the participant will be able to:
• critically review and interpret recent literature in pulmonary and critical care medicine;
• apply recent literature in pulmonary and critical care medicine to clinical practice;
4:30 p.m. - 5:30 p.m.

OPENING CEREMONY
WALTER E. WASHINGTON CONVENTION CENTER
Hall E (Middle Building, Level 2)

The American Thoracic Society invites you to attend the Opening Ceremony for the 2017 International Conference. The keynote speaker is Nobel Laureate James Heckman, PhD, MA, from the Center for the Economics of Human Development at the University of Chicago. Professor Heckman has devoted his professional life to understanding the origins of major social and economic problems related to inequality, social mobility, discrimination, skill formation and regulation, and to devising and evaluating alternative strategies for addressing those problems.

Also during the Opening Ceremony will be an address by ATS President David Gozal, MD, MBA and the presentation of several Respiratory Health Awards.

The following awards will be presented:
Public Service Award: Michelle M. Cloutier, MD, Hartford, CT
World Lung Health Award: Surendra K. Sharma, MBBS, MD, PhD, New Delhi, India
Jo Rae Wright Award for Outstanding Science: Hallie C. Prescott, MD, MSc, Ann Arbor, MI

5:30 p.m. - 6:30 p.m.

THE NETWORKING EXCHANGE
FOR EARLY CAREER PROFESSIONALS
MARRIOTT MARQUIS WASHINGTON
University of DC/Catholic University (Level M1)

The Networking Exchange for Early Career Professionals is an annual networking event for early career professionals and first time conference attendees. This one hour event is intended to provide a relaxed atmosphere where attendees can network with peers, ATS leaders, program directors, associate program directors and division directors, as well as other prominent thought leaders. Cocktails and appetizers will be provided.

The Membership Committee, Training Committee, and the Members in Transition and Training Committee (MITT) jointly host the Networking Exchange for Early Career Professionals.

Conference badges are required for admission.
Space is limited. There is no additional fee.
The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.
A1  CLINICAL YEAR IN REVIEW 1  
9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER 
Hall E (Middle Building, Level 2) 

Target Audience 
Providers including physicians; registered nurses; advanced practice nurses; respiratory therapists; physician assistants; trainees including residents and fellows; and clinical researchers.

Objectives 
At the conclusion of the session, the participant will be able to:

1. Apply new clinical research knowledge to clinical practice;
2. Describe new strategies for managing the care of common conditions in pulmonary, critical care, and sleep;
3. Apply new findings regarding key conditions in pulmonary, critical care, and sleep.

The annual Clinical Year in Review symposia topics are reviews of key clinical research publications over the last year. Each speaker is asked to review the 5-7 most important and influential publications on their topic in the prior year.

Chairing: D.J. Lederer, MD, MS, New York, NY  
D.W. Ford, MD, MSCR, Charleston, SC  
V.E. Ortega, MD, PhD, Winston-Salem, NC

9:15  New Tools to Support Acute Respiratory Failure  
D. Brodie, MD, New York, NY

9:45  General Critical Care  
D.W. Ford, MD, MSCR, Charleston, SC

10:15  The Brain and Critical Care  
T.P. Bleck, MD, MCCM, Chicago, IL

10:45  Sleep Disordered Breathing  
S.S. Redline, MD, MPH, Boston, MA

A2  JAMA AND THE NEW ENGLAND JOURNAL OF MEDICINE. DISCUSSION ON THE EDGE: REPORTS OF RECENTLY PUBLISHED PULMONARY RESEARCH  
9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER 
Room 207 A-B (South Building, Level 2) 

Chairing: G.T. O’Connor, MD, MS, Associate Editor, JAMA  
J.M. Drazen, MD, Editor-in-Chief, New England Journal of Medicine

Speakers And Talks To Be Announced

A3  FELLOWS CASE CONFERENCE  
9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER 
Ballroom C (South Building, Level 3)

Target Audience 
Clinicians, nurses, fellows, residents, and researchers looking to broaden their clinical acumen to facilitate clinical and translational research.

Objectives 
At the conclusion of this session, the participant will be able to:

1. Recognize clinical, radiographic, and pathologic findings of rare diseases or unusual presentations of common diseases;
2. Gain insight into clinical decision-making skills which will improve the quality of learners’ practice and potentially improve quality of care for the learner’s patients;
3. Develop strategies to evaluate patients with common symptoms that include uncommon/rare diseases in the differential diagnosis when appropriate.

This session will consist of unique cases presented and discussed by fellows with a panel of clinical experts to moderate the discussion and provide commentary. The cases will provide new insights into disease pathogenesis, diagnosis, and/or treatment. Selected cases will include clear clinical teaching points with review of associated pathology and radiology as appropriate. Finally, the discussion will highlight medical decision making important for both physicians-in-training and seasoned clinicians.

Chairing: L.E. Crotty Alexander, MD, San Diego, CA

9:15  Welcome and Introduction  
L.E. Crotty Alexander, MD, San Diego, CA  
K. Burkart, MD, MSc, New York, NY

9:20  Case Presentations  
The Mystery Lungs: Is Smoking or Asthma the Cause?  
A.A. Alsaad, MD, Jacksonville, FL  
Climbing High: A Rare Complication of High Altitude Pulmonary Edema  
N. Mansouri, MD, Boston, MA
**A4 DETERMINANTS OF LONG-TERM OUTCOMES AMONG CRITICALLY ILL OLDER ADULTS: FROM CELL TO POPULATION**

**Assembly on Critical Care**

9:15 a.m. - 11:15 a.m.  WALTER E. WASHINGTON CONVENTION CENTER

**Room 146 A-B (Middle Building, Street Level)**

**Target Audience**
Clinical and translational scientists who study the basic and clinical aspects of critical illness; nurses, physicians, pharmacists, therapists and social workers who provide care in the intensive care unit (ICU), inpatient providers caring for patients transferred from the ICU, and outpatient providers who care for ICU survivors

**Objectives**
At the conclusion of this session, the participant will be able to:

- identify important risk factors that increase vulnerability in older adults, such as frailty, disability, and aging biology and understand the effects of these risk factors on long-term outcomes for older survivors of critical illness;
- gain an understanding of the role of longitudinal studies of aging in advancing the science of critical care outcomes research and how these studies have improved our understanding of prognosis in a way that can be applied at the bedside, and ways that longitudinal functional information can be added into future studies;
- facilitate the integration of geriatrics and critical care research to improve the care of older adults with critical illness by identifying funding opportunities for aging-related critical care research from the National Institute of Aging;

Older adults comprise the majority of patients admitted to ICUs each year. The aging population and improved survival from critical illness is expected to drive a significant increase in the number of older ICU survivors with life-altering physical and cognitive impairments. This session will explore age-related biological processes and clinical factors that affect long-term outcomes from a clinical and translational science perspective, including ways to enhance care for critically ill older adults. Finally, this session will explore the role of aging-related research in understanding outcomes after critical illness and introduce attendees to research programs from the National Institute on Aging.

**Chairing:** L. Ferrante, MD, New Haven, CT
N.E. Brummel, MD, Nashville, TN
W.J. Ehlenbach, MD, Madison, WI

**9:15 Aging Biology and Critical Illness: Bidirectional Mechanistic Insights**
D.C. Files, MD, Winston-Salem, NC

**9:35 Phenotypic, Deficit Accumulation, and Social Perspectives of Frailty in Older Adults with Critical Illness**
N.E. Brummel, MD, Nashville, TN

**9:55 The Importance of Pre-ICU Factors on Long-Term Outcomes Among Critically Ill Older Adults**
L. Ferrante, MD, New Haven, CT

**10:15 Personalizing ICU Care for Older Adults: Applying Outcomes Research to Older Adults with Critical Illness**
W.J. Ehlenbach, MD, Madison, WI

**10:35 Finding Hidden Data About Pre-ICU Functioning to Understand the Long Arc of Your Patient’s Life**
T.J. Iwashyna, MD, PhD, Ann Arbor, MI

**10:55 Meet the NIA: Research Opportunities at the Nexus of Aging and Critical Illness**
S. Zieman, MD, PhD, Bethesda, MD
At the conclusion of this session, the participant will be able to:

- learn new findings about the contribution of paternal epigenetics for disease programming for chronic disease.

The developmental origins of health and disease theory is based on evidence that a suboptimal environment during fetal and neonatal development can impact the evolution of adult-onset disease. A compromised prenatal (and early postnatal) environment leads to increased risk of a number of chronic diseases. DOHaD research is only just emerging as a significant force with respect to lung health and disease. This session will highlight fundamental elements of the DOHaD theory, leveraging examples of significant advances in other disease areas, as well as presenting current significant advances being made with respect to an array of lung disorders.

**Chairing:** A.J. Halayko, PhD, Winnipeg, Canada
M. Konigshoff, MD, PhD, Aurora, CO

**9:15**  
**DOHaD Theory: How In Utero Mechanisms Identify Therapeutic Targets for Hypertension**  
S.T. Davidge, PhD, Edmonton, Canada

**9:41**  
**The Airway Microbiome at Birth: Setting the Stage for Subsequent Lung Disease**  
C.V. Lal, MD, Birmingham, AL

**10:04**  
**Environmental Shaping of the Innate Immune Response: Mechanisms for Asthma Protection in Kids**  
A.I. Sperling, PhD, Chicago, IL

**10:27**  
**Pulmonary Effects of Maternal Smoking or Vaping During Pregnancy on Lung Development, Epigenetics, and Life Long Lung Health**  
E.R. Spindel, MD, PhD, Beaverton, OR

**10:50**  
**Sex-Specificity in Transgenerational Inheritance: Noncoding RNAs, Environmental Epigenetics and Disease**  
W. Yan, MD, PhD, Reno, NV

---

**A6 BARBARIANS AT THE GATE: VIRUSES AND THE AIRWAY EPITHELIUM IN ASTHMA**

**Assemblies on Allergy, Immunology and Inflammation; Environmental, Occupational and Population Health; Pediatrics; Respiratory Cell and Molecular Biology**

**9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER**

**Ballroom A (South Building, Level 3)**

**Target Audience**
Lung health providers, trainees, and those involved in research or clinical care related to asthma and lung infections. This topic is expected to appeal to both scientists and clinicians.

**Objectives**
At the conclusion of this session, the participant will be able to:

- understand and describe new advances in the molecular understanding of common childhood respiratory viruses;
- describe the role of the airway epithelium in mediating host-environment interactions.

Viral respiratory infections are the most common causes of wheezing in infants and young children and are associated with an increased risk of developing childhood asthma. In addition, viral respiratory infections are common triggers of asthma exacerbations in adult and pediatric patients with pre-existing asthma. The mechanisms by which viral respiratory infections increase future risk of asthma and cause asthma exacerbations are uncertain. Investigators in the NIAID-funded Asthma and Allergic Disease Cooperative Research Center (AADCRC) shed light on these mechanisms through basic, translational and clinical investigation. These studies have yielded new insights into the central role of viral infection in the pathogenesis of asthma and the role that the airway epithelium plays in mediating host-virus interactions. This symposium will present these new discoveries and place them in the context of human disease.

**Chairing:** P.G. Woodruff, MD, MPH, San Francisco, CA
D. Byers, MD, PhD, St. Louis, MO
R.S. Peebles, MD, Nashville, TN

**9:15**  
**Epithelial Barrier Programs in Asthma and Allergic Disease**  
M.J. Holtzman, MD, St. Louis, MO

**9:35**  
**Host and Viral Determinants of Infant and Childhood Allergy and Asthma**  
T. Hartert, MD, MPH, Nashville, TN

**9:55**  
**Mechanisms and Environmental Determinants of Rhinovirus Illness Severity**  
J.E. Gern, MD, Madison, WI

**10:15**  
**Epithelial Determinants of Childhood Asthma**  
G.K. Hershey, MD, PhD, Cincinnati, OH

**10:35**  
**Epithelial Control of Responses to Allergen Challenge and Viral Exacerbation**  
S.F. Ziegler, PhD, Seattle, WA

---

These sessions and the International Conference are supported by an educational grant from **Teva Pharmaceuticals**. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
of pulmonary rehabilitation services, clinical researchers, and physicians in training.

**Objectives**
At the conclusion of this session, the participant will be able to:

- identify five areas of controversy in the field of pulmonary rehabilitation medicine;
- describe how the latest advances in pulmonary rehabilitation can modify and optimize existing practices in the care of patients with chronic pulmonary disease;
- apply a balanced and evidence-based view to current controversies in pulmonary rehabilitation medicine.

There are ongoing controversial issues in pulmonary rehabilitation medicine that significantly impact the overall approach to the care of patients with chronic pulmonary disease. This symposium will explore these knowledge gaps through the vehicle of the pro/con debate. The specific topics will be debated by an international faculty of experts who will provide balanced and evidence-based information regarding these controversial areas to guide and improve current clinical practice.

**Chairing:** M.L. Moy, MD, MSc, Boston, MA
W. Man, MD, PhD, Harefield, United Kingdom

9:15 **PRO:** We Can Increase Access to Pulmonary Rehabilitation
C.L. Rochester, MD, New Haven, CT

9:25 **CON:** We Cannot Increase Access to Pulmonary Rehabilitation
C.M. Garvey, FNP, MSN, MPH, San Francisco, CA

9:39 **PRO:** A Mortality Study is Needed to Prove Efficacy of Pulmonary Rehabilitation
R. Casaburi, MD, PhD, Torrance, CA

9:49 **CON:** A Mortality Study is Not Needed to Prove Efficacy of Pulmonary Rehabilitation
B.R. Celli, MD, Boston, MA

10:03 **PRO:** “Add-Ons” Should Be Used in Conventional Pulmonary Rehabilitation
S.P. Bhatt, MD, Birmingham, AL

10:13 **CON:** “Add-Ons” Should Not Be Used in Conventional Pulmonary Rehabilitation
H. Demeyer, PhD, Leuven, Belgium

10:27 **PRO:** Pulmonary Rehabilitation Should Be Delivered at Home
A.E. Holland, PhD, Melbourne, Australia

10:37 **CON:** Pulmonary Rehabilitation Should Not Be Delivered at Home
J. Bourbeau, MD, Montreal, Canada

10:51 **PRO:** Directly Measured Physical Activity Should Be Routinely Assessed in Clinical Care
T. Troosters, PhD, Leuven, Belgium

11:01 **CON:** Directly Measured Physical Activity Should Not Be Routinely Assessed in Clinical Care
H.Q. Nguyen, PhD, RN, Pasadena, CA

There will be a 5-minute discussion after each talk.

**A8**

**A PRO/CON DEBATE: CONTROVERSIES IN PAH PATHOGENESIS**

**Assembly on Pulmonary Circulation**
9:15 a.m. - 11:15 a.m.  MARRIOTT MARQUIS WASHINGTON Liberty Ballroom I-L (Level M4)

**Target Audience**
Basic, translational and clinical researchers and clinicians with an interest in pulmonary arterial hypertension

**Objectives**
At the conclusion of this session, the participant will be able to:

- summarize the evidence why the immune system plays a role in the etiology of pulmonary arterial hypertension;
- learn about the opposing processes of endothelial cell apoptosis and proliferation that both play a role in the pathogenesis of PAH and probably even at the same time;
- critically weigh the role of shear stress and dysfunctional BMPR2 signaling in the development of PAH.

This session will focus on controversies in the understanding of the pathogenesis of pulmonary arterial hypertension (PAH). By employing a pro/con debate style, this session will critically evaluate opposing views of how pulmonary hypertension develops, identify points of agreement and disagreement with the ultimate goal to reach a consensus to identify novel treatment targets for PAH.

**Chairing:** E.F. Spiekerkoetter, MD, Palo Alto, CA
W.M. Kuebler, MD, PhD, Toronto, Canada

9:15 **Pulmonary Arterial Hypertension Is an Autoimmune Disease**
M. Nicolls, MD, Stanford, CA

9:25 **Pulmonary Arterial Hypertension Is NOT an Autoimmune Disease**
A. Olschewski, MD, Graz, Austria

9:35 **Rebuttal**

9:40 **Rebuttal**

9:45 **Hemodynamic Stress Is the Most Important Driver in the Pathogenesis of Occlusive Neointimal Lesions in PAH**
K. Abe, MD, PhD, Fukuoka, Japan

9:55 **Hemodynamic Stress Is NOT the Most Important Driver in the Pathogenesis of Occlusive Neointimal Lesions in PAH**
M. Rabinovitch, MD, Stanford, CA

9:55 **Rebuttal**

10:05 **Rebuttal**

10:10 **Rebuttal**

10:15 **Pulmonary Hypertension Is a Disease of Endothelial Cell Apoptosis NOT Proliferation**
D. Stewart, MD, Ottawa, Canada
10:25 Pulmonary Hypertension Is a Disease of Proliferation and NOT Endothelial Cell Apoptosis
S.Y. Chan, MD, PhD, Pittsburgh, PA

10:35 Rebuttal

10:40 Rebuttal

10:45 BMPR2 Signaling Is the Central Therapeutic Target in PAH
N. Morrell, MD, Cambridge, United Kingdom

10:55 BMPR2 Signaling Is NOT the Central Therapeutic Target in PAH
S. Archer, MD, Kingston, Canada

11:05 Rebuttal

11:10 Rebuttal

This session and the International Conference are supported by an educational grant from Actelion Pharmaceuticals US, Inc. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

BASIC • CLINICAL • TRANSLATIONAL

A9 IN MEMORY OF PETER T. MACKLEM: EMERGENT PHENOMENA AND HETEROGENEITY IN RESPIRATORY DISEASE

Assemblies on Respiratory Structure and Function; Allergy, Immunology and Inflammation; Pulmonary Circulation; Respiratory Cell and Molecular Biology; Sleep and Respiratory Neurobiology

9:15 a.m. - 11:15 a.m. MARRIOTT MARQUIS WASHINGTON
Marquis Ballroom 5 (Level M2)

Target Audience
Those with an interest in complex phenomena in the lung originating from interactions among the elements of a system or organ such as the cells of the epithelial cell layer, airways within the bronchial tree in asthma, and blood vessels in the vascular tree in pulmonary hypertension

Objectives
At the conclusion of this session, the participant will be able to:

• gain knowledge on how emergent behavior can explain phenomena of lung diseases such as ventilation defects during bronchoconstriction, and how it might be indicative of idiopathic pulmonary hypertension;
• identify emergent phenomena in lung physiology and lung disease for further investigation or the development of novel treatment approaches.

Lung environment interactions have the potential to trigger seemingly small changes in the lung, which may have much greater impact on the lung through Emergent Phenomena. Expanding on Peter Macklem’s article “Emergent phenomena and the secrets of life” (J. Appl. Physiol., 104: 1844-1846, 2008), the session will review key concepts of emergent behavior where the spontaneous development of self-organized order among ensembles occurs, resulting in patterns that can be neither predicted nor explained by examining the isolated components. The session will explore the role of emergent phenomena in health and disease processes such as asthma, breathing during sleep, and pulmonary arterial hypertension.

Chairing: G.K. Prisk, DSc, PhD, La Jolla, CA
T. Winkler, PhD, Boston, MA
J.P. Butler, PhD, Boston, MA

9:15 Cell Migration and Long Range Correlations
J.J. Fredberg, PhD, Boston, MA

9:35 Emergent Oscillatory Behavior in Breathing
J.P. Butler, PhD, Boston, MA

9:55 Airway Instability and Runaway Bronchoconstriction
T. Winkler, PhD, Boston, MA

10:15 The Mechanical Consequences of Emergent Behavior in the Lung
J.H.T. Bates, DSc, PhD, Burlington, VT

10:35 Nonlinear Dynamics and Pulmonary Arterial Hypertension
S.R. Hopkins, MD, PhD, La Jolla, CA

10:55 General Discussion
G.K. Prisk, DSc, PhD, La Jolla, CA

There will be a 5-minute discussion after each talk.

A10 A PRO/CON DEBATE IN PEDIATRIC ASTHMA

Assemblies on Pediatrics; Allergy, Immunology and Inflammation; Clinical Problems; Environmental, Occupational and Population Health

9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER
Ballroom B (South Building, Level 3)

Target Audience
Providers of pediatric asthma care, including registered nurses and advanced practice nurses

Objectives
At the conclusion of this session, the participant will be able to:

• discuss recent data about early allergen exposure and asthma;
• explain the use of FeNO as a method of monitoring asthma control as well as Vitamin D supplementation in the treatment of asthma;
• apply recent data to the treatment of preschool children with intermittent asthma.

This pro/con session will review the evidence on four current controversies in pediatric asthma: 1) Early environmental allergen exposure prevents asthma; 2) Vitamin D supplementation should be a part of asthma management; 3) FeNO should be a standard part of asthma monitoring; and 4) Intermittent ICS is preferred therapy for preschool children with intermittent asthma. Each speaker will review current literature as they present their argument either for or against the topic statement.

Chairing: T. Simoneau, MD, Hartford, CT
E. Forno, MD, MPH, Pittsburgh, PA
A. Bush, MD, London, United Kingdom
9:15  Early Allergen Exposure Prevents Asthma  
W. Phipatanakul, MD, Boston, MA

9:25  Early Allergen Exposure Does Not Prevent Asthma  
G.B. Marks, MBBS, PhD, Sydney, Australia

9:35  General Discussion

9:41  Rebuttal  
W. Phipatanakul, MD, Boston, MA

9:45  Vitamin D Supplementation Should Be a Part of Asthma Management  
B.L. Chawes, MD, PhD, Copenhagen, Denmark

9:55  Vitamin D Supplementation Should Not Be a Part of Asthma Management  
J.C. Celedon, MD, DrPH, Pittsburgh, PA

10:05  General Discussion

10:11  Rebuttal  
J.C. Celedon, MD, DrPH, Pittsburgh, PA

10:13  Rebuttal  
B.L. Chawes, MD, PhD, Copenhagen, Denmark

10:15  FeNO Measurement Should Be a Standard Part of Asthma Monitoring  
A. Bush, MD, London, United Kingdom

10:25  FeNO Measurement Should Not be a Standard Part of Asthma Monitoring  
M. Pijnenburg, MD, PhD, Rotterdam, Netherlands

10:35  General Discussion

10:41  Rebuttal  
A. Bush, MD, London, United Kingdom

10:43  Rebuttal  
M. Pijnenburg, MD, PhD, Rotterdam, Netherlands

10:45  Intermittent ICS Is the Preferred Management for Preschool Children with Intermittent Asthma  
L. Bacharier, MD, St. Louis, MO

10:55  Intermittent ICS Is Not the Preferred Management for Preschool Children with Intermittent Asthma  
F. Ducharme, MD, Montreal, Canada

11:05  General Discussion

11:11  Rebuttal  
L. Bacharier, MD, St. Louis, MO

11:13  Rebuttal  
F. Ducharme, MD, Montreal, Canada

This session and the International Conference are supported by an educational grant from Teva Pharmaceuticals. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
At the conclusion of this session, the participant will be able to:

Objectives

and industry settings clinical investigators involved in translational and clinical research in both academic Health care professionals, patients and patient-support groups; clinicians and practicing clinicians. Topics will provide special emphasis on the role of wearable technology in the prevention, identification, and management of pulmonary diseases, with relevant information for both clinical and translational researchers and practicing clinicians. Topics will provide special emphasis on the role of wearable technology in interventions designed to reach vulnerable populations; consider the future prospects for wearable devices in the prevention, identification, and management of pulmonary diseases.

This session will provide a state of the art discussion of the current and future role of wearable technology in the prevention and management of pulmonary diseases, with relevant information for both clinical and translational researchers and practicing clinicians. Topics will provide special emphasis on the role of wearable technology in interventions designed to reach vulnerable populations and to promote pulmonary health equity. The session will also describe considerations when conducting clinical studies dependent on or to further develop wearable technology for the prevention and management of pulmonary diseases.

Chairing: G.T. Ferguson, MD, Farmington Hills, MI
T.M. Powell-Wiley, MD, MPH, Bethesda, MD
B.J. Make, MD, Denver, CO

9:15 Wearable Devices and Smoking Cessation: What Have We Learned About Using Wearables in Behavior Change?
S.A. Murphy, PhD, Ann Arbor, MI

9:39 The Role of Wearable Devices in Sleep Medicine
M. Hirshkowitz, PhD, Houston, TX

10:03 Use of Mobile Health Technology in Vulnerable Populations
T.M. Powell-Wiley, MD, MPH, Bethesda, MD

10:27 Wearable Technology in Assessing the Impact of Pulmonary Rehabilitation
F.C. Sciurba, MD, Pittsburgh, PA

10:51 Activity Monitors for Precision Assessment of Activity in COPD Patients
R. Bowler, MD, PhD, Denver, CO

The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.

MINI SYMPOSIUM

A14 COPD: SYSTEMS BIOLOGY AND COMORBIDITY
9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER Room 202 A (South Building, Level 2)

Chairing: D.D. Sin, MD, Vancouver, Canada
M.G. Foreman, MD, Atlanta, GA
F.C. Sciurba, MD, Pittsburgh, PA

Oral Presentations


MINI SYMPOSIUM

A15 CRITICAL CARE: THE FUTURE OF CRITICAL CARE? REGIONALIZATION AND CLOSING THE GENDER GAP
9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER Room 146 C (Middle Building, Street Level)

Chairing: H.B. Gershengorn, MD, Bronx, NY
G.D. Rubenfeld, MD, MSc, Toronto, Canada
C.S. Calfee, MD, San Francisco, CA

Oral Presentations


10:15 A Comparison of Outcomes Between a High-Volume and Other Long-Term Care Hospitals in the Chicago Market: An Examination of Patients on Prolonged Mechanical Ventilation/B. Demiralp, F. He, K. Koenig, D. Hengesbach, J. Prister, Rockville, MD, p.A1019


10:45 Longer Interhospital Transfer Times for Critical Care Patients Are Associated with Increased Mortality/A. Neumeier, B.J. Clark, M. Moss, Aurora, CO, p.A1021

Featured Speaker 2
11:00 Regionalization of Critical Care/Speaker To Be Announced

MINI SYMPOSIUM

A16 WHY SHOULD WE BE CONCERNED ABOUT E-CIGARETTES?
9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER Room 147 A-B (Middle Building, Street Level)

Featured Speaker 2
11:00 Regionalization of Critical Care/Speaker To Be Announced

The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.
Chairing: D. DeMeo, MD, MPH, Boston, MA
M.G. Foreman, MD, Atlanta, GA
I. Jaspers, PhD, Chapel Hill, NC

Oral Presentations

9:30 Particles Released from Primary E-Cigarette Vaping: Particle Size Distribution and Particle Deposition in the Human Respiratory Tract/Q. Meng, Y. Son, H. Kipen, D. Laskin, S. Schwander, C. Delinevo, Piscataway, NJ, p.A1023


10:15 E-Cigarettes Cause Human Bronchial Epithelial Cell Apoptosis and Death as Well as Altered Cytokine Profile/M. Ween, J. Whittall, S. Hodge, Adelaide, Australia, p.A1026


11:00 The Effect of E-cigarettes (EC) on Nasal Platelet Activating Factor Receptor (PAFR) Expression/L. Miyashita, R. Suri, J. Grigg, London, United Kingdom, p.A1029


10:00 Increased Physical Activity Associated with Decreased IL-6 and CRP in Patients with COPD/Z. Chen, V.S. Fan, K. Pike, N. Yee, S. Borson, S. Adams, R. Kohen, G. Matute-Bello, H.Q. Nguyen, Seattle, WA, p.A1033


A18 U GOT THE LOOK: DRUGS, TOXINS, GENES AND RISK ASSESSMENT IN PULMONARY HYPERTENSION

9:15 a.m. - 11:15 a.m. MARRIOTT MARQUIS WASHINGTON Liberty Ballroom M-P (Level M4)

Chairing: G.A. Heresi, MD, Cleveland, OH
W. Seeger, MD, Giessen, Germany

Oral Presentations

9:30 Uncovering a Link Between Prescription Amphetamine-Based Stimulants and Pulmonary Hypertension - Data from a Northern California Multi-Specialty, Mixed Payer, Health Care System/E.M. Stewart, C.M. Rajasingh, H. Hedlin, R.J. Romanelli, S.R. Wilson, V. De Jesus Perez, R.T. Zamanian, Stanford, CA, p.A1039

9:45 Genetic Analysis of 2,156 WHO Group 1 PAH Patients Enrolled in the PAH Biobank/M. Pauciulo, K. Lutz, C. Winslow, A. Walsworth, M. Barve, A. Reponen, L. Martin, H. He, W. Nichols, Cincinnati, OH, p.A1040


10:30 Exercise Hemodynamics in the Screening for Pulmonary Vascular Disease in Patients with Portal Hypertension - Results from a Prospective Cross-Sectional Study/P. Douschan, G. Kovacs, R. Stauber, V. Foris, S. Pfeiffer, F. Gruber, V. Stadlbauer-Kollner, D. Kniepeiss, G. Zollner, P. Fickert, A. Avian, A. Olischewski, H. Olischewski, Graz, Austria, p.A1043


11:00 Pulmonary Arterial Hypertension Treatment with Carvedilol for Heart Failure/S. Farha, D. Saygin, M. Park, C. Roach, S.A. Comhair, K. Highland, J. Hammel, D. Newmann, F. DiFilippo, W.W. Tang, S. Erzurum, Cleveland, OH, p.A1045

10:00 In Primary Airway Epithelial Cells, a Mechanically-Induced Unjamming Transition Is Distinct from the Epithelial-Mesenchymal Transition/J. Mitchel, R. Hirsch, I. Stancil, M. O’Sullivan, J. Notohomb, J.P. Butler, J.A. Park, Boston, MA, p.A1049


10:30 Development of a Model to Study the Directs Effects of Matrix Stiffening on Airway Epithelial Cell Barrier Function in Asthma/N. Roy, E. Turner-Branne, A. West, Winnipeg, Canada, p.A1051


IFN-γ-Producing Th17 Cells Exhibit Increased Programmed Death-1 Receptor Expression and Altered Effector Functions/L. Celada, W.P. Drake, Nashville, TN, p.A1065


Inflammatory Biomarkers in Patients with Sarcoidosis Associated Pulmonary Hypertension: The Registry of Sarcoidosis Associated Pulmonary Hypertension (ReSAPH)/P. Heukels, J. Van Hulst, M. Van Nimwegen, K. Beckzer, M. Wijnenbeek, R.P. Baughman, M. Kool, Rotterdam, Netherlands, p.A1070


The information contained in this program is up to date as of March 9, 2017.

For the most current session information, please visit the online program itinerary.
SUNDAY • MAY 21


704 Perceptions of Data Quality and Accuracy During ICU Round/J.A. Gold, K. McGrath, V. Mohan, Portland, OR, p.A1077

705 Variation in the Content and Format of Rounding Checklists in the Intensive Care Unit/D. Saha, B. Hallam, C. Kuza, K. Rak, M.M. Heuson, J. Kahn, Pittsburgh, PA, p.A1078


710 Intensive Care Unit Survivors with an Alcohol Use Disorder Are Less Likely to Follow-Up with Outpatient Providers Following Hospital Discharge/B. Borg, I.S. Douglas, M. Hull, A. Keniston, B.J. Clark, M. Moss, Aurora, CO, p.A1083


712 Epidemiology of Adolescent Sepsis-Like Syndromes Presenting to Adult Hospital Emergency Departments/ L.V.R. Evans, R.S. Watson, J. Caccillo, D.C. Angus, C.W. Seymour, Pittsburgh, PA, p.A1085


714 Differences in Mortality Event Rates After Sepsis: Comparison of 90-Day In-Hospital Mortality, ARDSnet Mortality, and All-Location Mortality, with Implications for RCT Design/S. Govindan, H.C. Prescott, T.J. Iwashyna, Ann Arbor, MI, p.A1087

715 Hospital ICU Admission Patterns for Pneumonia Are Stable from Year to Year/T.S. Valley, H.C. Prescott, H. Wunsch, T.J. Iwashyna, C.R. Cooke, Ann Arbor, MI, p.A1088


A23 EMERGING STRATEGIES TO TRAIN MEDICAL PROFESSIONALS

9:15 a.m. - 11:15 a.m.

MARRIOTT MARQUIS WASHINGTON

Marquis Ballroom 9-10 (Level M2)

Poster Viewing
9:15-10:00

Discussion
10:00-11:15

Chairing: W.G. Carlos, MD, MSCR, Indianapolis, IN
A.K. Brady, MD, Seattle, WA
M.M. Hayes, MD, Boston, MA


1002 Impact of Training in Basic Critical Care Echocardiography on Critical Care Physician Utilization of Formal Echocardiography/U. O’Toole, R. Clouser, J.D. Farkas, A. Lee, L. Leclair, Burlington, VT, p.A1095


1006 Quality Improvement in Ultrasound Education/A. Keenan, P. Bachan, Minneapolis, MN, p.A1099

1007 ICU Innovations: Case Study of Quality Improvement Education Implementation at Two Sites with Contrasting Results/E. Warr, K. Sterba, A.J. Goodwin, E. Johnson, D.W. Ford, Charleston, SC, p.A1100


1009 Longitudinal Assessment of Fellow Attitudes, Knowledge and Competency in Critical Care Ultrasound Across Four Institutions/L. Miyakawa, A. Love, P. Patrawalla, New York, NY, p.A1102


1011 Urgent and Emergent Medical Conditions: Entrustment Decisions at the End of Medical School/A.S. Clay, N. Knudsen, B. Li, T. Scialla, K. Rehder, R. Blessing, H.-J. Li, Durham, NC, p.A1104


1016 Piloting a Targeted, Spaced, Mastery-Learning Global Health Point-of-Care Ultrasound Curriculum for Internal Medicine Residents/S. Maximous, P. Lamberty, C. Spagnoletti, Pittsburgh, PA, p.A1109

1017 A Novel Blended Learning Course on Ultrasound for Rapid Assessment of Acute Respiratory Failure/D. Pradhan, V. Mukherjee, B. Zakhary, H. Sauthoff, New York, NY, p.A1110


---

**POSTER DISCUSSION SESSION**

**A24** IPF: CLINICAL STUDIES, THERAPEUTICS, AND MORE I

9:15 a.m. - 11:15 a.m.  WALTER E. WASHINGTON CONVENTION CENTER

Room 150 B (Middle Building, Street Level)

**Poster Viewing**

9:15-10:00

**Discussion**

10:00-11:15

**Chairing:** L. Richeldi, MD, PhD, Rome, Italy

D.E. Antin-Ozernik, MD, New Haven, CT

M. Wijsenbeek, MD, PhD, Rotterdam, Netherlands


**203** The Significance of Adding Rheumatological Assessment to the Multidisciplinary Team in the Diagnosis of Interstitial Lung Disease (ILD)/L. Israeli-Shani, G. Epstein Shochet, Y. Levi, M. Kutchuk, M. Koslow, D. Shitrit, Kfar Saba, Israel, p.A1118


---

*For the most current session information, please visit the [online program itinerary](#).*
206 Six-Minute-Walk Test (6MWT) and Pulmonary Function in Interstitial Lung Disease (ILD) Patients/Z. Hu, C. Que, Beijing, China, p.A1121


209 Physicians’ Perspectives on the Use of Domiciliary Oxygen Therapy in Interstitial Lung Disease/Y.H. Khor, N.S. Goh, A.E. Holland, C.F. McDonald, Heidelberg, Australia, p.A1124


220 Screening Autoimmune Serologies in the Assessment of Interstitial Lung Disease/M. Alsumrain, F. De Giacomi, S. Mirza, T. Moua, Rochester, MN, p.A1135

221 Translation and Initial Validation of the King’s Brief Interstitial Lung Disease Questionnaire for Idiopathic Pulmonary Fibrosis/T. Skovhus Prior, S. Birring, O. Hilberg, E. Bendstrup, Aarhus C, Denmark, p.A1136


Chairing: M.N. Gong, MD, MS, Bronx, NY
D.K. Costa, PhD, RN, Ann Arbor, MI
A. Amaral, MD, Toronto, Canada


302 Utilization of EHR Based Order-Set to Improve Adherence to Lung Protective Ventilation/E. Jonas, J.A. Gold, S. Nonas, Portland, OR, p.A1141


306 Mandatory Documentation of Tidal Volume Adjusted for Predicted Body Weight on the Respiration Flow Sheet Improves Compliance with Low Tidal Volume Ventilation Strategy: A 5-Year Tertiary Care Center Experience/ M.E. Dauterive, F. Houssmand, M. Mazer, A. Mohan, Greenville, NC, p.A1145


314 Reduced Hospital Length of Stay in Medical Intensive Care Unit Respiratory Failure Patients Using an Embedded Psychiatry Model: A Prospective Cohort Analysis/M. Bui, D. Wiensky, R. Thom, D. Talmason, S. Hurwitz, M. O’Reilly, D. Gitlin, A.F. Massaro, Boston, MA, p.A1153

315 Effect of an Emergency Department Intensive Care Unit on Medical Intensive Care Unit Admissions/J. Du, K.J. Gunnerson, R.C. Hyzy, Ann Arbor, MI, p.A1154


319 Catheter Types at Higher Risk for Central Line Associated Bloodstream Infections in the ICU/H. Ho, C. Chenoweth, Ann Arbor, MI, p.A1158

320 Comparative Resource Utilization and Workload in Patients with Pandemic H1N1 Pneumonia, Non-H1N1 Viral Pneumonia and Non-Viral Acute Respiratory Distress Syndrome (ARDS)/G. Vazquez-Grande, S. Kethreddy, A. Kumar, Winnipeg, Canada, p.A1159


324 Pilot Implementation of a Novel ICU Admission, Discharge, Triage Tool at an Academic Medical Center/S.I. Kumar, S. Kim, K. Winnie, J.P. Cobb, J. Brown, Los Angeles, CA, p.A1163

A26  DIAGNOSIS AND TREATMENT OF TUBERCULOSIS
9:15 a.m. - 11:15 a.m.  WALTER E. WASHINGTON CONVENTION CENTER
Room 144 A-C (Middle Building, Street Level)

Poster Viewing  9:15-10:00
Discussion  10:00-11:15

Chairing:  A. Cattamanchi, MD, San Francisco, CA
F. Blanc, MD, PhD, Nantes, France
D. Horne, MD, Seattle, WA


103  Rapid Point-of-Care Diagnosis of Tuberculosis in Patients with Persistent Cough/M. Gillette, R. Ahmad, R. Bencher, L. Xie, D. Elsinger, D. Walt, S. Carr, Cambridge, MA, p.A1166


106  Diagnostic Accuracy of Xpert Mtb/Rif Assay in Stool Samples for the Diagnosis of Paediatric Pulmonary Tuberculosis: A Pilot Study/C. Cattamanchi, San Francisco, CA, p.A1173


111  Loop Mediated Isothermal Amplification (LAMP) in Respiratory Specimens for the Diagnosis of Paediatric Pulmonary Tuberculosis: A Pilot Study/P. C. Vaidya, K.S. Sreedeeep, S. Sethi, M. Singh, R. Yadav, Chandigarh, India, p.A1175

112  The Use of Branched-DNA In Situ Hybridization to Diagnose Mycobacterial Infection in Formalin Fixed-Paraffin Embedded Tissues/B.L. Aguilar Rodriguez, R. Hussien, P. Hunt, J. McCune, J.J. Vasquez, San Francisco, CA, p.A1176


114  Loop Mediated Isothermal Amplification (LAMP) in Respiratory Specimens for the Diagnosis of Paediatric Pulmonary Tuberculosis: A Pilot Study/P. C. Vaidya, K.S. Sreedeeep, S. Sethi, M. Singh, R. Yadav, Chandigarh, India, p.A1175

115  Low Plasma Levels of Anti Tuberculosis Drugs as a Risk Factor for Non Response in Patients with Pulmonary Tuberculosis on Category II (Retreatment) Regimen/T. Gupta, R. Jain, A. Mohan, U.B. Singh, T. Velpandian, A. Bhatnagar, R. Guleria, New Delhi, India, p.A1179


117  Changes in Serum CRP, Iß2 Microglobulin and Neopterin Levels with TB Treatment/J.F. Mendy, T. Togun, S. Donkor, J. Sutherland, M. Ota, Banjul, Gambia, p.A1181

118  Effect of Adjuvant Inhalation of Sodium Bicarbonate 8.4% with Persistent Cough/M. Gillette, R. Ahmad, R. Bencher, L. Xie, D. Elsinger, D. Walt, S. Carr, Cambridge, MA, p.A1166


121  Clinical Study on Treatment Regimen with Including Clofazimine and Amoxicillin/Clavulanic Acid for Active Tuberculosis Among Symptomatic People Living with HIV Undergoing Intensified Case Finding/J.A. Tornheim, S.R. Ganatra, A. DeLuca, R.A. Banka, A. Gupta, Z.F. Udwadia, Baltimore, MD, p.A1184

### A27 BRONCHIECTASIS AND LUNG INFECTION

#### 9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER

<table>
<thead>
<tr>
<th>Room 201 (South Building, Level 2)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Poster Viewing</strong></td>
</tr>
<tr>
<td>9:15-10:00</td>
</tr>
<tr>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>10:00-11:15</td>
</tr>
</tbody>
</table>

#### POSTER DISCUSSION SESSION

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>124</td>
<td>Harnessing Social Media to Improve Patient-Centred Directly Observed Therapy (D.O.T) Among Patients with Drug Resistant Tuberculosis (DR TB)/ M.S. Namusobya, S.M. Namiro, S. Adakun, C. Batte, Kampala, Uganda</td>
<td>p.A1188</td>
<td>509</td>
<td></td>
</tr>
<tr>
<td>502</td>
<td>Similarities and Differences Between the Pediatric Upper and Lower Airway Microbiome/ K.M. Kloepfer, S.E. Ross, C.M. Hemmerich, D.B. Rusc, S.D. Davis, Indianapolis, IN</td>
<td>p.A1191</td>
<td>512</td>
<td></td>
</tr>
<tr>
<td>504</td>
<td>Childhood Pneumonia Is a Risk Factor for COPD Development but Not Progression in the COGPDGene Study/ L.P. Hayden, J.D. Crapo, E.K. Silverman, C.P. Hersh, Boston, MA</td>
<td>p.A1193</td>
<td>514</td>
<td></td>
</tr>
<tr>
<td>518</td>
<td>Respiratory Syncytial Virus Infection Alters the Human Fetal Neuroprogenitor Cell Fate and Survival/ A. Belkadi, F. Rezaee, T.J. Harford, V. Bokun, L. Sophie, G. Piedmonte, Cleveland, OH</td>
<td>p.A1207</td>
<td>528</td>
<td></td>
</tr>
<tr>
<td>519</td>
<td>Testing Macrophages as a Novel RSV Therapeutic/ T.J. Moraes, Y. Cen, M. Litvack, W. Duan, M. Post, Toronto, Canada</td>
<td>p.A1208</td>
<td>529</td>
<td></td>
</tr>
</tbody>
</table>

For the most current session information, please visit the online program itinerary.


Enhanced Ventilatory Response to Exercise in Patients with Heart Failure Is Associated with the Severity of Obstructive Sleep Apnea/L.R.A. Bittencourt, S. Javaheri, D.M. Servantes, A.C.P. Kravchychyn, D.R. Almeida, S. Tufik, Sao Paulo, Brazil, p.A1242


Central Sleep Apnea-Cheyne Stokes Respirations and Right Sided Heart Catheterization Measures of Cardiac Performance in Pulmonary Arterial Hypertension/H. Paz Y Mar, M. Venkata Subramani, J. Morales Estrella, X. Han, X. Wang, N. Chaisson, R. Mehra, Cleveland, OH, p.A1244

Mean Arterial Pulmonary Pressure as a Predictor of the Severity of Sleep-Disordered Breathing in Patients with Pulmonary Arterial Hypertension/J.L. Morales-Estrella, H. Paz Y Mar, M. Venkata Subramani, X. Han, X. Wang, R. Mehra, N. Chaisson, Cleveland, OH, p.A1245


Volitional Initiated Breaths Do Mimic Automatic Breathing and Allow PaCO2 Homeostasis/P. Haouzi, B. Chenuel, Hershey, PA, p.A1247

### A30 BIOMARKERS IN THORACIC ONCOLOGY: PREDICTING OUTCOMES

**RAPID: RAPID ABSTRACT POSTER DISCUSSION**

**9:15 a.m. - 11:15 a.m.  MARRIOTT MARQUIS WASHINGTON**

**Marquis Ballroom 3-4 (Level M2)**

**Abstract Summaries**
9:15-9:45

**Poster Viewing/Discussion**
9:45-11:15

**Chairing:** P. Nana-Sinkam, MD, Richmond, VA

**Contributors:**

- **902** Expediting Molecular Targeted Therapy Using Real-Time Liquid Biopsy in Non-Small Cell Lung Cancer/V. Ifeacho, M. Sachdeva, P. Hegde, M. Peterson, D. Upadhyay, Fresno, CA, p.A1249
- **904** Difference of Programmed Death-Ligand 1 Expression in Subtypes of Adenocarcinoma of the Lung/C. Son, M.-S. Roh, P.-J. Choi, Busan, Korea, Republic of, p.A1251
- **910** A Combined Score of Biomarkers in Sputum May Be an Indicator for Lung Cancer/A. Bar-Shai, S. Shenhar-Tsarfaty, A. Ahimor, N. Ophir, M. Sitterman, M. Rotem, Y. Alcalay, Y. Schwarz, E. Fireman, Ashkelon, Israel, p.A1257
- **913** Mass Spectrometry Based Proteomic Analysis for Prognostication in Lung Cancer/S. Ratcliff, V. Ifeacho, T. Santiago, D. Upadhyay, M. Peterson, Fresno, CA, p.A1260
- **915** ERCC1 and RRM1 Expression Patterns Are Promising Prognostic Indicators of Patients with Non-Small Cell Lung Cancer/J. Jiang, J. Han, Y. Zhang, Guangdong, China, p.A1262

### A31 MECHANISMS IN CYSTIC FIBROSIS AND OTHER BRONCHIECTATIC DISEASES

**THEMATIC POSTER SESSION**

**9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER**

**Area K, Hall B-C (Middle Building, Lower Level)**

**Viewing:** Posters will be on display for entire session.

**Discussion:**
11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

**Contributors:**

- **P981** Cystic Fibrosis Transmembrane Conductance Regulator Channel (CFTR) Controls Phosphatase and Tensin Homolog (PTEN)-Dependent Immunity: A Role in Cystic Fibrosis Pathology/S. Riquelme, K. Kitur, B. Hopkins, A. Wolfe, R. Parsons, A.S. Prince, New York, NY, p.A1266


Reduced HVCN1 in Neutrophils of Individuals with Cystic Fibrosis Alters Phagosomal pH and Degranulation/N. Browne, M.M. White, M. Milner, C. Foley, F. Gargoum, P. Hawkins, S. Qayyum, E. Reeves, N.G. McElvaney, Dublin, Ireland, p.A1272


A Comparison of the Transcriptional and Translational Inflammatory Profiles of Primary Airway Epithelial Cells from CF and Non-CF Donors/Y. Colon-Cortes, M.A. Hasan, G. Aslanidi, Gainesville, FL, p.A1274


Low pH Compromises an Essential Neutrophil Function: It Suppresses NETosis/N. Palaniyar, M.A. Khan, Toronto, Canada, p.A1276


Validating New Methods of Quantifying Neutrophil Extracellular Traps in Sputum and Bronchoalveolar Lavage from Patients with COPD and Bronchiectasis/E. Pumphrey, H. Keir, C. Fong, O. Sibila, G. Suarez-Cuartin, S. Finch, T.C. Fardon, A.J. Dicker, J.D. Chalmers, Dundee, United Kingdom, p.A1279


A Comparative Study of Tissue Remodeling and Inflammatory Immune Cell Infiltration in Patients Treated by Lung Transplantation for Severe COPD Who Have Either the ZZ Phenotype of Alpha-One Antitrypsin Deficiency or the Centrilobular Phenotype of Emphysema Destruction Commonly Observed in Smokers/D. Kinose, D.M. Vasilescu, F. Chu, M. Downey, W.M. Elliott, N. Tanabe, T.-L. Hackett, S. Verleden, B. Vanaudenarde, J.D. Cooper, J.C. Hogg, Otsu, Japan, p.A1281


A Protein Complex of Phe508del-CFTR, NHERF2, and LPA2 Regulates IL-8 Secretion from Airway Epithelial Cells/2. Zhang, S. Kong, G.J. Tigyi, W. Zhang, Memphis, TN, p.A1283

Opposing Roles of Klotho and Fibroblast Growth Factor 23 in TGF Î²-Induced Airway Inflammation in Cystic Fibrosis/ S. Krick, S. Paredes Aller, C. Aguiar, A. Grabner, E. Mendes, N. Baemuln, M. Wolf, C. Faule, M. Salathe, Miami, FL, p.A1284


Regulation of Cathelicidin LL-37 Expression by Pseudomonas Aeruginosa in Human Bronchial Cystic Fibrosis Epithelial Cells/C. Abrial, J. Da Silva, L. Touqui, Paris, France, p.A1288

Contribution of Prevotella Melaninogenica and Its Hemolysin phyA to Disease in Cystic Fibrosis/R.L. Carlson, M. Harasym, J. Franz, J.D. Londino, Jolla, CA, p.A1289

Distinct Expression of 33, â and â-ENaC Subunits in Ciliated Cells of Porcine Airways/G. Flores-Delgado, P.M. Quinton, La Jolla, CA, p.A1290

Targeting Pig Distal Lung Epithelial Progenitor Cells by Adeno-Associated Viral Vectors/I. Li, C. Brommell, B. Hamilton, L. Powers, J. Zabner, Iowa City, IA, p.A1291


P195 Effect of Airway Calibre on Sensitivity to Rostral Fluid Shift in Lower Airway Response to Rostral Fluid Shift in Asthmatic Men

P193 Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Improves

Facilitator: F.A. Hernandez, MD, Providencia, Chile

A32 ASTHMA AND ALLERGY CLINICAL STUDIES

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area C, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: F.A. Hernandez, MD, Providencia, Chile


P202 Dose Lung Function Monitoring Play an Important Role in Assessing Current Asthma Control?/J. Wang, L. Ma, X. Zhang, H.P. Zhang, L. Wang, G. Wang, Chengdu, China, p.A1308

P203 Adherence to Outpatient Clinic Visits by Patients with Asthma/T. Tajiri, T. Sado, A. Sokai, K. Gotoh, Y. Nakamura, H. Kita, Takatsuki-shi, Japan, p.A1309

P204 The Evaluation of Impulse Oscillometry in the Diagnosis of Exercise-Induced Bronchoconstriction/R.R. Nahapetian, C. Bime, C.E. Berry, Tucson, AZ, p.A1310

P205 Fractional Exhaled Nitric Oxide (FeNO) as Monitoring Tool for Bronchial Asthma: An Indian Study/D. Bhattacharyya, Y. Garg, New Delhi, India, p.A1311


P208 The Relationship Between Fractional Exhaled Nitric Oxide and Forced Expiratory Volume in One Second in Asthma/J. Dummer, M. Amer, J. Cowan, A. Gray, Dunedin, New Zealand, p.A1314

P209 The Relationship Between Anxiety and Serum Inflammatory Cytokines in Patients with Asthma/T. Moghim, K. Fukunaga, K. Masaki, M. Matsuoka, S. Okuzumi, R. Baba, T. Tanosaki, T. Kamatani, Y. Suzuki, T. Betsuyaku, Tokyo, Japan, p.A1315


P224 Asthma in the Elderly: Discrepancies Between Clinical, Physiological and Inflammatory Parameters/J. Gregoire, C. Robitaille, M.-E. Boulay, M. Bertrand, L.-P. Boulet, Quebec, Canada, p.A1330

P225 Examining the Role of Nitric Oxide in Asthma Self-Management in Older Adults/R. Folz, A. Jorayeva, B. Beatty, J. Myers, R. Gopalraj, B. J. Polivka, Cleveland, OH, p.A1331

P226 Associations Between Asthma Severity and Production of, or Responsiveness to, Th17-Associated Cytokines in Pediatric Asthmatics/J. W. McAllees, T. Baker, X. Zhang, J. Biagini Myers, M. Butsch Kovacic, I. P. Lewkovich, Cincinnati, OH, p.A1332

A33 CLINICAL STUDIES IN OBSTRUCTIVE LUNG DISEASE

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Area L, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators


P1078 Peripheral Th2-Related Biomarkers in Chronic Obstructive Pulmonary Disease (COPD) Patients in the GLUCOLD (Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease) Study/W. Tew, P. Kulkami, C. Holweg, C. A. Brandsma, W. Timens, M. Grimbaldeston, P. Hiemstra, M. van den Berge, M. Neighbors, South San Francisco, CA, p.A1334


P1081 Pharmacokinetics of a 4-Week Up-Titration Regimen of Rofumilast in the OPTIMIZE Study/A. Facius, N. Bagul, P. Gardiner, H. Watz, Zurich, Switzerland, p.A1337


A34 CLINICAL AND CELLULAR STUDIES IN ALLERGIC DISEASE

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area C, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators


P231 Cellular and Acellular Factors Influence Mast Cell Phenotype/ Y. Ren, G.S. Pryhuber, T.J. Mariani, Rochester, NY, p.A1349


P238 Determining Medical and Cost Soundness of Using Specific IgE in Older Adults with Asthma in Lieu of SPT/J. Polivka, E. Brooke, R. Folt, B. Beatty, R. Gopalaraj, A. Jorayeva, J. Myers, Louisville, KY, p.A1356

P239 MicroRNA-1 Levels Determine the Type of Inflammatory Remodeling in Chronic Rhinosinusitis/A. Korde, X. Zhang, S.S. Takyar, New Haven, CT, p.A1357


P247 Characteristics of Patients with Severe, Uncontrolled, Eosinophilic Asthma Enrolled in an Observational French Cohort (COBRA)/M. Aubier, G. Thabut, C. Fabry-Vendrand, Paris, France, p.A1364


P251 Severe Asthma in Primary Care in Canada: A Longitudinal Study of the Clinical Burden and Economic Impact Based on Linked Electronic Medical Record Data/D. Husereau, J. Goodfield, R. Leigh, R. Borrelli, M. Cloutier, A. Gendron, D. Marvin, Edmonton, Canada, p.A1368


P253 Impact of Asthma Control Status on Lung Function and Patient Well-Being Assessments in Patients with Severe Asthma/X. Xu, S. O’Quinn, I. Hirsch, G. Gopalan, Gaithersburg, MD, p.A1370


P259 Galectin-3 Expression in Monocyte-Derived Macrophages from Severe Asthmatics/M. Erriah, K. Pabreja, K.J. Baines, M. Fricker, J.L. Simpson, Newcastle, Australia, p.A1376


P1103  The Short-Term Impact of Symptom-Defined COPD Exacerbation Recovery on Health Status and Lung Function/L. Murray, N. Leidy, Bethesda, MD, p.A1400

Facilitator:  V.G. Press, MD, MPH, Chicago, IL


P1106  Depression and Health-Related Quality of Life in Patients with Chronic Obstructive Pulmonary Disease/N. Malik, K.K. Chima, Lahore, Pakistan, p.A1403


P1110  Cost Associated with COPD Exacerbations and Other Respiratory Events in Commercial and Medicare Part D Populations/R.H. Stanford, M. Borse, A. Shewale, Research Triangle Park, NC, p.A1407


P1112  Use of Triple COPD Therapy Among Incident Users of LAMA or LAMA/LABA/R.H. Stanford, B. Hahn, M. Hull, C. Blauer-Peterson, A. Buikema, Research Triangle Park, NC, p.A1409


P1115  Continuing Care with Nebulized Bronchodilators After Hospital Discharge and Impact on Readmissions: Analysis of Medicare COPD Beneficiaries Receiving Arformoterol Vs Nebulized Short-Acting Agents/V. Ganapathy, L. Xie, A. Keshishian, Q. Zhang, O. Baser, Marlborough, MA, p.A1412


P1117  A Robust Statistical Model of Adherence to Inhaled Medication/ G. Greene, R. Conroy, R. Costello, F. Doyle, Dublin, Ireland, p.A1414


P1119  Patient Device Satisfaction with eFlow Closed System Nebulizer: Results from the GOLDEN-5 Study in Patients with Moderate-to Very-Severe Chronic Obstructive Pulmonary Disease (COPD)/E.M. Kerwin, J.F. Donohue, G.T. Ferguson, A. Ozol-Godfrey, V. Ganapathy, Medford, OR, p.A1416

P1120  Smoking Knowledge, Attitudes, Practice and Behavior in Outpatient Individuals with COPD in Zunyi City, China/W. LianHong, Zun Yi, China, p.A1417


P1122  Outcomes with High-Frequency Chest Wall Oscillation Among Patients with Bronchiectasis or COPD/D. Weycker, F. Seifer, G. Hansen, Brookline, MA, p.A1419


---

**THEMATIC POSTER SESSION**

A38  **IMPROVING QUALITY AND OUTCOMES OF CRITICAL CARE**

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER

Area E, Hall B-C (Middle Building, Lower Level)

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

**Facilitator:**  C.H. Weiss, MD, Chicago, IL


P495  High Versus Low Dose Thiamine and Outcomes in Patients with Severe Alcohol Withdrawal: A Propensity-Matched Cohort Study/S. Gu, M. Moss, D. Everett, B.J. Clark, Aurora, CO, p.A1425


Facilitator:  T.S. Valley, MD, MSc, Ann Arbor, MI


P501  Integration of an Advanced Practice Behavioral Health Clinician into a Medical Intensive Care Unit/C.R. Fister, M. Cavanaugh, A. Schwartz, M.G. Benninghoff, M. Vest, T. Horton, R. Guerry, V. Maheshwari, Newark, DE, p.A1431


Facilitator:  P.R. Menon, MD, PhD, Burlington, VT


THEMATIC POSTER SESSION

A39  AUTOIMMUNE LUNG DISEASE: CASE REPORTS

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER

Area C, Hall B-C (Middle Building, Lower Level)

Viewing:  Posters will be on display for entire session.

Discussion:  11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator:  J. Solomon, MD, Denver, CO

P263  A Case of Pulmonary-Renal Syndrome Caused by Streptococcal Infection/J. Shimokawa, H. Nagano, H. Kawakita, Y. Raita, T. Kishaba, Uruma, Japan, p.A1442

P264  A Co-Occurrence of Intestinal Pneumonia with Autoimmune Features and Usual Interstitial Pneumonia/C.T. Lee, R. Vij, A.N. Husain, M.E. Strek, Chicago, IL, p.A1443

P265  Intestinal Lung Disease: A Presentation for a Rare Autoimmune Condition/M. Kalani, T. Sharma, Pittsburgh, PA, p.A1444

P266  Cryptogenic Organizing Pneumonia Presenting at Sentinel Ulcerative Colitis Exacerbation/S.B. Brosnahan, S. D’Annunzio, R. Condos, New York, NY, p.A1445

P268 Cough and Mediastinal Lymphadenopathy Leading to an Unexpected Diagnosis of Lupus/J. Hall, R. Suyyagh, Phoenix, AZ, p.A1447


P272 A New Kid in Town or a Quintessential Masquerader/H. Grewal, ATS 2017  Washington, DC

P273 A Case of Relapsing Polychondritis Solely Presenting with Chronic Cough: A Rare Presentation of a Rare Disease/M. Li, Y. Zeng, J. Wang, Shenzhen, China, p.A1452

P274 Tracheobronchopathica Osteochondroplastica Presenting with Epistaxis and Atrophic Rhinitis/T. Holte, V. Bandi, Houston, TX, p.A1453

P275 Pulmonary Manifestation of IBD: A Case Report/C. Rincon-Prieto, T. Luckhardt, MD, MS, Birmingham, AL

P276 A Rare Case: Granulomatosis with Polyangiitis Presenting as Diffuse Alveolar Hemorrhage/A. Alpavalaru, A. Talwar, A. Singh, S. Elapavaluru, Pittsburgh, PA, p.A1466

P277 Fibrillary Glomerulonephritis: Another Cause of Bleeding Lung/K. Patel, A. Talwar, T. Cheema, M. Balaan, Pittsburgh, PA, p.A1456

P278 Pulmonary Renal Syndrome with ANCA Negative Pauci-Immune Glomerulonephritis in a Patient with Monoclonal Gammopathy/ M.S. Rizvi, P.D. Scanlon, Rochester, MN, p.A1457


P281 Diffuse Alveolar Hemorrhage as a Rare Manifestation of Rheumatoid Arthritis/A. Osman, P. Galiatsatos, S. Bose, S.K. Danoff, Baltimore, MD, p.A1459


P286 Case of Pauci-Immune Pulmonary Capillaritis Treated with Rituximab/A. Alsatli, C. Hayner, Cincinnati, OH, p.A1465


P288 Pericardial Tamponade as a Rare Manifestation of Acute Microscopic Polyangiitis/M.H. Bourne, U. Specks, T. Peikert, Rochester, MN, p.A1467


P293 A Window into the Soul: A Case of Transmural Ulceration of the Tracheobronchial Tree/A. Olson, Y. Samra, C. Trillo, M. Barnes, Gainesville, FL, p.A1472

P294 Adult Still’s Disease with Pulmonary Involvement as a Paraneoplastic Syndrome Caused by a Seminoma/P.D. Hiles, A.J. Skabelund, Fort Sam Houston, TX, p.A1473

P295 Pulmonary Necrobiosis Nodules - A Rare Manifestation of Crohn’s Disease/H. Koneru, J.P. Sugunaraj, S. Penupolu, Danville, PA, p.A1474

P296 Treated IgG4 Disease with Progression of Massive Pleural Effusion/L. Pei Yu, Taipei, Taiwan, p.A1475

P297 Organizing Pneumonia Masking the Diagnosis of IgG4 Related Lung Disease: A Case of a 79 Year Old Man with Myelodysplastic Syndrome/B. Noumi, A. Attaway, M. Nagaraja, R. Folz, Cleveland, OH, p.A1476


P300 Acute Fibrinous Organizing Pneumonia in a Patient with An Extremely Rare Presentation of Renal Cell Carcinoma as Chronic Eosinophilic Pneumonia and Rheumatoid Arthritis: An A Case of Pulmonary S. Dendriform Pulmonary Ossification/T. Umeda, R. Tomic, E. Primary Sjogrens Syndrome Causing Pleural Effusions/ T. Sikka, Temple, TX, p.A1489

P301 The Remicade Escapade: Infliximab Induced Acral Psoriasis in a Patient with Refractory Sarcoidosis/Z. Shakir, N. Sweiss, Chicago, IL, p.A1480


P303 The Price of the Perfect Smile: A Dental Ceramist’s Journey from Respiratory Collapse and Back/T.T. DeCato, A. Badke, Salt Lake City, UT, p.A1482


P306 Lane-Hamilton Syndrome - A Case of Pulmonary Hemosiderosis Associated with Celiac Disease/B. Ayesha, A. George Jacob, R. Tuekten, Iowa City, IA, p.A1485

P307 Best Treatment for a Rare Cause of Airway Obstruction? A Case of Tracheal Pemphigoid Responsive to Cyclophosphamide and Prednisone/M.S. Norton, M. Doherty, J. Hildebrandt, Rochester, MN, p.A1486


P310 Acute Fibrinous Organizing Pneumonia in a Patient with Cryoglobulinemia and Hepatitis C/J.Z. Morales, A. Bhatia, T. Bessich, J. Alukal, A. Basavaraj, New York, NY, p.A1502

THEMATICAL POSTER SESSION

A40 CYSTIC FIBROSIS AND NON-CYSTIC FIBROSIS BRONCHIECTASIS

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Area K, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00; authors will be present for individual discussion 12:00-1:00; authors will be present for discussion with assigned facilitators

Facilitator: M.P. Boyle, MD, Baltimore, MD


P1019 Broncho-Pulmonary Arterial Fistula Misdiagnosed as Pulmonary Emboli, Presenting as Massive Hemoptysis in a Patient with Cystic Fibrosis/S. Velani, M. Ayache, C.N. Myers, S. Manvar, C.V. Teba, Cleveland, OH, p.A1493


P1022 Focal Bronchiectasis Due to Alpha-1 Antitrypsin Deficiency Complicated by Mycobacterium Avium-Intracellulare Infection/R.M. Burkes, P. Noone, Chapel Hill, NC, p.A1496


P1026 Genetic Testing, a Valuable Tool in the Diagnosis of Primary Ciliary Dyskinesia/Y. Hamzavi Abdi, B. Kaplan, Great Neck, NY, p.A1500

P1027 Mounier-Kuhn Disease, a Rare Cause of Dyspea Associated with Pulmonary Nocardiasis, Restrictive Lung Physiology, and IgM Deficiency/S.R. Shadix, Z. Zhang, B. Tatsu, S. Ghandehari, Los Angeles, CA, p.A1501

Facilitator: M.P. Boyle, MD, Baltimore, MD

P1028 It’s Not Just Another Cystic Fibrosis Exacerbation/S. Bhatia, T. Heynekamp, C. Cotton, Albuquerque, NM, p.A1502

P1029 Cystic Fibrosis Mutations Discovered in a 72 Year Old Woman with Pulmonary Nocardiasis, Restrictive Lung Physiology, and Ciliary Dyskinesia/Y. Hamzavi Abdi, B. Kaplan, Great Neck, NY, p.A1503

P1030 ECMO Without Anticoagulation as a Bridge to Lung Transplantation/A. Brueder, M. Prickett, M. Jain, Chicago, IL, p.A1504


The information contained in this program is up to date as of March 9, 2017.

For the most current session information, please visit the online program itinerary.
A41 LAM AND OTHER CYSTIC LUNG DISEASE: CASE REPORTS

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area K, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: N. Gupta, MD, Cincinnati, OH

P1034 Decline and Recovery of Lung Function with the Initiation and Cessation of Lumacaftor-Ivacaftor/C.J. Richards, L. Sicilian, I. Neuringer, Boston, MA, p.A1508


Facilitator: M. Myerburg, MD, Pittsburgh, PA


P1043 Population Pharmacokinetic (PK) Analysis in Non-Cystic Fibrosis Bronchiectasis (NCFB) Patients Under 32.5 mg bid Intermittent Therapy with Ciprofloxacin Dry Powder for Inhalation (DPI)/H. Stass, S. Willmann, A. Henningson, Wuppertal, Germany, p.A1517


P1046 A Quantitative and Qualitative Study to Understand Symptom Burden in Patients with Bronchiectasis/E. Dudgeon, M. Crichton, G. Scott, S. Finch, T.C. Fardon, J.D. Chalmers, Dundee, United Kingdom, p.A1520


P1049 Cardiovascular Outcomes Following a Respiratory Tract Infection Amongst People with Bronchiectasis: A Population Based Study/V. Navaratnam, A.A. Root, I. Douglas, L. Smeeth, R. Hubbard, J. Quint, Nottingham, United Kingdom, p.A1523
P1058 Disseminated Pulmonary Lymphangiomatosis with Bone Involvement in an Adult Patient/A. Rajagopal, J. McCormick, Lexington, KY, p.A1531

P1059 An Intriguing Case of Pulmonary Langerhans Cell Histiocytosis Following Treatment for Chronic Lymphocytic Leukemia/F. Siddiqui, S. Nathan, A. Brown, C. King, Roanoke, VA, p.A1532

Facilitator: A.S. Kristof, MD, Montreal, Canada


P1063 A Rare Case of Pulmonary Non-Langerhans Cell Histiocytosis/S. Castillo, M. Hamblin, Kansas City, KS, p.A1536

P1064 Rare Presentation of Congenital Lobar Emphysema in an Adult/M.A. Zulqarnain, A. Rajasekaran, Lexington, KY, p.A1537


P1073 Diagnosis and Treatment of Non-Traumatic Chylothorax Using Advanced Lymphatic Imaging and Percutaneous Lymphatic Embolization/M. Itkin, G. Nadolski, J. Johnstone, Y. Dori, Philadelphia, PA, p.A1547

P1074 Clinical Outcomes of Patients with Sarcoidosis After 5 Years Follow-Up in Israel: Differences from the ACCESS Study/D. Shritit, G. Epstein Shochet, N. Markevych, L. Israeli-Shani, Y. Levi, Kfar Saba, Israel, p.A1548


Facilitator: N. Patel, MD, Philadelphia, PA

P1076 Retrospective Analysis of 40 Patients with Cryptogenic Organizing Pneumonia Treated with Clarithromycin and 22 Patients Treated with Prednisone/E. Radzikowska, E. Wiatr, D. Gawryluk, P. Rudzinski, I. Bestry, R. Langfort, K. Roszkowski-Sliz, Warsaw, Poland, p.A1550


P1079 Mycophenolate Versus Placebo for the Treatment of Systemic Sclerosis-Related Interstitial Lung Disease/D.P. Tashkin, E. Volkmann, M.D. Roth, N. Li, D. Khanna, D. Forus, R. Elashoff, Los Angeles, CA, p.A1553
P907 Characterization of CT Scan in Birt-Hogg-Dube Syndrome Compared with Non-BHD Diffuse Cysts Lung Diseases in Chinese Patients/ Xian, T.; Xu, Y.; Liu, Y.; Zhan, X.; Zhang, K.-F.; Xu, Beijing, China, p.A1554


P910 Sarcoïdosis - the Frequency of Extrapulmonary Changes in Patients Diagnosed in the Pulmonary Hospital in Olsztyn/A. Doboszynska, M. Kolis-Zielinska, A. Romaszko, E. Malinowska, Olsztyn, Poland, p.A1557


P914 Frequency and Risk Factors Associated to Interstitial Lung Abnormalities (ILA) in Asymptomatic Older (>60 Years) Individuals/I. Buenda-Roldan, J. Martinez-Espinosa, M. Mejia, E. Montes, M. Checa, M. Konigshoff, A. Pardo, M. Selman, Mexico City, Mexico, p.A1561


Facilitator: C.A. Pereira, MD, Sao Paulo, Brazil


THEMATIC POSTER SESSION

A43 NON-IPF ILD: CLINICAL STUDIES

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Area J, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion

12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: R. Hallowell, MD, Boston, MA


P928 Family History of Autoimmunity in Chronic Hypersensitivity Pneumonitis/D. MacDonald, R. Tomic, H. Kim, M. Bhargava, D. Perlman, Minneapolis, MN, p.A1574

P929 Use of Mycophenolate Mofetil as a Steroid Sparing Agent in Chronic Hypersensitivity Pneumonitis/D. MacDonald, R. Tomic, H. Kim, M. Bhargava, D. Perlman, Minneapolis, MN, p.A1575

P930 Pulmonary Hypertension in Patients with Hypersensitivity Pneumonitis/J. Im, A. Mathur, M. Padilla, S. Dua, New York, NY, p.A1576
P931 Dendriform Pulmonary Ossification in Interstitial Lung Disease/J.R. Castaneda-Nerio, A.M. Nambiar, C. Restrepo, San Antonio, TX, p.A1577

P932 IgG4-Related Respiratory Disease and Its Mimickers/ S. Matsui, S. Minamoto, H. Yamamoto, T. Handa, Y. Waseda, M. Mishima, K. Kuto, Toyama, Japan, p.A1578


Facilitator: C. Johnson, MD, Baltimore, MD

P936 Understanding the Pulmonary Phenotypes of Patients with Systemic Sclerosis/J. Post, T. Bang, C. Meadows, A. Fischer, T.M. Bull, J.S. Lee, Aurora, CO, p.A1582

P937 A Case-Series of Hard Metal Pneumoconiosis/J. Chiarchiaro, D. Facilitator, C. Johnson, MD, Baltimore, MD


P940 Acute Fibrinous and Organizing Pneumonia: One Case Report and Literature Review/H. Zhang, Fuzhou, China, p.A1586


Facilitator: S.E. Hines, MD, MSPH, Baltimore, MD

P945 Management of Spontaneous Pneumothorax and Safety of Air Travel in Patients with Pulmonary Langerhans Cell Histiocytosis/A. Singla, E.J. Koprals, F.X. McCormack, N. Gupta, Cincinnati, OH, p.A1591


P948 Measurement of Avian Antigen in Household Dust for Management of Chronic Bird-Related Hypersensitivity Pneumonitis/M. Sema, Y. Miyazaki, N. Inase, Tokyo, Japan, p.A1594


P950 Analysis of Diagnosis and Therapeutic Effect on Thirty-Seven Subjects with Biopsy-Proven Cryptogenic Organizing Pneumonia/H. Li, Shanghai, China, p.A1596


P76 A Novel Management of Distal Active Haemoptysis by an
P77 A Novel Bronchoscope Method (Saline Injection Method) for
P78 Two Stents to Close a Bronchopleural Fistula/B.F. Rodrigues,
Y. Sarda, L. Frey, F.A. Almeida, Cleveland, OH, p.A1603
P79 A Novel Approach to Resection of an Endobronchial
Hamartoma with Sheath-Guided Cryoprobe/F. Chau-Etchepare,
K. Yoneda, N. Stollenwerk, Sacramento, CA, p.A1604
P80 Perioperative Management of Massive Hemoptysis during a
Flexible Bronchoscopy: Case Report and Review of the
Literature/J.C. Segura Salguero, L. Diaz, J.R. Lutz, A.M. Posada,
V. Ronderos, Bogota, Colombia, p.A1605
P81 A Novel Bronchoscope Method (Saline Injection Method) for
Complete Extraction of Ruptured Pulmonary Hydatid Cyst/M.E.
Hejazi, S. Tahsini Tekkantapeh, S. Hasani, Y. Hejazi, Tabriz, Iran,
p.A1606
P82 A Novel Management of Distal Active Haemoptysis by an
Intrabronchial Valve and TISSEEI/C.J.-H. Pan, D.J. Arnold, T.
Saghaie, A. Ing, Concord, Australia, p.A1607
P83 Endobronchial Embolization for Life-Threatening Hemoptysis
with Endobronchial Watanabe Spigot: First Reported Case in
Malaysia/S.S. Kho, S.K. Chan, M.C. Yong, S.T. Tie, Kuching,
Malaysia, p.A1608
P84 Tracheobronchial Stents Insertion Using Telescopin
Technique: A Successful Intervention for
Post-Pneumonectomy Bronchopleural Fistula/T. Abdo, C.
Hamilton, S.J. Deb, A. Awab, Oklahoma City, OK, p.A1609
P85 An Interesting Case of a Successful Autologous Blood Patch
Pleurorhesis After Iatrogenic Pneumothorax with Persistent Air
P86 Re-Expansion Pulmonary Edema as a Complication of
Endo-Bronchial Valves Placement/Y. Dotan, N. Marchetti, G.J.
Criner, Philadelphia, PA, p.A1611
P87 Delayed Diagnosis of Traumatic Left Main Bronchial Fracture
Treated with Endobronchial Stenting/V. Keenan, S.G. John, E.
Shostak, J.S. Ilowite, P. Spiegler, Mineola, NY, p.A1612
P88 Successful Use of Intraluminal Alteplase and Dornase in a
Pregnant Woman with Complicated Parapneumonic
Effusion/D.E. Amariie, Y.S. Sangwan, B.-C. Tran, R. Yao, J.N.
Kopelman, E.J. Britt, A. Sachdeva, E.M. Pickering, Baltimore, MD,
p.A1613
P89 A Nontraditional Approach to Diagnosing an Elusive
Bronchoesophageal Fistula/B.R. Miller, E. Abramian,
Philadelphia, PA, p.A1614
P90 Bronchoscopic Management of Tracheal Kaposi Sarcoma:
Report of a Case with an Unusual Presentation and Evolution/
P.S. Zhu, T. Vandemoerle, Montreal, Canada, p.A1615
P91 A Rare Complication of Electromagnetic Navigation Guided
Bronchoscopy/S. Baig, O. Pistun, New Brunswick, NJ, p.A1616
P92 An Unusual Pattern of Pulmonary Involvement of Chronic
Lymphocytic Leukemia/J.J. Yoo, T.J. Harkin, M.B. Beasley, New
York, NY, p.A1617
P93 Cerebral Air Embolism as a Possible Cause of Acute Stroke
During Therapeutic Endobronchial Application of Argon
Plasma Coagulation/V. Kanchustambham, S. Patolia, S. Saladi, E.
Rakey, St. Louis, MO, p.A1618
Facilitator:  A. Majid, MD, Boston, MA
P94 An Unusual Case of Tracheoesophageal Fistula (TEF)
Presenting as Bowel Ileus and Managed with Dual Stenting/A.
Vyas, M. Tatusov, J. Memoli Wang, J. Khalilzadeh, Washington,
DC, p.A1619
P95 Acquired Tracheomalacia Secondary to Excessive Cuff
Inflation/W. Atchley, K.S.S. Kakkerla, V. Vilensky, N. Meena, Little
Rock, AR, p.A1620
P96 Azygos Continuation of the IVC (ACIV) Mimicking a Mediastinal
Mass/S. Shankar, M. Amith Shenoy, I. Malhotra, P. Chandar, A.
Rai, H. Desoky, P. Irulkull, P. Gozenput, B. Shamian, R. Bernstein,
C. Senerivante, Y. Kuper, Brooklyn, NY, p.A1621
P97 Successful Recanalization of Complete Left Mainstem
Bronchus Occlusion Using Combined Fluoroscopic
Wire-Assisted and Bronchoscopic Approach/R.J. Cho, E.
Podgaetz, H.E. Dinner, Minneapolis, MN, p.A1622
P98 Rescue Self-Expandable Metal Stenting Following Traumatic
Tracheal Injury/W.G. Shakespeare, P. Tsai, V. Bandi, Houston,
TX, p.A1623
P99 Experimental Endobronchial Use of Pneumatic Lithotripter in a
Symptomatic Case of Tracheobronchopathia
Osteochondroplastica (TO)/A. Kiani, M. Pourabdollah Toutkaboni,
M. Pourabdollah Toutkaboni, A. Tabibi, A. Abedini, Tehran, Iran,
p.A1624
P100 Pneumopericardium During Transbronchial Needle
Aspiration/R. Shrestha, M.K. Zaman, A. Yankovich, Memphis, TN,
p.A1625
P101 A Two Stent Solution to a Critical Left Main Bronchial
Obstruction/C.M. Batzlaff, K. Sakata, J.J. Mullon, R.M. Kern,
Rochester, MN, p.A1626
P102 A Case of Stridor Caused by Bilateral Main Stem Bronchial
Obstruction/I. Charoenpong, D.N. Smith, J. Yun, S. Zuqarnain,
Brooklyn, NY, p.A1627
Facilitator:  D. Gompelmann, MD, Heidelberg, Germany
P103 Chylothorax and Trapped Lung Secondary to Pulmonary
Coccidiomycosis Treated with Intrapleural Application of
Amphotericin B/H. Edriss, S. Edwards, T. Mahmood, R. Alalawi,
Lubbock, TX, p.A1628
P104 Delayed Mediastinal Hematoma After Intubation/S.
GunterMaher, A.N. Chary, R.E. Walter, R.C. Holladay, S.
Kalanjeri, Shreveport, LA, p.A1629
P132 Impact of Aspiration Type on EBUS-TBNA and EUS-b-FNA Efficacy in Patients with Mediastinal Adenopathy/I. Sivokozov, S. Sokolov, N. Li, S. Pavlova, I. Shabalina, D. Sazonov, O. Yun, O. Lovacheva, G. Evgushenko, Moscow, Russian Federation, p.A1658

P133 Impact of Aspiration Type on EUS-FNA Efficacy in Patients with Malignant and Benign Mediastinal Lesions/I. Sivokozov, M. Burdyukov, D. Dedushkin, S. Sokolov, S. Pavlova, E. Artemkin, B. Lensky, I. Yurichev, Moscow, Russian Federation, p.A1659


P137 A Unique Pattern of Increased Mucosal Vascularity on Bronchoscopy in Patients with Pulmonary Hypertension and Cardiac Disease/M. Barry, R.N. Channick, C.L. Channick, Boston, MA, p.A1664

Facilitator: L. Yarmus, DO, Baltimore, MD


P144 Decompression Bronchoscopy for Patients with Hyperinflation Due to Emphysema -9 Month Follow-Up/A.C. Mehta, A. Kumar, L. Lam, T.R. Gildea, Y. Meli, Cleveland, OH, p.A1671

Facilitator: G.C. Michaud, MD, New York, NY


P146 Assessment of Interlobar Fissure Integrity in Patients with Bronchial Valves Due to Prolonged Air Leak/M. Sierra-Ruiz, C. Ghattas, F. Kheir, E. Folch, A. Majid, Boston, MA, p.A1673


P148 Use of Smart Phone in-Built Flashlight as Light Source in Bronchoscopy or Thoracoscopy/V. Deshmukh, Nagpur, India, p.A1675


A46 EOSINOPHILS AND COPD

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER Area L, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion

12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: P.G. Woodruff, MD, MPH, San Francisco, CA

P1126 Effects with Allergic Phenotypes Using Blood Eosinophilic Counts and IgE Levels in Patients with COPD/S.-L. Cheng, Taipei, Taiwan, p.A1679

P1127 Association of CT Measured Pulmonary Artery Size with Blood Eosinophil Counts and IgE Levels in Patients with COPD/J. Thiboutot, C. Mallow, W. Justice, D.J. Feller-Kopman, H. Lee, L. Yarmus, Baltimore, MD, p.A1680


P1129 Longitudinal Assessment of Blood Eosinophil Counts in a COPD Cohort/K. Burns, C. Wrona, S. Sethi, Buffalo, NY, p.A1682

THEMATIC POSTER SESSION

ATS 2017 • Washington, DC

The information contained in this program is up to date as of March 9, 2017.

For the most current session information, please visit the online program itinerary.
The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.
THEMATIC POSTER SESSION

A48 COPD: ISSUES IN HEALTH CARE DELIVERY
9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area L, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: J.A. Krishnan, MD, PhD, Chicago, IL

P1153 Medication Adherence and Patient-Reported Outcomes in Subjects with Chronic Obstructive Pulmonary Disease/M. Kusunose, S. Nakamura, K. Senda, K. Nishimura, Obu, Japan, p.A1704


P1155 Practice Patterns and Care Gaps According to COPD Physician Diagnosis in Primary Care/W. Alsowayan, Montreal, Canada, p.A1706


P1159 Bronchial Artery Embolisation in the Management of Hemoptysis: Experience from an Indian Tertiary Care Centre/D. Bhattacharyya, V. Rastogi, Y. Garg, New Delhi, India, p.A1710

P1160 Initial Clinical Experience Using 3D Printing and Patient-Specific Airway Stents: Compassionate Use of 3D Printed Patient-Specific Airway Stents/B.P. Young, M.S. Machuzak, T.R. Gillde, Cleveland, OH, p.A1711


Facilitator: R.A. Mularski, MD, MSHS, MCR, Portland, OR


P1167 Can an Emergency Department Observation Unit Reduce Hospital Admissions for COPD Exacerbation/?J.B. Gutteridge, J. Yeo, S.S. Braman, New York, NY, p.A1718


P1169 Impact of Pulmonary Consultation on Discharge Coding and Management of Hospitalized Patients with Admission Diagnosis of COPD Exacerbation/D. Connolly, S. Arfaie, Z. Bham, J. Fine, Norwalk, CT, p.A1720


Facilitator: R. Benzo, MD, MSc, Rochester, MN

P1173 “High Risk” Patients with Chronic Obstructive Pulmonary Disease(COPD) Have a Poor Prognosis and Need to Be Able to Access Palliative Care Services/Q.A. Syed, M. Apps, D. Mukeherjee, M. Nkere, S.A. Aneke, J. Minter, Basildon, United Kingdom, p.A1724

P1174 COPD in Patients 90 Years of Age and Older Residing in Inner-City Chicago: Preliminary Observations/M. Tole, I. Rubinstein, D.R. Fraidenburg, Chicago, IL, p.A1725


P1178 Exacerbations and Healthcare Resource Utilization in Patients with Airflow Limitation Diseases Attending a Primary Care Setting: The PUMA Study/M. Montes de Oca, C. Aguirre, M.V. Lopez Varela, M. Laoucho-Contreras, A. Casas, F.A. Surmont, Caracas, Venezuela, p.A1729


Facilitator: J. Bourbeau, MD, Montreal, Canada


P1185 A Computer Guided Consultation in Standardizing COPD Care: Observations in a Real Life Setting/R.M. Angus, L. Davies, E. McKnight, K. Sergeant, M.G. Pearson, Liverpool, United Kingdom, p.A1736


P1188 Self-Management as Measured by the CRQ-Mastery Score Is an Independent Predictor of COPD Readmissions/S. Mirza, P. Novotny, R. Benzo, Rochester, MN, p.A1739

P1189 Determining the Prevalence of COPD in Primary Care Setting by Using a Telemedicine Spirometry Program. A Screening Study/N. E. Guzman-Bouilloud, A. Ramirez-Venegas, R.H. Sansores-Martinez, O. Perez Bautista, C. Sanchez-Romero, M. Velazquez Uncal, C. Aguilera-Arellano, Mexico City, Mexico, p.A1740


P1192 Map the Gap: Using Regional Mapping to Compare Pulmonologists Workforce to Chronic Obstructive Pulmonary Disease Prevalence Geographically/M. Rachid, A. Shah, K. Ahmad, A. Krikorian, Oak Lawn, IL, p.A1743

THEMATIC POSTER SESSION

A49 ISSUES IN COPD

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Area L, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion

12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: D. Mannino, MD, Lexington, KY


The information contained in this program is up to date as of March 9, 2017.

For the most current session information, please visit the online program itinerary.

P1198 The Association of Airflow Limitation with Occupational Exposures in a Sample of Rural Adults in Iowa/P.K. Henneberger, M.J. Humann, X. Liang, B.C. Doney, K.M. Kelly, J.M. Cox-Ganser, Morgantown, WV, p.A1748

P1199 The Occupations at Increased COPD Risk in the Large Population-Based UK Biobank Cohort/Se De Matteis, D. Jarvis, A. Darnton, L. Rushton, P. Cullinan, London, United Kingdom, p.A1749


P1201 Lung Cancer Resection and Postoperative Outcome in Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease/E. Roy, J. Rheault, M.-A. Pigeon, Y. Lacasse, F. Maltais, P. Ugalde, Quebec, Canada, p.A1751

P1202 The Effect of Particulate Matter on Admission of COPD and Asthma in Shijiazhuang City/Y.X. Xin, M.D. Yang, Shijiazhuang, China, p.A1752

P1203 Chronic Obstructive Pulmonary Disease Mortality in Sub-Saharan Africa and the Caribbean/J.I. Obi, A. Mehari, R. Gillum, Washington, DC, p.A1753

Facilitator: C.E. Berry, MD, Tucson, AZ

P1204 Are There Gender Differences in COPD? Two-Year Follow-Up of Patients in the Real-life DACCORD Cohort/C.-P. Creie, P. Kardos, C. Vogelmeier, R. Buhl, N.S. Lossi, C. Mailander, H. Worth, Bovenden, Germany, p.A1754


P1209 Use of Artificial Intelligence and Traditional Methods in the Miss Diagnosis of COPD/A.R. Bastidas Goyes, D. Botero Rosas, Bogota, Colombia, p.A1759


P1213 Prevalence and Determinants of Chronic Obstructive Pulmonary Disease in a Rural Area in Cameroon/B. H. Mbatchou Nghane, F. Ebanga, Y. Nnomo, N. Essomba, E. Afane Ze, Douala, Cameroon, p.A1763

### A50 CRITICAL CARE: GETTING STRONGER - MEASURING AND IMPROVING FUNCTION IN ICU SURVIVORS

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Area E, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion

12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: D. Needham, MD, Baltimore, MD

A.E. Turnbull, DVM, MPH, PhD, Baltimore, MD


P514 Physical Functional Intensive Care Test (PFIT) and De Morton Mobility Index (DEMMI): Cross Cultural Validation and Reliability of the Brazilian Portuguese Version/V. Da Silva, R. Pires-Neto, L. Vieira, N. De Morton, L. Denehy, S.M. Parry, Brasilia, Brazil, p.A1765

P515 Functional Mobility Scores and Discharge Disposition in the Parkland MICU: A Descriptive Study/D.H. Yang, M. Weinreich, S. Park, J.L. Martin, D. Needham, M.K. Ong, B. Kamdar, Los Angeles, TX, p.A1766


Facilitators: M.E. Kho, PT, PhD, Hamilton, Canada
S.E. Jolley, MD, MSc, New Orleans, LA


P522 Implementation of an Early Mobility Algorithm in a Neurosurgical Intensive Care Unit/K. Raines, J. Singh, B. Amato, J. Retelski, Charlotte, NC, p.A1773

P523 The Role of Rehabilitation Leadership in a Multidisciplinary Intensive Care Lung Rescue Unit: Our Experience at the University of Maryland Medical Center/K.S. Omanwa, C.L. Wells, J. Menaker, D. Johnson, Baltimore, MD, p.A1774

P524 Integrating the Critical Care Physiotherapy Workforce in UK Critical Care Research/B. Connolly, N. Pattison, M. Shaw, P. Dark, London, United Kingdom, p.A1775

P525 Estimating Oxygen Consumption from Minute Ventilation (Ve) During Rehabilitation in Mechanically Ventilated Patients Recovering From Critical Illness/C. Black, M. Singer, M. Grocott, London, United Kingdom, p.A1776

P526 Patients with More Ventilator Free Days Achieve a Greater Percentage of Registered Dietitian Protein Recommendations for Enteral Feeding over the First Two Weeks of Medical ICU Admission/M.G. McCusker, M. Serra, A.C. Verceles, Baltimore, MD, p.A1777


Facilitators: B. Connolly, BSc(Hons), MSc, PhD, London, United Kingdom
P.E. Morris, MD, Lexington, KY


P529 Functional Status After a Burn ICU Stay/T.B. Figueiredo, R.C. Pires-Neto, Sao Paulo, Brazil, p.A1780

P530 Late Mobilization: In Hospital Physical Therapy After Intensive Care Unit Transfer/L.A.P. Callahan, A.P. Kelly, G.S. Supinski, Lexington, KY, p.A1781

P531 Functional Status at Discharge From Long-Term Acute Care Hospital Is Not Associated with Baseline Functional Status/E. Magno, T.V. Quinn, R. Balk, J.A. Greenberg, Chicago, IL, p.A1782

P532 The Effect of Acute Illness on the Course of Chronic Disease: The Example of Multiple Sclerosis/A. Garland, L. Metz, R.A. Marrie, Winnipeg, Canada, p.A1783


P535 The Effects of High Protein Intake and Mobility-Based Rehabilitation on Ventilator Weaning and Discharge Status in Survivors of Critical Illness/S.R. Wappel, O. Ali, E. Parker, A.C. Verceles, Baltimore, MD, p.A17575

---

**THEMATIC POSTER SESSION**

**A51 CRITICAL CARE: RISK STRATIFICATION AND PROGNOSTICATION - FROM BEDSIDE TO BIG DATA**

9:15 a.m. - 4:15 p.m.  
WALTER E. WASHINGTON CONVENTION CENTER  
Area E, Hall B-C (Middle Building, Lower Level)

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:15-12:00: authors will be present for individual discussion  
12:00-1:00: authors will be present for discussion with assigned facilitators

**Facilitators:** H. Wunsch, MD, MSc, Toronto, Canada  
I. Barbash, MD, Pittsburgh, PA


**P538 Predictors of Bacteremia from the Complete Blood Count in Patients in the Intensive Care Unit/N. Maniar, R. Cavallazzi, Louisville, KY, p.A1786**

P568 Medication-Wide Association Study in Sepsis and Suspected Infection/A.P. Sales, M. Mayhew, J. Greene, T. Wasson, V. Liu, Livermore, CA, p.A1816

P569 Post-ICU Mechanical Ventilation: Weaning Outcomes in 15,724 Patients Reported from the National Association of Long Term Hospitals (NALTH) Health Information System (NHIS)/J.J. Votto, L. Koenig, T.F. Kirby, J. Dollard, New Britain, CT, p.A1817


P572 Complicated Influenza PIRO Score for Predicting Mortality in Patients with Virology Proven Influenza Admitted to Intensive Care Unit (ICU)/W.-F. Fang, M.-C. Chan, K.-Y. Yang, C.-K. Kao, C.-C. Sheu, H.-C. Wang, S.-J. Liang, C.-Y. Lin, C.-H. Huang, W.-C. Perng, C.-L. Wu, Kaohsiung, Taiwan, p.A1820


P574 Association Between Rothman Index (RI) and Post-Discharge Patient Outcomes in the Medical Intensive Care Unit (MICU)/H.A.M. Fakih, S. Daouk, L. Mramba, I. Faruqi, Gainesville, FL, p.A1822


THEMATIC POSTER SESSION

A52 CRITICAL CARE CASE REPORTS: ADULT AND PEDIATRIC SEPSIS AND ICU INFECTIONS

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area M, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: M.E. Prekker, MD, MPH, Minneapolis, MN
R. Mehta, MD, Maywood, IL

P1279 Puzzling Battle between the Ps/A. Arjuna, K.D. Scatliffe, P. Patel, Newark, NJ, p.A1824


P1281 An Uncommon Deadly Gastrointestinal and Liver Mucormycosis with Disseminating Mucormycosis Secondary to Immunosuppressive Condition of Acute Severe Myocarditis in a 14 Year Old Girl/Y. Zhang, Z. Chen, D. Hong, H. Yang, H. Li, S. Shi, Beijing, China, p.A1826


P1283 A Rare Case of Candida Albicans Acalculous Cholecystitis in a Patient Being Treated for Severe Clostridium Difficile/K. Bally, D. Railwa, Brooklyn, NY, p.A1828

P1284 An Unusual Case of Non-Fatal Severe Acute Respiratory Distress Syndrome Secondary to Disseminated Aspergillus Fumigatus in an Immunocompetent Host/A. Rajagopal, M. Khosravi, Lexington, KY, p.A1829

P1285 Staphylococcal Scalded Skin Syndrome in an Adult Intensive Care Unit Patient/A. Rajagopal, M. Khosravi, Lexington, KY, p.A1830


Facilitators: S. Murthy, MD, Vancouver, Canada
G. Mortamet, MD, MSc, Montreal, Canada


P1291 An Unexpected Case of Sepsis: Always Keep Searching/J. Ramos-Rossy, W. Rodriguez-Cintron, J. Torres-Palacios, San Juan, PR, p.A1836


P1293 A Rare Case of Adult Community-Acquired Escherichia Coli Meningitis as a Complication of Bacteremia and Urinary Tract Infection/S. Griffith, H. Poonyagariyagorn, Portland, OR, p.A1838

P1295 Subdural Empyema Following a Tooth Extraction/Z. Bhatti, J.A. Ben Gabr, D. Landsberg, Syracuse, NY, p.A1840


P1297 Purpura Fulminans Secondary to Streptococcal Pneumonia Bacteremia in an Asplenic Adult Patient/H. Madina, N.M. Vasquez, T. Loethen, W. Parker, Columbia, MO, p.A1842

P1298 Streptococcus Anginosus Calculous Cholecystitis in an Immunocompromised Patient with Septic Shock/A.C. Miller, S. Santosh, St. Louis, MO, p.A1843

Facilitators: B. Ergen, MD, Izmir, Turkey
S.D. Levy, MD, Boston, MA


P1300 Group A Streptococcus Bacteremia from Acute Pharyngitis: A Rare Source/S. Katepalli, H.A. Cheema, R.I. Pargament, York, PA, p.A1845


P1306 Disseminated Nocardia Cyriacigeorgica Associated with Long-Term Low Dose Steroid Use/I.I. Maduforo, S. Ahmad, Longview, TX, p.A1851


Facilitators: I.D. Peltan, MD, MSc, Murray, UT
O.T. Ranzani, MD, MSCE, Sao Paulo, Brazil

P1309 Case Report of Extensive Air Pockets Surrounding Liver Metastases Due to Non-Typhoid Salmonella/V. Kaul, S. Easaw, X. Han, T. McGarry, Elmhurst, NY, p.A1854

P1310 Purpura Fulminans Resulting from Pasteurella Multocida Sepsis/A. Behal, L. Srinivasan, Waukegan, IL, p.A1855

P1311 Acute Respiratory Failure Due to Severe Sepsis from Necrotizing Fasciitis Due to Actinomyces in a Sickle Cell Disease Patient/P. Catella, N. Shah, S. Wiesel, A. Khalil, M. Cooper, A. Cullford, Staten Island, NY, p.A1856


P1316 Atypical Complications of an Unexpected Case of Lemierre’s Disease/N. Mehta, V. Cimino, M. Hershman, D. Wisa, S. Patel, B. Husta, New York, NY, p.A1861


Facilitators: V. Kaul, MD, Elmhurst, NY
D. Pradhan, MD, New York, NY


P1321 An Atypical Presentation of Necrotizing Fasciitis/D. Zusin, Bethesda, MD, p.A1866


P1326 Munchausen’s Syndrome Masquerading as Septic Shock/P.H. Huang, A.M. Szema, South Setauket, NY, p.A1871

P1327 Too Hot to Handle: 10 Month Old Presenting with Fever of 45 Degrees Celsius/R.K. Kagunoto, I. Kihurani, Nairobi, Kenya, p.A1872
A53  CRITICAL CARE: PROBLEMS RELATED TO INTUBATION, WEANING, AND EXTUBATION

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER  
Area E, Hall B-C (Middle Building, Lower Level)

Discussion:
11:15-12:00: authors will be present for individual discussion  
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators:
N.D. Ferguson, MD, MSc, Toronto, Canada  
J. Chen, MD, Bronx, NY


P581  Deadspace to Tidal Volume Ratio as a Predictor of Extubation Success/J.A. Gehlbach, A.G. Miller, C.P. Hornik, I.M. Cheifetz, I.O. Farrag, M. Al Hallag, Giza, Egypt, p.A1877

P582  Diaphragm Ultrasound as a Predictor of Liberation from Prolonged Mechanical Ventilation/M.G. Sperry, O. Ali, A.C. Veveres, Baltimore, MD, p.A1878


Facilitators:
R.G. Wunderink, MD, Chicago, IL  
J. Mosier, MD, Tucson, AZ


P589  Patient Characteristics and Outcomes of Weaning from Prolonged Mechanical Ventilation at Zablocki Veterans Affairs Medical Center/J.A. Kelbe, M. Ellis, A. Anton, Milwaukee, WI, p.A1885


THEMATIC POSTER SESSION

A54  CRITICAL CARE: OUTCOMES IN RESPIRATORY FAILURE

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER  
Area E, Hall B-C (Middle Building, Lower Level)

Discussion:
11:15-12:00: authors will be present for individual discussion  
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators:
J.A. Gold, MD, Portland, OR  
S.K. Sahetya, MD, Baltimore, MD


P596  Higher Expiratory End-Tidal Oxygen Correlates with Worse Outcomes in a Cohort of Ventilated Trauma and Burn Patients/D. Younan, J. Zhang, R. Johnson, R. Clark, M. Mathru, D. Miller, Mountain Brook, AL, p.A1890


P598  Clinical Outcome Associated with the Use of Different Inhalation Method with and Without Humidification in Asthmatic Mechanically Ventilated Patients/M.E.A. Abdelrahim, I.O. Farrag, M. Al Hallag, Giza, Egypt, p.A1892
P623 Maximum ICU SOFA Score is a Better Predictor of 1-Year Mortality than SOFA on ICU Admission Among Patients Requiring Prolonged Ventilatory Support/T.V. Quinn, E. Magno, B. Varghese, R. Balk, J.A. Greenberg, Chicago, IL, p.A1913


Facilitators: T.J. Iwashyna, MD, PhD, Ann Arbor, MI
M. Afshar, MD, Chicago, IL


P626 Evaluation of the Quick Sequential Organ Failure Assessment Score in Patients Attributing Critical Illness Population at a University Hospital/M. Katsoulis, R. Balk, Chicago, IL, p.A1916


P628 Diagnostic Differences Between SOFA Scores and SIRS Criteria in an ICU Cohort/J. Willoughby, A. Damodaran, P. Belvitch, Chicago, IL, p.A1918


P630 The New York State Mandated Public Reporting Initiative for Sepsis/M. Afshar, MD, Chicago, IL


P1330 A Rare Case of Mediastinal Hematoma Leading to Right Ventricular Outflow Tract Obstruction/P. Soni, S. Chadha, V. Kumar, A. Rai, A. Saxena, A. Sadiq, N. Aggarwal, Y. Kupfer, Brooklyn, NY, p.A1920


P1334 Unusual Presentation of Aortic Insufficiency in a Patient with Active Endocarditis in the Setting of ERDS/A.J. Shah, K. Liu, Syracuse, NY, p.A1924


P1336 Acquired Left Ventricular Outflow Tract to Right Atrial Fistula Due to Tricuspid Valve Endocarditis/O. Nadeem, A. Motwani, S. Parikh, J. Borgi, M. Hudson, Detroit, MI, p.A1926

P1337 A Case of Native Valve Staphylococcus Epidermidis Endocarditis with Cardiac Abscess Formation/E. Cordes, C. Jacob, M. Loehrke, Kalamazoo, MI, p.A1927


Facilitators: M.M. Mansour, MD, Stony Brook, NY
N.M. Kanodra, MBBS, Seattle, WA

P1340 Anaerobic Purulent Pericarditis with Cardiac Tamponade Caused by Bacteroides Fragilis/S. Saouma, V. Spagnola, N. Mobarakai, J. Lafferty, Staten Island, NY, p.A1930


P1342 Rare Case of Cardiac Tamponade Due to a Transudative Effusion in a Patient with Nephrotic Syndrome/M.S. Ali, M. Ganesh, L. Paz Rios, B. Mba, Milwaukee, WI, p.A1932

P1343 Cardiac Tamponade from Anaerobic Purulent Pericarditis/L. Schmidt, B. Self, Roanoke, VA, p.A1933

P1344 Rapidly Evolving Cardiac Tamponade in a Case of Viral Pericarditis/E.Y. Chang, Q. Ngo, A.F. Chaudhry, R. Sachdeva, Atlanta, GA, p.A1934
P1345 Postpericardiotomy Syndrome (PPS) After a DeBakey Type 1 Aortic Dissection Repair Leading to a Massive Cardiac Tamponade/U. Tarig, J.B. Stansberry, T. Jones, T.T. Nguyen, R.A. Khan, Orlando, FL, p.A1935


P1348 Reverse Takotsubo Cardiomyopathy Presenting as Nonocclusive Mesenteric Ischemia/G.S. Thind, S. Sivsammye, Kalamazoo, MI, p.A1938


Facilitators: S.R. Kudchadkar, MD, Baltimore, MD S.J. Denstaedt, MD, Ann Arbor, MI

P1351 Heart Failure - Is It Lupus Myocarditis or Peripartum Cardiomyopathy?/G. Malhotra, S. Sivaraman, A. Fulambarker, North Chicago, IL, p.A1941

P1352 Post-Partum Cardiomyopathy Complicated by NSTEMI in Setting of Cocaine Use/M.A. Zulqarnain, A. Rajasekaran, North Chicago, IL, p.A1942

P1353 Heart Failure as a Cause of Protein Loosing Enteropathy/M. Ali, A. Latkineh, A. Nakhle, Z. Saleh, D. Jacobi, Detroit, MI, p.A1943

P1354 Beriberi Induced Cardiomyopathy Requiring Salvage VA-ECMO/S. Kothari, A. Shah, S. Patel, J. Denk, Oak Lawn, IL, p.A1944


P1358 Congenital Absence of Left Coronary Artery: A Rare Coronary Circulation Anomaly/W. Humayun, A. Ghanai, A. Balaratna, M. Naglik, Abington, PA, p.A1948

P1359 Severe Coarctation of the Aorta in an Asymptomatic Adult, an Incidental Discovery/M. Greer, F. Hannallah, Dallas, TX, p.A1949


Facilitators: G.L. Anesi, MD, MBE, Philadelphia, PA N. Hajizadeh, MD, MPH, Manhasset, NY


P1364 Uncommon Cause of Right ventricular Outflow Tract Obstruction in a Young Female/S. Marupudi, A. Amjad, M.I. Ahmad, Winston-Salem, NC, p.A1954


P1366 Eat Your Heart Out: Right Heart Collapse from Bowel Obstruction/S. Assar, A. Nakhle, M. Lazar, Detroit, MI, p.A1956


P1368 Fibrotic Lung Disease Due to Pulmonary Vein Stenosis Following Catheter Ablation for Atrial Fibrillation/K.G. Coonse, S. Hoskote, Rochester, MN, p.A1958

P1369 Gas Exchange and Hemodynamic Consequences of Severe Hemolysis Induced by Insertion of an Impella Device in a Patient with Cardiogenic Shock/L. Rodgers, C.A. Keller, Jacksonville, FL, p.A1959

P1370 PICC’ing Your Way into the Pericardium/L. Miyakawa, M. Bergman, Y.I. Lee, New York, NY, p.A1960


THEMATICAL POSTER SESSION

A57 CRITICAL CARE CASE REPORTS: CARDIOVASCULAR DISEASE II

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER Area M, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: S. Dhar, MD, Lexington, KY F. Moazed, MD, San Francisco, CA


Facilitators: N. Ali, MD, Columbus, OH
R. Kohn, MD, Philadelphia, PA

P1405 Cerebral Hemorrhage Due to Blast Cell Crisis: A Case Report

P1406 Do Not Take Two Aspirin and Wait to Call in the Morning: A Rare and Potentially Life-Threatening Cause of Post-Partum Headache in the ICU.

P1407 Hemorrhage in Posterior Reversible Encephalopathy Syndrome as a Complication of Tacrolimus Therapy
M.S. Rizvi, P.D. Scanlon, Rochester, MN, p.A1995

P1408 Hypothermia Induced Thrombocytopenia with Subdural and Intracerebral Hemorrhage
S. Soni, Urbana, IL, p.A1996

P1409 Critical Cerebral Vasospasm Due to Post-Surgical Hemorrhage After Transspheinal Resection of a Pituitary Macroadenoma

P1410 Anoxic Brain Injury Presenting as Pseudo Subarachnoid Hemorrhage in the Medical Intensive Care Unit

P1411 Arterial Air Embolism- An iatrogenic phenomenon with Fatal Consequences

P1412 Cerebral Air Emboli After Percutaneous Computed Tomography-Guided Transthoracic Needle Biopsy of the Lung

P1413 Keep an Eye on the Air: A Case of Presumed Air by Vitrectomy

P1414 Cerebral Arterial Air Emboli Caused by Aggressive Bag Valve Ventilation

Facilitators: D. Bates, MD, La Jolla, CA
G.J. Soto, MD, Bronx, NY

P1415 A Severe Case of Cerebral Air Embolism Following a Massive Iatrogenic Venous Air Embolism After Contrast Enhanced CT

P1416 Regression: An Atypical Presentation of Lupus Cerebritis

P1417 A Rare Case of Pembrolizumab-Associated Autoimmune Limbic Encephalitis Following Treatment of Malignant Melanoma

P1418 A Rare Case of Post Infectious Encephalitis

P1419 Bickerstaff Brainstem Encephalitis (BBE) a Rare Variant of GBS Mimicking as Meningitis

P1420 Zika Virus-Associated Guillain-Barre Syndrome in a Returning United States Traveler

P1421 Moyamoya Syndrome: An Atypical Cause of Encephalopathy

P1422 Non-Alcoholic Wernicke's Encephalopathy Leading to Progressive Neurological Failure
V. Pathak, M. Ricker, Raleigh, NC, p.A2010

P1423 Unusual Cause of Altered Mental Status: Hyponatremia Encephalopathy Without Hepatic Dysfunction

P1424 Recovery After Prolonged Hypoglycemic Coma from Extreme Hypoglycemia

Facilitators: A. Goffi, MD, Toronto, Canada
M.G. Patel, MD, Maywood, IL

P1425 An Extreme Case of Dialysis Disequilibrium Syndrome Leading to Brain Death

P1426 Hypertensive Encephalopathy Associated Vasogenic Edema Causing Intracranial Hypertension and Brain Death

P1427 Diffuse Cerebral Edema from Acute Pancreatitis Induced by Hypertriglyceridemia

P1428 A Case of Hydrocephalus Secondary to Intraventricular Neurocysticercosis

P1429 Tetanus: An Innovative Treatment Strategy for Refractory Spasticity

P1430 Desmopressin Induced Severe Hyponatremia with Central Pontine Myelinolysis

P1431 A Rare Cause of Cardiac Arrest - Devic's Disease
S. Palakuru, B. Koka, Houston, TX, p.A2019

P1432 Severe Spinal Stenosis as a Cause of Froin's Syndrome in a Critically Ill Patient

P1433 Impact of Sympathetic Storm (From Brain Trauma) on Ventilator Dependence
P.M. Thalanayar, L.O. James, M. Sanger, New York, NY, p.A2021

P1434 Tetanus Caused by a Traditional Healer's Efforts to Treat Squamous Cell Carcinoma
P. Saikali, H. Sequeira, S. Winter, S. Shumbairerwa, Norwalk, CT, p.A2022
THEMATIC POSTER SESSION

A59 EPIDEMIOLOGY OF AIRWAYS AND CHRONIC LUNG DISEASES

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Area L, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: S. London, MD, DrPH, Research Triangle Park, NC


P1222 Effectiveness of Training Patients in the Accurate Use of Inhalers for the Treatment of Bronchial Asthma Via DVD/K. Takita, R. Kondo, T. Horiguchi, Aichi, Japan, p.A2030

Facilitator: L. Hooper, MD, MPH, Seattle, WA

P1223 An Evidence Based Approach to the Use of Incentive Spirometry in General Medical Patients: A Descriptive Population Study/N. Motayar, I. Naqvi, G.B. Malka, Cincinnati, OH, p.A2031


P1228 Asthma and Asthma Symptoms in Teachers in 50 Elementary Schools in a Large City/J.M. Cox-Ganser, J.-H. Park, J. Roseman, S. Game, Morgantown, WV, p.A2036


Facilitator: S. Guerra, MD, PhD, MPH, Tucson, AZ


P1236 Association Between Endotoxin, Damp Housing and Current Wheeze in Adults Living in Two First Nations Communities/H.C. Erythropel, S.V. Jabba, T.M. Pahwa, Saskatoon, Canada, p.A2044

P1238  Determinants of Incident Asthma-COPD Overlap Compared to Asthma and COPD Alone: A Prospective Study of 55,110 Middle-Aged Adults/C.B. Barnes, Z.J. Andersen, K. Overvad, A. Tjønneland, C.S. Ullik, Hvidovre, Denmark, p.A7584


P1458  Experimentation of Hookahs and Tobacco Consumption Among College Students/M.F. Rabahi, L.A. Souza Oliveira, Goiania, Brazil, p.A2046


P1462  Is Sleep Behavior Related to Tobacco Use and Physical Activity Capacity in Pulmonary Care Patients/J.C. Brown, A. Satti, A. Tate, G. Ma, F. Patterson, Philadelphia, PA, p.A2050


P1464  Vaping and Tension Pneumothorax: A Life-Threatening Association/T. Lo, Kailua, HI, p.A2052

P1465  Electronic Cigarette and Tobacco Product Use in Adolescents in Johannesburg - Results from a Survey/E. Shaddock, Johannesburg, South Africa, p.A2053


P1470  Your Heart. Your Heart on Drugs ... Any Questions?/K. Sanchez, J. Acloque, A.A. Agosto-Mujica, J.R. Aleman-Ortiz, Ponce, PR, p.A2058

P1471  Aspiration of Cocaine Filter: A Rare Complication of Smoking Crack Cocaine/M. Wakin, R.B. Mitchell, A. Modak, C.P. Bulathsinghala, S. Surani, Corpus Christi, TX, p.A2059

P1472  Status Epilepticus from Nasal Insufflation of Wellbutrin/Sharara, A. Fasanya, V. Gandhi, K. Malik, Pittsburgh, PA, p.A2060


P1476  Cannabis Induced Broncho Pneumonitis Leading to Fatal Cardiac Arrhythmia/W.P. Kyaw, M.S. Win, T.W. Naing, Brooklyn, NY, p.A2064

P1477  Almost Legal but Still Potentially Lethal: A Case of Marijuana Induced Hemoptysis/A.A. Husain, A.R. Thopu, M. Parker, Atlanta, GA, p.A2065

P1478  DAHzed and Confused: Alveolar Hemorrhage Associated with Synthetic Cannabinoid Use/B. Wendlandt, D. Henke, Chapel Hill, NC, p.A2066


P1481  Impact of Electronic Cigarette Exposure on the Pulmonary Circadian Rhythm/A. Lechasseur, J. Routhier, E. Jubinville, M. Hamel-Augier, J.-C. Berube, S. Aubin, M.-E. Pare, M.-J. Beaulieu, C. Duchaine, Y. Bosse, M.C. Morissette, Quebec, Canada, p.A2069

ATS 2017 • Washington, DC  The information contained in this program is up to date as of March 9, 2017.  For the most current session information, please visit the online program itinerary.
**SUNDAY • MAY 21**

**A61 TUBERCULOSIS DISEASE: HOST RESPONSE AND DIAGNOSTICS**

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

_Area D, Hall B-C (Middle Building, Lower Level)_

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:15-12:00: authors will be present for individual discussion

12:00-1:00: authors will be present for discussion with assigned facilitators.

**Facilitator:** M. Mirsaedi, MD, Miami, FL

---

**P367** The Role of Interleukin (IL)-4 and T-Helper (Th)-2-Like Cytokines in the Host Immune Response to Tuberculosis/A.S. Pooran, M. Davids, A. Nel, A. Shoko, J. Blackburn, K.U.J. Dheda, Cape Town, South Africa, p.A2070


**P371** Relation of Leptin, TNF-Alpha and IL-6 with Respiratory and Peripheral Muscle Strength, and Nutritional Status in Active Pulmonary Tuberculosis/D.R. Silva, E.C. Skupien, T.K. Lazzari, S.E. Coutinho, Porto Alegre, Brazil, p.A2074


**P373** Diagnostic Ability of Specialists on the Areas Other than Respiratory Medicine in Relation to Pulmonary Tuberculosis in the Emergency Department/H. Takata, C. Nishio, H. Tomioka, Kobe, Japan, p.A2076

**P374** More than a Decade of Tuberculosis Diagnosis in MRC Unit, the Gambia(MRCG)/F.S. Mendy, A.K. Faburay, O. Secka, A. Ayorinde, T.I. Faal-Jawara, J. Otu, Banjul, Gambia, p.A2077

**P375** Challenges in the Diagnosis and Management of Pediatric Pulmonary Tuberculosis in Madagascar/E. Cordes, R. Roach, Kalamazoo, MI, p.A2078

**P376** Leukocyte Count and Its Diagnostic Value in Newly Diagnosed Tuberculosis Patients at the Douala General Hospital, Cameroon/B.H. Mbathou Nghane, E. Abinkeng Tazfiu, E. Ngouadjieu Dongho, H. Luma Namme, Douala, Cameroon, p.A2079


**P383** Drug Resistance Pattern Among Extrapulmonary Tuberculosis Cases in a Tertiary Care Center in India/S.K. Sharma, J. Chaubey, B.K. Singh, R. Sharma, A. Mittal, New Delhi, India, p.A2086

**P384** Xpert MTB/RIF Assay in Bronchoalveolar Lavage Specimen in Smear Negative Pulmonary Tuberculosis/D. Bhattacharyya, M. Kumar, Delhi Cantt, India, p.A2087


**P386** Gene Chip Technology to Detect Mycobacteria and Resistance in the Application of Tuberculous Empyema/X. Chen, Fuzhou, China, p.A2089


---

**THEMATIC POSTER SESSION**

**A61 TUBERCULOSIS DISEASE: HOST RESPONSE AND DIAGNOSTICS**

**9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER**

_Area D, Hall B-C (Middle Building, Lower Level)_

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:15-12:00: authors will be present for individual discussion

12:00-1:00: authors will be present for discussion with assigned facilitators.

**Facilitator:** K.U.J. Dheda, MD, PhD, Cape Town, South Africa

---

**P1482** Acute Pulmonary Effects of Aerosolized Nicotine in Rodents/S. Ahmad, I. Zafar, N. Mariappan, M. Husain, A. Ahmad, Birmingham, AL, p.A7585

**P1483** E-Cigarette Vapor Inhalation Leads to Impaired Arteriolar Vascular Function in Mice/B. Erdreich, W.K. Mandler, I.M. Olfert, Morgantown, WV, p.A7586
A62 TREATMENT OF TUBERCULOSIS

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Area D, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: C.A. Magis-Sucre, MD, PhD, Groenbeck, Netherlands

P388 Elevated IL-33 in Tuberculous Pleural Effusion: A Novel Biomarker

P389 Measurement of Interferon-Gamma (IFN-γ) and IFN-γ-Inducible Protein 10 (IP-10) in Combination on Pleural Fluid as an Alternative to Adenosine Deaminase for Diagnosis of Tuberculosis

P390 The Diagnostic Challenge of Pleural Tuberculosis - Criteria

P391 Cytological Diagnosis of Tuberculosis of Eosinophilic Material with Dark Brown Particles

P392 The Advantage of Fine Needle Aspiration Biopsy Compared to Ziehl Neelsen Examination in Tuberculous Lymphadenitis

P393 The Validity of Pleuroscopy in Diagnosing Tuberculosis and Lung Cancer: A Malaysian Tertiary Hospital’s Experience

P394 Functional and Structural Outcomes in Patients with Pulmonary Tuberculosis Occurred in Pediatric Age

P395 Abdominal TB: An Analysis of the St. Michael’s Hospital TB Clinic’s Experience in Toronto, Canada

P396 Tuberculosis in Octogenarian Patients Between 2011-2016 in Fundacion Valle del Lili, a Reference Hospital in Latin America

P397 Characterization of a 2013-2016 Cohort of Patients with Multi-Drug Resistant Tuberculosis (MDR-TB) with Major Surgical Management in Fundacion Valle del Lili, a Reference Hospital in Latin America

P398 Comparison of Active and Chronic Tuberculosis Patients with Tracheobronchial Stenosis: Clinical, Radiological, Bronchoscopic and Outcome Differences

P399 Characteristics and Outcome Analysis of Tuberculous Tracheobronchial Strictures: A South-East-Asian Single-Centre Experience of 141 Patients During an 18-Years Period

P400 Predictors of Delay to Accessing Care among Tuberculosis Patients in Southern India

P401 The Effect of Metformin on Smear and Culture Conversion of Pulmonary Tuberculosis

P402 The Effect of Metformin on Culture Conversion in Tuberculosis Patients with Diabetes Mellitus

P403 Are There Factors that Predict Intensive Care Unit Admission in Patients with Active Mycobacterium Tuberculosis Infection: A Retrospective, Cohort Study

P404 Evaluation of Host Markers for Tracking Early Treatment Response in Newly Diagnosed Pulmonary TB Patients: Early Bactericidal Activity (EBA) Study

P405 Clinical Outcomes of Critically Ill Patients with Tuberculosis, a Nationwide Analysis with the Korean Intensive Care Unit National Data (KIND)

P406 Smoking Influences the Conversion of Sputum and the Quantity of Acid-Fast Bacilli Bacteria in Intensive Phase Treatment Among TB Patients in Banda Aceh, Indonesia

P407 The Effect of Metformin on Culture Conversion in Tuberculosis Patients with Diabetes Mellitus

P408 The Effect of Metformin on Smear and Culture Conversion of Diabetic Patients with Tuberculosis

P409 Prevention and Outcomes of Xpert MTB/RIF-Detected Drug Susceptible and Resistant Tuberculosis in a Post-Conflict Region of the Democratic Republic of the Congo

Facilitator: C.A. Magis-Sucre, MD, PhD, Groenbeck, Netherlands
P420 A Rare Case of Pulmonary Eosinophilia Caused by Hypotension and Hypoxia After 30 Days of Steroids: A Case Extrapulmonary Coccidiomycosis Masquerading as Facilitator: C.A. Hage, MD, Indianapolis, IN
9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER A63 CASE REPORTS: FUNGAL J.-S. Chang,


THEMATIC POSTER SESSION

A63 CASE REPORTS: FUNGAL
9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER Area D, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: C. A. Hage, MD, Indianapolis, IN


P420 A Rare Case of Pulmonary Eosinophilia Caused by Coccidioidomycosis/E. Mlodzinski, C. Kyung, A. Surani, H. Ojeda-Martinez, P. Belligund, Brooklyn, NY, p.A2120


P422 Bronchoscopy Reveals a Diagnostic Headache: A Case of Central Nervous System Blastomycosis/J. H. Lyou, J. Longoria, M. Davoudi, Orange, CA, p.A2122


P427 Cryptococcal Meningitis and Pneumonia in an Immunocompetent Host Associated with Pigeon Exposure/J. Morante, S. Sarkar, M. Mora, J. Friedman, F. Bagheri, M. Babury, Jamaica, NY, p.A2127

Facilitator: E. M. Carmona, MD, PhD, Rochester, MN


P430 Coexisting Pulmonary Cryptococcosis and Pulmonary Tuberculosis in an Immunocompetent Host/S. Vanaik, N. Patel, A. Wani, Philadelphia, PA, p.A2130

P431 Spiculated Lung Nodule: A Rare Presentation of Subacute Invasive Aspergillosis/B. Bajantri, M. Adrish, Bronx, NY, p.A2131

P432 Disseminated Rhizopus Infection Diagnosed Via Endobronchial Biopsy/P. Eckerle, C. M. Kniese, F. Sheski, Indianapolis, IN, p.A2132

P433 Invasive Pulmonary Aspergillosis Following a Short Course of Steroids in an Immunocompetent Patient/N. Pletukhina, V. Keenan, A. Matela, J. Pang, S. Chawla, S. Salzman, Mineola, NY, p.A2133

P434 Cryptococcal Pleural Effusion - Rare Presentation/V. R. K. Angirekula, E. Warren, Cleveland, OH, p.A2134


Facilitator: O. Epelbaum, MD, Valhalla, NY

P437 Pulmonary Histoplasmosis Causing Stroke-Like Symptoms/M. Zefir, J. S. Imam, T. Bhattacharya, M. Reza, W. Bosch, Jacksonville, FL, p.A2137

P438 A Rare Association with Aspergilloma: Intralobar Pulmonary Sequestration/A. Ritwani, B. Stephenson, A. Vinayak, Washington, DC, p.A2138


The information contained in this program is up to date as of March 9, 2017. For the most current session information, please visit the online program itinerary.

ATS 2017 • Washington, DC

P441 Penicillium marneffei Presenting as a Pneumonia and Obstructive Airway Disease Exacerbation/S. Chaaban, K. Thavarajah, Detroit, MI, p.A2141


P444 Pneumonia by Pneumocystis Jiroveci in a Diabetic Patient/A. Grosso, M.M. Perin, S.D. Leiva Aguero, R. Berenguer, P. Vujacicich, C.M. Luna, Buenos Aires, Argentina, p.A2144


Facilitator: S.T. Qureshi, MD, Montreal, Canada

P446 Oro-Pleural Tube and Candida Empyema/R. Zulfikar, R. Sangani, Facilitator: S.T. Qureshi, MD, Montreal, Canada


P450 Atypical Presentation of Invasive Pulmonary Aspergillosis in an Immunosuppressed Patient/C. Chan, N. Shukla, N. Gupta, A. Singla, Dayton, OH, p.A2150


P453 Pulmonary Alveolar Proteinosis Complicated by Blastomycosis/M.J. Hellmann, K. Luckett, K. Hudock, Cincinnati, OH, p.A2153

P454 Acute Pulmonary Blastomycosis with ARDS in an Immunocompetent Patient/J. Chambers, M. Sehring, N.A. Smith, Peoria, IL, p.A2154

Facilitator: C.C. Kennedy, MD, Rochester, MN

P455 Pneumocystis Pneumonia with Rare Histological Finding of Granulomatous Inflammation in an Immunocompromised Patient with Chronic Lymphocytic Leukemia on Obinutuzumab/C. Donatelli, C.V. Teba, M.C. Yang, J. Kazakov, J. Alderson, Cleveland, OH, p.A2155


P460 Chronic Pulmonary Blastomycosis Mimicking Pulmonary Tuberculosis/M. Koroscil, San Antonio, TX, p.A2160

P461 Pulmonary Histoplasmosis During Vedolizumab Therapy for Crohn’s Disease/F. Zahiruddin, X. Nan, J. Zimmerman, Houston, TX, p.A2161

P462 Invasive Pulmonary Aspergillosis in a Steroid-Dependent Asthmatic/B.A. Jaumally, A. Salem, Baltimore, MD, p.A2162

P463 Acute Histoplasmosis Lymphadenitis Diagnosed by TBNA/D. Mabe, Bethesda, MD, p.A2163

THEMATIC POSTER SESSION

A64 BRONCHOPULMONARY DYSPLASIA
9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area F, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: S.H. Guttentag, MD, Nashville, TN

P633 Outcomes in Preterm Infants After Using 24-Hour Oxygen Saturation Histogram to Titrate Oxygen/M.D. Go, M. Rosenberger, C. Mahajan, St. Petersburg, FL, p.A2164


Facilitator:  V. Bhandari, MD, DrMed, Philadelphia, PA


P641  Evaluating Maternal Preeclampsia as a Risk Factor for Developing Bronchopulmonary Dysplasia/M. Sagar, C. Ogborn, M.R. Beeram, V.N. Raju, L. Mallett, Temple, TX, p.A2172


Facilitator:  K. Lingappan, MD, Houston, TX

P645  Time Dependant Effects of Mechanical Ventilation and Hyperoxia on Central Signalling Pathways in the Developing Lung Identified by Comprehensive Transcriptome Analysis/A. Hilgendorf, T. Pritzke, M. Markmann, P.S. Oak, M. Koschlig, H. Bossain, T.J. Desai, Munich, Germany, p.A2176


P649  MicroRNA and Protein Expression in the Pathogenesis of Pulmonary Hypertension of the Newborn/P. Silveyra, C. Oji-Mmuo, R. Siddaiah, Hershey, PA, p.A2180

THEMATIC POSTER SESSION

A65  PEDIATRIC CASE REPORTS: SLEEP AND RESPIRATORY PHYSIOLOGY

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER

Area F, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator:  J. Lew, MD, Washington, DC

P651  An Unorthodox Treatment Regimen to Prevent Recurrence of High Altitude Pulmonary Edema (HAPE) in a Young Skier/M. Kostrubia, A.M. Szema, South Setauket, NY, p.A2181

P652  Pulmonary Artery Embolism in a Child with Sickle Cell Trait: A Rare Association/A.A. Asseri, A. Shati, A. Al-Hanshani, I. Zedani, Tucson, AZ, p.A2182


P655  The Other Tonsils: Complex Chiari Malformation Teaches a Sleep Apnea Lesson/T.-V. Tran, S.M.M. Hawkins, B. O’Neill, T. Wine, P.C. Stillwell, Aurora, CO, p.A2185

P656  Keep a Patent Mind: An Unusual Cause of Hypoxemia in an 8-Year Old/A. St-Laurent, D. Zielinski, Montreal, Canada, p.A2186


The information contained in this program is up to date as of March 9, 2017.

For the most current session information, please visit the online program itinerary.
THEMATIC POSTER SESSION

**A66** THE MANY FACES OF ASTHMA IN CHILDHOOD

*9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER*

**Area F, Hall B-C (Middle Building, Lower Level)**

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

**Facilitator:** Y. Belessis, MBBS (Hons), MPH, PhD, Sydney, Australia


**P661** Long-Term Asthma-Related Readmission in Children Previously Admitted to the Intensive Care Unit for Asthma/S.M. Tse, M.E. Hartman, Montreal, Canada, p.A2190

**P662** A Retrospective Review Correlating Seasonal Pediatric Asthma Hospitalizations with Air Pollution, Viral Counts, and Demographic Factors/K.A. King, E. Min, Z. He, Wilmington, DE, p.A2191

**P663** Assessment of Stepwise Asthma Treatment in Dutch Children/A. Arabkhazaei, S. Vijerberg, C. Van Der Ent, J. Raajmakers, A.-H. Maitland-van Der Zee, Utrecht, Netherlands, p.A2192


**P666** The Effect of Cow-Milk Consumption on Respiratory Symptoms and Pulmonary Functions in Asthmatic and Non-Asthmatic Children/Y. Koren, K. Armoni Domany, G. Gut, O. Tavor, N. Maika, Y. Sivan, Tel Aviv, Israel, p.A2195

**Facilitator:** S. Zaidi, MD, Washington, DC


**P668** Development of an Asthma Awareness Film in London Secondary Schools/K. Harris, L. Ahendra, L. Cameron-Mowat, J. Allder, J. James, T. Casement, J. Grigg, London, United Kingdom, p.A2197


**P670** The Phenotype of Severe Preschool Asthmatics and Their Response to Add-On Therapy/C. Seaton, K. Hildebrand, A. Pow, C.L. Yang, Vancouver, Canada, p.A2199


**P672** Serum Testosterone Levels in Children with Asthma/S.K. Gadre, J.G. Zin, Cleveland, OH, p.A2201

**P673** Exercise Induced Bronchoconstriction in Obese Children with and Without History of Asthma/E. Concepcion, E. Manillich, H. Lee, New York, NY, p.A2202

**Facilitator:** K. Tsirilakis, MD, New Hyde Park, NY


**P679** Exercise Challenge Testing in Pediatric Patients with Exercise Induced Dyspnea - Is It Good Enough?/R. Bhatia, E. Schwendeman, Akron, OH, p.A2208


---

The information contained in this program is up to date as of March 9, 2017.

For the most current session information, please visit the online program itinerary.
BREAKDOWN: THE CELLULAR CONTRIBUTION TO PULMONARY HYPERTENSION

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area O, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: S.Y. Chan, MD, PhD, Pittsburgh, PA


P1548 Upregulation of Serum Response Factor (SRF) Contributes to Hypoxia Pulmonary Hypertension by Promoting Smooth Muscle Cells Proliferation Via Increasing Bcl-2 Expression/R. Wang, P. Wu, X. Ding, G. Fei, Hefei, China, p.A2238

P1549 CaMKII Is Necessary for Increased Proliferation and Migration of Pulmonary Arterial Smooth Muscle Cells in Pulmonary Hypertension/J. Huetsch, H. Jiang, L. Shimoda, Baltimore, MD, p.A2239

P1550 A Novel Cell Culture Model to Study Cytoskeletal Defects in Pulmonary Arterial Hypertension/R.W. D’Amico, J.D. West, Nashville, TN, p.A2240


P1554 Endostatin Suppresses the Inhibitors of DNA Binding/Differential Transcription Factors (ID1) and Promotes Pulmonary Artery Endothelial Cell Death/A. Goyanes, L. Wang, L. Varela, L. Johnston, M. Aladlin, T.M. Kolb, P.M. Hassoun, R.L. Damico, Baltimore, MD, p.A2244

Facilitator: D.E. Green, MD, Atlanta, GA

P1555 Effect of Over Expression of Natriuretic Peptide Receptor-A (NPR-A) and Receptor-C (NPR-C) on Pulmonary Vascular Endothelial Barrier Function/J.R. Klinger, H. Duong, L. Duran, O. Liang, A. Kumar, E.O. Harrington, Providence, RI, p.A2245


P1557 Hypoxia Inducible Factor-1α Increases Bone Morphogenetic Protein Receptor 2 Signaling in Pulmonary Artery Endothelial Cells (PAECs)/J. Kuang, X. Tian, S. Dannewitz Prosseda, A. Tian, D. Cornfield, M.R. Nicolls, E.F. Spikerkoetter, Stanford, CA, p.A2247


P1559 O-GlcNAc Transferase Regulates Angiogenesis in Idiopathic Pulmonary Arterial Hypertension/J. Barnes, L. Tian, N.E. Mellor, S.A. Comhair, R. Dweik, Cleveland, OH, p.A2249


P1561 Activation of Macrophages by Pulmonary Artery Adventitial Fibroblasts Towards a Pro-Inflammatory Phenotype Requires Notch Signaling Activity/M.J. Ostaff, S. Siddel, G.M. DeMasellis, M. Frid, A. Flockton, K.C. El Kasmi, K.R. Stenmark, Aurora, CO, p.A2251

P1562 Increased Pro-Inflammatory Alveolar Macrophage Polarization by TLR3 Agonists in Mice with Pulmonary Hypertension/G.M. DeMasellis, M.J. Ostaff, S. Riddle, E. Grayck, K.C. El Kasmi, K.R. Stenmark, Aurora, CO, p.A2252


P1566 The Effect of Cell Free Hemoglobin and/or Hypoxia on the Inflammatory Response of Pulmonary Microvascular Endothelial Cells: Possible Implications for PAH/S. Mumby, R. Graham, I. Adcock, London, United Kingdom, p.A2256

P1567 Role of CXCR3 in the Apoptosis-Resistance of Endothelial Progenitor Cells in HIV-Induced Pulmonary Hypertension/L. Farkas, D. Farkas, S. Chelvanambi, C. Cool, M.A. Clauss, Richmond, VA, p.A2257

P1568 Proliferative, Hyper-Migratory Phenotype and JAK/STAT Activation in Dermal Fibroblasts from Patients with Pulmonary Arterial Hypertension and Caveolin-1 Loss-of-Function Mutations/S. Gairhe, K.S. Awad, E. Austin, J.M. Elinoff, R.L. Danner, Bethesda, MD, p.A2258

P1569 Lymphocyte Specific Protein Tyrosine Kinase (LCK), a Novel Facilitator: The Role of HIFs in Maintaining Pulmonary Artery Fibroblast ROS Production and DNA Instability of Adventitial Fibroblasts in Schistosoma and Hypoxia PH/K. Connelly, W.M. Kuebler, Toronto, Canada, p.A2259


P1574 The Role of HIFs in Maintaining Pulmonary Artery Fibroblast Phenotypes in Pulmonary Hypertension/H. Zhang, C.-J. Hu, M. Li, A. Folkton, K.R. Stenmark, Aurora, CO, p.A2264


P1579 Bicalutamide Ameliorates Hypoxia-induced Pulmonary Artery Smooth Muscle Cell Proliferation/S. Guo, Y. Yang, Y. Zhou, Q. Zuo, X. Li, Chengdu, China, p.A2269

P1580 Role of Integrin β5 for the Phenotype of Human Pulmonary Microvascular Endothelial Cells: Implications for Endothelial-to-Mesenchymal Transition and Pathogenesis of Pulmonary Hypertension/N. Blanchard, D. Farkas, C. Cool, L. Farkas, Richmond, VA, p.A2270


P1593 Transition from PDE-5 Inhibitors to Riociguat in Pulmonary Hypertension/N. Weir, A.W. Brown, J. DeSantis, C. King, D. Lewis, D. Franco-Palacios, S.D. Nathan, O.A. Shlobin, Falls Church, VA, p.A2282

P1594 Comparison of Treatment Outcomes in a Cohort of Patients with Pulmonary Arterial Hypertension Treated with Inhaled Treprostinil Alone or in Combination with a Phosphodiesterase 5 Inhibitor/J. Swisher, R. Overton-Barnes, Knoxville, TN, p.A2283

Facilitator: W.H. Fares, MD, MSc, New Haven, CT


P1598 Results of the Prospective, Multicenter, Single-Arm, Open-Label, Phase 4 MOTION Study of Riociguat in Pulmonary Arterial Hypertension/N. Sood, A. Aranda, D.M. Platt, A. LaRose, F. Kleinjung, G. O’Brien, Columbus, OH, p.A2287

P1599 Single Center Experience in Transitioning Pulmonary Arterial Hypertension Patients from Intravenous Epoprostenol to Oral Selexipag/Z. Safdar, Houston, TX, p.A2288

P1600 The Effect of Chronic Dosing of Riociguat on Acute Hypoxic Pulmonary Vasoconstriction in Respiratory Disease/L. Thirugnanasothy, G. MacGowan, G. Parry, J. Simpson, P. Corris, Newcastle upon Tyne, United Kingdom, p.A2289


P1602 Role of Cardiopulmonary Exercise Testing in Assessing Treatment of Pulmonary Arterial Hypertension and Impact of a Change to a Macitentan-Containing Regimen/P.A. Corris, D. Jakovljevic, L. Thirugnanasothy, Newcastle upon Tyne, United Kingdom, p.A2291


Facilitator: H.J. Ford, MD, Chapel Hill, NC


P1608 Initial Combination Therapy with Macitentan and Tadalafil in Newly Diagnosed Patients with Pulmonary Arterial Hypertension: Results from the OPTIMA Trial/O. Sitbon, M. Canuet, F. Picard, G. Prevot, E. Bergot, V. Cottin, F. Bauer, B. Degano, V. Gressin, P. Clerson, G. Simonneau, Le Kremlin-Bicetre, France, p.A2297


P1610 OPUS Registry: Treatment Patterns with Macitentan in Patients with Pulmonary Arterial Hypertension/K. Chin, R.N. Channick, N.H. Kim, E. Muros-Le Rouzic, M. Selej, V. McLaughlin, Dallas, TX, p.A2299
SUNDAY • MAY 21

P1619 Comparative Clinical Efficacy and Safety of Low-Intensity Hypertensive Urgency and Pulmonary Embolism/H.I. Joshi, S.S. Facilitator: N.H. Kim, MD, La Jolla, CA


P1611 Safe, Successful, and Effective Transition from a SQ Prostacyclin Analog (Treprostinil) to Oral Prostacyclin Receptor Agonist (Selexipag)/H. Edris, D. Schuller, K. Nugent, I. Huizara, Lubbock, TX, p.A2300

P1616 Experience of One Year of Balloon Pulmonary Angioplasty in a Single Center: Safety and Short Term Results/E. Monti, E. Gotti, M. Palazzini, F. Dardi, A. Rinaldi, A. Albini, N. Tanese, A. Manes, N. Galie, Bologna, Italy, p.A2304


P1618 Does the Time of Day a Pulmonary Embolism Response Team (PERT) Is Activated Affect Time to Intervention or Outcome?/J.N. McNeill, A. With, Y. Chang, C. Kabrel, R.N. Chinnick, Boston, MA, p.A2317


P1616 Experience of One Year of Balloon Pulmonary Angioplasty in a Single Center: Safety and Short Term Results/E. Monti, E. Gotti, M. Palazzini, F. Dardi, A. Rinaldi, A. Albini, N. Tanese, A. Manes, N. Galie, Bologna, Italy, p.A2304


P1620 Spectrum of Chronic Thromboembolic Pulmonary Hypertension/A.P. Fernandez, D.E. Ailone, V.E. Gregorietti, Florencio Varela, Argentina, p.A2308


P1626 The Use of Sildenafil in Acute Pulmonary Embolism A Novel Treatment of Computed Tomography Angiogram for Pulmonary Embolism/L.M. Harris, V. Mehta, N.B. Harris, M.S. Davey, R. Shrestha, J.P. McDonald, L. Morrow, Omaha, NE, p.A2315

P1627 Mandatory Use of the Wells Score Increases the Positive Yield of Computed Tomography Angiogram for Pulmonary Embolism/M. Harris, V. Mehta, N.B. Harris, M.S. Davey, R. Shrestha, J.P. McDonald, L. Morrow, Omaha, NE, p.A2315

P1628 Incidence of Clinically Relevant Findings on CT Pulmonary Angiography Negative for Pulmonary Embolism/Y. Vayntrub, N. Seam, N.A. Avila, D. Mobarek, Washington, DC, p.A2316

P1629 Does the Time of Day a Pulmonary Embolism Response Team (PERT) Is Activated Affect Time to Intervention or Outcome?/J.N. McNeill, A. With, Y. Chang, C. Kabrel, R.N. Chinnick, Boston, MA, p.A2317


The information contained in this program is up to date as of March 9, 2017. For the most current session information, please visit the online program itinerary.


P1637 Implementation of Data Visualization Dashboard Can Improve the Venous Thromboembolism (VTE) Prophylaxis Compliance and Reduce the VTE Incidence in Hospitalized Patients’/S. Patil, B. Patel, S. Kaushal, M. Ayad, K. Gopal, T. Johnson, Houston, TX, p.A2325


P1640 Patient and Clinician Perspectives on Usability and Acceptability of a Patient-Centered Decision Aid for Left Ventricular Assist Device Treatment/I.S. Blumenthal-Barby, K.M. Kostick, R. Volk, C.R. Bruce, S.A. McCurdy, J.D. Estep, Houston, TX, p.A2328

P1641 First Idiopathic Venous Thromboembolism- Are We Following National Institute for Health and Care Excellence (NICE) Guidelines?/C.A. Lynch, R.M. Ortiz Comino, J. Mukherjee, Warwick, United Kingdom, p.A2329


---

**THEMATIC POSTER SESSION**

**A70** PULMONARY REHABILITATION IN LUNG TRANSPLANTATION AND THE ACUTE SETTING

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER

Area B, Hall B-C (Middle Building, Lower Level)

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:15-12:00: authors will be present for individual discussion

12:00-1:00: authors will be present for discussion with assigned facilitators

**Facilitator:** M.N. Bartels, MD, MPH, Bronx, NY


**P155** The Effects of Co-Morbid Heart Disease on Recovery Following Hospitalisation for an Exacerbation of Chronic Respiratory Disease and Early Rehabilitation Intervention/N.J. Greening, T.C. Harvey-Dunstan, S.F. Hussain, E. Chaplin, M.D. Morgan, M.C. Steiner, S.J. Singh, Leicester, United Kingdom, p.A2333


**Facilitator:** N.J. Greening, MBBS, PhD, Leicester, United Kingdom


**P161** Multi-Disciplinary Outpatient Care of Ventilator-Assisted Adults in a University Setting/I.P. Brown, J. Hanley, K. Rochefort, A. Kurili, H. Schotland, R.G. Sitrim, Ann Arbor, MI, p.A2339


**P163** Delivering a Home-Based Telehabilitation Exercise Program for a Lung Transplant Candidate/J. Choi, A. Hergenroeder, J. Kostra, M. Morrell, A. DeVito Dabbs, Pittsburgh, PA, p.A2341


A72 MECHANISMS DRIVING FIBROSIS
9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area A, Hall B-C (Middle Building, Lower Level)

The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.


P15 Stabilization of Transforming Growth Factor β Receptor II Promotes Transforming Growth Factor β-1 Signaling in Lung Fibroblast/A.M. Jacko, L. Nan, S. Li, J. Tan, J. Zhao, D. Wang, D.J. Kass, Y. Zhao, Pittsburgh, PA, p.A2389

Facilitator: Y. Akl, MD, Cairo, Egypt

P16 Herpes Simplex Virus (HSV) Can Induce Acute Exacerbations of Established Pulmonary Fibrosis by Increasing IL-17A Secretion/T. Chen, D. Weng, H. Li, Shanghai, China, p.A2390

P17 Lactate Dehydrogenase Expression and Activity Is Altered in Alveolar Type II Cells from Patients with Idiopathic Pulmonary Fibrosis/D.A. Newton, R.G. Lottes, M.K. Paintilla, R.M. Ryan, J.E. Baatz, Charleston, SC, p.A2391


P21 Expression of TGFβ Activators by Bronchial Epithelial Cells (BECs) from Asthmatic and Healthy Children/K. Barrow, S.R. Reeves, T. Kolstad, M. White, M. Naushab, J.S. Debley, Seattle, WA, p.A2395

P22 The Role of Histone Deacetylase 9 in Idiopathic Pulmonary Fibrosis/P. Sarvari, P. Chelladurai, M. Korfei, E. Olson, A. Gunther, W. Seeger, S.S. Pullamsetti, Bad Nauheim, Germany, p.A2396

Facilitator: C. Albera, MD, Turin, Italy


P29 Novel Treatment Strategy for Pulmonary Fibrosis by a Hybrid Inhibitor of Peripheral Cannabinoid-1-Receptors (CB(1-R) and Inducible NO Synthase (iNOS))/R. Cinar, B.R. Gochuico, M.R. Iyer, J.K. Park, W.A. Gahl, K. Gunos, Rockville, MD, p.A2403

Facilitator: N. Sandbo, MD, Madison, WI

P30 Autotaxin Inhibitor GLPG1690 Affects TGFβ-induced Production of the Pro-Fibrotic Mediators CTGF, IL-6 and ET-1 in Fibroblasts/B. Coornaert, I. Duys, J. Van Der Schueren, E. Van Der Aar, B. Heckmann, Mechelen, Belgium, p.A2404

P31 OPG May Protect Bleomycin-Induced Pulmonary Fibrosis by Inhibiting SMAD2/3 Dependent TGF-β1 Activation/D. Weng, R. Zheng, H. Li, B. Ge, Shanghai, China, p.A2405


P34 Non-Small Cell Lung Cancer (NSCLC) Gene Signature in Idiopathic Pulmonary Fibrosis (IPF)/H. Ulke, K. Mutze, D. Wagner, M.M. Stein, M. Lindner, J. Behr, A. Gunther, M. Königshoff, Munich, Germany, p.A2408


A73 BEYOND CIGARETTE SMOKE IN COPD
9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area L, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: A.M. Manicone, MD, Seattle, WA


P1244 Decreased Particulate Matter (PM) Phagocytic Activity of Type M2-Monocyte Derived Macrophages/K. Yamasaki, S.W. Ra, D.A. Ngan, D.D. Sin, S.V. Eeden, Vancouver, Canada, p.A2415


P1246 Regulation and Function of Non-Canonical WNT-5A in Human Lung Fibroblasts/F. Ciolek, K. Heinzelmann, O. Eickelberg, M. Königshoff, H. Baarsma, Munich, Germany, p.A2417


Facilitator: R. Guzy, MD, PhD, Chicago, IL

P1249 In Vitro Effects of Water Pipe Smoke Condensate on the Endocytosis Activity of Type II Alveolar Epithelial Cells (A549)/E. Mortaz, S.D. Alipoor, M. El-Sabban, J. Garssen, I. Adcock, Tehran, Iran, p.A2420


P1251 The Deletion of CXCR3 Gene Can’t Prevent from COPD After Long Term of Cigarette Smoking Exposure in Mice/T. Liu, Z. Shi, X’an, China, p.A2422


P1257 Comparison of Cigarette Smoke and Wood Smoke-Induced Mucin Gene Expression/D.D. Tassfagzi, Albuquerque, NM, p.A2428


Facilitator: G. Liu, MD, PhD, Birmingham, AL


P1262 Tristetraprolin Regulates Cigarette Smoke Induced TNF-Alpha Expression Through an mRNA Decay Mechanism/P. Che, X. Zhao, G. Cai, M. Hu, C.-Y. Chen, X. Han, Q. Ding, Birmingham, AL, p.A2433
A74  REGULATORY MECHANISMS OF THE MOLECULAR PATHWAYS IN FIBROSIS

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER
Area A, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator:  N. Sandbo, MD, Madison, WI

P38  Nintedanib Inhibits Pro-Fibrotic Mediators with Relevance in Connective Tissue Disease-Associated Interstitial Lung Diseases/L. Wollin, A. Ostermann, V. Brauchlie, C. Williams, Biberach, Germany, p.A2450


P40  Unphosphorylated PTEN Inhibits TGFβ-Induced Aberrant Cell Motility in Epithelial Cells Via Differential Phosphatase Activities/N. Hashimoto, K. Sakamoto, S. Miyazaki, Y. Hasegawa, Nagoya, Japan, p.A2452

P41  Nintedanib Effectively Inhibits Carbon Nanotube-Induced Fibrotic Responses in Human Alveolar Epithelial Cells, Fibroblasts and Pulmonary Microvascular Endothelial Cells/ A. Thorley, P. Ogger, M. Legorburo-Schofield, T. Tetley, L. Wollin, London, United Kingdom, p.A2453


Facilitator: C. Agostini, MD, Padua, Italy

P47 Matrix Metalloproteinase (MMP)-28 Is Expressed in Alveolar Epithelial Cells in Idiopathic Pulmonary Fibrosis and Increases Their Proliferation and Migration/M. Maldonado, B. Ortiz-Quintero, I. Herrera, R. Ramirez, C.A. Staab-Weijnjit, O. Eickelberg, A. Salgado-Aguayo, M. Selman, A. Pardo, Mexico City, Mexico, p.A2459


P55 The Expression of TH17 Cells. Treg Cells and Their Cytokines in Peripheral Blood in Patients with Sarcoidosis/Y. Zhou, H. Li, Shanghai, China, p.A2467

Facilitator: E. Bargagli, MD, Florence, Italy


P62 Identification of Twist1 E-Box Binding Motifs in the Genes Encoding CXCL12 and RelB/X. Li, J. Tan, S. Yu, J.A. Dutta, D.J. Kass, Y. Zhang, Pittsburgh, PA, p.A2474


Facilitator: A. Brown, MD, BSN, Atlanta, GA

P64 Exogenous Induction of Unphosphorylated Tumor Suppressor Phosphatase and Tensin Homolog Deleted on Chromosome 10 Modulates Transforming Growth Factor β-Induced Extracellular Matrix Expression in Lung Fibroblasts/N. Omote, N. Hashimoto, M. Kimura, S. Miyazaki, A. Ando, K. Sakamoto, Y. Hasegawa, Nagoya, Japan, p.A2476


A75 BIG AND BIGGER (DATA): OMICS AND BIOMARKERS OF LUNG DISEASES

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Area G, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00; authors will be present for individual discussion

12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: C. Anderlind, MD, Boston, MA
Y. Saygideger Kont, MD, Ankara, Turkey


P746 Bronchoalveolar Lavage Fluid Metaproteome in Acute Respiratory Failure/P.D. Jagtap, K.J. Viken, J.E. Johnson, T.F. McGowan, T.J. Griffin, R. Hunter, J.D. Rudney, M. Bhargava, Minneapolis, MN, p.A2487

P747 Rbx1 Regulates Trabeculation by Controlling Cardiomyocyte Multi-Layering/P. Sarvari, J. Rasouli, O. Stone, D. Stainier, Bad Nauheim, Germany, p.A2488


P750 The Isolation and Whole-Genome Sequence Analysis of an Imipenem Heteroresistant Acinetobacter Baumannii Clinical Isolate AB85/C. Bai, P. Li, Y. Huang, W. Niu, Y. Liu, X. Yuan, H. Liu, J. Zheng, Beijin, China, p.A2491

Facilitator: J.L. Gomez, MD, New Haven, CT

P751 Functional Genetics of Lung Function Associated Gene GPR126/R.J. Hall, I.P. Hall, I. Sayers, Nottinham, United Kingdom, p.A2492


P754 Genome Wide Expression Profiling of Peripheral Blood Identifies Transcriptomic Signatures Associated with COPD Phenotypes/J.H. Yun, A. Lamb, M. Parker, R.P. Chase, P.J. Castaldi, C.P. Hersh, Boston, MA, p.A2495

P755 Comparative Transcriptomics Analyses of the Different Growth States of Multidrug-Resistant Acinetobacter Baumannii/S. Li, X. Yan, H. Li, T. Qi, B. Wang, Shijiazhuang, China, p.A2496

P756 Multi-Compartment, Multi-Omics Integration Affords Power to Facilitate Detection of Molecular COPD Sub-Phenotypes in Small Cohorts/A.M. Wheelock, C.-X. Li, Stockholm, Sweden, p.A7590
A76 WHAT'S IN THE TOOL BOX TO ASSESS LUNG FUNCTION

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area G, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: B. Oppenheimer, MD, New York, NY

P757 Transcriptome Analysis of Type I and II-Gated Alveolar
Epithelial Cells Derived from Human Lung Explants/S. Chu,
Y. Sakairi, K. Konishi, R.S. Kelly, R.P. Chase, A. Blau, K. Tsouy, S.
Poli, J. Villaiba, H.J. Goldberg, P.C. Camp, Jr., S. El-Chemaly, G.
Wasiko, M. Perrella, B.A. Raby, I. Rosas, Boston, MA, p.A7591

P758 Genome-wide DNA Methylation Analysis at Different Stages of
Normal Mouse Lung Development/C.R. Espinotza, D. Chhabra, T.
Nicola, N. Ambalavanan, J.S. Hagood, San Diego, CA, p.A7592

P759 Difficulties in Pulmonary Laboratory Interpretation: The
Complex Restrictive PFT Pattern: Clinical and
Radiological Analysis of a Novel Restrictive PFT Pattern/R.

P760 Examination of Utility of MostGraph-01 in Cough Variant
Asthma Diagnosis/Z. Isobe, Fukaya City, Japan, p.A2497

P761 Volume Dependence of Respiratory Mechanics Determined by the
Forced Oscillation Technique During Relaxed Expiration/J. Peters,

P762 Simplifying the Measurement of Airway Distensibility
Assessed by the Forced Oscillation Technique/S.
Mailhot-Larouche, M. Lachance, M. Bullone, R.J. Dandurand, L.-P.
Boulet, M. Laviolette, G. King, C. Farah, Y. Bosse, Quebec,
Canada, p.A2499

P763 FOT by GOLD Classification, and Correlation with PFTs and
Patient Reported Outcomes in Community Practice COPD/R.J.
Dandurand, M. Dandurand, J. Bourbeau, D.H. Eidelman, Montreal,
Canada, p.A2500

P764 Diurnal Variability of Lung Function and Its Association with
Sleep Among Patients with COPD/K. Jetmalani, L. Harkness, C.

P765 Impulse Oscillometry for Monitoring Lung Transplant
Recipients: A Sensitive Tool for Bronchiolitis Obliterans
Disease?/H. Salvador, P. Devillier, T. Perez, C. Picard, A. Hamid,
F. Lambinet, M. Stern, L.-J. Couderc, H. Neveu, A. Roux,
Suresnes, France, p.A2502

P766 Spirometry Trends and Utility of Fractional Exhaled Nitric
Oxide Measurement in Bronchiolitis Obliterans Syndrome in
Hematopoietic Stem Cell Transplant Recipients/P. Ballal, P.G.
Arndt, Minneapolis, MN, p.A2503

P767 Comparison of Lung Function Parameters as Predictors of
Dyspnea in Restrictive Lung Disease/S. Baez, W.
Rodriguez-Cintron, F. Del Olmo, E. Adorno-Fontanez, J.
Torres-Palacios, San Juan, PR, p.A2504

P768 The ‘Complex Restrictive’ PFT Pattern: Clinical and
Radiological Analysis of a Novel Restrictive PFT Pattern/R.

P769 Adjustment of the Severity of Obstruction in Patients with
Mixed Obstructive-Restrictive Pulmonary Function Testing/J.
Hunninghake, A.J. Skabelund, J. Hull, M.J. Morris, Fort Sam
Houston, TX, p.A2507

P770 Diagnosis of Obstructive Lung Disease in Young Veterans:
Improving the Sensitivity of Spirometry/A.H. Cho, C. Bolinger,
A. Medinger, Washington, DC, p.A2508

P771 Diagnosis of Obstructive Lung Disease in Young Veterans:
Improving the Sensitivity of Spirometry/A.H. Cho, C. Bolinger,
A. Medinger, Washington, DC, p.A2508

Facilitator: R.A. Wise, MD, Baltimore, MD

P772 Difference Between Maximal and Submaximal Effort on FEV1 -
Possible Connection to Tracheomalacia in Cystic Fibrosis/D.
Vilozni, G. Rosenberg, M. Lave, I. Sarouk, B.-E. Bar-Aluma, M.
Ashkenazi, M. Soudack, J. Jacobson, A. Dagan, O. Efrati,
Ramat-Gan, Israel, p.A2509

P773 Real-Life Data: Utility of Micro-Spirometer Piko-6 for Diagnosis
of COPD in Primary Care/M. Barrueco Ferrero, V. Hidalgo Sierra,
Gonzalez Ruiz, Salamanca, Spain, p.A2511

P774 Validation of Spirometry Prediction Equations in Western
Kenya/D. Paul, D. Lagat, J. Egger, D. Murdoch, L.G. Que, P.
Kussin, Durham, NC, p.A2512

P775 Diagnostic Accuracy of Bronchodilator Response for Asthma

P776 Risk of Paradoxical Bronchoconstriction After Inhaled
Albuterol During Lung Function Testing/A.J. Schissler, B.R.
Celli, Boston, MA, p.A2514

P777 The Impact of Obesity on Maximal Voluntary Ventilation: A
Look Through 13 Years of Spirometric Data/S. Mahmoud Assaf,
P.H. Patel, S. Patolia, H. Wilson, G.L. Ruppel, R.P. Nayak, St.
Louis, MO, p.A2515

P778 Correlation Between FEV1/FVC Ratio, Total Lung Capacity, and
Single-Breath Diffusing Capacity/T. DeCato, M.J. Hegewald,
O. Linares, D.S. Collingridge, A.H. Morris, Salt Lake City, UT,
p.A2516

P779 Correlation Between FEV1/FVC Ratio, Total Lung Capacity, and
Single-Breath Diffusing Capacity/T. DeCato, M.J. Hegewald,
O. Linares, D.S. Collingridge, A.H. Morris, Salt Lake City, UT,
p.A2516

P780 Coaching Patients to Control for Intrathoracic Pressure
Differences May Improve DLCO Measurement Accuracy Using
the Single Breath DLCO/DLNO Technique/C. Fernoyle, K.E.
Coffman, B. Johnson, Rochester, MN, p.A2517

P781 An Alternative Approach to the Measurement of the Diffusing
Capacity of the Lungs for Carbon Monoxide (DLCO) in
Infants/E. Lima Leite Praca, C. Tiller, J. Kisle, R.S. Tepper,
Indianapolis, IN, p.A2518
The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.


Persistent Hyperventilation Following High Altitude Exposure J.A. Hirota, PhD, Hamilton, Canada

Ventilatory Chemoreflexes in Individuals of Himalayan Ancestry Residing at Sea Level E. Heinrich, M. Djokic, F. Powell, T.S. Simonson, La Jolla, CA, p.A2543

Cigarette Smoke Exposure Generates a Unique Peroxidized Phosphatidylcholine Fingerprint in the Lung A. Jha, A.J. Stampsfl, Winnipe, Canada, p.A2544

Facilitator: J.A. Hirota, PhD, Hamilton, Canada


Acute Effects of Electronic Cigarette Use on Lung Functions in Healthy and Asthmatic Individuals M.-E. Boulay, C. Henry, Y. Boisse, L.-P. Boulet, M.C. Morissette, Quebec City, Canada, p.A2547


Increased Airway Narrowing Capacity of Bronchial Segments from Preterm Lambs in an Ovine Model of Chorioamnionitis A. Chang, J. Pillow, S. Ahmadi-Noorbakhsh, P. Noble, Crawley, Australia, p.A2549


A79 TAKING CONTROL OF BREATHING: RESPIRATORY MUSCLES, INNERVATION, AND GAS EXCHANGE

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER
Area G, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: G.S. Supinski, MD, Lexington, KY


P815 Cineradiographic Analysis of Respiratory Movements in a Murine Model for Late Parkinson’s Disease Submitted to Stress/P. S. De Campos, L.R. De Souza Mendes Kawamura, K. Hasegawa, Y. Kumei, J.L. Lopes Zeredo, Brasilia, Brazil, p.A2566


Facilitator: G.C. Sieck, PhD, Rochester, MN


P821 Usefulness of Measuring Oxygen Pressure in Mask-Inspired Gas to Evaluate Alveolar-Arterial O2 Difference While Breathing 100% Oxygen/C. Deudon, J. Bouvard, S. Turquier, J.-C. Gierant, Lyon, France, p.A2572

P822 Relation of Dyspnea to Static Lung Hyperinflation in Chronic Airflow Limitation/M. Slootsky, M. Koc, M. Miller, A. Baydur, Los Angeles, CA, p.A2573


A80-A NOVEL THERAPIES FOR OSA

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER
Area H, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: D.M. Rapoport, MD, New York, NY
S.A. Joosten, MBBS, BMedSc, PhD, Clayton, Australia


P842 Use of Non-Invasive Mechanical Ventilation to Prevent Hypoxia During Bronchoscopy in Patients with Sleep Apnea or at High Risk of Sleep Apnea/A. Babbar, F. Siddiqi, M. Faisal, A. Bajwa, A. Agarwal, M. Patel, J. Curjy, V. Seeram, L.M. Jones, M. Louis, K. Treger, Jacksonville, FL, p.A2576

P843 Restoration of Sleep Quality Using a Novel Biomimetic Protocol for the Resolution of Obstructive Sleep Apnea/G.D. Singh, Beaverton, OR, p.A2577

P845 The Effects of Supplemental Oxygen on Obstructive Sleep Apnea During CPAP Withdrawal: Preliminary Data from a Randomised Control Trial/ C. Turnbull, A. Johar, N. Petousi, J.R. Stradling, Oxford, United Kingdom, p.A2579

P846 Patient and Clinician Insights for Dissemination and Implementation Planning of a Patient-Centered Decision Aid for Left Ventricular Assist Device (LVAD) Treatment/K.M. Kostick, R. Volk, C.R. Bruce, S.A. McCurdy, J.D. Estep, J.S. Blumenthal-Bartby, Houston, TX, p.A2580

Facilitators: K.P. Strohl, MD, Cleveland, OH
O. Lyons, MBCh, Toronto, Canada


P851 Evaluation of Automated Oxygen Fl owrate Titration (FreeO2) in a Model of Induced Cyclic Desaturations in Healthy Subjects Reproducing Desaturations During Central Apneas/F. Leplouche, P.-A. Bouchard, E. L’Her, F. Series, Quebec, Canada, p.A2585


Facilitators: E.M. Davis, MD, Charlotte, NC
M. Baltzan, MD, Montreal, Canada

For the most current session information, please visit the online program itinerary.
A80-C NOVEL DIAGNOSTIC APPROACHES TO SDB

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Area H, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: H. Schneider, MD, PhD, Baltimore, MD
L. Taranto Montemurro, MD, Boston, MA
O. Basolu, MD, Istanbul, Turkey

P872 The Effects of Anthropometric Parameters on Screening Obstructive Sleep Apnea Using Breathing Sounds During Wakefulness/A.M. Elwaili, S. Meza-Vargas, Z. Moussavi, Winnipeg, Canada, p.A2604


P875 Addition of Frontal EEG to Home Sleep Apnea Testing to Diagnose Adult Obstructive Sleep Apnea: Does a More Accurate Determination of Sleep Time Make a Difference? M. Light, T. Casimire, C. Chua, V. Koushyk, O. Burschtin, I. Ayappa, D. M. Rapoport, La Jolla, CA, p.A2607


Facilitators: P. J. Strollo, MD, Pittsburgh, PA
K. Kairaitis, MBBS, PhD, Westmead, Australia/
J. E. Orr, MD, La Jolla, CA


P880 Pulse Transit Time in Pregnant Women with and Without Obstructive Sleep Apnea/B. Link, G. Bourjeily, M. Bublitiz, M. Pengo, T. Sequeira, E. Adoadoadi, B. Hott, Providence, RI, p.A2612

Facilitators: J. Kirkness, PhD, Baltimore, MD
S. A. Landry, PhD, Notting Hill, Australia


P884 Association Between Mallampati Score and Tongue Volume/R. A. B. De Athayde, F. Schorr, E. Gebirig, G. Lorenzi-Filho, P. Genta, Sao Paulo, Brazil, p.A2616

P885 Gender Differences in Polysomnographic Findings in Egyptian Patients with Obstructive Sleep Apnea Syndrome/H. Assal, E. Kamal, Cairo, Egypt, p.A2617

Facilitators: J. Kirkness, PhD, Baltimore, MD
S. A. Landry, PhD, Notting Hill, Australia


P887 Poor Inter-Rater Reliability in Interpretation of Overnight Oximetry Despite Worksheet Assistance/M. Ayache, A. M. May, K. P. Strohl, Cleveland, OH, p.A2619


WS1 TURNING DATA INTO WISDOM: DATABASES AND REGISTRIES FOR BETTER LUNG CANCER OUTCOMES

Registration Fee: $75 (includes box lunch)
Attendance is limited. Pre-registration is required.

Target Audience
Lung cancer clinicians who wish to learn more about the content and structure of cancer registries, how to use and improve the data to create better clinical outcomes and how to build datasets for lung cancer screening.

Objectives
At the conclusion of this session, the participant will be able to:
- recognize the types of data collected by registries, the limitations of that data and how to access that data;
- identify requirements of data collection for quality improvement, research and in particular for lung cancer screening.

Outcomes research and quality improvements in lung cancer use a range of data sources including clinical trials, administrative and insurance-linked registries. The complexities of lung cancer screening call for high quality, accessible and relevant information, requirements that demand much of routinely collected clinical data. Administrative registries have advantages (large numbers, population cohorts) and disadvantages (retrospective, inaccessible). For many practicing lung cancer clinicians, registry data are not clinically relevant, despite the high levels of expenditure and effort required for their collection. This session will explore clinically relevant approaches to registry data that attendees can use to improve lung cancer outcomes.

Chairing:
E.C. Stone, MBBS, MMed,
Darlinghurst, Australia
M.K. Gould, MD, MS, Pasadena, CA

11:45 More than Just Excel: A Brief Introduction to Databases for Clinicians
E.C. Stone, MBBS, MMed, Darlinghurst, Australia

11:50 The Value of a Comprehensive National Lung Cancer Database: The Danish Experience
E. Jakobsen, MD, MPM, Odense, Denmark

12:05 What Do Databases Offer for Clinical Practice? Lessons from U.S. Registry Data (Including SEER and AQuIRE)
D.E. Ost, MD, MPH, Houston, TX

12:20 The Promises and Pitfalls of Data Linkage: Experience from the Victorian Lung Cancer Registry
R. Stirling, BSc(Hons), MBChB, Melbourne, Australia

12:35 Building a Database for Clinicians: The ACR Lung Cancer Screening Registry
E.A. Kazerooni, MD, Ann Arbor, MI
12:50 Interactive Discussions  
E.A. Kazerooni, MD, Ann Arbor, MI  
D.E. Ost, MD, MPH, Houston, TX  
R. Stirling, BSc(Hons), MBChB, Melbourne, Australia  
E. Jakobsen, MD, MPM, Odense, Denmark

1:10 Summary of Session and Final Questions to Panel  
M.K. Gould, MD, MS, Pasadena, CA

---

**WS2 GLOBAL HEALTH CAREERS IN PULMONARY AND CRITICAL CARE MEDICINE**

This Forum is part of the ATS initiative to offer programs specifically geared toward the professional development of trainees, fellows, and students to aid in the pursuit of successful careers in pulmonary, critical care, and sleep medicine.

Pre-registration is required. Attendance is limited. There is no additional fee.

**Assembly on Critical Care; Member in Transition and Training (MITT)**

**11:45 a.m. - 1:15 p.m.**  
**MARRIOTT MARQUIS WASHINGTON Capitol/Congress (Level M4)**

**Target Audience**
Early career professionals (junior faculty, fellows, residents, students) interested in careers in global health

**Objectives**
At the conclusion of this session, the participant will be able to:
- understand different strategies to develop a successful career in global health;  
- network with established global health faculty.

This intimate session will provide early career professionals an invaluable opportunity to interface and network with pulmonary and critical care faculty with established global health careers. Panelists will include both junior and senior faculty and will highlight different pathways to achieving success, including academic/research, private practice, non-governmental organization (NGO), faith-based medical education, and hybrid models. The end of the session will provide Q&A time to allow participants to interact directly with faculty.

**Chairing:** A. Papali, MDCM, Baltimore, MD  
N.K. Adhikari, MD, Toronto, Canada

**11:45 Acute Liver Failure**  
A.E. Morris, MD, Seattle, WA

**11:55 How to Have a Successful Academic Global Health Career**  
A. Papali, MDCM, Baltimore, MD

**12:07 Productive Research in LMICs: The Importance of Partnerships**  
S. Gordon, MD, Blantyre, Malawi

**12:19 Faith-Based Global Health Careers**  
B.W. Lee, MD, Pittsburgh, PA

---

**12:31 Global Health and Medical Education**  
E.J. Carter, MD, Providence, RI

**12:43 WHO Consulting**  
R. Fowler, MD, MDCM, MSc, Toronto, Canada

**12:55 General Discussion**
L1  
**AMERICAN LUNG ASSOCIATION AIRWAYS CLINICAL RESEARCH CENTERS CLINICAL TRIALS**

12:15 p.m. - 1:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER

**Room 143 A-C (Middle Building, Street Level)**

**Target Audience**
Physicians, clinical scientists, nurses, paraprofessionals, educators, health care providers

**Objectives**
At the conclusion of this session, the participant will be able to:
- understand predictors of treatment failure and the non-reversible airway obstruction in children;
- learn new methods of evaluating outcomes in asthma;
- understand the validity of the asthma control score in asthmatic smokers.

The purpose of the ALA-ACRC is to conduct clinical trials with practical importance to adults and children with asthma and COPD. ACRC has produced manuscripts from data analyzed from the LASST, MICT, SCS, and REACH trials. For the LASST trial, the primary hypothesis was that stopping LABA would be inferior to reducing ICS dose and continuing LABA; the secondary hypothesis was that reduced ICS/LABA would be non-inferior to stable ICS/LABA. The primary outcome was time to treatment failure. The MICT trial hypothesized that incorporation of mobile devices and the internet into a study design that tests interventions to reduce morbidity in pediatric asthma would result in a lower-cost method for conducting a clinical trial and encourage more families to participate. The SCS trial was designed to evaluate the performance characteristics of study questionnaires (ACT and ASUI) and composite measures of asthma control (EPAC and TRS) for people with asthma who are active smokers. The objective of the REACH trial was to systematically characterize a diverse cohort of children with airflow obstruction resistant to BD.

**Chairing:**
- W.C. Bailey, MD, Birmingham, AL
- R.A. Wise, MD, Baltimore, MD

**12:15 Predictors of Treatment Failure in LASST**
E. DiMango, MD, New York, NY

**12:30 Using iPads and the Internet to Conduct Clinical Trial Visits**
K. Blake, PharmD, Jacksonville, FL

**12:45 Validity of Asthma Control Score in Asthmatic Smokers**
X. Soler, MD, PhD, San Diego, CA

**1:00 Non-Reversible Airway Obstruction in Children**
S. Krishnan, MD, Valhalla, NY

L2  
**AIR POLLUTION AND PUBLIC HEALTH**

12:15 p.m. - 1:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER

**Room 202 A (South Building, Level 2)**

**Target Audience**
Health care providers, patients and researchers interested in the respiratory and other health effects of air pollution

**Objectives**
At the conclusion of this session, the participant will be able to:
- understand recent findings on health effects of air pollution in the context of public health;
- understand EPA activities to communicate public health risks linked to wildland fires;
- promote to the health care community the need to communicate to patients the risks that air pollution may pose to them.

The session will present information on new research endeavors at the EPA regarding the communication of the public health implications of air pollution, with a specific focus on a) wildfires and respiratory health, b) EPA’s efforts to communicate with the public on health effects of air pollution and c) integrating air pollution risk communication into health care delivery and practice.

**Chairing:**
D. Costa, ScD, Research Triangle Park, NC

**12:15 Introduction**
D. Costa, ScD, Research Triangle Park, NC

**12:20 AQI and Community Outreach**
S. Stone, MS, Research Triangle Park, NC

**12:35 Wildland Fire Smoke and Public Health**
A. Rappold, PhD, Chapel Hill, NC

**12:50 Air Pollution and the Health Care System**
W. Cascio, MD, Chapel Hill, NC

L3  
**WORK-RELATED LUNG DISEASE: STILL WITH US**

12:15 p.m. - 1:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER

**Room 202 B (South Building, Level 2)**

**Target Audience**
Providers of lung health; clinicians and other professionals providing preventive, diagnostic, and therapeutic services to employers and to workers at risk for work-related lung disease; and those interested in conducting research in the field.

**Objectives**
At the conclusion of this session, the participant will be able to:
- learn about new requirements for protecting workers from coal mine dust and silica, and proposed requirements for beryllium;
- gain new findings about respiratory toxicity of diacetyl and related compounds;
- learn about continuing burden of work-related respiratory disease and opportunities to set a national research and service agenda for the nation.

This session will address continuing challenges to the elimination of work-related respiratory disease, highlight several examples of ongoing work in the field, and provide attendees with information about NIOSH efforts to set research priorities for the next decade and how they can become involved.
**U.S. FOOD AND DRUG ADMINISTRATION**

**L4  PULMONARY UPDATE FROM THE U.S. FOOD AND DRUG ADMINISTRATION**

**12:15 p.m. - 1:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER**  
Room 204 A-C (South Building, Level 2)

**Target Audience**  
Clinicians in practice, researchers, pharmaceutical industry representatives, international regulators

**Objectives**  
At the conclusion of this session, the participant will be able to:
- discuss the most recent FDA approvals for pulmonary indications.
- understand the regulatory framework for these approvals and lessons learned;
- learn about the FDA’s new labeling initiatives for opioid medicines for cough indications;
- understand the regulatory challenges in drug development for cystic fibrosis and how these can be overcome.

The most recent regulatory FDA actions including discussion of current safety and efficacy issues of products for pulmonary indications, and clinical trials design issues will be discussed. The recent agency actions regarding opioid medicines for cough indication in children and an update on the long-acting-beta agonist (LABA) safety issues will be presented. The regulatory challenges for drug development in cystic fibrosis (CF) in view of the recent approvals of drugs for specific mutations will be presented.

**Chairing:**  
L.I. Gilbert-McClain, MD, Silver Spring, MD

**12:15  Update on Current Pulmonary Issues at FDA**  
L.I. Gilbert-McClain, MD, Silver Spring, MD  
P. Materni, MD, Silver Spring, MD

**12:40  Pulmonary Safety Update from the FDA**  
S. Seymour, MD, Silver Spring, MD

**12:55  Regulatory Considerations for Drug Development in Cystic Fibrosis**  
R. Lim, MD, Silver Spring, MD

**1:10  Questions and Answers**  
L.I. Gilbert-McClain, MD, Silver Spring, MD

**L5  RESEARCH FUNDING OPPORTUNITIES**

**12:15 p.m. - 1:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER**  
Room 102 A-B (South Building, Street Level)

**Target Audience**  
Any ATS members who are conducting research and seeking for research funding

**Objectives**  
At the conclusion of this session, the participant will be able to:
- describe the research priorities of each funding agency represented on the panel;
- identify a funding agency that is most closely aligned with the attendee’s research interest.

This session will introduce programs and research grant opportunities offered from various funding agencies. Speakers will present current research priorities and mechanisms of research funding available from each agency.

**Chairing:**  
J. Choi, PhD, RN, Pittsburgh, PA  
J.A. Tate, PhD, RN, Columbus, OH

**12:15  ATS Foundation**  
A.M. Tager, MD, Charlestown, MA

**12:27  American Lung Association**  
S. Rappaport, MPH, New York, NY

**12:39  National Institute of Nursing Research**  
K. Huss, PhD, Bethesda, MD

**12:51  National Center for Complementary Integrative Health**  
L.M. Mudd, PhD, Bethesda, MD

**1:03  National Heart Lung and Blood Institute**  
L. Reineck, MD, Bethesda, MD

**L6  PHENOTYPING IN THE SUBPOPULATIONS AND INTERMEDIATE OUTCOME MEASURES IN COPD (SPIROMICS) STUDY**

**12:15 p.m. - 1:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER**  
Room 145 A-B (Middle Building, Street Level)

**Target Audience**  
Those with clinical or research responsibilities;

**Objectives**  
At the conclusion of this session, the participant will be able to:
- learn about imaging phenotyping of COPD;
- learn about molecular phenotyping of COPD;
- learn about clinical phenotyping of COPD.
At the conclusion of this session, the participant will be able to:

Objectives
Health care providers who manage patients with asthma (children and adults)

Target Audience
Providers of lung health; those with clinical or research responsibilities; those needing instruction in areas of medicine outside of their specialty

Chairing: L. Postow, PhD, Bethesda, MD  
R.G. Barr, MD, DrPH, New York, NY

12:15 Overview of SPIROMICS  
R.G. Barr, MD, DrPH, New York, NY  

12:20 Using Clinical Markers to Identify Subpopulations at Higher Risk for Poor Outcomes  
C. Martinez, MD, MPH, Ann Arbor, MI

12:35 Defining COPD Disease Severity and Phenotype Through Sputum Mucin Concentration Analyses  
M. Kesimer, PhD, Chapel Hill, NC

12:45 Clinical Implications of Airway Branch Patterns and Other Imaging Findings in SPIROMICS  
B.M. Smith, MD, MS, New York, NY

1:00 Lung Microbiota Patterns and Immune Responses in COPD  
Y.J. Huang, MD, Ann Arbor, MI

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE, DIVISION OF LUNG DISEASES, NIH

L8 LUNG DISEASE PROJECTS IN TRANS-OMICS FOR PRECISION MEDICINE (TOPMED) PROGRAM

12:15 p.m. - 1:15 p.m.  
WALTER E. WASHINGTON CONVENTION CENTER

Target Audience
Providers of lung health; those with clinical or research responsibilities; those needing instruction in areas of medicine outside of their specialty

Objectives
At the conclusion of this session, the participant will be able to:

• demonstrate the WGS efforts in precision medicine initiative and its potential as diagnostic tool and in discovery of therapeutic targets;
• discuss the impact of rare genetic variants in disease development;
• display the ways to perform big data analysis and relevant resources that will be available for the research community.

NHLBI's Trans-Omics for Precision Medicine (TOPMed) is part of the NIH's Precision Medicine Initiative and designed to generate scientific resources that will enhance our understanding of the fundamental biological processes underlying HLBS disorders. The TOPMed program will integrate -omics (e.g., genomic, proteomic, metabolomic) and phenotypic data in an effort to improve the prediction, prevention, diagnosis, and treatment of these disorders. In its first two years, TOPMed has done whole genome sequencing (WGS) for more than 70,000 DNA samples of many common diseases, including COPD, asthma, and sleep apnea. This session will present the initial results of these disease studies.

Chairing: W.W. Busse, MD, Madison, WI  
M.M. Freemer, MD, MPH, Bethesda, MD

12:15 Does Alendronate Preserve LABA-Induced Bronchoprotection in Adults with Asthma?  
J. Cardet, MD, Boston, MD

12:30 Does Yellow Zone Inhaled Corticosteroid Reduce Severe Asthma Exacerbations in Children?  
D.J. Jackson, MD, Madison, WI

1:00 Panel Discussion

L7 ASTHMANET CLINICAL TRIAL RESULTS

12:15 p.m. - 1:15 p.m.  
WALTER E. WASHINGTON CONVENTION CENTER

Target Audience
Health care providers who manage patients with asthma (children and adults)

Objectives
At the conclusion of this session, the participant will be able to:

• understand the efficacy of high dose inhaled corticosteroids to prevent exacerbations in children who are in the "yellow zone" on their asthma action plan;
• gain understanding of the efficacy of high dose inhaled corticosteroids to reduce symptoms in children who are in the "yellow zone" on their asthma action plan;
• understand mechanisms that may contribute to the reduction in the response to long acting bronchodilators with chronic use in patients with asthma and a possible approach to management.

Results of two clinical trials conducted by the multi-site clinical trial network funded by NHLBI, AsthmaNet, will be presented. One of the studies, "ALendronate for Asthma" trial (ALFA), is a study in adults to assess if alendronate can restore the bronchoprotective effect which may be diminished with chronic use of long acting beta agonists. The other study, Step-Up Yellow Zone Inhaled Corticosteroids To Prevent Exacerbations (STICS), is a study of how to manage children with asthma when they get into the “yellow zone” on their asthma action plan in order to prevent severe exacerbations.

Chairing: S.S. Redline, MD, MPH, Boston, MA  
W. Gan, PhD, Bethesda, MD

12:15 Initial Results from Whole Genome Sequence of Cleveland Family Study on CFS Sleep Apnea  
S.S. Redline, MD, MPH, Boston, MA

12:30 Whole Genome Sequencing Analysis of Asthma Drug Response in Minority Children  
E.G. Burchard, MD, MPH, San Francisco, CA

12:45 Initial Whole Genome Sequence Results for Asthma in a Costa Rican Population Isolate  
S. Weiss, MD, Boston, MA

1:00 Whole Genome Sequencing of Severe Chronic Obstructive Pulmonary Disease  
E.K. Silverman, MD, PhD, Boston, MA

The information contained in this program is up to date as of March 9, 2017.  
For the most current session information, please visit the online program itinerary.
L9  MAPPING LUNG HEALTH AND DISEASE WITH THE MOLECULAR ATLAS OF LUNG DEVELOPMENT

Target Audience
Providers of lung health, medical fellows in training, and basic and clinical researchers interested in lung biology, developmental biology, chronic lung disease pathogenesis, pediatrics, bioinformatics, and systems biology

Objectives
At the conclusion of this session, the participant will be able to:
• learn the newest datasets of LungMAP that could inform lung research;
• learn the innovative technologies for molecular profiling, imaging, and data analysis of the developing lung;
• learn how to access and use the LungMAP resources.

Molecular Atlas of Lung Development (LungMAP) is an NHLBI-sponsored program. The overall goal of this program is to build an open-access reference resource by creating a comprehensive molecular atlas of the late-stage developing lung with data and reagents available to the research community. Speakers will show how the approach/systems biology/bioinformatics can be used to inform clinical medicine-discovery of biomarkers and processes in development that are recapitulated in disease/repair. The session will also elucidate how understanding alveolar cells and intracellular communication forms the lung and informs the processes altered in disease.

Chairing:
S.M. Palmer, MD, MHS, Durham, NC
S. Lin, PhD, Bethesda, MD

12:15 Transcriptomic Analysis of Pulmonary Cell Lineages Using Single Cell RNAseq in Health and Disease
J.A. Whitsett, MD, Cincinnati, OH

12:30 Application of Advanced Proteomic, Lipidomic, and Metabolomics Technologies to Challenges in Lung Biology and Medicine
R. Corley, PhD, Richland, WA

12:45 Systems Biology to Integrate Non-Coding RNAs, DNA Methylation, and Epigenetics During Alveologenesis
N. Ambalavanan, MD, Birmingham, AL

1:00 Presenting, Visualizing, and Integrating LungMAP Omics Data
R.F. Clark, PhD, Research Triangle Park, NC

MEET THE PROFESSOR SEMINARS

CME Credits Available: 1
Registration Fee: $70.00 (includes box lunch.)
Attendance is limited. Pre-registration is required.
12:15 p.m. - 1:15 p.m. MARRIOTT MARQUIS WASHINGTON

MP401 BIOMARKERS IN SEVERE ASTHMA
N. Hanania, MD, MS, Houston, TX
George Washington University (Level M1)

MP402 NEW FLEISCHNER SOCIETY GUIDELINES FOR PULMONARY NODULES
A.C. Mehta, MBBS, Cleveland, OH
Georgetown University (Level M1)

MP403 NEW INSIGHTS INTO CHRONIC ALLOGRAFT DYSFUNCTION AFTER LUNG TRANSPLANTATION: EMERGING PHENOTYPES AND TREATMENT PARADIGMS
J.L. Todd, MD, Durham, NC
A.R. Glanville, MBBS, MD, Sydney, Australia
Howard University (Level M1)

MP404 SCLERODERMA ASSOCIATED INTERSTITIAL LUNG DISEASE: ADVANCES IN MANAGEMENT
K.B. Highland, MD, Cleveland, OH
Gallaudet University (Level M1)

MP405 APPROACH TO THE TREATMENT OF BRONCHIECTASIS
G. Tino, MD, Philadelphia, PA
Catholic University (Level M1)

MP406 IMMUNOSUPPRESSION AND BEYOND: PRACTICAL STRATEGIES IN CONNECTIVE TISSUE DISEASE-ASSOCIATED INTERSTITIAL LUNG DISEASE
L.D. Morrison, MD, Durham, NC
University of DC (Level M1)

MP407 REAL-WORLD CHALLENGES IN THE DIAGNOSIS OF IPF
A.M. Nambiar, MD, San Antonio, TX
Marquis Salon 14 (Level M2)

MP408 CRITICAL CARE MANAGEMENT OF ACUTE ON CHRONIC LIVER FAILURE
R. Subramanian, MD, Atlanta, GA
Marquis Salon 13 (Level M2)

MP409 SARCOIDOSIS PRIMARY CARE
A. Berman, MD, Newark, NJ
Marquis Salon 12 (Level M2)

MP410 NEUROLOGICAL DISASTERS IN THE ICU
T.P. Bleck, MD, Chicago, IL
Union Station (Level M3)

MP411 HOW TO MANAGE PATIENTS WITH SEVERE COMMUNITY-ACQUIRED PNEUMONIA
C. Feldman, MD, PhD, Johannesburg, South Africa
Chinatown (Level M3)
**MP412** PRACTICAL CONSIDERATIONS FOR PRAGMATIC TRIALS OF BEHAVIORAL INTERVENTIONS
H.Q. Nguyen, PhD, RN, Pasadena, CA  
Mount Vernon Square (Level M3)

**MP413** INTERPRETATION AND APPLICATION OF THE PEDIATRIC POLYSOMNOGRAM REPORT
S. Bhargava, MD, Palo Alto, CA  
Judiciary Square (Level M3)

**MP414** ROLE OF E-TECHNOLOGY, INCLUDING TELEREHABILITATION, IN THE MANAGEMENT OF CHRONIC LUNG DISEASE
M. Stickland, PhD, Edmonton, Canada  
A.E. Holland, PhD, Melbourne, Australia  
LeDroit Park (Level M3)

**MP415** OBESE ASTHMA: UNDERSTANDING AND MANAGING A COMPLEX PROBLEM
G.S. Skloot, MD, New York, NY  
Shaw (Level M3)

**MP416** MULTIPLE BED PARTNERS AND OTHER SUCCESSFUL COLLABORATIONS
R.R. Grunstein, MBBS, MD, PhD, Glebe, Australia  
Treasury (Level M4)

---

**ME1** TEACHING WITH SIMULATION: PRACTICAL SOLUTIONS TO COMMON PROBLEMS
Registration Fee: $70 (includes box lunch)  
Attendance is limited. Pre-registration is required.

12:15 p.m. - 1:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER
Room 101 (South Building, Street Level)

**Target Audience**
Members of the multi-disciplinary health care team, including physicians, nurses, pharmacists, respiratory therapists and other medical educators who use simulation-based medical education (SBME) to teach important concepts, including interprofessional education (IPE) to train teams, procedural training and communication skills that are best taught by simulation modalities

**Objectives**
At the conclusion of this session, the participant will be able to:

- overcome barriers for implementing simulation at home institution;
- learn new methods of training through simulation.

Through case study examples, this session will provide practical guidance on specific ways the participant can best use simulation-based medical education (SBME) to address educational needs at their home institution. Participants will learn how each of the speakers use SBME to address specific common educational questions, such as strategies for debriefing interprofessional teams and delivering bad news to patients and families.

**Speakers:**
- N. Seam, MD, Bethesda, MD
- N. Knudsen, MD, Durham, NC
- J. Chiarchiaro, MD, MS, Pittsburgh, PA

---

**TSS1** EVOLVING CONCEPTS IN EARLY COPD
Registration Fee: $170 for full series (includes continental breakfast or box lunch)  
Attendance is limited. Pre-registration is required.

This is a 4-part series. Those registering for this seminar series will be registered for all 4 parts. The topics and schedule for each part are listed below.

**Sunday 12:15 p.m. - 1:15 p.m.**  MARRIOTT MARQUIS WASHINGTON  
Monument (Level M4)

Preventing Lung Function Decline in Early COPD
P. Calverly, MBChB, Liverpool, United Kingdom

**Monday 12:15 p.m. - 1:15 p.m.**  MARRIOTT MARQUIS WASHINGTON  
Monument (Level M4)

The Symptomatic Smoker: The Need to Bring Back Gold
P.G. Woodruff, MD, MPH, San Francisco, CA

**Tuesday 12:15 p.m. - 1:15 p.m.**  MARRIOTT MARQUIS WASHINGTON  
Monument (Level M4)

Screening for COPD: Beyond the Current Guidelines
R.A. Wise, MD, Baltimore, MD

**Wednesday 7:00 a.m. - 8:00 a.m.**  MARRIOTT MARQUIS WASHINGTON  
Monument (Level M4)

Chronic Bronchitis Without Airflow Obstruction: Epidemiology, Phenotype, and Clinical Consequences
C. Martinez, MD, MPH, Ann Arbor, MI
A81 NURSING YEAR IN REVIEW

Assemblies on Nursing; Behavioral Science and Health Services Research; Clinical Problems; Critical Care
2:15 p.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 102 A-B (South Building, Street Level)

Target Audience
Clinicians, researchers, registered nurses, and advanced practice nurses who care for individuals and their families who experience critical illness across the states of critical illness and long-term recovery

Objectives
At the conclusion of this session, the participant will be able to:

- describe current knowledge in symptom science, communication and decision making, ICU survivorship, oncology-critical care, implementation science and telehealth in critical care;
- identify current gaps in knowledge in the topic areas;
- identify future research directions and clinical practice initiatives targeted to advance symptom science, communication and decision making, ICU survivorship, oncology-critical care, implementation science and telehealth in critical care.

This session will review the current state of knowledge in critical care. Topic areas will include: (1) symptom science; (2) implementation science in critical care; (3) communication and decision making; (4) critical care in persons with cancer; (5) intensive care unit survivorship; and (6) telehealth in critical care. Each speaker will review recent studies, discuss current gaps and highlight implications to clinical practice and future research.

Chairing: J. Choi, PhD, RN, Pittsburgh, PA
J.A. Tate, PhD, RN, Columbus, OH

2:15 Symptom Science the ICU Setting: Implications for Future Research
L.L. Chlan, PhD, RN, Rochester, MN

2:35 Implementation Science
D.K. Costa, PhD, RN, Ann Arbor, MI

2:55 End of Life Communication in the ICU
J.B. Seaman, PhD, RN, Pittsburgh, PA

3:15 Topics in Onco-Critical Care
J.A. Tate, PhD, RN, Columbus, OH

3:35 ICU Survivorship
J. Choi, PhD, RN, Pittsburgh, PA

3:55 Updates on the Use of Telemedicine in the ICU
R.M. Kleinpell, PhD, RN, Chicago, IL

A82 IDIOPATHIC PULMONARY FIBROSIS: CONTROVERSIES IN MANAGEMENT - PRO/CON DEBATE

Assemblies on Clinical Problems; Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Environmental, Occupational and Population Health; Nursing
2:15 p.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Ballroom A (South Building, Level 3)

Target Audience
Clinicians, registered nurses, advanced practice nurses, other allied health staff, researchers, investigators in basic and clinic science pertinent to interstitial lung disease, and sponsors for research

Objectives
At the conclusion of this session, the participant will be able to:

- discuss controversial topics in IPF diagnosis and management with patients when engaging in shared decision making about diagnosis and treatment;
- apply current treatment data to the diagnosis and management of patients with IPF;

Significant progress has been made in the management of idiopathic pulmonary fibrosis (IPF). While the 2011 and 2015 evidence based guidelines have empowered clinicians and patients to make informed decisions regarding diagnosis and treatment, significant controversies exists. The goal of this session is to surface controversies frequently encountered in routine clinical practice. The session will be in the format of four Pro/Con provocative debates between experts that will give attendees increased insight into the management of IPF.
Chairing: G. Raghu, MD, Seattle, WA

2:15 Introduction
G. Raghu, MD, Seattle, WA

2:20 PRO: Patients with IPF Should Be Treated for Gastroesophageal Reflux
Y. Ghebre, PhD, Houston, TX

2:34 CON: Patients with IPF Should Be Treated for Gastroesophageal Reflux
M. Kreuter, MD, Heidelberg, Germany

2:48 PRO: Surgical Lung Biopsy Is Required to Eliminate Other Diagnoses Before Making a Diagnosis of IPF
G. Raghu, MD, Seattle, WA

3:02 CON: Surgical Lung Biopsy Is Required to Eliminate Other Diagnoses Before Making a Diagnosis of IPF
Y. Inoue, MD, PhD, Osaka, Japan

3:16 PRO: Multidisciplinary Discussion Is Necessary in Ascertaining a Diagnosis of IPF
S.K. Danoff, MD, PhD, Baltimore, MD

3:30 CON: Multidisciplinary Discussion Is Necessary in Ascertaining a Diagnosis of IPF
Y. Inoue, MD, PhD, Osaka, Japan

3:44 PRO: N-Acetylcysteine Is Useful for Some Patients with IPF
F.J. Martinez, MD, New York, NY

3:58 CON: N-Acetylcysteine Is Useful for Some Patients with IPF
J. Behr, MD, Munich, Germany

A83 GREAT CASES: CLINICAL, RADIOLOGIC, AND PATHOLOGIC CORRELATIONS BY MASTER PHYSICIANS

Council of Chapter Representatives

2:15 p.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Ballroom C (South Building, Level 3)

Target Audience
Clinicians in the fields of pulmonary and critical care medicine, pediatric pulmonology, sleep medicine, thoracic surgery, and infectious disease

Objectives
At the conclusion of this session, the participant will be able to:

- integrate the clinical presentation, radiologic and pathologic findings for seven challenging cases;
- understand the clinical reasoning used to determine differential diagnosis by Master clinicians using a multidisciplinary approach;
- describe the associated pathology and radiology of the cases.

Learners will have the opportunity to observe master clinicians approach challenging clinical problems by working through 7 unknown cases selected from the abstract pool. Collaboration with a master radiologist reviewing the films and a master pathologist reviewing pathology slides will demonstrate the multidisciplinary approach to difficult cases. The audience will participate through interactive questions that are tallied electronically. Additional discussion by presenters and master panelists will enhance the educational experience.

Chairing: S.P. Kantrow, MD, New Orleans, LA
S. Kirtland, MD, Seattle, WA

2:15 Case Presentations
She Who Sings Frightens Away Her Ills
J. Nguyen, MD, Sylmar, CA

The Naked Trachea
U. Chaddha, MBBS, MD, Los Angeles, CA

Mysterious Masses
B. Tran, MD, Baltimore, MD

There’s Nothing Cute About this Chest Syndrome
M.J. Bruehl, MD, Chapel Hill, NC

A Nagging Pimple
H. Kular, MD, Houston, TX

When a Bird Is a Herring: Guilt by Association
K.S. Sai Kakkera, MBBS, Little Rock, AR

Zebras Have Hooves Too
P. Charoenpong, MD, Brooklyn, NY

3:25 Experts

Master Clinicians
S.I.S. Rounds, MD, Providence, RI
M.I. Schwarz, MD, Aurora, CO
P.C. Stillwell, MD, Aurora, CO

Master Radiologist
A.G. Wilcox, MD, Los Angeles, CA

Master Pathologist
J.L. Myers, MD, Ann Arbor, MI

A84 THE NEW ENGLAND JOURNAL OF MEDICINE AND JAMA. DISCUSSION ON THE EDGE: REPORTS OF RECENTLY PUBLISHED CRITICAL CARE RESEARCH

This session will provide a forum for attendees to interact with the authors and editors about papers published in the New England Journal of Medicine and JAMA. Papers presented will be recent publications, selected by the editors, to be of significant importance to the field of critical care medicine. Attendees will have the opportunity to hear presentations directly from the author and address questions to both the authors and editors. The discussion is intended to provide a unique insight into these papers, the selection process, and how the research applies directly to the field of critical care medicine.

2:15 p.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 207 A-B (South Building, Level 2)

Chairing: J.M. Drazen, MD, Editor-in-Chief, New England Journal of Medicine
P.B. Fontanarosa, MD, MBA, Executive Editor, JAMA

Speakers And Talks To Be Announced
At the conclusion of this session, the participant will be able to:

### Objectives

- describe the exposome concept as it relates to the risk and pathogenesis of chronic disease;
- learn new findings about the potential to apply ‘omics technologies to monitor exposures and associated biological responses related to a spectrum of adult and childhood lung diseases;
- consider the potential of developing biomarkers for lung disease prevention and treatment based on monitoring the exposome.

The term “exposome” refers to the totality of exposures individuals experience from conception until death and its impact on risk of chronic diseases. Exposures can include toxicants in the environment, diet, lifestyle choices and socioeconomic status. People have unique genetic, epigenetic, health status, and physiological characteristics that can change in response to prior exposures, and make them more or less susceptible to stressors in their environment. This session will outline the exposome concept and highlight current research that is examining a breadth of biological, chemical and environmental influences that contribute to development, susceptibility and presentation of lung disease.

**Target Audience**

Those conducting translational research; those conducting basic or discovery research; those conducting clinical research; research and clinical fellows; graduate students; providers of lung health

**Chairs:**

C. Carlsten, MD, MPH, Vancouver, Canada

J.E. Bourke, PhD, Clayton, Australia

**CLINICAL**

### A85 THE EXPOSOME CONCEPT: UNDERSTANDING IMPACT ON LUNG HEALTH AND DISEASE

Assemblies on Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology; Respiratory Structure and Function

2:15 p.m. - 4:15 p.m. MARRIOTT MARQUIS WASHINGTON Independence Ballroom E-H (Level M4)

**Target Audience**

Those conducting translational research; those conducting basic or discovery research; those conducting clinical research; research and clinical fellows; graduate students; providers of lung health

**Objectives**

At the conclusion of this session, the participant will be able to:

- identify current policies in place that pertain to decisions regarding diagnosis and treatment of OSA and discuss their effectiveness in clinical practice;
- discover areas in which an absence of policy amounts to significant heterogeneity in clinical practice but also inconsistencies in physician/hospital billing practices of OSA;
- engage and possibly participate in a call for action in which organizations such as the ATS will need to lobby government to enhance the diagnosis and management of OSA and deal with the burden of untreated OSA.

Obstructive Sleep Apnea (OSA) is highly prevalent with many recent advances evolving the practice of Sleep Medicine. This symposium will critically examine the current approved and unapproved methods for OSA diagnosis and current criteria used to define treatment efficacy. In addition, the societal repercussions of undiagnosed or untreated OSA will also be discussed with attention placed to the hazard of OSA on driving and work safety and a call for policy change. In all proposed presentations, speakers will emphasize current existing policies or lack thereof, discussing how these play as obstacles to meaningful clinical practice in the care of patients with OSA.

**Chairs:**

R. Bhattacharjee, MD, San Diego, CA

J.L. Pepin, MD, PhD, Grenoble, France

M.J. Morrell, PhD, London, United Kingdom

**2:15 General Discussion: Current State of OSA, Implications of OSA on Individuals, on Society, on Government**

R.J. Kimoff, MD, Montreal, Canada

**2:30 What’s in a Number? How Diagnosis of OSA Is Determined by a 4 or a 3**

N.M. Punjabi, MD, PhD, Baltimore, MD

**2:50 Diagnosing Pediatric OSA: Is Home Testing Plausible?**

C. Marcus, MBChB, Philadelphia, PA

**3:10 Inpatients with Possible OSA: Should, Can, and How Do We Study Them in Hospital?**

B. Prasad, MD, Chicago, IL
### A87 ATS Mythbusters: One OME to Rule Them All: We Will Find a Common Prime Mover for Pulmonary Fibrosis

**Assemblies on Respiratory Cell and Molecular Biology; Allergy, Immunology and Inflammation; Respiratory Structure and Function**

2:15 p.m. - 4:15 p.m.  
**Marriott Marquis Washington**  
Marquis Ballroom 5 (Level M2)

**Target Audience**  
Clinicians with interest in mechanism of disease, basic scientists, postdocs, fellows and PhD/ MSc students

**Objectives**  
At the conclusion of this session, the participant will be able to:

- understand the complexity of pathogenesis of lung injury and repair;
- learn about “omics” and how they are relevant to chronic fibrotic lung diseases.

This is a new session in the very successful series of ATS Mythbusters, in which leading researchers give talks relevant to a controversial hypothesis, after which expert “mythbusters” discuss its validity, and audience members ultimately vote on whether the myth has been accepted or busted. In this provocative session, the hypothesis to be examined is that as we learn more about fibrogenesis, a common prime mover will emerge as the driving force in most cases of pulmonary fibrosis. Speakers will present evidence supporting the proposition that abnormalities in the “OMICS” or “OMES” that emerge as the driving force in most cases of pulmonary fibrosis. Speakers will present evidence supporting the proposition that abnormalities in the “OMICS” or “OMES” that they discuss are driving the abnormal tissue injury and repair seen in fibrotic lung diseases, especially IPF. The candidate OMEs proposed to be the main culprit in the pathology of pulmonary fibrosis are the genome, the transcriptome, the proteome, the microbiome or the metabolome. The session will debate whether abnormalities in one of these OMEs “rules them all” in pulmonary fibrosis.

**Chairing:**  
M.R.J. Kolb, MD, PhD, Hamilton, Canada  
A.M. Tager, MD, Charlestown, MA  
R.G. Jenkins, MD, PhD, Nottingham, United Kingdom

#### BASIC • TRANSLATIONAL  
**SCIENTIFIC SYMPOSIUM**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15</td>
<td>Introduction</td>
<td>M.R.J. Kolb, MD, PhD, Hamilton, Canada</td>
</tr>
<tr>
<td>2:21</td>
<td>The Genome Drives Injury and Fibrosis in the Lung</td>
<td>T.E. Fingerlin, PhD, Denver, CO</td>
</tr>
<tr>
<td>2:35</td>
<td>The Transcriptome Drives Injury and Fibrosis in the Lung</td>
<td>D. Kass, MD, Pittsburgh, PA</td>
</tr>
<tr>
<td>2:49</td>
<td>The Proteome Drives Injury and Fibrosis in the Lung</td>
<td>O. Eickelberg, MD, Munich, Germany</td>
</tr>
<tr>
<td>3:03</td>
<td>The Metabolome Drives Injury and Fibrosis in the Lung</td>
<td>P.J. Sime, MD, Rochester, NY</td>
</tr>
</tbody>
</table>

**Parker B. Francis Speaker**

### A88 SEX, SUGAR, SALT AND STRESS: NEUROHORMONAL SIGNALING AS A NOVEL THERAPEUTIC TARGET IN RIGHT VENTRICULAR FAILURE

**Assemblies on Pulmonary Circulation; Critical Care; Respiratory Cell and Molecular Biology**

2:15 p.m. - 4:15 p.m.  
**Marriott Marquis Washington**  
Liberty Ballroom I-L (Level M4)

**Target Audience**  
Basic, translational and clinical researchers interested in right ventricular function in health and disease. Clinicians (especially interists, pulmonologists/intensivists, and cardiologists) interested in RV and LV function as well as in RV-directed therapies in pulmonary vascular diseases. Nurses and respiratory therapists interested in pulmonary vascular disease and RV function

**Objectives**  
At the conclusion of this session, the participant will be able to:

- learn new findings about common modifiers of hormonal signaling in cardiovascular diseases;
- understand how sex steroids, glucose and fatty acid metabolism, the renin-angiotensin-aldosterone system and the catecholaminergic system regulate RV function in health and disease;
- identify novel strategies to target hormone signaling in clinical trials.

This session will focus on the role of neurohormonal signaling in modifying right ventricular (RV) function in pulmonary hypertension (PH). While it has long been known that hormones affect left ventricular function, recent data identified neurohormonal signaling as a major modifier of RV function. However, the exact mechanisms of how sex steroids, insulin, the renin-angiotensin-aldosterone system and the catecholaminergic system affect RV function are only incompletely understood. In addition, optimal strategies for harnessing these pathways therapeutically are still unknown. This multidisciplinary session will address these knowledge gaps by providing novel evidence indicating how hormones affect cardiomyocyte function and by discussing novel results from phase I and II clinical trials.

**Chairing:**  
M.R.J. Kolb, MD, PhD, Hamilton, Canada  
A.M. Tager, MD, Charlestown, MA  
R.G. Jenkins, MD, PhD, Nottingham, United Kingdom

#### BASIC • CLINICAL • TRANSLATIONAL  
**SCIENTIFIC SYMPOSIUM**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15</td>
<td>Introduction</td>
<td>M.R.J. Kolb, MD, PhD, Hamilton, Canada</td>
</tr>
<tr>
<td>2:21</td>
<td>The Genome Drives Injury and Fibrosis in the Lung</td>
<td>T.E. Fingerlin, PhD, Denver, CO</td>
</tr>
<tr>
<td>2:35</td>
<td>The Transcriptome Drives Injury and Fibrosis in the Lung</td>
<td>D. Kass, MD, Pittsburgh, PA</td>
</tr>
<tr>
<td>2:49</td>
<td>The Proteome Drives Injury and Fibrosis in the Lung</td>
<td>O. Eickelberg, MD, Munich, Germany</td>
</tr>
<tr>
<td>3:03</td>
<td>The Metabolome Drives Injury and Fibrosis in the Lung</td>
<td>P.J. Sime, MD, Rochester, NY</td>
</tr>
</tbody>
</table>

**Parker B. Francis Speaker**
A89 SMOLDERING TB: EXPLORING THE FULL SPECTRUM OF INFECTION WITH MTB

Assemblies on Microbiology, Tuberculosis and Pulmonary Infections; Clinical Problems; Pediatrics
2:15 p.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
East Salon A-C (South Building, Street Level)

Target Audience
All audiences ranging from those who provide clinical care to those with infection with Mtb (both LTBI and TB disease), to those with an interest in the host/pathogen interaction, to those with a broader interest in other disease that are often termed latent.

Objectives
At the conclusion of this session, the participant will be able to:

- learn about new findings in the underlying pathophysiology and immunology of “smoldering” TB;
- develop an improved understanding of those factors associated with a high risk of developing TB once infected.

Infection with Mycobacterium tuberculosis (Mtb) is often categorized as either “active” or “latent”. However, it is increasingly clear that infection with Mtb results in a much broader range of clinically relevant outcomes. Understanding the molecular and immunologic basis of this spectrum of infection is clinically relevant, as identifying those at risk for progression to disease following infection has the potential to facilitate the eradication of TB worldwide.

Chairing: P. LoBue, MD, Atlanta, GA
D.M. Lewinsohn, MD, PhD, Portland, OR

2:15 The Epidemiology of Subclinical TB
C.R. Horsburgh, MD, Boston, MA

2:35 PET/CT: A Window Into Incipient TB
R. Wilkinson, PhD, Cape Town, South Africa

2:55 Predicting TB Progression
D. Zak, PhD, Seattle, WA

3:15 Clearance of Mtb Following Infection
E. Nardell, MD, Boston, MA

3:35 Animal Modeling
P. Lin, MD, Pittsburgh, PA

3:55 Can Infection with Mtb Be Prevented?
D.M. Lewinsohn, MD, PhD, Portland, OR

There will be a 5-minute discussion after each talk.
2:15 The Genomic Response to Sepsis
T. van der Poll, PhD, Amsterdam, Netherlands

2:35 Metabolic Adaptation Establishes Disease Tolerance to Sepsis
M. Soares, PhD, Oeiras, Portugal

2:55 Potato or Potahto: Immune Exhaustion Vs. Innate Immune Suppression
D. Remick, MD, Boston, MA

3:15 Poking the Cyclops in the Eye! Disruption in Immune Surveillance and Outcomes from Sepsis
P. Kubes, PhD, Calgary, Canada

3:35 Microbial Surveillance and Pulmonary Microbiome
I.S. Douglas, MD, Denver, CO

3:55 Contextualizing Sepsis Research: Where Are the Translational Signals Pointing To?
J. Marshall, MD, Toronto, Canada

There will be a 5-minute discussion after each talk.

---

A91 CATCHING FIRE: THE GLOBAL HEALTH ISSUE OF HOUSEHOLD AIR POLLUTION

Assemblies on Environmental, Occupational and Population Health; Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology; Clinical Problems; Microbiology, Tuberculosis and Pulmonary Infections; Pediatrics; Respiratory Structure and Function

2:15 p.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 145 A-B (Middle Building, Street Level)

Target Audience
Basic and clinical scientists, clinicians, public health officials, students, post-doctoral trainees with an interest in global environmental health, health disparities, exposure assessment, household air pollution, and toxicological mechanisms of biomass smoke inhalation

Objectives
At the conclusion of this session, the participant will be able to:

- gain knowledge about the current data on the global health effects of exposure to household air pollution and strategies designed to reduce HAP-induced diseases;
- understand experimental methods that can be used to investigate the impact of the inhalation of HAP;
- understand the socioeconomic and cultural factors that contribute to the health disparity issue of HAP.

Household air pollution (HAP) arises from the indoor burning of biomass such as wood, animal dung, and crop residues or coal for cooking and heating, resulting in high levels of particulate matter, carbon monoxide, volatile organic compounds, and other pollutants within the home. These have deleterious effects on lung health, including lung growth during childhood, respiratory infections, asthma, COPD, and lung cancer. This is a global health problem, particularly in developing countries but is also relevant to economically deprived areas of high income countries. This session will provide information about the respiratory health effects of exposure to biomass smoke. The talks will discuss epidemiological, experimental (cellular and molecular pathways), and risk-mitigation evidence related to the toxicological effects of household air pollution. Policy makers need to be made aware of the effects of household air pollutants.

Chairing:
P.J. Sime, MD, Rochester, NY
G.P. Downey, MD, Denver, CO
N. Lugogo, MD, Durham, NC
P.J. Barnes, MD, DSc, London, United Kingdom
R. Vlahos, PhD, Bundoora, Australia

2:15 Household Air Pollution: A Call to Action
A. Lee, MD, MS, New York, NY

2:25 Inflammatory Lung Diseases in Vulnerable Populations Exposed to HAP
S. Salvi, MD, PhD, Pune, India

2:40 Household Air Pollution Exposure Occurs in Developed Countries As Well!
A. Sood, MD, MPH, Albuquerque, NM

2:55 Studying Biologic Mechanisms of HAP-Induced Diseases
C.E. McCarthy, MS, Rochester, NY

3:15 The Role of Biomass Smoke in Respiratory Infections
S. Gordon, MD, Blantyre, Malawi

3:35 Translational Approaches to Understand the Effects of Biomass Smoke
I. Jaspers, PhD, Chapel Hill, NC

3:55 Does Exposure to Household Air Pollution Increase Cardiovascular Morbidity and Mortality?
J.R. Balmes, MD, San Francisco, CA

---

A92 IT'S NOT DOROTHY ANDERSEN'S CF ANYMORE

International Conference Committee Chair’s Symposium

2:15 p.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Ballroom B (South Building, Level 3)

Target Audience
Individuals involved in the care of people with cystic fibrosis, including those involved in basic, translational and clinical investigations of CF and others with primary interests in related diseases; individuals interested in lung biology and disease

Objectives
At the conclusion of this session, the participant will be able to:

- understand and describe the latest information about CF pathogenesis, animal and laboratory models, and the evolution of CF lung disease in infants and young children;
- improve caregiver understanding of current CF therapies (including both efficacy and side effects) and the rapidly evolving therapeutic pipeline, which will enable better integration when discussing treatment options with patients, families and loved ones.
• understand the complex future landscape directed at helping all individuals with CF, targeting both the mutation- and theratype-specific cause, as well as agents for symptomatic improvement that are agnostic to CFTR genotype.

This symposium features an inspiring patient perspective and the latest scientific, clinical, and translational information about CF. State of the art presentations focus on mechanisms leading to mucociliary dysfunction and lessons learned about disease pathogenesis from animal models. Leading edge investigations of early CF lung disease during infancy in those identified by neonatal screening are highlighted. The drug discovery pipeline and development of agents targeting both the underlying cause and therapeutics used for symptomatic improvement are illuminated. The session concludes with a presentation on clinical research challenges and future directions aimed at helping all children and adults with CF.

Chairing:  
S.D. Davis, MD, Indianapolis, IN  
S.H. Randell, PhD, Chapel Hill, NC

2:15 Introduction  
S.D. Davis, MD, Indianapolis, IN

2:20 A Patient’s Perspective  
E. Kramer-Golinkoff, Bala Cynwyd, PA

2:30 CF in the Lungs’ Most Formative Years  
S. Stick, MBBS, Perth, Australia


This symposium is supported by an educational grant from Vertex Pharmaceuticals, Inc. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

A94 IMPROVING ASTHMA MANAGEMENT: RESEARCH AT THE FOREFRONT

Chairs:  
K.A. Riekert, PhD, Baltimore, MD  
J.K. Gerald, MD, PhD, Tucson, AZ

Oral Presentations:


A95  ACUTE PNEUMONIA: CLINICAL STUDIES

2:15 p.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER

West Salon G-I (South Building, Street Level)

Chairing:  G.W. Waterer, MBBS, PhD, MBA, Perth, Australia

J.E. Chastre, MD, Paris, France

O. Sibila, MD, PhD, Barcelona, Spain

Oral Presentations:


A96  BEST OF PEDIATRICS

2:15 p.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER

Room 202 A (South Building, Level 2)

Chairing:  A.C. Koumbourlis, MD, MPH, Washington, DC

P.E. Moore, MD, Nashville, TN

Oral Presentations:


Featured Speaker
4:00 Lessons My Patients Have Taught Me/P.E. Moore, MD, Nashville, TN

MINI SYMPOSIUM

A97 MOLECULAR TARGETS AND PATHWAYS IN AGING

2:15 p.m. - 4:15 p.m. MARRIOTT MARQUIS WASHINGTON
Marquis Ballroom 6 (Level M2)
Chairing: G.S. Budinger, MD, Chicago, IL
M. Konigshoff, MD, PhD, Aurora, CO
M. Sauler, MD, New Haven, CT

Oral Presentations

2:15 Aging Lung Fibroblasts Show a Defect in Cystine Transport that Results in Dysregulation of the Extracellular Redox Environment and Increased Expression of Extracellular Matrices/W.H. Watson, J.D. Ritzenhalter, T.J. Burke, I.N. Zelko, E. Torres-Gonzalez, J. Roman, Louis ville, KY, p.A2654


3:00 Aging Slows Ciliary Beat Frequency of Wild Type, but Not Protein Kinase C Epsilon Knockout Mice/K.L. Bailey, D.M. Katafiasz, J.H. Sisson, T.A. Wyatt, Omaha, NE, p.A2697


3:30 Variability in Stretch Amplitude Partially Restores Age-Related Decline in Mitochondrial Structure and Function in Lung Fibroblasts/E. Bartolak-Suki, B. Suki, Boston, MA, p.A2659


4:00 Aged Mice Display a Distinct Blood CD4+ T Cell Profile Before and After Influenza Infection/B.D. Singer, K. Helmin, A. Mc Quattie-Pimentel, C.-I. Chen, H.C. Do-Umehara, S. Budinger, A.V. Misharin, Chicago, IL, p.A2661

MINI SYMPOSIUM

A98 SEEING IS BELIEVING: USING NOVEL IMAGING TECHNIQUES TO UNDERSTAND THE LUNG IN HEALTH AND DISEASE

2:15 p.m. - 4:15 p.m. MARRIOTT MARQUIS WASHINGTON
Independence Ballroom A-D (Level M4)
Chairing: J.C. Woods, PhD, Cincinnati, OH
E.A. Hoffman, PhD, Iowa City, IA

Oral Presentations


3:00 Inflammatory and Non-Inflammatory Contributions to Ventilation Heterogeneity in Severe Poorly-Controlled Asthmatics/S.V. Svenningsen, R.L. Eddy, H.F. Lim, P. Nair, G. Parraga, Hamilton, Canada, p.A2665


4:00  Pulmonary Vessels on Computed Tomography in Early Stages of Chronic Obstructive Pulmonary Disease/J.-P. Charbonnier, E. Van Rikxoort, S. Humphries, C. Schaefer-Prokop, D. Lynch, Nijmegen, Netherlands, p.A2669
A103 COPD: DISEASE PROGRESSION AND PROGRESSION

2:15 p.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Room 209 A-C (South Building, Level 2)

Poster Viewing 2:15-3:00
Discussion 3:00-4:15

Chairing: S.P. Bhatt, MD, Birmingham, AL
J.M. Bon, MD, MS, Pittsburgh, PA
R.A. Wise, MD, Baltimore, MD
712 Developing a Risk Prediction Model for Readmission During Follow-Up Visit After a COPD Exacerbation/C. Lau, G. Sathiyamoorthy, B. Small, H. Bhadsavle, D. Saygin, X. Han, X. Wang, U. Hatipoglu, Cleveland, OH, p.A2722

713 Frailty Assessment for Predicting Readmission and Discharge Disposition Among Patients Hospitalized for Chronic Obstructive Pulmonary Disease Exacerbation/T. Golden, N. Toosizadeh, C.E. Berry, Y. Mei, M. Miramontes, C. Zaldizar, J. Mohler, L. Ghazala, Tucson, AZ, p.A2723


717 Risk Factors for Hospital Admission with a Respiratory Illness in a Comparative Effectiveness Cohort of Patients with Chronic Obstructive Pulmonary Disease (COPD)/J. Veljanovski, D.R. Oueltette, Detroit, MI, p.A2727


721 Combined Impact of Early Life Factors and Smoking on Adult FEV1 Trajectory - A Prospective 64 Year National Birth Cohort Study/J.P. Allinson, R. Hardy, G.C. Donaldson, S.O. Shaheen, D. Kuh, J.A. Wedzicha, London, United Kingdom, p.A2731


724 The Effect of Vitamin D on the Lung Function and Quality of Life in Obstructive Airway Disease in Korea/S.-T. Uh, S.M. Koo, Y.K. Kim, K.U. Kim, D.J. Kim, S. Park, Seoul, Korea, Republic of, p.A2734


A104 CRITICAL CARE: IMPROVING ICU EXERCISE, REHABILITATION, RECOVERY, AND SURVIVORSHIP

2:15 p.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Room 151 A (Middle Building, Street Level)

Poster Viewing 2:15-3:00

Discussion 3:00-4:15

Chairing: C.L. Hough, MD, Seattle, WA

A.A. Hope, MD, MSCE, Bronx, NY

R.N. Bakhrud, MD, Winston-Salem, NC


304 Observation of Physical Activity Patterns in Patients Intubated at Least 48 Hours in Intensive Care/A. Pastva, B. Koermer, L. Southam, L. Delmedico, S. Foley, K. Hambrick, L. Johnson, J. Thompson, V. Sabol, Durham, NC, p.A2739


307 The Oxygen Cost of Rehabilitation in Mechanically Ventilated Patients/C. Black, M. Singer, M. Grocott, London, United Kingdom, p.A2742


309 Early Mobilization Program in the Parkland MICU: 18 Month Follow-Up/D.H. Yang, M. Weinreich, S. Dickason, J. Herman, J. Brown, M. Leveno, Dallas, TX, p.A2744


315 Arm Cycling in Critically Ill Medical-Surgical Patients in the Acute Care Setting/M. McCaughan, K. Obovov, W. Perry, D. Ajami, L. Campisilan, A. Molloy, F. Clarke, J. Rudkowski, D.J. Cook, M.E. Kho, Hamilton, Canada, p.A2750

316 A Comparison of Early and Enhanced Rehabilitation of Mechanically Ventilated Patients in Critical Care Compared to Standard Care (REHAB): A Single Site Feasibility Randomized Controlled Trial/D. McWilliams, C. Jones, G. Atkins, E. Reeves, C. Snellson, Birmingham, United Kingdom, p.A2751


322 Characterization of Depressive Symptoms and Antidepressant Prescribing Among ICU Survivors in the Critical Care Recovery Center (CCRC)/S. Wang, C. Mosher, K. Kirk, Y.N. Kheir, S. Lasiter, S.H. Khan, M. Boustani, B.A. Khan, Indianapolis, IN, p.A2757


325 Primary Care Physicians’ Perceptions of Outpatient Care for Survivors of Critical Illness/A.A. Liou, W.D. Schweickert, D.C. Files, R.N. Bakhu, Winston-Salem, NC, p.A2760

POSTER DISCUSSION SESSION

A105 CRITICAL CARE: IMPROVING PROGNOSTICATION IN CRITICAL ILLNESS

2:15 p.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Room 151 B (Middle Building, Street Level)

Poster Viewing

2:15-3:00

Discussion

3:00-4:15

Chairing: C.K. Grissom, MD, Murray, UT
K.S. Mathews, MD, MPH, New York, NY
V. Liu, MD, MS, Oakland, CA


402 Predicting Outcomes and Prognosis in ARDS/S. Wachtel, A.A. Asuni, A. Rogers, J. Levitt, Stanford, CA, p.A2762

The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.


507 Particle Size Characterization of Nebulized Albuterol Delivered by a Jet Nebulizer Through Pediatric Endotracheal Tubes/A. Berinski, S. Kumanar, Little Rock, AR, p.A2812


### A108 LITTLE RED CLOT: NEW FRONTIERS IN THE MANAGEMENT OF ACUTE AND CHRONIC THROMBOEMBOLIC DISEASE

**2:15 p.m. - 4:15 p.m.**  
**MARRIOTT MARQUIS WASHINGTON**

<table>
<thead>
<tr>
<th>Session Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster Viewing</td>
<td>Marquis Ballroom 9-10 (Level M2)</td>
</tr>
<tr>
<td>Discussion</td>
<td>3:00-4:15</td>
</tr>
</tbody>
</table>

**Chairing:**  
K.N. Goss, MD, Madison, WI  
T.M. Bull, MD, Aurora, CO  
R.N. Channick, MD, Boston, MA

**1001** Dysfunctional Endothelial Cells in Patients with Chronic Thromboembolic Pulmonary Hypertension/O. Tura-Ceide, V. Smolders, L. Piccari, N. Aventin, C. Moren, T. Paul, J. Garcia-Lucio, I. Blanco, V.I. Peinado, N. Chamorro, M. Castella, J.A. Barbera, Barcelona, Spain, p.A2830

**1002** Discordance Between Imaging Modalities in the Evaluation of Chronic Thromboembolic Pulmonary Hypertension: A Single Center Experience/D. Furfaro, J. Azadi, T. Houston, T.M. Kolb, R.L. Damico, P.M. Hassoun, S. Mathai, Baltimore, MD, p.A2831

**1003** Chronic Thromboembolic Disease Without Pulmonary Hypertension - a Single Surgical Centre’s Experience/E.M. Swietlik, D. Taboada, A. Ruggiero, E. Bales, A. Fletcher, J. Cannon, K. Sheares, D. Jenkins, J. Pepke-Zaba, M. Toshner, Cambridge, United Kingdom, p.A2832


**1007** Histological and Immunohistological Predictors of Physiological Outcome in Pulmonary Artery Thromboendarterectomy Specimens/G. Eng, J. Rodriguez-Lopez, R.N. Channick, R. Kradin, Boston, MA, p.A2836


---

**A109 HIGHLIGHTS IN PULMONARY REHABILITATION: ILD, ADJUNCTS, AND INSPIRATORY MUSCLE TRAINING**

**2:15 p.m. - 4:15 p.m.**  
**MARRIOTT MARQUIS WASHINGTON**

<table>
<thead>
<tr>
<th>Session Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster Viewing</td>
<td>Marquis Ballroom 1-2 (Level M2)</td>
</tr>
<tr>
<td>Discussion</td>
<td>3:00-4:15</td>
</tr>
</tbody>
</table>

---


**1011** Development of a Claims-Based Algorithm to Identify Patients with Chronic Thromboembolic Pulmonary Hypertension/S. Teal, W. Auger, R.J. Hughes, K.S. Lewis, D.R. Ramey, J. Fabian, Berlin, Germany, p.A2840

**1012** Effect of Balloon Pulmonary Angioplasty on Right Ventricular Afterload in Chronic Thromboembolic Pulmonary Hypertension/C. Gerges, M. Gerges, N. Skoro-Sajer, R. Sadushi-Kolici, I. Campean, B. Moser, S. Taghavi, W. Klepetko, H. Matsubara, I.M. Lang, Vienna, Austria, p.A2841

**1013** Predictors of Right Ventricular Reversibility After Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension/R. Asano, T. Ogo, S. Fukui, A. Tsuji, J. Ueda, N. Konagai, Y. Morita, T. Fukuda, S. Yasuda, Suita, Japan, p.A2842


**1015** Contrast Enhanced Computed Tomography and the Presence of Intra-Thoracic Air/S. Chandrarathne, W. Khan, H. Jones, R. Owen, D. Vethanayagam, Edmonton, Canada, p.A2844


---

**Note:** The information contained in this program is up to date as of March 9, 2017. For the most current session information, please visit the online program itinerary.
811 Automatically Adjusted Oxygen Flow Rates (FreeO2) Optimizes Oxygenation and Improves Walking Distance During Exercise in Hypercapnic O2-Dependent Chronic Obstructive Pulmonary Disease (COPD)/I. Vivodtzev, E. L’Her, G. Vottero, C. Yankoff, A. Granier, V. Mayer, D. Veale, F. Maltais, F. Lellouche, J.L. Pepin, Grenoble, France, p.A2856


815 Effects of Combined Cycle Ergometer and Inspiratory Muscle Training in Patients with Stable Chronic Obstructive Pulmonary Disease/X. Chen, P. Luo, Y. Chen, Y. Huang, K. Wang, Y. Hu, W. Xu, Guangzhou, China, p.A2861

A110 ADVANCES IN THORACIC ONCOLOGIC DIAGNOSTICS

2:15 p.m. - 4:15 p.m. MARRIOTT MARQUIS WASHINGTON Marquis Ballroom 3-4 (Level M2)

Abstract Summaries

2:15-2:45

Poster Viewing/Discussion

2:45-4:15

Chairing: J.L. Bessich, MD, New York, NY

J. Puchalski, MD, New Haven, CT

D.H. Sterman, MD, New York, NY

A. Vachani, MD, MS, Philadelphia, PA

901 Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction (BROADWAY Trial)/C. Mallow, J. Thiboutot, A. Lerner, R. Semaan, B. Salwen, H. Lee, D.J. Feller-Kopman, K. Seward, L. Yarmus, Baltimore, MD, p.A2862


<table>
<thead>
<tr>
<th>Session No.</th>
<th>Title</th>
<th>Authors/Details</th>
<th>Location/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>906</td>
<td>Clinical Relevance of Nodal Staging in Metastatic Lung Cancer: Is There a Difference Between Conventional Imaging Modalities and EBUS-TBNA/</td>
<td>P.S. Zhu, T. Vandenhootele, Montreal, Canada, p.A2867</td>
<td></td>
</tr>
<tr>
<td>908</td>
<td>The Effect of Rapid On-site Evaluation on Diagnostic Yield for Peripheral Bronchoscopy Cases/</td>
<td>K. Haas, A. Chen, St. Louis, MO, p.A2869</td>
<td></td>
</tr>
<tr>
<td>918</td>
<td>Effects of Sample Processing in Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA) of Mediastinal Lymphadenopathy/</td>
<td>C. Pan, S. Amirmalek, A. Ing, T. Saghai, Sydney, Australia, p.A2880</td>
<td></td>
</tr>
</tbody>
</table>
SUNDAY • MAY 21

4:30 p.m. - 5:45 p.m.
RESPIRATORY HEALTH AWARDS PRESENTATION OF THE AMBERSON LECTURE,
TRUDEAU MEDAL AND DISTINGUISHED ACHIEVEMENT AWARDS
WALTER E. WASHINGTON CONVENTION CENTER
Hall E (Middle Building, Level 2)

Amberson Lecture
The Amberson Lecturer is an individual with a career of major lifetime contributions to clinical or basic pulmonary research and/or clinical practice. The Lecture is given in honor of James Burns Amberston, an international authority on chest disease and tuberculosis.

Lecturer: Peter D. Pare, MD, Vancouver, Canada
Lecturer Title: The Smoking Gun: Genetics and Genomics Reveals Causal Pathways for COPD

Trudeau Medal
The Trudeau Medalist is an individual with lifelong major contributions to prevention, diagnosis and treatment of lung disease through leadership in research, education, or clinical care. This award was established in 1926 and is given in honor of Edward Livingston Trudeau, a founder and the first president of the American Lung Association.

Awardee: Sharon I.S. Rounds, MD, Providence, RI

Distinguished Achievement Awards
The Distinguished Achievement Award is given to individuals who have made outstanding contributions to fighting respiratory disease through research, education, patient care, or advocacy.

Awardees: Jack Gauldie, DSc, PhD, Hamilton, Canada
Steven D. Shapiro, MD, Pittsburgh, PA

6:30 p.m. - 8:30 p.m.
SECTION MEMBERSHIP MEETING
The Section meetings are open to all ATS members and other interested individuals. Items to be discussed include the Sections’ current projects and future directions.

GENETICS AND GENOMICS
RENAISSANCE WASHINGTON DOWNTOWN
Meeting Room 4 (Meeting Room Level)

Chairing: Sadis Matalon, PhD, Sc.D. (Hon.), Birmingham, AL
Carl W. White, MD, Denver, CO

6:30 p.m. - 8:30 p.m.
ASSEMBLY MEMBERSHIP MEETINGS
The fourteen Assemblies are the primary groups of the American Thoracic Society. Each Assembly holds an annual Membership Meeting at the International Conference. All Assembly members and other interested individuals are invited to attend. The Assembly Membership Meetings provide an update on the Assembly’s activities via the Assembly’s Leadership and provide Assembly members the chance to have input on future directions, information on how to get involved and networking opportunities. Voting results for the Assembly’s future leaders will also be announced. The Assembly Membership Meetings will be held on Monday, May 22, 5:00 p.m. - 7:00 p.m., with the exception of the Assemblies on Behavioral Science and Health Services Research and Pediatrics (see below.)

BEHAVIORAL SCIENCE
AND HEALTH SERVICES RESEARCH
RENAISSANCE WASHINGTON DOWNTOWN
Grand Ballroom South (Ballroom Level)

Chairing: Christopher H. Goss, MD, MSc, Seattle, WA
This meeting will be held on Sunday, May 21st

PEDIATRICS
RENAISSANCE WASHINGTON DOWNTOWN
Grand Ballroom Central (Ballroom Level)

Chairing: James Chmiel, MD, MPH, Cleveland, OH
This meeting will be held on Sunday, May 21st

The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.
7:00 p.m. – 9:00 p.m.
STRATEGIES FOR TB CONTROL: POSTER SESSION
MARRIOTT MARQUIS WASHINGTON
Marquis Ballroom 1-2 (Level M2)
Sponsored by:
U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION STOP TB USA

This public health poster forum will focus on innovative techniques, which are helping to meet the challenges of TB control, prevention, and elimination in the United States. Specific topics include: targeted TB testing and treatment of latent TB infection; conducting/expanding contact investigations; performing outbreak investigations; improving treatment adherence; addressing multi-drug-resistant TB; dealing with TB related to HIV/AIDS; providing TB education; and building TB-related coalitions.

Target Audience:
National, state and local TB program staff, public health professionals (nurses, physicians, epidemiologists), pulmonary specialists, infectious disease specialists, TB and HIV clinicians, epidemiologists, TB consultants, laboratory scientists, and microbiologists.

Chairing: N. Shah, MD, Richmond, CA
K. Schmidt, MPH, Atlanta, GA
The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.
FACULTY DEVELOPMENT SEMINAR

FD1  DEMYSTIFYING “WHAT YOU WANT TO BE WHEN YOU GROW UP”

Pre-registration is required. Attendance is limited. There is no additional fee.

7:00 a.m. - 8:00 a.m.  WALTER E. WASHINGTON CONVENTION CENTER
Room 101 (South Building, Street Level)

Target Audience
Clinical and research fellows, post-doctoral fellows, residents, and junior faculty in the early stages of a career in academic pulmonary, allergy, critical care, and/or sleep medicine

Objectives
At the conclusion of this session, the participant will be able to:

• identify career opportunities in academic settings, private practice, and industry research;

• understand the differences between tenure track and non-tenure track pathways within academic medicine;

• understand how expectations of performance and benchmarks for promotion vary depending on career path.

Graduate and postgraduate trainees and early career faculty must choose from a variety of career tracts and settings, but may have little exposure to the breadth of career opportunities that exist or the different expectations and benchmarks that define success within these different career paths. The goal of this session is to bring together representatives from the worlds of academic medicine, private medical practice, and industry research for an interactive panel discussion that will allow the attendee to explore the options that exist for career development through a moderated interaction between the panel discussants and the attendees.

Chairing: J.C. Horowitz, MD, Ann Arbor, MI

Speakers:
- M. Gyetko, MD, Ann Arbor, MI
- T. Hartert, MD, MPH, Nashville, TN
- C. Baleeiro, MD, Chattanooga, TN
- T.R. Martin, MD, East Hanover, NJ
- P. Rowe, MD, Bridgewater, NJ

ATS 2017 • Washington, DC

The information contained in this program is up to date as of March 9, 2017.

For the most current session information, please visit the online program itinerary.
**B1 CLINICAL YEAR IN REVIEW 2**

9:15 a.m. - 11:15 a.m.  
WALTER E. WASHINGTON CONVENTION CENTER  
Hall E (Middle Building, Level 2)

**Target Audience**
Providers including physicians; registered nurses; advanced practice nurses; respiratory therapists; physician assistants; trainees including residents and fellows; clinical researchers

**Objectives**
At the conclusion of this session, the participant will be able to:

- apply new clinical research knowledge to clinical practice;
- describe new strategies for managing the care of common conditions in pulmonary, critical care, and sleep;
- apply new findings regarding key conditions in pulmonary, critical care and sleep.

The annual Clinical Year in Review symposia topics are reviews of key clinical research publications over the last year. Each speaker is asked to review the 5-7 most important and influential publications on their topic in the prior year.

**Chairing:**  
D.J. Lederer, MD, MS, New York, NY  
D.W. Ford, MD, MSCR, Charleston, SC  
V.E. Ortega, MD, PhD, Winston-Salem, NC

9:15 ILD  
T.J. Corte, MBBS, BSc(Med), PhD, Sydney, Australia

9:45 Asthma  
E. Bleecker, MD, Winston-Salem, NC

10:15 COPD  
M.K. Han, MD, MS, Ann Arbor, MI

10:45 Pulmonary Vascular Diseases  
A.R. Hemnes, MD, Nashville, TN

**This session and the International Conference are supported by educational grants from Actelion Pharmaceuticals US, Inc., AstraZeneca LP, Teva Pharmaceuticals.**

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

**B2 THE LONG-TERM OXYGEN TREATMENT TRIAL (LOTT): IMPLICATIONS FOR COPD PATIENT CARE**

9:15 a.m. - 11:15 a.m.  
WALTER E. WASHINGTON CONVENTION CENTER  
Ballroom A (South Building, Level 3)

**Target Audience**
All those interested in the detailed use of supplemental oxygen in the largest group of COPD patients ever examined, including registered nurses and advanced practice nurses.

**Objectives**
At the conclusion of this session, the participant will be able to:

- state the results of the long-term oxygen treatment trial;
- discuss the rationale for the development of the long-term oxygen treatment trial;
- identify the issues that affect compliance with oxygen in COPD patients.

Long-term oxygen therapy is one of the most common therapies that COPD patients receive. There have been no studies of significance being conducted in the last 30 years examining use of supplemental oxygen in COPD patients. The National Heart Lung Blood Institute long-term oxygen treatment trial is the largest and longest trial ever conducted examining the feasibility and effectiveness of oxygen supplementation in patients with COPD. Specifically if provides little information regarding the use of supplemental oxygen in patients with mild to moderate hypoxia at rest or with normoxia and desaturation only with exercise.

**Chairing:**  
G.J. Criner, MD, Philadelphia, PA  
W.C. Bailey, MD, Birmingham, AL  
A.L. Fuhlbrigge, MD, Aurora, CO

9:15 Rationale for the Long-Term Oxygen Treatment Trial (LOTT)  
R.A. Wise, MD, Baltimore, MD

9:30 Design of the Long-Term Oxygen Treatment Trial  
J. Cooper, MD, Birmingham, AL

9:45 Methods and Data Analysis of the Long-Term Oxygen Treatment Trial  
F.C. Sciurba, MD, Pittsburgh, PA

10:00 Main Outcomes of the Long-Term Oxygen Treatment Trial  
G.J. Criner, MD, Philadelphia, PA

10:15 Types of Devices and Compliance with O2 Therapy in LOTT  
A.L. Fuhlbrigge, MD, Aurora, CO

10:30 PRO: Oxygen Therapy Benefits Patients with Mild to Moderate Hypoxemia at Rest and Those with Desaturation on Exertion Only  
F.J. Martinez, MD, New York, NY

10:40 Con: Oxygen Therapy Benefits Patients with Mild to Moderate Hypoxemia at Rest and Those with Desaturation on Exertion Only  
R.D. Yusen, MD, MPH, St. Louis, MO

10:50 Rebuttal  
F.J. Martinez, MD, New York, NY

10:55 Rebuttal  
R.D. Yusen, MD, MPH, St. Louis, MO

11:00 Panel Discussion  
G.J. Criner, MD, Philadelphia, PA  
W.C. Bailey, MD, Birmingham, AL  
A.L. Fuhlbrigge, MD, Aurora, CO

**This session and the International Conference are supported by an educational grant from AstraZeneca LP.**

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
B3 THE CANCER MOONSHOT: ATS = MISSION CONTROL FOR LUNG CANCER

Assemblies on Thoracic Oncology; Clinical Problems; Respiratory Cell and Molecular Biology
9:15 a.m. - 11:15 a.m. MARRIOTT MARQUIS WASHINGTON
Marquis Ballroom 6 (Level M2)

Target Audience
All clinicians who care for patients with lung cancer and other thoracic malignancies; all researchers, using multiple methodologies, who are involved with thoracic malignancy research

Objectives
At the conclusion of this session, the participant will be able to:
- identify the critical role the NCI Moonshot will play in cancer detection and treatment research for years to come;
- recognize research gaps in detecting and treating lung cancer;
- foster multifaceted collaborations across the lung cancer research and clinical care continuum.

The ATS is a vital partner in NCI's Cancer Moonshot. Soon, lung cancer care and research will be characterized by molecular diagnosis and targeted treatment and will be personalized, safe, effective, and affordable. This symposium will highlight three areas along the lung cancer continuum that are most relevant for ATS members including 1) prevention and screening, 2) nodules and early detection, and 3) development of novel therapies to treat early stage disease. Each speaker will discuss at least one Moonshot focus including, early cancer detection, immunotherapy and combination therapies, genomic profiling of tumor and surrounding cells, and enhanced data sharing.

Chairing: V.C. Broaddus, MD, San Francisco, CA
N.T. Tanner, MD, MSCR, Charleston, SC
M.M. Fuster, MD, San Diego, CA
P. Mazzone, MD, MPH, Cleveland, OH

9:15 Introduction to the NCI’s Cancer Moonshot
D. Lowy, MD, Bethesda, MD

9:37 Lung Cancer Prevention: The Launch Pad for the Moonshot
R.L. Keith, MD, Denver, CO

9:51 Lung Cancer Screening: The Booster Rockets for the Moonshot
L. Kinsinger, MD, MPH, Washington, DC

10:05 Lung Cancer Early Detection and Biomarkers: The Fuel for the Moonshot
P. Nana-Sinkam, MD, Richmond, VA

10:19 Lung Cancer Screening and Pulmonary Nodule Evaluation: How Do We Help Everyone Who Wants to Go to the Moon Get There and Back Safely?
M.K. Gould, MD, MS, Pasadena, CA

10:33 Lung Cancer Immunotherapy: Building a Force-Field of Protection
S. Dubinett, MD, Los Angeles, CA

B4 HUMANIZING THE INTENSIVE CARE UNIT: NEW PERSPECTIVES ON AN OLD PROBLEM

Assemblies on Critical Care; Behavioral Science and Health Services Research
9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 146 A-B (Middle Building, Street Level)

Target Audience
All clinicians, registered nurses and advanced practice nurses who practice in an intensive care unit

Objectives
At the conclusion of this session, the participant will be able to:
- introduce novel ways to address advance care planning and communication in the ICU.
- define and recognize psychological contributions to Post-intensive Care Syndrome in ICU Patients and Family Members.
- describe practical approaches to facilitating humanization of the ICU, including development of Patient Advisory councils.

The new frontiers of critical care emphasize the potential impact on patients and their loved ones of a critical illness, including long-lasting negative physical and psychological outcomes. The ICU has been clinician-centered in the past, but there is an increasing desire to make the ICU more patient and family-centered. This session explores many of the necessary components of a more humane, patient and family-centered ICU, using research and pioneering new perspectives to reframe the experience of the ICU. Three of the objectives of the session are to increase understanding of critical care physicians regarding important long term outcomes after critical illness; provide attendees with tools to implement interventions in their ICU; change the structure of guidance through the process of shared decision making.

Chairing: E. Hirshberg, MD, MS, Salt Lake City, UT
E.K. Kross, MD, Seattle, WA
W.D. Schweickert, MD, Philadelphia, PA

9:15 A Patient’s Perspective
S. East, Bossier City, LA

9:20 The Psychology of Dehumanization
R.O. Hopkins, PhD, Murray, UT

9:35 Evidence-Based Communication in the ICU
J.R. Curtis, MD, MPH, Seattle, WA
B5 SMOKERS WITH PRESERVED SPIROMETRY: EARLY COPD?

Assemblies on Respiratory Structure and Function; Clinical Problems; Environmental, Occupational and Population Health; Respiratory Cell and Molecular Biology

9:15 a.m. - 11:15 a.m. MARRIOTT MARQUIS WASHINGTON

Independence Ballroom E-H (Level M4)

Target Audience
Professionals with clinical and/or research responsibilities; basic, applied and clinical scientists, respiratory therapists/technologists, population health scientists

Objectives
At the conclusion of this session, the participant will be able to:

- learn new findings about clinical features as well as physiological abnormalities in smokers with normal spirometry;
- gain better insight into the limitations of spirometry in the identification of abnormalities in these patients;
- gain new strategies to manage the care of smokers with normal spirometry and a better understanding of their prognoses.

Despite the known health effects of tobacco smoking, a large proportion of smokers have preserved spirometry, and only a third go on to develop chronic obstructive pulmonary disease. This symposium focuses on the latest research on smokers, with evidence of abnormalities in some despite normal spirometric lung function, whether it is possible to identify those at risk of future lung function decline, and whether they warrant clinical intervention.

This will be a unique opportunity to draw together exciting recent data ranging from large cohort studies such as SPIROMICS and COPDGene, imaging studies, to sophisticated tests of small airway function, and cellular and molecular changes in this population within a larger context.
- gain understanding in the ways of maximizing the effectiveness and minimizing the side effects of chronic mechanical ventilation.

Pediatric pulmonologists are consulted routinely on patients admitted to the Neonatal and Pediatric Intensive Care Units, and they usually assume full responsibility for those who require prolonged or chronic mechanical ventilator support at home. However, controversies persist regarding the physiologic basis and supportive clinical data for selecting ventilator strategies and how to optimize acute and long-term outcomes in children with acute and chronic respiratory failure. In addition, pediatric fellowship programs from diverse fields of pulmonary, critical care and neonatology, often lack sufficient training in specific approaches towards mechanical ventilation. This session intends to provide a comprehensive review of the currently available ventilators and the strategies one can employ for the introduction, management and weaning off mechanical ventilation. Special emphasis will be given to patients with special conditions such as preterm and term infants with diverse forms of acute respiratory failure; bronchopulmonary dysplasia; pulmonary hypertension; congenital heart disease; airway problems (e.g. tracheobronchomalacia and neuromuscular disorders). Recent guidelines from the ATS on home mechanical ventilation as well as pediatric pulmonary hypertension provide additional and timely information for this session as well.

Chairing: A.C. Koumbourlis, MD, MPH, Washington, DC
S.H. Abman, MD, Aurora, CO

9:15 The Role of the Pediatric Pulmonologist in the Care of Mechanically Ventilated Patients
A.C. Koumbourlis, MD, MPH, Washington, DC

9:25 Modalities for Invasive and Non-Invasive Ventilatory Support: Indications and Limitations
C.J.L. Newth, MBChB, Los Angeles, CA
A.C. Koumbourlis, MD, MPH, Washington, DC

9:45 Ventilatory Strategies for Acute Respiratory Failure in Preterm and Term Infants
A. Greenough, MD, MBBS, London, United Kingdom

10:05 Ventilatory Strategies for Infants with Established BPD and Pulmonary Hypertension
S.H. Abman, MD, Aurora, CO

10:25 Choosing Ventilatory Support for Patients with Neuromuscular Disorders
G. Perez, MD, Washington, DC

10:45 Caring of and Weaning the Ventilated Child at Home
A. Halbower, MD, Aurora, CO

11:05 Round Table Discussion
A.C. Koumbourlis, MD, MPH, Washington, DC
S.H. Abman, MD, Aurora, CO
C.J.L. Newth, MBChB, Los Angeles, CA
A. Greenough, MD, MBBS, London, United Kingdom
G. Perez, MD, Washington, DC
A. Halbower, MD, Aurora, CO

B7 FROM RESEARCH TO BEDSIDE: OPTIMIZING WELL-BEING THROUGH INTEGRATIVE THERAPY

Assemblies on Nursing; Behavioral Science and Health Services Research; Critical Care; Pulmonary Rehabilitation
9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 102 A-B (South Building, Street Level)

Target Audience
Providers of lung health, those with clinical or research interests in Integrative Therapies, including registered nurses and advanced practice nurses

Objectives
At the conclusion of this session, the participant will be able to:
- critically examine the use of integrative therapies: mindfulness, music, Tai-Chi;
- discuss the issues surrounding the safety and efficacy of nutritional supplements as viewed from the FDA;
- describe the safety, efficacy, care coordination and research needs of integrative therapies.

Holistic care through appropriate integration of complementary therapy has the potential to optimize health and well-being for patients with chronic lung disease. To maximize integrative therapies’ benefits while reducing potential harm, critical appraisal and relevant application of popular complementary therapies is needed. In addition to addressing this “bench to bedside” paradigm, the session will begin from patients’ perspective that will expand its scope to international perspective with regards to complementary therapy practice.

Chairing: T.T. Von Visger, MSN, CNS, CCNS, PCCN, Columbus, OH
N. Liang, MD, San Diego, CA

9:15 Patient Education/A Patient’s Perspective
V. Sharma, PhD, Oakland, CA

9:35 Mindfulness for Patients with COPD
R. Benzo, MD, MSc, Rochester, MN

9:55 Music Intervention in Critically Ill Patients
R. Benzo, MD, MSc, Rochester, MN

10:15 Tai Chi Practice for Patients with Pulmonary Conditions
J. Adams, PhD, Sydney, Australia

There will be a 5-minute discussion after each talk.
B8 REALIZING THE PARIS CLIMATE AGREEMENT TO IMPROVE CARDIO-PULMONARY HEALTH: WHERE SCIENCE MEETS POLICY

Assemblies on Environmental, Occupational and Population Health; Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Clinical Problems; Critical Care; Microbiology, Tuberculosis and Pulmonary Infections, Pediatrics; Environmental Health Policy Committee; International Health Committee

9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 147 A-B (Middle Building, Street Level)

Target Audience
Clinicians, researchers and practitioners focused on the prevention and treatment of respiratory and/or cardiovascular disease.

Objectives
At the conclusion of this session, the participant will be able to:

- create a science policy forum where scientists and Washington policymakers can have a bi-directional dialogue to improve future interactions;
- educate ATS members and others as to the potential human health benefits of climate mitigation;
- inspire ATS members and others to get involved in enhancing the role of science and medicine in Washington policy making.

Climate change has been described by the Lancet Commission as “the greatest public health opportunity of the 21st Century.” This scientific symposium will objectively examine this opportunity with a focus on cardio-pulmonary health and public policy. The symposium will open with the perspective of a physician from Cameroon discussing the effects of climate change on the health of people in Africa. A series of speakers will review evidence of cardio-pulmonary health effects of greenhouse gas emissions and climate change, and identify vulnerable populations. Finally, a former EPA administrator and U.S. Senator will discuss challenges and opportunities of the 2015 Paris Climate Agreement for physicians, scientists and patients.

Chairing:
M.B. Rice, MD, MPH, Boston, MA
K.E. Pinkerton, PhD, Davis, CA
G.D. Thurston, DSc, Tuxedo, NY

9:15 Climate Change in Africa: A Physician’s Perspective from Cameroon
M.M. Nganda, MD, Douala, Cameroon

9:20 Understanding Climate Science and Policy: What Doctors Should Know
M.B. Rice, MD, MPH, Boston, MA

9:40 Air Pollution Health Effects of Energy Sources: Which Are the Most Toxic?
G.D. Thurston, DSc, Tuxedo, NY

9:55 Hot Temperatures and Ground-Level Smog: Who Is Most Likely to Die?
J. Schwartz, PhD, Boston, MA

10:15 Effects of Climate Change on Children and Adults with Asthma
K.C. Nadeau, MD, PhD, Stanford, CA

10:35 Public Health, Climate Change, and the EPA: What’s Next?
C. Browner, JD, Washington, DC

10:55 Making the Paris Agreement a Reality: Challenges and Opportunities
S. Whitehouse, JD, U.S. Senator, RI

There will be a 5-minute discussion after each talk.

B9 GAMING THE SYSTEM OR SAVING LIVES: PAY FOR PERFORMANCE IN THE 21ST CENTURY

Assemblies on Behavioral Science and Health Services Research; Clinical Problems; Critical Care; Environmental, Occupational and Population Health; Nursing

9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 204 A-C (South Building, Level 2)

Target Audience
Clinicians, researchers, and administrators seeking to understand pay for performance and its impact on clinical practice

Objectives
At the conclusion of this session, the participant will be able to:

- learn about theories behind P4P from a clinical and payer perspective;
- gain new strategies to deploy P4P initiatives at their local institutions, particular to ATS conditions, to improve the care delivered to patients;
- learn about pitfalls related to P4P, particular to ATS conditions.

With the growing prominence of quality improvement, an associated emphasis has been on pay for performance. However, despite billions of dollars spent, it is unclear how efficacious these interventions are in improving care. In this session, attendees will hear from experts on innovative research regarding pay for performance: effectiveness, evidence of “gaming” and unintended consequences, and the future of incentivized health care as it pertains to ATS conditions. This is especially pertinent given ATS ownership over COPD quality measures along with the recent deployment of sepsis core measures. Attendees will learn about the recent evidence and practical implications behind these initiatives.

Chairing:
S. Govindan, MD, Ann Arbor, MI
A.S. Gershon, MD, MSc, Toronto, Canada
B. Patel, MD, Houston, TX

9:15 ICU Quality Metrics in the U.K.: Past Experience and Implications for P4P
K. Rowan, PhD, MSc, London, United Kingdom

9:35 To Game or Not to Game: Unintended Consequences of Pay for Performance
C.R. Cooke, MD, MSc, Ann Arbor, MI

9:55 P$P: The Payer Perspective
R. Duseja, MD, MS, Woodland, MD
10:15 Sepsis Core Measures: In Need of Resuscitation?
J. Stevens, MD, Boston, MA

10:35 Back to Basics: Are Comprehension and Efficacy of Quality Metrics Linked?
S. Govindan, MD, Ann Arbor, MI

10:55 P4P and QI: A Call to Arms
M. Howell, MD, MPH, Chicago, IL

B10 SEPSIS GOES TO WASHINGTON: REGULATIONS, DEFINITIONS, AND RESEARCH SHAPING THE FUTURE OF SEPSIS

Assemblies on Critical Care; Behavioral Science and Health Services Research; Clinical Problems; Nursing
9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 145 A-B (Middle Building, Street Level)

Target Audience
Pulmonary and critical care, emergency room, and hospital physicians, trainees, researchers, administrators, nurses, and other clinicians interested in learning how new regulations, definitions, and research will shape the future of sepsis

Objectives
At the conclusion of this session, the participant will be able to:
• understand the goals of the SEP-1 measure and its potential impact on patient care;
• learn how the new sepsis definitions and technology can be merged to perform more effective clinical trials;
• discover how new research will bring more personalized care of patients with sepsis in the future.

The recent CMS SEP-1 core measure, Sepsis-3 definitions, and cutting edge research will shape the future of sepsis over the coming years. This session will reflect the unique location of the annual International ATS Conference this year by including talks discussing the development and future of SEP-1, the concerns voiced by major societies regarding this measure, and how the readmission reduction programs can be leveraged to improve the lives of sepsis survivors. The session will also highlight how the new sepsis definitions could impact future clinical trial design and bedside care. Finally, new research that will bring precision medicine to septic patients will be discussed.

Chairing: M.M. Churpek, MD, MPH, PhD, Chicago, IL
M. Mikkelsen, MD, MSCE, Philadelphia, PA
R.C. Hyzy, MD, Ann Arbor, MI

9:15 A Patient’s Perspective
C. Lentz, Highlands Ranch, CO

9:20 Improving Sepsis Care through CMS Core Measures: The Development and Future of SEP-1
S. Townsend, MD, San Francisco, CA

9:39 Should We Stand Behind SEP-1? Concerns from Major Societies and How We Can Do Better
R.C. Hyzy, MD, Ann Arbor, MI

9:58 It’s Not Just About the ICU: The Potential Impact of SEP-1 and New Sepsis Definitions on Patients in the ED and on the Wards
M.M. Churpek, MD, MPH, PhD, Chicago, IL

10:17 The Future of Sepsis Clinical Trials: Merging the New Definitions and Novel Clinical Trial Methods to Perform More Effective Studies
C.W. Seymour, MD, MSc, Pittsburgh, PA

10:36 Bringing Precision Medicine to Sepsis: Emerging Methods to Personalize Sepsis Care
N.J. Meyer, MD, MS, Philadelphia, PA

10:55 The Evolution of Sepsis Performance Metrics: From 3- and 6-Hour Bundles to the New Frontier of Hospital Readmission and Longer-Term Mortality
M. Mikkelsen, MD, MSCE, Philadelphia, PA

There will be a 5-minute discussion after each talk.

B11 THE LUNG ENDOTHELIUM PRO/CON SESSION: THE KEY CULPRIT IN CHRONIC LUNG DISEASE

Assemblies on Respiratory Cell and Molecular Biology; Pulmonary Circulation
9:15 a.m. - 11:15 a.m. MARRIOTT MARQUIS WASHINGTON
Marquis Ballroom 5 (Level M2)

Target Audience
Basic, translational and clinical scientists as well as clinicians

Objectives
At the conclusion of this session, the participant will be able to:
• understand the contribution of endothelium to a range of lung processes;
• identify the existing controversies and complexities in cell focused studies in the lung;
• identify new opportunities for cell-based lung studies.

Although the endothelium is well-recognized to be a critical component of acute lung injury and lung cancer, its role in chronic lung disease remains controversial. We will have experts in their respective fields present lively, opposing points of view, based on their investigations as well as the general literature, to help elucidate the issues with the goal of informing and elucidating the pathogenetic, diagnostic and therapeutic aspects of a range of lung diseases.

Chairing: P.J. Lee, MD, New Haven, CT
I. Petrache, MD, Denver, CO
E.R. Neptune, MD, Baltimore, MD

9:15 PRO: The Endothelium Is Key to COPD
M. Sauler, MD, New Haven, CT

9:25 CON: The Endothelium Is NOT Key to COPD
A.O. Yildirim, PhD, Neuherberg, Germany

9:40 PRO: The Endothelium Is Key to ILD
B. Shea, MD, Providence, RI
9:55 CON: The Endothelium Is NOT Key to ILD  
E. Herzog, MD, PhD, New Haven, CT

10:10 PRO: The Endothelium Is Key to Pulmonary Hypertension  
H. Chun, MD, New Haven, CT

10:25 CON: The Endothelium Is NOT Key to Pulmonary Hypertension  
T. Stevens, PhD, Mobile, AL

10:40 PRO: The Endothelium Is Key to Asthma  
K. Asosingh, PhD, Cleveland, OH

10:50 CON: The Endothelium Is NOT Key to Asthma  
P.A. Verhoef, MD, PhD, Chicago, IL

11:00 General Discussion

This session and the International Conference are supported by educational grants from Actelion Pharmaceuticals US, Inc, AstraZeneca LP, Teva Pharmaceuticals. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

---

**B12 THE IMPORTANCE OF TECHNOLOGY IMPLEMENTATION IN RESPIRATORY CARE AND PUBLIC HEALTH**

Drug/Device Discovery and Development Committee; Assembly on Behavioral Science and Health Services Research

9:15 a.m. - 11:15 a.m.  
WALTER E. WASHINGTON CONVENTION CENTER  
Room 202 B (South Building, Level 2)

Target Audience
Researchers and clinicians interested in integrating drugs, devices and technologies into health systems and practice

Objectives
At the conclusion of this session, the participant will be able to:
- understand the relative importance of implementation technology as a critical step following discovery and development;
- appreciate the value of disciplines and competencies overlooked in the bridge from discovery to public health;
- gain understanding of the examples of cutting edge technology that failed to achieve their full health impact.

The session will use examples to highlight the importance of optimal implementation of technology (e.g. drugs, devices, procedures) following the journey of discovery and development. These examples will stress competencies and disciplines often overlooked in implementing advances in health science.

Chairing: T. Witek, DrPH, Toronto, Canada  
T.F. Reiss, MD, New Hope, PA

9:15 Optimizing Integration of Respiratory Care Innovation  
T. Witek, DrPH, Toronto, Canada

9:35 Humanomics Trumps Genomics: Very Practical Perspectives on Technology Implementation  
J.M. Fitzgerald, MB, MCh, BAO, MD, Vancouver, Canada

10:05 The Negative Impact of Human Behavior and Organizational Inertia on Maximizing Personalized Lung Cancer Care  
N. Leighl, MD, Toronto, Canada

10:35 Beyond Bronchodilators: What Is Missing in COPD Care  
B. R. Celli, MD, Boston, MA

10:55 Health Information Technology: Long on Promises but Still Very Short on Details  
J. Bourbeau, MD, montreal, Canada
B14  CLINICAL TRIALS ACROSS PULMONARY DISEASE
9:15 a.m. - 11:15 a.m.  MARRIOTT MARQUIS WASHINGTON
Liberty Ballroom I-L (Level M4)

Late Breaking Mini Symposium

Chairing:  S.K. Danoff, MD, PhD, Baltimore, MD
D.C. Files, MD, Winston-Salem, NC
N.H. Kim, MD, La Jolla, CA

Oral Presentations


10:00  Inhaled Liposomal Ciprofloxacin in Patients with Bronchiectasis and Chronic Pseudomonas Aeruginosa Infection: Results from Two Parallel Phase III Trials (ORBIT-3 and -4)/C. Haworth, A. Wanner, J. Froehlich, T. O’Neal, A. Davis, I. Gonda, A. O’Donnell, Cambridge, United Kingdom, p.A7604


10:45  A Randomised, Double-Blind, Placebo-Controlled Trial to Compare the Early Administration of Simvastatin in the Prevention and Treatment of Delirium in Critically Ill Ventilated Patients (MoDUS Trial)/V.J. Page, A. Casarin, E.W. Ely, X.B. Zhao, C. McDowell, L. Murphy, D.F. McAuley, Watford, United Kingdom, p.A7607

11:00  MK-7264, a P2X3 Receptor Antagonist, Reduces Cough Frequency in Patients with Refractory Chronic Cough: Results from a Randomized, Controlled, Phase 2b Clinical Trial/J.A. Smith, M.M. Kitt, A.H. Morice, S.S. Birring, L.P. McGarvey, M.R. Sher, A.P. Ford, Manchester, United Kingdom, p.A7608

B15  COPD EXACERBATIONS AND READMISSIONS
9:15 a.m. - 11:15 a.m.  WALTER E. WASHINGTON CONVENTION CENTER
Room 207 A-B (South Building, Level 2)

Chairing:  S. Sethi, MD, Buffalo, NY
G.J. Criner, MD, Philadelphia, PA
J. Quint, MSc, PhD, London, United Kingdom

Featured Speaker

9:15  Is Optimized Treatment of Exacerbations Enough to Optimize Prevention of Readmissions?/D.H. Au, MD, MS, Seattle, WA,

Oral Presentations

9:30  A Novel Real-Time Risk Predictor Model Created Using Electronic Health Data to Reduce COPD Readmissions/A. Fee-Mulhearn, P. Diaz, Columbus, OH, p.A2887


11:00 A Retrospective Cohort Study Assessing the Impact of an Oscillating Positive Expiratory Pressure (OPEP) Device in Chronic Obstructive Pulmonary Disease (COPD) Patients with Chronic Bronchitis on Hospital Re-Admissions and Length of Stay/J. Suggett, V. Kushnarev, D. Coppolo, B. Carlin, London, Canada, p.A2893

11:00 Mycobacterial Host Defenses/Speaker To Be Announced

MINI SYMPOSIUM

B17 MYCOBACTERIAL HOST DEFENSES

9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER

Room 143 A-C (Middle Building, Street Level)

Chairs: J.M. Keane, MD, Dublin, Ireland
M. Divangahi, PhD, Montreal, Canada

Oral Presentations


Featured Speaker

11:00 Mycobacterial Host Defenses/Speaker To Be Announced

The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.
B18  PEDIATRIC ASTHMA
9:15 a.m. - 11:15 a.m.  WALTER E. WASHINGTON CONVENTION CENTER
Ballroom B (South Building, Level 3)

Chairing:
D. Rastogi, MD, Bronx, NY
G. Perez, MD, Washington, DC
C. Rosas-Salazar, MD, MPH, Nashville, TN

Oral Presentations
9:15 Infant to 3 Year Longitudinal Analysis of Lung Function Among Infant Wheeze Phenotypes in the Canadian Healthy Infant Longitudinal Development (CHILD) Birth Cohort/P.


11:00 Prenatal Vitamin D Supplementation Reduces Risk of Asthma/Recurrent Wheeze in Early Childhood: A Meta-Analysis of Two Randomized Controlled Trials/B.L. Chawes, H. Wolsk, A.A. Litonjua, B.W. Hollis, K. Bonnelykke, J. Waage, H. Bisgaard, S. Weiss, Copenhagen, Denmark, p.A2915

B19  HOST RESPONSES TO INFLUENA
9:15 a.m. - 11:15 a.m.  MARRIOTT MARQUIS WASHINGTON
Independence Ballroom A-D (Level M4)

Chairing:
L. Kobzik, MD, Boston, MA
K.M. Ridge, PhD, Chicago, IL

Oral Presentations


10:00 Prevention of Lung Injury in Juvenile Influenza A Virus Infection/B.M. Coates, N. Ravindran, K.M. Ridge, Chicago, IL, p.A2919

10:15 Post-Infection Treatment with Liponucleotides Attenuates H1N1 Influenza A Virus-Induced ARDS in Mice/P. Davis, L.M. Doolittle, P. Woods, L. Joseph, L. Rosas, Columbus, OH, p.A2920


11:00 Modulation of Lung Inflammation Ameliorates Influenza-Induced Mortality, Morbidity, and Lung Injury/S. Tundup, P. Jayaguru, A. Desmelt, V. Raje, T. Harris, A. Kadi, Charlottesville, VA, p.A2923

B20  BIG DATA COMES TO SLEEP MEDICINE
9:15 a.m. - 11:15 a.m.  WALTER E. WASHINGTON CONVENTION CENTER
Room 152 A-B (Middle Building, Street Level)

Chairing:
S. Parthasarathy, MD, Tucson, AZ
S.S. Redline, MD, MPH, Boston, MA
A. Pack, MBChB, PhD, Philadelphia, PA

The information contained in this program is up to date as of March 9, 2017. For the most current session information, please visit the online program itinerary.
Oral Presentations


10:00 Altitudinal Central Apneas and Adherence to Positive Airway Pressure Therapy/S. Merali, D. Yiu, D. Combs, S. Shetty, G. Jean-Louis, S. Parthasarathy, Tucson, AZ, p.A2927


10:30 REM-Related Sleep Apnea and All-Cause Mortality/R.N. Aurora, J. Kim, C. Crainiceanu, N.M. Punjabi, Baltimore, MD, p.A2929


### RAPID: RAPID ABSTRACT POSTER DISCUSSION

**B21 ALTERATIONS IN MICROBIOME AND VIROME IN LUNG DISEASE**

9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER Room 151 B (Middle Building, Street Level)

#### Abstract Summaries

Poster Viewing/Discussion 9:15-9:45

**Poster 401** Correlation of Lung Microbiota with Metabolomic Profiles and Pulmonary Function Tests in Bronchoalveolar Lavage Fluid in HIV Infection/K. Uppal, A.M. Morris, V. Tran, L. Huang, L. Tipton, E. Ghe din, D.P. Jones, S.K. Cribs, Atlanta, GA, p.A2932


**Poster 404** Surfactant Protein D Deficiency Increases Survival After CLP by Regulating the Gut Microbiome/A. Arciniegas, J. Englert, C. Isabelle, L. Brown, M. Perrella, M. Cernadas, R. Baron, Boston, MA, p.A2935

**Poster 405** A Population Study of the Upper Airway Microbiota in Busselton, Western Australia/E. Turek, M.J. Cox, P. James, A.L. James, M. Hunter, B. Musk, M. Moffatt, W. Cookson, London, United Kingdom, p.A2936


**Poster 409** Characterization of Lower Airway Microbiome and Its Correlation with Lung Cancer/-X. Liu, J.-M. Qu, Shanghai, China, p.A2940


418 Effect of Short-Term Alpha-1 Antitrypsin Augmentation Therapy on the Lung Microbiota of Individuals with Alpha-1 Antitrypsin Deficiency/M.E. Kirst, J. Nolte, J. Lascano, F. Rouhani, M.L. Brantly, Gainesville, FL, p.A2949


424 Ecological Bias in the Lung with Multiple Displacement Amplification (MDA)/B.C. Keller, C.L. Monaco, Columbus, OH, p.A2955


Regulation of Epithelial IL33 Expression by a Mast Cell Feed Forward Loop/M.C. Altman, Y. Lai, J.D. Nollin, A. Piliponsky, W.A. Altemeier, J.S. Debley, T.S. Hallstrand, Seattle, WA, p.A2961


Adipose Tissue-Derived Exosomes Modulate Pro- and Anti-Inflammatory Responses of Mouse Airways Epithelial Cells/M.E. Poynter, J.L. Ather, A. Norman, K. Van Der Vliet, A.E. Dixon, Burlington, VT, p.A2964


Evidence of a Dysfunctional Soluble Guanylate Cyclase in Human Airways Smooth Muscle Cells Derived from Asthma/A. Ghosh, R.A. Panettieri Jr., S.C. Erzurum, D.J. Stuehr, Cleveland, OH, p.A2966

A Type-2 Inflammatory Background Alters the Functional Response of Airway Mast Cells/M.L. Fajt, J.B. Trudeau, L.B. Schwartz, F. Holguin, S.E. Wenzel, Pittsburgh, PA, p.A2967

Vesicular Suppressor of Cytokine Signaling 3 Secreted by Alveolar Macrophages Dampens Asthma-Related Inflammation in Airway Epithelial Cells/C. Draijer, J.M. Speth, L.R.K. Penke, J. Bazzill, J.J. Moon, M. Peters-Golden, Ann Arbor, MI, p.A2968

Sputum IL-27 Gene Expression in Asthma Endotypes/J.L. Simpson, K. Patreja, K.J. Baines, F. Eyres, M. Yang, P. Nair, P. Foster, P.G. Gibson, Newcastle, Australia, p.A2969


IL-33 Plays a Unique Role in the Cross-Talk Between Epithelial Cells and Mast Cells/R.C. Murphy, J.D. Nollin, Y. Lai, A. Piliponsky, W.A. Altemeier, T.S. Hallstrand, Seattle, WA, p.A2971

Mammalian Target of Rapamycin Is a Key Molecule for Eosinophil Differentiation in Bone Marrow/C. Zhu, L. Xia, F. Li, Z. Li, Y. Wu, S. Ying, Z. Chen, H. Shen, W. Li, Hangzhou, Zhejiang, China, p.A2972

618 Hypoxia Enhances Type 2 CD8+ T Cell Differentiation and Airway Hyperresponsiveness/F. Ning, K. Takeda, M. Schedel, E. W. Gelfand, Denver, CO, p.A2974

619 Sex Differences in ILC2-Specific Chemokine Release During Chronic OVA-Induced Lung Inflammation in BALB/C Mice/K. J. Warren, J. A. Pavlik, J. M. DeVasure, J. Sweeter, J. Dickinson, J. H. Sisson, J. Poole, Omaha, NE, p.A2975


622 A Cell-Specific MicroRNA-Driven Pathway Controls the Recruitment of Eosinophils in Type 2 Inflammation/A. Korde, F. Ahangari, M. Haslip, A. Gonzalez, S. S. Takyar, New Haven, CT, p.A2978

623 Critical Role of IRAK-M in Regulating Antigen-Induced Airway Inflammation and Airway Hyperresponsiveness/J. Gao, M. Ahangari, M. Haslip, A. Gonzalez, S. S. Takyar, New Haven, CT, p.A2978

624 Mouse Model of Human Enterovirus D68 Asthma Exacerbation/C. Rajput, J. K. Bentley, J. Lei, M. Han, J. Hinde, M. B. Hershenhorn, Ann Arbor, MI, p.A2980

625 Opposing Actions of Leptin and Glucagon-Like Peptide-1 (GLP-1) to Regulate Interleukin-13 (IL-13)-Directed Airway Fibroblast Responses/J. L. Ingram, M. Ghio, A. Hegde, J. Wong, D. D’Alessio, L. Que, J. K. Walker, V. McQuade, Durham, NC, p.A2981

702 Impact of Integrated Dose Counter on Healthcare Utilization and Disease Control in Medicare Patients with Asthma and/or Chronic Obstructive Pulmonary Disease Using Albuterol Sulfate Inhalation Aerosol (ProAir® HFA)/B. E. Chipps, T. Ferro, L. Wang, S. Shrestha, O. Baser, R. Parikh, Sacramento, CA, p.A2983


706 The Association of Exercise-Induced Wheeze and Other Asthma Symptoms to Emergency Department Visits and Hospitalizations in a Large Cohort of Urban Adolescents/J. M. Bruzese, C. F. Gould, D. Evans, M. Perzanowski, New York, NY, p.A2987

707 The National Burden of Poorly Controlled Asthma in Children in the U.S.: Results from a Nationally Representative Study/P. Sullivan, V. Ghoshchyan, P. Narvarthnam, H. Friedman, A. Kavati, P. Xiang, B. Ortiz, B. Q. Lanier, Denver, CO, p.A2988


715 The Readiness of Children with Asthma to Carry and Use Their Quick-Relief Inhalers: Can We All Agree?/M. Dennin, V.G. Press, S. Ignoffo, A. Hull, L. Sharp, A. Volerman, Chicago, IL, p.A2996


723 Evaluation of Trainhaler and Flo-Tone CR Training Devices to Evaluate of Trainhaler and Flo-Tone CR Training Devices to


Chairing: R. Bartz, MD, Chapel Hill, NC
T.D. Girard, MD, MSCI, Pittsburgh, PA
J.R. Beitler, MD, MPH, San Diego, CA


304 Comparison of High Inspiratory Pressure Versus Low Inspiratory Pressure Noninvasive Ventilation in Acute COPD Exacerbation/B. Rahimi, F. Ghaemi, S. Peiman, Tehran, Iran, p.A3010


312 Silent Spaces from Electrical Impedance Tomography in the Bedside Assessment of Lung Recruitment: A Comparison with the Pressure Volume Curve/S. Spadaro, G. Scaramuzzo, S.H. Bohm, C. Turrini, A. Waldmann, T. Mauri, C.A. Volta, Ferrara, Italy, p.A3018


Unpredictable Transpulmonary Pressure During Recruitment Maneuvers May Lead To Overdistension or Under-Recruitment/E. Baedorf Kassis, S. Loring, R. Ritz, D. Talmor, Boston, MA, p.A3021


Body Mass Index and Outcome in Patients with Acute Respiratory Distress Syndrome Ventilated by High Frequency Oscillatory Ventilation or Conventional Ventilation/H. Tlayjeh, Y.M. Arabi, N. Ferguson, F. Lamontagne, A.C. Arroliga, V. Danesh, G. Dominguez-cherit, E. Jimenez, A. Mullaly, B. Staub, M.O. Meade, Riyadh, Saudi Arabia, p.A3026

Major Bleeding Events During Veno-Venous Extracorporeal Membrane Oxygenation; Comparing Two Different Heparin Infusion Strategies/A. Bosak, S. Sultan, R. Raschke, Phoenix, AZ, p.A3027

Efficacy and Safety of Argatroban in Patients with Acute Respiratory Distress Syndrome (ARDS) and Extracorporeal Membrane Oxygenation (ECMO)/M. Menk, P. Briem, A. Goldmann, M. Gassner, D. Schweiberger, S. Weber-Carstens, Berlin, Germany, p.A3028


Comparison of Early Prone Positioning and Extracorporeal Membrane Oxygenation in Influenza-Related Acute Respiratory Distress Syndrome/K.-W. Chang, L.-C. Chiu, H.-C. Hu, K.-C. Kao, Taoyuan, Taiwan, p.A3031

MONDAY MORNING

POSTER DISCUSSION SESSION

B25 ASTHMA EPIDEMIOLOGY: EXACERBATIONS, ADMISSIONS, READMISSIONS, AND ED VISITS

9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 201 (South Building, Level 2)

Poster Viewing
9:15-10:00

Discussion
10:00-11:15

Chairing: J.C. Celedon, MD, DrPH, Pittsburgh, PA
L. Avila, MD, San Jose, Costa Rica
S. Sharma, MD, MPH, Aurora, CO


504 Characteristics of a Large Nationally Representative UK Primary Care Asthma Population and Their Incidence and Determinants of Asthma Exacerbations/C. Bloom, F. Nissen, L. Smeeth, P. Cullinan, J. Quint, London, United Kingdom, p.A3035


506 Reduction of Exacerbations by Baseline Indicators of Asthma Severity in Children Receiving Omalizumab/S. J. Szefler, T.B. Casale, K. Rosen, B.L. Trzaskoma, T. Haselkorn, B. Ortiz, W.W. Busse, Aurora, CO, p.A3037

507 Key Findings and Clinical Implications from Multicenter Retrospective Study of Admission Due to Asthma Exacerbation in China/J. Lin, X. Bin, D. Yang, Beijing, China, p.A3038

508 Demographic Parameters Related to 30-Day Readmission of Patients with Asthma: Cohort Study of the Healthcare Cost and Utilization Project’s Nationwide Inpatient Sample from 2009-2013/A. Attaway, N. Solanki, J. McKell, Cleveland, OH, p.A3039

509 National Rates of 30-Day Hospital Readmissions for Adults with Asthma Exacerbation/A. Goizueta, E. Cobina, R. Cholankeril, L. Gonzalez, R. El-Bizri, Providence, RI, p.A3040
9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER

Room 150 B (Middle Building, Street Level)

Poster Discussion Session

B26 CIGARETTES, E-CIGARETTES, MARIJUANA: EPIDEMIOLOGY AND MECHANISMS

9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER

Poster Viewing 9:15-10:00

Discussion 10:00-11:15


E-cigarette Vapor Chronic Inhalation Modulates Pulmonary Physiology in Mice/J. Shin, D. Mathew, L.E. Crotty Alexander, San Diego, CA, p.A3066

Chronic E-Cigarette Vapor Inhalation Induces Hepatic Fibrosis in Mice/C.J. Javier, A. Du, A. Tran, L.E. Crotty Alexander, San Diego, CA, p.A3067


Altered Expression of Genes Involved in Inflammatory Response and Fibrosis by Human Bronchial Epithelial Cells Exposed to E-Cigarette Liquid: Relation to the Effect of Cigarette Smoke/S. Altraja, M. Mitt, A. Altraja, Tartu, Estonia, p.A3070


Cannabis Use Among Adults with Alcohol Use Disorders in Colorado/J.T. Hua, M. Afshar, E.J. Kovacs, E.L. Burnham, Aurora, CO, p.A3072


Altered Expression of Genes Involved in Inflammatory Response and Fibrosis by Human Bronchial Epithelial Cells Exposed to E-Cigarette Liquid: Relation to the Effect of Cigarette Smoke/S. Altraja, M. Mitt, A. Altraja, Tartu, Estonia, p.A3070


Cannabis Use Among Adults with Alcohol Use Disorders in Colorado/J.T. Hua, M. Afshar, E.J. Kovacs, E.L. Burnham, Aurora, CO, p.A3072


Spirometric Lung Function Abnormalities in HIV-Infected Subjects Naive to Antiretroviral Therapy/E.W. Fedura Yone, A.D. Balkissou, M.-C. Madjoumessi, C. Kuaban, Yaounde, Cameroon, p.A3083
112 HIV Infection Is an Independent Risk Factor for Decreased Prevalence of Low DLCO in HIV+ Nonsmokers and Smokers


114 The Burden of Respiratory Viral Illness in HIV-Infected Patients/S.A. Sellers, K. Dover, D. Wohl, M. Miller, D. Dittmer, W. Fischer, Chapel Hill, NC, p.A3088


118 Effect of Earning Potential on the Outcome of Tuberculosis and HIV Co Infection Management in Nigeria/T.A. Salami, Ekpoma, Nigeria, p.A3092


120 Impact of Xpert MTB/RIF Assay on Treatment Success Rates in Multi-Drug-Resistant Tuberculosis Patients in Ugu District Kwazulu-Natal South Africa/T.C. Mahwire, P. Naidoo, M. Zunza, Port Shepstone, South Africa, p.A3094

121 Impact of Xpert MTB/RIF on Outcome of HIV-Associated Tuberculosis in Nigeria/M.O. Akanbi, C.J. Achenbach, A. Ani, O. Agbajie, B. Taiwo, P. Akande, R. Murphy, Chicago, IL, p.A3095


125 Diagnosis of Pulmonary Tuberculosis in HIV-Infected and Uninfected Children Using Xpert MTB/Rif Ultra/H. J. Zar, L. Workman, M. Nicol, Cape Town, South Africa, p.A7610
1007 Lower DLco% Identifies Worse Exercise Pulmonary Hypertension and Reduced Recovery of Pulmonary Artery Pressures in a Mixed Population/M.G. Risbano, W.D. Wallace, Pittsburgh, PA, p.A3105


1010 A Pilot Study Assessing the Change in Physical Activity in Response to Treatment in Pulmonary Hypertension/S. Sthamparanathan, S. Charman, G. Gorman, M. TreNeill, D. Jakovljevic, P.A. Corris, Newcastle upon Tyne, United Kingdom, p.A3108


1012 Fitbit Vs Six Minute Walk in PAH/ S. Sehgal, A. Chowdhury, F. Rabih, A. Gadre, K.B. Highland, Cleveland, OH, p.A3110

1013 Six Weeks of Treadmill Training with a High Intensity Interval or Mild Continuous Exercise Approach Increases Cardiac Output in a Sugen-Hypoxia Rat Model of Pulmonary Arterial Hypertension/M.B. Brown, A. Frump, G. Long, A.J. Fisher, R. Presson, T. Lahm, Indianapolis, IN, p.A3111

1014 Hemodynamic and Exercise Effects of Different Types of Initial Oral Combination Therapy in Pulmonary Arterial Hypertension/A. Albini, F. Dandi, A. Rinaldi, E. Monti, N. Tanese, E. Gott, M. Palazzini, A. Manes, N. Galie, Bologna, Italy, p.A3112


1017 Lower DLco% Identifies Worse Exercise Pulmonary Hypertension and Reduced Recovery of Pulmonary Artery Pressures in a Mixed Population/M.G. Risbano, W.D. Wallace, Pittsburgh, PA, p.A3105

1018 Accuracy of Accelerometer (Fitbit® ChargeHR™) Measured Distance and Heart Rate in Patients with Pulmonary Arterial Hypertension/A. Chowdhury, S. Sehgal, F. Rabih, A. Gadre, K.B. Highland, Cleveland, OH, p.A3116
B30 MECHANISMS OF AIRWAY SMOOTH MUSCLE CONTRACTILITY AND RELAXATION: POTENTIAL THERAPEUTIC TARGETS

Poster Viewing 9:15-10:00
Discussion 10:00-11:15

Chairing: B. Camoretti-Mercado, PhD, Tampa, FL
S.J. Gunst, PhD, Indianapolis, IN
D.A. Deshpande, PhD, Philadelphia, PA

S100 Family Protein, S100A4, Regulates Tension Generation in Airway Smooth Muscle (ASM) in Response to Contractile Stimulation by Regulating the Polymerization of Non-Muscle (NM) Myosin (NM) Myosin/W. Zhang, S.J. Gunst, Indianapolis, IN, p.A3142

An Age Dependent Change in Airway Contractility and Ca2+ Signaling of Airway Smooth Muscle in Precision Cut Lung Slices from Mouse and Human/Y. Bai, X. Ai, Boston, MA, p.A3143


Altered Airway Smooth Muscle Mass and Contractility Responses in an Ovalbumin Murine Model of Asthma During the Inflammation Resolution Phase as Assessed by Precision Cut Lung Slices (PCLS) and Immunohistochemistry/C. Billington, M.R. Hill, A. Bullock, B. Liu, A.N. Habgood, S. Miller, P. Petache, Denver, CO, p.A7611
### Theme: Pre-Clinical and Translational Studies in Asthma

**B31**

**9:15 a.m. - 4:15 p.m.**

**WALTER E. WASHINGTON CONVENTION CENTER**

**Area K, Hall B-C (Middle Building, Lower Level)**

#### Viewing:
Posters will be on display for the entire session.

#### Discussion:
11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P981</td>
<td>Dual AMCase/CHIT1 Inhibitor OAT-889 Reverses Pulmonary Inflammation and Airway Remodeling in Two Mice Models of Airway Inflammation</td>
<td>B. Dymek, M. Miacki, A.M. Zdziarska, M. Mazurkiewicz, M. Salamon, R. Koraliewski, A. Golebiowski, J. Golab, K. Dzwonek, P. Skjepekiewicz</td>
</tr>
<tr>
<td>P983</td>
<td>Using Nocturnal Heart Rate to Assess Asthma Control/M. Huffaker, M. Carchia, B. Harris, D. Cornfield, Palo Alto, CA</td>
<td>P.A3166</td>
</tr>
<tr>
<td>P987</td>
<td>Club Cell Secretory Protein Deficiency Leads to Altered Lung Function in Naive Mice</td>
<td>J. Ledford, K.J. Addison, J. Rojas-Quintero, S. Guerra, C. Owen, F.D. Martinez, M. Kraft, Tucson, AZ</td>
</tr>
<tr>
<td>P988</td>
<td>Short Peptides Derived from the Lectin Domain of Surfactant Protein A2 Attenuate IL-13 Induced Mucin Production in Asthma and Normal Subjects</td>
<td>J. Ledford, D. Francisco, K.J. Addison, J. Rojas-Quintero, S. Guerra, C. Owen, F.D. Martinez, M. Kraft, Tucson, AZ</td>
</tr>
<tr>
<td>P989</td>
<td>IL-13 Gene Expression in Endobronchial Biopsies: A Marker of Airway Smooth Muscle Hypercontractility in Severe Equine Asthma</td>
<td>M. Bullone, R. Bolvin, A. Vargas, J.-P. Lavoie, St-Hyacinthe, Canada</td>
</tr>
<tr>
<td>P990</td>
<td>A New Inhalation Nanoparticle-Anti-IL-6 Therapy for Treatment of Asthma</td>
<td>M. Rincon, A. Clemments, C. Landy, D. Champagne, Burlington, VT</td>
</tr>
</tbody>
</table>

---

*The information contained in this program is up to date as of March 9, 2017. For the most current session information, please visit the online program itinerary.*

P992 IL-4 Dependent IL17Rb Gene Transcription Requires Coordinate Autocrine IL-25 Signaling in Monocytes and Alveolar Macrophages/S. Kanth, G. Gong, J. Tedrow, S.E. Wenzel, R. Mallampalli, N.M. Weathington, Pittsburgh, PA, p.A3175

P993 Exhaled Breath Condensate from Asthmatic Patients Deactivates AMPK and Increases Oxidized CaMKII in Human Bronchial Smooth Muscle Cells/L. Kaphalia, J.L. McCracken, W.J. Calhoun, Galveston, TX, p.A3176


P1004 Real World Effectiveness and Safety of Anti-IL-5/Mepolizumab in an Academic Severe Asthma Clinic/P. Zhang, C.A. Vitari, S.E. Wenzel, Pittsburgh, PA, p.A3187

P1005 Improvement in Patient-Reported Activity Impairment, Stress, and Tiredness in Patients with Severe, Uncontrolled Asthma with Eosinophilic Inflammation: Pooled Results from Two Phase III Trials of Benralizumab/S. O’Quinn, X. Xu, I. Hirsch, G. Gopalan, Gaithersburg, MD, p.A3188


P1007 Early Decreases in Blood Eosinophil Levels with Reslizumab/P. Chaney, M. McDonald, M. Garin, K. Murphy, Marseille, France, p.A3190

P1008 Short Term Variability of FEV1, Reversibility and ACQ6 During Run-In of a CRD007 Asthma Study IV/Backer, D. Dencheva, M. Necki, D. Singh, M.F. Flensburg, G. Tomling, Copenhagen, Denmark, p.A3191


P1012 A Randomized, Double-Blind, Placebo-Controlled, Three-Way Crossover Incomplete Block Study to Assess the Dose Responsiveness of Exhaled Nitric Oxide to Advair® Diskus® in Asthmatic Subjects/R. Allan, S. Haughie, E.M. Kerwin, J. Ward, Sandwich, United Kingdom, p.A3195

**THEMATIC POSTER SESSION**

**B32 THERAPEUTIC TRIALS IN ASTHMA**

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER

Area K, Hall B-C (Middle Building, Lower Level)

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

**Facilitator:** G.E. Zabert, MD, Neuquen, Argentina

P998 Improvements in Asthma Symptom Control, Quality of Life, and Perception of Treatment Effectiveness After Omalizumab Initiation in Adolescents and Adults: Results from a 48-Week, Observational Study/T.F. Carr, E. Gonzalez-Reyes, E. Antonova, B. Trzaskoma, A. Igbal, S.L. Limb, N.M. Griffin, W. Lumry, Tucson, AZ, p.A3181

P999 Asthma Control Status During Pregnancy and Its Relationship with Vitamin D Level: An Observation from the Vitamin D Antenatal Asthma Reduction Trial (VDAART)/H. Mirzakhani, G.T. O’Connor, L. Bachanier, R.S. Zeiger, M.X. Schatz, S. Weiss, A.A. Litonjua, Boston, MA, p.A3182

P1000 Effect of Tiotropium Respimat® 2.5 µg Add-On to ICS or ICS+Controller Medications on Clinical Outcomes in Adults and Adolescents with Asthma Across Severities/E. O. Melzter, A. Shailk, M. Engel, R. Sigmund, W. Berger, San Diego, CA, p.A3183
P1013 A Randomized Double-Blind Placebo and Active-Controlled Five-Way Crossover Study to Assess the Dose Responsiveness of Methacholine-Induced Bronchial Hyperreactivity to Single Inhaled Doses of Advair® Diskus® in Adult Asthmatics/R. Allan, S. Haughie, R.C. Ahrens, J. Ward, Sandwich, United Kingdom, p.A3196


P1020 Two Years Follow Up After Injection Omalizumab Therapy: An Indian Study/D. Bhattacharyya, S. Singh, T.A. Kumar, Y. Garg, New Delhi, India, p.A3203


P1022 Analysis of the Relationship Between Handheld and Clinic-Based Spirometry Measurements in a Randomized, Double-Blind, Placebo-Controlled Study of Beclomethasone Dipropionate Via Breath-Actuated Inhaler for Persistent Asthma/E.M. Kerwin, G. Yiu, L. Hickey, C.J. Small, Medford, OR, p.A3205


---

**THEMATIC POSTER SESSION**

**B33 TH2 ENDOTYPE IN ASThma**

**9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER**

**Area K, Hall B-C (Middle Building, Lower Level)**

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

**P1028 Immunoglobulin E (IgE) Levels, Allergen Sensitization and Obstruction Indices Define High Eosinophilic Cohorts (HEC, >200 uL) Vs. Low (LEC, <200 uL) in Inner City Severe Asthma/J. Mantas, S. Aslam, M. Adam, A. Arsalan, R. Dhingra, T. Thakur, N. Tambe, E.S. Schulman, Philadelphia, PA, p.A3209

**P1029 Relative Allergen Content of Commercial Aspergillus Fumigatus Extracts Determined by Human Monoclonal IgE/M.A. Wurth, D. Horvath, S.A. Smith, Nashville, TN, p.A3210

**P1030 Analysis of Serum Allergen-Specific IgE of Patients with Allergic Diseases in Coastal and Inland China/W. Luo, B. Sun, G. Zeng, Z. Wu, Guangzhou, China, p.A3211


**P1032 Serum Periostin and Type 2 Helper Composite Score in Optimally Treated Asthmatics/S. Loukides, E. Konstantellou, G. Papatheodorou, K. Kostikas, E. Papathanasiou, S. Papiris, N.G. Koulouris, P. Bakakos, Athens, Greece, p.A3213


**P1035 Predictors and Outcome of Persistent Airway Eosinophilia in Adults with New-Onset Asthma/H. Coumou, G.A. Westerhof, S.B. De Nijs, E. Bel, Amsterdam, Netherlands, p.A3216


P501 Airway Levels of CX3CL1 Are Increased in Subjects with Asthma Compared to COPD and Normal Controls/T. Morimoto, J.P. Olivera, S. Beaudin, A. Schlatman, K. Howie, C. Obminsky, G. Nusca, R. Semih, G. Gauvreau, P. O’Byrne, Hiroaki, Japan, p.A3231


P505 MIR-365-2 Is Involved in IL-17-Mediated Asthma in Mouse Model/Y. Chang, X. Dang, D. Shang, X. Qu, W. Wang, Y. Li, D. Xu, Q. Hamid, Xi’an, China, p.A3235


Effect of Particulate Matter 2.5 on the Expression and DNA Methylation Pattern of Asthma-Related Genes in Bronchial Epithelial Cells/P. Tripathi, F. Deng, A. Scruggs, Y. Chen, S.K. Huang, Ann Arbor, MI, p.A3240


Effect of the CHI3L1 rs4950928 Polymorphism on IgE and Identifying Stable and Dynamic CpG Sites Pre- and Post-Adolescence Transition Via a Longitudinal Genome-Scale Study/L. Han, H. Zhang, S. Oggou, A. Kaushal, H. Arshad, W. Karmaus, J. Holloway, S. Ewart, Memphis, TN, p.A3248

Increased Serum CX3CL1 (Fractalkine) Levels in Asthma Patients with Psychological Symptoms/M. Zhu, Y. Ji, Chengdu, China, p.A3250


HLA Associations Differ in European Americans and African Americans with Idiopathic Inflammatory Myopathy Associated Interstitial Lung Disease/C. Johnson, A. Schiﬀenbauer, L. Rider, T. O’Hanlon, F. Miller, S. Danoff, Baltimore, MD, p.A7613


B35 TRANSLATIONAL STUDIES IN LUNG TRANSPLANTATION
9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion


Stratification of Chronic Lung Allograft Dysfunction Phenotypes Using Proteomic Profiling Of Bronchoalveolar Lavage Fluid/N.F. Smirnova, H.B. Schiller, N. Kneidinger, J. Behr, M. Mann, O. Eickelberg, Munich, Germany, p.A3256

Forkhead BOX F1 Is aNegative Regulator of Inflammatory Responses in Human Lung-Resident Mesenchymal Stem Cells/P. Cao, N. Walker, Y. Acki, V.N. Lama, Ann Arbor, MI, p.A3257

Autotaxin as a Therapeutic Target for Bronchiolitis Obliterans After Lung Transplantation/P. Cao, Y. Acki, N. Walker, V.N. Lama, Ann Arbor, MI, p.A3258


The information contained in this program is up to date as of March 9, 2017.

For the most current session information, please visit the online program itinerary.
P534  PI3Kinase Dependent Regulation of Sin1 by Pro-Fibrotic Mediators in Lung-Resident Mesenchymal Cells/N. Walker, D. Finger, V.N. Lama, Ann Arbor, MI, p.A3260


THEMATIC POSTER SESSION

B36  MACROPHAGES: BASIC AND TRANSLATIONAL STUDIES

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area E, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

P540  Alveolar Macrophage Secretion of Suppressor of Cytokine Signaling 3 Is Dysregulated in a Mouse Model of Lung Cancer/J.M. Speth, D.J. Schneider, V.G. Keshamouni, M. Peters-Golden, Ann Arbor, MI, p.A3263


P544  Interferon Gamma Null Mice Lose Less Weight and Have More CD64+, Siglec-F+, Ly6C+ Alveolar Macrophages During S. Pneumoniae Pneumonia than Wild Type Mice/O. Giddings, J. Mock, J.C. Gomez, J.R. Martin, C.M. Doerschuk, Chapel Hill, NC, p.A3267

P545  Chronic Cigarette Smoke Exposure Increases the Number of Lung Tissue Macrophages with Greater Changes in the M1 than the M2 Phenotype in Both Humans and Mice/N. Shetty, M. Aksoy, G. Calendo, M.R. Wolfson, S. Kelsen, Philadelphia, PA, p.A3268

P546  Distinct Functions of Toll-Interacting Protein (TOLLIP) Isoforms in Inflammatory Regulation/P.-C. Hou, S.-F. Ma, R.-T. Huang, D. Wu, M. Krause, C. Flores, Y. Fang, I. Noth, Chicago, IL, p.A3269

P547  Apoptosis Signaling and Interaction of Toll-Interacting Protein (TOLLIP) Isoforms with Antioxidant N-Acetylcysteine (NAC)/P.-C. Hou, S.-F. Ma, R.-T. Huang, D. Wu, M. Krause, C. Flores, Y. Fang, I. Noth, Chicago, IL, p.A3270

P548  S-Nitrosylation of Clopidogrel Inhibits LPS Induced Macrophage Activation Through NO/Soluble Guanylate Cyclase Pathways/C. Guo, S. Kamat, X. Xu, A. Gow, Piscataway Township, NJ, p.A3271


P552  TRIM72 Regulates Complement Phagocytosis in Alveolar Macrophage Via Facultative Inhibition of CR1/N. Nagre, X. Cong, C. Terrazas, J.M. Schreiber, A. Satoskar, X. Zhao, Norfolk, VA, p.A3275


P554  Alveolar Macrophages Regulate the Susceptibility of Alveolar Epithelial Cells to Influenza Virus Infection/L.A.L. Somerville, A. Cardani, T. Braciale, Charlottesville, VA, p.A3277

P555  The Receptor for Advanced Glycation End Products (RAGE) is Dysregulated in a Mouse Model of Lung Cancer/J.M. Speth, D.J. Schneider, V.G. Keshamouni, M. Peters-Golden, Ann Arbor, MI, p.A3266

THEMATIC POSTER SESSION

B37  INNOVATIONS IN PROFESSIONAL EDUCATION

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area B, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

For the most current session information, please visit the online program itinerary.
P75 Teaching Skills of Quality Improvement in a Subspecialty Fellowship: A Team Project in the Ambulatory Setting/S. Chakupurakal, M. Mohanraj, J. Shapiro, M. O’Sullivan, New York, NY, p.A3279


P78 Five Year Evaluation of an Interactive Respiratory Therapy Curriculum in Pediatric Pulmonology Fellowship Training/N. Villafranco, J. Lawrence, M. Jolly, L. Traplena, J. Rama, Houston, TX, p.A3282


P80 Successful Use of a Simulation Laboratory as a Tool to Decrease Central Line Blood Stream Infections (CLABSI)/S. Baez, W. Rodriguez-Cintron, A. Espallat, C. Diaz, O. Cantres-Fonseca, San Juan, PR, p.A3284


P83 Standardize the Pulmonary and Critical Care Medicine Fellowship Selection Process/B. White, S. Ghamande, Temple, TX, p.A3287

P84 Simulation Training Improves Intern Code Captain Readiness for Code Blue Execution/G. Tsai-Nguyen, C. Columbus, A. Mora, Dallas, TX, p.A3288

P85 Multidisciplinary Low-Fidelity Code Blue Simulation Training Improves House Staff Comfort with Code Blue Events at a Tertiary Medical Center/E.A. Yu, M. Dhande, W. Gionfriddo, D. Harris, N.M. Pradhan, J. Fouad, K.E. Roberts, Boston, MA, p.A3289

P86 Simulation Training Reveals Code Blue Execution Challenges in Tracheostomy Patients/A. Mora, G. Tsai-Nguyen, A. Smith, C. Columbus, Dallas, TX, p.A3290


P90 Stress Evaluation During Endotracheal Intubation on a Simulation Model/E. L’Her, N.S. Marjanovic, C. Teiten, Brest, France, p.A3294

P91 Assessment of a Critical Care Ultrasound Fellowship Curriculum/D. Pham, A. Trivedi, A. Anderson, St. Louis, MO, p.A3295


P100 Implementation of a Multifaceted Faculty Development Program/J. M. Stil, M. H. Hooper, H. L. Newton, A. C. Parks-Savage, Norfolk, VA, p.A3304

B38  ASTHMA: A PANORAMIC VIEW

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER
Area K, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator:  S. Pakhale, MD, MSC, Ottawa, Canada

P1041  A Standardized Electronic Medical Records Database Has Enabled Epidemiologic Studies and Revealed the Change in Asthma Therapy Among the Different Hospitals Which Have Incompatible Hospital Information Systems/C. Okada, S. Imai, H. Horiguchi, K. Fushimi, Tokyo, Japan, p.A3306


P1048  Poor Asthma Control Despite Medication Use in Patients with Severe Symptoms and Elevated Eosinophil Levels/C. Martin, J.C. White, L. Bengston, S.X. Sun, Eden Prairie, MN, p.A3313


Facilitator:  M.O. Clutter, PhD, Dallas, TX


P1051  Factors Associated with Level of GP Service Use in Asthma: Longitudinal Analysis of Data from 1921-26 and 1946-51 Cohorts of Australian Longitudinal Study on Women's Health (ALSWH)/P. Eftekhar, P. Forder, M. Harris, J. Byles, Callaghan, Australia, p.A3316


P1054  A Respiratory Care Enhancement Program: Integrating Advanced Practice Provider-Delivered Specialty Care into the Primary Care Setting/C. Leighton, S.E. Wenzel, L. Reid, J. Furnier, B. Reynolds, Pittsburgh, PA, p.A3319

P1055  Living with Asthma: Patients' Drawings of Their Perceptions and Experiences/M.M.Y. Cheung, B. Saini, L. Smith, Camperdown, Australia, p.A3320


Facilitators:  L.B. Gerald, MSPH, PhD, Tucson, AZ
I.K. Oguzulgen, MD, Ankara, Turkey


MONDAY MORNING

**THEMATIC POSTER SESSION**

**B39 COUGH: RARE AND COMMON**

**9:15 a.m. - 4:15 p.m.**

**WALTER E. WASHINGTON CONVENTION CENTER**

Area B, Hall B-C (Middle Building, Lower Level)

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:15-12:00: authors will be present for individual discussion

12:00-1:00: authors will be present for discussion with assigned facilitators

---


**P1065** New Measures of Adherence to Inhaled Therapy in Patients with Asthma/C. Nguyen, J.M. Foster, H. Reddel, C. Thamrin, Sydney, Australia, p.A3330

**P1066** Placebo Pressurized Metered Dose Inhalers (pMDIs): Understanding How to Maximize Our Use of These Valuable Training Aids/M.J. Sanders, Harlow, United Kingdom, p.A3331

**P1067** Effects of a Refresher Seminar for Inhalation Therapy Instructors Provided as a Form of Practical Training/Y. Komase, C. Yoshimura, A. Shiraki, I. Higashimoto, T. Oguma, T. Horie, Yokohama, Japan, p.A3332

**Facilitator:** A. Voleman, MD, Chicago, IL

---


**P1069** Respondent Understanding and User Experience with the Asthma Daily Symptom Diary (ADSD), a Novel Patient-Reported Outcome Measure/L.M. Nelsen, A. Gater, N. Bonner, R. Hall, H. Staunton, S. Eremenco, Collegeville, PA, p.A3334


**P1071** Applying the COM-B Model to Designing a Tailored Physical Activity Intervention for Sedentary African American Women with Asthma/S. Nyenhuis, J. Ma, L. Sharp, Chicago, IL, p.A3336

**P1072** Community Health Worker Case-Detection of Asthma in a Resource-Poor Community in Nicaragua/M. Crocker, C.E. Loughlin, S. Becker-Dreps, Chapel Hill, NC, p.A3337


**Facilitator:** A.H. Case, MD, Atlanta, GA

---


**P1079** An Unusual Cause of Chronic Productive Cough in an Immunocompetent Female/K. Spencer, O. Lewis, A. Thomas, Washington, DC, p.A3344

**Facilitator:** M. Seidelman, MD, Silver Spring, MD

---

**P1080** Chronic Cough of Unknown Primary/G.M. Molina-Pallete, C. Ray, Detroit, MI, p.A3345

**P1081** Chronic Cough: A Case of Obfuscation/S. Soman, N. Ramesh, M. Mercader, A. Adams, New York, NY, p.A3346

**P1082** Not All Coughs Are Due to Upper Airway Cough Syndrome: An Unusual Manifestation of Endobronchial Hamartoma/S. Ahmad, A. Arshad, M.J. Mador, Buffalo, NY, p.A3347

**P1083** Primary Endobronchial Leiomyoma: A Rare Benign Pulmonary Neoplasm/M. Nagaraja, R. Abdul Rahman, J. Faress, Cleveland, OH, p.A3348

**P1084** Pancreaticobiliary Adenocarcinoma Presenting as Chronic Cough/I.R. Stanford, E.D. Parker, A. Buikema, Research Triangle Park, NC, p.A7618

**P1085** Intractable Cough/L. Krveshi, T. Everett, D. Oelberg, Danbury, CT, p.A3349

**P1086** Not All Coughs Are Due to Upper Airway Cough Syndrome: An Unusual Manifestation of Endobronchial Hamartoma/S. Ahmad, A. Arshad, M.J. Mador, Buffalo, NY, p.A3347

**P1087** Bronchodilator Tests in Patients with Asthma/O. Lewis, A. Thomas, Washington, DC, p.A3344

**Facilitator:** M. Seidelman, MD, Silver Spring, MD

---

**P1088** Isolated Left Upper Lobe Trachobronchopathia Osteochondroplastica/A. Kravac, J. Piao, D. Stoeckel, St. Louis, MO, p.A3352

**P1089** Solitary Bronchial Papilloma: A Rare Differential for Bronchial Obstruction with Malignant Potential/S. Hashim, Worcester, MA, p.A3353


**Facilitator:** R.S. Irwin, MD, Worcester, MA
P120  A Persistent Cough that Won’t Go Away: An Unusual Case of Tracheal Diverticulum/P. Sharma, N. Niraula, Chattanooga, TN, p.A3355

P121  Cough Due to a Cyst: Congenital Abnormalities in Adults/J. Paralkar, N. Ramesh, A. Miller, New York, NY, p.A3356


P123  Traditional Japanese Herbal (Kampo) Medicines Can Control a Cough/N. Miyamoto, Izumo, Japan, p.A3358

---

**THEMATIC POSTER SESSION**

**B40  SARCOIDOSIS: ILLUSTRATIVE CASES AND CLINICAL SERIES**

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER

**Area B, Hall B-C (Middle Building, Lower Level)**

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

**Facilitator:** W.P. Drake, MD, Nashville, TN

**P125**  Extrapulmonary Sarcoidosis Presenting with Diffuse Osteolytic Skeletal Lesions/C.M. Kriese, B.A. Khan, Indianapolis, IN, p.A3359


**P128**  Co-Existing Sarcoidosis and Lymphoma: Biological Relationship or Fortuitous Occurrence?/E. Solbes, R. Harper, Sacramento, CA, p.A3362

**P129**  Splenic Sarcoidosis: A Case of Spontaneous Disease Reactivation Limited to the Spleen/H. Mezughi, I. Shahoub, F. Zeid, Huntington, WV, p.A3363

**P130**  Diabetes Insipidus Causing Severe Hypernatremia from Neurosarcoidosis/G.W. Williams, D. Kadanov, A. Dodhi, Memphis, TN, p.A3364


**P133**  Coexisting Sarcoidosis and Multiple Myeloma Presenting as Acute Leg Weakness and Chest Pain/C. Terry, M. Luthra, A. Esper, Atlanta, GA, p.A3367

**P134**  Systemic Sarcoidosis Secondary to Anti-TNF Therapy/S. Sood, A.L. Anderson, St. Louis, MO, p.A3368

**P135**  A Rare Case of Secondary Pulmonary Alveolar Proteinaceous Disease in a Patient with Solid Organ Malignancy/K. Bakhj, J. Most, Philadelphia, PA, p.A3369


**P137**  Analysis of Sarcoidosis Cases Followed at University of Sao Paulo Medical School of Brazil/L. Paez Vargas, R.R. Miranda, F.E. Arimura, A.F. Amaral, M.R. oliveira, R.A. Kairalla, C.R.R. Carvalho, B.G. Balsi, Sao Paulo, Brazil, p.A3371

**Facilitator:** M.A. Judson, MD, Albany, NY

**P138**  A Case of Sarcoidosis Presenting with Foot Drop/A. El-bakush, K. Parikh, B. Keleher, A. Ismail, R. Shaw, Greenville, NC, p.A3372

**P139**  Sarcoid Involvement of Breast Tissue/A. Rasheed, L. Gerolemou, V. Bhargava, H. Roukoz, R. Cogswell, Minneapolis, MN, p.A3373

**P140**  Systemic Sarcoidosis Secondary to Anti-TNF Therapy/B. Most, Philadelphia, PA, p.A3374

**P141**  Bilateral Lung Masses Due to Necrotizing Sarcoid Granulomatosis/B. Hay, K. Shiolo, J. Englert, Columbus, OH, p.A3375

**P142**  Severe Hypercalcemia as a Presenting Feature of Sarcoidosis in a Patient on Etanercept Therapy/R. Samannan, V. Doshi, B. Saksouk, Oklahoma City, OK, p.A3376

**P143**  Bilateral Lung Masses Due to Necrotizing Sarcoid Granulomatosis/B. R. Hay, K. Shiolo, J. Englert, Columbus, OH, p.A3377


**P146**  Sarcoidosis: A Unique Case of Esophageal Perforation/D. Pereira, L.G.C.A. Lima, C.S.G. Freitas, C.R.R. Carvalho, B.G. Balsi, Sao Paulo, Brazil, p.A3380

**P147**  Pulmonary Sarcoidosis Associated with Anti-PD-L1 Therapy/R. Balestra, Cincinnati, OH, p.A3381

**P148**  Treatment of Cardiac Sarcoidosis with Once Monthly Intravenous Methylprednisolone Infusions/J. Perlman, M. Bhargava, H. Roukoz, R. Cogswell, Minneapolis, MN, p.A3382


**Facilitator:** M. Kreider, MD, Philadelphia, PA

**P150**  Lymphocytic Pleural Effusion in a Sarcoid Fibrosing Mediastinitis Patient Treated with Vasodilator Therapy for Pulmonary Hypertension/R. Prakobkit, E. Spiekerkoetter, J.L. Hsu, Stanford, CA, p.A3384


P897 A Unique Manifestation of Anti-Synthetase Syndrome in an Indian Male/M.S. Siddiqui, S. Williams, J. Tomashesfki, Cleveland, OH, p.A3398


P899 Amyopathic Dermatomyositis and Interstitial Lung Disease Associated with Anti-NXP2 Autoantibody/T.P. Reed, N. Gupta, Cincinnati, OH, p.A3400

P900 Atypical Presentation of Anti-Jo-1 Positive Interstitial Lung Disease/V. Gandhi, M. Hewston, A. Fasanya, R. Sharara, T. Cheema, Pittsburgh, PA, p.A3401

B41 ANTISYNTHETASE SYNDROME AND AUTOIMMUNE MYOSITIS ASSOCIATED ILD: CASES FROM THE WARDS

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Area J, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion

12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: M. Acosta Lara, MD, Birmingham, AL

P901 A Rare Case of Antisynthetase Syndrome Presented with Cardiogenic Shock as an Initial Presentation/M. Mahmoud, R. Awdish, K. Thavarajah, Detroit, MI, p.A3402

P902 With ChiLD- A Case of Antisynthetase Syndrome in Pregnancy/H.P. Saikumar, D.J. Maselli, A.M. Nambiar, San Antonio, TX, p.A3403

P903 Bamboo Nodes Reveal Antisynthetase Syndrome as Cause of Interstitial Lung Disease/X. Wu, R.J. Kaner, New York, NY, p.A3404

P904 Severe Pulmonary Hypertension and Myocarditis in a Patient with Overlapping Sjogren and Antisynthetase Syndrome/E.J. Cano, M. Khaja, Bronx, NY, p.A3405

P905 Dermatomyositis and Associated Vasculopathy Causing Tracheal Necrosis and Spontaneous Pneumomediastinum/C.L. Oberg, R. Hiensch, S. Dua, New York, NY, p.A3406


B42 INTERSTITIAL LUNG DISEASE: A Potpourri of Cases

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Area J, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion

12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: M. Padilla, MD, New York, NY


P944 Steroid Dependent Chronic Eosinophilic Pneumonia Treated Successfully with Azathioprine; a Novel Therapy Reported on Two Patients/G. Sathiayamoorthy, C. Lau, M. Latifi, J.G. Parambl, Cleveland, Ohio, p.A3444


P946 Acute Eosinophilic Pneumonia in a Patient with Influenza Infection - a Coincidence or an Association?/S. Velani, C. Myers, S. Manvar, J. Faress, E. Van Lunteren, Cleveland, Ohio, p.A3446

P947 Cryptogenic Organizing Pneumonia After a Motor Vehicle Accident/ A.E. Reyes Esteves, L.A. Soto, H. Bhatti, Orlando, FL, p.A3447


P952 Low Predictive Value of High-Resolution Computed Tomography (HRCT) Patterns Other than Usual Interstitial Pneumonia (UIP) Highlight the Continued Need for a Surgical Lung Biopsy to Make an Accurate Diagnosis of Interstitial Lung Disease/ S. Benzaquen, J.L. Myers, S. Coyle, R. Balestra, A. Dargent, Miami, FL, p.A3451

P953 The Impact of CT-Detected Usual Interstitial Pneumonia Pattern as the Decision-Making Factor for Treatment of Lung Cancer/N. Patel, MD, New York, NY, p.A3451


P1561 Massive Spontaneous Hemothorax Secondary to Metastatic Angiosarcoma/S. Baez, W. Rodriguez-Cintrón, J. Torres-Palacios, San Juan, PR, p.A3495

P1562 Recurrent Unexplained Pleural Effusion in Young Female? Think Outside the Box/M. Rachid, E. Mekhaeil, Oak Lawn, IL, p.A3496

P1563 Ovarian Hyper Stimulation Syndrome an Uncommon Cause of Pleural Effusion/U. Kulsum, A. Shah, A. Shalonov, Jamaica, NY, p.A3497

P1564 A Rare Cause of Pleural Effusion/A. Gallo De Moraes, U. Durani, Cape Town, South Africa, p.A3498


P1567 A Rare Case of Primary Effusion Lymphoma Post Cardiac Transplant with HIV Negative and HHV8 Positive Serology/I. Kugasia, A. Kumar, E. Epelbaum, Valhalla, NY, p.A3501


P1572 Demons-Meigs Syndrome: A Rare Cause of Pleural Effusion/V. Pletukhina, M. Weinstein, Mineola, NY, p.A3506

P1573 Cerebrospinal Fluid Induced Pleural Effusion: Delayed Complication of a Ventriculopleural Shunt/B. Seth, N. Bosch, F. Schembri, H.W. Farber, Boston, MA, p.A3507

P1574 Pleural Effusion from Peripheral Inserted Central Catheter/B.W. Tullos, K. Bridges, K. Harkins, A. Wilhelm, Jackson, MS, p.A3508

P1575 A Rare Case of Recurrent Contralateral Pleural Effusions with Intra-Abdominal Ventriculoperitoneal Shunt Repositioning/H.A. Cheema, R.C. Brammer, K. Vipul, York, PA, p.A3509


P1584 Poland Syndrome and Spontaneous Pneumothorax - a Thought-Provoking Association/M.I.M. Afonso, J. Cemlyn-Jones, C. Robalo Cordeiro, Coimbra, Portugal, p.A3518


P1591  An Atypical Tension Pneumothorax/D. Terrington, S. Murugan-Sukumar, Z. Babar, A. Connolly, A. Arya, Norwich, United Kingdom, p.A3526


P1593  Vomiting Induced Spontaneous Pneumomediastinum Should Be Differentiated from Boerhaave’s Syndrome: A Case Report/H. Sharma, A. Tiwari, M.S. Khan, B. Saha, Toledo, OH, p.A3527


P1602  A Tertiary Care Center’s Experience with Management of Pleural Infections/M. Frohlich, C. Robitaille, A. Hirsch, P. Ernst, L. Sakr, Montreal, Canada, p.A3535

P1603  Pleural Fluid Lactate Dehydrogenase/Adenosine Deaminase Ratio for the Differentiation of Tuberculous and Parapneumonic Effusions in Pathological Confirmed Patients/J. Wang, X. Xie, Y. Zeng, Guangzhou, China, p.A3536

Facilitator:  G. Krishna, MD, Mountain View, CA

P1604  Pitfalls of a Non-Algorithm Based Pleural Effusion Workup in a Large Community Teaching Hospital/K. Juenger, C. McElyea, S. Gullapalli, N. Mohan, A. Abeje, J. Vempilly, Fresno, CA, p.A3537


P1607  Surgical Outcome After Video Assisted Thoracoscopic Resection of Thoracic Endometriosis and Total Visceral Covering Technique in Patients of Refractory Catamenial Pneumothorax/T. Mizobuchi, M. Kunihara, S. Yamanaka, H. Ebana, H. Kataoka, Tokyo, Japan, p.A3540

P1608  Change in Practice of Insertion and Management of Intercostal Drains Over Seven Years in a UK District General Hospital/P. Russell, S. Clarke, E. Denneney, M. Anwar, U. Ekeowa, S. Naik, R. Ragatha, Harlow, United Kingdom, p.A3542


P1611  Clinical Features and Management of Hepatic Hydrothorax/J. Im, C.L. Oberg, L. DiFabrizio, G.B. Chun, New York, NY, p.A3544


Facilitator:  D. Chandra, MD, MSc, Pittsburgh, PA

P1613  Outcomes of Talc Pleurodesis Beyond Six Months in Patients Treated for Malignant Pleural Effusion/L. Ahmed, London, United Kingdom, p.A3546


P1617  Diagnostic Accuracy of Tumor Markers for Malignant Pleural Effusion: A Derivation and Validation Study/W. Wang, X.B. Pei, K. Zhai, J.Y. Liu, Q. Zhou, Beijing, China, p.A3550


P1620  Intrapleural Instillation of tPA and DNase for Symptomatic Loculated Malignant Pleural Effusion/E. Rivera-Flores, F. Kheir, S. Fernandez Bussy, M. Parikh, A. Majid, Boston, MA, p.A3553


Facilitator:  D.J. Feller-Kopman, MD, Baltimore, MD


P1623  The Use of Medical Thoracoscopy in the Management of Pleural Infection: A Systematic Review/A. Shujaat, Buffalo, NY, p.A3556


P1626  Case Series of Intrapleural 5mg tPA and 5mg of DNase for 72 Hours for Non-Surgical Therapy of Empyema - Lower Dose with Same Results?/H. Avella, S.R. Mummadi, Hillsboro, OR, p.A3559


B46  TRANSPLANTATION: CASE REPORTS AND CLINICAL STUDIES

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER

Area O, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator:  M. Porteous, MD, Philadelphia, PA


P1633  Cerebral Toxoplasmosis in a Solid Organ Transplant Recipient; the Flip Side of Prolonged Immune Suppression/A. Timrini, Shelbyville, IN, p.A3565


P1636  Closure of Bronchopleural Fistula with Endobronchial Valves in a Single Lung Transplant Recipient/S. Yau, A. Goodarzi, T. Kaleekal, N. Sinha, J. Youssef, Houston, TX, p.A3568


P1638  A Rare Presentation of Post-Transplant Lymphoproliferative Disorder as Isolated Splenomegaly in a Lung Transplant Recipient/S. Razvi, J. Ali, J.P. Corrales, Detroit, MI, p.A3570

Facilitator:  A. Iacono, MD, Baltimore, MD

P1639  Acute Fibrous and Organizing Pneumonia in a Lung Transplant Patient Managed Without Calcineurin Inhibitors/M.G. Patel, S. Quddus, Maywood, IL, p.A3571

P1640  Bone Marrow Failure Secondary to Short Telomere Syndrome After Lung Transplantation/S. Guo, P. La Porte, D.M. Sayah, Los Angeles, CA, p.A3572


P1643 Tacrolimus-Induced Thrombotic Microangiopathy (TMA) in Orthotopic Lung Transplant Patients: A Case Series/J. Whitson, C.A. Hage, Indianapolis, IN, p.A3575


P1649 Traits Associated with Successful Double Lung and Heart-Lung Transplantation in Patients Bridged with Extracorporeal Membrane Oxygenation/N.A. Braus, S. Peters, G.J. Scheers, J.P. Scott, R.C. Daly, M.E. Wylam, C.C. Kennedy, Rochester, MN, p.A3581


P1651 Outpatient Transitioning from Injectable Prostacyclins to Inhaled Treprostinil in Pulmonary Hypertension/L. Kimmig, S. Coslet, L. Palen, R. Bag, Chicago, IL, p.A3583


---

**THEMATIC POSTER SESSION**

**B47** LONG ACTING BRONchodilATOR THERAPY IN COPD I

*9:15 a.m. - 4:15 p.m.* WALTER E. WASHINGTON CONVENTION CENTER

**Area D, Hall B-C (Middle Building, Lower Level)**

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

**Facilitator:** A. Anzuedo, MD, San Antonyo, TX


- P358 Dose Selection for SUN-101/eFlow® Phase 3 Clinical Studies: Results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer) Phase 2 Dose-Finding Studies/J.F. Donohue, T. Goodin, R. Tosiello, A. Wheeler, Chapel Hill, NC, p.A3591

**Facilitator:** M.B. Drummond, MD, Chapel Hill, NC


Facilitator: G.T. Ferguson, MD, Farmington Hills, MI

P365 Safety and Tolerability of Relefenacin, a Novel Once-Daily Nebulized Long-Acting Muscarinic Antagonist: Results of Two 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Trials in Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease/G. Feldman, C.N. Barnes, E.J. Moran, B. Haumann, S. Pendyala, G.D. Crater, Spartanburg, SC, p.A3598


P368 Treatment Modification and Costs in Patients with Chronic Obstructive Pulmonary Disease Initiating Long-Acting Bronchodilator Monotherapy/M. DePietro, L. Bengtson, J. McPheeters, K. Fox, J. Davis, Wilmington, DE, p.A3601

P369 The Effect of Aciclovirum Bromide 400 μg on the Relief of Daily Symptoms Associated with Chronic Obstructive Pulmonary Disease, Including Cough/J.A. Smith, M. McGarvey, A.H. Morice, S.S. Birring, J.A. Wedzicha, M. Notari, R. Segarra, B. Seoane, D. Halpin, M.K. Han, F. Voss, M. Miravitlles, Exeter, United Kingdom, p.A3602


Facilitator: J.F. Donohue, MD, Chapel Hill, NC

P371 A Five-Way Crossover Study to Compare Systemic Absorption and Bronchodilator Effect of Glycopyrrolate After a Single Dose Delivered by Nebulizer (SUN-101) or a Dry Powder Inhaler (Seebri) and in Patients with COPD (GOLDEN-7)/F.Y. Ali, B.R. Leaker, G.C. Nicholson, D. Singh, P.J. Barnes, London, United Kingdom, p.A3604


P373 Interpretation of Safety Findings in Clinical Effectiveness Trials: Insights from the Salford Lung Study (SLS COPD)/S.D. Collier, C. Crawford, N. Gaeckle, A. Criner, B. Seoane, D. Singh, L. McGarvey, Toronto, Canada, p.A3606


THEMATICAL POSTER SESSION

B48 COPD AND COMORBIDITIES

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Area D, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion

Facilitator: R.G. Barr, MD, DrPH, New York, NY

P378 Significance of Prolonged QTc in Acute Exacerbations of COPD Requiring Hospitalization/K. Vermeersch, O. Van Oekelen, R. Willems, W. Janssens, Louvain, Belgium, p.A3610


P380 Cardiovascular Function in Patients Admitted to Hospital for an Acute Exacerbation of Chronic Obstructive Pulmonary Disease/D. Fuhr, C. Lee, W. Michaelchuk, A. Brotto, I. Andersson, B. Byers, B. Rowe, R. Leagh, R. Daman, M. Bhutani, M. Stickland, Edmonton, Canada, p.A3612


Facilitator: D.D. Sin, MD, Vancouver, Canada


P413 Trends in the Incidence of Stroke, by Subtype, in People with Chronic Obstructive Pulmonary Disease (COPD)/M. To, MD, PhD, Koshigaya-City, Japan

P414 COPD and BMI Among Low- and Middle-Income Countries/M. Grigsby, T. Siddharthan, B. Morgan, W. Checkley, Baltimore, MD, p.A3646

P415 COPD and Periodontitis - Shared Pathophysiology or Shared Risk?/S. Hobbies, S. Parmar, S. Chrichard, I. Chapple, E. Sapey, R.A. Stockley, Birmingham, United Kingdom, p.A3648

P416 Risk of Chronic Obstructive Pulmonary Disease in Women of Reproductive Age with Pelvic Inflammatory Disease: A Nationwide Population-Based Cohort Study/T.-C. Shen, C.-H. Li, C.-Y. Tu, T.-C. Hsia, Taichung, Taiwan, p.A3649

P417 Prevalence and Determinants of Chronic Obstructive Pulmonary Disease in Patients with Stable Heart Failure in Douala General Hospital, Cameroon/B.H. Mbatchou Nghane, F. Kamdem, V. Che, A. Dzudie, M. Nganda, H.R. Ngole, S. Mandengue, Douala, Cameroon, p.A3650


P420 Impact of Obesity in Chronic Obstructive Pulmonary Disease (COPD). Observational Study in Mexican Population in the General Hospital of Mexico “Dr. Eduardo Liceaga”/Y. Mares, M. Diaz, R.R. Hernandez, Mexico City, Mexico, p.A3653


P422 The Degree of Atherosclerosis Is an Independent Predictor of Six-Minute-Walk Distance in Patients with Chronic Obstructive Pulmonary Disease - Data from COPDGene Study/D. Li, R. Casaburi, C. Tan, J.D. Crapo, G.R. Washko, B.J. Make, D.A. Lynch, J. Hokanson, M.J. Budoff, Los Angeles, CA, p.A3655

THEMATIC POSTER SESSION

B49 COPD: SYMPTOM AND CLINICAL ASSESSMENT
9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Area D, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: R.D. Yusen, MD, MPH, St. Louis, MO
M. To, MD, PhD, Koshigaya-City, Japan


P426 COPD Patients with Increasing COPD Assessment Test (CAT) Score During 3 Years/H. Irie, S. Chubachi, A. Tsutsumi, N. Kamemura, I. Nakachi, A. Umeda, N. Miyagi, H. Nakamura, K. Asano, T. Betsuyaku, Tokyo, Japan, p.A3659
P1280 Nasal Highflow (NHF) in Combination with an Aerosol Delivery Device Improves Lung Function/J. Braunlich, H. Wirtz, Leipzig, Germany, p.A3680


P1284 Can High-Flow Nasal Cannula Reduce Endotracheal Intubation in Adult Patients with Acute Respiratory Failure? A Meta-Analysis/Y. Ni, J. Luo, B. Liang, Z. Liang, Chengdu, China, p.A3684


Facilitators: M.A. Matthay, MD, San Francisco, CA E. Vail, MD, New York, NY


P1288 Impact of Sedation and/or Analgesia During Noninvasive Positive Pressure Ventilation in the Patients of Acute Exacerbation of Chronic Obstructive Pulmonary Disease After Extubation/Y. Ni, T. Wang, B. Liang, Z. Liang, Chengdu, China, p.A3688

P1289 Role of CPAP in the Management of Acute Respiratory Failure Due to Community Aquired Pneumonia in ARDS/N.T. Awad, Mumbai, India, p.A3689

P1290 Effectiveness of Non-Invasive Ventilation in Patients with Bronchiectasis/F. Ciftci, S. Erol, A. Ciledag, A. Kaya, Ankara, Turkey, p.A3690


Facilitators: R.C. Hyzy, MD, Ann Arbor, MI S. Panu, MD, MSc, Columbus, OH


P1297 Urine Levels as Index of Lung Deposition and Systemic Bioavailability Associated with the Use of Different Inhalation Method with and Without Humidification in Mechanically Ventilated Asthmatic Patients/M.E.A. Abdelrahim, I.O. Farrag, M. Al Hallag, Giza, Egypt, p.A3697


Facilitators: M.B. Amato, MD, PhD, Sao Paulo, Brazil A. Trammell, MD, Atlanta, GA


P1303 Exploring the Relationship Between Mean Arterial Pressure and Airway pH in Mechanically Ventilated Adults/A. Montpetit, K. Wickliff, M.A. Zulqarnain, A. Kelly, E.P. Cassity, P.E. Morris, Lexington, KY, p.A3703

P1304 Comparison of Central Venous Pressure and Esophageal Pressure for Measurement of Work of Breathing, Effort and Lung Mechanics in Spontaneously Breathing Patients/P. Biselli, R.S. Nobrega, Sao Paulo, Brazil, p.A3704
B51  CRITICAL CARE: MANAGING AN ICU - WHO COMES IN AND PREVENTING COMPlications

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER

Area M, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators.

Facilitators: G.B. Allen, MD, Burlington, VT
S. Ahmed, MD, Albuquerque, NM


Facilitators: B.T. Thompson, MD, Boston, MA
N.E. Brummel, MD, Nashville, TN

P1319  Prevalence of Oral Care Application Difficulty in Mechanically Ventilated Adults/C. M. Dale, L. Burry, O. Smith, L. Rose, Toronto, Canada, p.A3718


P1322  Significant Number of Patients Suffer Major Adverse Events After Continuous-Flow Left Ventricular Assist Device Implantation: A Meta-Analysis/M. Chizinga, Waterbury, CT, p.A3721


P1325  A Comparison of Outcomes in a Medical Step Down Unit Using a Non-Physician Provider Model/S. Amin, O. Koukoularis, J. Aliotta, Providence, RI, p.A3724


P1327  The Quality of Interprofessional Rounds Is Not Associated with Compliance with Evidence-Based Practices/A. Amaral, R. Pinto, G. Pichutti, S. Rossato, A. Iqbal, E. Wilcox, E. Fan, Toronto, Canada, p.A7622

Search

Facilitators: P.R. Menon, MD, PhD, Burlington, VT
A. Sapru, MD, Los Angeles, CA

P1340 Acute Respiratory Distress Syndrome After Cardiac Arrest/E. Sacks, J. Elmer, C. Callaway, Pittsburgh, PA, p.A3735

P1341 Evaluation of Long Term Acute Care Hospital’s Code Blue Outcomes and Immediate Post Code Survival/S. Farooqi, M. Nagel, A. Mora, Dallas, TX, p.A3736

P1342 Predictors of In-Hospital Mortality After Rapid Response Team Calls in a 274 Hospital Nationwide Sample/C. Shappell, A.M. Snyder, D. Edelson, M.M. Churpek, Chicago, IL, p.A3737

P1343 Predictors of Mortality in Adults with Cardiac Arrest Undergoing Coronary Angiogram/G. Thippeswamy, C. Loeb, P.B. Parikh, J. Patel, Stony Brook, NY, p.A3738


THEMATIC POSTER SESSION

MONDAY MORNING

B52 CRITICAL CARE: CARDIAC ARREST OUTCOMES

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area M, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: W.J. Ehlenbach, MD, MSc, Madison, WI
K.M. Berg, MD, Boston, MA


P1331 Deja Vu: Repeat Cardiac Arrests on Multiple Admissions/K. Eng, R. Sell, R. CA, p.A3726


P1333 In-Hospital Cardiac Arrest Among Patients with Malignancy/S. Rosen, K. Yang, Y. Targhi, M.F. Odish, R. Sell, J.R. Beiler, San Diego, CA, p.A3728

P1334 Code Status in the Operating Room/E. Sonntag, S. Pedram, J. Levenson, Richmond, VA, p.A3729

Facilitator: A. Montgomery-Yates, MD, Lexington, KY

P1335 Improving Rapid Response and Cardiac Arrest Outcomes by Resident Simulation Training/N. Durairajan, C. Inman, S. Lee, Detroit, MI, p.A3730


P1338 Delay in Initiation of Hypothermia and High Rate of Hyperthermia After Completion of Targeted Temperature Management in Patients with Cardiac Arrest in a Tertiary Hospital ICU/U. Tariq, T. Mahramus, C. Hunley, T. Jones, J. Sadowsky, R.A. Khan, Orlando, FL, p.A3733


THEMATIC POSTER SESSION

B53 CRITICAL CARE: IMAGING IN THE ICU

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area M, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: G.A. Schmidt, MD, Iowa City, IA
A. Patrawalla, MD, Newark, NJ


P1347 Accuracy of Bedside Ultrasound by Internal Medicine Residents to Evaluate Central Venous Catheter Placement/C. Ghattas, M. Kundal, F. Farooq, F. Celestin, P. LaCamera, J.L. Breeze, S. Rafeq, Boston, MA, p.A3741

P1348 Impact of Point of Care Ultrasound in an Academic Medical Intensive Care Unit/A. Anderson, W. Isakow, St. Louis, MO, p.A3742

P1349 Optimizing Ultrasound Settings for B-Lines on Lung Ultrasound - an In-Vitro Pilot Study/C.N. Schmickel, A.A. Menon, F. Schembri, Boston, MA, p.A3743


THEMATIC POSTER SESSION

B54 CRITICAL CARE: GOLDILOCKS SYNDROME - GETTING THE PRESSURE AND VENT "JUST RIGHT" IN ARDS AND ACUTE RESPIRATORY FAILURE

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER Area M, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: L.J. Brochard, MD, Toronto, Canada T. Mauri, MD, Milan, Italy


P1359 Protective Effects of Positive End-Expiratory Pressure in Short-Term Positive-Pressure Ventilation in a Mouse Model of Ventilator-Induced Acute Lung Injury/L. Cagle, L. Franzia, A. Lindberth, J. Last, N. Kenyon, Davis, CA, p.A3752

P1360 PEEP Targeted at Positive Regional Transpulmonary Pressure Reduces Lung Inflammation in an Experimental Model of Severe ARDS in Pigs/M. Herzog, T. Bluth, T. Kiss, A. Braune, R. Huhle, J. Herold, P. Herzog, A. Denz, L. Vivona, J. Kotzerke, M. Gama De Abreu, Dresden, Germany, p.A3753


P1363 The P/F Ratio (PaO₂/Fio₂) X PEEP X 10: A Pilot Approach to Calculate the Severity of Oxygenation/ARDS with PEEP/P. Sunitha, Singapore, Singapore, p.A3756

P1364 Electrical Impedance Tomography at Clinical Practice: Case Series/K.T. Timenetsky, D. Camieli-Cazati, C.S.A. Azevedo, M. Beraldo, R.A.C. Eid, Sao Paulo, Brazil, p.A3757

Facilitators: E.C. Goligher, MD, PhD, Toronto, Canada R.D. Hite, MD, Cleveland, OH


P1369 Driving Pressure Is the Most Predictive Respiratory Mechanical Parameter in ARDS (2016 Influenza A H1N1, Mexico City)/J.L. Sandoval Gutierrez, R. Garcia Torrenera, C. Guadarrama Perez, C. Castro Lopez, Mexico City, Mexico, p.A3762

P1370 Driving Pressure Greater than 14cmH2O Is Associated with Increased Mortality When Tidal Volume Less Than 8 ml/kg in Septic Patients with Acute Respiratory Distress Syndrome/M.-C. Chan, C.-L. Wu, Taichung, Taiwan, p.A3763


P1373 Closed-Loop Adjustment of Oxygen Flowrate with FreeO2 in Patients with Acute Coronary Syndrome: Comparison of Automated Titration with FreeO2 (Set at Two SpO2 Target) and of Manual Titration. A Randomized Controlled Study/M.T. Huynh Ky, P.-A. Bouchard, J. Morin, E. L’Her, J.-F. Sarrazin, P. Lellouche, Quebec, Canada, p.A3766
THEMATIC POSTER SESSION

B55  CRITICAL CARE CASE REPORTS: DRUG OVERDOSES

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER  
Area M, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: J. Siner, MD, New Haven, CT
S. Pasha, MD, Lexington, KY
P.1376 Cocaine Induced Bronchospasm Mimicking Acute Asthma Exacerbation/ N. Tipirneni, M. Vora, A. Weinacker, Palo Alto, CA, p.A3768
P.1379 MDMA and Life-Threatening Multiorgan Failure/L. Alsharhan, M. Campos, Miami, FL, p.A3770
P.1386 MDMA and Life-Threatening Multiorgan Failure/L. Alsharhan, M. Campos, Miami, FL, p.A3770
P.1380 An Antiparasitic in My Cocaine? A Rare Cause of Vasculitis and Acute Renal Failure/N.A. Smith, M. Sehrg, J. Chambers, B. Aulakh, Peoria, IL, p.A3771
P.1383 Cardiac Arrest Due to Severe Metformin-Associated Lactic Acidosis/G.F. Shaughnessy, D.R. Nelson, Rochester, MN, p.A3775

THEMATIC POSTER SESSION

B56  CRITICAL CARE CASE REPORTS: ICU TOXICOLOGY

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER  
Area M, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: R. Matthay, MD, New Haven, CT
M.E. Wilson, MD, Rochester, MN
P.1385 Metformin Associated Lactic Acidosis/T. Umeda, T. Minami, E. Summerhill, K. Bartolomei, Minneapolis, MN, p.A3776
P.1386 Unintended Consequences of Lipid Emulsion Therapy in Severe Bupropion Overdose/U. Miller, K. Chapla, Madison, WI, p.A3777
P.1388 A Case of Propofol Infusion Syndrome in the Intensive Care Setting/N. Miller, A. Garbarino, J. Jennnings, Detroit, MI, p.A3779
P.1392 Linezolid Induced Thrombocytopenia, Lactic Acidosis, Hypoglycemia and Warfarin Toxicity/R. Mishra, B. Goel, T. Vakde, Bronx, NY, p.A3783
P.1401 tPA Administration with ACE-Inhibitor Use Leading to Orolinguinal Edema: A Commonly Forgotten Association/A. Sharma, E. Nadler, J. Goralnik, Farmington, CT, p.A3792
P.1402 Cyclical Fevers, Not an Infection; Herbal Tea Induced Liver Injury/N. Ishak Gabra, A. Malloob, V. Tolia, R.E. Jean, New York, NY, p.A3793

The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.
Thematic Poster Session

B58 Occupational Lung Disease: Case Studies, Epidemiology, and Mechanisms

9:15 a.m. - 4:15 p.m.  
Walter E. Washington Convention Center  
Area A, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: P.K. Henneberger, MPH, ScD, Morgantown, WV

P1  Reactive Airway Dysfunction Syndrome (RADS) in a Surgeon After Exposure to Duraseal Fume in the Operating Room/A. Riehani, T. Raza, D. Young, East Lansing, MI, p.A3843


P5  Occupational Exposure and the Risk of Chronic Obstructive Lung Disease and Mortality - A Swiss Large-Scale Cohort Study/M.A. Puhan, A. Strassmann, M. Bopp, A.J. Turk, H. Dressed, Zurich, Switzerland, p.A3847


The information contained in this program is up to date as of March 9, 2017.

For the most current session information, please visit the online program itinerary.

ATS 2017 • Washington, DC
**B59 CHEMICAL EXPOSURES**

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: L.A. Veress, MD, Aurora, CO

**P36 Bronchiolitis Obliterans in a Civilian Survivor of a Chemical Warfare Attack**/S. Shimizu-Saito, P. Diaz, Columbus, OH, p.A3876


**P40 Respiratory Symptoms and Lung Function Among Residents Exposed to Forest Fire in Riau, Sumatra, Indonesia 2015**/J.Z. Rozali, A.D. Susanto, E. Samedro, T. Takada, T. Kikuchi, Japan, p.A3880


Facilitator: T.A. Wyatt, PhD, Omaha, NE


**P43 Sub-Chronic Mouse Model of Chemical-Induced Asthma**/J. Vanorbeek, L. Pollaris, S. Van Den Broucke, S. Seys, B. Nemeroy, P. Hoet, Leuven, Belgium, p.A3883


**B60 ENVIRONMENTAL DUST AND PARTICULATES IN AIRWAY DISEASE**

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: D.J. Romberger, MD, Omaha, NE


**P49 Housing Type Modulates Oxidant Levels and Antioxidant Defenses in Swine Airway Epithelial Tissue**/R. Ranabhat, C.J. McClendon, J.T. Waterman, Greensboro, NC, p.A3888


**P51 Agricultural Dust Exposure Induces IL-10 Production in Tissue Macrophages Which May Have a Role in Airway Inflammation and Repair**/D. Chandra, M. Sapkota, J.M. DeVasure, J. Poole, T.A. Wyatt, Omaha, NE, p.A3890

**P52 MyD88 Regulates Airway Mucin Secretion in the Context of Agricultural Organic Dust Injury**/J. Dickinson, J. Sweeter, A. Nelson, J. Poole, Omaha, NE, p.A3891


**P54 Indoor Airborne Dust/Particulate Matter Causes Occupational Respiratory Disease: Novel Lipidocentric Mechanism of Airway Inflammation**/S.J. Campbell, P. Kauffman, N. Parinandi, S. Kotha, T. Gurney, S. Varikuti, A. Satoskar, Columbus, OH, p.A3893


**P56 The ProS Peptide of Porcine Cathelicidins Is an Active Component of Swine Concentrated Animal Feeding Operations (CAFOs) Dust and a Novel Activator of EGF Receptor Signaling**/M.L. Toews, N.A. Schultz, P.R. Dodman, G. Tian, P.S. Ciborowski, R.G. Bennett, F.G. Hamel, A.J. Heires, T.M. Nordgren, D.J. Romberger, Omaha, NE, p.A3895

Facilitator: S. Krychuk, PhD, Saskatoon, Canada

**P57 Associations Between Radon and PM<sub>2.5</sub> Exposures and Risk of Lung Cancer Incidence in US Women**/T. VoPham, F. Laden, J.E. Hart, Boston, MA, p.A3896

The information contained in this program is up to date as of March 9, 2017. For the most current session information, please visit the online program itinerary.


P62 Utilizing the HapMap Lymphoblastoid Biorepository as an In-Vitro Model for Diesel Exhaust Toxicity/W. Gladowell, O. Yost, J. Li, X. Wang, D. Bell, I. Gilmour, J. Ciencewicki, S. Kleeberger, Research Triangle Park, NC, p.A3901


P64 Comparison of Time Lag Effects of Wintertime California and China PM in Healthy Young Mice/X.L. Sun, W. Li, D.E. Young, H.Y. Wei, L.L. Cui, K.J. Bein, Q. Zhang, J.J. Zhang, A. Magana-Mendez, K.E. Pinkerton, Jinan, China, p.A3903


P68 Where Are They? The Occurrence of Legionella Pneumophila and Mycobacterium Avium at Residential and Office Buildings/M. Donohue, Cincinnati, OH, p.A3907


P71 Effect Modification of Exposure to PM2.5 on Airway Inflammation and Lung Function by the Presence of Protein PAI-1 in a Cohort of Obese Adolescents in Mexico City/A. Barraza-Villarreal, J.C. Cruz, H. Moreno-Macias, F. Huang, L. Hernandez-Cadena, Cuernavaca, Morelos, Mexico, p.A3910


B61 BACTERIAL RESPIRATORY INFECTIONS
9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Area L, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: M. Prickett, MD, MPH, Chicago, IL


Time to Blood Culture Positivity as a Predictor of Clinical Outcomes and Severity in Adults with Bacteremic Pneumococcal Pneumonia/C. Cilloniz, A. Ceccato, C. De La Calle, A. Gabarrus, C. Garcia-Vidal, A. Salazar, M. Almela, A. Soriano, J.A. Martinez, F. Marco, A. Torres, Barcelona, Spain, p.A3920

Facilitators: A. Torres, MD, Barcelona, Spain


Clinico-Radiological Correlation of Bacterial Pneumonia/R. Tsuzuki, S. Noma, T. Ebisuadani, A. Tokumoto, A. Ohtsuki, K. Nakashima, M. Misawa, M. Aoshima, Kamogawa City, Japan, p.A3924


Can You Tell What It Is Yet? An Investigation into Identification of Consolidation of Chest X-Rays in Patients Diagnosed with Community Acquired Pneumonia/A. Jackson, A. Bridgman, B. Black, A. Youzguin, Southport, United Kingdom, p.A3929

Facilitator: A. Sayiner, MD, PhD, Izmir, Turkey

Predictors for Antimicrobial De-Escalation Among Hospitalized Patients with Culture-Positive Pneumonia/Z. Zhang, N. Ariyoshi, L. Majewski, H. Chung, J. Dworkin, G. Devendra, Honolulu, HI, p.A3930


The Role of Cold Air in the Deposition of Ultrafine Infectious Bioaerosols in the Respiratory Tract/A.N. Ishmatov, Tomsk, Russian Federation, p.A3932


Focus on Characteristics of the Lower Respiratory Tract Microbiome in Pseudomonas Aeruginosa Ventilator-Associated Pneumonia Patients/X. Qi, D. Yang, L. Zhou, Y.-W. He, J. Liu, Shanghai, China, p.A3935


The information contained in this program is up to date as of March 9, 2017. For the most current session information, please visit the online program itinerary.

Facilitator: E. Mortensen, MD, MSc, Simsbury, CT


P1107 Cardiac Troponin I as a Severity Predictor in Hospitalized Patients with Community Acquired Pneumonia/S. Peiman, S.F. Allameh, N. Abbasi, A. Charejoo, A. Abdollahi, Tehran, Iran, p.A3942


P1109 Risk Factors for Drug-Resistant Community-Acquired Pneumonia/A. Sayiner, H. Erbey, Y. Kaptan, S. Aydemir, A. Tunger, Izmir, Turkey, p.A3944

P1110 Healthcare-Associated Pneumonia (HCAP) and Hospital-Acquired Pneumonia (HAP) - Bacterial Etiology, Antibiotic Resistance and Mortality/S. Kumar, R.A. Jan, B.A. Parikh, A. Majid, Boston, MA, p.A3945


Facilitator: M.I. Restrepo, MD, MSc, San Antonio, TX


P1114 AntibioticTherapy for Patients with Community-Acquired Pneumonia Associated with Advanced Chronic Obstructive Pulmonary Disease: Would Be Special Concerns for Patients Admitted to the Intensive Care Unit/A. Sadigov, F. Abdullayev, K. Agayeva, Baku, Azerbaijan, p.A3949


P1117 Predictive Performance of Quick Sepsis-Related Organ Failure Assessment for Mortality and Intensive Care Unit Admission Among Patients with Community-Acquired Pneumonia/F. Tokioka, H. Okamoto, Y. Washio, A. Yamazaki, A. Ito, T. Ishida, Okayama, Japan, p.A3952


P1119 Bacterial Colonization During Stent Trial in Excessive Central Airway Collapse/D. Wootton, G. Airey, L. Keogan, O. Eneje, L. Probert, Liverpool, United Kingdom, p.A7626

P1120 Comparison of 3 Prognostic Scores in Patients with Sepsis Secondary to Community-Acquired Pneumonia Attended at the Emergency Department/C. Hincapie, J. Asuntar, F. Jaime, Medellin, Colombia, p.A3955

P1121 Incidence and Utility of Blood Cultures in Patients Admitted with Pneumonia Classified by Severity and Healthcare Exposure/D. Zhang, A. Makam, Dallas, TX, p.A3956


B62 NON-TUBERCULOUS MYCOBACTERIA: CLINICAL ASPECTS AND CASES

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER Area L, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will present for individual discussion. 12:00-1:00: authors will be present for discussion with assigned facilitators.
B63  LATENT TUBERCULOSIS INFECTION AND EPIDEMIOLOGY OF TUBERCULOSIS DISEASE
9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER
Area L, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators
Facilitator: K.A. Cohen, MD, Boston, MA


P1189 Does Indoor Air Pollution Enhance the Risk of Tuberculosis Infection?/M.D. Schweitzer, V. Patel, M. Mirsaeidi, A. Foster, N. Kumar, Miami, FL, p.A3983

P1190 Complex Dynamics Between Indoor Air Pollution, Pneumonia and Pediatric Tuberculosis; An Explorative Study from Developing Country/N.K. Bhatta, R.R. Singh, Dharan, Nepal, p.A3984

P1191 Depicting Recent Transmissions of Multi-Drug Resistant Tuberculosis in Shanghai, China: A Population-Based Genotypic and Geospatial Study/X. Wei, D. Li, E. Ge, C. Yang, S. Tsui, X. Shen, Q. Gao, Toronto, Canada, p.A3985


Facilitator: D. Horne, MD, MPH, Seattle, WA


P1198 Prevalence of Latent Tuberculosis Among Exposed Population of Medical Students as Compared with Unexposed Population of Non-Medical Students and Its Relation with Duration of Exposure/D. Chaudhry, N. Jain, S. Singh, B. Prajapat, A. Agarwal, Rohtak, India, p.A3992


P1201 The Correlation of Serum Adenosine Deaminase and Tuberculin Test for Diagnosis of Latent Tuberculosis in Close Contact Persons/W. Phuengpathom, Hadyai, Songkla, Thailand, p.A3995


P1203 Drug Resistant Tuberculosis at an University Hospital in Brazil: Clinical and Microbiological Profile/A.P. Santos, J.M. Leung, S. Riva, A.C. Carvalho, M.A. Vieira, A. Kritski, F. Mello, Rio de Janeiro, Brazil, p.A3997

Facilitator: C. Yoon, MD, MPH, San Francisco, CA/

P1204 Tuberculin Skin Test Variability and Impact of Tuberculin Skin Test on Subsequent QuantiFERON®-TB Gold In-Tube Test Results/W.C. Whitworth, E. Iliev-Hughes, G. Mazurek, Atlanta, GA, p.A3998


P1209 Comparison of Tuberculin Skin Test with Interferon Gamma Release Assay (QuantiFERON®) for Detection of Latent Tuberculosis Infection in Cancer Patients/L. Galindo Pedraza, A.M. Callejas Gutierrez, D.A. Suarez Zamora, A.M. Baldon Elorza, D.M. Palacios Ortiz, C. Hanabergh, M.P. Caicedo Verastegui, Bogota, Colombia, p.A4003

P1210 Utilization of Interferon Gamma Release Assays (IGRAs) for the Detection of Latent Tuberculosis Infection (LTBI) at a Tertiary Care Hospital/G.M. Molina-Pallete, J. Kansagra, I. Brar, Detroit, MI, p.A4004

THEMATIC POSTER SESSION

B64 FUNGAL INFECTIONS AND INFECTIONS IN NON-HIV IMMUNOCOMPROMISED HOSTS
9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER
Area L, Hall B-C (Middle Building, Lower Level)

Facilitator: J.J. Saukkonen, MD, West Roxbury, MA


P1213 Burden of Tuberculosis in Adult Patients with Diabetes Mellitus/A. Mohan, P. Sumanth Reddy, B.S. Kumar, A. Sachan, D.P. Kumar, K.V.S. Sama, Tirupati, India, p.A4007


P1215 Pediatric and Adolescent Tuberculosis After the Chernobyl Disaster/L. Gorbach, Minsk, Belarus, p.A4009


Facilitator: A.H. Limper, MD, Rochester, MN


P1223 Emerging Pulmonary Fungal Isolates from Patients with Hematologic Malignancies/J. Wong, P. Ballal, P.G. Arndt, Minneapolis, MN, p.A4015


P1225 Liquid-Based Cytopathology Test as a Novel Method to Identify Aspergillus in Patients with Invasive Pulmonary Aspergillosis/Y. Shen, C. Wan, L. Chen, Y. Jiang, F. Wen, Chengdu, China, p.A4017


P1228 Mortality Rate of Aspergillus Infection Following Thoracic Transplant: Retrospective Study Using UNOS (United Network for Organ Sharing) Database/V. Gupta, S. Kukrety, M.A. Narayana, R. Walters, R. Vivekanadan, Omaha, NE, p.A4020

Facilitator: S.E. Evans, MD, Houston, TX


P1230 Blastomycosis: Clinical Presentation, Diagnosis, Treatment, and Prognosis in a Large Public Hospital in Chicago/W. Makhlouff, E. Elgezawy, S. Farghaly, Assiut, Egypt, p.A4021


The information contained in this program is up to date as of March 9, 2017. For the most current session information, please visit the online program itinerary.

P1234 Pneumocystis Pneumonia with Discordant PCR Results from Induced Sputum and BAL Samples: A Mayo Clinic Experience/K. Pennington, J. Wilson, P. Escalante, Rochester, MN, p.A4026


**THEMATIC POSTER SESSION**

**B65 HOST-PATHOGEN INTERACTIONS**

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Area L, Hall B-C (Middle Building, Lower Level)

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:15-12:00: authors will be present for individual discussion

12:00-1:00: authors will be present for discussion with assigned facilitators

**Facilitator:** S.K. Cribs, MD, MSc, Atlanta, GA


P1239 Impaired Host Defense Against Klebsiella Pneumonia in Diet-Induced Obese Mice Is Associated with Reduced CD64+, CD11c+ Macrophages, CD64+, CD 11c+ Dendritic Cells, and Neutrophil Counts in the Alveolar Space In Vivo and Diminished Neutrophil Bactericidal Function/P. Mancuso, J.L. Curtis, C.M. Freeman, C. Griffin, K. Singer, Ann Arbor, MI, p.A4030

P1240 Activation of α7 nAChR Promotes IL-4-Induced Macrophages M2 Polarization Under Influenza A Virus Infection/X. Su, Z. Gao, Y. Huang, Shanghai, China, p.A4031

P1241 Respiratory Syncytial Virus Induces a Signaling Cascade During Entry, Resulting in Recruitment of Its Receptor, Nucleolin, to the Cell Surface/C. Griffiths, L. Bilawchuk, K. Jamieson, L. Jensen, D. Proud, D. Marchant, Edmonton, Canada, p.A4032

P1242 Lung Epithelial Cell-Derived Exosomes Facilitate the Propagation of Inflammatory/D. Zhang, H. Lee, Y. Jin, Boston, MA, p.A4033


P1244 Myddosome-Activated Epithelial TRAF6 Is Required for Synergistic TLR-Induced Resistance to Pneumonia/V.V. Kulkarni, Y. Wang, J. Pantaleon-Garcia, M. Leiva, S.R. Bhupanapadu Sunkesula, S. Wall, S. Batres, S.E. Evans, Houston, TX, p.A4035

P1245 Activation of Lung Epithelial NFκB and STAT3 Signaling Pathways Is Required for Inducible Resistance to Pseudomonas Infection/Y. Wang, V.V. Kulkarni, J. Pantaleon-Garcia, M.M. Leiva-Juarez, S.E. Evans, Houston, TX, p.A4036


**Facilitator:** S.T. Qureshi, MD, Montreal, Canada

P1251 Role of Mitogen Activated Protein Kinase Kinase Three (MKKK3) in Influenza A Infection/J.O. Joerns, P.J. Lee, P. Mannam, A. Srivastava, J.L. Koff, Y. Sun, M. Haslip, A.M. Mulenos, New Haven, CT, p.A4042

P1252 Obesity Is Associated with Increased Neutrophil Recruitment to and Impaired Neutrophil Clearance from the Airspace During H1N1 Influenza Infection/M. Rincon, M. Porto, L. Hoyt, S. Ventronne, N. Ubags, M.C. Antkowiak, B.T. Suratt, Burlington, VT, p.A4043

P1253 Mitochondrial Reactive Oxygen Species in Lung Epithelial Cells Are Induced by Oligodeoxynucleotides in a MyD88 and TRAF6-Independent Manner/M.M. Leiva-Juarez, V.V. Kulkarni, X. Wang, S.S. Bupapanapadu, S. Batres, S.E. Evans, Houston, TX, p.A4044
P1254 Regulation of Proinflammatory Cytokine by Vitmain B2 in Influenza A/H5N1 Virus Infected Human Alveolar Epithelial Cells and Macrophages/M.C.W. Chan, R.W.Y. Chan, M.M.T. Ng, R.H.H. Ching, J.S.M. Peiris, Hong Kong, Hong Kong Prc, p.A4045


P1126 CASE REPORTS: BACTERIAL INFECTIONS

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Area L, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: M.S. Niederman, MD, New York, NY

P1126 Septic Thrombophlebitis of Internal Jugular Vein and Septic M.S. Niederman, MD, New York, NY

Facilitator: R.F. Grossman, MD, Mississauga, Canada

P1133 Cavitary Pneumonia Due to Salmonella Enteritidis/R. Pillai, K. Doo, J.S. Mendelson, A. Lubinsky, New York, NY, p.A4056


P1135 Legionella Pneumonia: A Rare Cause of Rhabdomyolysis/M. Hasan, J. Alukal, R. Mundada, Y.R. Sedhai, Darby, PA, p.A4058


P1137 Lactobacillus, Not so Benign/R. Zulfikar, P. Jain, Clarksburg, WV, p.A4060

P1138 Pneumonia Caused by Chryseobacterium Indolgenes As a Cause of Prolonged Respiratory Failure After Heart Surgery/B. Hirsh, B. Dolan, K. Parametman, S.A. Gregory, Wynnewood, PA, p.A4061

P1139 Pulmonary Hemorrhage by Leptospirosis/M.M. Perin, S.D. Leiva Aguero, A. Putreue, C.M. Luna, Buenos Aires, Argentina, p.A4062


P1142 Peptostreptococcus Superinfection as Initial Presentation of Squamous Cell Carcinoma/J. Alderson, S. Velani, C.V. Teba, M.C. Yang, J. Kazakov, Richmond Heights, OH, p.A4065

P1143 Multi Drug Resistant Acinetobacter Junii Pneumonia Is a Ventilator Dependent Patient: A Rare Organism in Critically Sick Adults/P. Bansal, V. Kaul, S. Easaw, T. McGarry, Elmhurst, NY, p.A4066

P1144 Nocardia Pneumonia, A Diagnosis Conundrum/P. Srivastav, K. Sitaraman, Syracuse, NY, p.A4067


Facilitator: C. Feldman, MD, PhD, Johannesburg, South Africa


P1147 A Rare Case of Empyema Necessitans Caused by Actinomyces Myeri/R. Kumar, A. Desai, Syracuse, NY, p.A4070
B67 INTERESTING AND UNUSUAL PEDIATRIC CASE REPORTS

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area F, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: F. Ogunlesi, MD, Washington, DC


P637 Right Ventricle to Pulmonary Artery Conduit Change with Nuss Operation for Relieving the Compression of the Extracardiac Conduit and the Coronary Arteries/S. Kim, P.J. Choi, E.-J. Kang, Y.-S. Lee, Busan, Korea, Republic of, p.A4088

Facilitator: H. Jalou, MD, Indianapolis, IN


P641 A Teenager with Chronic Cough and Multiple Cavitary Lung Lesions/F. Neemuchwala, A.P. Popova, Ann Arbor, MI, p.A4092

P642 A Case Report of a 10-Year-Old Boy with Pulmonary Paraganglioma/L. De Keyzer, S. Gammons, J. Wang, G. Shah, S. Nair, Dallas, TX, p.A4093

Facilitator: E. Belteton, MD, Las Victorias, Guatemala

P643 Inflammatory Myofibroblastic Tumor of the Lung Presenting as an Incidental Pulmonary Nodule in a Wheezy Infant/H. Hamdan, P. Schochet, Dallas, TX, p.A4094

P644 High Flow Nasal Cannula and Aerosolized Morphine to Treat Symptomatic Dyspnea During End-of-Life Care/S.E. Morgan, S.M. Mosakowskii, K. Phinizy, Philadelphia, PA, p.A4096


P649 Just Say No to Aspirating Styrofoam: A Collaborative Persistent Cough and Post Obstructive Bronchitis Due to a Congenital Heart Disease Associated Trisomy 21 with Down Syndrome and Subclavian Aberrant Artery: A Case Hypothermia and Acute Heart Failure in an Infant: Congenital Lobar Emphysema Intervention Decision in Infant The Use and Outcomes of Long-Term Non-Invasive Ventilation

**THEMATIC POSTER SESSION**

**B68 CARDIOVASCULAR DISEASE IN THE PICU**

9:15 a.m. - 4:15 p.m. **WALTER E. WASHINGTON CONVENTION CENTER**

_Area F, Hall B-C (Middle Building, Lower Level)_

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

**Facilitator:** E. Carter, MD, Mesa, AZ

P655 The Use and Outcomes of Long-Term Non-Invasive Ventilation in Infants/P.K. Bedi, K. Dehaan, M. Castro-Codesal, J.E. MacLean, Edmonton, Canada, p.A4105

P656 Validating Biomarker Phenotyping for Triage of Sepsis to the Pediatric Intensive Care Unit in Children Age 1 Month to 17 Years/B. Mickiewicz, G. Thompson, J. Blackwood, C.N. Jenne, B. Winston, H.J. Vogel, A.R. Joffe, Calgary, Canada, p.A4106


**Facilitator:** C. Towe, MD, Cincinnati, OH


**Facilitator:** P. Sammut, MD, Omaha, NE


P669 Physician Use of Steroids in Pediatric Shock: Comparison of Data Obtained from a Survey Versus a Retrospective Chart Review/A. Liu, K. Menon, Ottawa, Canada, p.A4119

**THEMATIC POSTER SESSION**

**B69 WHEN KIDS CANNOT SLEEP (OR BREATHE)**

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER

Area F, Hall B-C (Middle Building, Lower Level)

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:15-12:00: authors will be present for individual discussion

12:00-1:00: authors will be present for discussion with assigned facilitators

**Facilitator:** I. Sami-Zakhari, MD, Washington, DC


**P675 Inspiratory-Expiratory Differences in Respiratory System Reactance and Resistance as Measured by Forced Oscillometry in Children with Cystic Fibrosis and Asthma/S. Krishnan, A.J. Dozor, Valhalla, NY, p.A4124**


**P679 Effectiveness of Supraglottoplasty for Correction of Neonatal Sleep Apnea Due to Laryngomalacia/A. Bandyopadhyay, J.E. Slaven, H. Muston, B.H. Matt, A. Daftary, Indianapolis, IN, p.A4132**


**P683 Auto-Adjustable Positive Airway Pressure Versus Polysomnographic Titration in Childhood Obstructive Sleep Apnea/R. Opasatian, A. Preuthiphan, Bangkok, Thailand, p.A4135**

**P684 Effectiveness of Supraglottoplasty for Correction of Neonatal Sleep Apnea Due to Laryngomalacia/A. Bandyopadhyay, J.E. Slaven, H. Muston, B.H. Matt, A. Daftary, Indianapolis, IN, p.A4132**

**P685 Transcatheter Potts Shunt Creation in Children: Technical Data and Mid Term Results/S. Bhargava, MD, Palo Alto, CA**


P698 Outcomes Following Adenotonsillectomy in Children with Moderate to Severe Obstructive Sleep Apnea/M.V. Bautista, A. Wise, Washington, DC, p.A4145


P699 The Physiological Profile of Rett Syndrome: Linear and Nonlinear Measures of Heart Rate Variability from In-Home Ambulatory Recordings Are Dependent on Genotype Functional Classes/M.S. Carroll, D.E. Weese-Mayer, Chicago, IL, p.A4148

Facilitator: E.B. Gauda, MD, Baltimore, MD

P700 Polysomnography Provides Useful Clinical Information in the Liberation from Respiratory Technology/A. Bashir, J. Henningfield, N. Thompson, L. D’Andrea, Milwaukee, WI, p.A4149


P702 Pulmonary Function Associated with Changes in Body Mass Index in a Cohort of Adolescents in Mexico City: Definitive Results Along 7 Years/L. Hernandez Cadena, J.C. Cruz, A. Barraza-Villarreal, H. Moreno-Macias, M.C. Escamilla Nunez, B. DEI Rio Navarro, Cuernavaca, Morelos, Mexico, p.A4151


Facilitator: K.A. Fagan, MD, Mobile, AL


P717 The Successful Transition from Oral to Intravenous Prostacyclin Therapy in a Functional Class IV WHO Group 1 Pulmonary Arterial Hypertension Patient/A.M. Gibbs, H. Poonyagariyagorn, Portland, OR, p.A4157


P720 A Unique Case of a Pulmonary Embolism that Occurred After Endothermal Heat-Induced Thrombosis After Endovenous Laser Ablation/A. Pelinescu, S. Yadam, K. Hu, N. Sacca, Pittsburgh, PA, p.A4160


Facilitator: K. Chin, MD, Dallas, TX

P724 Hepatopulmonary Syndrome and Telomerase (TERT) Mutation: A Rare Association/T. Kukkadapu, S. Gupta, J. Gossage, Augusta, GA, p.A4164

P725 A Rare Cause of Pulmonary Hypertension/J. Ramos-Rossy, E. Gonzalez, W. Rodriguez-Cintron, E. Adorno-Fontanez, San Juan, PR, p.A4165


P728 33 Year Old Man with Hemothysis: A Deeper Look into Unilateral Atresia of Pulmonary Artery/C. Risquez, F.M. West, N. Narula, A. Sanders, New York, NY, p.A4168
P729  Cardiogenic Shock Reversal in Severe Pulmonary Hypertension After Arteriovenous Fistula Ligation/M. Ayache, M. Matta, R. Schilz, Cleveland, OH, p.A4169

P730  Pulmonary Hemorrhage Following Percutaneous Edge to Edge Mitral Valve Repair/M. Ayache, M. Mayuga, J. Kazakov, Cleveland, OH, p.A4170

P731  Thrombolytic Therapy in Patients with Atrial Thrombus and Submassive Pulmonary Embolism/A. Patel, G. Pierson, J. Gordon, Pueblo, CO, p.A4171


Facilitator:  J.R. Klinger, MD, Providence, RI

P733  Pulmonary Vein Thrombosis Due to IVIG Use in Guillain-Barre Syndrome/Y. Kawar, D. Starosta, Detroit, MI, p.A4173

P734  Which Came First, the PAH or the VSD?/N.M. Pradhan, R. Estefie, K.E. Roberts, Boston, MA, p.A4174

P735  An Unusual Mimic of Chronic Thromboembolic Pulmonary Hypertension/K. Gill, K. Kerr, V. Balasubramanian, Fresno, CA, p.A4175

P736  Pulmonary Arterial Hypertension and Acute Cervical Myelopathy - Nightmare Scenario with Fairytale Ending/K. Gill, V. Balasubramanian, Fresno, CA, p.A4176


P738  A Novel Cause of Platypnea Orthodeoxia Syndrome/C. Cann, A. Cords, M. Gordon, Philadelphia, PA, p.A4178

P739  Challenges in Clinical Decision Making: A Patient with Type B Aortic Dissection Presenting with Pulmonary Embolism/O. Bhaty, A.S. Jhand, N. Alkhafaji, A. Mooss, Omaha, NE, p.A4179

P740  Cardiac Tamponed Masking as Decompensated RV Failure in a PH Patient/J.C. Onyenekwe, R. Awdish, Detroit, MI, p.A4180

Facilitator:  A.J. Bryant, MD, Gainesville, FL

P741  The PE that Never Was: A Rare Case of Combined PVOD and Pulmonary Vein Thrombosis/K. Albujoq, R. Awdish, S. Hegab, Hampl, J. Herget, Prague, Czech Republic, p.A4181


P745  Chronic Massive Thromboembolic Pulmonary Embolism Secondary to Unidentifiable Thrombophilia/A.H. Alraiyes, Y. Fu, Zion, IL, p.A4185


THEMATIC POSTER SESSION

B71 PULMONARY HYPERTENSION LIFE: ANIMAL MODELS AND EX VIVO STUDIES IN PULMONARY HYPERTENSION

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Area G, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator:  P.M. Hassoun, MD, Baltimore, MD

P783  Perinatal Hypoxia Causes Differential Expression of Potassium Channels that Is Gender-Specific/P.P. Jain, J. Novotna, V. Hampl, J. Herget, Prague, Czech Republic, p.A4189

P784  Gender Differences in the Life-Long Effects of Maternal Diabetes on Offspring Pulmonary Circulation/P.P. Jain, O. Vajnerova, J. Herget, V. Hampl, Prague, Czech Republic, p.A4190


P786  Inhibition of Fatty Acid Amide Hydrolase (FAAH) Prevents Pulmonary Hypertension Via Activation of CB2 Receptors/O. Wenzel, M. Matthey, E. Silantyeva, L. Wohm, B.K. Fleischmann, Bonn, Germany, p.A4192

P787  KAR5585, a First-in-Class Oral Tryptophan Hydroxylase 1 (TPH1) Inhibitor as a Novel Candidate for the Treatment of Pulmonary Arterial Hypertension/V. Paralkar, P. Pearson, J.W. Mason, S.-X. Li, S. Curry, R. Aiello, P.U. Feig, New Haven, CT, p.A4193


Dual ETA/ETB, But Not ETA-Selective Endothelin Receptor Inhibition Attenuates α-Naphthylthiourea - Induced Vascular Leakage and Pulmonary Hypertension/S. P. Tofovic, R. Zhang, O. Rafikova, M. Iglarz, J. Hu, Pittsburgh, PA, p.A4198

Chronic Treatment of Nintedanib Ameliorates the Development of Pulmonary Hypertension and Vascular Remodeling in Mice/S. Patel, W. Bradley, T. Jilling, S. Matalon, Birmingham, AL, p.A4197


Heart Failure-Induced Diaphragmatic Weakness Is Prevented with Central Acting Therapeutics that Alleviate PERK Upregulation and EIF2α Phosphorylation/A. Foster, M.J. Platt, A. Eadie, N. Romanova, C. Murrant, K. Brunt, J.A. Simpson, Guelph, Canada, p.A4208

Pulmonary Hypertension and Vascular Remodeling in Mice Exposed to Crystalline Silica/N. Zeiko, J.X. Zhu, J.D. Ritzenthaler, J. Roman, Louisville, KY, p.A4209

Sirt1 Activity Is Required for the Protective Effects of the Female Sex in the Response to Chronic Hypoxia/M. Taha, Y. Deng, M.W. McBurney, D.J. Stewart, Ottawa, Canada, p.A4210


Heart Failure-Induced Diaphragmatic Weakness Is Prevented with Central Acting Therapeutics that Alleviate PERK Upregulation and EIF2α Phosphorylation/A. Foster, M.J. Platt, A. Eadie, N. Romanova, C. Murrant, K. Brunt, J.A. Simpson, Guelph, Canada, p.A4208

Pulmonary Hypertension and Vascular Remodeling in Mice Exposed to Crystalline Silica/N. Zeiko, J.X. Zhu, J.D. Ritzenthaler, J. Roman, Louisville, KY, p.A4209

Sirt1 Activity Is Required for the Protective Effects of the Female Sex in the Response to Chronic Hypoxia/M. Taha, Y. Deng, M.W. McBurney, D.J. Stewart, Ottawa, Canada, p.A4210


The information contained in this program is up to date as of March 9, 2017.

For the most current session information, please visit the online program itinerary.


P820 Small Extracellular Vesicles Are Reduced in Rats with Severe Pulmonary Hypertension/D. Lachant, A. Light, D. Haight, R.J. White, Rochester, NY, p.A4226

P821 Genetic Background (Mouse Strain) as Determinant of the Role of Resistin Like Molecule in the Response to Pulmonary Exposure with Antigen and Urban Fine Dust/ G. Grunig, S.-H. Park, Tuxedo, NY, p.A4227


P825 ASK-1 Inhibition Reverses Established Disease in a SUGEN/Hypoxic Rat Model of Pulmonary Hypertension/K.S. Wilson, H. Buist, G. Jayasekera, J. Liles, G.R. Budas, S. Fairfax, C. Hughes, M. Nilsen, C. Church, M. MacLean, A. Peacock, D. Welsh, Glasgow, United Kingdom, p.A4231

B72 OTHERS HERE WITH US: CLINICAL FEATURES OF PULMONARY VASCULAR DISEASE I
9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area G, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: S. Mathai, MD, MHS, Baltimore, MD


P751 Discordance Between Pulmonary Capillary Wedge Pressure (PCWP) and Left Ventricular End-Diastolic Pressure (LVEDP): A Challenge in Diagnosing Pulmonary Artery Hypertension (PAH)/A.K. Chen, I. Ismail-Sayed, S. Penopulo, D. Bandyopadhyay, Danville, PA, p.A4233

P752 yEaRNA-RV: Pilot Study to Evaluate the Utility of Equilibrium Radionuclide Angiography in Pulmonary Arterial Hypertension/A. Light, M. Mackin, R. Schwartz, R.J. White, Rochester, NY, p.A4234

P753 Hormonal and Reproductive History in Female Patients with Pulmonary Arterial Hypertension (PAH) Group 1 and Pulmonary Hypertension (PH) Group 2 Disease/Y. Kate, I.R. Preston, N.S. Hill, K.E. Roberts, Boston, MA, p.A4235

P754 SHAPE Submaximal Exercise Testing in Pulmonary Arterial Versus Pulmonary Venous Hypertension/E. Batchelor, A. Ortega, F. Torres, K. Chin, S. Bartolome, Dallas, TX, p.A4236

P755 Blood Pressure Response to the 6-Minute Walk Test (6MWT) in Group 1 and Group 2 Pulmonary Hypertension/D. Narayanan, Y. Kate, I.R. Preston, N.S. Hill, K.E. Roberts, Boston, MA, p.A4237


B73  PULMONARY REHABILITATION IN COPD

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER
Area D, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator:  R. ZuWallack, MD, Hartford, CT


P451 Portable Positive Pressure Device to Relieve Dyspnea After Exercise in COPD Patients: A Pilot Study/W. Hardy, A. Cropp, D. Laman, J. Jasko, P. Nisha, Murrysville, PA, p.A4267

P452 Feasibility of Home-Based Pulmonary Rehabilitation in Patients with COPD/J.P. Hoult, K.M. Kramer, S. Seifert, R. Benzo, Rochester, MN, p.A4268

Facilitator:  F. Cortopassi, PT, RPFT, MBA, New Haven, CT

P453 Physical Activity, Systemic Inflammation, and Cardiovascular Disease in COPD-OSA/R. Goldstein, C. Fitzgibbons, D.J. Gottlieb, M.L. Moy, Boston, MA, p.A4269

P454 Active for Life with COPD: Preliminary Study/J.L. Larson, M.K. Han, E. McAuley, Ann Arbor, MI, p.A4270

P455 Do the Cardiac Neuroautonomic Adjustments Reflect Limitation in Activities of Daily Living in Patients with Chronic Obstructive Pulmonary Disease?/A.G. Agnoletto, E.Z. Kabbach, C.I. Monteiro, R. Cabiddu, J.F. Barbosa, A. Borghi-Silva, R.G. Mendes, Sao Carlos, Brazil, p.A4271


Facilitator:  E.N. Schachter, MD, New York, NY


P458 Can the Results of a Pre-Rehabilitation Cardiopulmonary Exercise Test Predict the Outcomes of a Pulmonary Rehabilitation Program in Chronic Obstructive Pulmonary Disease?/D. Nieri, G. Corona, G. De Cusati, R. Vargiu, M.A. Roggi, S. Antonelli, S. Santerini, M. Pedreschi, B. Vagaggini, P. Paggiaro, Pisa, Italy, p.A4274

B74  PULMONARY REHABILITATION FOR NON-COPD DIAGNOSES

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER
Area B, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator:  D. Brooks, PhD, Toronto, Canada

P163 The Relation of Functional Mobility to Pulmonary Function, Respiratory Muscle Strength, Functional Exercise Capacity, Quality of Life and Disease Severity in Patients with Chronic Heart Failure/B. Naci, R. Demir, Z. Yigit, H.N. Gurses, Istanbul, Turkey, p.A4278


P166 Preoperative Exercise Training for Patients with Non-Small Cell Lung Cancer: A Cochrane Systematic Review/C.L. Granger, V. Cavalheri, Parkville, Australia, p.A4281

P167 Oxygen Requirements and Relationship to Exercise Capacity and Aerobic Training in Advanced Interstitial Lung Disease/L. Wickerson, D. Brooks, D. Reid, J. Granton, L.G. Singer, S. Mathur, Toronto, Canada, p.A4282

Effects of Hypertonic Saline on Sputum Clearance in Patients with Bronchiectasis

A Systematic Review and Meta-Analyses of Airflow for the Relief of Chronic Refractory Breathlessness in People with Advanced Cardio-Respiratory Diseases and Mild Hypoxaemia

Whole Body Vibration Improves Distance Walked and Muscle Strength in Patients with Chronic Kidney Disease: A Randomized Controlled Trial

The information contained in this program is up to date as of March 9, 2017.

For the most current session information, please visit the online program itinerary.
P203 Inhibition of Fibrinolytic Activity and Fibrin Deposition Affect Activation of Peripheral Brain-Derived Neurotrophic Factor (BDNF)/G. Florova, R. Idell, R. Girard, T. Gaidenko, M. Chamiso, K. Koenig, S. Idell, A. Komissarov, Tyler, TX, p.A4305

P204 A Novel Cell Culture Device to Study the Cross-Talk Between Cells Simultaneously Exposed to Different Oxygenation Mimicking the Hypoxic Gradients Within Tumors/I. Almendros, N. Campillo, B. Falcons, R. Colina, D. Navajas, R. Farre, Barcelona, Spain, p.A4306


---

THEMATIC POSTER SESSION

B76 DRIVERS OF CELL FATE, SENESCENCE, AND PHENOTYPE

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area C, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: P.J. Wolters, MD, San Francisco, CA

P207 Derivation of Lung Specific Mesenchymal Progenitors from iPSCs/H.A. Marquez, W. Shi, D.N. Kotton, Boston, MA, p.A4307


P211 Alveolar Fibroelastosis in Bronchiolitis Obliterans After Lung and Stem Cell Transplantation: A Comparative Analysis of Morphological and Molecular Motifs/D. Jonigk, Hannover, Germany, p.A4311

Facilitator: B. Ding, PhD, New York, NY


---

THEMATIC POSTER SESSION

B77 ROLE OF EPITHELIAL CELLS IN ACUTE LUNG INJURY

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area C, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: S. Adnot, MD, PhD, Creteil, France


P214 Effect of Calorie Restriction on Lung Stem Cells and Its Interaction with Aging/A.E.M. Hegab, M. Ozaki, T. Betsuyaku, Tokyo, Japan, p.A4314


P217 Deriving Alveolar Type 2 Cells from Pluripotent Stem Cells to Model Surfactant Protein C (SP-C) Mutations In Vitro/K.-D. Alysandratos, M. Serra, S. Mulugeta, M.F. Beers, D.N. Kotton, Boston, MA, p.A4317


P221 Nuclear Receptor REV-ERBα Regulates Cigarette Smoke-Induced Lung Inflammation/I.K. Sundar, M.T. Selii, I. Rahman, Rochester, NY, p.A4321
P232 Lung Epithelial Cells Shed Procoagulant Microvesicles in
Cell-Free Hemoglobin Increases Lung Epithelial Permeability
Tissue Clearing and Light Sheet Microscopy Can Be Used to

P235 c-Jun N-Terminal Kinase-Mediated Activation of Nedd4-2
Drives Hypercapnia-Induced Polyubiquitination and
Endocytosis ENaC in the Alveolar Epithelium/P. Gwozdzinska,
W. Seeger, I. Vadasz, Giessen, Germany, p.A4334

P236 Attenuation of Acute Lung Injury by Upregulating SP-B
Expression Via Pulmonary Epithelial Cell Specific Knockdown
of NAMPT/L. Wu, L.G. Bi, M.N. Nsumu, D.P. Heruth, L.Q. Zhang,
S.Q. Ye, Kansas City, MO, p.A4335

P237 Regulation of p53-Mediated Changes in the uPA-Fibrinolytic
System and in Lung Injury by Loss of Surfactant Protein-C
Expression in Alveolar Epithelial Cells/B. Puthusseri, A.
Marudamuthu, N. Tiwari, V. Gopu, J. Fu, S. Idell, S. Shetty, Tyler,
TX, p.A4336

P238 FBXO17 Regulates Glycogen Synthase Kinase-3β (GSK3β)
Polyubiquitination and Proteasomal Degradation in Lung
Epithelial Cells/T. Suber, J. Wei, A.M. Jacko, J. Zhao, Y. Zhao,
R. Mallampalli, Pittsburgh, PA, p.A4337

P239 CpG DNA Promotes Lysosomal Degradation of the Receptor
for Advanced Glycation End Products (RAGE) Through F Box
Protein FBXO10-Mediated Ubiquitination/J. Evankovich, A.
McKelvey, S. Dunn, T. Lear, B. Chen, R. Mallampalli, Pittsburgh,
PA, p.A4338

P240 CD18-Dependent Adhesion of Mononuclear Cell-Derived
Microparticles Is Essential for Their Proinflammatory Effect on
Lung Epithelial Cells/F. Neri, C. Balia, V. Scalise, R. Pedrinelli, P.
Paggigio, A. Celli, Pisa, Italy, p.A4339

P241 Iron Oxide and Titanium Dioxide Nanoparticles Induce
Changes in Stiffness of Human Lung Cells/I. Almendros, V.R.
Oliveira, J.J. Uriarte, W.A. Zirn, R. Farre, D. Navajas, Barcelona,
Spain, p.A4340

P242 TRIM72/Cav1 Interaction Determines Repair Inflow and
Fibrogenesis Outflow in Pulmonary Fibrosis/X. Cong, N. Nagre,
W. Huang, J. Herrera, J.M. Schreiber, M.A. Clements, L.L.
Wellman, P. Bitterman, R. Hubmayr, Norfolk, VA, p.A4341

P243 Antagonistic Relationship Between Na,K-ATPase αβ
Heterodimers and FXYD5 in the Regulation of the Alveolar
Epithelial Barrier/O. Vinog, E. Tokhtaeva, P. Brazee, P.N. Soni,
A. Yemelyanov, Y. Wen, G. Sashs, J.I. Sznajder, L.A. Dada, Los
Angeles, CA, p.A4342

P244 Improved Expansion of Primary Human Airway Epithelial Cells
Using a Novel Defined and Feeder-Free Medium that Promotes
Maintenance of Their Mucociliary Differentiation Potential in
Later Passages/J. Hou, T. Brown, M.J. Riedel, T.E. Thomas, A.C.
Eaves, S.A. Louis, Vancouver, Canada, p.A4343

P245 Human Epidermal Growth Factor Receptor-2 and 3 Signaling
Implicated in Regulating Alveolar Epithelial Permeability with
Cyclic Stretch/N. Yehya, M.J. Song, G.G. Lawrence, S.S.
Margulies, Philadelphia, PA, p.A4344

P246 Bik Selectively Induces Cell Death Only in Hyperplastic but Not
Resting Airway Cells/Y. A. Mebratu, H.S. Chand, Y. Tesfaigzi,
Albuquerque, NM, p.A4345

P247 Type VI Collagen Regulates Pulmonary Epithelial Cell
Phenotype and Function/J. Mereness, S. Bhattacharya, Q. Wang,
S. Solletti, Y. Ren, R.S. Misra, H. Huyck, A. Howell, U.O.R.M.
Center, G.S. Pryhuber, T.J. Mariani, Rochester, NY, p.A4346


P253 Beta Adrenergic Antagonism Causes Dose Related Ciliary Dysrhythmia in Intact Mammalian Airways/A. Van As, J.D. Cantrell, A.D. Cantrell, J.C. Pezzulo, West Chester, PA, p.A4352

THEMATIC POSTER SESSION
B78 ROLE OF ENDOTHELIAL CELLS IN ACUTE LUNG INJURY
9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area C, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: G. Hu, MD, PhD, Chicago, IL

P255 Group V Secretory Phospholipase A2 Mediates MRSA-Induced Endothelial Permeability and Acute Lung Injury/L. Meliton, H. Wang, Y. Epshstein, E. Letsiou, S.M. Dudek, Chicago, IL, p.A4353


P261 TRPC4 Senses Endoplasmic Reticulum Calcium Depletion and Contributes to Store Operated Calcium Entry/N. Xu, A. Buford, L. Ayers, T. Stevens, Mobile, AL, p.A4359

Facilitator: E.F. Spierker, MD, Palo Alto, CA


P263 The Dynamic Behavior and Role of Neutrophil Entrapment in Pulmonary Microcirculation in Murine Sepsis-Induced ARDS Model: Real-Time Intravital Microscopy Study/ Park, K. Choe, H. Seo, Y. Hwang, E. Song, J. Ahn, P. Kim, Daejeon, Korea, p.A4361


P267 Heparan Sulfate Fragments Directly Protect Pulmonary Microvascular Endothelial Cells Against Extracellular Histone-Induced Injury/Y. Zhang, S.M. Haeger, K.L. Dailey, J.A. Ford, Y. Yang, E.P. Schmidt, Bejing, China, p.A4365


Facilitator: R.S. Knipe, MD, Boston, MA


P271 Intravascular Delivery of Purified Human Focal Adhesion Kinase Protects Against Acute Lung Injury


P273 Elevated AC10 Expression in Pulmonary Microvascular Endothelial Cells Increases Permeability and Decreases Proliferation/W. Pitts, C.-S. Choi, R. KC, S.L. Sayner, Mobile, AL, p.A4371

P274 Barrier Disruptive Versus Barrier Protective Agonists Alter Sodium Bicarbonate Cotransporter Phosphorylation in Pulmonary Microvascular Endothelial Cells/S.L. Sayner, C.-S. Choi, Mobile, AL, p.A4372

P275 Salt-Inducible Kinase Activity Does Not Affect Pulmonary Endothelial Cell Proliferation/N. Xu, T. Stevens, Mobile, AL, p.A4373

Facilitator: A.J. Goodwin, MD, MSCR, Charleston, SC

P276 S.Pneumoniae Induces Endothelial Calcium-Signaling Through Thromboxane A2 Receptor/M. Kiefmann, C. Bornchen, A. Schuster, A. Mecklenburg, F. Gniech, S. Hammerschmidt, R. Kiefmann, Hamburg, Germany, p.A4374


P278 Regulation of Endothelial Barrier Function in Adult and Neonatal Hypoxia Induced Lung Injury/L. Ying, C.M. Alvira, D.N. Cornfield, Stanford, CA, p.A4376


P285 GAT-107, a Novel Ago-PAF of $\alpha_7$ Nicotinic Acetylcholine Receptor, Restores Hyperoxia-Compromised Macrophage Function/A. Gauthier, R. Sitapara, L. Mantell, G. Thakur, Jamaica, NY, p.A4379


Facilitator: C.J. Britto-Leon, MD, New Haven, CT

P288 Endothelial Cell Secreted Macrophage Migration Inhibitory Factor (MIF) Regulates Pericyte Contractility to Decrease Barrier Function/A.S. Pellowe, M. Sauer, R. Liu, M.R. Harris, B. Calderon, Y. Zhang, J.S. Pober, R. Bucala, P.J. Lee, A. Gonzalez, New Haven, CT, p.A4382


P290 Induction of Neutrophil Apoptosis by Bcl-2 Inhibitor Reduces PM-Induced Airway Inflammation/X. Wang, M. Luo, S. Ying, H. Shen, Hangzhou, China, p.A4384

P291 Pre-Activation of Mesenchymal Stromal Cells to Enhance Bacterial Clearance in Septic Lung Injury/E.J. Murphy, Westmeath, Ireland, p.A4385

Facilitator: R.M. Tighe, MD, Durham, NC


P293 Differential Effects of TrxR1 Inhibitors on Glutathione Induction in Murine Lung Macrophages/S. Wall, J.L. Casey, Q. Li, K. Dunigan, R. Li, A.B. Carter, T.E. Tipple, Birmingham, AL, p.A4387


P295 Role of AMP-Activated Protein Kinase in Ethanol-Induced Lipid Accumulation in the Lung/A. Banerjee, F. Romero, D. Schirner, R. Summer, Philadelphia, PA, p.A4389

Facilitator: M. Casalino-Matsuda, PhD, Chicago, IL

P296 Role of Endocytosis in the Response of Pulmonary Macrophages to Oxidized Pulmonary Surfactant/N. Hamel-Augier, M. Talbot, M. Pineault, J. Routhier, E. Jiboville, M.-E. Pare, S. Aubin, M.C. Morissette, Quebec, Canada, p.A4390
P297 Regulatory T Cell Specific Uhrf1 Deficiency Leads to Spontaneous Lymphoproliferative Lung Inflammation/B.D. Singer, K. Helmin, Chicago, IL, p.A4391

P298 Fatty Acid Ethyl Esters Produced by Ethanol Exposure Impair Murine Macrophage Phagocytosis/L. Kaphalia, R. Kakumanu, B.S. Kaphalia, W.J. Calhoun, Galveston, TX, p.A4392


B80-A MECHANISMS AND MODELS OF ACUTE LUNG INJURY

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Area C, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion

12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: B.D. Southern, MD, Cleveland, OH


P304 FTY720 (S)-Phosphonate Protects Against Staphylococcus Aureus-Induced Acute Lung Injury in Mice/H. Wang, L. Wang, L. Meliton, E. Letsiou, V. Natarajan, S.M. Dudek, Chicago, IL, p.A4397


P308 Differential Susceptibilities of Cytochrome P450 (CYP)1a1/1a2 Double Knockout and Cyp1a1/1a2/1b1 Triple Knockout Mice to Hyperoxic Lung Injury In Vivo/B. Moorthy, L. Wang, W. Jiang, X. Couroucli, K. Lingappan, Houston, TX, p.A4401


P310 Modulating MyD88 pre-mRNA Splicing to Treat Inflammatory Lung Diseases/K.R. Davidson, W.J. Janssen, S. Alper, Denver, CO, p.A4403


P312 NOS2-Derived Nitric Oxide Regulates Expression of Surfactant Protein B/J. Guan, R. Baron, Boston, MA, p.A4405

P313 Activation of Unfolded Protein Response in Br2 Inhalation Injury-Induced Pulmonary Fibrosis/A. Ahmad, L. Am, N. Vetel, H. Paiste, M. Carlisle, M. Athar, M. Gorbatyuk, S. Aggarwal, S. Matalon, Birmingham, AL, p.A4406

P314 VEGFR1 Tyrosine Kinase Signaling Activates Bleomycin-Induced Pulmonary Fibrosis/H. Amano, R. Takahashi, M. Shibuya, M. Majima, Sagamihara, Japan, p.A4407

P315 The Molecular Mechanism of Enhanced Protein Arginine Methylation Transferase 1 Stability in Lung Diseases/Y. Lai, J. Li, X. Li, C. Zou, Pittsburgh, PA, p.A4408

P316 Relationship Between Elevated Soluble CD74 and Severity of Experimental and Clinical ALI/ARDS/G. Wu, Y. Sun, K. Wang, B. Zhu, Z. Xia, Shanghai, China, p.A4409


P318 Simultaneous Roles of Pulmonary and Renal Surfactant Protein D on Lung-Kidney Crosstalk in Bacterial Pneumonia-Induced Acute Kidney Injury/G. Wang, J. Du, O. Abdel-Razek, Syracuse, NY, p.A4411


P323 Recruitment of Inflammatory Cells Is Triggered by Lung Extracellular Vesicle-Containing miRNAs in Acid-Induced Acute Lung Injury
H. Lee, D. Zhang, Y. Jin, Boston, MA, p.A4416

P324 Activation of c-Jun/AP-1 Transcription Factor Causes Neutrophilic Lung Inflammation During Loss of WWOX Expression

P325 Alterations of Macrophage Phenotype in Amiodarone-Induced Pulmonary Fibrosis

P326 Decellularized Human Lung Slices as ECM Scaffolds to Study Lung Tissue Regeneration: Effects of Exposure Time


P328 Identification of Paraquat-Induced Lung Injury and Fibrosis in Mice Via Intraperitoneal Injection in Various Dose and Exposure Time/H. Sun, J. Zhang, J. Kang, Q. Liu, P. Huang, L. Jiang, T. Ma, D.A. Schwartz, Nanjing, China, p.A4421


P331 Expression of Tm4sf1 Marks a Novel Alveolar Stem Cell Population Which Expands After Injury to Regenerate the Alveolar Epithelium in Mouse and Human Lung/W. Zacharias, D. Frank, J. Zepp, F. Alkhaleel, M. Morley, E. Morrissey, Philadelphia, PA, p.A4424

P332 Inhibition of Lung Tissue Non-Specific Alkaline Phosphatase Attenuates Influenza-Induced Acute Lung Injury/P. S. Woods, L.M. Doolittle, L.E. Rosas, I.C. Davis, Chicago, IL, p.A4425


Facilitator: M. Sala, MD, Chicago, IL

P1263 An In-Vivo and In-Vitro Analysis of Prostaglandin-Endoperoxide Synthase 2 (Ptgs2) and the Response to Respiratory Syncytial Virus (RSV)/R.M.K.D. Gunasingha, W. Gladwell, O. Yost, S. Kleeberger, Durham, NC, p.A4427

P1264 IRE-1 Signaling as Putative Therapeutic Target to Dampen Lung Injury in Influenza Virus-Induced Pneumonia/C. Schmoldt, I. Shalashova, C. Peteranderl, L. Jankauskaite, A.I. Vazquez Armentariz, S. Pieschka, A. Gunther, S. Herold, Giessen, Germany, p.A4428


Facilitator: R.S. Hagan, MD, PhD, Chapel Hill, NC

B80-C GETTING MODELED: BIOENGINEERING AND COMPUTATIONAL METHODS

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Area E, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: G.N. Maksym, PhD, Halifax, Canada

P558 Simulation Study of High Frequency Oscillation Ventilation (HFOV) by the Use of a 4D Lung Model and Computational Fluid Dynamics (CFD)/H. Kitaoka, Tokyo, Japan, p.A4434

P559 Simulation Study of Nasal High-Flow Oxygen Therapy by the Use of a 4D Lung Model and Computational Fluid Dynamics (CFD)/H. Kitaoka, Tokyo, Japan, p.A4435


Facilitator: J. Choi, PhD, Iowa City, IA


P565 Negative Pressure Inflation Facilitates Pulmonary Acinar Bypass Perfusion in Isolated Rat Lungs/R.L. Conhaim, G.S. Segal, K.E. Watson, Middleton, WI, p.A4441

P566 Non-Newtonian Dynamics of Mucus Transport in Simple Conduits/H. Kumar, B. Mauroy, Auckland, New Zealand, p.A4442

P567 Anatomical Factors Influencing the Collapsing Pressure in Obstructive Sleep Apnea/J. Janczy, T. Woodson, G. Garcia, Milwaukee, WI, p.A4443

B80-D EVERYTHING YOU WANTED TO KNOW ABOUT AIRWAY SMOOTH MUSCLE BUT WERE AFRAID TO ASK

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Area E, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: C.A. Singer, PhD, Reno, NV


P571 The Effects of the β2-Agonist Indacaterol and the Anticholinergic Glycopyrrolate on the Constriction of Large and Small Intrapulmonary Airways in a Guinea Pig Model of COPD/B. Han, A.B. Zuidhof, H. Meurs, H. Maarsingh, M. Schmidt, Groningen, Netherlands, p.A4446

P572 Interactions Between Glycopirrolon and Indacaterol on Cholinergic Neurotransmission and Contractile Response in Bovine Trachealis/M. Baroflio, G. Barisione, V. Brusasco, Genoa, Italy, p.A4447


P574 Male and Female Sex Steroids Lower Guinea Pig Airway Smooth Muscle Tone and Intracellular Ca2+ Basal Levels/ B. Sommer, E. Flores-Soto, J. Reyes-Garcia, A. Carbajal-Garcia, E. Campuzano-Gonzalez, L.M. Montano, Mexico City, Mexico, p.A4449


P576 Changes of Contractile Phenotype in Response to Pro-Proliferative Stimuli in Airway Smooth Muscle Cells/A. Panariti, M. Kuan, T. Sun, M. O’Sullivan, J.G. Martin, Montreal, Canada, p.A4451

Facilitator: T. Tran, PhD, Singapore, Singapore

P577 Impact of Sphingosine Analogs on Airway Smooth Muscle Cell Proliferation and Apoptosis/D.R. Gendron, P. Blais Lecours, A.-M. Lemay, D. Marsolais, Quebec, Canada, p.A4452

P578 ASK1 Inhibition Prevented Mitogen-Induced Human Airway Smooth Muscle Growth in Chronic Obstructive Pulmonary Disease/A. Kota, D. Xenaki, D.A. Deshpande, B.G. Oliver, P. Sharma, Sydney, Australia, p.A4453


B80-E  FROM BENCH TO BEDSIDE: THE RIGHT VENTRICLE, PULMONARY VEESELS, AND THEIR DISORDERS

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER

Area E, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator:  J.E. Bourke, PhD, Clayton, Australia

P583  The Fatty Acid Amide Hydrolase Inhibitor URB597 Activates TRPA1 Ion Channels in Primary Human Airway Smooth Muscle Cells/X. Liu, B. Liu, I.P. Hall, Nottingham, United Kingdom, p.A4458


P585  Heterogeneity of the Airway Smooth Muscle Layer in Asthma/ A. James, J. Elliot, P. Noble, A. Jacques, F. Green, Perth, Australia, p.A4460

P586  The Volume Fraction of Collagen-IV is Increased Within the Airway Smooth Muscle Layer in Chronic Obstructive Pulmonary Disease/J. Elliot, S.-A. Drew, A. Cairncross, P. Noble, A. James, Perth, Australia, p.A4461

P587  Serum from Asthmatic Mice Potentiates the Effects of Tracheal Stromal Cells in Experimental Allergic Asthma/S. Abreu, D. Xisto, J. Kitoko, F.F. Cruz, A. Silva, N. Blanco, T. Oliveira, M. Morales, C.C. Dos Santos, D.J. Weiss, P.R. Rocco, Rio de Janeiro, Brazil, p.A4462

P588  Runx-Related Transcription Factor 2 (RUNX2) Is a Potential Regulator of Connective Tissue Growth Factor (CTGF) in Asthmatic Airway Smooth Muscle/J. Wang, Q. Ge, B.G. Oliver, A. Ashton, L. Dong, J. Burgess, Jinan, China, p.A4463

P589  S100A4 Regulates Airway Smooth Muscle (ASM) Inflammation and Its Transition to Synthetic Phenotype by Acting on ‘Receptors for Advanced Glycation End Products’ (RAGE)/Y. Wu, W. Zhang, S.J. Gunst, Indianapolis, IN, p.A4464

P590  Extracellular Stimuli Regulate Transitions in Airway Smooth Muscle (ASM) Phenotype Through the Differential Activation of Integrin-Linked Kinase (ILK)/PINCH/Parvin (IPP) Complex/Y. Huang, S.J. Gunst, Indianapolis, IN, p.A4465

P591  Regulation of Airway Smooth Muscle Phenotype by Retinoic Acid/F. Chen, R. Krishnan, A. Fine, Boston, MA, p.A4466


P593  Identification of Rare Variants in ASB2 Influencing Susceptibility of Scleroderma-Associated Pulmonary Arterial Hypertension by Exome Sequencing and Network Analysis/Q. Liu, N. Rafaela, M. Boorgula, A.E. Berger, P.M. Hassoun, K.C. Barnes, L. Gao, Baltimore, MD, p.A4469

P594  Histomorphological and Molecular Characterization of Human and Sugen 5416/Hypoxia Induced Plexiform Vasculopathy/L. Magel, Hannover, Germany, p.A4468

P595  Inhibition of miR-21 Suppresses miR-223 in Estrogen-Treated Experimental Pulmonary Hypertension/S. Zhang, P. Yuan, T.-X. Chen, R. Zhang, J.-M. Liu, Z.-C. Jing, Shanghai, China, p.A4473

P596  Inhibition of miR-21 Suppresses miR-223 in Estrogen-Treated Experimental Pulmonary Hypertension/S. Zhang, P. Yuan, T.-X. Chen, R. Zhang, J.-M. Liu, Z.-C. Jing, Shanghai, China, p.A4473


P600  IL-13 Accelerates the Proliferation of Pulmonary Artery Endothelial Cells Via Down-Regulation of miR-424 and miR-503/K. Takagi, T. Matsuyma, H. Matala, K. Kamikawa, T. Kumamoto, M. Watanabe, K. Mizuno, M. Yamakuchi, H. Inoue, Kagoshima City, Japan, p.A4474

Facilitator:  R. Harper, PhD, Adelaide, Australia


Facilitator:  H. Poor, MD, New York, NY

P605  Improvement of Exercise Capacity and Ventilatory Efficiency in Patients with Pulmonary Embolism After Anticoagulant Therapy/J.-M. Liu, D. Huang, J. Guo, L. Wang, W. Yang, Q. Zhao, S. Gong, J. Rong, Shanghai, China, p.A4478

P607 Difference in Exercise Capacity and Ventilatory Efficiency Between Chronic Obstructive Pulmonary Disease Associated Pulmonary Hypertension and Idiopathic Pulmonary Hypertension/J.-M. Liu, H. Liu, J. Guo, Q. Zhao, W. Yang, L. Wang, S. Gong, J. Rong, Shanghai, China, p.A4480


P612 Modified Desaturation Distance Ratio (mDDR) Predicts Prognosis in Patients with Pulmonary Arterial Hypertension/F. Burgos, X. Alisia-Restoy, Y. Torralba Garcia, J.A. Barbera, I. Blanco, Barcelona, Spain, p.A4485

---

**THEMATIC POSTER SESSION**

**B80-F** A TWITCH IN TIME: AIRWAY HYPERRESPONSIVENESS AND COUGH

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Area E, Hall B-C (Middle Building, Lower Level)

**Viewing:** Posters will be on display for entire session.

**Discussion:**
- 11:15-12:00: authors will be present for individual discussion
- 12:00-1:00: authors will be present for discussion with assigned facilitators

**Facilitator:** W. Mitzner, PhD, Baltimore, MD


---

**THEMATIC POSTER SESSION**

**B80-G** CARDIOVASCULAR DISEASE AND SDB

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Area H, Hall B-C (Middle Building, Lower Level)

**Viewing:** Posters will be on display for entire session.

**Discussion:**
- 11:15-12:00: authors will be present for individual discussion
- 12:00-1:00: authors will be present for discussion with assigned facilitators
Facilitators: Y. Peker, PhD, Istanbul, Turkey  
N.A. Shah, MD, MPH, New York, NY

P841 Association of Improvement in Heart Function with Changes in Sleep Parameters in Chronic Heart Failure Patients Treated for Sleep Apnea/K. Murase, K. Ono, T. Yoneda, M. Akao, S. MiKi, R. Nohara, M. Mishima, T. Kimura, D.P. White, K. Chin, Kyoto, Japan, p.A4500


P844 No Mortality Effects of Adaptive Servoventilation Therapy to Treat Central Sleep Apnea in Heart Failure Patients with Reduced Ejection Fraction. The Bad Oeynhausen ASV-Registry/O. Oldenburg, B. Wellmann, A. Buchholz, T. Bitter, H. Fox, D. Horstkotte, K. Wegscheider, Bad Oeynhausen, Germany, p.A4503

P845 Older Veterans with OSA and Hypertension Demonstrate Adverse Hemodynamic Profile/J. Hussain, I. Imayama, S. Bekkam, M. Tam, B. Prasad, Chicago, IL, p.A4504

P846 Abnormal Respiratory Pattern During Radiofrequency Catheter Ablation in Patients with Atrial Fibrillation/Y. Tomita, T. Kasai, K. Narui, Tokyo, Japan, p.A4505


Facilitators: L.F. Drager, MD, Sao Paulo, Brazil  
V. Kundel, MD, New York, NY


P849 Cortical Arousal Role in Cardiovascular Risk Assessment of Patients with Obstructive Sleep Apnea and Resistant Hypertension/O.C. Deleau, V.C. Cosei, A.-M. Zaharie, A.-E. Malaut, F.D. Mihaltan, Bucharest, Romania, p.A4508


P851 Characteristics of Carotid Artery Elasticity and Stiffness in Young Male Patients with Arterial Hypertension, Obesity and Severe Sleep Apnea Syndrome/E. Elfmova, M. Tripolen, T. Balakhonova, O. Pogorelova, A. Lifvin, A. Rogoz, I. Chazova, Moscow, Russian Federation, p.A4510


Facilitators: G. Lorenzi-Filho, MD, Sao Paulo, Brazil  
F. Barbe, MD, Lleida, Spain


P860 Hypoxia Inducible Factor-1 Plays a Major Role in Cardiomyocyte Calcium Homeostasis and Sensitivity to Myocardial Ischemia-Reperfusion After Chronic Intermittent Hypoxia/E. Belaidi, S. Moulin, J.L. Pepin, C. Arnaud, D. Godin-Riboud, Grenoble, France, p.A4519
THEMATIC POSTER SESSION

B80-H  METABOLIC CONSEQUENCES OF SDB
9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER
Area H, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators
Facilitators: M. Kohler, MD, Zurich, Switzerland
O. Mesarwi, MD, LA Jolla, CA


P865 Circulating Exosomal miR21 and miR320 in Obstructive Sleep Apnea/D. Sanz-Rubio, I. Martin-Burriel, V. Gil, J.M. Marin, Zaragoza, Spain, p.A4523


P867 The Association Between the Level of Glycemic Control with Incidence Risk of OSA in Patients with Type 2 Diabetes Mellitus/Y. Arliny, Banda Aceh, Indonesia, p.A4525

Facilitators: E. Tasali, MD, Chicago, IL
S. Pramsohler, MSc, PhD, Bad Aibling, Germany

P868 Relationship Between Serum Osteoprotegerin Levels and Bone Mineral Density Measurements in Patients with Obstructive Sleep Apnea Syndrome/Y. Intepe, E. Yildirim, M. Korkmaz, S. Karacavus, A.Y. Gocmen, Yozgur, Turkey, p.A4526


THEMATIC POSTER SESSION

B80-I  NEUROCOGNITIVE FUNCTION AND SLEEP DISORDERED BREATHING
9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER
Area H, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators
Facilitators: I. Ayappa, PhD, New York, NY
C.M. Hoyos, MPH, PhD, Forestville, Australia/
H.K. Yaggi, MD, MPH, New Haven, CT/
H. Sharifi, MD, Stanford, CA

P872 The Association Between Nocturnal Hypoxemia, Subjective Sleepiness, and Glycemic Control in Patients with Type 2 Diabetes Mellitus/R.N. Aurora, N.M. Punjabi, Baltimore, MD, p.A4530


P874 Gestational Diabetes and Inflammation: The Exacerbating Role of OSA/S. Amin, M. Bublitz, S. Martin, L. Larson, M. Carpenter, S. De La Monte, G. Bourjeily, Providence, RI, p.A4532


P877 Risk of Sleep Disorders in Patients with Type 1 Diabetes Mellitus: A Nationwide Population-Based Cohort Study/C.-H. Li, W.-C. Chen, C.-Y. Chen, Y.-C. Shen, T.-C. Shen, Taichung, Taiwan, p.A4535


For the most current session information, please visit the online program itinerary.
B80-J INTERVENTIONAL PULMONOLOGY IN THORACIC ONCOLOGY

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER
Area N, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

THEMATIC POSTER SESSION

<table>
<thead>
<tr>
<th>Posters</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>P882 Obstructive Sleep Apnea Increased Accident Risk Among Taxi Drivers in Jakarta, Indonesia/A.D. Susanto, B. Hisyam, L.S. Maurits, F. Yunus, Jakarta, Indonesia, p.A4538</td>
<td></td>
</tr>
<tr>
<td>P884 Inflammatory Markers Are Associated with Obstructive Sleep Apnea (OSA) in Parkinson’s Disease (PD)/D. Ho-Wo-Cheong, M. O’Sullivan, V.P. Mery, A.L. Lafontaine, A. Robinson, P. Gros, J. Martin, A. Benedetti, R.J. Kimoff, M. Kaminska, Montreal, Canada, p.A4540</td>
<td></td>
</tr>
<tr>
<td>P886 Impaired Decision Making Is Related with Memory Deficits in Obstructive Sleep Apnea Patients/H. Yuan, L. Mu, S. Hua, L. Peng, Changchun, China, p.A4542</td>
<td></td>
</tr>
<tr>
<td>P889 The Cyclic Behavior of Microvascular Hemodynamics During Sleep in Patients with Obstructive Sleep Apnea Syndrome/G. Cotta Ramusino, C. Gregori-Pla, P. Zirak, I. Blanco, A.M. Fortuna Gutierrez, A. Mola Ausiro, T. Durduran, M. Mayos Perez, Barcelona, Spain, p.A4545</td>
<td></td>
</tr>
<tr>
<td>P891 Damage of Inner Ear Sensory Hair Cells Via Mitochondrial Damage of Inner Ear Sensory Hair Cells Via Mitochondrial Damage of Inner Ear Sensory Hair Cells Via Mitochondrial Damage of Inner Ear Sensory Hair Cells Via Mitochondrial</td>
<td>p.A4547</td>
</tr>
<tr>
<td>Facilitator: J.A. Akulian, MD, MPH, Chapel Hill, NC</td>
<td></td>
</tr>
<tr>
<td>P1459 EBUS TBNB for Clarification of PET Positive FDG Avid Intrathoracic Lymph Nodes in a Tuberculosis Endemic Setting/U. Shah, N. Kishore, N. Dayal, New Delhi, India, p.A4550</td>
<td></td>
</tr>
<tr>
<td>P1462 Yield and Complications of Endobronchial Ultrasound Using the ExpectTM Endobronchial Ultrasound Needle/K. Diab, F.-M. Kong, E. Bendaly, Indianapolis, IN, p.A4553</td>
<td></td>
</tr>
<tr>
<td>P1463 Endobronchial Ultrasound-Transbronchial Needle Aspiration (EBUS-TBNA) and Endoscopic Ultrasound-Fine Needle Aspiration (EUS-FNA) for Investigation of Mediastinal Lymphadenopathy in a UK District General Hospital/C. Nimmo, J. Gates, A. Kumar, R. Banka, Ilford, United Kingdom, p.A4554</td>
<td></td>
</tr>
<tr>
<td>Facilitator: J.A. Akulian, MD, MPH, Chapel Hill, NC</td>
<td></td>
</tr>
<tr>
<td>P1469 The First 100 Patients: A Tertiary Care Center’s Experience with EBUS-TBNA/B. Lindgren, M. Garabedian, Los Angeles, CA, p.A4560</td>
<td></td>
</tr>
</tbody>
</table>

P1471 Endobronchial Ultrasound as a Diagnostics Modality for Lung Cancer, Tuberculosis, Sarcoidosis and Lymphoma/P.S. Pandya, O. Kon, W. Lynn, R. Mathur, London, United Kingdom, p.A4562


Facilitator: A.A. Balekian, MD, MS, Los Angeles, CA


Facilitator: A.A. Balekian, MD, MS, Los Angeles, CA


P1479 Clinical Outcomes in Patients with Non-Small-Cell Lung Cancer Admitted to the ICU: A Retrospective Study/A. Jazieh, Y.M. Arabi, Riyadh, Saudi Arabia, p.A4580


P1482 Photodynamic Therapy for Peripheral Lung Cancers Using Composite-Type Optical Fiberscope of 1.0 mm in Diameter/J. Usuda, Tokyo, Japan, p.A7637


P1485 Physical Activity Behaviour After a Diagnosis of Lung Cancer Differs Between Countries: An Observational Cohort Study/ J. Ni, L. Denehy, J. Feng, L. Xu, Y. Wu, C. Granger, Nantong, City, China, p.A4576


P1489 Efficacy of Epidermal Growth Factor Receptor- Tyrosine Kinase Inhibitors on Non- Small Cell Lung Cancer Harboring Rare EGFR Mutations/L.-C. Chang, K.-Y. Chen, J.-Y. Shih, Taipei, Taiwan, p.A4578

P1490 Impact of Mild to Moderate COPD on Prognosis and Feasibility for Chemotherapy in Patients with Lung Cancer/I. Hirama, K. Kido, Tokyo, Japan, p.A4581

P1491 Association Between Exercise Tolerance and Patient-Reported Outcomes in Lung Cancer Survivors/D. Ha, A.L. Ries, M.M. Fuster, La Jolla, CA, p.A4579


Facilitator: A.A. Balekian, MD, MS, Los Angeles, CA
P1496 Study Evaluating Single-Center Retrospective Enteral Nutrition on the Survival of NSCLC Patients with Stage 3 or 4/A.
Bouterfas, M. Patout, B. Melloni, Limoges, France, p.A4584


P1499 Renal Toxicity in Elderly Patients After Cisplatin-Based Chemotherapy Using the Short Hydration Method/Y. Ito, T. Niwa, A. Tsuchida, Y. Matsuo, C. Komaki, Gifu, Japan, p.A4587


P1501 Clinical Response to Crizotinib as a 1st and 2nd Line Therapy in ALK Positive Lung Cancer in an Indian Population/A.M. Bamania, D.S. Sahni, A. Mohan, P.S. Malik, K. Madan, V. Hadda, G. Khilnani, R. Guleria, New Delhi, India, p.A4589


P1504 Primary Lung Cancer - a Clinicopathological Study from India/D. Bhattacharya, S. Kakar, New Delhi, India, p.A4592

P1505 Implantation of Radioactive Iodine125 Seed in Relapsed Resistant Adenoid Cystic Carcinoma of Lung/Y. Xiong, Q. Li, Shanghai, China, p.A4593


P1509 Long Term Results of VATS-SP Lobectomy for Lung Cancer/R. Ferreira, A. Sena, C. Carvalheiro, J. Cruz, Lisbon, Portugal, p.A4597

P1510 Quantitative Assessment of Ercrator Spinae Predict Mortality and Hospital Length of Stay After Lobectomy/K. Harris, C. Roche, S. Yendamuri, J. Kamysh, S. Singh Dhillon, Valhalla, NY, p.A4598

P1511 Pericardial Window for Malignant Pericardial Effusion with Lung Cancer Have Worse Long-Term Outcomes than Other Cancers/R.J. Chen, T.-C. Shen, Z. Hashmi, Indianapolis, IN, p.A4599

Facilitator: M.M. Wahidi, MD, MBA, Durham, NC

P1512 Characterization of Lung Nodules in Head and Neck Cancer/A. Conterato, A. Belanger, B. Chera, J.A. Akulian, Chapel Hill, NC, p.A4600

P1513 A Research About Minimally Invasive Thoracolaparoscopic Esophagogastrostomy in Chest (408 Cases Reports)/Y. Liu, K. Fan, B. Yang, Beijing, China, p.A4601


P1515 Time to Treatment Outcomes from a Dedicated Pulmonary Nodule Clinic/V.K. Holden, S.R. Wappel, A.C. Verceles, J. Deepak, Baltimore, MD, p.A4603


P1517 An Interdisciplinary Lung Cancer Clinic with Respirologists and Oncologists: A Quality Improvement Pilot Project to Decrease Time to Oncology Assessment and Treatment for Patients with a New Diagnosis of Lung Cancer/G. Digby, H.M. Vaid, R. Selvam, N. Bhardwaj, S. Sandhu, S. Edmunds, E. Brown, A. Robinson, Kingston, Canada, p.A4605

B80-L GENERAL THORACIC ONCOLOGY

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area N, Hall B-C (Middle Building, Lower Level)

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: L.M. Kamman, MD, St. Paul, MN
P. Lee, MBBS, PhD, Singapore, Singapore

P1520 Correlation of EGFR Mutation Status to Venous Thromboembolism in Patients with Lung Adenocarcinoma/H. Shahzad, D. Datta, Farmington, CT, p.A4807


Facilitator: W.A. Bulman, MD, New York, NY


P1527 Clinical and Misdiagnosed Analysis of Primary Pulmonary Lymphoma: A Retrospective Study/X.Y. Huang, D. Yao, L.X. Wang, Wenzhou, China, p.A4614


Facilitator: G.L. Narsavage, PhD, MSN, RN, APRN, Columbia, SC


P1534 Late Presentation of Lung Cancer in the Developing World and the Unique Challenges We Face in Managing this Disease: Assessment of Quality of Life (QOL), Performance Status (PS) and Their Correlation with Staging at the Time of Diagnosis/A. Khanna, Delhi, India, p.A7638

B80-M IMAGING IN THORACIC ONCOLOGY

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area N, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: C.M. Kinsey, MD, MPH, Burlington, VT

P1535 An Audit of CT Chest Reports and Their Potential Impact on the Workup of Patients with Suspected Lung Cancer/A. Weinstock, C. Savard, A.V. Gonzalez, Montreal, Canada, p.A4621


P1538 All Clinical Stage I Non-Small Cell Lung Cancer Patients Need Brain Imaging/T. Ando, H. Kage, M. Saito, Y. Amano, Y. Goto, T. Nagase, Tokyo, Japan, p.A4624

Facilitator: G.L. Narsavage, PhD, MSN, RN, APRN, Columbia, SC
Facilitator: T. Harkin, MD, New York, NY

P1539 Imaging Hemoptysis: Normal Computed Tomography Has High Negative Predictive Value for Lung Cancer/

P1540 Accuracy of FDG-PET to Diagnose Lung Cancer in Northwest Ohio/
N. Kozodoy, A. Flora, J.C. Willey, Toledo, OH, p.A4626

P1541 Can PET/CT Predict the Diagnostic Yield of Ultrasound-Guided Transthoracic FNA?

Facilitator: V.S. Nair, MD, Stanford, CA

P1542 Evaluate the Utility of the Computed Bioconductance Measurement in the Diagnosis of Lung Cancer/

P1543 Computed Tomography (CT) and Photon Emission Tomography (PET) Findings and Endobronchial Ultrasound (EBUS) Fine Needle Aspiration (FNA) Results in an Area with Endemic Histoplasmosis/
A. Flora, N. Kozodoy, F. Netry, J. Willey, Toledo, OH, p.A4629

P1544 Effects of Incidental Coronary Artery Calcification Visualized During Lung Cancer Screening on Cardiovascular Risk Prediction/
M. Pirzadeh, A. Ghosh, K. Sloan, A.J. Walkey, Boston, MA, p.A7639

The annual ATS Women’s Forum recognizes the achievements and supports the advancement of women in pulmonary, critical care, and sleep medicine and research. We are pleased to have Redonda Miller, MD, MBA, of The Johns Hopkins Hospital, as our speaker. In May, 2016 Dr. Miller became the hospital’s eleventh president and the first woman to hold the position in the hospital’s 127-year history. She has a long history with Johns Hopkins starting with earning her medical degree there. While at Hopkins’ Department of Medicine, Dr. Miller focused her academic and clinical career on medical education and women’s health. She will discuss issues that are relevant to female medical professionals followed by a question and answer period.

In addition, the 2017 Elizabeth A. Rich, MD Award, which honors the memory and work of Elizabeth Rich, MD, will be presented to a female ATS member. The awardee is given to a woman who has made significant achievements in the practice or science of pulmonary, critical care, or sleep medicine; demonstrated leadership in her field; and has shown dedicated mentorship of junior colleagues. The 2017 award recipient is Zea Borok, MD, Professor Department of Medicine, Ralph Edgington Chair, Chief Division of Pulmonary Critical Care and Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA. Dr. Borok will also address the audience.

The forum provides a valuable opportunity for women to meet new colleagues and ATS leaders. Men are also welcome to attend the forum. Attendees will find value in the inspirational messages and career insights the speakers share as well as vibrant networking opportunities.

The forum is organized and presented by the ATS Membership Committee, and will be hosted by Yolanda Mageto, MD, MPH, chair of the committee.

Conference badges are required for admission.

Space is limited and admittance is on a first-come, first-served basis. There is no additional fee. A plated lunch will be served.
**WS3  MEDICAL SIMULATION TO IMPROVE ICU SAFETY**

**Registration Fee:** $75 (includes box lunch)

Attendance is limited. Pre-registration is required.

Assemblies on Critical Care; Behavioral Science and Health Services Research; Nursing

**11:45 a.m. - 1:15 p.m.  MARRIOTT MARQUIS WASHINGTON**

Archives (Level M4)

**Target Audience**

Nurses, physicians, respiratory therapists, simulation technicians and other medical educators who train teams of interprofessional groups related to critical care (code teams, rapid response teams, ICU teams) and/or those nurses, physicians, respiratory therapists, simulation technicians and other medical educators who train teams of interprofessional groups related to critical care (code teams, rapid response teams, ICU teams) and/or those who assess competence of critical care providers (physicians, nurses, mid-level practitioners) to perform critical care procedures.

**Objectives**

At the conclusion of this session, the participant will be able to:

- recognize the simulation-based educational platforms that can be used to improve ICU safety;
- apply team debriefing concepts to effectively train interdisciplinary critical care teams;
- use simulation to implement a deliberate practice model and a testing process to establish competence prior to performance of critical care procedures.

This workshop will explore the concepts of simulation-based medical education (SBME) as related to ICU safety, specifically interprofessional education (IPE) also known as team training, as well as deliberate practice and assessment of competence to perform critical care procedures. We will start the workshop reviewing these concepts, the data regarding these practices with respect to ICU safety will and areas of uncertainty. We will then break into small groups led by facilitators so that each group can practice debriefing interprofessional critical care teams as well as develop a deliberate practice model and competency for procedural training relevant to their practice at their home institution.

**Chairing:**

N. Seam, MD, Bethesda, MD
N. Knudsen, MD, Durham, NC

**11:45**  Simulation and ICU Safety
N. Seam, MD, Bethesda, MD

**12:00**  Practical Tips to Effective Debriefing
G. Ng, MS, CNM, RNC-OB, C-EFM, New York, NY

**12:10**  Practicum: Debriefing Critical Care Teams in Simulation
G. Ng, MS, CNM, RNC-OB, C-EFM, New York, NY
N. Knudsen, MD, Durham, NC

**12:40**  Practicum: Competency for Critical Care Procedures
J. Mikita, MD, Bethesda, MD
N. Seam, MD, Bethesda, MD

**1:10**  Conclusions/Next Steps
N. Knudsen, MD, Durham, NC

---

**WS4  CAREER ADVANCEMENT FOR CLINICIAN EDUCATORS: FOSTERING LEADERSHIP, SCHOLARSHIP AND OPPORTUNITIES FOR SUCCESS**

**This Forum is part of the ATS initiative to offer program specifically geared toward the professional development of trainees, fellows and students to aid in the pursuit of successful careers in pulmonary, critical care and sleep medicine.**

Pre-registration is required. Attendance is limited. There is no additional fee.

Assembly on Behavioral Science and Health Services Research; Members in Transition and Training Committee; Education Committee; Section on Medical Education

**11:45 a.m. - 1:15 p.m.  MARRIOTT MARQUIS WASHINGTON**

Capitol/Congress (Level M4)

**Target Audience**

Trainees and junior faculty interested in careers as clinician educators although all clinician educators are likely to benefit from this session.

**Objectives**

At the conclusion of this session, the participant will be able to:

- identify opportunities for scholarship and leadership in medical education locally, regionally and nationally;
- better understand existing career opportunities and strategies for successful acquisition of a job as a clinician educator;
- describe opportunities for production of scholarly work as a clinician educator.

During this interactive session, participants will have the opportunity to hear from successful, nationally recognized clinician educators in pulmonary and critical care medicine regarding career pathways in the field. The focus will be on career development and job attainment. Topics will include developing a clinical niche, scholarly productivity and finding opportunities for collaboration and leadership locally, regionally and nationally through organizations like the ATS.

**Chairing:**

S. Kassutto, MD, Philadelphia, PA
T.S. Wang, MD, Los Angeles, CA

**11:45**  Introduction and Overview of Clinician Educator Career Pathways in Pulmonary and Critical Care
S. Kassutto, MD, Philadelphia, PA
T.S. Wang, MD, Los Angeles, CA

**11:55**  Job Hunting and Negotiations
J. Hansen-Flaschen, MD, Philadelphia, PA
H. Fessler, MD, Baltimore, MD
J.T. Poston, MD, Chicago, IL
R. Kotloff, MD, Cleveland, OH
J.W. McCallister, MD, Columbus, OH
G. Ng, MS, CNM, RNC-OB, C-EFM, New York, NY
R. Kotloff, MD, Cleveland, OH
G. Tino, MD, Philadelphia, PA
T.S. Wang, MD, Los Angeles, CA
M.M. Hayes, MD, Boston, MA
### CLINICAL

<table>
<thead>
<tr>
<th>Adult Clinical Core Curriculum Working Group</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>11:45 a.m. - 1:15 p.m.</strong> WALTER E. WASHINGTON CONVENTION CENTER</td>
</tr>
<tr>
<td>Hall E (Middle Building, Level 2)</td>
</tr>
</tbody>
</table>

**Target Audience**
Practicing internists and subspecialists in Pulmonary, Critical Care, and Sleep medicine who work in a clinical setting and are currently engaged in maintenance of certification

**Objectives**
At the conclusion of this session, the participant will be able to:
- remain current with medical knowledge relevant to their practice in pulmonary, critical care, and sleep medicine;
- evaluate their understanding of key skills and content areas in pulmonary, critical care and sleep medicine, as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
- support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The ATS Clinical Core Curriculum Symposia focus on a 3-year content cycle of key medical content in the areas of Pulmonary, Critical Care, and Sleep Medicine. The topics are also aligned with corresponding MOC Medical Knowledge modules. This symposium is intended to assist clinicians with staying current with the growth of information relevant to their medical practice, as well as provide an opportunity to evaluate individual knowledge and skills while earning MOC Medical Knowledge points.

**Chairing:** C.L. Channick, MD, Boston, MA

<table>
<thead>
<tr>
<th>11:45</th>
<th>Venothromboembolic Disease (Acute to Chronic)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15</td>
<td>Pleural Disease</td>
</tr>
<tr>
<td>12:45</td>
<td>Smoking Cessation, Electronic Cigarettes, and Other Adjuncts (VAPE)</td>
</tr>
</tbody>
</table>

### CENTERS FOR DISEASE CONTROL AND PREVENTION

<table>
<thead>
<tr>
<th>L11</th>
<th>UPDATE FROM CDC’S TB TRIALS CONSORTIUM AND THE TB EPI STUDIES CONSORTIUM</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>12:15 p.m. - 1:15 p.m.</strong> WALTER E. WASHINGTON CONVENTION CENTER</td>
<td></td>
</tr>
<tr>
<td>Room 143 A-C (Middle Building, Street Level)</td>
<td></td>
</tr>
</tbody>
</table>

**Target Audience**
Clinicians and other health professionals involved in clinical and public health aspects of TB prevention, clinical care and control

**Objectives**
At the conclusion of this session, the participant will be able to:
- utilize better the new diagnostics for LTBI;
- improve the management of LTBI in the private sector;
- describe new findings about shorter treatments for active TB.

CDC’s two TB research consortia are engaged in clinical trials and epidemiologic studies relevant to the clinical and public health management, and prevention of tuberculosis. This session provides updates from both groups.

**Chairing:** P. Nahid, MD, MPH, San Francisco, CA
C. Ho, MD, MPH, Atlanta, GA

| 12:15 | Mining Health Insurance Claims to Examine LTBI Testing, Treatment, and Cure in the Private Sector |
| 12:30 | Updates on IGRA Sub-Studies From the Tuberculosis Epidemiologic Studies Consortium |
| 12:45 | TBTC: Update on Progress Towards Ultra-Short Therapies for Latent TB Infection |
| 1:00  | TBTC: Shorter Therapy for Active Drug-Sensitive Tuberculosis |

### NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) NIH

<table>
<thead>
<tr>
<th>L12</th>
<th>HOW DO RESPIRATORY MICROBES CONTRIBUTE TO ASTHMA?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>12:15 p.m. - 1:15 p.m.</strong> WALTER E. WASHINGTON CONVENTION CENTER</td>
<td></td>
</tr>
<tr>
<td>Room 207 A-B (South Building, Level 2)</td>
<td></td>
</tr>
</tbody>
</table>

**Target Audience**
ATS conference attendees with an interest in clinical asthma, microbiology (virology and microbiome), mechanisms of allergic inflammation, and genetic pathways that regulate risks for asthma and immune response to microbes, and are associated with asthma exacerbations

**Objectives**
At the conclusion of this session, the participant will be able to:
At the conclusion of this session, the participant will be able to:

• Objectives
  - public health specialists
  - Basic and clinical researchers, physicians, pulmonologists and community and preventive strategies are being explored to protect children's health and also at the same time can inform public policy changes to reduce exposure to chemical pollutants in the ambient air.

Chairing: S.S. Nadadur, PhD, Durham, NC
K.C. Nadeau, MD, PhD, Stanford, CA

12:15 • Introduction
S.S. Nadadur, PhD, Durham, NC

12:20 • The Role of Indoor Allergens and Pollutants in Childhood Asthma: Findings from the Johns Hopkins Center for Childhood Asthma in the Urban Environment
G.B. Diette, MD, MHS, Baltimore, MD

12:37 • Multifaceted Effects of Tobacco Smoke on Immunity
K.C. Nadeau, MD, PhD, Stanford, CA

12:54 • Environmental Influences on Child Health Outcomes (ECHO) Program
K. Gray, PhD, Research Triangle Park, NC

L13 • ENVIRONMENTAL INFLUENCES ON CHILDREN'S PULMONARY HEALTH

12:15 p.m. - 1:15 p.m. • WALTER E. WASHINGTON CONVENTION CENTER
Room 204 A-C (South Building, Level 2)

Target Audience
Clinicians in practice, researchers, pharmaceutical industry representatives, international drug regulators

Objectives
At the conclusion of this session, the participant will be able to:

• recognize key aspects of the generic drug regulatory approval process, and how the Office of Generic Drugs (OGD) evaluates bioequivalence for complex inhaled generic drug products, using a weight-of-evidence approach;
• describe product-specific recommendations and guidances for generic drug products recently posted by the Office of Generic Drugs (OGD), with a focus on how these can inform complex orally inhaled and nasal generic drug development;
• articulate how emerging technologies and innovative approaches are being utilized for FDA-funded research, FDA guidance development, and regulatory decision-making.

This session will describe respiratory product development of generic drugs within the U.S., focusing on paths forward to bring safe and effective generic respiratory products to the American public. A general overview will summarize the generic drug approval process, focusing on the weight-of-evidence approach to bioequivalence used. Discussion of recent posted regulatory guidance and product approvals will provide the audience a greater understanding of the generic approval process, and how the use of emerging technologies and outcomes of research projects contribute to scientific understanding for these complex orally inhaled and nasal drug products to inform regulatory actions will be explained.
Chairing: K.A. Witzmann, MD, Silver Spring, MD

12:15 Introduction
K.A. Witzmann, MD, Silver Spring, MD

12:18 Overview of FDA Generic Inhaled Drug Approval Process
M. Luke, MD, PhD, Silver Spring, MD

12:35 Update for Generic Orally Inhaled and Nasal Drug Products
K.A. Witzmann, MD, Silver Spring, MD

12:52 Emerging Technologies for Bioequivalence of Orally Inhaled and Nasal Drug Products
D.S. Conti, PhD, Silver Spring, MD

1:09 Questions and Answers
K.A. Witzmann, MD, Silver Spring, MD

---

**VA CAREER DEVELOPMENT AWARDS: HOW THEY CAN LAUNCH ACADEMIC CAREERS**

12:15 p.m. - 1:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 102 A-B (South Building, Street Level)

**Target Audience**
Young pulmonary investigators; VA-based pulmonary investigators

**Objectives**
At the conclusion of this session, the participant will be able to:
- learn about opportunities to conduct pulmonary research through the VA Career Development Program;
- determine how he/she can transition to an independent research career through participating in period of mentored training in the VA that also will allow him/her to be an academic pulmonary faculty member during the period of training;
- determine eligibility and requirements, as well as how to apply, for a VA Career Development Award.

The VA Career Development Program is intended to attract talented researchers working in areas of particular importance to the health of veterans. The awards provide 3-5 years of full salary support, usually at the Assistant Professor level. The program has a rich history of supporting young investigators who have gone on to become funded VA-based scientists. Awardees participate in an interactive, mentored training program that leads to independence in research. The goal of this session is to increase awareness among pulmonary investigators of this important career development program.

Chairing: J.K. Brown, MD, San Francisco, CA
K. Myrie, PhD, Washington, DC
L. Nici, MD, Providence, RI

12:15 Disease Progression in COPD
P.J. Castaldi, MD, MSc, Boston, MA

12:25 COPD Genetics: From GWAS to Sequencing
M.H. Cho, MD, MPH, Boston, MA

12:35 Paraseptal Emphysema in COPDGene
E. Regan, MD, PhD, Denver, CO

12:45 Defining Disease Axes of COPD
G. Kinney, MPH, PhD, Denver, CO

12:55 Parenchyma in Chest CT Scans
G. Washko, MD, Boston, MA

---

**PREVENTION AND EARLY TREATMENT OF ACUTE LUNG INJURY CLINICAL TRIAL NETWORK (NHLBI PETAL)**

12:15 p.m. - 1:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 147 A-B (Middle Building, Street Level)

**Target Audience**
Practicing critical care and emergency medicine clinicians and clinical researchers would benefit from this session. This includes fellows, students, nurses, and other medical professionals; persons interested in clinical trial design and conduct would also benefit from this session.
Objectives
At the conclusion of this session, the participant will be able to:

- understand the goals and structure of the PETAL network;
- learn new findings about ongoing PETAL trials;
- results may suggest new strategies to manage care of ARDS patients.

This session will provide an update on the NHLBI Prevention and Early Treatment of Acute Lung injury (PETAL) clinical trials network. The session will describe progress in ongoing trials and plans for future trials.

Chairing:
R.G. Brower, MD, Baltimore, MD
A.L. Harabin, PhD, Bethesda, MD
L. Reineck, MD, Bethesda, MD

12:15 PETAL Introduction
R.G. Brower, MD, Baltimore, MD

12:20 Results from LOTUS-FRUIT Trial
M.N. Gong, MD, MS, Bronx, NY

12:35 Results from the VIOLET Trial
A. Ginde, MD, MPH, Aurora, CO

12:50 Update on the ROSE Trial
D. Huang, MD, Pittsburgh, PA

1:00 Introduction to CLOVERS
N. Shapiro, MD, MPH, Boston, MA

L18 NEW INSIGHTS ABOUT SEVERE ASTHMA FROM THE NHLBI SEVERE ASTHMA RESEARCH PROGRAM

12:15 p.m. - 1:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER
Room 152 A-B (Middle Building, Street Level)

Target Audience
Providers of lung health, especially providers who manage patients with asthma; Investigators interested in mechanisms of disease in asthma.

Objectives
At the conclusion of this session, the participant will be able to:

- learn about current deep-phenotyping of PH;
- learn about integrative genomics analyses in PAH;
- learn about right ventriculo-arterial physiologic and morphologic phenotyping.

Pulmonary hypertension (PH) currently has no cure, thus PH research remains a high priority for NHLBI. Recently, NHLBI launched a major multi-center clinical study of PH named: Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics (PVDOMICS). This program includes one data coordinating center (DCC) and six clinical centers that conduct observational clinical studies and data analysis in patients with all types of PH. Currently, the program has completed setting up the protocol and started patient enrollment in 2016. This session will introduce this NHLBI program and present data from the study.

Chairing:
L. Xiao, MD, PhD, Bethesda, MD
N.S. Hill, MD, Boston, MA
G.J. Beck, PhD, Cleveland, OH

12:15 Overview of NHLBI PVDOMICS Program and Initial Progress Report
N.S. Hill, MD, Boston, MA
12:27 PROs in PH: Leveraging PVDOMICS to Understand the Patient Perspective  
S. Mathai, MD, MHS, Baltimore, MD

12:39 Integrative Genomics Analyses in PAH  
M. Aldred, PhD, Cleveland, OH

12:51 Invasive CPET for Deep Physiologic Phenotyping  
D. Systrom, MD, Boston, MA

1:03 Right Ventriculo-Arterial Physiologic and Morphologic Phenotyping in Hispanic and Non-Hispanic Cohorts  
F. Rischard, MD, Tucson, AZ

OCCUPATIONAL SAFETY AND HEALTH ADMINISTRATION, DEPARTMENT OF LABOR

L20 THE OCCUPATIONAL SAFETY AND HEALTH ADMINISTRATION’S RULE ON RESPIRABLE CRYSTALLINE SILICA

12:15 p.m. - 1:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Room 202 B (South Building, Level 2)

Target Audience
Health care professionals who are interested in learning more about OSHA’s respirable crystalline silica rule, especially those who may provide medical examinations required under the rule.

Objectives
At the conclusion of this session, the participant will be able to:

- understand the respirable crystalline silica rule and what is required under that rule such as controls to protect workers and required medical tests;
- recognize workers who are at risk of developing silica-related disease based on jobs they perform, diagnose disease in those workers, and determine when a specialist evaluation is appropriate;
- understand how to counsel workers based on the findings of the medical examination and report the appropriate information to the employer so that the workers’ privacy is not compromised.

Presenters will give an overview of OSHA’s respirable crystalline silica (silica) rule, which affects 2.3 million workers in the United States. Attendees will learn how workers are exposed to silica in various industries and the health risks to those workers – including silicosis, lung cancer, other non-malignant lung disease, and kidney disease. Presenters will summarize the rule requirements including the new permissible exposure limit, exposure assessments, controlling exposures, limiting access to high exposure areas, housekeeping, and worker training. The course will focus on medical surveillance requirements and resources available to health care professionals who will be conducting medical examinations.

Chairing: D. O’Connor, MPH, Washington, DC

12:15 Introduction of Speakers  
D. O’Connor, MPH, Washington, DC

12:17 Health Risks of Silica Exposures and Benefits of New Rule  
S. Schayer, PhD, Washington, DC

12:28 Industries with Silica Exposures and Overview of Rule  
J. Schifano, JD, MPH, Washington, DC

12:39 Overview of Medical Surveillance Requirements of Rule  
A. Iannucci, MS, Washington, DC

12:50 Guidance and Resources for Health Care Professionals  
K. Fagan, MD, MPH, Washington, DC

1:05 Panel Discussion
MP511  CLINICAL ADVANCES IN PLEURAL INFECTION AND IN PNEUMONIA
Y.C.G. Lee, MBChB, PhD, Perth, Australia
G.W. Waterer, MBBS, PhD, MBA, Perth, Australia
Chinatown (Level M3)

MP512  RESPIRATORY SYMPTOM RESEARCH: CONSIDERATIONS FOR PROPOSALS, PUBLICATIONS, AND REVIEWERS
P.M. Meek, PhD, RN, Denver, CO
Mount Vernon Square (Level M3)

MP513  NEW FRONTIERS IN G PROTEIN COUPLED RECEPTORS: RELEVANCE TO ASTHMA AND COPD
D.A. Deshpande, PhD, Philadelphia, PA
Judiciary Square (Level M3)

MP514  HOSPITAL SLEEP MEDICINE: THE ELEPHANT IN THE ROOM
S. Sharma, MD, Philadelphia, PA
LeDroit Park (Level M3)

MP515  TARGETED THERAPY FOR LUNG CANCER: WHAT THE PULMONOLOGIST NEEDS TO KNOW
J.R. Jett, MD, Denver, CO
Shaw (Level M3)

ME2  EDUCATIONAL VIDEOS: WHY AND HOW TO MAKE THEM
Registration Fee: $70 (includes box lunch)
Attendance is limited. Pre-registration is required.
12:15 p.m. - 1:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER
Room 101 (South Building, Street Level)

Target Audience
Anyone interested in making videos to teach patients, medical students, residents, fellows, faculty and/or other medical health professionals.

Objectives
At the conclusion of this session, the participant will be able to:

• create an educational video;
• critically review educational videos;
• choose and use software to make videos.

During this session, you will have the opportunity to create a short educational video under guidance from the facilitators. We will start by providing some hints and tips on best practices for video creation. We will review a few of the frequently used programs for video creation. We will then help participants make a short video in groups using freely available software and a prepared storyboard. You will be able to keep this video and you will have learned the skills necessary to start producing your own educational videos. Participants will need to bring their own laptop.

Speakers: A.S. Clay, MD, Durham, NC
W.G. Carlos, MD, MSCR, Indianapolis, IN
R. Adamson, MBBS, Seattle, WA
M.C. Miles, MD, Winston-Salem, NC
Monday Afternoon, May 22

1:15 p.m. - 2:15 p.m.
VISIT THE EXHIBIT HALL
Take this opportunity between sessions to visit the Exhibit Hall to gain practical knowledge to advance care and research. Exhibitors will be on hand to provide information on pharmaceutical products, medical equipment, publications and research services.

2:15 p.m. - 4:15 p.m.
PRESENTATION OF THE RECOGNITION AWARDS FOR SCIENTIFIC ACCOMPLISHMENTS
WALTER E. WASHINGTON CONVENTION CENTER
Room 204 A-C (South Building, Level 2)
As part of the ATS Respiratory Health Awards, the Recognition Awards for Scientific Accomplishments is given to individuals for outstanding scientific contributions in basic or clinical research to the understanding, prevention and treatment of lung disease. Those considered for the award are recognized for either scientific contributions throughout their careers or for major contributions at a particular point in their careers.
Chairing: A.J. Halayko, PhD, Winnipeg, Canada
A. Malhotra, MD, San Diego, CA
Awardees:
2:15 Progress in Subdividing Asthmatics Into Biologically Defined Subgroups
John V. Fahy, MD, MSC, San Francisco, CA
2:45 Navigating the Complexity of Antigen Presentation in the Lung
Andrew Fontenot, MD, Boulder, CO
3:15 HIV-Associated Lung Disease: From Pneumocystis to the Microbiome
Alison Morris, MD, MS, Pittsburgh, PA
3:45 Grease on the Fire: Regulation of Fibrosis by the Lipid Mediators LPA and S1P
Andrew M. Tager, MD, Boston, MA

The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.
B81  PEDIATRIC YEAR IN REVIEW

Assemblies on Pediatrics; Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Clinical Problems; Environmental, Occupational and Population Health; Respiratory Structure and Function

2:15 p.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER  Ballroom B (South Building, Level 3)

Target Audience
Pediatric pulmonologists; registered nurses; advanced practice nurses; respiratory therapists; virologists; behavioral scientists; epidemiologists

Objectives
At the conclusion of this session, the participant will be able to:

- describe the effect of human rhinovirus on the respiratory and immune systems;
- discuss health disparities in respiratory illnesses and their causes;
- identify the ways environmental exposures affect respiratory health.

The Pediatric Year in Review provides a summary of important research that was published during the preceding year on the topics that were selected for presentation. For this year the session will concentrate on factors not directly related to the respiratory system but with great impact on respiratory health. The areas that will be covered include the impact of the respiratory viruses (especially human rhinovirus); the impact of health disparities; the impact of environmental factors; and the impact of precision medicine (with focus on Cystic Fibrosis). The presentations will be made by well known experts in the respective fields.

Chairing:
A.C. Koumbourlis, MD, MPH, Washington, DC
P.E. Moore, MD, Nashville, TN

2:15  PRO: Blood Eosinophils Are a Useful Biomarker to Guide Therapy in COPD
I. Pavord, MD, Oxford, United Kingdom

2:27  CON: Blood Eosinophils Are NOT a Useful Biomarker to Guide Therapy in COPD
K.F. Rabe, MD, PhD, Grosshansdorf, Germany

2:39  PRO: Long-Term Oxygen Therapy Benefits COPD Patients with Moderate Hypoxemia
L.M. Fabbri, MD, Modena, Italy

2:51  CON: Long-Term Oxygen Therapy Does NOT Benefit COPD Patients with Moderate Hypoxemia
R.A. Wise, MD, Baltimore, MD

3:03  PRO: Inhaled Corticosteroids Are Required to Maximize Reduction in Acute Exacerbations
S.D. Singh, MD, NP, Manchester, United Kingdom

3:15  CON: Inhaled Corticosteroids Are NOT Required to Maximize Reduction in Acute Exacerbations
J.A. Wedzicha, MD, PhD, London, United Kingdom

3:27  PRO: Interventions Can Reduce COPD Readmissions
B. Thomashow, MD, New York, NY

3:39  CON: Interventions Do NOT Reduce COPD Readmissions
J.A. Krishnan, MD, PhD, Chicago, IL

3:51  PRO: Pharmacotherapy Slows Disease Progression in COPD
C. Jenkins, MD, MBBS, Concord, Australia

This session and the International Conference are supported by an educational grant from Vertex Pharmaceuticals, Inc.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

The information contained in this program is up to date as of March 9, 2017. For the most current session information, please visit the online program itinerary.
At the conclusion of this session, the participant will be able to:

**Objectives**

- Respiratory therapists; any provider of lung health; rheumatologists, transplant), registered nurses, advanced practice nurses, students, fellows, physicians (clinical and research oriented, pulmonologists, any provider of lung health

**Target Audience**

Students, fellows, physicians (clinical and research oriented, pulmonologists, rheumatologists, transplants), registered nurses, advanced practice nurses, respiratory therapists; any provider of lung health

**Objectives**

At the conclusion of this session, the participant will be able to:

- Discuss new findings regarding the evolving understanding of interstitial pneumonia with autoimmune features;
- Develop new strategies in the management of patients with CTD-ILD;
- Identify current knowledge gaps in best clinical practices for patients with CCI, and distinguish CCI from other reasons for prolonged ICU care;
- Accurately identify patients with CCI, recognize important subgroups of patients with CCI, and distinguish CCI from other reasons for prolonged ICU care;
- Prognosticate for patients with CCI and incorporate outcomes into high-quality communication during the decision to pursue prolonged life sustaining treatments;
- Identify current knowledge gaps in best clinical practices for patients with CCI, and describe the need for future clinical trials and health services research.

### CLINICAL

#### CLINICAL TOPICS IN PULMONARY MEDICINE

| CME Credits Available: 2 | Nursing Contact Hours Available: 2.4 |

#### B83 A MULTIDISCIPLINARY, CASE-BASED APPROACH TO HOT TOPICS IN CTD-ILD

**Assembly on Clinical Problems**

2:15 p.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Ballroom C (South Building, Level 3)

**Target Audience**

Students, fellows, physicians (clinical and research oriented, pulmonologists, rheumatologists, transplants), registered nurses, advanced practice nurses, respiratory therapists; any provider of lung health

**Objectives**

At the conclusion of this session, the participant will be able to:

- Develop new strategies in the management of patients with CTD-ILD;
- Discuss new findings regarding the evolving understanding of interstitial pneumonia with autoimmune features;
- Describe the risks and benefits of novel therapies impacting the health and quality of life of CTD-ILD patients.

This session will cover complex clinical scenarios encountered in the care of patients with connective tissue associated ILD. We will discuss 3 key issues - the role of ILD pattern in evaluation and treatment, the newly termed condition interstitial pneumonia with autoimmune features (IPAF), and finally the role of therapy beyond conventional immunosuppression (adjunctive treatment, PH specific therapy and the role of transplant). This session will cover timely topics related to CTD-ILD using a case-based format to introduce the topics, which also allows for increased participation by national and international colleagues. The panel discussion at the end will allow for audience participation and a discussion of topics not covered by this session. We will also use an audience response system to gauge practice patterns/beliefs before and after the talks.

**Chairing:** J.S. Lee, MD, Aurora, CO

A. Fischer, MD, Aurora, CO

#### 2:15 Session Introduction

J.S. Lee, MD, Aurora, CO

#### 2:25 Difficult Case 1

K.R. Flaherty, MD, MS, Ann Arbor, MI

J.H. Chung, MD, Chicago, IL

C. Cool, MD, Aurora, CO

#### 2:40 UIP Vs. NSIP - Does It Really Make a Difference in CTD-ILD?

V. Cotin, MD, PhD, Lyon, France

### BEHAVIORAL • CLINICAL • TRANSLATIONAL

#### CRITICAL CARE TRACK

| CME Credits Available: 2 | MOC Points Available: 2 |

#### B84 CHRONIC, PERSISTENT, PROLONGED, AND JUST PLAIN STUCK: INSIGHTS IN CHRONIC CRITICAL ILLNESS

**Assemblies on Critical Care; Behavioral Science and Health Services Research**

2:15 p.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Room 146 A-B (Middle Building, Street Level)

**Target Audience**

Critical care clinicians; clinical and health services researchers who focus on critical care

**Objectives**

At the conclusion of this session, the participant will be able to:

- Accurately identify patients with CCI, recognize important subgroups of patients with CCI, and distinguish CCI from other reasons for prolonged ICU care;
- Prognosticate for patients with CCI and incorporate outcomes into high-quality communication during the decision to pursue prolonged life sustaining treatments;
- Identify current knowledge gaps in best clinical practices for patients with CCI and describe the need for future clinical trials and health services research.

Chronic critical illness (CCI) refers to a group of patients with ongoing organ failure who survive the acute phase of critical illness but remain dependent on intensive care. More and more patients are developing CCI; long-term outcomes in this population are poor, and clinicians feel very uncomfortable about the care of these patients. We aim to identify the cutting edge of the current understanding of CCI and highlight important knowledge and practice gaps that warrant future research and practice change.
The information contained in this program is up to date as of March 9, 2017.
2:15 Extracellular Vesicle Biology, Trafficking, Key Concepts and Functions
J. Lotvall, MD, PhD, Gothenburg, Sweden

2:45 Extracellular Vesicle Transfer from Macrophages to Epithelium Facilitates Homeostasis and Is Deregulated in Inflammatory Disease
M. Peters-Golden, MD, Ann Arbor, MI

3:15 Exosomal miRNA in Chronic Inflammatory Lung Disease
A.M. Wheelock, PhD, Stockholm, Sweden

3:45 Human Mesenchymal Stem Cell Microvesicles for the Treatment of Acute Lung Injury
J. Lee, MD, San Francisco, CA

There will be a 5-minute discussion after each talk.

---

2:15 Lung Tumor Microenvironment: Targeting Tumor Fibroblasts
S.M. Albelda, MD, Philadelphia, PA

2:39 Reprogramming of Tumor Associated Macrophages As a Novel Anti Cancer Therapy
R. Savai, PhD, Bad Nauheim, Germany

3:03 Re-Educating Lung Tumor Microenvironment by Targeting Inflammatory Cytokine Network
S.J. Moghaddam, MD, Houston, TX

3:27 Augmenting Antigen Presentation with Chemokines for Lung Cancer Therapy
S. Dubinett, MD, Los Angeles, CA

3:51 Tumor- Lymphatic Interactions in the Lung Carcinoma Microenvironment
M.M. Fuster, MD, San Diego, CA

There will be a 5-minute discussion after each talk.

---

B87 REPROGRAMMING OF LUNG TUMOR MICROENVIRONMENT: A PATH TO CANCER CARE FOR BETTER THERAPEUTIC BENEFIT

Assemblies on Thoracic Oncology; Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology; Respiratory Structure and Function

Target Audience
Clinicians and scientists who are interested in understanding the tumor microenvironmental (TME) contribution to lung cancer progression and novel therapeutic developments targeting TME in lung cancer would benefit from this symposium.

Objectives
At the conclusion of this session, the participant will be able to:

- understand the tumor promoting/ tumor inhibitory properties of various tumor microenvironmental cells;
- become aware of clinical trials targeting tumor microenvironment in lung cancer;
- gain understanding of novel therapeutic interventions aimed at treating lung cancer by reprogramming “tumor microenvironmental cells”.

Lung cancer is the leading cause of cancer deaths worldwide. Although standard treatment regimens have produced promising results, outcomes for patients with lung cancer are still considered disappointing. Recent data provide evidence that the tumor environment is a leading player in carcinogenesis. Understanding the lung tumor microenvironment (TME) and the complex bidirectional interplay between the tumor and lung microenvironment in lung cancer is essential in designing effective therapies.

---

B88 THE GENE-ENVIRONMENT INTERACTION IN INTERSTITIAL LUNG DISEASE

Assemblies on Environmental, Occupational and Population Health; Clinical Problems

Target Audience
Clinicians caring for patients with Interstitial Lung Disease; basic, translational and population health scientists investigating genetic and/or environmental risk factors for Interstitial Lung Disease

Objectives
At the conclusion of this session, the participant will be able to:

- strengthen their clinical assessment of ILD patients, with improved environmental exposure histories and order genetic testing where available and indicated;
- acknowledge the importance of comprehensive assessments and recognize the knowledge gaps in environmental exposure assessment in ILD;
- contribute to integrated research programs that combine genetic, epigenetic and non-genetic risk factors for ILD, leading to an enhanced understanding of these diseases and ultimately, optimized patient management.

This session will present current state of the art scientific knowledge on the genetic and environmental risk factors for the development and progression of ILD, with a focus on integration of knowledge. Concepts and methods relevant to specific environmental and occupational exposure assessment will be presented. The integration of genetic and non-genetic factors will be discussed as an important tool for future research to enhance our understanding of these complex diseases.
B89 IMMUNOCOMPROMISED HOST PNEUMONIA: EXPANDING RISKS AND NOVEL MANAGEMENT STRATEGIES

Assemblies on Microbiology, Tuberculosis and Pulmonary Infections; Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Clinical Problems; Critical Care; Environmental, Occupational and Population Health; Respiratory Cell and Molecular Biology

2:15 p.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

West Saloon G-I (South Building, Street Level)

Target Audience
Basic, translational or clinical scientist who investigate mechanisms of susceptibility to infection; clinicians caring for patients with immunocompromising conditions or those with respiratory infections; scientists studying host responses to infection and antimicrobial mechanisms; environmental and public health experts who identify populations at risk for pneumonia and sources of infectious threats

Objectives
At the conclusion of this session, the participant will be able to:

• identify risks for pneumonia in populations not conventionally considered immunocompromised;

• gain new strategies to mitigate risks of pneumonia in patients at elevated risk;

• identify mechanisms of host dysfunction in patients with chronic non-pulmonary diseases.

Pneumonias are a leading cause of morbidity in all populations, but exact an extreme toll on patients with immunocompromising conditions. Advances in science and medicine have extended the spectrum of patients identified to be at high risk of pneumonia, both through an expanding array of immunosuppressive agents and regimens and through an increased ability to identify immune dysfunction in patients with chronic medical conditions not previously thought to impair host responses. This session will provide state of the art updates on diagnosis and management of immunocompromised host pneumonia with emphasis on novel mechanisms underlying immune dysfunction.

Chairing:
S.E. Evans, MD, Houston, TX
M.I. Restrepo, MD, MSc, San Antonio, TX
K.A. Crothers, MD, Seattle, WA

2:15 HIV-Associated Pneumonia
K.A. Crothers, MD, Seattle, WA

2:35 Novel Biologic Agents and Pneumonia
J.M. Keane, MD, Dublin, Ireland

2:55 Pneumonia in Patients with Solid Organ Transplants
C.A. Hage, MD, Indianapolis, IN

3:15 Pneumonia in Stem Cell Transplantation and Cancer Chemotherapy
S.E. Evans, MD, Houston, TX

3:35 Pneumonia in the Elderly
M.I. Restrepo, MD, MSc, San Antonio, TX

3:55 Pneumonia in Immunocompromising Metabolic Conditions
S. Aliberti, MD, Milan, Italy

There will be a 5-minute discussion after each talk.
discuss an evidence based approach to the evaluation, treatment and disposition of PE patients in the Emergency Department. Finally, we will present some case vignettes dealing with the previously discussed topics. Using "Audience Participation Devices" we will have the attendees register their management decisions. The cases will then be discussed by the panel and the audience, thus driving home the points made in the earlier discussions.

Chairing: T.M. Bull, MD, Aurora, CO
R.N. Channick, MD, Boston, MA
B. Rivera-Lebron, MD, MS, Pittsburgh, PA

2:15 PRO: IVC Filters Play an Important Role in the Management of PE
V.F. Tapson, MD, West Hollywood, CA

2:30 CON: IVC Filters Should Rarely Be Used in Acute PE
T.M. Bull, MD, Aurora, CO

2:50 PRO: Thrombolytics for Intermediate Risk PE
S. Konstantinides, MD, PhD, Mainz, Germany

3:05 CON: Thrombolytics for Intermediate Risk PE
D. Jimenez, MD, PhD, Madrid, Spain

3:25 PE Out of the ED
J.A. Kline, MD, Indianapolis, IN

3:50 You Make the Call: Real Life Cases of PE. What Would You Do? What Was Actually Done? What Was the Outcome?
R.N. Channick, MD, Boston, MA
B. Rivera-Lebron, MD, MS, Pittsburgh, PA

Translating evidence based care into clinical practice is a difficult and challenging endeavor. With mounting emphasis on high quality evidence based care, increasingly complex interventions and growing interest in funding implementation science efforts, clinicians and researchers alike require a firm grasp of implementation science and its application in health care. This session will introduce participants to implementation science in pulmonary, critical care, sleep, and pediatric medicine. It will provide current examples of implementation science approaches in these settings and provide practical approaches as to how to minimize the gap between theory, research and clinical practice.

Chairing: D.K. Costa, PhD, RN, Ann Arbor, MI
C.H. Weiss, MD, Chicago, IL
M.N. Gong, MD, MS, Bronx, NY

2:15 Quality Improvement on Speed? Defining What Implementation Science Is and Is Not
L.C. Feemster, MD, MSc, Seattle, WA

2:25 Is Implementation Local or Global? How Implementation Science Frameworks Can Guide Research and Practice
D.K. Costa, PhD, RN, Ann Arbor, MI

2:35 Where’s the Bulls Eye? Identifying Targets for Implementation in Pulmonary Rehabilitation
S.J. Singh, PhD, Leicester, United Kingdom

2:50 Implementation During Imperfect Evidence: Lung Cancer Screening
D.E. Midthun, MD, Rochester, MN

3:05 When Guidelines Aren’t Enough: Barriers to Implementing Tuberculosis Guidelines for Children and Adults
P. LoBue, MD, Atlanta, GA

3:20 Beyond Barriers: Strategies to Optimize Implementation in CPAP Treatment Adherence Research
T. Weaver, PhD, RN, Chicago, IL

3:35 Competing Interests? Strategies for Collaborative Implementation with Multiple Stakeholders
K.J. Cummings, MD, MPH, Morgantown, WV

3:50 Show Me the Money! Funding Priorities for Translating Evidence Into Practice
L. Price, PhD, Bethesda, MD

4:00 Questions and Answers: Panel Discussion
D.K. Costa, PhD, RN, Ann Arbor, MI
• learn about the history of AJRCCM and its development to a full respiratory and critical care journal;
• understand some of the best past and current papers in AJRCCM and how they have influenced clinical practice and research;
• learn about key changes in medical publishing and how to prepare for them (e.g., data sharing).

This is the AJRCCM Centenary Symposium to celebrate 100 years of the journal. We would like to show how the journal has evolved through the years and embraced developments in medical research and publishing. We will discuss key papers in respiratory medicine and critical care that have changed medical practice and then review some of the current, recently accepted papers in the journal. The session will end with a special lecture by Dr. Jeff Drazen on developments in medical publishing and how they enhance publications.

Chairing: J.R. Balmes, MD, San Francisco, CA
R. Hubmayr, MD, Rochester, MN

2:15 AJRCCM at 100
J.A. Wedzicha, MD, PhD, London, United Kingdom

2:30 Key Papers That Have Changed Practice: Respiratory
P. Calverley, MBChB, Liverpool, United Kingdom

2:45 Key Papers That Have Changed Practice: Critical Care
L.J. Brochard, MD, Toronto, Canada

3:00 AJRCCM Centenary Papers: COPD
F.J. Martinez, MD, New York, NY

3:15 AJRCCM Centenary Papers: Asthma
F.D. Martinez, MD, Tucson, AZ

3:30 AJRCCM Centenary Papers: Critical Care
B.T. Thompson, MD, Boston, MA

3:45 Recent Developments in Medical Publishing and a Look to the Future
J.M. Drazen, MD, Boston, MA

This session and the International Conference are supported by educational grants from AstraZeneca LP, Teva Pharmaceuticals, Vertex Pharmaceuticals, Inc. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
2:45 Cytomegalovirus Relapsers After Lung Transplantation - at Risk for Other Herpesvirus Disease, Post-Transplant Lymphoproliferative Disease, or Malignancy?/S.A. Winters, J.F. McDyer, H.C. Mannem, Pittsburgh, PA, p.A4640

3:00 Outcomes of Lung Transplantation Using Lungs from Increased Risk Donors Compared to Conventional Risk Donors/F. Siddiqui, C. King, O. Shlobin, M. Bowen, M. Fergoso, S. Nathan, A. Brown, Roanoke, VA, p.A4641


3:30 Need of Dialysis During Index Hospitalization After Lung Transplant Surgery: Independent Predictors and Association with Early and Late Survival/A. Banga, M. Mohanka, L. Mahan, S. Bollineni, J. Mullins, V. Kazza, F. Torres, Dallas, TX, p.A4643

3:45 Change in Body Mass Index (BMI) and Mortality Following Lung Transplantation/E.S. Clausen, C.W. Frankel, S.M. Palmer, P.J. Smith, Durham, NC, p.A4644

4:00 Probe-Based Confocal Laser Endomicroscopy in the Diagnosis of Acute Lung Rejection: Results of a Prospective Multicenter Trial/C.A. Keller, D.A. Arenberg, M. Smith, S. Islam, Jacksonville, FL, p.A7640

---


---

MINI SYMPOSIUM

NEW INSIGHTS FROM WORLD TRADE CENTER PARTICULATE EXPOSURE STUDIES

2:15 p.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Chairing: J.P. Wisnivesky, DrPH, MD, New York, NY
M. Gulati, MD, New Haven, CT
S.E. Hines, MD, MSPH, Baltimore, MD

Oral Presentations


3:15 Estrogen Receptor-Dependent Attenuation of Hypoxia-Induced Changes in the Bone Morphogenetic Protein Pathway of Pulmonary Hypertensive Rats/A. Frump, B. Yakubov, M. Albrecht, J. McClintick, T. Lahm, Indianapolis, IN, p.A4657


B97 FLIPPING THE SWITCH: DETERMINANTS OF FIBROSIS
2:15 p.m. - 4:15 p.m. MARRIOTT MARQUIS WASHINGTON Marquis Ballroom 6 (Level M2)

Chairing: T.M. Maher, MD, MSc, PhD, London, United Kingdom
D. Kass, MD, Pittsburgh, PA
M.N. Ballinger, PhD, Columbus, OH

Oral Presentations


3:15 Lung Mesenchymal Cell-Specific Deletion of Serum Response Factor Is Associated With Improved Survival in Bleomycin-Induced Pulmonary Fibrosis/K. Bernau, E. Torr, J.K. Aoki, N. Sandbo, Madison, WI, p.A4665


MINI SYMPOSIUM
B98 OSA AND CORONARY ARTERY DISEASE: ARE WE SAVE-ING LIVES?
2:15 p.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER Room 152 A-B (Middle Building, Street Level)

Chairing: J.L. Pepin, MD, PhD, Grenoble, France
G. Hamilton, MD, PhD, Clayton, Australia
N.A. Shah, MD, MPH, New York, NY

Oral Presentations


2:45 Cardiovascular Outcomes in Revascularized Coronary Artery Disease Patients With Obstructive Sleep Apnea Syndrome on CPAP Treatment: The Observational Arm of the RICCADSA Cohort/Y. Peker, H. Gintz, C. Eulenburg, E. Thunstrom, Istanbul, Turkey, p.A4671


3:30  Elucidation of Circulating Proteomic Signatures in Obstructive Sleep Apnea and Paroxysmal Atrial Fibrillation/R. Mehra, J. Barnard, D. Van Wagoner, Cleveland, OH, p.A4674


Featured Speaker
4:00  OSA Treatment and CVD: Where Are We Now?/C.M. O’Connor, MD, Falls Church, VA

RAPID: RAPID ABSTRACT POSTER DISCUSSION

B101  ADVANCES IN ASTHMA

2:15 p.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER

Abstract Summaries
2:15-2:45

Poster Viewing/Discussion
2:45-4:15

Chairing: M. Kraft, MD, Tucson, AZ
S. Sharma, MD, MPH, Aurora, CO

601  Asthma Exacerbations and Lung Function Decline in a Pooled Analysis of Adolescents and Adults From Randomized Controlled Trials of Omalizumab/W.G. Busse, B.E. Chipp, K. Rosen, B. Ortiz, T. Haselkorn, B.L. Trzaskoma, B.Q. Lanier, S.J. Szefer, Madison, WI, p.A4676


603  Benralizumab Significantly Reduced Oral Corticosteroid Dosages and Asthma Exacerbation Rates for Patients With Severe, Uncontrolled Asthma: Results of the ZONDA Phase III Trial/P. Nair, S.E. Wenzel, K.-F. Rabe, A. Bourdin, N. Lugogo, P. Kuna, P. Barker, S. Sproule, S. Ponnambali, M. Goldman, Hamilton, Canada, p.A4678


606  A Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of VR942 (UCB4144) in Healthy Subjects and Repeated Doses in Mild Asthmatics/G. Burgess, E. Jones, L. Larsson, F. Morgan, R. Palframan, A. Scrimgeour, M.J. Main, Chippenham, United Kingdom, p.A4681

607  Asthma Symptom Improvements with Benralizumab Are Associated with Improvements in Activity Functions and Quality of Life for Patients with Severe, Uncontrolled Asthma: Results of Pooled Phase III Benralizumab Studies/X. Xu, S. O’Quinn, I. Hirsch, G. Gopalan, Gaithersburg, MD, p.A4682

608  Effect of Mepolizumab on Exacerbations in Asthma Patients with Features Common in COPD/S. Yancey, F.C. Albers, N. Gunsoy, S. Harris, O. Keene, Research Triangle Park, NC, p.A4683


610  Quantitative Analysis of Extent and Lobar Distribution of Air Trapping in Asthmatic Patients Using FACT-Digital Lung™/C. Jin, Z. Liang, L. Zhao, Y. Guo, Xi’an, China, p.A4685


613  Efficacy of Reslizumab in Asthma Patients Eligible for Omalizumab Treatment/M. Humbert, M. Castro, M. McDonald, M. Germarino, Le Kremlin Bicetre, France, p.A4688


617  Among Asthmatic Children, the Major Allele of IFIH1 SNP rs3747517 Is Associated with a Lower Risk of Asthma Exacerbation and Greater Bronchial Epithelial Cell (BEC) Expression of Interferon-Regulated Genes (ISGs) in Response to Ex Vivo RSV Infection/R. James, M.C. Altman, S.R. Reeves, T. Kolstad, S.F. Ziegler, J.S. Debley, Seattle, WA, p.A4692


P177 Longitudinal Follow-Up Data from Enrollees in the COPD Foundation Patient-Powered Research Network: Methods and Outcomes/D.M. Mannino, R. Choate, J. Walsh, R.A. Mulerski, C. Pasquale, W. Clark, E. Malanga, S. Gillespie, M.A. McBurnie, P. Crawford, Lexington, KY, p.A4701


P182 Updated Outcomes for; Hospital Utilization for COPD Patients Enrolled in a Home Based Pulmonary Population Health Program Using Respiratory Therapists in Partnership with a Medicare Advantage Plan/A.H. Greene, Camboro, NC, p.A4706


717 Asthma-COPD Overlap Syndrome (ACOS) and Childhood Asthma Are Risk Factors for Active COPD but Not Disease Progression in the COPDGene Study/L.P. Hayden, M.E. Hardin, J.D. Crapo, E.K. Silverman, C.P. Hersh, Boston, MA, p.A4716

718 Asthma-COPD Overlap and Mortality from Chronic Lower Respiratory Diseases/E. Forno, A. Mendy, T. Niyonsenga, J. Gasana, Pittsburgh, PA, p.A4717

719 Asthma COPD Overlap Syndrome and COPD Are Associated with Higher Mortality Rates in US: Data from the Third National Health and Nutrition Examination Survey (NHANES III)/S. Kumbhare, C.B. Strange, Charleston, SC, p.A4718


721 Co-Morbidities Associated with Asthma-COPD Overlap Syndrome (ACOS) in U.S. Veterans/S. Bujarski, A. Parulekar, A. Spiegelman, A. Sharafkhaneh, N. Hanania, Houston, TX, p.A4720


727 Asthma-COPD Overlap Syndrome (ACOS) and Childhood Asthma Are Risk Factors for Active COPD but Not Disease Progression in the COPDGene Study/L.P. Hayden, M.E. Hardin, J.D. Crapo, E.K. Silverman, C.P. Hersh, Boston, MA, p.A4716

728 Asthma-COPD Overlap and Mortality from Chronic Lower Respiratory Diseases/E. Forno, A. Mendy, T. Niyonsenga, J. Gasana, Pittsburgh, PA, p.A4717

729 Asthma COPD Overlap Syndrome and COPD Are Associated with Higher Mortality Rates in US: Data from the Third National Health and Nutrition Examination Survey (NHANES III)/S. Kumbhare, C.B. Strange, Charleston, SC, p.A4718


731 Co-Morbidities Associated with Asthma-COPD Overlap Syndrome (ACOS) in U.S. Veterans/S. Bujarski, A. Parulekar, A. Spiegelman, A. Sharafkhaneh, N. Hanania, Houston, TX, p.A4720


735 Cognitive Effects of Hypoxemia in Smokers with COPD/L. Garcia-Gomez, V. Noe-Diaz, R.H. Sansoares, A. Ramirez-Venegas, Mexico City, Mexico, p.A4714


737 Asthma-COPD Overlap Syndrome (ACOS) and Childhood Asthma Are Risk Factors for Active COPD but Not Disease Progression in the COPDGene Study/L.P. Hayden, M.E. Hardin, J.D. Crapo, E.K. Silverman, C.P. Hersh, Boston, MA, p.A4716

738 Asthma-COPD Overlap and Mortality from Chronic Lower Respiratory Diseases/E. Forno, A. Mendy, T. Niyonsenga, J. Gasana, Pittsburgh, PA, p.A4717

739 Asthma COPD Overlap Syndrome and COPD Are Associated with Higher Mortality Rates in US: Data from the Third National Health and Nutrition Examination Survey (NHANES III)/S. Kumbhare, C.B. Strange, Charleston, SC, p.A4718


741 Co-Morbidities Associated with Asthma-COPD Overlap Syndrome (ACOS) in U.S. Veterans/S. Bujarski, A. Parulekar, A. Spiegelman, A. Sharafkhaneh, N. Hanania, Houston, TX, p.A4720


B103 CLINICAL STUDIES IN BRONCHIECTASIS, IMMUNODEFICIENCY, AND DRUG INDUCED LUNG DISEASE

2:15 p.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Room 144 A-C (Middle Building, Street Level)

Poster Viewing 2:15-3:00
Discussion 3:00-4:15

Chairing: A.E. O’Donnell, MD, Washington, DC
K.N. Olivier, MD, MPH, Bethesda, MD
E.C. Dassenbrook, MD, MHS, Cleveland, OH

The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.
POSTER DISCUSSION SESSION

B004 SARCOIDOSIS: CLINICAL STUDIES ON DIAGNOSIS, PROGNOSIS AND THERAPY

2:15 p.m. - 4:15 p.m. MARRIOTT MARQUIS WASHINGTON

Marquis Ballroom 9-10 (Level M2)

Poster Viewing 2:15-3:00
Discussion 3:00-4:15

Chairing: A.S. Morgenthau, MD, New York, NY
G.E. Westney, MD, Atlanta, GA
S.R. Russell, MD, Chicago, IL


1004 Acthar Gel for Sarcoidosis Associated Calcium Dysregulation/ A. Modi, F. Ilyas, N. Rane, M.A. Judson, MD, Albany, NY, p.A4749


For the most current session information, please visit the online program itinerary.

1012 A Retrospective Review of Patients with Sarcoidosis Attending a Tertiary Referral Centre; Prevalence of Cardiac Involvement and Comment on Management Approach/H. Garthwaite, J. Porter, London, United Kingdom, p.A4757

1013 Sarcoidosis Has Better Outcome than COPD and IPF After Lung Transplant in the USA/S. Roghaee, E. Diaz, R. Calderon, M. Campos, G. Holt, M. Mirsaeidi, Miami, FL, p.A4758

1014 Standardised Translation of the King's Sarcoidosis Questionnaire (KSQ) into Eleven Languages/S. Birring, H. Kool, R.P. Baughman, Rotterdam, Netherlands, p.A4759


1018 Best Prognostic Indicator for Sarcoidosis/G. Kirkil, R.P. Baughman, London, United Kingdom, p.A4763


1021 IL-8 and VEGF in Patients with Sarcoidosis Associated Pulmonary Hypertension: The Registry of Sarcoidosis Associated Pulmonary Hypertension (ReSAPH)/P. Heukels, K. Rogers, S. Liu, I. Asante, S. Louie, Los Angeles, CA, p.A4766


B105 CRITICAL CARE: MECHANISTIC AND TRANSLATIONAL INSIGHTS INTO ARDS

2:15 p.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER

Poster Viewing 2:15-3:00

Discussion 3:00-4:15

Chairing: N.J. Meyer, MD, MS, Philadelphia, PA

E.J. Schenck, MD, New York, NY

C.C. Dos Santos, MD, Toronto, Canada


203 Postoperative Acute Respiratory Distress Syndrome: A Prospective Biomarker Analysis/H. Yadav, A. Bartley, S. Keating, L. Meade, R. Carter, O. Gajic, D.J. Kor, Rochester, MN, p.A4770


207 Compromised Sirt-2 Histone Deacetylase Activity in Aged Mice Is Associated with Sustained and Aggressive Inflammatory Pathway Activation in the Lung/G.S. Thangjam, N. Barabutis, C. Dimitropoulou, B. Gregory, J.D. Catravas, Norfolk, VA, p.A4774


211 Effects of Prostaglandin Family Lipid Mediators on Agonist-Induced Lung Endothelial Permeability and Inflammation/A. Stitikov, N. Sarich, M.M. Yung, A. Meliton, K. Birukov, A. Birukova, Chicago, IL, p.A4778

212 Esterification of Iloprost Enhances Its Barrier Protective Effects on Pulmonary Endothelium/F. Meng, T. Ohmura, M.M. Yang, A. Birukova, K. Birukov, Chicago, IL, p.A4779


215 Decreased Mitochondrial Flexibility and Prolonged Fatty Acid Oxidation Contribute to a Unique Metabolic Phenotype in Old Mice After LPS-Lung Injury/K. Gibbs, C.-C. Chuang Key, M. Liu, L. Purcell, C. Liu, J. Parks, D.C. Files, Winston-Salem, NC, p.A4782

216 Two Runx1 Isorforms Determine the Outcome in ARDS/I. Predescu, T.G. Shah, S. Qin, C. Bardita, N. Jeganathan, R. Balk, D. Predescu, Chicago, IL, p.A4783


223 Inhaled Thrombolitics May Prevent Lung Injury/R.L. Conhaim, W.F. Dovi, K.E. Watson, Middleton, WI, p.A4790


B106 PRENATAL, PERINATAL, AND CHILDHOOD EXPOSURES IN LUNG DISEASE

2:15 p.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Room 151 B (Middle Building, Street Level)

Abstract Summaries 2:15-2:45

Poster Viewing/Discussion 2:45-4:15

Chairs: A.A. Litonjua, MD, MPH, Boston, MA
T.D. LeVan, PhD, Omaha, NE
E. Melen, MD, DrPH, Stockholm, Sweden


Chronic Azithromycin Use in Cystic Fibrosis and Risk of Treatment-Emergent Respiratory Pathogens/J.D. Cogen, F. Onchiri, J. Emerson, M. Rosenfeld, Seattle, WA, p.A4841


An Investigation into Usefulness of Exhaled Nitric Oxide and Atoxy as Markers of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis/K. Keown, M. Chivers, Vancouver, Canada, p.A4844


Chronic Inflammation and Infection Leads to Worse Structural Lung Disease in Young Children with Cystic Fibrosis/I. Rosenow, C. Mok, L. Turkovic, C.P. Murray, P.D. Sly, S. Ranganathan, S. Stick, Subiaco, Australia, p.A4846


Determining Lung Infection Etiology in CF Patients Using Breath and Other Biofluids/J. Hill, M. Nasir, H. Bean, E. Zemanick, A. Ashare, A. Gifford, A. Smolinska, Hanover, NH, p.A4848


Cysteamine-Mediated Clearance of Multi-Drug Resistant Pathogens from Cystic Fibrosis Macrophages/B.T. Kopp, C. Shrestha, K. Assani, L.S. Schlesinger, Columbus, OH, p.A4850


Structural Analysis of the Airway Tree in Explanted Lungs with Severe COPD Using a Combination of MDCT, microCT and Histology/N. Tanabe, D.M. Vasilescu, H.O. Coxson, M. Kirby, D. Kinose, Y. Nakano, P.D. Pare, J.C. Hogg, Vancouver, Canada, p.A4871

Comparison of Pre- and Post-Bronchodilator Spirometry: Discordance Airflow Obstruction/S. Fortis, M. Eberlein, A.P. Comellas, Iowa City, IA, p.A4872


Interactive Effects of PEEP and FIO₂ During Anesthesia: Different Consequences Indicated by Computed Tomography (CT) Versus Electric Impedance Tomography (EIT)/J.R. Melo, B.M. Ribeiro, M.A.M. Nakamura, C.C.A. Morais, M.A. Beraldo, S. Gomes, M.B.P. Amato, M.R. Tucci, Sao Paulo, Brazil, p.A4874


Intrapulmonary Artery and Airway Reactivity Is Altered in Precision Cut Lung Slices from a Rat Model of Pulmonary Arterial Hypertension/M. Lam, M. FitzPatrick, R. Harper, P.N. Reynolds, J.E. Bourke, Melbourne, Australia, p.A4876


3-Year Survival Among Early Stage Lung Cancer Patients Treated with Lobectomy vs SBRT/D. Albano, T. Bilfinger, K. Chokshi, B. Nemesure, Stony Brook, NY, p.A4885

Racial and Geographic Disparities in Early Lung Cancer Resection in a Nationwide Hospital Database/A.A. Balekian, A. Kim, Los Angeles, CA, p.A4886


Novel Perspective to Choose Suitable Cases for Segmentectomy- Regularity and Clinical Significance of Intrapulmonary Lobar and Segmental Lymph Nodes Metastasis in cT1N0M0 Stage Lung Adenocarcinoma/F. Xiao, D. Liu, Y. Guo, C. Liang, Beijing, China, p.A4888


Necessity of Nodule Risk Stratification in Patients Undergoing Lung Cancer Screening/S. Allamneni, S. Shofer, Durham, NC, p.A4893


Incidental Pulmonary Nodules in Veterans Undergoing Lung Cancer Screening: Description of a Large Cohort/V. Mehta, A. Blake, K. Bhatia, F. Ratnaraj, A. Herman, L. Morrow, Omaha, NE, p.A4896


Clinical Indicators of Survival in Stage IV Lung Cancer: The Place of Nodal(N) and Metastases(M) Descriptors/P.S. Zhu, T. Vandemoortele, Montreal, Canada, p.A4902


### ASSEMBLY MEMBERSHIP MEETINGS

The fourteen Assemblies are the primary groups of the American Thoracic Society. Each Assembly holds an annual Membership Meeting at the International Conference. All Assembly members and other interested individuals are invited to attend.

The Assembly Membership Meetings provide an update on the Assembly’s activities via the Assembly’s Leadership and provide Assembly members the chance to have input on future directions, information on how to get involved and networking opportunities. Voting results for the Assembly’s future leaders will also be announced.

The Assembly Membership Meetings will be held on Monday, May 22, 2017, 5:00 p.m. - 7:00 p.m., with the exception of the Assemblies on Behavioral Science and Health Services Research and Pediatrics (see below.)

#### ALLERGY, IMMUNOLOGY AND INFLAMMATION
- **Location:** GRAND HYATT WASHINGTON
- **Ballroom:** Independence Ballroom B-E (Independence Level 5B)
- **Chairing:** Mitchell A. Olman, MA, MD, Cleveland, OH

#### BEHAVIORAL SCIENCE AND HEALTH SERVICES RESEARCH
- **Location:** RENAISSANCE WASHINGTON DOWNTON
- **Ballroom:** Grand Ballroom South (Ballroom Level)
- **Chairing:** Christopher H. Goss, MD, MSc, Seattle, WA
  *This meeting will be held on Sunday, May 21st.*

#### CLINICAL PROBLEMS
- **Location:** GRAND HYATT WASHINGTON
- **Ballroom:** Constitution Ballroom C (Constitution Level 3B)
- **Chairing:** Sanjay Sethi, MD, Buffalo, NY

#### CRITICAL CARE
- **Location:** RENAISSANCE WASHINGTON DOWNTON
- **Ballroom:** Grand Ballroom South (Ballroom Level)
- **Chairing:** Carolyn S. Calfee, MD, San Francisco, CA

#### ENVIRONMENTAL OCCUPATIONAL AND POPULATION HEALTH
- **Location:** RENAISSANCE WASHINGTON DOWNTON
- **Ballroom:** Renaissance Ballroom East (Ballroom Level)
- **Chairing:** Jack R. Harkema, DVM, PhD, East Lansing, MI

#### MICROBIOLOGY, TUBERCULOSIS AND PULMONARY INFECTIONS
- **Location:** GRAND HYATT WASHINGTON
- **Ballroom:** Declaration A-B (Declaration Level 1B)
- **Chairing:** Kevin P. Fennelly, MD, MPH, Bethesda, MD

#### NURSING
- **Location:** RENAISSANCE WASHINGTON DOWNTON
- **Ballroom:** Renaissance Ballroom West B (Ballroom Level)
- **Chairing:** Eileen G. Collins, PhD, Chicago, IL

#### PEDIATRICS
- **Location:** RENAISSANCE WASHINGTON DOWNTON
- **Ballroom:** Grand Ballroom Central (Ballroom Level)
- **Chairing:** James Chmiel, MD, MPH, Cleveland, OH
  *This meeting will be held on Sunday, May 21st.*

#### PULMONARY CIRCULATION
- **Location:** RENAISSANCE WASHINGTON DOWNTON
- **Ballroom:** Grand Ballroom North (Ballroom Level)
- **Chairing:** Troy Stevens, PhD, Mobile, AL

#### PULMONARY REHABILITATION
- **Location:** RENAISSANCE WASHINGTON DOWNTON
- **Ballroom:** Renaissance Ballroom West A (Ballroom Level)
- **Chairing:** Carolyn L. Rochester, MD, Cheshire, CT

#### RESPIRATORY CELL AND MOLECULAR BIOLOGY
- **Location:** GRAND HYATT WASHINGTON
- **Ballroom:** Independence Ballroom F-I (Independence Level 5B)
- **Chairing:** Irina Petrache, MD, Denver, CO

#### RESPIRATORY STRUCTURE AND FUNCTION
- **Location:** GRAND HYATT WASHINGTON
- **Ballroom:** Independence Ballroom A (Independence Level 5B)
- **Chairing:** Blanca Camoretti-Mercado, PhD, Tampa, FL

#### SLEEP AND RESPIRATORY NEUROBIOLOGY
- **Location:** GRAND HYATT WASHINGTON
- **Ballroom:** Constitution Ballroom B (Constitution Level 3B)
- **Chairing:** Susheel P. Patil, MD, PhD, Baltimore, MD

#### THORACIC ONCOLOGY
- **Location:** RENAISSANCE WASHINGTON DOWNTON
- **Ballroom:** Congressional Hall A (Ballroom Level)
- **Chairing:** Michael K. Gould, MD, MS, Pasadena, CA

---

The information contained in this program is up to date as of March 9, 2017.

For the most current session information, please visit the [online program itinerary](#).
ASSEMBLY DINNERS AND RECEPTIONS

Assembly members and non-members, students and fellows are invited to join us for an evening of networking, great company, and camaraderie. This is a wonderful opportunity to introduce young members and trainees to Assembly leaders, to connect with old friends and to set up new interactions and collaborations.

Pre-registration and an additional fee are required. Seating is limited.

The following Assemblies will hold a dinner or reception on Monday May 22, 2017 from 7:00 p.m. - 10:00 p.m. immediately following the Assembly Membership Meetings.

<table>
<thead>
<tr>
<th>Assembly Name</th>
<th>Location</th>
<th>Fellow</th>
<th>Member</th>
<th>Non-Member</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assembly on Allergy, Immunology and Inflammation &amp; Assembly on Respiratory Cell and Molecular Biology</td>
<td>Grand Hyatt Washington, Constitution Ballroom A (Constitution Level 3B)</td>
<td>$30.00</td>
<td>$50.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Assembly on Critical Care Reception</td>
<td>Renaissance Washington Downtown, Congressional Hall B (Ballroom Level)</td>
<td>$25.00</td>
<td>$45.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Assembly on Microbiology, Tuberculosis and Pulmonary Infections Reception</td>
<td>Grand Hyatt Washington, Penn Quarter A-B (Declaration Level 1B)</td>
<td>$30.00</td>
<td>$50.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Assembly on Pediatrics Dinner</td>
<td>Renaissance Washington Downtown, Grand Ballroom Central (Ballroom Level)</td>
<td>$65.00</td>
<td>$75.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Assembly on Respiratory Structure and Function Reception</td>
<td>Grand Hyatt Washington, Independence Ballroom A (Independence Level 5B)</td>
<td>$40.00</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Assembly on Sleep and Respiratory Neurobiology Reception</td>
<td>Grand Hyatt Washington, Wilson - Arlington (Constitution Level 3B)</td>
<td>$30.00</td>
<td>$50.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Assembly on Thoracic Oncology Reception</td>
<td>Renaissance Washington Downtown, Mount Vernon Square A (Meeting Room Level)</td>
<td>$20.00</td>
<td>$35.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>

Dinner/Reception Disclaimer – Event prices reflect menu selections.

For more information on the Assembly Dinners and Receptions please visit the ATS Assembly home page at: http://www.thoracic.org/members/assemblies/about
PCC3  PEDIATRIC CLINICAL CORE CURRICULUM

Target Audience
Pediatric pulmonary and critical care physicians who work in a clinical setting and are currently engaged in maintenance of certification

Objectives
At the conclusion of this session, the participant will be able to:

- remain current with medical knowledge relevant to their practice in pediatric pulmonology;
- evaluate their understanding of key skills and content areas in pediatric pulmonology as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
- support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The Pediatric Core Curriculum symposia promote lifelong learning and the enhancement of the clinical judgment and skills essential for practicing pediatricians. The symposia will address topics that have been identified by an ATS pediatric working group, which is comprised of members of the ATS Education Committee and the International Conference Committee, who have identified important areas within pediatric medicine (including severe asthma, ILD, BPD, pulmonary hypertension and pulmonary manifestations of pulmonary disease). Attendees will increase their medical knowledge as a result of attending this symposium, and this will be measured by a comparison of pre-test vs. post-test results on the corresponding maintenance of certification module. The ATS Pediatric Core Curriculum will focus on a 3-year content cycle of key medical content in the area of pediatric medicine.

Chairing: M.K. Abe, MD, Chicago, IL

7:00  BPD: Pathophysiology and NICU Management
E.G. Shepherd, MD, Columbus, OH

7:30  BPD: Outpatient Management
H.B. Panitch, MD, Philadelphia, PA
Trainees and early career faculty must plan carefully in order to succeed in the critical first phase of their careers - the first 7 years after their initial appointment. During this crucial phase of their nascent careers, they must establish their own professional career independent of their previous supervisors/mentors in their areas of focus that may include research, clinical care, education, and/or creative professional activity. This is in addition to the stresses of personal and family life that may sometimes overshadow professional development. There are very different expectations and benchmarks that define success within these different career paths in both academic and non-academic institutions that may not be clear to trainees or early career faculty. The goal of this session is to bring together representatives from academic institutions and industry for an interactive panel discussion to allow attendees to explore the options for career development through a moderated interaction between the panel discussants and the attendees.

Chairing: G.P. Downey, MD, Denver, CO

Speakers: M. Peters-Golden, MD, Ann Arbor, MI
A. Morris, MD, Pittsburgh, PA
A. Rogers, MD, MPH, Palo Alto, CA
C.S. Calfee, MD, San Francisco, CA
M.B. Fessler, MD, Research Triangle Park, NC
J.J. Reilly, MD, Aurora, CO

The information contained in this program is up to date as of March 9, 2017. For the most current session information, please visit the online program itinerary.
C1 CLINICAL YEAR IN REVIEW 3

9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER
Hall E (Middle Building, Level 2)

Target Audience
Providers including physicians; registered nurses; advanced practice nurses; respiratory therapists; physician assistants; trainees including residents and fellows; clinical researchers

Objectives
At the conclusion of this session, the participant will be able to:

- apply new clinical research knowledge to clinical practice;
- describe new strategies for managing the care of common conditions in pulmonary, critical care, and sleep;
- apply new findings regarding key conditions in pulmonary, critical care and sleep.

The annual Clinical Year in Review symposia topics are reviews of key clinical research publications over the last year. Each speaker is asked to review the 5-7 most important and influential publications on their topic in the prior year.

Chairing:
D.J. Lederer, MD, MS, New York, NY
D.W. Ford, MD, MSCR, Charleston, SC
V.E. Ortega, MD, PhD, Winston-Salem, NC

9:15 Tuberculosis and Nontuberculous Mycobacteria
C.L. Daley, MD, Denver, CO

9:45 The Host Microbiome in Lung Disease
Y.J. Huang, MD, Ann Arbor, MI

10:15 Bronchiectasis
J.D. Chalmers, MD, PhD, Dundee, United Kingdom

10:45 Lung Transplantation
L.G. Singer, MD, Toronto, Canada

This session and the International Conference are supported by an educational grant from Insmed Incorporated.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

C2 PRACTICE CHANGING CLINICAL TRIALS IN PLEURAL DISEASES: IMPACT ON DAY-TO-DAY CARE

Assemblies on Clinical Problems; Critical Care
9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER
Ballroom A (South Building, Level 3)

Target Audience
Clinicians and allied health professionals with clinical and research responsibilities in respiratory diseases; especially chest physicians, interventional pulmonologists, medical oncologists, respiratory nurses, thoracic surgeons, internists, general physicians and junior staff; scientists engaged in translational respiratory research

Objectives
At the conclusion of this session, the participant will be able to:

- review the latest clinical trial evidence on best management of malignant pleural effusions, especially regarding the use of indwelling pleural catheters vs pleurodesis as well as future directions in the field;
- understand and review the latest clinical trial evidence on best management of pleural infection, especially intrapleural therapy with IPA DNase, and the ongoing work on their best delivery regimes;
- review the latest research finding in mesothelioma and how it should influence clinical care.

The last five years, but particularly in the past 24 months, we have seen a significant number of multicentered clinical trials completed in pleural diseases. Their results have direct and immediate impact on day-to-day clinical practice of pleural disease management. Most of these studies have been published in high impact journals: including trials on malignant effusions, e.g. the Therapeutic Intervention in Malignant Effusion (TIME)-1 and -2 trials (both in JAMA), on mesothelioma including the SMART trial (in Lancet Oncology), the MAPPs and Meso-VATS trials (both in Lancet), and on pleural infection e.g. the Multicentre Intrapleural Sepsis Trial (MIST)-2 (in NEJM), and on pneumothorax, e.g. the minocycline trial (in Lancet). Several large trials including the Australasian Malignant Pleural Effusion (AMPLE)-1, ASAP and MIST-3 have just been completed. The proposed session will summarize the key findings of the latest studies and ongoing ones.

Chairing:
V.C. Broaddus, MD, San Francisco, CA
Y.C.G. Lee, MBChB, PhD, Perth, Australia

9:15 Breathlessness with Pleural Effusion: Latest Results on Why and How to Measure
E. Mishra, MRCP, DPhil, Norwich, United Kingdom

9:30 Practice Changing Clinical Trials in Malignant Pleural Effusions
Y.C.G. Lee, MBChB, PhD, Perth, Australia

9:55 Practice Changing Clinical Trials in Pleural Infection
N.M. Rahman, MD, PhD, Oxford, United Kingdom

10:20 Practice Changing Clinical Trials in Malignant Mesothelioma
D.H. Sterman, MD, New York, NY

10:45 Practice Changing Clinical Trials in Pneumothorax
N.A. Maskell, MD, Bristol, United Kingdom

11:00 Novel Intervention and Imaging Impacting on Pleural Management
D.J. Feller-Kopman, MD, Baltimore, MD

There will be a 5-minute discussion after each talk.
C3 OBESITY AND LUNG DISEASE

Assemblies on Clinical Problems; Behavioral Science and Health Services Research; Environmental, Occupational and Population Health
9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER
Ballroom C (South Building, Level 3)

Target Audience
Providers of lung health, registered nurses; advanced practice nurses

Objectives
At the conclusion of this session, the participant will be able to:
- describe new strategies for managing the care of individuals with an overlap of lung disease and obesity;
- integrate newly acquired knowledge into clinical practice by personalizing management of obese individuals with pulmonary diseases;
- improve patient related outcomes by delivering personalized healthcare.

Obesity is known to negatively affect the lung function. In some pulmonary disorders (COPD) obesity has been viewed in the past to offer a protective role in survival. Nevertheless, the prevalence of obesity has increased alarmingly in the past years changing epidemiology and significant body of research strongly suggests negative impact of obesity on the lung health. In addition obesity is a risk factor for many chronic diseases and will advance comorbidities for pulmonary disorders leading to worse outcomes. Current guidelines lack tailored approach to obese individuals with pulmonary disorders. Nevertheless, experts in the field believe that personalized management is needed for these individuals.

Chairing: T. Beiko, MD, Charleston, SC
A.E. Dixon, MD, Burlington, VT

9:15 Impact of Obesity on Pulmonary Mechanics
N. Berend, MD, Sydney, Australia

9:35 Asthma and Obesity
A.E. Dixon, MD, Burlington, VT

9:55 COPD and Obesity
T. Beiko, MD, Charleston, SC

10:15 OSA/Obesity Hypoventilation Syndrome and Obesity
A.R. Schwartz, MD, Baltimore, MD

10:35 Acute Respiratory Distress Syndrome and Obesity
A.J. Goodwin, MD, MSCR, Charleston, SC

10:55 Pulmonary Hypertension and Obesity
A.R. Hemnes, MD, Nashville, TN

There will be a 5-minute discussion after each talk.

This session and the International Conference are supported by an educational grant from Teva Pharmaceuticals.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
10:50 PRO: It’s Time to Get Our Patients Moving!
W.D. Schweickert, MD, Philadelphia, PA

11:05 Panel Discussion

BASIC • TRANSLATIONAL
BASIC SCIENCE CORE
CME Credits Available: 2

C5 EARLY LIFE ENVIRONMENTAL PROGRAMMING OF CHRONIC LUNG DISEASE
Assemblies on Allergy, Immunology and Inflammation; Environmental, Occupational and Population Health; Microbiology, Tuberculosis and Pulmonary Infections; Pediatrics; Respiratory Cell and Molecular Biology; Respiratory Structure and Function
9:15 a.m. - 11:15 a.m. MARRIOTT MARQUIS WASHINGTON Independence Ballroom E-H (Level M4)

Target Audience
Basic scientists, physician scientists and clinicians interested in learning about environmental factors that may affect peri- and postnatal development of immunity and lung function, ultimately predisposing pediatric populations to the development of chronic adult disease.

Objectives
At the conclusion of this session, the participant will be able to:
- describe what is currently known about normal immune and lung development during early life;
- gain an understanding of why early childhood is a window of susceptibility to environmental exposures;
- consider novel strategies to prevent or limit the detrimental respiratory/immune effects of environmental exposures.

There is growing evidence to suggest that chronic lung disease in adults originate from events that take place during peri- or postnatal development. This session will communicate recent advances in our understanding of how early life environmental exposures (air pollutants, microbes, viruses) contribute to the development of chronic lung disease in children and adults. Leading experts will discuss the distinct responses of pediatric populations to environmental exposures using experimental animal models and human studies, with an emphasis on parameters of immunity and lung function.

Chairing:
L.A. Miller, PhD, Davis, CA
I.P. Lewkowich, PhD, Cincinnati, OH

9:15 The Intersection of the Environment and the Development of Asthma
S.A. Cormier, PhD, Memphis, TN

9:35 Maternal Asthma, Air Pollutant Exposures and Neonatal Health
P. Mendola, PhD, Bethesda, MD

9:55 Influence of Age and Environment on Innate Immune Function
L.A. Miller, PhD, Davis, CA

10:15 Developmental Differences in the Response to Rhinovirus Infection
M.B. Hershenson, MD, Ann Arbor, MI

10:35 The Early Life Microbial Environment and Asthma
E. von Mutius, MD, MS, Munich, Germany

10:55 Impact of Environmental Pollutants on T Cell Populations
K.C. Nadeau, MD, PhD, Stanford, CA

There will be a 5-minute discussion after each talk.

BEHAVIORAL • CLINICAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2
Nursing Contact Hours Available: 2.4

C6 REDUCING READMISSIONS FOR COPD: STRATEGIES, ISSUES AND RESULTS
Assemblies on Behavioral Science and Health Services Research; Clinical Problems; Nursing; Pulmonary Rehabilitation
9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER Room 146 C (Middle Building, Street Level)

Target Audience
Multi-disciplinary providers interested in improving care for patients with COPD. Registered nurses, advanced practice nurses, respiratory therapists, pharmacists, physicians, psychologists, clinicians and researchers interested in quality improvement and implementation science. Hospital administrators; those interested in learning about emerging evidence of effective strategies to reduce re-hospitalization for patients with COPD

Objectives
At the conclusion of this session, the participant will be able to:
- identify social determinants of health that place patients at risk for readmission after hospitalization for AECOPD;
- describe interventions that can be implemented in clinical practice to improve quality of care for patient with COPD, with a goal of reducing readmissions;
- identify limitations of common quality improvement designs and discuss newer designs that allow for valid inferences from these initiatives.

Hospitals are being penalized for excessive COPD readmission. During the 2016 conference, BSHSR sponsored a workshop to bring together experts in COPD to present their current approaches to reduce COPD readmission. We will review lessons learned from the workshop, including:
1) Effects of social determinants of health on readmission and the role of patient navigators to overcome disparities;
2) Issues of when and how to deliver scarce interventions, using pulmonary rehab as the model;
3) Important considerations when entering value-based partnerships with health care payers; and
4) Innovative mechanisms to overcome traditional silos of care delivery, including inter-professional teams and telehealth technologies.

Chairing:
L.C. Feemster, MD, MSc, Seattle, WA
D.H. Au, MD, MS, Seattle, WA
V.G. Press, MD, MPH, Chicago, IL
At the conclusion of this session, the participant will be able to:

**Objectives**

- Understand and learn new findings about the relationship of microbiome profiles in pediatric inflammatory airway diseases; their implementation into precision medicine for pulmonary vascular diseases;
- Identify future areas of research that are needed to describe how the microbiome profile in pediatric inflammatory airway diseases might be altered to decrease the risk of disease onset or disease progression.

The airway microbiome affects the development and severity of many pediatric inflammatory airway conditions, including chronic lung disease of prematurity, asthma, cystic fibrosis, and chronic otitis media with effusion. The cross-talk between the microbiota in various locations within the airway, as well as microbiota within the intestines, also has an impact on overall pulmonary health and immunity. This session, encompassing a diverse mix of national and international experts, will focus on both local and systemic effects of the microbiome in the upper and lower airways, temporal changes, and modulation of lung health via the gastrointestinal microbiome.

### BASIC • TRANSLATIONAL

#### SCIENTIFIC SYMPOSIUM

**C7 EVOLUTION AND IMPACT OF THE MICROBIOME IN PEDIATRIC INFLAMMATORY AIRWAY DISEASES**

*Assemblies on Pediatrics; Respiratory Cell and Molecular Biology*

**9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER**

**Ballroom B (South Building, Level 3)**

**Target Audience**

Pediatric pulmonologists, basic and translational scientists investigating the airway microbiome and its impact on the origins of lung diseases.

**Objectives**

At the conclusion of this session, the participant will be able to:

- learn new findings about the influence of the microbiome on the development of pediatric inflammatory airway diseases;
- understand and learn new findings about the relationship of microbiome profiles and diversity to disease severity in pediatric inflammatory airway diseases;
- identify future areas of research that are needed to describe how the microbiome profile in pediatric inflammatory airway diseases might be altered to decrease the risk of disease onset or disease progression.

### BASIC • CLINICAL • TRANSLATIONAL

#### SCIENTIFIC SYMPOSIUM

**C8 PRECISION MEDICINE IN PULMONARY VASCULAR DISEASES: ARE WE READY FOR THE FUTURE?**

*Assemblies on Pulmonary Circulation; Behavioral Science and Health Services Research; Clinical Problems; Environmental, Occupational and Population Health; Respiratory Cell and Molecular Biology*

**9:15 a.m. - 11:15 a.m. MARRIOTT MARQUIS WASHINGTON**

**Liberty Ballroom I-L (Level M4)**

**Target Audience**

Medical professionals who specialize in caring for patients with pulmonary vascular disorders; research scientists interested in pulmonary vascular biology; translational scientists; industry professionals; graduates and postgraduates students interested in pulmonary vascular biology.

**Objectives**

At the conclusion of this session, the participant will be able to:

- understand how precision medicine can improve clinical management of pulmonary vascular disorders;
- learn new findings about genomic, proteomic and metabolic techniques and their implementation into precision medicine for pulmonary vascular diseases;
- introduce the concept of pharmacogenomics and how it can help design new treatment strategies for patients.
Precision medicine is an approach that takes into account individual variability in genes, environment, and lifestyle to identify clinical phenotypes that would benefit from targeted and highly effective therapies. Given the growing advances in our understanding of the pathobiology and management of pulmonary vascular disorders such as pulmonary arterial hypertension (PAH), pulmonary embolism (PE) and chronic thromboembolic pulmonary hypertension (CTEPH), the time is ripe to discuss how a precision medicine strategy could help facilitate the translation of scientific discoveries into clinical tools that can help improve our capacity to properly identify the optimal treatment strategy for these patients.

Chairing: C.E. Ventetuolo, MD, MS, Providence, RI
M. Wilkins, MD, London, United Kingdom
R.T. Zamanian, MD, Stanford, CA

9:15 A Patient's Perspective
K.A. Lewis, Round Hill, VA

9:20 Precision Medicine: A Novel Paradigm to Improve Our Understanding and Management of Pulmonary Vascular Disorders
V. De Jesus Perez, MD, Stanford, CA

9:35 Genetics for Pulmonary Vascular Disorders: A Blueprint for Action
E. Austin, MD, Nashville, TN

9:55 Proteomics and Risk Stratification for Pulmonary Vascular Diseases: Role of Precision Medicine
R.T. Zamanian, MD, Stanford, CA

10:15 Capturing the Clinical Heterogeneity of Pulmonary Vascular Diseases with Metabolomics
M. de Perrot, MD, MSc, Toronto, Canada

10:35 Pharmacogenomics for Pulmonary Vascular Diseases: Role in Drug Discovery
M. Wilkins, MD, London, United Kingdom

10:55 Role of a Comprehensive Electronic Medical Record in Precision Medicine: What Is Needed
E. Brittain, MD, Nashville, TN

This session and the International Conference are supported by an educational grant from Actelion Pharmaceuticals US, Inc.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACME) and are free of the control of commercial interests.

Target Audience
Basic and translational scientists working lung diseases. Lung health researchers, students, fellows, residents with clinical and research backgrounds

Objectives
At the conclusion of this session, the participant will be able to:

- learn about signaling and pathways for mitochondrial biogenesis and dysfunction in pulmonary health consequences;
- understand and learn the current research findings on mitochondrial dysfunctions in various pulmonary diseases and current/future thoughts/hypotheses on mitochondrial research;
- gain strategies for targeting mitochondrial dysfunction using various therapeutic approaches in clinical settings and animal models of pulmonary diseases based on stem cell transfer of mitochondria or activation of mitochondrial biogenesis, and/or removal of damaged/impaired mitochondria by selected/targeted approaches based on signaling pathways.

Emerging evidence sheds light on new mitochondrial functions that are not related to cellular energy production, which involve mitophagy (removal of damaged/impaired mitochondria from a cell prior to cell death) and mitochondrial protein quality control in aging. Mitochondrial function is associated with fusion, fission, and mitophagy in health and disease. The goal of this symposium is to highlight the recent advances of mitochondria research in lung cell biology, particularly in mitochondria biogenesis, dysfunctional mitophagy, redox changes, metabolism, pulmonary infections, cell signaling, and repair or rejuvenation of the damaged mitochondria upon stress in the interdisciplinary areas of pulmonary diseases (acute lung injury, pulmonary hypertension, idiopathic pulmonary fibrosis/interstitial lung diseases, and COPD).

Chairing: I. Rahman, PhD, Rochester, NY
P.J. Lee, MD, New Haven, CT
S. Meiners, PhD, Munich, Germany
M. Goldklang, MD, New York, NY

9:15 Mitochondria Dysfunction and Biogenesis in Lung Disease
A.M.K. Choi, MD, New York, NY

9:35 Mitochondrial Metabolism and Cellular Redox Signaling
N.S. Chandel, PhD, Chicago, IL

9:55 Mitochondrial Dysfunction by Pulmonary Infection
C. Piantadosi, MD, Durham, NC

10:15 Mitochondria-Nuclear Signaling and Mitosenescence in Airway Diseases and During Exacerbations
I. Rahman, PhD, Rochester, NY

10:35 Mitochondrial Biogenesis, Dysfunction, and Signaling in Pulmonary Fibrosis
A.L. Mora, MD, Pittsburgh, PA

10:55 The Role of Mitochondria in Pulmonary Vascular Remodeling
E.D. Michelakis, MD, PhD, Edmonton, Canada

There will be a 5-minute discussion after each talk.
At the conclusion of this session, the participant will be able to:

Objectives

- understand the implications of poor PAP adherence as an issue that affects not just individual patient care, but also the planning and interpretation of important large-scale randomized trials in the field of SDB;
- learn and understand how technological, behavioral, and/or peer-driven approaches to maximize adherence may be incorporated into routine care, and planned research studies;
- understand how routinely collected PAP adherence metrics may be incorporated into big data analytics, and how this approach may impact policies regarding minimum PAP adherence thresholds currently in place in clinical practice.

This session will provide a context for why the issue of poor PAP adherence is a major challenge facing the sleep field. Speakers will discuss the impact that poor PAP adherence has on our ability to perform robust clinical trials, as well as various interventions designed to promote PAP adherence including behavioral therapies, technological approaches, and peer support. Finally, we will discuss the opportunities our field has in being at the forefront of adherence-behavior research by using objective adherence metrics gathered via remote monitoring in big data analyses.

Chairing: J. Bakker, PhD, Boston, MA
S. Parthasarathy, MD, Tucson, AZ
T. Weaver, PhD, RN, Chicago, IL

9:15 PAP Adherence: Reflections from a PAP User
A. Flipse, Adelphi, MD

9:20 Pivotal Trials and PAP Adherence: How to Mend the Achilles Heel?
S. Kuna, MD, Philadelphia, PA

9:40 Disparities in PAP Adherence: Can We Close the Gap?
S. Parthasarathy, MD, Tucson, AZ

9:59 CBT for Promoting PAP Adherence: The Awakening!
C. Stepnowsky, PhD, La Jolla, CA

10:18 Peer Support for CPAP Adherence: Step Right Up!
J. Bakker, PhD, Boston, MA

10:37 Technology Promotes PAP Adherence: Paging Dr. Watson, IBM
D. Hwang, MD, Fontana, CA

10:56 Adherence Tracking and Informatics: Big Data, Big Plans
R.J. Schwab, MD, Philadelphia, PA

There will be a 5-minute discussion after each talk.
10:55  Smoke Signaling in Epigenetic Chromatin Modifications in COPD
I.K. Sundar, PhD, Rochester, NY

This session and the International Conference are supported by educational grants from AstraZeneca LP, Teva Pharmaceuticals. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

C12  PHYSICIAN PAYMENT IN THE UNITED STATES: PAST, PRESENT AND FUTURE OR WHAT IS MACRA (MEDICARE ACCESS AND CHIP REAUTHORIZATION ACT OF 2015)
Clinical Practice Committee; Assembly on Clinical Problems; Environmental, Occupational and Population Health
9:15 a.m. - 11:15 a.m.  WALTER E. WASHINGTON CONVENTION CENTER
Room 102 A-B (South Building, Street Level)

Target Audience
U.S. based practicing clinicians who will be faced with implementing MACRA, the new quality based physician payment system

Objectives
At the conclusion of this session, the participant will be able to:

• learn about the new CMS Quality Payment Program;
• prepare provider practice for MACRA;
• understand the quality measures required for MACRA.

This session will introduce the participants to CMS’s new quality based physician reimbursement model that is designed to replace the current fee-for-service model. This new complex approach will effect all practicing physicians in the U.S. over the next 3 years.

Chairing:  S. Hoffmann, MD, Morgantown, WV
K. Nicolacakis, MD, Cleveland, OH

9:15  Introduction
S. Hoffmann, MD, Morgantown, WV

9:25  CMS Update on MACRA
K. Bryant, JD, Baltimore, MD

10:00  Tips for MIPS (The Merit-Based Incentive Payment System)
O. Hussain, DO, Melrose Park, IL

10:15  APMs (Advanced Alternative Payment Models) or Who’s Ready for Prime Time?
K. Nicolacakis, MD, Cleveland, OH

10:30  MIPS or APMs: What Is Right for You?
S. Hoffmann, MD, Morgantown, WV

10:40  Big System Vs. Little Practice: What You Need to Know
R.M. Hamrick, MD, Richmond, VA

10:55  Preparation and Questions and Answers: Apocalypse or Not
K.L. Kovitz, MD, MBA, Elk Grove Village, IL

MINI SYMPOSIUM

C13  TRANSLATIONAL RESEARCH IN ASTHMA
9:15 a.m. - 11:15 a.m.  WALTER E. WASHINGTON CONVENTION CENTER
Room 204 A-C (South Building, Level 2)

Chairing:  S.E. Wenzel, MD, Pittsburgh, PA
T.S. Hallstrand, MD, MPH, Seattle, WA
L.E. Crotty Alexander, MD, San Diego, CA

Oral Presentations

9:15  Longitudinal RNA Sequencing Data of Induced Sputum in Asthma Patients Reveals Stable Transcriptional Endotypes of Asthma Associated with Asthma Severity/X. Yan, Q. Liu, J.V. Gomez, C. Holm, L. Cohn, G. Chupp, New Haven, CT, p.A4908


11:00  Role of Airway ILC2 and ILC3 Compared to Th2 and Th17 Cells in Paediatric Severe Therapy Resistant Asthma (STRA)/P. Nagakumar, L. Artusio, V. Fainardi, L. Fleming, A. Bush, C.M. Lloyd, S. Saglani, London, United Kingdom, p.A4915
### C14 INTERSTITIAL LUNG DISEASE: ADVANCES ACROSS THE FIELD

**9:15 a.m. - 11:15 a.m.** WALTER E. WASHINGTON CONVENTION CENTER
Room 145 A-B (Middle Building, Street Level)

**Chairing:**
V. Cottin, MD, PhD, Lyon, France
K.B. Highland, MD, Cleveland, OH
M. Salisbury, MD, Ann Arbor, MI

**Oral Presentations**


10:15 Inflammation: New Staging for Idiopathic Pulmonary Fibrosis/C15 WHEN MICROBES ATTACK: HOST-PATHOGEN INTERACTIONS

9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER

**Chairing:**
S.E. Evans, MD, Houston, TX
H. Koziel, MD, Boston, MA
A.E. Sammarasinghe, PhD, Memphis, TN

**Oral Presentations**


10:45 Riboflavin Metabolism Variation Among Clinical Isolates of Streptococcus Pneumoniae Results in Differential Activation of MAIT Cells/M. Harriff, C. McMurtrey, N. Hartmann, M. Sorensen, J.P. Mizgerd, W. Hildebrand, M. Kronenberg, D.M. Lewinsohn, Portland, OR, p.A4929


---

The information contained in this program is up to date as of March 9, 2017. For the most current session information, please visit the online program itinerary.
C16  BRONCHOPULMONARY DYSPLASIA TURNS 50
9:15 a.m. - 11:15 a.m.  WALTER E. WASHINGTON CONVENTION CENTER
Room 202 A (South Building, Level 2)

Chairing:  L.M. Nogee, MD, Baltimore, MD
A. Hibbs, MD, Cleveland, OH

Oral Presentations
9:45  S52F Point Mutation in the DNA-Binding Domain of FoxF1 Causes ACD/MPV Phenotype and Impairment in STAT3 Signaling/A. Pradhan, V. Ustiyan, C. Bolte, Y. Zhang, A. Porollo, Y.-C. Hu, T.V. Kalin, V.V. Kalinichenko, Cincinnati, OH, p.A4933
10:30  The Effect of Extended Continuous Positive Airway Pressure (CPAP) on Lung Volumes in Stable Premature Infants: A Randomized Controlled Trial/T. Wilkinson, S. Bourne, R. DeVos, M. North, A. Chauhan, B. Green, T. Brown, V. Cornelius, Southampton, United Kingdom, p.A4940
10:45  BPD Turns 50!/E. Motoyama, MD, Pittsburgh, PA,

Featured Speaker
10:45  BPD Turns 50!//E. Motoyama, MD, Pittsburgh, PA,


10:00 Blocking YKL-40 (Chitinase-Like Protein Chitinase 3) Attenuates IL-13-Induced Airway Hyper-Responsiveness in a Human Precision Cut Lung Slicе Model/C. Koziol-White, V. Nezgovorova, L. Cohn, G. Chupp, R. Panettieri, New Brunswick, NJ, p.A4948


11:00 Airway Smooth Muscle Tone Increases Airway Responsiveness in Young Healthy Adults/M. Gazzola, K. Lortie, C. Henry, S. Mailhot-Larouche, D.G. Chapman, C.Y. Seow, P.D. Pare, G. King, L.-P. Boulet, Y. Bosse, Quebec, Canada, p.A4952


10:30  DNA Repair Protein XPC Alters Pro-Tumoral IL6 Inflammation in a Mouse Model of Lung Cancer Chemoprevention/E.J. Ostrin, N. Unver, O. Delgado, M. Caetano, K. Zeleke, A. Cumpian, X. Tang, H. Wang, H. Katayama, I. Wistuba, S.J. Moghaddam, S.M. Hanash, Houston, TX, p.A4955


11:00  Targeted Therapy of Lung Cancer: The Role of Osteopontin for Cancer Evolution and Heterogeneity/L. Shi, C. Chen, X. Wang, Shanghai, China, p.A4959

C19  MOLECULAR MECHANISMS OF DYSREGULATED INFLAMMATION, PROLIFERATION, AND REPAIR IN THORACIC ONCOLOGY

9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER

Room 202 B (South Building, Level 2)

Chairs: C. Bai, M.D., Shanghai, China
M. Konigshoff, M.D., PhD, Aurora, CO
S.D. Spivack, M.D., MPH, Bronx, NY

Featured Speaker

9:15  Overview/C.A. Powell, M.D., New York, NY

9:30  The ADAM17/IL-6 Trans-Signalling Axis as a Therapeutic Target in Lung Adenocarcinoma/B. Jenkins, S. Alhayyani, G. Brooks, A. Miller, L. McLeod, W. Ferlin, S. Rose-John, S. Ruwanpura, Clayton, Australia, p.A4953


The information contained in this program is up to date as of March 9, 2017. For the most current session information, please visit the online program itinerary.
304 Integrative Genomic Analysis of Lung Tissue Gene Expression Identifies Potential COPD Genes

305 Chronic Obstructive Pulmonary Disease Subtyping Through Multiple-Omics Data Integration

306 Whole Exome Sequencing Analysis of Severe COPD

307 Differential Gene Expression Between Cannabis and Tobacco Smoke Exposure

308 Human Small Airway-on-a-Chip: A Novel Microphysiological System to Model Lung Inflammation, Accelerate Drug Development and Enable Inhalational Toxicology-Analysis

309 Multi-Omic Biomarker Signatures Are Predictive of the Allergen-Induced Late Phase Asthmatic Response

310 Whole Genome Sequencing Study on Bronchodilator Drug Response in Ethnically Diverse Children with Asthma

311 Puberty-Associated DNA Methylation Changes in Females Are Near Estrogen Responsive Genes and Implicated in Immune Processes

312 Identifying Subject-Specific Regulatory Networks of Asthma Control

313 Glucocorticoid Pharmacogenetic Loci Are Associated with Healthcare Utilization in Inhaled Corticosteroid Treated Asthma Subjects from Different Ethnic Groups

314 Role of the CDHR3 Variant (Cys529→Tyr) in Early-Onset Adult Asthma in Japanese Populations

315 Gene Expression Study of Childhood Asthma and Atopy in a Rural Environment

316 Allelic Imbalance in COPD Candidate Genes

317 Identification of Novel Single Nucleotide Polymorphisms Associated with Acute Respiratory Distress Syndrome by Meta-Analysis of Exome-seq Data
M. Xiong, D.P. Heruth, S. Chaudhary, O.L. Zhang, Q.S. Ye, Kansas, MO, p.A4976

318 Interleukin 6 Promoter Polymorphisms Modify the Effect of Smoking on the Risk of Adult Asthma
T.K. Lajunen, J.K. Jaakkola, M.S. Jaakkola, Oulu, Finland, p.A4977

319 Transcriptional Responses to Lipopolysaccharide, Poly I:C and House Dust Mite Extract of Tissue Resident Memory CD4 and CD8 T Cells in Human Lungs
N. Schoettler, J. Huffman, C.L. Hrusch, A.I. Sperling, C. Ober, Chicago, IL, p.A4978

320 Functional Exploration of the CDHR3 Asthma Risk Gene by CRISPR-Cas9 Gene Knockout in Primary Airway Epithelium

321 Metabolomics as a Novel Method to Explore the Relationship Between Asthma and Vitamin D
R.S. Kelly, A.A. Litonjua, S. Weiss, J. Lasky-Su, Boston, MA, p.A4980

322 TGF-β Genes in Obese Asthmatics Have Altered Expression Profiles Compared to Lean Asthmatics

323 Transcriptional Analysis of Regulatory T Cells in Experimental Acute Lung Injury Resolution
J. Mock, C.F. Dial, H. Dang, M.K. Tune, C.M. Doerschuk, Chapel Hill, NC, p.A4982

324 Quantitative Proteomics Reveals Novel Fibrotic Networks of Myeloid-Derived Suppressor Cell and Monocytes in IPF

325 A Recurrent De Novo Mutation in COPA Causes Follicular Bronchiolitis in an Icelandic Family
### POSTER DISCUSSION SESSION

**C22 COPD PHENOTYPES**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:15 a.m.-11:15 a.m.</td>
<td>WALTER E. WASHINGTON CONVENTION CENTER</td>
<td>707 Fissure Integrity and Emphysema Distribution in Patients with Severe Chronic Obstructive Pulmonary Disease/D. Gompelmann, M. Schuhmann, K. Kontogianni, C.P. Heussel, J. Tschirren, R. Eberhardt, F.J.F. Herth, Heidelberg, Germany, p.A4985</td>
<td>M.K. Han, MD, MS, Ann Arbor, MI</td>
</tr>
<tr>
<td></td>
<td>Room 209 A-C (South Building, Level 2)</td>
<td>708 Characterization of COPD Patients Treated with Inhaled Triple Therapy Containing Inhaled Corticosteroids [ICS], Long-Acting Beta2-Agonists [LABA], and Long-Acting Muscarinic Antagonists [LAMA] in the UK) Mullerova, J. Maskell, W.H. Meeraus, D. Galkin, F.C. Albers, C. Gait, Uxbridge, United Kingdom, p.A4986</td>
<td>M.K. Han, MD, MS, Ann Arbor, MI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>709 Does Mortality Differ Between Comorbidty Phenotypes in Patients with Advanced COPD?/D. James, N.J. Greening, N. Toms, G. Woltmann, R.C. Free, P. Haldar, M.C. Steiner, R.A. Evans, Leicester, United Kingdom, p.A4987</td>
<td>M.K. Han, MD, MS, Ann Arbor, MI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>710 Longitudinal Lung Function and Mortality in Preserved Ratio Impaired Spirometry (PRISm) in the COPDgene Study/E.S. Wan, S. Fortis, J. Hokanson, D. DeMeeo, J.D. Crapo, E.K. Silverman, Boston, MA, p.A4988</td>
<td>M.K. Han, MD, MS, Ann Arbor, MI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>712 Blood Total Lymphocyte Count and Prognosis of Patients with COPD: An Analysis of Data from the Hokkaido COPD Cohort Study and the Rotterdam Study/M. Suzuki, L. Lahousse, H. Makita, S. Konno, K. Shimizu, H. Kinura, G.G. Brusselle, M. Nishimura, Sapporo, Japan, p.A4990</td>
<td>M.K. Han, MD, MS, Ann Arbor, MI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>714 Ectopic Adiposity and Cardiometabolic Status in COPD: A CanCOPD Substudy/V. Coats, J.-P. Despres, N. Almeras, D.D. Sin, R. Rabasa-Lhoret, W.C. Tan, J. Bourbeau, F. Maltais, Quebec, Canada, p.A4992</td>
<td>M.K. Han, MD, MS, Ann Arbor, MI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>715 Blood Total Lymphocyte Count and Prognosis of Patients with COPD: An Analysis of Data from the Hokkaido COPD Cohort Study and the Rotterdam Study/M. Suzuki, L. Lahousse, H. Makita, S. Konno, K. Shimizu, H. Kinura, G.G. Brusselle, M. Nishimura, Sapporo, Japan, p.A4990</td>
<td>M.K. Han, MD, MS, Ann Arbor, MI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>716 Characterizing Clinical and Imaging Phenotypes of COPD Within the DECAMP Consortium/G. Radin, F. Duan, E. Billatos, B. Snyder, C. Stevenson, C. Gatsonis, G.T. O’Connor, M. Lenburg, G. Washko, A. Spira, Boston, MA, p.A5002</td>
<td>M.K. Han, MD, MS, Ann Arbor, MI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>717 Effect of Emphysema Heterogeneity and ADRB2 Polymorphisms on Bronchodilator Response in Patients with COPD/M. Nojiri, S. Mizuno, T. Okawa, K. Nakagawa, K. Osanai, T. Ishizaki, H. Toga, Ishikawa, Japan, p.A5003</td>
<td>M.K. Han, MD, MS, Ann Arbor, MI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>719 Prospective Diagnostic Algorithm to Differentiate Asthma, ACOS and COPD/D. Everaerts, L. Dupont, K. De Bent, K. Denauw, S. Verschueren, N. Lorent, P. Van Bleydenbergh, W. Janssens, Leuven, Belgium, p.A5005</td>
<td>M.K. Han, MD, MS, Ann Arbor, MI</td>
</tr>
</tbody>
</table>


724 Effect of Spirometry Measures on the Relationship Between Eosinophilia and All-Cause Mortality/P. Sharma, R. Qayyum, Chattanooga, TN, p.A5008

725 Roll of Small Airways in Patients with Chronic Obstructive Pulmonary Disease Associated to Biomass Smoke/N.E. Guzman-Bouilloud, M. Velazquez-Uncal, A. Aranda-Chavez, J. Duenas-Morales, O. Perez-Bautista, R. Hernandez-Zenteno, F. Flores, R.H. Sansores, A. Ramirez-Venegas, Mexico City, Mexico, p.A5009

C23 CRITICAL CARE: WHAT CAN BE MEASURED CAN BE IMPROVED - INVESTIGATING THE EPIDEMIOLOGY AND OUTCOMES OF PATIENTS WITH ACUTE CRITICAL ILLNESS

9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER

Room 150 B (Middle Building, Street Level)

Poster Viewing
9:15-10:00

Discussion
10:00-11:15

Chairing: A.J. Walker, MD, MSc, Boston, MA

H.C. Prescott, MD, MSc, Ann Arbor, MI

C.E. Cox, MD, MPH, Durham, NC


202 The Effect of Neighborhood Socioeconomic Status on Sepsis-Attributable Mortality/P. Galiatsatos, K. Littleton, J. Pietri, M. Grant, E. Brigham, E.S. Chen, Bethesda, MD, p.A5011

203 Trends in the Weekend Effect Observed in Sepsis from Years 2006 to 2013, a Retrospective NIS Study/S. Baig, A. Szabo, L. Rein, S. Ahmad, New Brunswick, NJ, p.A5012


206 Evidence Supporting the Obesity Survival Paradox Among Over 11,000 Adults with Sepsis/D. Pepper, J. Sun, C. Rhee, M. Klompas, A.F. Suffredini, S. Kadri, Bethesda, MD, p.A5015

207 Accuracy of the Centers for Medicare and Medicaid Services ICD-10-CM Codes in Identifying Sepsis Among Critically Ill Adults/A. Dunatchik, M.W. Semler, T.W. Rice, J.D. Casey, Nashville, TN, p.A5016

208 Hospital Perceptions of Medicare’s Sepsis Quality Reporting Initiative/L. Barbash, K. Rak, C. Kuza, J. Kahn, Pittsburgh, PA, p.A5017


211 Fluid Resuscitation and Mortality in Sepsis with End-Stage Renal Disease/J. Lee, S.L. Taylor, J.Y. Adams, Sacramento, CA, p.A5020


214 A Regional Analysis of Patient Outcomes and Medicare Payments for Sepsis Patients Treated in Long-Term Care Hospitals and Skilled Nursing Facilities/B. Demiralp, F. He, L. Koenig, D. Hengesbach, J. Prister, Rockville, MD, p.A5023


218 Investigating the Impact of Different Suspicion of Infection Criteria on the Accuracy of qSOFA, SIRS, and Early Warnings Scores/M. M. Churpek, A.M. Snyder, S. Sokol, N.N. Pettit, D.P. Edelson, Chicago, IL, p.A5027


221 Prospective Surveillance of All-Cause Pneumonia in Mechanically Ventilated Patients/K. Fisher, T. Trupka, P. Juang, S. Mickey, M.H. Kollef, St. Louis, MO, p.A5030


223 Role of Fluid Management in Risk for Tracheostomy in ARDS/A. Sharma, S. Patel, R. Vashisht, A. Duggal, R.D. Hite, Cleveland, OH, p.A5032


Baseline Functional Impairment Is Associated with the Placement of Limitations on Aggressive Care in Critically Ill Adults/C. Winterbottom, A. Ahasic, M.P. Knauer, C.E. Pulaski, K. Araujo, M. Doyle, M. Pisani, New Haven, CT, p.A5037

Changes in Code Status During Terminal Hospitalization Predict Intensity at the End of Life in ICU Patients/S. Richter, Los Angeles, CA, p.A5038

Palliative Care in Cirrhosis: A NIS Database Study Looking at Intensive Care Resource Utilization/M. Holub, M. Kang, A. Sutherland, Newark, NJ, p.A5039


Time to Location of Goals of Care Documentation in the EMR for Patients Who Experienced a Rapid Response Event/S. Choudhury, C.A. Austin, S.S. Carrol, Chapel Hill, NC, p.A5041


End of Life Care Dynamics in Muslim Patients Admitted to a Tertiary Hospital in Saudi Arabia/I. Khalid, R. Qutob, F.N. Yamani, I.A. Qushmaq, T.J. Khalid, R. Fowler, Jeddah, Saudi Arabia, p.A5047


Parental Opinions About Types of Consent Acceptable for Observational Research in a PICU Before and After Background Information/C. Garros, J. Hodson, J. Pugh, J. Duff, G. Garcia Guerra, A.R. Joffe, Edmonton, Canada, p.A5049


Does Timing of the First Family Meeting Affect Family Satisfaction with Intensive Care Unit Care?/L.Z. Hillenkamp, L.J. Van Scoy, Hershey, PA, p.A5051


Nursing Perspectives Regarding End of Life Care in the Intensive Care Unit/R. Sedhom, D. Barrie, New Brunswick, NJ, p.A5057


Doctors’ Experiences of Moral Distress in End-of-Life Care Decisions in the Intensive Care Unit/U. St Ledger, D.F. McAuley, J. Reid, A. Begley, L. Prior, B. Blackwood, Belfast, United Kingdom, p.A5059


Nursing Perspectives Regarding End of Life Care in the Intensive Care Unit/R. Sedhom, D. Barrie, New Brunswick, NJ, p.A5057


Doctors’ Experiences of Moral Distress in End-of-Life Care Decisions in the Intensive Care Unit/U. St Ledger, D.F. McAuley, J. Reid, A. Begley, L. Prior, B. Blackwood, Belfast, United Kingdom, p.A5059


422 Nursing Perspectives Regarding End of Life Care in the Intensive Care Unit/R. Sedhom, D. Barrie, New Brunswick, NJ, p.A5057


425 NON-TUBERCULOUS MYCOBACTERIA: FROM BENCH TO CLINIC

9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER

Poster Viewing 9:15-10:00
Discussion 10:00-11:15

Chairing: K.L. Winthrop, MD, MPH, Portland, OR
A. Floto, MD, PhD, Cambridge, United Kingdom
D.E. Griffith, MD, Tyler, TX


109 Epidemiology of Pulmonary Nontuberculous Mycobacterial Disease in Patients with Cystic Fibrosis in the United States, 2010-2014/J. Adjemian, K.N. Olivier, R. Prevots, Bethesda, MD, p.A5068


112 Mycobacterium Shimoidi - a Rare but Increasingly Recognised Pulmonary Pathogen/D. Schraufnagel, M. Mirsaeidi, Miami, FL, p.A5071


114 The Role of Nontuberculous Mycobacteria and Other Bacterial Pathogens in Aetiology of Tuberculosis (TB)- Like Syndromes in Resource-Poor Settings. A Case Study of Northeastern, Tanzania/A.S. Hoza, S.G. Mfinanga, I. Moser, B. Konig, Morogoro, Tanzania, p.A5073


119 Treatment and Health-Related Quality of Life in Patients with Pulmonary Nontuberculous Mycobacterial Disease/E. Henkle, A. Quittner, E. Saez-Flores, G.P. Ranches, K.L. Winthrop, Portland, OR, p.A5078

120 The Relationship Between Interferon-g/Interleukin-17 Production and Clinical Effects of Antibiotic Therapy on Non-Tuberculous Mycobacterial Infection/H. Kobayashi, Suzuka, Japan, p.A5079


C26 ASTHMA IN INFANTS AND CHILDREN

9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER

Poster Viewing 9:15-10:00
Discussion 10:00-11:15

Chairing: D.K. Pillai, MD, Washington, DC
T.J. Moraes, MD, PhD, Toronto, Canada

POSTER DISCUSSION SESSION


Neutrophil Elastase Restores Muscarinic 3 Receptor (M3R) Expression that Has Been Suppressed by Interleukin (IL)-13/K. Komiya, T. Akaba, Y. Kozaki, B.K. Rubin, Richmond, VA, p.A5084


Stability of Remodeling-Associated and Immunomodulatory Gene Expression by Primary Bronchial Epithelial Cells from Asthmatic and Healthy Children Over Increasing Cell Passage/S.R. Reeves, K. Barrow, M. White, T. Kolstad, M. Naushab, J.S. Deiley, Seattle, WA, p.A5086


The Triple Roles of Preterm Birth in the Development of Childhood Asthma/H. He, M.E. Hughes, X. Wang, Chengdu, China, p.A5090

Oxygenation Index and Lung Recovery in Extracorporeal Life Support (ECLS) for Near Fatal Pediatric Asthma/R. Kohlbirg-Davis, C.L. Carroll, H. Schiott, A.S. Cowl, Hartford, CT, p.A5091


ECG Changes of Right Ventricular Strain Do Not Predict Hemodynamic or Clinical Improvement in Patients Undergoing Pulmonary Thromboendarterectomy/F. Raza, H. Al-Maluli, A. Vaidya, F. Rogers, P. Forfia, Philadelphia, PA, p.A5115


Echo and Magnetic Resonance Imaging in Pulmonary Hypertension: The Relationship of 2 Dimensional -Speckle Tracking Echocardiography Strain Rate and Magnetic Resonance Ejection Fraction of the Right Ventricle/T. Crowe, G. Jayasekera, A. Mackenzie, M. Brewis, C. Church, M. Johnson, P. Sonecki, A. Peacock, Glasgow, United Kingdom, p.A5117


The Effect of Upfront Combination Therapy on Right Ventricular Volumes in Patients with Pulmonary Arterial Hypertension/A. E. Huis in’t Veld, M. Van De Veerdonk, J. T. Marcus, H. J. Bogaard, A. Vonk Noordegraaf, Amsterdam, Netherlands, p.A5119


Right Ventricular Ejection Doppler Envelope by Echo Characterizes PA Hemodynamics in Portopulmonary Hypertension/S. Mizra, M. Krowka, G. Kane, Rochester, MN, p.A5121


R.A.P.I.D.: RAPID ABSTRACT POSTER DISCUSSION

C28 FROM TARGETS TO THERAPIES IN FIBROSIS

9:15 a.m. - 11:15 a.m. MARRIOTT MARQUIS WASHINGTON

Abstract Summaries
9:15-9:45

Poster Viewing/Discussion
9:45-11:15

Chairing: E. Herzog, MD, PhD, New Haven, CT
K. Atabai, MD, San Francisco, CA
K. K. Kim, MD, Ann Arbor, MI


902 Pulmonary Fibrosis Following Targeted Type II Alveolar Epithelial Cell Injury Requires the Somatomedin B Binding Function of Plasminogen Activator Inhibitor-1 but Not Vitronec tin/J. A. Roussey, N. Subbotina, M. Dotson, A. Vink, J. J. Osterholzer, T. Sisson, Ann Arbor, MI, p.A5124

903 Telomerase Reverse Transcriptase Deficiency in Type II Alveolar Epithelial Cells Enhanced Bleomycin-Induced Pulmonary Fibrosis/T. Liu, F. Gonzalez De Los Santos, Z. Wu, Y. Zhao, S. H. Phan, Ann Arbor, MI, p.A5125

904 Mice with Mutant E1A-Binding Protein-300 kD (p300(S89A)) Are Protected from Bleomycin-Induced Lung Fibrosis/M. Sunohara, T. Sasaki, P. Floody, B. Zhou, E. D. Crandall, M. Kahn, Z. Borok, Los Angeles, CA, p.A5126


916 Alveolar Type 2 Cell Dynamics and Long-Term Effect of Allogenic Alveolar Type 2 Cell Transplantation in Murine Bleomycin-Induced Lung Injury/K. Hasegawa, A. Sato, S. Sato, K. Tanimura, K. Uematsu, Y. Hamakawa, S. Muro, Kyoto, Japan, p.A5138


918 A Role for Primary Cilia in the Pathogenesis of Pulmonary Fibrosis/S. Garantziotis, C.S. Trempus, Research Triangle Park, NC, p.A5140


820 Investigating Alveolar Mechanics with Time-Resolved Optical Coherence Tomography (OCT) and Intravitral Microscopy (IVM) in Rats/C. Schnabel, E. Koch, Dresden, Germany, p.A5166


823 Static Versus Dynamic PET Scanning for Quantification of Lung Inflammation in Experimental ARDS/A. Braune, T. Kiss, T. Bluth, J. Kotzerke, M. Gama De Abreu, Dresden, Germany, p.A5169

824 Simultaneous Imaging Of Airway Liquid Absorption And Muco-Ciliary Transport Rates with PET/J.G. Venegas, J.L. Hernaiz, M. Papisov, E. Lage, A. Santos, M.A. Lessa, S. Weise, C. Kosour, Boston, MA, p.A5170


C30 LUNG CANCER SCREENING: WHO, WHY, WHERE, AND HOW MUCH

9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER Room 206 (South Building, Level 2)

Abstract Summaries 9:15-9:45

Poster Viewing/Discussion 9:45-11:15

Chairing: H.C. Cain, MD, New Haven, CT
H. Kathuria, MD, Boston, MA
D.E. Midthon, MD, Rochester, MN
J.A. Gorden, MD, Seattle, WA

The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.

ATS 2017 • Washington, DC
601 SNP-Based Risk Score Outperforms a Clinical Model for Dying of Lung Cancer in the NLST-ACRIN Sub-Study (N=10,054)/R.P. Young, F. Duan, E. Greco, R.J. Hopkins, C. Chiles, G.D. Gamble, D. Aberle, Auckland, New Zealand, p.A5172


605 The Effects of Lung Cancer Screening Decision Intervention on Patient Knowledge, Intentions to Screen and Decisional Satisfaction/E. Banas, C. Hughes Halbert, L. Dai, N. Tanner, Charleston, SC, p.A5176


607 Lung Cancer Screening with Low Dose CT: Two Year Experience at Providence Veteran Affairs Medical Center/J.V. Baptiste, M. Jankowich, L.L. Nici, Providence, RI, p.A5178

608 The Clinical Benefit and Cost-Effectiveness of Adding a Smoking Cessation Program to a Simulated Lung Cancer Screening Program in Saskatchewan, Canada/R. Bethune, L. Wu, D. Goodridge, C. Hergott, N. Osgood, B. Manns, Y. Tian, T. Sherin, E. Penz, Saskatoon, Canada, p.A5179


613 Adherence to National Comprehensive Cancer Network Guidelines Within a Veterans’ Administration Medical Center Program for Lung Cancer Screening/J.J. Saukkonen, S. Yoon, A. Jat, R. Goldstein, West Roxbury, MA, p.A5184


617 Increasing Referrals to a Lung Cancer Screening Program in an Outpatient Clinic/J.T. Moyers, I. Hendrickson, M. Schoepflin-Sanders, Portland, OR, p.A5188


619 Compliance with Lung Cancer Screening Implementation in an Urban Teaching Hospital Internal Medicine Clinic/C. Olazagasti, D. Sampat, J. Filopeci, D. Chow, D. Steiger, New York, NY, p.A5190


621 Alpha-1 Antitrypsin Patients’ Perceptions Regarding Lung Cancer Risk and Screening/S. Kariyawasam, A. Butler, C.B. Strange, D. Kahn, Danbury, CT, p.A5192


623 Stratification of NLST-ACRIN Screening Participants Identifies the “Sweet Spot” of Screening by Identifying Early Stage Lung Cancers Most Amenable to Curative Surgery (N=10,054)/R.P. Young, R.J. Hopkins, F. Duan, E. Greco, C. Chiles, D. Aberle, G.D. Gamble, Auckland, New Zealand, p.A7656
C31  BASIC AND TRANSLATIONAL STUDIES ON THE ROLE OF THE EPITHELIUM

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER

Area N, Hall B-C (Middle Building, Lower Level)

Poster Viewing

Discussion:  11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator:  H. Kage, MD, PhD, Tokyo, Japan


P1459  microRNAs as Potential Epigenetic Targets to Restore the Airway Epithelial Integrity in Asthmatics/F. Moheimani, T. Williams, J. Koops, A.T. Reid, P.M. Hansbro, P.A. Wark, D. Knight, New Lambton, Australia, p.A5196

P1460  The Isoprenoids FPP and GGPP Augment IL13-Induced Eotaxin-3 Production in Human Airway Epithelial Cells: A New Target for Treating Airway Eosinophilia?/A.A. Zeki, M. Arif, S. Ott, Sacramento, CA, p.A5197

P1461  Inhibition of ABCC4 Attenuates Extracellular Cyclic AMP Transport and Pro-Inflammatory Immune Responses in Human Airway Epithelial Cells/R. Huff, C.F. Rider, D. Yan, R. Newton, M. Giembycz, J.A. Hirota, Vancouver, Canada, p.A5198

P1462  The Regulation of IL-13 Signaling Via IL-13 Receptor Subunits in Airway Epithelial Repair/S.-Y. J. Yang, A. Singh, D.R. McQuade, F. Holguin, Aurora, CO, p.A5199


P1466  Effect of Clarithromycin on IL-13-Induced Goblet Cell Metaplasia in Guinea Pig Airway Epithelial Cells: Role of TMEM16A/K. Hara, M. Kondo, M. Tsuji, J. Tamaoki, Tokyo, Japan, p.A5203


P1468  Spleen Tyrosine Kinase Induces MUC5AC Expression in Human Airway Epithelial Cell/Y. Kim, Y.S. Choi, H.G. Na, C.H. Bae, S.-Y. Song, Daegu, Korea, Republic of, p.A5205


P1478  Novel Role for Protein Kinase D in Regulating Airway Epithelial Cytokine Secretion and Barrier Integrity/J. Veaze, T. Chapman, T. Smyth, S. Hillman, S. Georas, Rochester, NY, p.A5215
P1479 Normal Human Bronchial Epithelium Release Tissue Factor Via ERK1/2 in Response to Lipopolysaccharide Stimulation/M.D. Davis, K. Komiyama, T. Akaba, B.K. Rubin, Richmond, VA, p.A5216

P1480 Role of Spleen Tyrosine Kinase (SYK) in the Airway Epithelium in Asthma/A. Martinez-Anton, D. Gras, C. Garulli, P. Dubreuil, P. Chanez, Marseille, France, p.A5217


P1482 Differential DNA Methylation in Bronchial Biopsies Between Persistent Asthmatics and Subjects in Asthma Remission/Induce Emphysemalike/T.A. Ajayi, K. Gabor, A. Melchior, T. Baydoun, J. Amsalem, M. van den Berge, Groningen, Netherlands, p.A7658


P353 Type 2 Inflammatory Responses Protect Against Lethal Staphylococcus Aureus Infection/P. Krishnakumar, A.I. Sperling, P.A. Verhoef, Chicago, IL, p.A5222


P355 MKP-1 Regulates LPS-Mediated IL-1α Production Through p38 Activation and HIF-1α Expression/P. Rai, M.B. Fessler, Research Triangle Park, NC, p.A5218


P363 Particulate Matter-Induced Pulmonary Injury Via Egr-1/Necroptosis Pathway Leading to NF-κB and AP-1 Activation/F. Xu, Z. Chen, H. Shen, Hangzhou, China, p.A5228


P366 Identification of a Region Within the Thrombospondin-1 Type III Domain with Inhibitory Activity Against Pseudomonas Aeruginosa Elastase Activity/W. Bain, J. Darell, T. Olonisakin, Y. Qu, J.M. Pilewski, J. Lee, Pittsburgh, PA, p.A5231


P368 The Effects of Inhaled Glucocorticoids on Growth of Pseudomonas Aeruginosa/J. Huang, L. Begley, Ann Arbor, MI, p.A5233

P369 The Role of IL-33 in Hyperoxia-Induced Lung Injury and BPD/L. C. Eldredge, R.S. Creasy, F. Roan, S.F. Ziegler, Seattle, WA, p.A7660


P375 Particulate Matter-Induced Pulmonary Injury Via Egr-1/Necroptosis Pathway Leading to NF-κB and AP-1 Activation/F. Xu, Z. Chen, H. Shen, Hangzhou, China, p.A5228

The information contained in this program is up to date as of March 9, 2017. For the most current session information, please visit the online program itinerary.
**C33** NOVEL BIOMARKERS IN LUNG DISEASE

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER

Area N, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion

12:00-1:00: authors will be present for discussion with assigned facilitators

---


**P1485** Aspergillus Fumigatus Alkaline Protease, Alp1 (Asp f 13) as a Biomarker for Severe Asthma/T. Basu, K.M. Drey, Bethesda, MD, p.A5236

**P1486** CXCL10 and Severe Asthma, a Possible Agent for Steroid Insensitivity/M. Gauthier, M. Raundhal, T.B. Oriss, P. Ray, S.E. Wenzel, A. Ray, Pittsburgh, PA, p.A5237


**P1490** Sputum IL-17A Levels Correlate with Biomarkers of Non-Eosinophilic Inflammation in Patients with Asthma/G. Hynes, S. Go, S.J. Thuiborn, C. Borg, C. Connolly, R. Shrimanker, L. Xue, M. Bafadhel, I. Pavorov, Oxford, United Kingdom, p.A5241

**P1491** Identification of IL-17F/Frequent Exacerbator Endotype in Asthma/F.L.M. Ricciardolo, A. Folino, F. Gallo, G. Ciprandi, A. Di Stefano, Orbassano (Torino), Italy, p.A5242


---

**C34** MECHANISMS OF HOST DEFENSE IN BACTERIAL AND FUNGAL INFECTIONS

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER

Area E, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion

12:00-1:00: authors will be present for discussion with assigned facilitators

---


**P1496** Ao-Val41 a Novel Biomarker of Proteinase 3 Activity/P. R. Newby, R.I. Carter, R.A. Stockley, Birmingham, United Kingdom, p.A5247


**P1498** YKL-40 as a Biomarker of Airway Disease in Severe Asthma/M.M.T.C. Cortez e Castro, G. Lockett, L. Lau, P. Howarth, J. Holloway, Lisbon, Portugal, p.A5249


**P1501** Serum Angiopoietin-2 Can Be a Biomarker in Acute Exacerbation of Interstitial Pneumonia/T. Tateishi, T. Fujie, H. Saito, Y. Miyazaki, N. Inase, Tokyo, Japan, p.A5252

**P1502** Molecular Alterations Across Multiple Tissues in Pulmonary Alveolar Proteinosis Patients Share Commonalities with Immune Related Lung and Autoimmune Disorders/S. Sridhar, A. Malur, E. Grant, M.A. Michaels, H. Liu, P. Ryan, M. Kavuru, M.J. Thomassen, Gaithersburg, MD, p.A5253

---

**The information contained in this program is up to date as of March 9, 2017.**

For the most current session information, please visit the online program itinerary.
C59  ASTHMA AND ALLERGY CELLULAR INVESTIGATIONS

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER
Area K, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators


P1011 Theracurmin®, a Highly Absorptive Nanoparticle Curcumin, Reduces Th2 Inflammatory Responses and Airway Mucus Production in Ovalbumin-Induced Murine Model of Asthma/K. Takeyama, S. Ashino, K. Orimo, J. Yagi, J. Tamaoki, Tokyo, Japan. p.A5310

P1012 A Different Composition of Exhaled Breathe Codensate in Pediatric Patients with Asthma, Cystic Fibrosis and Healthy Controls/F. Kopriwa, Olomouc, Czech Republic. p.A5311


P1015 Cellular Analysis of Induced Sputum by Chipcytometry/M. Muller, C. Hennig, A. Mirenska, O. Holz, J.M. Hohlfeld, Hannover, Germany. p.A5314


P1017 Basophils in Healthy Individuals, Asthma and COPD Display Marked Heterogeneity in Expression Pattern of Tryptase and Carboxypeptidase-3JP. Siddhuraj, M. Mori, L. Bjerner, J. Erjefalt, Lund, Sweden. p.A5316


C36 ASTHMA AND ALLERGY: CASE SERIES AND REPORTS

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area K, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators


P1024 Allergic Bronchopulmonary Mycosis Caused by Cladosporidium/A. Berglund, A. George, A.J. Skabelund, Ft. Sam Houston, TX. p.A5322


P1026 Straw-ing for Air/R.A. Estrada, M. Velez, San Antonio, TX. p.A5324

P1027 Tick Bites and Delayed Anaphylaxis to Red Meat: Rare Alpha-Gal Allergy in Florida/S.W. Robison, Jacksonville, FL. p.A5325


P1031 Biologics or Bronchial Thermoplasty? Using a Case-Based Approach to Select from Advanced Asthma Therapies/A. A.R. Estrada, M. Velez, San Antonio, TX. p.A5329

P1032 Paecilomyces Hypersensitivity Syndrome: Allergic Fungal Inflammation In Vivo/A. Berglund, A. George, A.J. Skabelund, Ft. Sam Houston, TX. p.A5330

The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.
P126 Predictors of Inappropriate Diagnosis and Management of Bronchiolitis/C. Rodriguez-Martinez, L. Sarmiento, G. Rojas-Soto, Bogotá, Colombia, p.A5354

Facilitator: B.E. Jones, MD, MSc, Salt Lake City, UT

P127 Medical and Pharmacy Costs Associated with the Treatment of Adult Patients with Community-Acquired Pneumonia in the Outpatient Setting/T. Lodise, P. Classi, P. Blumberg, S. Murty, G. Tillotson, Albany, NY, p.A5355


P131 Spirometric and Image Findings Among Children and Adolescents Users of Inhaled Illicit Drugs/W. Saasouh, B.C. Harvey, A. Turan, Cleveland, OH, p.A5361

Facilitator: J.M. Foster, PhD, Sydney, Australia


P133 Capturing the Complexity of FEV1 Dynamics with Median Quantile Regressions Splines/N. Huynh, J. Billings, R. Jain, J.L. Koff, A.M. Mulenos, D. Rosenbluth, C. Teneback, D.J. Conrad, San Diego, CA, p.A5361

P134 Assessment of the Feeding Swallowing Impact Survey as a Quality of Life Measure in Children with Laryngeal Cleft Before and After Repair/M.S. Fracchia, C. Hersh, G. Diercks, S. Hardy, C. Hartnick, Boston, MA, p.A5362

P135 Obese Patients Have Same Frequency of Post-Operative Respiratory Depression as Defined by Low Minute Ventilation Events/W. Saasouh, B.C. Harvey, A. Turan, Cleveland, OH, p.A5363

P136 A Quality Improvement Project to Assess Obstructive Lung Disease Exacerbation Discharges/J.M. Chowdhury, M. Kosa, B. Simcox, V. Sheth, A. Maheshwari, M. Korman, Darby, PA, p.A5364

P137 Bronchoalveolar Lavage Fluid Cellular Analyses Differ by Laboratory Technique/L. Barss, K.A. Johannson, Calgary, Canada, p.A5365


P139 Comparative Analysis of Quality of Service Between Nurse Practitioners and Physicians in a Specialty Clinic/L. O’Hare, D.P. Kirkpatrick, Birmingham, AL, p.A5387

Facilitator: N. Thakur, MD, MPH, San Francisco, CA


P142 Review of Instructions for Use (IFUs) of Intravascular Medical Devices (IMDs) After an FDA Safety Warning Using a Human Factors Engineering Heuristic/H. Shanawani, T. Bagian, Ann Arbor, MI, p.A5370

P143 Estimated Blood Loss (EBL) Documentation of Anesthesia Vs Surgery Improved Due to Electronic Medical Record (EMR) but Still Far from Accuracy - Revisiting Literature After 44 Years/I. Ratmani, F. Bokhari, S. Zaidi, Houston, TX, p.A5371

P144 Cardiovascular Thoracic Surgery Multidisciplinary Team Collaboration for the Fast Track Open Heart Patient/M. Richardson, Danville, PA, p.A5372

P145 Barriers to Optimal Hypertension Management in Rural District Hospitals in Rwanda: A Cross-Sectional Study/J.P. Sibomana, Muhanga, Rwanda, p.A5373


P147 Depression Associated with Cardiac Surgery and the Role of Fatalism/P.A. Trainor-O’Malley, New York, New York, NY, p.A5375


P150 Oxygen Prescribing Practice Continues to Be Poor - Does Training of Clinicians Need to Be Changed?/J.U. Rafique, A. Hashim, S. Chandran, Manchester, United Kingdom, p.A5378


C38 UNDERSTANDING THERAPEUTICS IN IPF

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER
Area M, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: M.K. Glassberg, MD, Miami, FL


P1280 Pharmacokinetics of Nintedanib in Subjects with Hepatic Impairment/K. Marzin, G. Kretschmar, R. Schlenker-Herceg, C. Dallinger, Biberach an der Riss, Germany, p.A5380


Facilitator: J. Behr, MD, Munich, Germany/


P1289 Patient Preferred Choice of Treatment with Nintedanib or Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): A Prospective Observational Study with Outcomes Over 1 Year at a Single Tertiary Center/B.F. Collins, L. Ho, M. Mayo, C. Mikacenic, J. Hayes, L. Mulder, C. Spada, G. Raghu, Seattle, WA, p.A5389

P1290 Effect of Pirfenidone on All-Cause Mortality (ACM) and Forced Vital Capacity (FVC) in Idiopathic Pulmonary Fibrosis (IPF) Patients with Low FVC and/or Low DLCO: Analysis of Pooled Data from ASCEND and CAPACITY/J.D. Nathan, U. Costabel, C. Albera, K.-U. Kirchgassler, W. Chou, P.W. Noble, Falls Church, VA, p.A5390


Facilitator: G. Raghu, MD, Seattle, WA


The information contained in this program is up to date as of March 9, 2017. For the most current session information, please visit the online program itinerary.
C39  BIOMARKERS AND PROGNOSTIC FACTORS IN ILD
9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER
Area M, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitator
Facilitator:  A.M. Tager, MD, Charlestown, MA


P1313 Validation of New Prediction Score in Inhalation Provocation Test for Chronic Hypersensitivity Pneumonitis/Y. Miyazaki, N. Inase, Bunkyo, Japan, p.A5412


Facilitator: E. Herzog, MD, PhD, New Haven, CT


P1326 A Prospective Cohort Study to Assess the Use of Fluodeoxyglucose Positron Emission Tomography (FDG-PET) in Assessing Treatment Response in Patients with Systemic Sclerosis Associated Interstitial Lung Disease/H. Garthwaite, C. Denton, A. Groves, J. Porter, London, United Kingdom, p.A5425


Facilitator: I. Rosas, MD, Boston, MA


P1331 Risk of Coronary Artery Disease in Patients with Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis/P. Charoenpong, Brooklyn, NY, p.A5430


P1335 Mid-Flow Rates Do Not Predict Mortality in Idiopathic Pulmonary Fibrosis Patients/F. Nunes, A.W. Brown, C. King, E. Battle, O.A. Shlobin, S.D. Nathan, Falls Church, VA, p.A5434


Facilitator: R. Raj, MD, Chicago, IL


P715 Calculating the Rate of Change (RoC) Rather than the Sitting Facilitator: A.E. Dimmock, MS, Hershey, PA

P716 The Impact of Right Ventricular Diastolic Pressure on Mortality in Patients with Idiopathic Pulmonary Fibrosis Facilitator: S.R. Devarajan, N. Hanania, MD, MS, Houston, TX


C40 DYSPNEA: CLINICAL STUDIES

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER Area G, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: A.E. Dimmock, MS, Hershey, PA


P715 Calculating the Rate of Change (RoC) Rather than the Sitting Facilitator: A.E. Dimmock, MS, Hershey, PA


C41 LONG ACTING BRONCHODILATOR THERAPY IN COPD II

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER Area L, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: N. Hanania, MD, MS, Houston, TX


P720 Discrepancy Between Pulse Oximetry and Arterial Oxygen Saturation at Rest and During Exercise Facilitator: R.W. Platt, A. Bhattacharyya, J. Ramos, A.R. Tonelli, Cleveland, OH, p.A5451


For the most current session information, please visit the online program itinerary.

P1080  Efficacy and Safety of SUN-101/eFlow (Nebulized Glycopyrrolate) in Moderate-To-Very-Severe COPD: Results from the Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer (GOLDEN) 3 and 4 Studies/E.M. Kerwin, J.F. Donohue, T. Goodin, R. Tosiello, A. Wheeler, G.T. Ferguson, Medford, OR, p.A5464


Facilitator:  J. Ohar, MD, Winston-Salem, NC


P1086  A Prospective, Non-Interventional, Multi-Center Study to Evaluate the Effectiveness of Glycopyrronum Bromide for the Treatment of COPD Patients in Real-World Clinical Practice (GLARE: Glycopyrropon Bromide for the mAnteinance tReatment of COPD in a reAl\textsuperscript{®}L.P. Chan, C.H. Lin, J.Y. Hsu, L.W. Hang, W.C. Huang, C.P. Chen, Changhua City, Taiwan, p.A5470


P1088  In-Vitro Characterization of the eFlow\textsuperscript{®} Closed-System (eFlowAr CS) Nebulizer with Glycopyrrolate Inhalation Solution (SUN-101)/S. Pham, G.T. Ferguson, E.M. Kerwin, T. Goodin, A. Wheeler, A. Bauer, Marlborough, MA, p.A5472

P1089  Evaluation of the Safety of Long-Term Use of Perforomist\textsuperscript{®} (Formoterol Fumarate) Inhalation Solution in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)/N. Hanania, S. Sethi, A. Kolunt, J. Ward, J. Spanton, D. Ng, Houston, TX, p.A5473


Facilitator:  C. Martinez, MD, MPH, Ann Arbor, MI


P1097  Efficacy and Safety of Formoterol Fumarate in Acute Exacerbation of Chronic Obstructive Pulmonary Disease/D. Zujovic, V. Zugic, Belgrade, Serbia, p.A5481

P1098  Clinical Effectiveness of Fluticasone Furoate/Vilanterol (FF/VI): The Impact on Exacerbations in COPD Patient Subgroups of the Salford Lung Study (SLS COPD)/N. Hanania, S. Sethi, A. Koltun, J. Ward, J. Spanton, D. Ng, Houston, TX, p.A5482

The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.

P1100 Single Inhaler Triple Therapy (ICS/LAMA/LABA) in Patients with Advanced COPD: Patient Reported Symptom and Inhaler Preference Results from the FULFIL Trial/M. Tabberer, D. Lomas, H. Barnacle, R. Birk, N. Brealey, C.-Q. Zhu, S. Pascoe, N. Locantore, D.A. Lipson, Uxbridge, United Kingdom, p.A5484

C42 DYSPNEA: CASE REPORTS

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER Area G, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: S. Bose, MD, MPH, New York, NY


P731 Unilateral Diaphragmatic Paralysis: A Rare Manifestation of Lyme Neuroborreliosis/B.B. Patel, S. Umar, Roanoke, VA, p.A5486

P732 Bronchogenic Cyst as the Cause of Respiratory Comprise in an Unilateral Diaphragmatic Paralysis: A Rare Manifestation of Diffuse Alveolar Maculopapular Disease/H. Saiyed, M. Bachan, R. Siegel, Z. Khan, Bronx, NY, p.A5487

P733 A Management Dilemma: Submassive Pulmonary Embolism Due to Diffuse Alveolar Maculopapular Disease/1. Bally, D. Railwah, Brooklyn, NY, p.A5488

P734 Stridor Mystery: Do We Really Need to Intubate?/R. Habibi, A.J. Altmirano, H. Friedman, P. Limbu, Evanston, IL, p.A5489

P735 Cocaine Related Coronary Artery Dissection and Renal Infarcts in Post Partum Female/A. Ali, M.A. Zulqarnain, Winston Salem, NC, p.A5490

P736 A Rare Case of Spontaneous Pneumatoceles in a Healthy Young Man/A. Wahab, S. Chaudhary, S.J. Smith, Flint, MI, p.A5491

P737 A Rare Case of Pulmonary Embolism Induced Symptomatic Bradycardia/P. Catella, S. Wiesel, A.H. Siddiqui, M. Chalhoub, Staten Island, NY, p.A5492

P738 Serial Lobar Lavage as an Alternative to Whole Lung Lavage for the Treatment of Symptomatic Pulmonary Alveolar Proteinosis/P. Shah, J. Lee, D. Hostler, Honolulu, HI, p.A5493

P739 Double Aortic Arch Causing Dyspnea in a Middle Aged Woman/M. Venkata Subramani, Cleveland, OH, p.A5494

P740 Pulmonary Alveolar Proteinosis (PAP) - a Rare Case of Adult Onset Congenital PAP/M. Kalani, R. Sharara, A. Kasaya, V. Gandhi, E. Bihler, Pittsburgh, PA, p.A5495

P741 A Case of Acute Eosinophil Pneumonia in a 27 Year-Old Pregnant Female/E. Salem, J. Stalica, Rochester, NY, p.A5496

Facilitator: P. Terry, MD, Baltimore, MD

P742 A Rare Case of Relapsing Polychondritis Presenting with Life Threatening Airway Collapse/A. Ali, F. Adeel, N. Kapa, M. Taleb, S. Rehman, J. Willey, H. Badi, Toledo, OH, p.A5497

P743 Giant Bulla with Hilar and Paratracheal Lymphadenopathy in a Young Male Smoker: A Rare Case Report/H. Khan, S. Chaudhary, A. Wahab, M. Khan, S.J. Smith, Flint, MI, p.A5498


P746 Idiopathic Subglottic Stenosis Presenting in Pregnancy/B. Noumi, A. Attaway, M. Nagaraja, R. Folz, Cleveland, OH, p.A5501


P748 A Rare Case of Pulmonary Embolism Induced Symptomatic Bradycardia/1. Bally, D. Railwah, Brooklyn, NY, p.A5503

P749 Severe Bradycardia/1. Bally, D. Railwah, Brooklyn, NY, p.A5504

P750 Breathtaking Brassiere: A Mysterious Case of Dyspnea with a Surprisingly Simple Explanation/A. Damodaran, I. Rubinstein, Chicago, IL, p.A5505


P752 When Anxiety Can Take the Breath Away Literally/M. Fariduddin, K. Yashi, Syracuse, NY, p.A5507


Facilitator: C. Bime, MD, MSC, Tucson, AZ

P754 Pulmonary Amyloid: A Rare Cause of Dyspnea and Hemoptysis/D. Nandiraju, B. Lashtari, W. Ward, Abington, PA, p.A5509

P755 Insidious Respiratory Failure in a 54-Year-Old Woman: The Clue to Diagnose a Family with Pompe Disease/M. Asadi Gharabaghi, A. Farid Rohani, S. Peiman, S. Kafan, M. Yadollahzadeh, Tehran, Iran, p.A5510

P756 Chest Pain and Dyspnea Secondary to a Rare Complication of Pancreatitis/E. Au, San Francisco, CA, p.A5511

P757 A Very Rare Cause of Low Oxygen Saturation (SaO2) with Normal Partial Pressure of Oxygen (PaO2)/J. Tu, J. Martinez, D. Yick, Sylmar, CA, p.A5512
P794  Acute Hypoxemic Respiratory Failure in a Patient with Metastatic Carcinoma; a Case of Programmed Death Ligand-1 Induced Pneumonitis/B.A. Silverman, K. Ramakrishna, J. Sugunaraj, D. Bandyopadhyay, Daville, PA, p.A5548

P795  Blinicyto (Blinatumomab) Induced Pneumonitis Case Report/A. Olson, J. Chertoff, A. Ataya, C. Trillo, M. Barnes, Gainesville, FL, p.A5549

P796  Rare but real: Pleural Effusion Associated with Bosutinib Therapy for Chronic Myeloid Leukemia (CML)/H.A.M. Fakih, S. Daouk, N. Moguilianskis, Gainesville, FL, p.A5550

Facilitator:  M. Hamblin, MD, Kansas City, KS

P797  Lenalidomide Induced Interstitial Lung Disease/H. Shahzad, J. Goralkin, E. Nadler, A. Qureshi, Farmington, CT, p.A5551

P798  A Rare Cause of Organizing Pneumonia: Idelalisib, an Oral Inhibitor of Phosphoinositide 3-Kinase Delta/A. Shakespeare, R. Franco, P. Sikka, U. Bhat, Temple, TX, p.A5552


P804  Crack Lung: A Rare but Potentially Fatal Complication of Cocaine Use/S. Soni, O. Siddiqui, H.K. Puttagunta, Urbana, IL, p.A5559


P807  Naloxone Induced Noncardiogenic Pulmonary Edema/N. Jiwa, H. Sheth, R. Silverman, Waterbury, CT, p.A5562


P811  Acute Eosinophilic Pneumonia Due to Extended-Release Exenatide/C. Akin, T. Sjulin, J. Hull, J. Reis, Sam Houston, TX, p.A5566


P813  Silver Nitrate Aspiration, a Potentially Life Threatening Complication/S. Nonas, MD, Portland, OR

P814  Sotalol Induced Diffuse Alveolar Hemorrhage/T. Pelleg, R.S. Kadakia, F. Siddiqui, F. Biscardi, S. Se, Roanoke, VA, p.A5569

Facilitator:  S. Nonas, MD, Portland, OR

P815  Desvenlafaxine-Induced Chronic Hypersensitivity Pneumonitis and a Literature Review of Venlafaxine-Induced Interstitial Pneumonitis/A. Flora, D. Pipoly, Toledo, OH, p.A5570

P816  Medialstitial Granulomatous Inflammation Secondary to Ruptured Silicone Breast Implants/S. Chaudhary, A. Wahab, H. Khan, M. Khan, S.J. Smith, A. Ghatol, Flint, MI, p.A5571

P817  Open Sesame/K. Cerreta, Salt Lake City, UT, p.A5572

P818  Carboxyhemoglobin as High as K2/N. Juul, A. Friedenberg, Palo Alto, CA, p.A5573

P819  A Case of Systemic Hypereosinophilia Associated with Doxycycline Administration/M. Nelson, P. Hoof, A. Mora, Dallas, TX, p.A5574

P820  An Extremely Rare Case of Diffuse Alveolar Hemorrhage (DAH) in an Elderly Female/A. Rasheed, M. Shahzadi, Z. Hashemi, H. Upadhyay, V. Vasudevan, L. Gerolemou, F. Arjomand, Brooklyn, NY, p.A5575

P821  ARDS? A Case of Methotrexate-Induced Acute Pneumonitis/I. Afzal, I. Wong, Lake Erie, PA, p.A5576


P823  Azathioprine Induced Lung Injury/C. Chan, P. Nystrom, Dayton, OH, p.A5578

---

C44  IMMUNODEFICIENCY: CASE REPORTS

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER

Area M, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion

12:00-1:00: authors will be present for discussion with assigned facilitators

The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.

P1350  Missed HIV Diagnosis with Devastating Acute Respiratory Failure from Pneumocystis jiroveci/U. I. Maduforo, C. R. Martin, I. Elueze, Longview, TX, p.A5580

P1351  Primary Pulmonary Kaposi’s Sarcoma as the Initial Presentation of HIV Infection/A. Dirwesseh, M. Khan, S. Fawwad, M. Smith, N. Karabulut, Trenton, NJ, p.A5581


P1353  Co-Presentation of Eosinophilic Granulomatosis with Polyangiitis with HIV Disease/D. Zisin, W. E. Harner, A. I. Philip, Bethesda, MD, p.A5583


P1359  Dabigatran as a Very Rare Cause of Autoimmune Hemolytic Anemia/M. A. Zulqarnain, M. Ali, Lexington, KY, p.A5589


P1361  An Expanding Pulmonary Abscess Associated with Hyperimmunoglobulin E Syndrome/M. Rendo, S. Wood, A. Young, San Antonio, TX, p.A5591

P1362  Diffuse Tree-in-Bud Opacities Due to Pulmonary Alveolar Proteinosis Secondary to GATA2 Deficiency/D. Kay, D. Karanovic, M. Roth, D. Mollura, C. Mollo, S. Holland, K. P. Fennelly, Washington, DC, p.A5592


P1364  Common Variable Immune Deficiency (CVID) as the Likely Cause of Recurrent Pneumonias and Rhinosinusitis with Underlying Cryptogenic Organizing Pneumonia (COP)/A. Rajasekaran, M. A. Zulqarnain, Orlando, FL, p.A5594

P1365  History Matters: A Shockingly Toxic “Strep” in the Right Direction/J. Miely, S. Pandya, Chicago, IL, p.A5595


P1367  Immunoglobulin G4-Related Lung Disease Mimicking Bronchiolitis Obliterans Organizing Pneumonia in Association with Common Variable Immunodeficiency Syndrome/J. Nauseef, M. T. Bender, A. L. Harvey, A. Chadburn, New York, NY, p.A5597

P1368  IgG4-Related Pulmonary Nodules Mimicking Malignancy/R. Shah, E. J. Brit, Baltimore, MD, p.A5598


P1370  Mistaken Identity: Granulomatous and Lymphocytic Interstitial Lung Disease (GLILD) and Common Variable Immune Deficiency (CVID) Initially Diagnosed as Sarcoidosis/N. Arger, K. D. Jones, K. Gundling, L. L. Koth, San Francisco, CA, p.A5600

P1371  An Unusual Mimicker of Asthma in an Active Duty Army Physician/C. Askin, J. Reis, Sam Houston, TX, p.A5601

THEMATIC POSTER SESSION

C45  EBUS AND AIRWAY INTERVENTIONS: IP CASE REPORTS

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER

Area M, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion

12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator:  J. Cicenia, MD, Cleveland, OH


P1376  Symptomatic Bronchogenic Cyst with Vascular Compression and Actinomycosis Superinfection Treated with Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-FNA)/A. J. Hayek, U. Bhat, T. Lat, P. Sikkia, Temple, TX, p.A5605

Endobronchial Ultrasound: An Alternative Modality for Bronchogenic Cyst Diagnosis/T. Abdo, C. Hamilton, L. Zhao, A. Awab, Oklahoma City, OK, p.A5607

Diagnosis of Mediastinal Recurrence of Seminoma with Endobronchial Ultrasound:A.H. Alraiyes, P. Tunsupon, Zion, IL, p.A5608

Facilitator: P. Shah, MD, London, United Kingdom


Endobronchial Ultrasound; Wait but That’s the Heart!!/R. Goodarte, L. Nunez, L. Zabala, Vijaypur, Karnataka, India, p.A5610


Foreign Body Aspiration Presenting As Empyema/B. Wolk, S. Shah, L. Chandi, New Delhi, India, p.A5612

Cherry Pit Extraction Leading to Incidental Finding of Carcinoid Tumor Treated with Argon Plasma Coagulation Laser/A. Patel, G. Piersio, J. Gordon, S. Purohit, Washington, DC, p.A5613

Unusual Case of Popcorn Gone Away/N. Biru, A.F. Shorr, J. VanWagner, Farmington, CT, p.A5614


Endobronchial Argon Plasma Coagulation for Post Intubation Life or Death: A Case of Near Complete Tracheal Obstruction/T. Case, A.P. Maskey, Nicholasville, KY, p.A5627

Endobronchial Argon Plasma Coagulation for Post Intubation Tracheal Stenosis in a Patient on Dual Antiplatelet Therapy/A. Agarwal, K. Cruz Morel, R. Terrigno, W. Abouzgheib, Camden, NJ, p.A5628

Re-expansion of a Unilateral Whole Lung Collapse After Endobronchial Intervention of a Non-Small Cell Lung Cancer/R. Mazo, A. Sadoughi, Bronx, NY, p.A5629

The information contained in this program is up to date as of March 9, 2017.

For the most current session information, please visit the online program itinerary.


P1409  Case Report: Intercostal Lung Herniation 14 Years After Mitral Valve Surgery/?N.-T. Ha, M. Milan, T. Botta, Danbury, CT, p.A5637

P1410  Pleural Plaques Due to Asbestos Exposure in Infancy/E. Solbes, R. Harper, Sacramento, CA, p.A5638


P1420  A Case of Hepatic Hydrothorax with a Persistent Lymphocytic Exudative Effusion that Developed After Laparoscopic Cholecystectomy and Liver Biopsy/A. Goizueta, E. Copelin, J. Mehang, Providence, RI, p.A5649

P1421  Pleural Fluid Eosinophilia as a Rare Complication of Mesalazine in Patient with Ulcerative Colitis/I. Lalani, D. Lourdusamy, W. Ghali, Long Branch, NJ, p.A5650


P1423  An Interesting Case of a Pleural Based Lesion as Seen on Chest X-Ray/P. Gurram, V. Wadhwa, V.S. Kopparapu, T. Pandey, Little Rock, AR, p.A5652


P1428  Pleural Effusion in the Setting of Isolated Right Heart Failure: A Novel Mechanism/A. Ajaekumar, M. Menson, B. Seth, H.W. Farber, F. Schembri, Boston, MA, p.A5657

P1429  A Unique Presentation of Coccidioidomycosis/S. Copeland, R. Alalawi, Lubbock, TX, p.A5658


P1433  Atypical Presentation of Pleural Tuberculosis: A Diagnostic Challenge in a German Student/J. Margapuri, M. Rath, J. Stoeckel, M. Bachan, Z. Khan, Bronx, NY, p.A5662

P1434  The Use of Ultrasound and Color Doppler to Localize Trans-Diaphragmatic Flow in Hepatic Hydrothorax/K.A. Gershwin, H. Sauthoff, New York, NY, p.A5663

P1435  Is Chest Tube Thoracostomy Contraindicated in Cirrhotic Patients? A Case of Spontaneous Bacterial Empyema in a Cirrhotic Patient Managed Via Chest Tube Thoracostomy/G. Venious, D. Herman, J.W. McCallister, Columbus, OH, p.A5664

P1436  A Rare Case of Superbug Acinetobacter Baumannii Related Empyema/M. Kashif, D. Arya, M. Khaja, Bronx, NY, p.A5665

P1437  Rapid Developing Empyema by Group F Beta Hemolytic Streptococci (Streptococcus Milleri)/M. Azharuddin, P. Dy, P. Shukla, A. Mathur, Long Branch, NJ, p.A5666


---

**THEMATIC POSTER SESSION**

**C48 COPD: CASE REPORTS I**

**9:15 a.m. - 4:15 p.m.** WALTER E. WASHINGTON CONVENTION CENTER

**Area L, Hall B-C (Middle Building, Lower Level)**

**Viewing:** Posters will be on display for entire session.

**Discussion:**
- 11:15-12:00: authors will be present for individual discussion
- 12:00-1:00: authors will be present for discussion with assigned facilitators

**Facilitator:** C. Martinez, MD, MPH, Ann Arbor, MI

**P1126** Extremely High Plasma Desmosine Level in a Patient with COPD and an Acute Incarcerated Inguinal Hernia/R. Janssen, M. Spanbroek, J.M. Van Den Ouweland, Nijmegen, Netherlands, p.A5697

**P1127** Use of Continuous High-Frequency Oscillation (CHFO) and Continuous Positive Expiratory Pressure (CPEP) Therapy in a Patient Admitted for COPD Exacerbation: Quality Improvement and Unexpected Benefits/C. Landon, J.M. Van Den Ouweland, Nijmegen, Netherlands, p.A5698

**P1128** Life2000: An Ambulatory Ventilator’s Role in Improving Outcomes for Pulmonary Compromised Patients/C. Landon, R. Gregg, Ventura, CA, p.A5699


**P1131** A GOLD Stage 3 COPD Patient «Cured» by One-Way Endobronchial Valves/E. Marchand, J.-P. D’Odemont, M.V. Dupont, Namur, Belgium, p.A5702

**P1132** A Case of Severe Chronic Obstructive Pulmonary Disease (COPD) Associated with Excessive Dynamic Airway Collapse (EDAC)/V. Baez Sosa, B.A. Jaumally, Baltimore, MD, p.A5703

---

**C49 COPD: TREATMENT**

**9:15 a.m. - 4:15 p.m.** WALTER E. WASHINGTON CONVENTION CENTER

**Area L, Hall B-C (Middle Building, Lower Level)**

**Viewing:** Posters will be on display for entire session.

**Discussion:**
- 11:15-12:00: authors will be present for individual discussion
- 12:00-1:00: authors will be present for discussion with assigned facilitators

**Facilitators:** R. Kalhan, MD, MS, Chicago, IL
- A. Gurgun, MD, Izmir, Turkey

**P1133** A Case of Cutis Laxa with Juvenile Emphysema Arising from Frameshift Mutations in Exon 30 of the Elastin Gene (ELN)/H. Namkoong, M. Ishii, K. Yagi, S. Chubach, A. Tsuji, K. Kosaki, T. Betsuyaku, Tokyo, Japan, p.A5704

**Facilitator:** C.E. Come, MD, MPH, Boston, MA

**P1134** Alpha 1-Antitrypsin Pi MZ vs Pi ZZ: Ramifications of a Mistaken Identity/K.L. Niehaus, N. Velasco, M. Rashkin, M. Brantly, R. Hebbeler-Clark, B.C. Trapnell, Cincinnati, OH, p.A5705

**P1135** Severe Bullous Lung Disease Associated with Neurofibromatosis Type 1/J.A. Kelbe, M. Ellis, J. Prudom, S. Ahmad, Milwaukee, WI, p.A5706


**P1137** Chronic Carbon Monoxide Retention in an Active Smoker: Is the Contribution of COPD and Sleep Disordered Breathing Underappreciated?/S. Verga, R. Sedhom, W. Khan, New Brunswick, NJ, p.A5708

**P1138** Alpha 1-Antitrypsin Deficiency with Normal Levels Presenting as a Diagnostic Challenge/S. Menon, S. Marupudi, M.I. Ahmad, F. Khan, A. Malik, Winston-Salem, NC, p.A5709


**P1140** Airway Tethering Following Insertion of Endobronchial Coils for Emphysema/C. Carbone, J. Killam, G.C. Michaud, New Haven, CT, p.A5711

**P1141** Post-Endoscopic Lung Volume Reduction Coil Associated Inflammatory Response/J. Killam, C. Carbone, G.C. Michaud, New Haven, CT, p.A5712

---

The information contained in this program is up to date as of March 9, 2017. For the most current session information, please visit the online program itinerary.
C50 CRITICAL CARE: NON-PULMONARY CRITICAL CARE PROBLEMS

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area D, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: T. Bice, MD, Chapel Hill, NC
T.W. Rice, MD, MSc, Nashville, TN

P373 Outcome of Patients with Blunt Chest Trauma Encountered at Emergency Department and Possible Risk Factors Affecting Mortality/Y.-M. Tsai, H.-K. Huang, H. Chang, S.-C. Lee, T.-W. Huang, Taipei City, Taiwan, p.A5743

P374 Sepsis and Ventilator Associated Events in Burn Injury Patients with Acute Respiratory Failure in a Color-Dust Explosion at a Waterpark in Taiwan/K.-Y. Yang, J.-Y. Feng, J.-Y. Chien, H.-C. Hu, C.-L. Tsai, F.-M. Hung, K.-C. Kao, K.-L. Huang, C.-J. Yu, Taipei, Taiwan, p.A5744

P375 Burn Size and Albumin Level Were Associated with Liberation from Mechanical Ventilation in Patients with Respiratory Failure in the Formosa Fun Coast Water Park Explosion/Y.-H. Chen, J.-Y. Feng, H.-C. Hu, C.-L. Tsai, F.-M. Hung, K.-Y. Yang, K.-C. Kao, K.-L. Huang, J.-Y. Chien, C.-Y. Yu, Taipei, Taiwan, p.A5745


P378 Experience with Temporary Inferior Vena Cava Filters: Indications, Complications and Retrieval Rates at a Community Hospital/M. Pekez, R. Bansal, C.A. Fay, L.J. Becker, K. Thakur, Upland, PA, p.A5748


P380 Acute Respiratory Distress After Coronary Artery Bypass/ Y.-S. Chien, J.-Y. Li, Taipei City, Taiwan, p.A5750

Facilitators: S.M. Brown, MD, MS, Murray, UT
K.M. Agun, MD, MS, West Haven, CT


P385 Tranexamic Acid Dosing for Chronic Renal Dysfunction Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass: Pharmacokinetic Modelling and New Dosing Strategy/A. Jerath, K.S. Pang, Q. Yang, M. Wasowicz, Toronto, Canada, p.A5755

P386 Predicting Diuretic Responsiveness in Acute Kidney Injury Patients in the Intensive Care Unit/S. Wongvibulsin, Y. Xu, S. Saria, Baltimore, MD, p.A5756

P387 Limited Utility of Renal Ultrasound in Evaluation of ICU Patients with Acute Kidney Injury/A. Wolfe, A. Mahoney, M. Exline, Columbus, OH, p.A5757
Facilitators: T.S. Valley, MD, MSc, Ann Arbor, MI
M. Pisani, MD, New Haven, CT


P393 Characteristics of Hospital Readmission Within 30 Days Following an Acute Exacerbation of CHF/H. Edriss, A. Castillo, K. Selvan, K. Nugent, Lubbock, TX, p.A5763

P394 Incidence of Right Ventricular Dysfunction in Patients with Takotsubo Cardiomyopathy: A Retrospective Analysis/G.S. Thind, R. Roach, Kalamazoo, MI, p.A5764


Facilitators: D.C. Scales, MD, PhD, Toronto, Canada
G.E. Weissman, MD, Philadelphia, PA


P401 Sleep in Critically Mechanically Ventilated Patients Receiving Continuous Intravenous Light Sedation/A. Guo, H. Yang, X. Wang, B. Tang, Y. Li, Beijing, China, p.A5771


Facilitators: J.D. Thornton, MD, MPH, Cleveland, OH M.W. Semler, MD, Nashville, TN

P415 Outcomes of Diabetic Ketoacidosis in a Busy Inner-City Intensive Care Unit, Can We Predict Mortality?/H.S. Arshad, J. Rodriguez, A. Smith, S. Venkatram, G. Diaz-Fuentes, Bronx, NY, p.A5784


P421 Use of Thromboelastography in Patient with Liver Cirrhosis for Guiding Blood Products Transfusion Prior to Procedures in Medical Intensive Care Unit/J. Yousef, M. Ghabril, K. Diab, Indianapolis, IN, p.A5790

P422 Risk Factors for Postpartum HELLP Syndrome Following Cesarean Delivery in Patients with Pregnancy Induced Hypertension/N. Fujimura, Y. Hiramoto, T. Nakagaki, J. Yoshino, Kurume, Japan, p.A5791

Facilitators: D. Hotchkin, MD, Portland, OR R.S. Stephens, MD, Baltimore, MD


THEMATIC POSTER SESSION

C52 CRITICAL CARE CASE REPORTS: UNUSUAL GI CAUSES OF CRITICAL ILLNESS

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Area O, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: Authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: C.R. Rackley, MD, Durham, NC J.A. Palakshappa, MD, MSCE, Philadelphia, PA

P1545 Ruptured Gastroduodenal Artery Aneurysm- Rare but Deadly Complication of Duodenal Ulcers/P.S. Minhas, J.K. Virdi, Abington, PA, p.A5798


P1550 Evidence of Pneumoperitoneum in Critical Care Ultrasound/H. Abdin, P. Patel, Houston, TX, p.A5803

Facilitator: S. Honiden, MD, MSc, New Haven, CT

P1551 High PaO2 for Non-Invasive Management of Pneumatosis Intestinalis/B.A. Gray, K. Boka, Houston, TX, p.A5804


For the most current session information, please visit the online program itinerary.
THEMATIC POSTER SESSION

C53 CRITICAL CARE: DELIRIUM AND THE EXPECTED AND UNEXPECTED CONSEQUENCES OF SEDATION/ANALGESIA IN THE ICU

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Area D, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: B.H. Singer, MD, PhD, Ann Arbor, MI
                  E. Wilcox, MD, MSc, Toronto, Canada


P434 Assessability and Validation of Intensive Care Delirium Screening Checklist (ICDSC) and the Confusion Assessment Method for ICU (CAM-ICU) in a Danish Neuro-Intensive Care Unit/L.K. Larsen, V.G. Froekjaer, J.S. Nielsen, Y. Skrobik, Y. Winkler, K. Moeller, M. Petersen, I. Egerod, Copenhagen, Denmark, p.A5812


P436 The Use of Brain Magnetic Resonance Imaging in the Evaluation of Delirium Among Critically Ill Patients/A. Mahoney, M. Exline, Columbus, OH, p.A5814


Facilitators: J.P. Kress, MD, Chicago, IL
                  R. Clouser, DO, Burlington, VT

P440 Delirium Duration and the Related Factors in Patients with Critical Illness/T. Liang, D. Sun, W. Chai, Beijing, China, p.A5818


<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
<th>Paper Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>P452</td>
<td>B. Anthracis Edema Toxin but Not Lethal Toxin Depresses the Contractile Response of Rat Aortic Tissue to Phenylephrine in an In-Vivo and in an Ex-Vivo Aortic Ring Model/D.A. Suffredini, X. Cui, Y. Li, Y. Fitz, P. Eichacker, Bethesda, MD</td>
<td>p.A5827</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P457</td>
<td>Attenuation of In Vitro Lipopolysaccharide (LPS) -Induced Inflammation by Histone Deacetylases (HDACs) Via Regulating uPA/PAI-1 Activities/W.-F. Fang, C.-Y. Lin, Y.-T. Fang, K.-T. Huang, H.-L. Huang, Y.-T. Chang, C.-H. Huang, M.-C. Lin, Kaohsiung, Taiwan</td>
<td>p.A5832</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P460</td>
<td>EP4 Receptor Mediates Endothelial Barrier-Enhancing and Anti-Inflammatory Effects of Oxidized Phospholipids (OxPAPC)/Y. Ke, G. Gawiak, Y. Tian, N. Sarich, A. Birukova, K. Birukov, Chicago, IL</td>
<td>p.A5835</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P461</td>
<td>Role of End Binding Protein-1 in EC Permeability Response to Barrier Disruptive and Barrier-Enhancing Agonists/T. Ohmura, Y. Tian, S. Son, N. Sarich, A. Birukova, Chicago, IL</td>
<td>p.A5836</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P462</td>
<td>P53 Protects and Enhances Endothelial Barrier Function by Stimulating Rac1 Signaling and Inhibiting RhoA Activity/N. Barabutis, C. Dimitropoulou, G.S. Thanjgam, B. Gregory, J.D. Catravas, Norfolk, VA</td>
<td>p.A5837</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P467</td>
<td>Acute Lung Injury by Gastric Juice Instillation: Activation of Apoptosis During Injury Resolution/P. Ayala, J. Torres, R. Vivar, G. Borzone, Santiago, Chile</td>
<td>p.A5842</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P471</td>
<td>Relative Telomere Length in Medical and Emergency Surgical Patients Mechanically Ventilated on the Critical Care Unit/C. Snelson, N.A. Duggal, H. Chahal, V. Pearce, U. Shaheen, D. McWilliams, E. Reeves, J. Lord, Birmingham, United Kingdom</td>
<td>p.A5846</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


P476 Statistical Comparison and Mortality Trends Between the Quick Sepsis Related Organ Failure Assessment (qSOFA) and Systemic Inflammatory Response Syndrome (SIRS) Amongst Haitian ICU Patients/A. Aneizi, R. Izurieta, C. Staley, A.C. Verceles, M.T. McCurdy, A. Papali, Baltimore, MD, p.A5848


P479 Critical Care Characteristics and Outcomes in a Resource-Constrained Rural Setting in Kenya Over 10 Years/E. D. Riviello, V. Liu, Kijaje, Kenya, p.A7670

C55 CRITICAL CARE: CRITICAL CARE IN LOW AND MIDDLE INCOME COUNTRIES

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER Area D, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: E.D. Riviello, MD, MPH, Boston, MA

P480 Noninvasive Ventilation in Acute Respiratory Failure: A Brazilian Web- Survey/In. A. Leligdowicz, MD, PhD, Toronto, Canada
J. Diaz, MD, San Francisco, CA


P482 A New Global and Comprehensive Model for ICU Ventilator Performance Evaluation/E. L’Her, N.S. Marjanovic, Brest, France, p.A5854


C56 CRITICAL CARE CASE REPORTS: ARDS

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER Area O, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: D.G. Fein, MD, Bronx, NY
H. Enuh, MD, Burlington, VT


P1558 ARDS Due to Adenovirus in a Patient with CVID Treated Successfully with Cidofovir and IVIG/R. Abdul Rahman, A. Attaway, R. Schilz, Cleveland, OH, p.A5862

P1559 Adenovirus Pneumonia as a Rare Cause of ARDS Requiring Extracorporeal Membrane Oxygenation/N.A. Smith, J. Meeker, S. Forrest, Orlando, FL, p.A5863

P1561 Lifesaving Prone Positioning in a Young Adult with ARDS and Human Metapneumovirus Pneumonia/L. Kallur, N.K. Bentley, A. El-Abbassi, D. Youssef, Johnson City, TN, p.A5865

P1562 Spontaneous Extrathoracic Lung Herniation in a Man with Coal Worker’s Lung/L. Kallur, A. Vanlandingham, N.K. Bentley, A. El-Abbassi, Johnson City, TN, p.A5866

P1563 Acute Respiratory Distress Syndrome Complicating Babesiosis and Lyme Coinfection/A.A. Munshi, B. Latimer, C. Bosse, Abington, PA, p.A5867


P1565 Achromobacter Xylosoxidans and Enterovirus-Rhinovirus Co-Infection Causing ARDS in a Patient with an Underlying Genetic Condition/J. Jaramillo, J. Garellek, New York, NY, p.A5869

Facilitators: D.H. Chong, MD, New York, NY

T. Dolinay, MD, PhD, Philadelphia, PA

P1566 The Failing Heart from a Bleeding Lung/A. Arjuna, H. Seetharamajju, J. Lee, Newark, NJ, p.A5870

P1567 Fatal Pulmonary Cryptococcosis in an Immunocompetent Patient/S. Medrek, U. Ayyala, Houston, TX, p.A5871

P1568 Rare Case of Acute Eosinophilic Pneumonia/R. Shah, M. Esposito, A. Talwar, E. Singas, New Hyde Park, NY, p.A5872


P1570 An Atypical Presentation of Acute Eosinophilia Pneumonia in a Traveler from the United Arab Emirates (UAE)/J. Kourouni, S. Patolia, S. Saladi, St. Frankos, Abington, PA, p.A5874


P1572 Negative Pressure Pulmonary Hemorrhage During Esophagogastroduodenoscopy in a Patient with Obstructive Sleep Apnea/A. Souka, O. Mahmod, D. Markley, A. Toscano, C. Decottis, Morristown, NJ, p.A5876


Facilitators: Y. Yeragunta, MD, Los Angeles, CA

J. Bringue, PhD, Sabadell, Spain

P1574 Anti-Synthetase Syndrome (ASS) Presenting as Acute Respiratory Distress Syndrome (ARDS) in a Patient Without Myositis Features/V. Kanchustambham, S. Patolia, S. Saladi, St. Louis, MO, p.A5878


P1576 A Rare Case of Lymphangitic Carcinomatosis from Adenocarcinoma of the Lung Presenting as ARDS/M. Young, M. Beg, H. Arshad, Pittsburgh, PA, p.A5880

P1577 Pulmonary Lymphangitic Carcinomatosis in Metastatic Breast Cancer/D. Chandra, J. Dickinson, Omaha, NE, p.A5881


THEMATIC POSTER SESSION

C57 CRITICAL CARE CASE REPORTS: HEMATOLOGY, ONCOLOGY, RHEUMATOLOGY, AND IMMUNOLOGY

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Area O, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion

12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: J.A. Gold, MD, Portland, OR

L. Richman, MD, New York, NY

P1584 Rosai-Dorfman Disease with Associated Hypercoagulability: A Rare Presentation of a Benign Disease/R. George, R. Sedhom, W. Khan, New Brunswick, NJ, p.A5887

P1585 Thrombosis Associated with Congenital Prothrombin Deficiency: A Severe Procoagulant Defect Contrasting with Thrombosis in a Congenital Prothrombin Deficient Family/L. Wang, J.-M. Liu, J. Rong, R. Han, Q. Zhao, S. Gong, J. He, Shanghai, China, p.A5888

P1586 Deep Venous Thrombosis?? Think Outside the Box!!/A. Salama, Y. Levin, F. Maksidy, Rochester, NY, p.A5889


P1588 Hyperbilirubinemia Causing Discordance of Anti-Xa and PTT in a Patient on Extracorporeal Life Support/P. Thangudu, B. Butcher, Pittsburgh, PA, p.A5891

P1589 The Case of the Curtailed Clotting Cascade/C. Bransdorfer, K. Gross, S. Naik, Farmington, CT, p.A5892

The information contained in this program is up to date as of March 9, 2017.

For the most current session information, please visit the online program itinerary.


P1593 Hypereosinophilia the Great Masquerader/ A. Tandon, Cincinnati, OH, p.A5896

Facilitators: S. Chawla, MD, New York, NY  R. Stevens, MD, Baltimore, MD

P1594 Respiratory Failure Due to Anterior Mediastinal Masses: A Critical Care Dilemma/ N. Visachelli, K. Miller, Richmond, VA, p.A5897


P1596 Diagnosis of Mediastinal Mass with Point of Care Ultrasound During Cardiac Arrest/ A. Rothman, L. Miyakawa, P. Patrawalla, Y.I. Lee, New York, NY, p.A5899

P1597 Mediastinal Hemangioma: Rare Presentation to an Unusual Diagnosis/ A.J. Shah, M.P. Paul, Syracuse, NY, p.A5900

P1598 Carcinoid Crisis - A Spontaneous Turn Of Events/ N. Adlakha, C. McLeod, S. Patel, New York, NY, p.A5901

P1599 Blush or Flush? A Preventable Case of Carcinoid Crisis/ J. Goralnik, I. Prenovitz, P. Grover, E. Nadler, A. Sharma, Farmington, CT, p.A5902


P1602 And It’s Back Again: A Case of a Recurring Vestibular Schwannoma/ E. Leung, J. Herzog, St. Louis, MO, p.A5905


Facilitators: E. Summerhill, MD, Pawtucket, RI  R. Parikh, MBBS, Burlington, VT

P1604 Anchoring to Death: An Unfortunate Case of Predecisional Information Distortion in the Diagnosis of End-Stage Lung Cancer/ J. Riggs, S. Steiner, B. Oppenheimer, New York, NY, p.A5907


P1606 Fatal Disseminated Intravascular Coagulopathy: A Rare Presentation of Systemic Amyloidosis/ V. Hoang, R. Hester, T. Teague, N. Kalakota, P. Patel, Houston, TX, p.A5909

P1607 Hemophagocytic Lymphohistiocytosis (HLH)- Cytokine Storm Still Often Underrecognized/ H.S. Bukamur, I. Shahoub, F. Zeid, Huntington, WV, p.A5910

P1608 B Cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (HLH) Presenting as Fulminant Liver Failure/ W. Mulvoy, S. Kapoor, Houston, TX, p.A5911

P1609 Airway Exchange Catheter Used in a Lymphoma Patient with Acute Respiratory Failure Who Failed to Be Mechanically Ventilated/ H.-C. Huang, S.-C. Chang, C.-S. Huang, Taipei, Taiwan, p.A5912


P1612 A 38-Year-Old Man with TAFRO Syndrome Successfully Treated with Tocilizumab and Recombinant Thrombomodulin/ Y. Takayama, T. Kubota, Y. Ogin, H. Ohnishi, K. Togitani, A. Yokoyama, Nankoku City, Japan, p.A5915

P1613 Metastatic Pancreatic Cancer: Mimicking the Great Mimicker/ J. Loeb, M. Gallegos, D. Loeffler, A. Usmani, Chicago, IL, p.A5916

Facilitators: S. M. Pastores, MD, 10065, NY  S.K. Sahetya, MD, Baltimore, MD

P1614 A Rare Case of Angioedema in a Patient with Neuroendocrine Tumor/ S. Bukhari, A. Dirweesh, H. Conaway, Trenton, NJ, p.A5917

P1615 Anakinra for the Treatment of Systemic Lupus Erythematosus Complicated by Macrophage Activation Syndrome/ K.J. Young, W.K. Yu, Taipei City, Taiwan, p.A5918

P1616 Adult Stills...When You Least Suspect It/ R.J. Perez, R. Foley, Farmington, CT, p.A5919


P1618 Hypocomplementemic Urticarial Vasculitis Syndrome: A Rare Potentially Lethal Disease/ Z. Atif, T. Arab, A. Cheema, F. Bagheri, A. Shalonov, Jamaica, NY, p.A5921

P1619 Double Trouble: Bullous Pemphigoid and Acquired Factor VIII Inhibitor in a Rapidly Decompensating Patient/ B. Hambley, A. Popa, A. Attaway, Cleveland, OH, p.A5922


P1621 Pyoderma Gangrenosum Complicating Pacemaker Insertion, Masquerading as Necrotizing Fasciitis and Distributive Shock in a Patient with Myelodysplastic Syndrome/ C.N. Myers, S. Velani, C.V. Teba, Cleveland, OH, p.A5924

P1622 Ten Years of Myelodysplasia: A Case of Hypoplastic Cellularity and An Increased Rate of Complications/ V. Hoang, J. Riggs, S. Steiner, B. Oppenheimer, New York, NY, p.A5925

For the most current session information, please visit the online program itinerary.
C58 CRITICAL CARE CASE REPORTS: NOTABLE CAUSES AND COMPLICATIONS IN ACUTE RESPIRATORY FAILURE

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER  
Area O, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: J. Liebler, MD, Los Angeles, CA  
M. Tamae Kakazu, MD, Grand Rapids, MI

P1624 Ambu Bag for Fast Diagnosing a Rare Iatrogenic Tracheoesophageal Fistula Secondary to a Tracheostomy/N.M. Gharra, S. Zeludkov, T. Bogoslavsky, Pardes Hanna, Israel, p.A5926


P1627 The Power of Negative Intrathoracic Pressure and a Rare Cause of Pulmonary Edema/G.F. Shaughnessy, P.D. Scanlon, Rochester, MN, p.A5929


P1632 Passage of Air from Thorax to Tongue; A Rare Case of Oropharyngeal Subcutaneous Empysema/G. Sikka, Z. Khan, M. Bachan, L. Varma, Bronx, NY, p.A5934


P1650  Tracheal Rupture: A Deadly Complication of a Routine Procedure/E.S. Josan, H. Storer, A. Mahajan, J. Green, L. Miller, Johnson City, TN, p.A5952

Facilitators: M. Langston, MD, Bronx, NY
E. Sacks, MD, Pittsburgh, PA


P1654  Choked on Chicken Skin: A Cruel End or a Content Beginning of a New Journey!!!/JJ. Shah, Chattanooga, TN, p.A5956


P1657  A New Association? A Case of Influenza-A Associated Purpura Fulminans Following Extracorporeal Membrane Oxygenation/M. Qi, M. Hsu, M. Reyes, S. Jiang, D. Roe, W.G. Carlos, Indianapolis, IN, p.A5959

P1658  Extracorporeal Membrane Oxygenation in Patients with Acute Severe Asthma/A. Magge, R. Pascaru, E. Salerno, West Hartford, CT, p.A5960

P1659  A Rare Case of Schmidt’s Syndrome Causing Circulatory Failure Successfully Rescued with ECMO/L. Jalota, D.W. Lee, Fresno, CA, p.A5961

P1660  Here Comes the Trickster: A Case of Non-Surgical Pneumoperitoneum in a 69 Year Old Woman/F. Khalid, S. Rehman, S. Gupta, Cleveland, OH, p.A5962


P494  Use of Diagnostic and Procedure Codes for Detecting Silicosis Among Commercial Health Insurance Beneficiaries/L.R. Kepple, M.L. Casey, J.M. Mazurek, Morgantown, WV, p.A5966

P495  The Analysis of Cholesterol and ox-LDL Levels in Alveolar Macrophages from Patients with Silicosis/H. Liu, X. Hao, W. Tian, Tangshan, China, p.A5967

Facilitator: M. Akgun, MD, Erzurum, Turkey

P496  Lidocaine Differentially Affects Acute and Late Phases of Silica-Induced Oxidative Stress and Pulmonary Fibrogenesis in Rats by Enhancement of Thioredoxin System/X. Hao, H. Liu, W. Tian, Tangshan, China, p.A5969

P497  Preventive and Early Therapeutic Effects of β-Glucan on Silica-Induced Oxidative Stress and Pulmonary Fibrogenesis in Rats by Enhancement of Thioredoxin System/X. Hao, H. Liu, W. Tian, Tangshan, China, p.A5969

P498  Proteomic Profile of Lung Fibroblasts Induced by TGF-β1 and Potential Roles in Rats Exposed to Silica/F. Yang, H. Xu, D. Xu, Tangshan, China, p.A5971

P499  Severe Diffuse Emphysema and Complicated Silicosis from Workplace Diatomaceous Earth Exposure/K. Vonfeldt, C. Rose, Denver, CO, p.A5972


THEMATIC POSTER SESSION

C60  INDOOR AIR POLLUTANTS: BIOMASS AND WOOD SMOKE

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER
Area E, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: N.E. Alexis, PhD, Chapel Hill, NC


ATS 2017 • Washington, DC
The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.
P555 Tuberculosis - The Great Masquerader/B. Wolk, K. Cao, Tampa, FL, p.A5998


P557 A Rare Complication of a Common Disease/S. Chakraborty, London, United Kingdom, p.A6000

P558 Late Diagnosis of Endobronchial Tuberculosis Leading to Tracheal Stenosis and Left Lung Collapse/K. C. Ma, L. K. Torres, E. Shostak, B.-G. Harvey, New York, NY, p.A6001

P559 Pericarditis Due to Paradoxical Reaction of Mediastinal Tuberculosis and Endobronchial Tuberculosis/T. Oba, H. Matsushima, M. Amano, K. Akasaka, Saitama, Japan, p.A6002

Facilitator: L. N. Friedman, MD, Milford, CT

P560 Koch’s with Kikuchi Disease Together in a Young Male/L. N. S. Tirunagari, A. Hasan, Hyderabad, India, p.A6003


P563 A Rare Case of Tuberculosis in Ribs and Soft Tissues of the Thorax/L. Fernandez, J. D. Yara, D. Arboleda, L. F. Sua, M. Velasquez, L. Gutierrez, Cali, Colombia, p.A6006


P565 Fatal Sepsis from Mycobacterium Tuberculosis in an HIV-Negative Alcoholic Female/G. J. Mitchon, J. L. Barlow, Seattle, WA, p.A6008

P566 Disseminated Tuberculosis-Typical or Atypical Presentation - We Need to Be Aware/I. S. Hadigal, E. Harman, Gainesville, FL, p.A6009

Facilitator: C. Yoon, MD, MPH, San Francisco, CA


P568 Flourish or Perish: A Case of Brisk Miliary Tuberculosis Development with Steroid Treatment in a PPD Negative Patient with Non-Caseating Granuloma/F. Kukhon, M. Barbour, A. Hasani, Y. Hejazi, Tabriz, Iran, p.A6011


P571 Acute Respiratory Distress Syndrome Due to Severe Pulmonary Tuberculosis Treated with Extracorporeal Membrane Oxygenation/N. Omote, Y. Kondoh, N. Hashimoto, H. Taniguchi, Y. Hasegawa, Nagoya, Japan, p.A6014


P573 A Case of a Rare Isoniazid Related Neurotoxicity/A. Andriotis, M. Abu Omar, M. Goyal, A. Qasrawi, O. Abughanimeh, M. A. Javed, G. Salzman, Kansas City, MO, p.A6016

THEMATIC POSTER SESSION

C62 CASE REPORTS: PULMONARY INFECTIONS - MISCELLANEOUS

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER Area E, Hall B-C (Middle Building, Lower Level)

Facilitator: P. Peyrani, MD, Louisville, KY

P575 Pulmonary Langerhans Cells Histiocytosis; an Important Differential in Patients with Human Immunodeficiency Virus/K. M. Patel, D. Subedi, Syracuse, NY, p.A6017


P577 Successful Medical Treatment of Multiple Pulmonary Hydatid Cysts with Albendazole/S. Tahnisi Tekantapeh, M. E. Hejazi, S. Hasani, Y. Hejazi, Tabriz, Iran, p.A6019


P579 Human Erlichiosis Presenting with Mediastinal Lymphadenopathy and Pleural Effusions/N. M. Vasquez, M. Fadila, W. Parker, Columbia, MO, p.A6021


P581 Pulmonary Arterial Hypertension in Patient with Both HIV and Schistosomiasis Infection/J. Ataucuri-Vargas, C.-P. Wu, Bronx, NY, p.A6023

P582 I Have Never Heard of Pulmonary Leishmaniasis, Have You?/M. Abu Omar, M. Goyal, A. Qasrawi, O. Abughanimeh, M. A. Javed, G. Salzman, Kansas City, MO, p.A6024

Facilitator: R. Nusrat, MD, Princeton, NJ


Facilitator: C.R. Marion, DO, PhD, New Haven, CT

Early Administration of Oseltamivir in Hospitalized Patients with Influenza Reduces Hospital Length of Stay/D. Reynolds, A. Bartley, L. Dou, O. Gajic, H. Yadav, Rochester, MN, p.A6061


Does Introduction of Respiratory Viral Assay Affect the Use of Antibiotics in Patients Admitted with Acute Exacerbation of COPD - a Single Center, Before-After Experience/M. Tickoo, S. Kurz, Boston, MA, p.A6063


Bacterial Coinfection in Pandemic 2016 Severe Complicated Influenza in Taiwan/W.-C. Chen, K.-Y. Yang, Taipei City, Taiwan, p.A6066


Primary Pulmonary Lymphangiectasis in a Male Infant with Transposition of Great Arteries/S.A. McGrath-Morrow, MD, Baltimore, MD

Cauliflower Lung: A Pediatric Pulmonary Presentation of Cutaneovisceral Angiomatosis with Thrombocytopenia (CAT)/D.B. Ezroj, M.A.A. Tablizo, M.V. Dorfman, Fresno, CA, p.A6068


Primary Pulmonary Lymphangiectasis in a Male Infant with Transposition of Great Arteries/R.A. Alshumrani, A.I. Cristea, G. Montgomery, S.D. Davis, Indianapolis, IN, p.A6071

A Non-Pulmonary Etiology for Persistent Tachypnea/A.O. Delecari, G. Subbaramo, Indianapolis, IN, p.A6072

A Two Year Old Boy with Persistent Respiratory Symptoms Caused by a Congenital Airway Anomaly/I.C. Kuklinski, St. Louis, MO, p.A6073

Six-Month Old Infant with Familial ACTA2 R179H Mutation, Severe Pulmonary Hypertension, Pulmonary Interstitial Glycogenosis, Moderate-to-Severe Pulmonary Hypoplasia, and Prune Belly Sequence/A.G. Cornell, A.L. Kirby, D.A. Sauer, K.R. Schmitz, G.H. Deutsch, K.W. Holmes, Portland, OR, p.A6074

Facilitator: T.E. Tipple, MD, Birmingham, AL

A Mediastinal Giant Mature Cystic Teratoma Revealed After Pleural Effusion Treated Twice as Tuberculosis/P.D.M. Katoto, Bukavu, Congo, Republic of, p.A6075

Unusual Pulmonary Manifestation of Chromosome 13q34 Duplication in a Newborn/N. Kotwal, R. Megalaa, F. Ogunlesi, A.C. Koubourlis, Washington, DC, p.A6076


C65 PEDIATRIC CASE REPORTS: BRONCHIECTASIS, CYSTIC FIBROSIS, AND LUNG INFECTIONS
9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area F, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: J.F. Chmiel, MD, MPH, Cleveland, OH
A.P. Lever, MD, Tlalpan, Mexico

P644 The Difficulty in Diagnosing Pulmonary Sequestration/A.A. Fajilan, J. Fu, Y. Carter, J. Vintch, Torrance, CA, p.A6079
Facilitator: A.P. Popova, MD, Ann Arbor, MI
P647 An Uncommon Cause of Massive Hemothorax/J.L. MacLeod, G. Bajwa, R. El-Bizri, Providence, RI, p.A6082
P650 If It Ain’t Broke, Don’t Fix It: A Case of Pneumonia Resulting from Biopsy of Dilated Bronchioles Distal to an Atretic Bronchus/Y. Samra, C. Harden, M. Barnes, H. Alnuaimat, A. Ataya, Gainesville, FL, p.A6085

P657 The Validity of a Positive Sweat Chloride Test in a Medically Complex Patient When Determining the Diagnosis of Cystic Fibrosis/S. Malhotra, Chicago, IL, p.A6091
P658 Non-Cystic Fibrosis Meconium Ileus Like Syndrome Found in the Chinese Patient/S. Malhotra, Chicago, IL, p.A6092
P659 Vomiting Associated with Cough- Not Always Post-Tussive/A.M. Mulholland, A. Ainsworth, N. Pillarisetti, Auckland, New Zealand, p.A6093
Facilitator: H. Chaney, MD, Washington, DC
P660 A 13-Year-Old Boy with Primary Ciliary Dyskinesia and Stubbornly Persistent Worsening Lung Function/H. Sohn, Los Angeles, CA, p.A6094
P661 From Normal FEV1 to Lung Transplant in 134 Days/S. Zak, C. Siracusa, Cincinnati, OH, p.A6095
P662 An Unusual Cause of Hypercarbia in Premature Twins/A.A. Fajilan, J. Fu, Y. Carter, J. Vintch, Torrance, CA, p.A6096
P663 Double Trouble: A Case of Ehlers-Danlos Syndrome Type IV in Cystic Fibrosis/R. Perkins, J.M. Majure, Jackson, MS, p.A6097
P665 Use of High Flow Nasal Insufflation and Improved Lung Function and Growth in Cystic Fibrosis/S.M. Paranjape, L.E. Ortiz, H. Schneider, Baltimore, MD, p.A6099
Facilitator: L. Caverly, MD, Ann Arbor, MI
P668 A Case of Pulmonary Nodules and Opacities in a Young Adult Female with Primary Ciliary Dyskinesia/M.V. Talamo Guevara, L. Camarda, S. Malhotra, M.A. Nevin, Chicago, IL, p.A6102
P669 Non-Resolving Pneumonia as the Presentation of Pulmonary Glomus Cell Tumor/M.Y. Prero, C.M. Oermann, Kansas City, KS, p.A6103
P671 From a Pain in the Leg to a Plugged Up Lung: An Unusual Complication of MRSA Pneumonia/L. De Keyzer, D. Rao, Dallas, TX, p.A6105
P672 Minocycline for ESBL Klebsiella Pneumonia in an Infant: Ethical Dilemmas?/J. Nikhilesh, A. Govinda, A. Nanera, Indore, India, p.A6104
P673 An Infant with a Vanishing Cystic Chest Lesion/V. Passi, K.A. King, L. Berman, L.E. Grissom, Wilmington, DE, p.A6107

For the most current session information, please visit the online program itinerary.
P674 Viral Respiratory Illness Causing Airflow Obstruction and Recurrent Hospitalization of a Child to Pediatric Intensive Care/S.E. Morgan, S. Mosakowski, B.L. Giles, G.M. Mutlu, P.A. Verhoef, Chicago, IL, p.A6108

P675 Diagnostic Dilemma: Pulmonary Nodules in a Child with Sickle Cell Disease/M. Sagar, T.A. Pham, L.T. Nguyen, C. Ogbon, Temple, TX, p.A6109

P676 Respiratory Failure in Patients with Cytomegalovirus Pneumonitis/M. Villamini-Osorio, S.M. Restrepo-Gualteros, O. Ramirez - Camacho, Bogota, Colombia, p.A6110

C66 PEDIATRIC CASE REPORTS: DIFFUSE LUNG DISEASES

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area F, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

P678 Diffuse Granulomatous Lung Disease: Sarcoidosis, Mycobacterial Disease or Both?/J.H. Rayment, F. Ratjen, Toronto, Canada, p.A6111


P680 COPA Mutation Causing Intestinal Lung Disease in an Infant/C. Quintana Grijalba, T. Simoneau, Hartford, CT, p.A6113


P685 Persistent Pulmonary Hypertension as a Result of Pulmonary Interstitial Glycogenosis/G.G. Still, P. Sammut, Omaha, NE, p.A6118


P690 Anti-TNF Therapy in Childhood Interstitial Lung Disease (NSIP)/F. Neemuchwala, C. Lumeng, Ann Arbor, MI, p.A6123

P691 Smoking Teenager with Diffuse Cystic Lung Disease/L.E. Ortiz, E.T. Zambidis, L.M. Sterni, Baltimore, MD, p.A6124

P692 Late Presentation of Lymphatic Abnormalities in a Child with Noonan Syndrome and a R1T1 Mutation/K. Harman, S. Maroo, J. Terry, M. Van Allen, C.L. Yang, Vancouver, Canada, p.A6125

P693 Infliximab Induces Remission in Steroid-Dependent Pulmonary Sarcoidosis in Pediatric Patient/A.R. Strang, C. Rose, Wilmington, DE, p.A6126


P695 Nonspecific Interstitial Pneumonia (NSIP) of Unusual Presentation/S.M. Restrepo-Gualteros, M. Villamini-Osorio, A. Parra, S. Pulido, O. Ramirez - Camacho, Bogota, Colombia, p.A6128


P698 Subpleural Cysts on Chest Tomography in Seven Months Old Baby with Tachypnea/E. Concepcion, G. Deutsch, H. Lee, New York, NY, p.A6131

P699 A Rare Cause of Recurrent Hemoptysis/Y. Yu, C.E. Loughlin, Chapel Hill, NC, p.A6132


C68  PEDIATRIC CASE REPORTS: AUTOIMMUNE DISEASES AND IMMUNODEFICIENCIES

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area F, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator:  D.I. Craven, MD, Cleveland, OH


P702  A Pediatric Case of Refractory Autoimmune Pulmonary Alveolar Proteinosis/C. Lee, St. Louis, MO, p.A6162


P705  MECP2 Duplication Syndrome: A Rare Cause of Immune Dysfunction and Recurrent Lower Respiratory Tract Infections/E. Hamberger, M. Buo, Palo Alto, CA, p.A6165

Facilitator:  G. Montgomery, MD, Indianapolis, IN

P706  Granulomatous Lymphocytic Interstitial Lung Disease in a Pediatric Case of Common Variable Immunodeficiency/M. Silva Carmona, R. Tillman, T.J. Vece, L. Forbes, N. Rider, R. Guillerman, J. Hicks, I. Chinn, Houston, TX, p.A6166

P707  Persistent Pneumonia in a Boy with Chronic Granulomatous Disease/K.W. Savary, M. Kattan, Y.Y. Demirdag, New York, NY, p.A6167

P708  Syntaxin Binding Protein 1 Mutation in a 3-Year-Old Female with Recurrent Viral Pneumonia/K. Gipson, J. Farmer, T.B. Kinane, Boston, MA, p.A6168

P709  Airway Obstruction, Weight Loss, and Gastroaparesis in an Undiagnosed Adolescent with HAE/C. Cox, A.M. Szema, South Setauket, NY, p.A6169


Facilitator:  M. Artea, MD, Ann Arbor, MI


P712  Fatal Asthma in a Pediatric Patient with Lung Aspergillosis and Primary Immunodeficiency/S. Pulido, Bogota, Colombia, p.A6172

P713  Chronic Bronchitis Secondary to Stevens-Johnson Syndrome/J.B. Bishara, C. Halaby, M. Pirzada, Mineola, NY, p.A6173

P714  Remission in Pediatric Patient with Idiopathic Pulmonary Capillaritis Treated with Pulse Steroids, Rituximab and IVIG/A.R. Vece, J. Gustave, Wilmington, DE, p.A6174

For the most current session information, please visit the online program itinerary.
Facilitator: T. Thenappan, MD, Minneapolis, MN

Use of Catheter Directed Thrombolysis to Treat Massive Pulmonary Embolism Complicated by Severe Refractory Hypercapnia/K. Gopalratnam, B. Alkin, J.S. Kwon, Bridgeport, CT, p.A6208


Fibrosing Mediastinitis Induced Pulmonary Hypertension and Respiratory Failure Successfully Treated with Pulmonary Venous Stent and Rituximab Therapy/N.S. Surapaneni, Z. Zhang, H. Hayreh, Los Angeles, CA, p.A6210


Successful Catheter-Directed Thrombolysis for Pulmonary Embolism During Pregnancy/A. Garbarino, N. Miller, G. Tatem, Detroit, MI, p.A6212


Pulmonary Artery Aneurysm in a Patient with Pulmonary Arterial Hypertension and Acute Respiratory Failure Successfully Treated with Pulmonary Venous Stent and Rituximab Therapy/N.S. Surapaneni, Z. Zhang, H. Hayreh, Los Angeles, CA, p.A6210

Facilitator: H.J. Bogaard, MD, PhD, Amsterdam, Netherlands


Prevalence of HIV-Associated Pulmonary Hypertension as Assessed by Transthoracic ECHO/N. Singh, S. Shah, J. Green, Brooklyn, NY, p.A6223


Facilitator: T. Thenappan, MD, Minneapolis, MN


Facilitator: A.J. Peacock, MD, Glasgow, United Kingdom


Central and Peripheral Limitations to Exercise Intolerance in Pulmonary Hypertension/S. Sthamparanathan, G. Gorman, M. Trencill, D. Jakovljevic, P.A. Coris, Newcastle upon Tyne, United Kingdom, p.A6230


Co-Relation of Different Parameters of Pulmonary Hypertension/A. Itlikhar, M. Cheema, Z. Muzaffar, F. Chaudhry, A. Smith, Roslyn, NY, p.A6232

Facilitator: H.J. Bogaard, MD, PhD, Amsterdam, Netherlands

Characterization of Patients With Extreme Pulmonary Arterial Hypertension/ A. Farber, Boston, MA, p.A6233

Prevalence of HIV-Associated Pulmonary Hypertension as Assessed by Transthoracic ECHO/N. Singh, S. Shah, J. Green, Brooklyn, NY, p.A6223
P955 Characteristics and Outcomes of Pulmonary Hypertension Patients in a Tertiary Referral Center/N. Maniar, C. Clarke, E. McDaniel, J.S. Smith, K. El-Kersh, Louisville, KY, p.A6233

Facilitator: R.J. Oudiz, MD, Torrance, CA

P956 Congenital Heart Disease Associated Pulmonary Arterial Hypertension and Eisenmengers Syndrome - An Alternative Therapeutic Approach/S.A. Suliman, E. McDaniel, K. El-Kersh, J.S. Smith, Louisville, KY, p.A6234


P958 Clinical Analysis of Behcet Disease Associated with Pulmonary Vascular Disease/L. Wang, J.-M. Liu, J. Rong, Q. Zhao, S. Gong, W.-H. Wu, Shanghai, China, p.A6236


P961 Discordance Between Pulmonary Capillary Wedge Pressure and Left Ventricular End-Diastolic Pressure in a Cohort of Patients with Pulmonary Hypertension/A. Jose, C. King, O. Shlobin, A. Brown, N. Weir, J. Kiernan, N. Cossa, S.D. Nathan, Washington, DC, p.A6239

Facilitator: R.P. Frantz, MD, Rochester, MN

P962 Baseline Characteristics in Pulmonary Hypertension Groups I and IV at Fundacion Valle del Lili, a Reference Hospital in Latin America/L. Fernandez, L. Gutierrez, D.C. Carrillo, W. Martinez, F. Sanabria, J.E. Gomez, Cali, Colombia, p.A6240

P963 National Trends in Diagnostic Methods for Pulmonary Hypertension, 2002-2015/D. Kim, K. Lee, E.S. Klings, D. Miller, R.S. Wiener, Boston, MA, p.A6241

P964 Patterns and Predictors of Guideline-Discordant Prescribing of Phosphodiesterase Type 5 Inhibitors for Pulmonary Hypertension in the VA/D. Kim, M. Freiman, D. Miller, E.S. Klings, A. Rose, W.R. Powell, R.S. Wiener, Boston, MA, p.A6242

P965 Real World Status and Management of Pulmonary Hypertension in Southwest of China/Y. Xiang, Chongqing, China, p.A6243


P967 Appropriate Screening for Pulmonary Arterial Hypertension in Systemic Sclerosis Patients/C. Lee, J. Elwing, Cincinnati, OH, p.A6245

The information contained in this program is up to date as of March 9, 2017. For the most current session information, please visit the online program itinerary.

Facilitator:  H.B. Rossiter, PhD, Torrance, CA

P836  The Utility of a Diagnostic Algorithm in Cardiopulmonary Exercise Testing Interpretation in Patients with Exercise Intolerance/M. Ghamloush, A. LeVee, N.S. Hill, Boston, MA, p.A6257

P837  Muscle Percentage of Destroyed Lung Patients with Pulmonary Hypertension and Its Relation to Exercise Capacity/D. Septianti, W. Aniwidyaningsih, B. Antariksa, B.B. Siswanto, I.H. Siahaan, Jakarta, Indonesia, p.A6258


P839  Comparison of Peak Exercise Performance When Utilizing Different Approaches of Calculating Ventilatory Reserve in Patients with Stable COPD/T.C. Harvey-Dunstan, S.J. Deacon, R.A. Evans, M.C. Steiner, S.J. Singh, M.D. Morgan, Leicester, United Kingdom, p.A6260


P1178  Histone Deacetylase 2 Suppresses IL17A-Mediated Airway Remodeling in COPD/T. Lai, B. Tian, C. Cao, Y. Hu, F. Xu, W. Li, S. Ying, Z. Chen, H. Shen, Hangzhou, China, A6264

P1179  Role of Acrolein in Cigarette Smoke-Induced Mucociliary Clearance Defects/V. Lin, W.S. Raju, L. Tang, Y. Li, L. Wilson, T. Berryhill, M. Mazur, P.L. Jackson, S. Barnes, J.E. Blalock, S. Rowe, Birmingham, AL, A6265

P1180  Ribosomal Protein S3 Gene Silencing Protects Against Cigarette Smoke-Induced Acute Lung Injury/J. Dong, W. Liao, H.Y. Peh, W.S.D. Tan, W.S.F. Wong, Singapore, Singapore, A6266

P1181  sRAGE as Biomarker for COPD, Introducing Novel LC-MS-Based Methods for the Quantification of Serum sRAGE Levels/S. D. Pouwels, F. Klint, N. Van Der Merbel, P. Horvatovich, N.H.T. Ten Hacken, R. Bischoff, Groningen, Netherlands, A6267


P1183  Prevalence of Pneumocystis Jirovecii Colonization in Patients with Chronic Obstructive Pulmonary Disease (COPD) in Bogota, Colombia/A. Canas, J.F. Bubanco, C. Hernandez, J.E. Cita, J.R. Garzon, Bogota, Colombia, A6269

P1184  Smad3 and P38 Pathways Mediate Cigarette Smoke-Induced Decreases in CFTR and BK Channel Activities Leading to Mucociliary Dysfunction/J. Sailland-Tschudi, A. Grosche, N. Baumlín-Schmid, J.S. Dennis, A. Schmid, S. Krick, M. Salathe, Miami, FL, A6270


P1186  Activating Transcription Factor 3 Represses Cigarette Smoke-Induced IL6 and IL8 Expression Via Suppressing Nuclear Factor-κB (NF-κB) Activation/Y. Wu, C. Cao, Z. Chen, S. Ying, H. Shen, W. Li, Hangzhou, China, A6272

Facilitator:  B. Crestani, MD, PhD, Paris, France

P1187  Protective Role of a Disintegrin and Metalloprotease 17 (ADAM17) in Elastase-Induced Emphysema in Mice/S. Suzuki, M. Ishii, T. Asakura, H. Namkoong, S. Okamori, K. Yagi, H. Kamata, S. Kagawa, K. Horiiuchi, N. Hasegawa, T. Betsuyaku, Tokyo, Japan, A6273

P1188  Interaction Between Tiotropium Bromide and Olodaterol in Human Bronchial Smooth Muscle/M. Calzetta, P. Rogliani, F. Facciolo, M.G. Matera, M. Cazzola, Rome, Italy, A6274

P1189  Interaction Between Tiotropium Bromide and Olodaterol in Small Human Airways/L. Calzetta, P. Rogliani, F. Facciolo, M.G. Matera, M. Cazzola, Rome, Italy, A6275

P1190  Tiotropium and Olodaterol Attenuate Smoke-Induced Aalveolar Cell Inflammation in Mice/Y. Hamakawa, A. Sato, K. Uematsu, K. Hasegawa, S. Sato, M.P. Pieper, S. Muro, Kyoto, Japan, A6276

P1192 Role of Allosteric GPCR Modulation in Cross Talk Between I2-Adrenergic and Muscarinic Receptors in Airway Smooth Muscle/H. Kume, O. Nishiyama, T. Isoya, Y. Higashimoto, Y. Tohda, Osakasayama, Japan, A6278

P1193 Ergothioneine Induces Antioxidant Enzymes in Human Lung Epithelial Cells In Vitro/M.A. Selo, S. Nickel, C.G. Clerkin, C. Ehrhardt, Dublin, Ireland, A6279

P1194 Role of Apoptosis Inhibitor of Macrophage (AIM) in Chronic Obstructive Pulmonary Disease (COPD)/H. Ge, M. Suzuki, H. Kimura, S. Konno, M. Nishimura, Shanghai, China, A6280


P1196 Restoration of HDAC2 by Vam3 Improves Corticosteroid Sensitivity/C. Tan, L. Xuan, C. Yao, B. Xu, H. Wang, Q. Hou, Beijing, China, A6282

P1197 Simple Prediction of MMP-9/TIMP-1 Ratio Derived from One of Biomarkers (The Study Is Limited to the Examination of MMP-9 and TIMP-1 from the Saliva Among Ex-Smokers with Chronic Obstructive Pulmonary Disease)/M. Mulyadi, M. Azhary, S. Sunnati, Banda Aceh, Indonesia, A6283

Facilitator: K.L. Gates, MD, Chicago, IL

P1198 Effect of Intereukin 13 on Human Tracheal Epithelial Cells/O.H. Wittekindt, H. Schmidt, K. Meller, V.E. Winkelmann, K. Thompson, M. Frick, P. Dietl, Ulm, Germany, A6284


P1201 NLRP 3 Inflammasome Activity Is Up Regulated in COPD and COPD Exacerbations/A. Bar-Shai, S. Langier, M. Siterman, M. Stark, S. Etkin, Y. Schwarz, N. Nachmias, Ashkelon, Israel, A6287

P1202 Up-Regulation of the Cholinergic System in a Model of Ex-Vivo Virus-Induced COPD Exacerbation - Role of Tiotropium Bromide/M. Contoli, A. Marcellini, G. Caramori, A. Papi, Ferrara, Italy, A6288

P1203 Establishment and Characterization of a Novel 3D Human In Vitro Small Airway Model/S. Constant, S. Huang, B. Boda, J. Vernaz, P. Alouani, L. Wiszniewski, Plan-les-Ouates, Switzerland, A6289

P1204 The Role of Human Antigen R (HuR) in Chronic Obstructive Pulmonary Disease (COPD)/N. Aloufi, P. Nair, K. Radford, D.H. Eidelman, C.J. Bagiole, Montreal, Canada, A6290

P1205 Molecular Mechanism of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Isorms-Regulated Inflammation Response in Acute Exacerbation of Chronic Obstructive Pulmonary Disease/Y. Zhu, X. Wang, Shanghai, China, A6291

P1206 Administtrating Glucocorticoids May Increase the Risk of Pulmonary Infection by Increasing the Expression of SDC1/D. Liu, J. Zhang, H.-X. Liu, J.-M. Qi, Shanghai, China, A6292


P1208 Increased Platelet-Monocyte Interaction in Stable COPD in Absence of Platelet Hyper-Reactivity/F. Aleva, G. Tamba, Q. De Mast, S. Simons, P. De Groot, Y. Heijdra, A. Van Der Ven, Nijmegen, Netherlands, A6294

Facilitator: J.L. Simpson, PhD, Newcastle, Australia

P1209 The Release of PAD2 and PAD4 from Neutrophils by Primary Granule Degranulation: A Link Between Alpha-1 Antitrypsin Deficiency and the Anti-CCP Autoimmune Response/D.L. Hunt, D.A. Cardiff, E. Reeves, N.G. McElvaney, Dublin, Ireland, A6295


P1211 Cigarette Smoke Medium Induces Apoptosis Via the Translocator Protein (TSPO) in Airways Pulmonary Cell Lines/K.W.K. Liu, M.S.M. Ip, J.C.W. Mak, Hong Kong, Hong Kong Prc, A6297

P1212 Critical Role of the Class A Scavenger Receptor on Alveolar Macrophages in Chronic Obstructive Pulmonary Disease/L. Xie, M. Zhou, Shanghai, China, A6298

P1213 Ascorbic Acid Protects Human Lung Epithelial Cells In Vitro from Tobacco Smoke-Induced Oxidative Damage/A. Yildiz Pekoz, O. Akbal, S. Sancar, M.A. Selo, C.G. Clerkin, S. Nickel, C. Ehrhardt, Istanbul, Turkey, A6299


P1215 TGF-Beta Suppresses CFTR Biogenesis and Function by Post-Transcriptional Gene Silencing/R. Dutta, S. Chinnapaiyan, V.S. Raju, H.J. Unwalla, Miami, FL, A6301

P1216 Eosinophilic COPD Exacerbation: New Phenotype and Different Approach to Treatment/R. Parikh, J. Miely, J. Torres, T.G. Shah, R. Tandon, Chicago, IL, A6302

The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.


P1241 Alpha 1 Antitrypsin (A1AT) Increases Macrophages Efferocytosis Via Mannose Binding Lectin (MBL) - Mannose Receptor (MAR) Signaling/A.M. Mikosz, R. Sandhaus, L.A. Maier, N.Y. Hamzeh, I. Petracek, K. Serban, Denver, CO, A6326

P1242 Effects of Chronic Smoking Exposure on the Lung and Cecal Microbiomes in Mice/F.S. Leitao Filho, S.W. Ra, A. Tam, J. Yang, D.A. Ngan, J. Wright, A. Churg, M. Sze, J. Leung, S.P. Man, D.D. Sin, Vancouver, Canada, A6327


P1244 Effects of a PPAR3 and LXR Agonists Combination Therapy on the Pulmonary Response to Cigarette Smoke/E. Jubinville, M. Maranda-Robitaille, M. Talbot, C. Thibault, M. Page, M.-J. Beaulieu, S. Pilote, S. Aubin, M.-E. Pare, B. Drolet, C. Simard, M.C. Morissette, Quebec, Canada, A6329


P1246 Investigating the Role of Alpha-1 Antitrypsin in the Regulation of Complement Activation/L. Fee, M.E. O’Brien, T.P. Carroll, M. Molloy, C. O’Connor, E. Reeves, N.G. McElvaney, Dublin, Ireland, A6331

P1247 Iron Loading Is Increased in Lung Tissue of COPD Patients/Reula, Via Mannose Binding Lectin (MBL) - Mannose Receptor (MAR) Signaling/A.M. Mikosz, R. Sandhaus, L.A. Maier, N.Y. Hamzeh, I. Petracek, K. Serban, Denver, CO, A6326

P1248 BAL Biomarkers Associated with the Progression of Emphysema in HIV-Infected Individuals/D. Khabbaz, S. Crouser, J. Drake, M. King, A. Ferketic, M. Gavrilin, M.D. Wewers, P. Diaz, Columbus, OH, A6333

P1249 Role of Sphingomyelin Synthase Regulated Micro Domain Signaling in Cigarette Smoke Induced Inflammation/R. Wadgaonkar, P. Geraghty, I. Kabir, R. Foronjy, Brooklyn, NY, A6334

P1250 Strategies to Identify Common Low Effect COPD Risk Variants/D. Morales, R. Zolondz, D. Craig, S. Qi, A. Baugh, A. Levin, A. Fedorov, S. Khuder, B. Mopidevi, J. Willey, Toledo, OH, A6335


P1252 Augmentation Therapy Increases Hydrogen Peroxide Accumulation in Peripheral Blood Mononuclear Cells of ZZ Alpha-1 Antitrypsin Deficiency Patients/F.J. Dasi, S. Pastor, A. Reula, S. Castillo, A. Escribano, Valencia, Spain, A6337

P1253 Alpha-1Antitrypsin Reduces Endoplasmic Reticulum Stress and Release of Inflammatory Cytokines in Cystic Fibrosis Primary Bronchial Epithelial Cells In Vitro/N. A. Gazdhar, C. Vonarburg, R. Spiring, S. Miescher, T. Geiser, Bern, Switzerland, A6338

P1254 TRPV1 Antagonism with XEN-D0501 in Chronic Obstructive Pulmonary Disease: Translation from Pre-Clinical Model to Clinical Trial/J.A. Smith, M.A. Birrell, M.A. Wortley, S.A. Maher, R. Dockry, P. Turner, P. Round, J. Ford, M.G. Belvisi, Manchester, United Kingdom, A6339


P1257 Alpha-1 Antitrypsin Augmentation Therapy Modulates Neutrophil Lipid Raft Structure and Cell Adhesion in Patients with Alpha-1 Antitrypsin Deficiency/M.M. White, B. Jundi, M.E. O’ Brien, N.G. McElvaney, E. Reeves, Dublin, Ireland, A6342


P1259 LnRNA NEAT1 Promotes IL-8 Expression in Fibroblasts Derived from COPD Patients and in Response to Cigarette Smoking/N. Ijiri, A. Panariti, A. Mogas, P. Nair, Q. Hamid, J. Martin, C. Baglole, Montreal, Canada, A6344

P1260 Inhaled Alpha-1-Antitrypsin Restores Lower Respiratory Tract Protease- Anti-Protease Homeostasis and Reduces Inflammation in Alpha-1 Antitrypsin Deficient Individuals: A Phase 2 Clinical Study Using Inhaled Kamada-API/M. Brantly, J. Tucker, N. Tov, Gainesville, FL, A6777

C75 FIBROSIS: CURRENT AND FUTURE APPROACHES

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Area A, Hall B-C (Middle Building, Lower Level)

Thematic Poster Session

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.
Facilitator:  E. Charbek, MD, St. Louis, MO


P2  Flow Cytometric Time-Course Analysis of Rat Alveolar Immune Cells During Bleomycin-Induced Lung Injury and Fibrotic Remodeling/E. Lopez Rodriguez, M. Ochs, L. Knudsen, C. Kloth, Hannover, Germany, p.A6345


Facilitator:  A.M. Casey, MD, Boston, MA

P10  Abnormal Resistance of Idiopathic Pulmonary Fibrosis Fibroblasts in Response to Radiation-Induced Apoptosis/R. Nho, J. Im, J.Y. Yhee, K. Kim, J. Lawrence, Minneapolis, MN, p.A6353


P14  Idiopathic Pulmonary Fibrosis Fibroblasts Are Resistant to TRAIL-Mediated Apoptosis by the Alteration of Forkhead Box O3a (FoxO3a) Dependent Death Receptor 4 (DR4)/J. Im, J.Y. Yhee, K. Kim, R. Nho, Minneapolis, MN, p.A6357


P16  Effect of Cigarette Smoke in Lung Fibroblasts and Epithelial Cells Role of CCL2 in Development of Idiopathic Pulmonary Fibrosis/S.S. Garcia Trejo, M.A. Checa Caratachea, V.M. Ruiz Lopez, A. Pardo Cemo, M.E. Selman Lama, Mexico City, Mexico, p.A6359


Facilitator:  S. Cerri, MD, PhD, Modena, Italy


P20  CSL312, a Novel Anti-FXII Antibody, Blocks FXII-Induced IL-6 Production from Primary Non-Diseased and Idiopathic Pulmonary Fibrosis Fibroblasts/M. Wong, J. Jaffar, L. McMillan, N.J. Wilson, M.J. Wilson, G. Westall, C. Panousis, Melbourne, Australia, p.A6363


P22  Respiratory Function and Quantitative Measurement of Fibrosis in a Rat Model of Bleomycin-Induced Lung Fibrosis/M.C. McElroy, M. Anderson, A. Young, P. Nath, S. Madden, A. Milne, L. Sherry, Edinburgh, United Kingdom, p.A6365


Facilitator: D.B. Chairman, MD, Columbia, MO

P28 Preclinical Studies Reveal Low Phosphate Diet as a Potential Therapy for Pulmonary Alveolar Microthiliasis/Y. Uehara, N.M. Verleden, T. Nawrot, J.E. McDonough, S. Shetty, B. Vanaudenaerde, W.A. Wuyts, S. Idell, R.O. Williams, Tyler, TX, p.A6369

P29 Validating a Novel Dried Blood Spot Card Test for the Diagnosis of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Within the National PAP Registry/B. Carey, A. Toth, C. Chaila, K. Uchida, B.C. Trapnell, Cincinnati, OH, p.A6371


P32 Quantification of Differential Fibrotic Lesions by Image Analysis in the Mouse Bleomycin Model of Pulmonary Fibrosis/L. Sherry, M. Anderson, A. Young, P. Nath, J. Baily, M.C. McElroy, S. Brockbank, S. Cruwys, Glasgow, United Kingdom, p.A6375


C76 HEAT SHOCK PROTEIN
9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area N, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

P1504 Bcl-2 Up-Regulation in Lung Fibroblasts Induced by HSP70 Autoantibodies is Mediated by Histone Modifications/Y. Sanders, H. Liu, X. Ly, T.N. Kim, X. Zhang, V.J. Thannickal, S.R. Duncan, Birmingham, AL, p.A6378


P1508 Cigarette Smoke Increases Secretion of GRP78 in the Human Lung/M. Aksoy, N. Shetty, S. Kelsen, Philadelphia, PA, p.A6382


P1510 Identification of Candidate Targets Involved in Bronchoalveolar Protection by Mesenchymal Stem Cells (MSC) in Hypoxic Induced Injury/N. Shologu, N. Dard, D. O’Toole, M. Scully, J. Laffey, Galway, Ireland, p.A6384

P156 In Neonatal Mice, CD103+ Dendritic Cells and Clec9a Signaling Are Required for Hyperoxia-Induced Enhanced Inflammatory Responses to Rhinovirus Infection/T. Cui, C.T. Fulton, A.P. Popova, Ann Arbor, MI, p.A6386

P157 MicroRNA-133a/b Plays a Role in Hyperoxia-Induced Decreased Lung Vascularization and Pulmonary Hypertension in Neonatal Mice/M. Sun, T. Chen, S. Patel, R. Ramchandran, J.U. Raj, Chicago, IL, p.A6387


P164 The Role of Forkhead Box O (FoxO) Transcription Factors in Stereological Monitoring of Post-Natal Lung Maturation in the Mouse/V. Bhandari, MD, DrMed, Philadelphia, PA


P166 Role of NQO1 in the Attenuation of Oxygen-Mediated Pulmonary Toxicity by Sulforaphane/R. Kalikott Thekkevedu, C. Chu, B. Moorhdy, Jackson, MS, p.A6395

P167 Interleukin-10 in Experimental Bronchopulmonary Dysplasia/E. Lignelli, W. Seeger, R. Morty, Bad Nauheim, Germany, p.A6397

Facilitator: S.D. Reynolds, PhD, Columbus, OH


P169 Mitochondrial Genome Variation and Risk of Bronchopulmonary Dysplasia (BPD) in Argentinian Infants/J. Marzec, M. Caballero, P. Acosta, F. Polack, S. Kleeberger, Durham, NC, p.A6399

Facilitator: C.D. Baker, MD, Aurora, CO


P173 Genomic Analysis Between Patients with Extreme Respiratory Outcomes Following Preterm Birth/I.A. Cristea, J. Renbarger, J. Harris, G. Jiang, Y. Liu, V.L. Ackerman, M. Geraci, S.D. Davis, Indianapolis, IN, p.A6403


P175 The Classification of ATP-Binding Cassette Subfamily a Member 3 (ABCA3) Mutations Using the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Classification System/T.B. Kinane, L. Denman, L. Yonker, Boston, MA, p.A6405


THEMATIC POSTER SESSION

C78 FIBROSIS: MEDIATORS AND MODULATORS

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Area A, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: C.M. Hogaboam, PhD, Los Angeles, CA


The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.
Pathway Analyses to Understand the Role of Eosinophilia in Interstitial Lung Disease, Systemic Sclerosis, and Esophagitis/S.E. Smith, M. Zarate, M.B. Scholand, Salt Lake City, UT, p.A6408

Pathway Analysis in IPF: Untangling the Relationships Among Key Cell-Signaling Molecules Involved in IPF Pathogenesis/S.E. Smith, A.D. Plante, M.B. Scholand, Salt Lake City, UT, p.A6409

CUB Domain Containing Protein 1/Transforming Growth Factor-Beta 1 Cross-Talk Regulates (Myo)fibroblast Differentiation/N. Noskovicova, K. Heinzelmann, G. Burgstaller, O. Eickelberg, Munich, Germany, p.A6410

Dimensionality, Composition and Stiffness Influence Fibrosis in Healthy and Pathological Pulmonary Artery Adventitial Fibroblasts/M. Floren, A. Flockton, W. Tan, K.R. Stenmark, Aurora, CO, p.A6411


Anti TNF-Alpha Treatment (Infliximab) Attenuates IPF Fibroblast-Mediated Increased Adhesion and Integrin A5 Expression/G. Epstein Shochet, E. Brook, L. Israeli-Shani, D. Shitrit, Kfar Saba, Israel, p.A6414


Hypoxia Modulates Human Pulmonary Arterial Adventitial Fibroblasts/Translocation of a TRPV4-PI3K g


Longitudinal Measurements of Circulating Fibrocytes as a Biomarker for Pulmonary Fibrosis in Idiopathic Pulmonary Fibrosis/V. Yu, M. Burdick, Z. Zhang, J.A. Belperio, M. Horton, B. Mehrad, Charlottesville, VA, p.A6424


Facilitator: S.K. Huang, MD, Ann Arbor, MI


Depletion of Cleavage Factor 25kDa Subunit (CFIm25) and Resulting Alternative Polyadenylation (APA) in Vascular Remodeling and Right Ventricle Hypertrophy in Pulmonary Hypertension/S.D. Collum, T. Mills, A. Hernandez, L. Han, J. Amione-Guerra, K.A. Youker, B. Akkanti, A. Guha, H. Karmouty-Quintana, Houston, TX, p.A6430


### C79 ADVANCING UNDERSTANDING OF OBSTRUCTIVE LUNG DISEASE: MEDICATIONS AND MECHANISMS OF DELIVERY

#### 9:15 a.m. - 4:15 p.m.
WALTER E. WASHINGTON CONVENTION CENTER

**Area L, Hall B-C (Middle Building, Lower Level)**

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

<table>
<thead>
<tr>
<th>Facilitator:</th>
<th>A. Togias, MD, Bethesda, MD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>P1262</strong></td>
<td>Dupilumab Rapidly and Significantly Improves Lung Function and Decreases Inflammation by 2 Weeks After Treatment Initiation in Patients with Uncontrolled Persistent Asthma/A. Papi, B.N. Swanson, H. Staudinger, P. Rowe, J. Maroni, S. Jayawardena, J. Hamilton, N. Amin, G. Pirozzi, B. Akinlade, N.M.H. Graham, A. Teper, Ferrara, Italy, A6444</td>
</tr>
</tbody>
</table>

---

**THEMATIC POSTER SESSION**

| P64 | Mesenchyme Associated Transcription Factor PRRX1: A Key Regulator of IPF Fibroblast/A. Froidure, E. Marchal-Duval, M. Ghanem, M. Jailet, G. Laura, A. Joannes, P. Mordant, A. Cazes, B. Crestani, A. Mailleux, Brussel, Belgium, A6434 |
| P65 | Modulation of Sphingosine-1-Phosphate Receptors Interferes with Connective Tissue Growth Factor Expression in Fibroblasts/D.R. Gendron, P. Blais Lecours, A.-M. Lemay, D. Marsolais, Quebec, Canada, p.A6435 |
| P66 | Identification of a Subset of Rapidly Dividing and High Collagen Expressing Fibroblasts Within a Heterozygous Cohort of Pulmonary Fibroblasts in Idiopathic Pulmonary Fibrosis/L. Rodriguez, B. Aljebur, S. Bui, L. Tran, G. Trujillo, S. Nathan, G. Grant, Fairfax, VA, p.A6436 |
| P70 | Type I Collagen Signaling Through DDR2 Receptor Regulates Fibroblast Apoptosis Through AKT/S. Jia, J.C. Horowitz, M. Agarwal, K.K. Kim, Ann Arbor, MI, p.A6440 |
| P71 | Transcriptional Regulation of MUC5B Expression in Idiopathic Pulmonary Fibrosis (IPF)/L.L.A. Sparks, B. Hellling, A.N. Gerber, V. Kandiyala, S.K. Sasse, B. Pederson, Y. Nakano, T. Okamoto, C. Evans, I. Yang, D.A. Schwartz, Aurora, CO, p.A6441 |
| P72 | Targeting Collagen Degradation to Treat Human Fibrotic Disease/M. J. Podolsky, A. Ha, K. Atabai, San Francisco, CA, p.A6442 |

---

For the most current session information, please visit the online program itinerary.


Effect of Roflumilast on Airway Blood Flow in COPD/E. Mendes, P. Rebolloso, L. Cadet, J. Arana, A. Schmid, A. Wanner, Miami, FL, A6451


Prevalence and Characteristics of Patients with COPD and Low Peak Inspiratory Flow Rate Recruited in a Phase 3 Development Program for Revefenacin, a Nebulized Once-Daily Long-Acting Muscarinic Antagonist/D.A. Mahler, S. Pendyala, C.N. Barnes, G.D. Crater, Hanover, NH, A6453

Facilitator: N. Scichilone, MD, Palermo, Italy

PBI-4425, a Novel First-in-Class Anti-Inflammatory/Anti-Fibrotic Compound, Reduces Pulmonary Emphysema and Cutaneous Hyperplasia in Tight-Skin (Fbn-1) Mouse/L. Gagnon, L. Geerts, M.-P. Cloutier, J. Richard, J. Ouboudinard, P. Laurin, B. Grouix, Laval, Canada, A6454


A Physiological Rationale for Epithelial Sodium Channel Inhibition and Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Therapy (Ivacaftor) in Primary Ciliary Dyskinesia/E.P. Ingenito, R. Haberman, K. Donn, R.C. Boucher, W. Dworakowski, J. Miller, Boston, MA, A6456


The Fate of Inhaled Simvastatin in the Lungs and Systemic Circulation/A.A. Zeki, M. Elbadawi-Sidhu, S. Ott, O. Fiehn, Sacramento, CA, A6459

THEMATIC POSTER SESSION

C80-A EVERYTHING YOU NEED TO KNOW ABOUT BRONCHOPULMONARY DYSPLASIA, CYSTIC FIBROSIS AND DIFFUSE PARENCHYMAL LUNG DISEASES

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: L.K. Rogers, PhD, Columbus, OH


Facilitator: M. Dowell, MD, Chicago, IL


P182 Lung Densitometry: MRI and CT Have Similar Spatial Patterns for Adults with Cystic Fibrosis/R.J. Theilmann, A. Yen, D.J. Conrad, La Jolla, CA, p.A6464


Facilitator: M. Padilla, MD, New York, NY

P186 Vitamin D Binding Protein and Alpha-1-Acid Glycoprotein Levels in Serum Are Associated with Lymphangiopulmonary Adenopathy/S. Miller, C. Coveney, D. Boocoock, S.R. Johnson, Nottingham, United Kingdom, p.A6468

The information contained in this program is up to date as of March 9, 2017. For the most current session information, please visit the online program itinerary.
C80-B  MULTI-MODALITY ASSESSMENT OF COPD, ASTHMA, AND ASTHMA-COPD OVERLAP SYNDROME

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER 
Area K, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator:  M.K. Han, MD, MS, Ann Arbor, MI


P1043  Effect of Ophioccephalus Striatus Extract on TNF-α, CRP and COPD Assesment Test (CAT) Score on Stable Muscle-Wasted COPD Patients/S. Djalalaksana, E. Kusumawardhani, Malang, Indonesia, p.A6479

P1044  Activation of the Unfolding Protein Response in the Vastus Lateralis of Patients with Respiratory Cachexia: Advanced COPD Versus Lung Cancer/E. Barreiro, A. Salazar-Degracia, E. Puig-Vilanova, J. Gea, Barcelona, Spain, p.A6480

P1045  Muscle-Specific microRNA Expression Differes in Vastus Lateralis Specimens from that of Myotubes in COPD Patients with Cachexia/E. Barreiro, S. Pascual-Guardia, A. Salazar-Degracia, E. Puig-Vilanova, C. Casadevall, J. Gea, Barcelona, Spain, p.A6481

P1046  Rate of FEV1 Decline in Patients with History of COPD Hospitalization: A 10-Year Retrospective Study/H. Wu, A. Medinger, Washington, DC, p.A6482

P1047  CComparison of the Forced Oscillation Technique and Spirometry in COPD and Alpha-1-Antitrypsin Deficient Patients/L.K.A. Lundblad, E. Piitulainen, P. Wollmer, Burlington, VT, p.A6483

P1048  The Relationship Between Forced Oscillation Technique Measurements and the COPD Assessment Test in Stable Chronic Obstructive Pulmonary Disease/A.M. Cotte, L. Seccombe, J.C. Watts, G. King, C. Thamrin, M. Peters, C. Farah, Sydney, Australia, p.A6484


P1051  Complex Physiological Assessment in COPD/B. Szucs, M. Petrekanits, J. Varga, Debrecen, Hungary, p.A6487


Facilitator: A.F. Gelb, MD, Lakewood, CA


P1057  Clinical Features and Outcomes Associated with Marked Bronchodilator Reversibility in Patients with Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Asthma-COPD Overlap Syndrome (ACOS)/R. Allehebi, M. Stanbrook, Toronto, Canada, p.A6493

P1058  Association Between Changes in Asthma Control and Measures of Lung Function/R. Allehebi, K.R. Chapman, Toronto, Canada, p.A6494


P1060  Lung Compliance and Resistance in Patients with Severe Persistent Asthma Before and After Undergoing Bronchial Thermoplasty: A Pilot Study/A. Baydur, R.R. Virdi, R. Barbers, Los Angeles, CA, p.A6496

P1061  Changes in Lung Function and Forced Oscillatory Technique (FOT) Parameters Following Bronchial Thermoplasty (BT) in Patients with Refractory Asthma/C. Farah, D. Langton, P. Pierucci, A. Ing, Sydney, Australia, p.A6497


P1064  Longitudinal Variation of Lung Function Considering FEV1’s Best Performance During Long-Term Treatment of Severe Asthma/P. C.A. Almeida, A. Souza-Machado, E.V. Ponte, N. Scichilone, R. Stelmach, A.A. Cruz, Salvador, Brazil, p.A6500

THEMATIC POSTER SESSION

C80-C  IMAGING METHODOLOGY AND APPLICATION TO LUNG DISEASE

9:15 a.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER

Area N, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: R.R. Rizi, PhD, Philadelphia, PA


Facilitator: J.C. Sieren, PhD, Iowa City, IA

The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.
P1525 Enhancing Lung Tumor Visibility Using In-Vivo Ultrasound as a Noninvasive Tool to Diagnose Trapped 18F-FDG PET/CT Plays a Valuable Role in Assessing Almost Facilitator: M. Kirby, PhD, Vancouver, Canada


Facilitator: M. Kirby, PhD, Vancouver, Canada

P1528 18F-FDG PET/CT Plays a Valuable Role in Assessing Almost Cartilages and Detecting Early or Atypical Relapsing Polychondritis/J. Wang, X. Xie, Y. Zeng, Guangzhou, China, p.A6517

P1529 Ultrasound as a Noninvasive Tool to Diagnose Trapped Lung/B. Flora, S. Ahmad, Stony Brook, NY, p.A6518

P1530 Is Tracheomalacia A Dynamic Condition?/M. Nygaard, F. Rasmussen, E. Bendstrup, O. Hilberg, Arhus, Denmark, p.A6519


P1532 Temporally-Resolved Computed Tomographic (CT) Imaging to Assess Regional Parenchymal Strain During Oscillatory Ventilation/J. Herrmann, M.K. Fuld, E.A. Hoffman, D.W. Kaczka, Iowa City, IA, p.A6522


C80-D SLEEP AND HEALTH POLICY
9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area H, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: S.R. Patel, MD, Pittsburgh, PA
M.E. Billings, MD, MSc, Seattle, WA


C80-E ADHERENCE TO OSA THERAPY: THE ACHILLES HEEL?

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Area H, Hall B-C (Middle Building, Lower Level)

**Viewing:** Posters will be on display for the entire session.

**Discussion:**

- 11:15-12:00: Authors will be present for individual discussion.
- 12:00-1:00: Authors will be present for discussion with assigned facilitators.

**Facilitators:** J. Bakker, PhD, Boston, MA
C. Chai-Coetzter, MBBS, PhD, Adelaide, Australia


**P852** Usefulness of a 5-Item Scale to Assess Sleep Health Status: Results of the Catalan Health Survey 2015/J. De Batlle, I.D. Benitez, M. Dalmases, A. Mas, O. Garcia-Codina, A. Medina-Bustos, J. Escarrabill, E. Salto, M. Sanchez-de-la-Torre, F. Barbe, Lleida, Spain, p.A6535


**P857** Adherence Predictors of Active and Sham Continuous Positive Airway Pressure in a Randomized Controlled Trial/A.M. May, T. Gharibeh, K.P. Strohl, J. Beno, L. Wang, A. Hurley, R. Mehra, Cleveland, OH, p.A6539


**P861** Predictors of Long-Term Adherence to Auto-Titrating Positive Airway Pressure Therapy in Coronary Artery Disease Patients with Non-Sleepy and Sleepy Obstructive Sleep Apnea/F.S. Luyster, P.J. Strollo, E. Thunstrom, Y. Peker, Pittsburgh, PA, p.A6543

**P862** Video Education to Improve CPAP Adherence (Sleep Apnea Video Education for CPAP or SAVE-CPAP Study): A Randomized Controlled Trial/A.S. Guralnick, J.S. Balachandran, S. Szutenbach, K. Adley, L. Emami, M. Mohammadi, J.M. Farman, V. Arora, B. Mokhlesi, Chicago, IL, p.A6544


**P864** Influence of a Real Time Feedback Patient Engagement Tool on Adherence to Positive Airway Pressure Therapy: Analysis of Big Data from a German Homecare Provider/H. Woehrle, M. Arzt, A. Graml, I. Fietze, P. Young, H. Teschler, J.H. Ficker, Blaubeuren, Germany, p.A6546

**P865** Quality of Life Challenges in Sleep Apnea - Experience of Sleep Laboratory from Cluj-Napoca, Romania/D.A. Todea, A.C. Thomazin, B. McCann, C. Bombardier, K. Becker, W.T. Longstreth, Jr., N. Watson, S. Khot, Seattle, WA, p.A6550


P869 Positive Airway Pressure adherence in Patients with Obstructive Sleep Apnea with Schizophrenia compared to matched controls/M. Saoud, M. Saeed, R. Metta, J. Mador, Buffalo, NY, p.A6552

P870 Performance of Adherence in the First 6 Months CPAP Use Associated with Anthropometric Variables, Type of Interface, Level Pressure, Comorbidities in Patients with OSA Belonging to the National OSA Program in the National Chest Institute/U.I. Marmolejo, R. Gutierrez, A. Cisternas, L. Soto, J.L. Molina, Santiago, Chile, p.A6553

THEMATIC POSTER SESSION

C80-F MANAGEMENT OF SLEEP DISORDERED BREATHING

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area H, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: S. Patil, MD, Baltimore, MD
R.J. Kimoff, MD, Montreal, Canada
S. Sinha, MD, New Delhi, India
M. Macrea, MD, MPH, PhD, Salem, VA


P879 Three-Month Adherence to Positive Airway Pressure Therapy for Treatment of Obstructive Sleep Apnea (OSA) in Patients Undergoing Ambulatory Versus in-Lab Pathways of Care. Results from a Rural Tertiary Care Academic Center/A. Alhaddad, R.C. Stansbury, B. Weaver, Morgantown, WV, p.A6560

THERAPEUTIC POSTER SESSION

C80-G THORACIC ONCOLOGY CASE REPORTS I

9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Area C, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: J.A. Akulian, MD, MPH, Chapel Hill, NC


P195 Spontaneous Renal Hemorrhage: A Rare Presentation of Post-Partum Metastatic Choriocarcinoma/O. Rahman, A.A.E. Sheikh, R. Kapoor, J. Ullman, Indianapolis, IN, p.A6568

P196 A Rare Case of Papillary Endobronchial Squamous Cell Carcinoma/F. Afridi, B. Pellini Ferreira, E. Geigel, Orlando, FL, p.A6569


Facilitator:  A.A. Balekian, MD, MS, Los Angeles, CA

P231 The Fourth Biopsy is the Charm/K. Wickstrom, H. Ateeli, D. L’Heureux, Tucson, AZ, p.A6603


P234 HPV Associated Squamous Cell Carcinoma of the Lung Presenting As CHF/B.P. Gargia, A. Mehta, D. Haynes, Jackson, MS, p.A6606

P235 The Coughing that Lead to the Coffin/K. Mathew, K. Buch, Lexington, KY, p.A6607

P236 Mucoepidermoid Carcinoma Presenting as an Endobronchial Lesion/E. Cristan, H. Ateeli, S. Chaudhary, Tucson, AZ, p.A6608

P237 Extranodal Hodgkin Lymphoma Relapse with Bilateral Cavitary Lung Nodules and Endobronchial Involvement/U. Popper, D. Sue, Torrance, CA, p.A6609

P238 “All that Wheezes Is Not Asthma”: A Case of Primary Adenoid Cystic Carcinoma of the Trachea/M.J. Calder, E.S. Rains, T.J. Meyer, Wynnewood, PA, p.A6610


P240 A Rare Malignancy in an Active Smoker/G. Lin, J. Wehner, V. Mohindra, San Jose, CA, p.A6612

Facilitator:  T. Vandemoortele, MD, Montreal, Canada


P244 Adenoid Cystic Carcinoma: The Uncommonly Common Primary Tracheal Tumor/E.J. Conuel, L. McCarthy, K. Neu, Albany, NY, p.A6616

P245 A Rare Case of an Endobronchial Lesion: Adenoid Cystic Carcinoma/A. Youssef, L. Kim, S. Benavides, A. Abolhoda, B. Saatian, F. Mazdisnian, Long Beach, CA, p.A6617

P246 Just Scratching the Surface/R.A. Estrada, T. Simpson, San Antonio, TX, p.A6618

P247 Pulmonary Adenofibroma: A Rare Benign Lung Lesion/P.T. Ngo, M. Elsavaw, Neptune, NJ, p.A6619

P248 Solitary Fibrous Tumor of the Pleura Presenting as Weight Loss and Abdominal Pain: A Rare Presentation of a Rare Tumor/J. M. Chowdhury, B. Lindgren, M. Kosa, V. Sheth, M. Korman, Darby, PA, p.A6620

P249 Spontaneous Tumor Lysis Syndrome and Acute Cholecystitis-Like Picture as Initial Presentation of Small Cell Lung Carcinoma/D. Qasrawi, T. Asif, O. Abughanimeh, R. Gaur, Kansas City, MO, p.A6621


Facilitator:  C. Anderlin, MD, Boston, MA

P251 A Rare Pleural Pearl/R. Zulfikar, S. Hadique, B. Erdreich, Morgantown, WV, p.A6623

P252 Endobronchial Malignancy Masquerading as Obstructive Lung Disease/N. Raya, S. Javidiparsijani, S.J. Quinn, M. Vashi, R. Tandon, Chicago, IL, p.A6624


P254 A Case Report of Widespread Bilateral Recurrence of Lung Adenocarcinoma After Complete Resection/K. Lipatov, J.F. Sanchez, Temple, TX, p.A6626

P255 An Unusual Recurrence of Remote Cutaneous Malignant Melanoma as Metastatic Endobronchial Melanoma/N. Nagori, V. Krishnan, Cleveland, OH, p.A6627


P257 A Rare Case of Small Cell Lung Cancer (SCLC) Presenting as an Endobronchial Lesion/M. Young, H. Arshad, R. Adurty, Pittsburg, PA, p.A6629


Facilitator:  T. Kubota, MD, PhD, Nankoku City, Japan


P262 Anesthesia Challenges Facing Giant Mediastinal Mass/J.C. Mora, S. Chhangani, Jacksonville, FL, p.A6635

P263 A Rare Case of Papillary Carcinoid Tumor of the Lung/S. Pandey, D. Wilson, A.P. Maskey, Lexington, KY, p.A6636


P265 Abdominal Pain and Malignant Melanoma Pleural Effusion/A. Olson, C. Harden, A. Ataya, C. Trillo, Gainesville, FL, p.A6638
C80-I THORACIC ONCOLOGY CASE REPORTS III
9:15 a.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Area C, Hall B-C (Middle Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: G.E. Holt, MD, PhD, Miami, FL


P280 Not All that Wheezes is Asthma/C. Onofrei, A. Rose, Indianapolis, IN, p.A6651

Facilitator: J. Wang Memoli, MD, Washington, DC

P281 The Silent Giant: A Rare Case of a Pleural Hemangiopericytoma/ S. Gorgis, P. Sen, J. Jennings, Detroit, MI, p.A6652

P282 Contralateral Recurrence of Inflammatory Myofibroblastic Tumour of the Lung Ten Years After Pneumonectomy/D.C. Vis, G. Gelfand, M. Kelly, A. Lee, K.A. Johansson, Calgary, Canada, p.A6653


P288 A Rare Case of Metastatic Pulmonary Osteosarcoma in Association with Non-Malignant Pleural and Pericardial Effusion/R. Mishra, B. Bajani, M. Blyyam, R. Duncalf, M. Adrish, Bronx, NY, p.A6659


Facilitator: J. Deepak, MD, MBBS, Baltimore, MD

P291 A Very Rare Case of Multifocal Endobronchial Diffuse B-Cell Lymphoma/B. Balakrishnan, R. Swarup, Ypsilanti, MI, p.A6662


P293 The Nonresolving Pneumonia: A Rare Case of Multiple Myeloma with Extramedullary Plasmacytoma/R. Postelnicu, J.L. Denson, V. Mukherjee, New York, NY, p.A6664


P295 One Room, Two Occupants: They Both Don’t Have to Be Related/I.U. Chaddha, P. Patil, N. Thawani, N. Ahmad, R. Walia, A.C. Mehla, T. Panchabhai, Los Angeles, CA, p.A6666

P297 Complete Remission by Radiotherapy Alone of Tracheal Squamous Cell Carcinoma Emerging 25 Years After Curative Resection for Lung Adenocarcinoma/T. Uno, K. Satoh, Niigata-City, Japan, p.A6668

P298 A Case of Recurrent Respiratory Papillomatosis Transformation to Metastatic Squamous Cell Carcinoma of the Lung/O. Bohn, F. Zamora, J. Leatherman, Minneapolis, MN, p.A6669

P299 Pleural Effusion as Unusual Presentation of Chronic Lymphocytic Leukemia/E. Alkhankan, M. Al Diwi, H. Al Krad, H. Aswad, F. Alkhankan, Huntington, WV, p.A6670


Facilitator: R. Kumar, MD, Philadelphia, PA


P302 Malignant Pleural Mesothelioma with a Gelatinous Course/M. Kaous, S. Faiz, Houston, TX, p.A6673


P304 What Lies Beneath: Squamous Cell Carcinoma Masquerading as Interstitial Lung Disease/E. Schuiteman, E. Otoupalova, W.B. Fields, Royal Oak, MI, p.A6675


P307 A Rare Case of Non-Small Cell Carcinoma Metastatic to Colonic Polyp Presenting with Life-Threatening Lower Gastrointestinal Bleed/I. Shahoub, N. Munn, M. Gusack, Huntington, WV, p.A6678


P310 A Rare Presentation of a Synchronous Adenocarcinoma of the Lung with Non-Hodgkin’s Lymphoma/K. Patel, Chicago, IL, p.A6681

### C80-J THORACIC ONCOLOGY CASE REPORTS IV

**9:15 a.m. - 4:15 p.m.** WALTER E. WASHINGTON CONVENTION CENTER

**Area C, Hall B-C (Middle Building, Lower Level)**

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

**Facilitator:** J. Toth, MD, Hershey, PA

**P311** Synchronous Pulmonary MALT Lymphoma and Cryptosporidium Infection: Coincidence or Causal Connection?/M. Kalani, S. Alhassan, T. Cheema, Pittsburgh, PA, p.A6682


**P314** Uterine Leiomyosarcoma One of the Rare Causes of Bilateral Pulmonary Nodules/H.S. Arshad, A. Bhulodkar, M. Khaja, Bronx, NY, p.A6685

**P315** A Case of Chylous Pleural Effusion as Unusual Presentation of Chronic Lymphocytic Leukemia/E. K. Alonso, C.R. Bellinger, Winston-Salem, NC, p.A6686

**P316** A Case of Simultaneous Multiple Primary Lung Cancers with Radiologic and Histopathologic Correlation/A. Tiwari, H. Sharma, M.S. Khan, H. Badi, Toledo, OH, p.A6686

**P317** 42-Year-Old Man with Acute Obstructive Respiratory Failure Secondary to Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma/L. A. Seaburg, L. Vande Vusse, K. Patel, Seattle, WA, p.A6687

**P318** Beating the Odds-Five Year Survival Rate of a Patient with Non Small Cell Lung Cancer/A. Magge, J. Goralkin, E. Nadler, R. Mutneja, O. Ibrahim, Farmington, CT, p.A6688


**Facilitator:** A.I. Saeed, MBBS, Albuquerque, NM

**P320** Renal Cell Carcinoma (RCC) Metastasize to Lung and Gall Bladder/M. Azharuddin, I. Lalani, M. Doraiswamy, M. Maniar, Long Branch, NJ, p.A6690

**P321** Balloon Bronchoplasty for the Management of Radiation-Induced Bronchial Stenosis/S.J. Kuperberg, M. Marks, K. Alonso, C.R. Bellinger, Winston-Salem, NC, p.A6691

**P322** Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH): A Case Presentation and Overview of Documented Cases/S. Bolis, Y. Mishinki, Allentown, PA, p.A6692

**P323** Pulmonary Mucoepidermoid Carcinoma: A Rare Primary Lung Tumor/E. Mims, D. Poch, S. Makani, San Diego, CA, p.A6693

P325 Pleuro-Pulmonary Angiosarcoma Presenting as Spontaneous Hemothorax and Bilateral Pulmonary Nodules/C. Onofrei, A. Rose, C.R. Sears, Indianapolis, IN, p.A6695


Facilitator: S. Benzaquen, MD, Cincinnati, OH

P328 Myelomatous Pleural Effusion as an Etiology of Dyspnea in a Patient with Multiple Myeloma/S. Vanaik, K. Sandhu, Philadelphia, PA, p.A6698

P329 Rare Case Report of Pulmonary Lymphangitic Spread in Rectal Cancer/S. Easaw, V. Kaul, M. Farokhi, P. Spiro, Elmhurst, NY, p.A6699

P330 Lung Adenocarcinoma Presenting as Carcinomatous Meningitis/K. Lam, Palo Alto, CA, p.A6700

P331 Needle in a Haystack: A Rare Pulmonary Presentation of Peripheral T Cell Lymphoma/A. Shahmohammadi, J. Wynne, E. Harman, Gainesville, FL, p.A6701


P334 Pulmonary Granular Cell Tumor Presenting with Post-Obstructive Pneumonia/S. Farooqi, M.S. Khan, V. Doshi, Oklahoma City, OK, p.A6704


Facilitator: K. Diab, MD, Indianapolis, IN

P336 Ectopic Adrenocorticotropin Hormone Production in a Patient with Adenocarcinoma of Lung/N.R. Bongu, P. Produturvar, Greenville, NC, p.A6706

P337 Peripheral Eosinophilia as the First Sign of Metastatic Lung Adenocarcinoma/G. Malhotra, A. Copur, North Chicago, IL, p.A6707

P338 Pulmonary Metastasis from Cervical Cancer 50 Years Later?/S. Castillo, H. Latham, Kansas City, KS, p.A6708


P340 Histologic Transformation from Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma with EGFR-Mutant Exons 20(S768I) and 21(L858R) to Small Cell Lung Carcinoma (SCLC): Case Report/L. Fernandez, L.F. Sua, J.D. Yara, A.M. Morales, L. Gutierrez, Cali, Colombia, p.A6710

P341 Multidisciplinary Management of a Primary Mediastinal Synoval Sarcoma with Large Tumor Burden/E. Howell, A.D. Can, B. Lasky, D. Hsi, Y. Carter, Torrance, CA, p.A6711

P342 A Case of Benign Solitary Fibrous Tumor Becoming Malignant/J.A. Ben Gabr, S. Nandavaram, G. Trikha, Syracuse, NY, p.A6713


Facilitator: J.A. Nations, MD, MBA, Bethesda, MD

P344 A Case of MALT Lymphoma as an Insidious Lung Mass/L. Chia, K.M. Phan, J. Resnikoff, San Diego, CA, p.A6715


P346 Lung Cancer One, Two, Three/E. Nadler, J. Goralnik, O. Ibrahim, A. Sharma, Farmington, CT, p.A6717


P348 A Case of Triple Metachronous Primary Lung Carcinomas/S. Park, Y. Choe, S. Kim, Y. Lee, H. Lee, Jeonju, Korea, Republic of, p.A6719

P349 A Tale of Carcinoid in a Veteran/P. Krishnan, R. Chakravarty, P. Ramadas, A. Abbasi, Syracuse, NY, p.A6720


Facilitator: J.A. Nations, MD, MBA, Bethesda, MD
**WS5 REVIEW OF THE NEW CYSTIC FIBROSIS DIAGNOSIS GUIDELINES**

Registration Fee: $75 (includes box lunch)

Attendance is limited. Pre-registration is required.

Assemblies on Pediatrics; Allergy, Immunology and Inflammation; Clinical Problems

11:45 a.m. - 1:15 p.m. MARRIOTT MARQUIS WASHINGTON Archives (Level M4)

**Target Audience**
Anyone who evaluates patients with respiratory disease

**Objectives**

At the conclusion of this session, the participant will be able to:

- interpret CFTR genetic testing as it applies to CF diagnosis, using CFTR2 as well as other resources;
- diagnose CF in infants with a positive CF newborn screen and to describe outcomes associated with inconclusive cases;
- apply ancillary testing in cases of suspected CF.

Historically, cystic fibrosis (CF) has been diagnosed in patients who present with a well defined phenotype and have an elevated sweat chloride. However, advances in our understanding of CF genetics and the growth of CF newborn screening have created new challenges to CF diagnosis. In response to these developments, the CF Foundation sponsored a consensus conference in October 2015 to revise the CF diagnostic guidelines, which were last updated in 2008. The goal of this workshop is to review the key changes in these guidelines.

**Chairing:** C.L. Ren, MD, Indianapolis, IN

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:45</td>
<td><strong>Introduction</strong></td>
</tr>
<tr>
<td></td>
<td>C.L. Ren, MD, Indianapolis, IN</td>
</tr>
<tr>
<td>12:00</td>
<td><strong>Applying Genetic Testing to the Diagnosis of CF</strong></td>
</tr>
<tr>
<td></td>
<td>P. Sosnay, MD, Baltimore, MD</td>
</tr>
<tr>
<td>12:25</td>
<td><strong>Diagnostic Challenges Arising from CF Newborn Screening</strong></td>
</tr>
<tr>
<td></td>
<td>C.L. Ren, MD, Indianapolis, IN</td>
</tr>
<tr>
<td>12:50</td>
<td><strong>The Role of Ancillary Testing in the Diagnosis of CF</strong></td>
</tr>
<tr>
<td></td>
<td>I. Sermet-Gaudelus, MD, Paris, France</td>
</tr>
</tbody>
</table>

This session and the International Conference are supported by an educational grant from Vertex Pharmaceuticals, Inc.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
WS6 CAREER DEVELOPMENT WORKSHOP: HOW TO START YOUR INDEPENDENT RESEARCH LABORATORY

This Forum is part of the ATS initiative to offer program specifically geared toward the professional development of trainees, fellows and students to aid in the pursuit of successful careers in pulmonary, critical care and sleep medicine.

Pre-registration is required. Attendance is limited. There is no additional fee.

Assemblies on Respiratory Structure and Function; Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Clinical Problems; Critical Care; Environmental, Occupational and Population Health; Microbiology, Tuberculosis and Pulmonary Infections; Pediatrics; Pulmonary Circulation; Respiratory Cell and Molecular Biology; Sleep and Respiratory Neurobiology; Thoracic Oncology

11:45 a.m. - 1:15 p.m. MARRIOTT MARQUIS WASHINGTON Capitol/Congress (Level M4)

Target Audience
Graduate students, PhD, MD, post-doctoral clinical fellows and faculty interested in identifying opportunities and obstacles in starting their independent research laboratory. Through lectures and discussion with six senior and recently hired investigators, the participants will learn successful strategies that can be employed at a variety of non-profit and for profit institutions.

Objectives
At the conclusion of this session, the participant will be able to:

• learn about the key challenges and opportunities in starting a new lab at an non-profit and a for profit institution;
• understand and gain the strategies to develop the budget for his/her lab;
• learn how to manage time between setting up the lab, research, teaching and grant writing.

Successful independent research is built on a strong research laboratory. But each newly hired investigator often faces a unique set of opportunities and challenges in getting their laboratory started. To sustain productivity during this initial period, appropriate plans are needed in the processes including negotiating the job terms, staffing the laboratory, and managing the time and personnel. The participants will hear from six members of the ATS community comprising of senior investigators and recently hired investigators each from educational institutions and industrial organizations or research laboratories.

Chairing:
D.T. Tambe, PhD, Mobile, AL
D. Kasahara, PhD, Boston, MA

11:45 Starting a New Lab at NIH
R. Balaban, PhD, Bethesda, MD

11:55 Common Successful Strategies Employed in the Startup Package
J. Solway, MD, Chicago, IL

12:05 Challenges and Opportunities at Large Versus Small Universities
T. Stevens, PhD, Mobile, AL

12:15 Starting a New Lab in an Engineering School
G.N. Maksym, PhD, Halifax, Canada

12:25 Managing to Set up a New Laboratory Together with Clinical Practice, Teaching and Grant Writing
C.C. Hardin, MD, PhD, Boston, MA

12:35 Developing the Budget
V. Anathy, PhD, Burlington, VT

12:45 General Discussion

CC4 SLEEP MEDICINE CLINICAL CORE CURRICULUM I

Adult Core Curriculum Working Group

11:45 a.m. - 1:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER Hall E (Middle Building, Level 2)

Target Audience
Practicing internists, subspecialists, registered nurses and advanced practice nurses in pulmonary, critical care, and sleep medicine who work in a clinical setting and are currently engaged in maintenance of certification.

Objectives
At the conclusion of this session, the participant will be able to:

• discuss current strategies for managing insomnia using pharmacologic therapies;
• discuss current strategies for managing insomnia using non-pharmacologic therapies;
• describe strategies for managing insomnia in patients with psychiatric diseases.

The ATS Clinical Core Curriculum Symposia focus on a 3-year content cycle of key medical content in the areas of Pulmonary, Critical Care, and Sleep Medicine. The topics are also aligned with corresponding MOC Medical Knowledge modules. This symposium is intended to assist clinicians with staying current with the growth of information relevant to their medical practice, as well as provide an opportunity to evaluate individual knowledge and skills while earning MOC Medical Knowledge points.

Chairing:
S. Jamil, MD, La Jolla, CA

11:45 Insomnia: Pharmacologic Therapies
M.E. Billings, MD, MSc, Seattle, WA

12:15 Insomnia: Non-Pharmacologic Therapies
P. Gehrman, PhD, Philadelphia, PA

12:45 Sleep in Psychiatric Diseases
J.L. Martin, PhD, North Hills, CA
MEET THE PROFESSOR SEMINARS

CME Credits Available: 1

Registration Fee: $70.00 (includes box lunch.)
Attendance is limited. Pre-registration is required.

12:15 p.m. - 1:15 p.m. MARRIOTT MARQUIS WASHINGTON

MP601 PRIMARY IMMUNODEFICIENCY AND PULMONARY DISEASE
A. Dosanjh, MD, San Diego, CA
George Washington University (Level M1)

MP602 LEARNING TO LEAD: TIPS FOR SUCCESS
M. Osborne, MD, PhD, Portland, OR
Georgetown University (Level M1)

MP603 APPROACH TO THE PATIENT WITH REFRACTORY CHRONIC COUGH
P. Dicpinigaitis, MD, Bronx, NY
Howard University (Level M1)

MP604 MULTIDISCIPLINARY ILD EVALUATION: USING CLINICAL AND HRCT TO MAKE A DIAGNOSIS
J. Dematte, MD, MBA, Chicago, IL
R. Agrawal, MD, Chicago, IL
Gallaudet University (Level M1)

MP605 PULMONARY SYMPTOMS IN SARCOIDOSIS: EVALUATION AND MANAGEMENT
M.A. Judson, MD, Albany, NY
Catholic University (Level M1)

MP606 DRUG-INDUCED MIMICS OF IDIOPATHIC LUNG DISEASES
P.B. Camus, MD, Dijon, France
A.H. Limper, MD, Rochester, MN
University of DC (Level M1)

MP607 CONNECTIVE TISSUE DISEASE AND THE LUNG: LESSONS LEARNED FROM DIFFICULT CASES
M. Kreider, MD, Philadelphia, PA
Marquis Salon 14 (Level M2)

MP608 HOW DO I PREPARE MY ILD PATIENT FOR LUNG TRANSPLANT?
D.E. Antin-Ozerkis, MD, New Haven, CT
Marquis Salon 13 (Level M2)

MP609 CHRONIC BRONCHITIS: NEW CONCEPTS, NEW TREATMENTS, NEW HOPE
V. Kim, MD, Philadelphia, PA
Marquis Salon 12 (Level M2)

MP610 WHEEZING WHILE YOU WORK: UPDATE ON EVALUATION AND MANAGEMENT OF WORK-RELATED ASTHMA
E.N. Schachter, MD, New York, NY
Union Station (Level M3)

MP611 BEYOND THE NTM GUIDELINES: WHAT TO DO WHEN THE STANDARD DRUGS DON'T WORK
K.N. Olivier, MD, MPH, Bethesda, MD
Chinatown (Level M3)

MP612 IN VITRO AND IN VIVO EXPOSURES TO EMERGING TOBACCO PRODUCTS: RESEARCH TO REGULATORY SCIENCE
I. Rahman, PhD, Rochester, NY
Mount Vernon Square (Level M3)

MP613 LUNG IMPEDANCE: MEASUREMENT AND INTERPRETATION
J.H.T. Bates, DSc, PhD, Burlington, VT
Judiciary Square (Level M3)

MP614 NONINVASIVE VENTILATION IN NEUROMUSCULAR DISEASE: BEYOND THE BASICS
L. Wolfe, MD, Chicago, IL
LeDroit Park (Level M3)

MP615 LUNG CANCER IN WOMEN: EPIDEMIOLOGY, RISKS, BIOLOGY AND OUTCOMES
M.P. Rivera, MD, Chapel Hill, NC
Shaw (Level M3)

MP616 OFFICIAL ATS DOCUMENTS: HOW TO GET INVOLVED
R. Dweik, MD, Cleveland, OH
K.C. Wilson, MD, Boston, MA
Treasury (Level M4)

MEDICAL EDUCATION SEMINAR

CME Credits Available: 1

ME3 PLAYING TO THE CROWD: HOW TO ENGAGE YOUR AUDIENCE IN LARGE GROUP TEACHING

Registration Fee: $70 (includes box lunch)
Attendance is limited. Pre-registration is required.

12:15 p.m. - 1:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 101 (South Building, Street Level)

Target Audience
Medical educators, teaching physicians, physician-scientists, and providers on the multidisciplinary healthcare team, including nurses, respiratory therapists, advanced practice providers, and pharmacists within pulmonary, critical care, and sleep medicine, who seek to develop necessary skills to become more effective educators in a large group setting

Objectives
At the conclusion of this session, the participant will be able to:

- engage the learner in large group teaching sessions by implementing new strategies to engage the audience;
- create effective, interactive questions using an audience response system to improve learning in a large group setting;
- Incorporate team based learning into their large group teaching.

Teaching in a large group setting is an essential skill for physicians, educators and multidisciplinary health care providers. This session will use an interactive format to provide strategies for the educator to better engage the learner in these large group settings. We will review techniques to enhance the delivery and presentation of educational content, demonstrate team based learning in an interactive format and effective use of audience response systems with the opportunity to learn how to create and embed questions into your presentations. Participants are encouraged to bring their own laptop and a power point presentation.

Speakers:
K. Burkart, MD, New York, NY
J.W. McCallister, MD, Columbus, OH
T.S. Wang, MD, Los Angeles, CA
J.T. Poston, MD, Chicago, IL

The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.
## THEMATIC SEMINAR SERIES

**CME Credits Available: 1**

### TSS1  EVOLVING CONCEPTS IN EARLY COPD

- **Registration Fee:** $170 for full series (includes box lunch)
- **Attendance is limited. Pre-registration is required.**
- **This is part 3 of a 4-part series. Those registering for this seminar series will be registered for all 4 parts. The program for the full series is included with the Sunday, May 21, 12:15 p.m. program.**
- **Tuesday 12:15 p.m. - 1:15 p.m.  MARRIOTT MARQUIS WASHINGTON Monument (Level M4)**

**Screening for COPD: Beyond the Current Guidelines**
R.A. Wise, MD, Baltimore, MD

---

## ATS 2017

**Where today’s science meets tomorrow’s care™**

**International Conference**

**Washington, DC**

**Tuesday Afternoon, May 23**

### CLINICAL

#### ADULT CLINICAL CORE CURRICULUM

- **CME Credits Available: 2**
- **MOC Points Available: 2**

### CC5  PULMONARY CLINICAL CORE CURRICULUM II

- **Adult Core Curriculum Working Group**
- **2:15 p.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER Hall E (Middle Building, Level 2)**

**Target Audience**
Practicing internists and subspecialists in Pulmonary, Critical Care, and Sleep medicine who work in a clinical setting and are currently engaged in maintenance of certification

**Objectives**
At the conclusion of this session, the participant will be able to:
- remain current with medical knowledge relevant to their practice in pulmonary, critical care, and sleep medicine;
- evaluate their understanding of key skills and content areas in pulmonary, critical care and sleep medicine, as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
- support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The ATS Clinical Core Curriculum Symposia focus on a 3-year content cycle of key medical content in the areas of Pulmonary, Critical Care, and Sleep Medicine. The topics are also aligned with corresponding MOC Medical Knowledge modules. This symposium is intended to assist clinicians with staying current with the growth of information relevant to their medical practice,
as well as provide an opportunity to evaluate individual knowledge and skills while earning MOC Medical Knowledge points.

Chairing: G.C. Michaud, MD, New York, NY

2:15 Lung Cancer Screening
N.T. Tanner, MD, MSCR, Charleston, SC

2:45 Lung Cancer Diagnosis
A.V. Gonzalez, MD, MSc, Montreal, Canada

3:15 Lung Cancer Staging
M. Liberman, MD, PhD, Montreal, Canada

3:45 Lung Cancer Treatment
S. Shojaee, MD, Richmond, VA

---

The Cutting Edge in Lung Transplantation

Assemblies on Clinical Problems; Allergy, Immunology and Inflammation

2:15 p.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Ballroom A (South Building, Level 3)

Target Audience
A broad range of providers that are involved in the care of lung transplant recipients, including physicians, surgeons, and other allied health professionals and trainees interested in pursuing lung transplantation.

Objectives
At the conclusion of this session, the participant will be able to:
- understand potential benefits and practical application of ex vivo lung perfusion;
- gain understanding of the heterogeneity of CLAD including how recent data supporting CLAD phenotypes has led to a revision in the approach used to diagnose and classify CLAD;
- discuss the impact of PGD on patient survival after lung transplant.

This session will discuss new information about the expanding technologies for ex vivo lung perfusion (EVLP) to improve donor lung quality, insights into prevention of primary graft dysfunction (PGD), and paradigm changes in our understanding of phenotypes and mechanisms of chronic lung allograft dysfunction (CLAD). There will be discussion of the rapidly growing use of EVLP, new mechanistic insights to PGD etiology and prevention, and the approach to phenotypes of CLAD, including restrictive CLAD, its diagnosis, radiographic and pathological correlates. The session will also address the impact of lung microbiome and pulmonary infections upon innate immunity and CLAD development.

Chairing: S.M. Palmer, MD, MHS, Durham, NC
J.A. Belperio, MD, Los Angeles, CA

2:15 Ex Vivo Lung Perfusion (EVLP): Changing the Practice of Lung Transplantation for the Better
M. Cypel, MD, MSc, Toronto, Canada

2:35 Rethinking Primary Graft Dysfunction and Its Prevention
J.D. Christie, MD, MS, Philadelphia, PA

2:55 Lung Transplant Microbiome and Implications for CLAD
L.P. Nicod, MD, Lausanne, Switzerland

3:15 Cytokine and Chemokine Signals Translate Infections to CLAD
J.A. Belperio, MD, Los Angeles, CA

3:35 New Insights into CLAD Phenotypes, Mechanisms and Treatment
S.M. Palmer, MD, MHS, Durham, NC

3:55 Panel Discussion

---

Pediatric Chest Rounds

Assemblies on Pediatrics; Allergy, Immunology and Inflammation; Clinical Problems; Critical Care; Microbiology, Tuberculosis and Pulmonary Infections; Nursing; Pulmonary Circulation; Sleep and Respiratory Neurobiology

2:15 p.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Ballroom C (South Building, Level 3)

Target Audience
Pediatric pulmonologists; pediatric intensivists; neonatologists; registered nurses; advanced practice nurses; respiratory therapists.

Objectives
At the conclusion of this session, the participant will be able to:
- recognize the varying presentation(s) of known and rare pulmonary disorders;
- recognize pitfalls of various diagnostic methods and how to synthesize the clinical with laboratory information;
- identify alternative diagnoses for common and uncommon respiratory signs and symptoms.

The Pediatric Chest Rounds present diagnostically and/or therapeutically clinically challenging cases selected from the case reports submitted every year. The cases are presented by pediatric pulmonary fellows and they are discussed by senior faculty who are experts in the respective fields. The presentations are interactive giving the opportunity to the audience to participate in the decision making process.

Chairing: S. Goldfarb, MD, Philadelphia, PA
J. Harrison, MBChB, MRCP, MRCPCH, Melbourne, Australia
J.P. Needleman, MD, Brooklyn, NY

2:15 Pediatric Clinical Cases
17 Year Old Female with Progressive Dyspnea and Pulmonary Nodules
A. Parra, MD, Bogota, Columbia

Expert Discussant
A. Casey, MD, Boston, MA

Two Year Old with Bronchiectasis
A. Sathyaprasad MD

Expert Discussant
S. Ogunlesi MD, Washington, DC
At the conclusion of this session, the participant will be able to:

Objectives
Implementation science researchers
Critical care physicians, Trainees and early career physicians, Nurses,
Target Audience

2:15 p.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Research; Nursing
Assemblies on Critical Care; Behavioral Science and Health Services
CME Credits Available: 2

2:15 C84 BEG, BORROW AND STEAL: THE CHALLENGE OF
Changing Physician Behavior in the ICU

Target Audience
Critical care physicians, Trainees and early career physicians, Nurses,
Implementation science researchers

Objectives
At the conclusion of this session, the participant will be able to:

• become familiar with evidence-based interventions and approaches
designed to modify physician behavior specific to critical care;
• integrate knowledge and evidence from the fields of behavioral science
and psychology to recognize current ICU care practices that are no longer
beneficial and different evidence-based approaches available to incentivize
de-adoption;
• acquire practical approaches that can be used to change physician
behavior to improve patient care and outcomes in the ICU.

It is an incontrovertible fact that patients routinely receive suboptimal care in
ICUs around the U.S., internationally, and sometimes even within our own
hospitals. Yet physicians demonstrate wide variation in care and are often slow
to align practice patterns with guidelines. In our session, experts in behavioral
psychology, implementation science, and critical care will define what is known
about behavior change, offer several examples of durable clinical practices that
have refused to change despite compelling evidence, and offer new insights into
strategies for improvement of use to all clinicians interested in affecting change.

Chaining: M.N. Gong, MD, MS, Bronx, NY
D.K. Costa, PhD, RN, Ann Arbor, MI
J. Stevens, MD, Boston, MA

2:15 “It Depends on the Clinician”: Drivers of Variation in Resource
Use in Critical Care
J. Stevens, MD, Boston, MA

2:30 The Necessary Ingredients: How Improving Unit Culture Sets
the Stage for Desired Physician Behavior
J. Marsteller, PhD, Baltimore, MD

2:45 De-Adoption of Unsuccessful Ideas: The Durability of the Use
of Pulmonary Artery Catheters
K. Rowan, PhD, MSc, London, United Kingdom

3:00 Glaring Failures: Physician Incentives and Other Failed Levers
of Change
J. Kahn, MD, MS, Pittsburgh, PA

3:15 Getting Moving: Successful Strategies that Have Mobilized
Patients and Clinicians
D.K. Costa, PhD, RN, Ann Arbor, MI

3:30 When Changing Physician Behavior Became My Job: Practical
Tools and Strategies for Improving Critical Care
M. Howell, MD, MPH, Chicago, IL

3:45 Question and Answer Session
M.N. Gong, MD, MS, Bronx, NY

The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.
increased synthesis of molecular chaperones that aid in the folding of nascent polypeptides and prevent protein misfolding and aggregation. They are also important for protein degradation and translocation across membranes as well as for the correct formation of macromolecular assemblies. The protein quality control and stress protection machineries require strict signaling modalities and transcriptional programs, which play a role in lifespan regulation and age-related diseases such as COPD and IPF.

Chairing: J.I. Sznajder, MD, Chicago, IL
A. Pardo, PhD, Mexico City, Mexico

2:15 Malfolded Protein Structure and Proteostasis in Lung Diseases
W. Balch, PhD, La Jolla, CA

2:45 The Role of Intracellular Heat Shock Protein 70 Deficiency in Idiopathic Pulmonary Fibrosis
J. Sellares, MD, PhD, Pittsburgh, PA

3:00 Therapeutic Inhibition of Hsp90 Attenuates Fibroblast Activation Involved in Severe Fibrotic Lung Disease
V. Sontake, MS, Cincinnati, OH

3:15 Activation of the Unfolding Protein Response in the Vastus Lateralis of Patients with Respiratory Cachexia: Advanced COPD Versus Lung Cancer
E. Barreiro, MD, PhD, Barcelona, Spain

3:30 HSF1 Activation Regulates the Transcriptional Activity of the Heat Shock and Unfolded Protein Responses Altering Myeloid Proteostasis and Driving Granulopoiesis
K.L. Gates, MD, Chicago, IL

3:45 Aberrant Cellular Quality Control and Stress Responses in the Alveolar Epithelium: Drivers of Fibrotic Lung Disease
M.F. Beers, MD, Philadelphia, PA

Pulmonary research has expanded rapidly over the last decade, resulting in clinical advances and changes in the treatment strategy and care for a number of disease states from rare diseases like pulmonary fibrosis to more systemic diseases like sleep apnea. This session will highlight progress and important trends among prevalent respiratory conditions as well as lung conditions caused by smoking, e-nicotine and air pollution.

Chairing: K.A. Connolly, BS, Danvers, MA
A. Malhotra, MD, La Jolla, CA

2:15 Introduction to Session
A. Malhotra, MD, La Jolla, CA

2:30 Annual PAR Awards Ceremony
K.A. Connolly, BS, Danvers, MA

2:40 Recent Advances: Air Pollution
M.B. Rice, MD, MPH, Boston, MA

2:50 Recent Advances: Obesity/Sleep Disorders
S.R. Patel, MD, Pittsburgh, PA

3:05 Recent Advances: Smoking and Electronic Nicotine Delivery Systems, E-Cigs
L.E. Crotty Alexander, MD, San Diego, CA

3:20 Recent Advances: Critical Care/ Acute Respiratory Distress Syndrome
J.R. Beitler, MD, MPH, San Diego, CA

3:35 Recent Advances: Idiopathic Pulmonary Fibrosis
S. Montesi, MD, Boston, MA

3:50 Panel Discussion
A. Malhotra, MD, La Jolla, CA
Necroptosis is a form of regulated cell death that results in the release of immunomodulatory DAMPs. Although mounting evidence suggests a critical role for necroptosis in the development of vascular disease, promotion of the tumor microenvironment and host-pathogen interactions, the importance of necroptosis in lung diseases is only beginning to be understood. This symposium will provide attendees with a basic understanding of necroptosis and its emerging role in the pathogenesis of lung diseases including COPD, ARDS and Pneumonia. Additionally, the interplay between necroptosis and other cell death pathways and the clinical use of necroptosis biomarkers will be examined.

Chairing: I. Brodsky, PhD, Philadelphia, PA
N.S. Mangalmurti, MD, Philadelphia, PA
A.M.K. Choi, MD, New York, NY

2:15 Necroptosis and Viral Infection
W.J. Kaiser, PhD, San Antonio, TX

2:40 Necroptosis in the Regulation of Pulmonary Inflammation
A.S. Prince, MD, New York, NY

3:05 Pleiotropic Functions of Necroptosis in Lung Diseases
A.M.K. Choi, MD, New York, NY

3:30 Necroptosis in the Development of Lung Injury
N.S. Mangalmurti, MD, Philadelphia, PA

3:55 Necroptosis: Can We Translate to Human Organ Injury Syndromes?
M.G.S. Shashaty, MD, Philadelphia, PA

Comorbidities should be identified, assessed and managed in the presence of COPD. This session will address these gaps.

Chairing: R.T. Disler, PhD, RN, Sydney, Australia
R. Kalhan, MD, MS, Chicago, IL
V.M. McDonald, PhD, New Lambton Heights, Australia

2:15 Comorbidities in COPD: The Cardiovascular COPD Conundrum
L. Vanfleteren, MD, PhD, Horn, Netherlands

2:40 Cognition As a Key Influence on COPD Self-Management and Intervention Efficacy
R.T. Disler, PhD, RN, Sydney, Australia

3:34 Anxiety, Depression and Psychological and COPD: Association and Impact on Management
M. Milic, MD, Washington, DC

This session and the International Conference are supported by an educational grant from AstraZeneca LP.
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

C88 COPD COMORBIDITIES: GREATER THAN THE SUM OF THE PARTS

Assemblies on Nursing; Behavioral Science and Health Services Research; Clinical Problems; Pulmonary Rehabilitation
2:15 p.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 102 A-B (South Building, Street Level)

Target Audience
Physicians, registered nurses, advanced practice nurses, physical therapists, physician assistants, physiotherapists, behavioral scientists, dieticians, respiratory therapists, respiratory care practitioners, pharmacists, involved in providing or directing patient-centered symptom management

Objectives
At the conclusion of this session, the participant will be able to:
• list selected, prevalent comorbidities associated with COPD;
• describe the adjustment to care approach and health care delivery related to the presence of multiple comorbidities;

COPD is a complex multi-component disease characterized by chronic systemic inflammation that frequently coexists with multiple comorbidities. Comorbidities in COPD are common at any stage of the disease, are important determinants of outcome and contribute to significant economic consequences. Despite this disease management strategies fail to provide clear recommendations on how
(NTM) remains substantially more complex. This session will review our current knowledge of microbiome and colonizing bacteria, existing and evolving therapies, and results from recent global phase 3 trials of inhaled antibiotics for NCFB.

Chairing: K.L. Winthrop, MD, MPH, Portland, OR
G. Tino, MD, Philadelphia, PA
C.L. Daley, MD, Denver, CO

2:15 A Patient’s Perspective
C. Warden, Reston, VA

2:20 Lung Microbiome in Patients with Non-Cystic Fibrosis Bronchiectasis
J.D. Chalmers, MBChB, PhD, Dundee, United Kingdom

2:39 Current Management of Non-Cystic Fibrosis Bronchiectasis
A.E. O’Donnell, MD, Washington, DC

2:58 Surgical Management of Non-Cystic Fibrosis Bronchiectasis and Nontuberculous Mycobacteria
J.D. Mitchell, MD, Aurora, CO

3:17 New Inhaled Antibiotics for Non-Cystic Fibrosis Bronchiectasis
T.R. Aksamit, MD, Rochester, MN

3:36 Epidemiology of Non-Cystic Fibrosis Bronchiectasis and Colonizing Bacteria
K.N. Olivier, MD, MPH, Bethesda, MD

3:55 New Evidence for the Treatment of Nontuberculous Mycobacteria
D.E. Griffith, MD, Tyler, TX

There will be a 5-minute discussion after each talk.

This session and the International Conference are supported by an educational grant from Insmed Incorporated.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

BEHAVIORAL • CLINICAL • TRANSLATIONAL

C90 PULMONARY REHABILITATION ACROSS HEALTH CARE SETTINGS

Assemblies on Pulmonary Rehabilitation; Clinical Problems; Critical Care; Nursing
2:15 p.m. - 4:15 p.m. MARRIOTT MARQUIS WASHINGTON Liberty Ballroom M-P (Level M4)

Target Audience
All clinicians with an interest in pulmonary rehabilitation, thoracic surgeons, critical care intensivists, clinical trainees, providers of pulmonary rehabilitation services, clinical researchers, registered nurses, advanced practice nurses

Objectives
At the conclusion of this session, the participant will be able to:

• deliver pulmonary rehabilitation to patients in varying health care settings;

• discuss the challenges of providing rehabilitation services over the whole spectrum of health care in order to optimize PR programs;

• identify novel clinical research opportunities in the field of pulmonary rehabilitation.

Pulmonary rehabilitation (PR) is a standard of care for symptomatic patients with chronic respiratory diseases and is a main example of personalized therapy. In the course of their disease, patients will be diagnosed, hopefully at an early stage, and (some of them) will develop towards severe end-stage disease. In between, exacerbations and hospitalizations and even a stay at the ICU can happen. Through this whole spectrum of health care, rehabilitation programs need to be adapted to these specific situations. Addressing the specific patient situation in the health care spectrum will contribute to improved impact and more effective implementation of PR by health care professionals.

Chairing: M.L. Moy, MD, MSc, Boston, MA
R. Goldstein, MD, Toronto, Canada

2:15 Early Outpatient Rehabilitation in Newly Diagnosed Patients with Chronic Respiratory Disease
F. Franssen, MD, PhD, Horn, Netherlands

2:35 Hospital-Based Early Mobility and Pulmonary Rehabilitation in Patients Hospitalized for Acute Exacerbations
N.J. Greening, MBBS, PhD, Leicester, United Kingdom

2:55 Long-Term Inpatient Pulmonary Rehabilitation in the Most Severe Patients
L. Vanfleteren, MD, PhD, Horn, Netherlands

3:15 Early Mobilization of Respiratory Patients in Intensive Care Units
D. Needham, MD, Baltimore, MD

3:35 Pulmonary Rehabilitation in the Pre- and Postoperative Setting in Patients Undergoing Lung Surgery
M. Maddocks, PhD, London, United Kingdom

3:55 Pulmonary Rehabilitation, Physical Activity and Exercise in Nursing Home Residents with Lung Disease
R.S. Novitch, MD, White Plains, NY

C91 TACKLING SEVERE PNEUMONIA AND SEPSIS: WHAT IS READY FOR PRIME TIME?

Assemblies on Critical Care; Microbiology, Tuberculosis and Pulmonary Infections
2:15 p.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER East Salon A-C (South Building, Street Level)

Target Audience
All health care professionals providing care to critically ill patients, including residents, fellows, mid-level providers and critical care physicians

Objectives
At the conclusion of this session, the participant will be able to:

• appropriately determine the best approach to diagnosis in patients with severe respiratory infections;
Those desiring an understanding of how to extract quantitative information from imaging studies. Providers of lung health; clinical trial investigators; basic and applied investigators who utilize imaging techniques; thoracic surgeons; radiologists and radiology technical staff; allied health workers

Objectives
At the conclusion of this session, the participant will be able to:

- learn new findings about screening for lung cancer and how machine learning techniques can increase the accuracy of detecting lung nodules;
- learn new findings about advances in CT imaging of pulmonary fibrosis and how CT-derived metrics can serve as biomarkers of diffuse interstitial lung disease;
- learn new findings about recent advances in CT quantification of vascular pathology in COPD.

Thoracic imaging is widely used in the diagnosis and monitoring of lung diseases. Imaging results are typically reported qualitatively. This session will describe the most advanced capabilities of imaging modalities in terms of accurate and precise radiologic assessment of major lung diseases.

Severe pneumonia and sepsis are important clinical problems for pulmonary and critical care providers. These conditions are a leading cause of hospitalization, mortality and resource consumption. This session highlights recent advances in diagnostics and therapeutics for these patients. The session addresses advances in diagnostics for severe respiratory infections and new data regarding immunomodulatory therapy, particularly the uncertainty in using glucocorticoid therapy, which will be presented via a pro-con debate. Several trials to date have shown conflicting results and we anticipate completion of the HYPRESS and ADRENAL trials by next year. Recent data suggests that immunosuppression may be common in sepsis, and reversing immunosuppression, rather than suppressing exaggerated inflammation may be necessary in some patients. Understanding this heterogeneity of the host response and optimal approaches for immunomodulation is important for clinicians. Finally, the session will discuss how precision medicine approaches can be used to resolve these uncertainties and help clinicians manage these patients.

Chairing: S. Yende, MD, MS, Pittsburgh, PA
M.L. Metersky, MD, Farmington, CT
G.W. Waterer, MBBS, PhD, MBA, Perth, Australia

2:15 MDR/XDR Pathogens: Older Drugs of Questionable Efficacy or Newer Expensive Drugs
R.G. Wunderink, MD, Chicago, IL

2:35 PRO: Patients with Severe Pneumonia and Patients with Septic Shock Should Be Treated with Corticosteroids
A. Torres, MD, Barcelona, Spain

2:55 CON: Patients with Severe Pneumonia and Patients with Septic Shock Should Be Treated with Corticosteroids
R. Hotchkiss, MD, St. Louis, MO

3:15 Beyond Steroids: New Immunomodulatory Interventions for Severe Pneumonia and Septic Shock
T. Welte, MD, Hannover, Germany

3:35 Care Models for Survivors of Severe Pneumonia and Sepsis
S. Yende, MD, MS, Pittsburgh, PA

3:55 Cutting Edge Diagnostics for Severe Respiratory Infections
G.W. Waterer, MBBS, PhD, MBA, Perth, Australia
Oral Presentations


2:30  Genetic Deletion of IL-36γ or IL-36 Receptor Reduces Mortality in Pseudomonas Aeruginosa Pneumonia: Possible Role for Prostaglandin E2/T. Aoyagi, M.W. Newstead, X. Zeng, M. Kaku, T.J. Standiford, Ann Arbor, MI, p.A6723


3:00  Myeloid TBK1 Signaling Contributes to Pathogenesis of Influenza Infection/R.S. Hagan, J.L. Torres-Castillo, C.M. Doerschuk, Chapel Hill, NC, p.A6725


MINI SYMPOSIUM

C95 COPD ADVANCES IN THERAPY

2:15 p.m. - 4:15 p.m.  WALTER E. WASHINGTON CONVENTION CENTER

Ballroom B (South Building, Level 3)

Chairing: N. Hanania, MD, MS, Houston, TX
R. Casaburi, MD, PhD, Torrance, CA
A. Anzueto, MD, San Antonio, TX

Oral Presentations


2:30  Program of Integrated Care for Patients with Chronic Obstructive Pulmonary Disease and Multiple Comorbidities (PIC COPD+): A Randomized Controlled Trial/L. Rose, L. Istanboulian, L. Carriere, A. Price, L. Lee, S. Rezaie, R. Shefai, I. Fraser, Toronto, Canada, p.A6739


MINI SYMPOSIUM
C96 CRITICAL CARE: NEW DISCOVERIES IN ARDS

MINI SYMPOSIUM

2:15 p.m. - 4:15 p.m. 
WALTER E. WASHINGTON CONVENTION CENTER
Room 145 A-B (Middle Building, Street Level)

Chairs: R.G. Brower, MD, Baltimore, MD
J.A. Bastarache, MD, Madison, TN
R. Baron, MD, Boston, MA

Oral Presentations


2:45 Elevated Plasma Concentrations of Soluble Suppressor of Tumorigenicity-2 (sST2) Accurately Discriminates Acute Respiratory Distress Syndrome from Acute Heart Failure/S.D. Levy, B.T. Thompson, M.A. Matthay, J.L. Januzzi, D.C. Christiani, E. Bajwa, Boston, MA, p.A6748


The information contained in this program is up to date as of March 9, 2017.

Diagnosing Occupational Asthma: Diagnostic Accuracies of Airway Responsiveness and Airway Inflammation/G. Racine, R. Castano, C. Lemiere, Montreal, Canada, p.A6760


HOT THINGS: INFLAMMATION, REMODELING, AND SYSTEMIC DISEASE IN PULMONARY HYPERTENSION

MINI SYMPOSIUM
C98


3:45 Pulmonary Hypertension-Induced Exercise Intolerance Is Improved with Exercise and Correlates with Expression of Skeletal Muscle Respiratory Chain Proteins/N. Kue, A. Vang, D.J. McCullough, T. Mancini, R.T. Clements, G. Choudhary, Providence, RI, p.A6768

4:00 Metabolic Syndrome and Heart Failure with Preserved Ejection Fraction: A New Model of Pulmonary Hypertension Associated with Left Heart Disease/B. Runchoux, F. Potus, E. Tremblay, R. Paulin, O. Boucherat, S. Provencher, S. Bonnet, Quebec, Canada, p.A6769

THE TUMOR MICROENVIRONMENT: TARGETING THE SOIL TO KILL THE TUMOR SEED

MINI SYMPOSIUM
C99

2:15 Overview/S.M. Albelda, MD, Philadelphia, PA, p.A6762

2:30 Reduced Expression of Transforming Growth Factor β Type-2 Receptor in Non-Small Cell Lung Cancer Drives IL-17A Independent Dependent Inflammation Via γδT Cells/K. Nolan, D. Tippimanchai, G. Verzosa, W. Zhao, H. Li, P. Simonian, S. Malikosi, Aurora, CO, p.A6770

2:45 Circulating Fibrocytes Depletion Results in Reduced Lung Tumor Growth and Metastasis by Modulating Macrophage Phenotype, Angiogenesis and Endothelin System/R. Savai, A. Asafova, X. Zheng, A. Schmall, A. Weigert, S.S. Pullamsetti, W. Seeger, Bad Neuheim, Germany, p.A6771

3:00 Tumor Cell-Intrinsic CTLA4 Regulates PD-L1 Expression in Non-Small Cell Lung Cancer/J. Li, H. Zhang, P. Dutta, J. Liu, N. Sabri, Y. Song, W.X. Li, La Jolla, CA, p.A6772


4:00 Chronic Inflammation in Chronic Obstructive Pulmonary Disease Induces Growth and Metastasis of Lung Cancer Cells Via IL-6/JAK/STAT3/NF-B Signaling Pathway/N. Wang, F. Liu, Q. Hong, C. Bai, Shanghai, China, p.A6776

C101 IPF: CLINICAL STUDIES, THERAPEUTICS, AND MORE II

2:15 p.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER Room 206 (South Building, Level 2)

Poster Viewing 2:15-3:00
Discussion 3:00-4:15

Chairing: D.J. Lederer, MD, MS, New York, NY, P.J. Sime, MD, Rochester, NY, H. Li, MD, PhD, Shanghai, China

601 Appropriateness of Prescribing Nintedanib for Idiopathic Pulmonary Fibrosis - an Institutional Experience/S. Yau, S. Raheem, A. Rueda, L. Pandit, S. Bujarski, Houston, TX, p.A6777


603 Real World Experience with Nintedanib in an ILD Clinic/S. Oliveira, L. Johns, M. Walshaw, E. Hillal, J. Holemans, Liverpool, United Kingdom, p.A6779


The information contained in this program is up to date as of March 9, 2017. For the most current session information, please visit the online program itinerary.


718 The Early Natural History of Sepsis: Symptoms and Visits in the Days Leading Up to Sepsis Hospitalization/K.M. DeMerle, H.C. Prescott, V. Liu, Ann Arbor, MI, p.A6818


721 Prehospital Diagnostic and Prognostic Biomarkers of Sepsis: A Prospective Cohort Study/C.W. Seymour, C. Martin-Gill, J. Kahn, C. Callaway, D.M. Yealy, D.C. Angus, Pittsburgh, PA, p.A6821


C103 OUTDOOR AIR POLLUTION: EPIDEMIOLOGY AND MECHANISMS

2:15 p.m. - 4:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 150 B (Middle Building, Street Level)

Poster Viewing 2:15-3:00
Discussion 3:00-4:15

Chairing: E. Garshick, MD, West Roxbury, MA
K. Cromar, PhD, New York, NY
J.A. Hirota, PhD, Vancouver, Canada


724 Oxidized Phosphatidylcholine in Human Airways Upon Exposure to Allergen and/or Diesel Exhaust/M.H. Ryu, A. Jha, C.D. Pascoe, A. Ravandi, A.J. Halayko, C. Carlsten, Vancouver, Canada, p.A6834


726 Particulate Matter and Ionomycin-Induced Neutrophil Extracellular Traps In Vitro/D. Woolding, O. Pena, D. Maestre-Batlle, C. Carlsten, Vancouver, Canada, p.A6836

727 Toxic Potential of Benz[a]pyrene and 9-Nitroanthracene Surface Modified Carbon Black Nanoparticles on None- and Pre-Damaged Mice Lungs in Long-Term Exposure/N. Schreiber, E. Kotte, B. Muller, Marburg, Germany, p.A6837


Antibiotic Prescribing Pattern for Pneumonia and Sepsis in Medical Wards and ICU and Effect of an Active Intervention Protocol in a Developing Country/R. Guleria, A. Mohan, N. Wig, A. Kapil, R.M. Pandey, P. Sohal, New Delhi, India, p.A6863


Impact of Prior Antibiotic Use on Outcomes for Those Subsequently Hospitalized with Pneumonia/E. Mortensen, M.L. Metersky, M. Chansard, A. Anzueto, Dallas, TX, p.A6865

Contemporary Situation of Community-Acquired Pneumonia in China: A Systematic Review/X. Tang, Y. Zhu, Y. Lu, J. Zhang, J. Qu, Shanghai, China, p.A6866


<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>C106</td>
<td>MONEY DON'T MATTER TONIGHT: PULMONARY HYPERTENSION ASSESSMENT, PROGNOSTICATION, AND TREATMENT</td>
<td><strong>2:15 p.m. - 4:15 p.m.</strong> MARRIOTT MARQUIS WASHINGTON Marquis Ballroom 9-10 (Level M2)</td>
</tr>
<tr>
<td></td>
<td>Poster Viewing</td>
<td>2:15-3:00</td>
</tr>
<tr>
<td></td>
<td>Discussion</td>
<td>3:00-4:15</td>
</tr>
<tr>
<td></td>
<td>Chairing:</td>
<td>R.F. Machado, MD, Chicago, IL R.T. Zamanian, MD, Stanford, CA A. Trammell, MD, Atlanta, GA</td>
</tr>
<tr>
<td>1005</td>
<td>Left Ventricular Assist Devices Can Reverse Pulmonary Hypertension Group 2 with Significantly Elevated Pulmonary Vascular Resistance</td>
<td>A. Selim, E. Raichlin, A. Burdorf, A. Siddique, M.J. Moulton, J. Um, B.D. Lowes, R. Zolty, Omaha, NE, p.A6898</td>
</tr>
</tbody>
</table>

1007 The Left and Right Ventricular End Diastolic Pressure Ratio as a Novel Marker of Disease Severity in a Cohort of Patients with Pulmonary Arterial Hypertension/A. Jose, C. King, O.A. Shlobin, A. Brown, N. Weir, J. Kiernan, N. Cossa, S.D. Nathan, Washington, DC, p.A6900


1009 Left Ventricular Strain and Dyssynchrony by Cardiac MR Feature Tracking in Idiopathic Pulmonary Arterial Hypertension/G. Jayasekara, T. Crowe, A. Mackenzie, C. McComb, K. Mangion, M. Johnson, C. Church, C. Berry, A. Radjenovic, A. Peacock, Glasgow, United Kingdom, p.A6902

1010 Left Atrial Function by Cardiac MRI in Idiopathic Pulmonary Arterial Hypertension(PH-HFpEF) and Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction(PH-HFpEF)/G. Jayasekara, T. Crowe, A. Mackenzie, C. Church, M. Johnson, A. Radjenovic, A. Peacock, Glasgow, United Kingdom, p.A6903


1017 Safety and Pharmacokinetics of Ralinepag (APD811) in Healthy Adult Subjects/J.R. Preston, M. Morgan, B. Raether, J. Adams, C. Lassen, R. Christopher, Boston, MA, p.A7689

Rapid: Rapid Abstract Poster Discussion

C107 MITOCHONDRIA AND METABOLIC ALTERATIONS IN LUNG DISEASE

2:15 p.m. - 4:15 p.m. MARRIOTT MARQUIS WASHINGTON

Marquis Ballroom 3-4 (Level M2)

Abstract Summaries

2:15-2:45

Poster Viewing/Discussion

2:45-4:15

Chairing:
M. Kang, MD, PhD, New Haven, CT
D.W. Kamp, MD, Chicago, IL
J. Bhattacharya, MD, DPhil, New York, NY

901 Role of Mitochondrial microRNAs in Alveolar Epithelial Type II Cells Response to Cigarette Smoke/A. Blumenthal-Perry, M. Hatzoglou, A. Degar, H. Kenche, K. Pandit, D. Krokowski, S.H. Guttentag, Y. Perry, P.A. Linden, G.S. Shadel, M.-J. Kang, N. Kaminski, Cleveland, OH, p.A6909

902 HIF-1α Is Required for Flow-Mediated Regulation of Endothelial Cell Metabolism/D. Wu, R.-T. Huang, M. Krause, R. Hamanaka, L.J. Witt, R. Nigdelioglu, A. Meliton, Y. Fang, G.M. Mutlu, Chicago, IL, p.A6910


907 Alveolar Epithelial Metabolic Dysfunction in Acute Lung Injury/N. Xie, J. Ge, S. Banerjee, H. Cui, V.J. Thannickal, G. Liu, Birmingham, AL, p.A6915

908 Glycoprotein Stanniocalcin 1-Mediated Cellular Glycolysis and Mitochondria Biogenesis Is Dependent Upon TLR4/Y. Zhang, P. Shan, P.J. Lee, New Haven, CT, p.A6916

Investigating Genome Wide DNA Methylation in Bronchial and Lung Fibroblasts from Healthy Individuals and Individuals with COPD/R.L. Clifford, N. Fishbane, P. Rajasekar, J.L. Mcla Isaac, L.M. McEwan, A. Fisher, M. Kobor, A.J. Knox, T.-L. Hackett, Nottingham, United Kingdom, p.A6939

Expression and Biological Functions of FAM13A and PTCH1 in Patients with Chronic Obstructive Pulmonary Disease/A. Tam, M. Obeidat, T.-L. Hackett, D. Dorschdei, G.K. Singhera, P.D. Pare, J.C. Hogg, D. Nickle, D.D. Sin, Vancouver, Canada, p.A6940

Transgenic Overexpression of microRNA-25 Regulates Cytokine and Chemokine Production in a Mouse Model of Allergic Inflammation/M. Ba, J. Hall, K. Hernandez, C.A. Singer, Reno, NV, p.A6941

Connective Tissue Growth Factor (CTGF) - a Key Factor in Asthmatic Airway Angiogenesis/O. Ge, J. Wang, D. Simcock, V. Kanabar-Raivadera, S. Hirst, J. Ward, S. Sawant, R. Van De Velde, B.G. Oliver, A. Ashton, J.K. Burgess, Sydney, Australia, p.A6942


Expression of α7 Integrin in a Mouse Model of Asthma Alleviates Inflammation/K. Hernandez, A. Aiyuk, M. Ba, R.D. Wuebbles, D.J. Burkin, C.A. Singer, Reno, NV, p.A6946


Lung-Resident Pericytes Acquire Myofibroblast Functions in a House Dust Mite-Driven Model of Asthma/J.R. Johnson, J.E. Rowley, R. Bloxham, P. Lavender, Birmingham, United Kingdom, p.A6948


The Role of Mitochondrial Proteins in the Regulation of Bitter Tastants-Induced Airway Smooth Muscle Cell Death/S. Pan, D.A. Deshpande, Philadelphia, PA, p.A6950

409  Effects of Inhaled Fluticasone on Upper Airway Collapsibility in Patients with Asthma/N. Nashi, T. Denman, D. Pegelow, R. Gangon, A. Xie, A. Mahotra, O. Broytman, M. Teodorescu, Madison, WI, p.A6983


413  Prevalence of Sleep Disordered Breathing in Patients with Cardiovascular Disease: Registry to Examine the Effect of CPAP on Cardiac Function in Hospitalized Patients with Sleep-Disordered Breathing and Cardiac Conditions/R.J. Schwab, M.E. Crocker, J. Riggs, G. Nathanson, L.W.-J. Kim, L. Chi, A. Benjafie, L. Wilies, N. Gooneratne, Philadelphia, PA, p.A6987


The information contained in this program is up to date as of March 9, 2017. For the most current session information, please visit the online program itinerary.
PCC4  PEDIATRIC CLINICAL CORE CURRICULUM

Pediatric Core Curriculum Working Group

Target Audience
Pediatric pulmonary and critical care physicians who work in a clinical setting and are currently engaged in maintenance of certification.

Objectives
At the conclusion of this session, the participant will be able to:

- remain current with medical knowledge relevant to their practice in pediatric pulmonology;
- evaluate their understanding of key skills and content areas in pediatric pulmonology as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
- support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The Pediatric Core Curriculum symposia promote lifelong learning and the enhancement of the clinical judgment and skills essential for practicing pediatrician. The symposia will address topics that have been identified by an ATS pediatric working group, which is comprised of members of the ATS Education Committee and the International Conference Committee, who have identified important areas within pediatric medicine (including severe asthma, ILD, BPD, pulmonary hypertension and pulmonary manifestations of pulmonary disease). Attorneys will increase their medical knowledge as a result of attending this symposium, and this will be measured by a comparison of pre-test vs. post-test results on the corresponding maintenance of certification module. The ATS Pediatric Core Curriculum will focus on a 3-year content cycle of key medical content in the area of pediatric medicine.

Chairing: A. Horani, MD, St. Louis, MO

7:00 Pulmonary Hypertension
E. Austin, MD, Nashville, TN

7:30 Pulmonary Manifestations of Rheumatologic Diseases
M. Kitcharoensakkul, MD, St. Louis, MO

---

SUNRISE SEMINARS

CME Credits Available: 1

Registration Fee: $50.00 (includes continental breakfast.)
Attendance is limited. Pre-registration is required.

7:00 a.m. - 8:00 a.m. MARRIOTT MARQUIS WASHINGTON

SS301 THE ROLE OF TRPV4 IN LUNG DISEASE: A TRP TO NEW THERAPEUTICS
R.G. Scheraga, MD, Cleveland, OH
George Washington University (Level M1)

SS302 DIFFUSE CYSTIC LUNG DISEASE: EVALUATION AND MANAGEMENT
L. Ho, MD, Seattle, WA
Georgetown University (Level M1)

SS303 TO TREAT OR NOT TO TREAT: CASES IN SARCOIDOSIS
M. Gulati, MD, New Haven, CT
Howard University (Level M1)

SS304 A PRACTICAL APPROACH TO THE PATIENT WITH INTERSTITIAL LUNG DISEASE: DIAGNOSIS AND MANAGEMENT
A.J. Podolanczuk, MD, New York, NY
Gallaudet University (Level M1)

SS305 RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: CLINICAL ASSESSMENT, PROGNOSIS, AND MANAGEMENT
Z. Yunt, MD, Denver, CO
Catholic University (Level M1)

SS306 QUANTITATIVE LUNG IMAGING IN COPD: AN UPDATE FOR CLINICIANS
A.A. Diaz, MD, MPH, Boston, MA
University of DC (Level M1)

SS307 CONTROVERSIES IN PLEURAL DISEASE MANAGEMENT: A PRO/CON DEBATE
O. Epelbaum, MD, Valhalla, NY
B. Husta, MD, New York, NY
Marquis Salon 14 (Level M2)

SS308 CHALLENGES IN PULMONARY FUNCTION TESTS: A CASE BASED APPROACH
M. Sala, MD, Chicago, IL
Marquis Salon 13 (Level M2)

SS309 HYPEROXIA IN CRITICAL CARE: WHY SHOULD WE CARE?
S. Pannu, MD, MSc, Columbus, OH
Marquis Salon 12 (Level M2)

SS310 IMPLICATION OF SMALL AIRWAYS DISEASE IN OCCUPATIONAL EXPOSURES
R.C. Stansbury, MD, Morgantown, WV
Union Station (Level M3)
SS311  LATENT TB INFECTION: CURRENT DIAGNOSTICS AND MANAGEMENT  
P. Escalante, MD, Rochester, MN  
Chinatown (Level M3)

SS312  PATIENT EXPERIENCE IN PULMONARY ARTERIAL HYPERTENSION  
L. Matura, PhD, RN, Philadelphia, PA  
Mount Vernon Square (Level M3)

SS313  CARDIOPULMONARY EXERCISE TESTING IN CHILDREN: WHAT A PROVIDER NEEDS TO KNOW  
R. Bhatia, MD, Akron, OH  
Judiciary Square (Level M3)

SS314  ADVANCED HEMODYNAMIC INTERROGATION OF THE PULMONARY CIRCULATION  
A. Tonelli, MD, MSc, Cleveland, OH  
LeDroit Park (Level M3)

SS315  (RE)-BUILDING LUNGS FOR TRANSPLANTATION: ADVANCES AND CHALLENGES IN WHOLE ORGAN BIOENGINEERING  
S.E. Gilpin, PhD, Boston, MA  
Shaw (Level M3)

SS316  NEW APPROACHES IN LUNG BIOLOGY ENABLED BY THE PRECISION CUT LUNG SLICE  
R. Krishnan, PhD, Boston, MA  
J.E. Bourke, PhD, Clayton, Australia  
Treasury (Level M4)

SS317  THE INTERFACE MATTERS: COMPARING DIFFERENT MASKS FOR OBSTRUCTIVE SLEEP APNEA TREATMENT  
P. Genta, MD, Sao Paulo, Brazil  
Mint (Level M4)

FACULTY DEVELOPMENT SEMINAR

FD3  STRATEGIES FOR FELLOWS AND EARLY CAREER FACULTY TO GET CLOSER TO WORK/LIFE BALANCE  
Pre-registration is required.  
Attendance is limited. There is no additional fee.  
7:00 a.m. - 8:00 a.m.  
WALTER E. WASHINGTON CONVENTION CENTER  
Room 101 (South Building, Street Level)

Target Audience  
Clinical and research fellows, post-doctoral fellows, residents, and junior faculty in the early stages of a career in academic pulmonary, allergy, critical care, and/or sleep medicine

Objectives  
At the conclusion of this session, the participant will be able to:
- identify areas of priority in their academic, personal, and family roles and responsibilities;
- understand there is no easy fix or one size fits all solution to the issue of work-life balance;
- identify strategies and practical ideas for how to balance both career and family obligations.

The demands of working in academic medicine are strenuous, exacerbated by the challenge of having to choose between time for your work, your family and yourself. This seminar will provide valuable insight and practical real-life strategies on balancing family life while developing a successful academic career. This session will feature a panel of successful faculty with experience in work-life balance at both a personal and professional level. This session will be divided into two components. First, participants will hear strategies and perspective from the panel. Subsequently, participants will have the opportunity to engage one-on-one with panelists in an interactive discussion.

Chairing: M.N. Ballinger, PhD, Columbus, OH

Speakers: J.M. Keane, MD, Dublin, Ireland  
A. Wang, MD, La Jolla, CA  
B.B. Moore, PhD, Ann Arbor, MI  
J.R. Curtis, MD, MPH, Seattle, WA  
M. Kraft, MD, Tucson, AZ

THEMATIC SEMINAR SERIES

TSS1  EVOLVING CONCEPTS IN EARLY COPD

Registration Fee: $170 for full series (includes continental breakfast)  
Attendance is limited. Pre-registration is required.  
This is part 4 of a 4-part series. Those registering for this seminar series will be registered for all 4 parts. The program for the full series is included with the Sunday, May 21, 12:15 p.m. program.

Wednesday 7:00 a.m. - 8:00 a.m.  
MARRIOTT MARQUIS WASHINGTON  
Monument (Level M4)

Chronic Bronchitis Without Airflow Obstruction: Epidemiology, Phenotype, and Clinical Consequences  
C. Martinez, MD, MPH, Ann Arbor, MI
The Keynote Series provides state of the art lectures on selected topics in an unopposed format to showcase major discoveries in pulmonary, critical care and sleep medicine. The speakers have been chosen by input from the members and various ATS committees with consensus built via the ATS executive committee.

K7 CLIMATE CHANGE AND GLOBAL WARMING: A GEOLOGICAL PERSPECTIVE
8:15 a.m. - 9:00 a.m. WALTER E. WASHINGTON CONVENTION CENTER
East Salon A-C (South Building, Street Level)

Speaker: K.R. Johnson, PhD, Washington, DC
This session will be chaired by A. Malhotra, MD, La Jolla, CA

K8 HYPOXIA-INDUCIBLE FACTORS IN PHYSIOLOGY AND MEDICINE
8:15 a.m. - 9:00 a.m. WALTER E. WASHINGTON CONVENTION CENTER
West Salon G-I (South Building, Street Level)

Speaker: G.J. Semenza, MD, PhD, Baltimore, MD
This session will be chaired by D. Gozal, MD, Chicago, IL

D2 BRONCHOSCOPIC LUNG VOLUME REDUCTION: IS IT FINALLY A REALITY?

Assemblies on Clinical Problems; Nursing; Pulmonary Rehabilitation; Respiratory Structure and Function
9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER
Ballroom A (South Building, Level 3)

Target Audience
Clinicians, clinical researchers, nurses, trainees in pulmonary medicine and research

Objectives
At the conclusion of this session, the participant will be able to:

- understand why hyperinflation is important in patients with COPD;
- become knowledgeable of the different forms of bronchoscopic lung reduction;
- recognize the differences between the various types of bronchoscopic lung reduction procedures and how one is more applicable than the other in an individual patient profile.

Hyperinflation is a major complication of COPD especially for patients who have predominantly emphysema as a structural cause of their disease. It affects patient’s exercise performance, quality of life, and contributes to increased mortality. Lung volume reduction surgery has been shown to be effective treatment in selected patients in improving lung function, quality of life and in a select subgroup survival. Bronchoscopic lung volume reduction which includes a variety of techniques plus other endoscopic treatments that can produce lung denervation have been recently demonstrated to have clinical benefit in some clinical trials that are focused on small numbers of patients followed for short periods of time. Recently, large randomized prospective randomized controlled trials have been conducted with a variety of bronchoscopic treatments that show promise to treat hyperinflation and improve patient outcome. In this session, leading international experts will discuss a variety of
bronchoscopic lung reduction techniques and provide an up-to-date summary of new findings and new directions in the exploration of these therapies to treat the hyperinflated COPD patient.

Chairing:
G.J. Criner, MD, Philadelphia, PA
F.J.F. Herth, MD, Heidelberg, Germany
F.C. Sciurba, MD, Pittsburgh, PA

9:15 Physiologic and Functional Basis for Lung Reduction
F.C. Sciurba, MD, Pittsburgh, PA

9:30 Selections of Patients for Bronchoscopic Lung Reduction
G.J. Criner, MD, Philadelphia, PA

9:45 Efficacy of Endobronchial Valve Treatment for Heterogenous or Homogeneous Emphysema
K. Klooster, PhD, Groningen, Netherlands

10:00 Efficacy and Mechanism of Implantable Lung Coils in Advanced Emphysema
P. Shah, MD, London, United Kingdom

10:15 Application of Sequential Bilateral Segmental Vapor Ablation Therapy in Advanced Emphysema: Efficacy and Safety
F.J.F. Herth, MD, Heidelberg, Germany

10:30 Total Lung Denervation: Impact on Lung Function, Dyspnea and Exercise Performance
D. Slebos, MD, PhD, Groningen, Netherlands

10:45 Integration of BLVR with LVRS and Transplant: Which Therapy for Which Patient
F.J.F. Herth, MD, Heidelberg, Germany

11:00 Panel Discussion
G.J. Criner, MD, Philadelphia, PA
F.C. Sciurba, MD, Pittsburgh, PA
F.J.F. Herth, MD, Heidelberg, Germany

This session and the International Conference are supported by an educational grant from AstraZeneca LP.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

### D3 DIAGNOSTIC DILEMMAS IN HYPERSENSITIVITY PNEUMONIA AND THE CLINICAL-RADIOLOGIC-PATHOLOGIC MULTIDISCIPLINARY STANDARD

Assemblies on Clinical Problems; Allergy, Immunology and Inflammation; Environmental, Occupational and Population Health

9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER

Ballroom C (South Building, Level 3)

Target Audience
Clinicians, researchers, trainees, and other health care providers at all levels with an interest in clinical and translational research and interstitial lung disease

Objectives
At the conclusion of this session, the participant will be able to:

- understand the clinical features of hypersensitivity pneumonia and current classification patients from a phenotypic standpoint;
- incorporate available diagnostic tests in the evaluation of a patient suspected of having hypersensitivity pneumonia;
- improve ability to counsel patients with regard to treatment and prognosis.

Hypersensitivity pneumonia (HP) is a commonly considered diagnosis when evaluating acute and chronic interstitial pulmonary syndromes, but making a confident diagnosis is hindered by the lack of validated diagnostic criteria. The multidisciplinary clinical-radiologic-pathologic approach can aid clinicians in accurately diagnosing interstitial lung diseases. In the case of HP, conflicting information or uncertainty about the relevance of various findings within each of these categories is problematic. This session will highlight current evidence and deficits in knowledge within each of these categories, and review the pathologic basis, treatment, and prognosis of the disease.

Chairing:
M. Salisbury, MD, Ann Arbor, MI
G. Raghu, MD, Seattle, WA
K.A. Johannson, MD, MPH, Calgary, Canada

9:15 Disease Definition, Clinical Features, Phenotypes, and a Case Presentation
G. Raghu, MD, Seattle, WA

9:35 Pathobiology of Hypersensitivity Pneumonia: Evidence for Genetic and/or Immunologic Mediation of Disease
M. Selman, MD, Mexico City, Mexico

9:55 Imaging in Diagnosis of Hypersensitivity Pneumonia: Sufficient to Make a Diagnosis in the Correct Clinical Setting?
D.A. Lynch, MD, Denver, CO

10:15 Role of Bronchoscopy, BAL, and Transbronchial Biopsy in HP
M. Vasakova, MD, PhD, Prague, Czech Republic

10:30 Histopathology in Diagnosis of HP: Distinctive Features and Mimics
J.L. Myers, MD, Ann Arbor, MI

10:45 Environmental Evaluation: Challenges in Antigen Identification
E. Fernandez Perez, MD, Denver, CO

11:00 Treatment of HP and Wrap-Up
M. Salisbury, MD, Ann Arbor, MI

There will be a 5-minute discussion after each talk.
improve the care of sepsis, ARDS, and general ICU supportive care; trainees of critical care medicine

Objectives
At the conclusion of this session, the participant will be able to:

- identify clinical practice protocols that have improved patient outcomes;
- identify areas where uncertainty exists regarding adhering to a protocol compared to personalizing care;
- improve understanding of the concept of how treatment effects heterogeneity, and how this could impact patient outcomes.

This session will consider two potentially conflicting goals that challenge intensive care unit clinicians and researchers: the desire to standardize care by protocolizing best practices, and the desire to personalize care to each patient’s individual physiology. The session will highlight advances in critical care outcomes that have been achieved through the adoption of protocols while acknowledging opportunities to improve care by a precision approach even when such personalization may violate protocols. The session will have broad appeal to trainees, clinicians, and scientists because it will blend evidence and expert opinion, and will highlight areas where uncertainty exists.

Chairing: N.J. Meyer, MD, MS, Philadelphia, PA
S. Yende, MD, MS, Pittsburgh, PA

9:15 Contextualizing the Precision Medicine Initiative for the ICU
N.J. Meyer, MD, MS, Philadelphia, PA

9:30 A Case for Protocolization: Applying a Business Mindset to ICU Care
H.B. Gershengorn, MD, Bronx, NY

9:45 Personalizing Lung Protection in ARDS with Tidal Volume Strategy and Neuromuscular Blockade
J.R. Beitler, MD, MPH, San Diego, CA

10:05 Personalizing Hemodynamic Management in the Post-ProMISE/ProCESS Era
M. Singer, MBBS, MD, London, United Kingdom

10:25 Sedation and Mobilization: Can We Personalize Protocols to Maximize Benefit?
W.D. Schweickert, MD, Philadelphia, PA

10:45 On the Horizon: Precision Immunotherapy Trials in Sepsis
S. Yende, MD, MS, Pittsburgh, PA

11:00 Panel Discussion
N.J. Meyer, MD, MS, Philadelphia, PA
H.B. Gershengorn, MD, Bronx, NY

Target Audience
Researchers and clinicians interested in the prevention of asthma

Objectives
At the conclusion of this session, the participant will be able to:

- integrate the information on how exposure to bacterial/bacterial extracts can reverse immune system deficits in asthmatic children;
- learn new findings on the clinical efficacy of bacterial immuno-modulating agents on clinical outcomes in asthmatic children;
- improved understanding of asthma prevention strategies.

Research into the primary prevention of the onset of asthma in children has been unsuccessful. Yet, we know asthma can be prevented, as it is rare in developing countries and in children from traditional farming communities. This and recent knowledge that bacterial lysates can both enhance deficient immune system responses in asthmatics and prevent asthma exacerbations strongly suggests that early life exposure to bacteria/bacterial products could prevent the development of asthma. A large new NIH study will explore this exciting possibility over the next 5 years. This symposium will examine scientific and clinical evidence that this approach can prevent asthma.

Chairing: P.N. Le Souef, MD, MBBS, Subiaco, Australia
W.W. Busse, MD, Madison, WI

9:15 A Patient’s Perspective
C. Eury, Washington, DC

9:20 The Effect of Bacterial Immunomodulation on Immune System Responses in Young Children
I. Laing, PhD, Subiaco, Australia

9:43 Does Exposure to Bacteria and Bacterial Lysates Reduce Wheeze in Children?
P.N. Le Souef, MD, MBBS, Subiaco, Australia

10:06 A Systems Biology Approach to Understanding Immune System Responses to Bacteria
R. Hancock, PhD, Vancouver, Canada

10:29 Short and Long-Term Effects of Viruses Versus Bacteria on Immune Responses in Asthma
S. Johnston, MD, MBBS, PhD, London, United Kingdom

10:52 Translational Medicine and Asthma Prevention in Children Using Bacteria or Bacterial Lysates
F.D. Martinez, MD, Tucson, AZ

There will be a 5-minute discussion after each talk.

This session and the International Conference are supported by an educational grant from Teva Pharmaceuticals

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
At the conclusion of this session, the participant will be able to:

Objectives

Target Audience

Clinicians who treat any medical conditions for which sleep is a relevant factor, and researchers who study sleep, cardiometabolic health, and/or epidemiology

Objectives

At the conclusion of this session, the participant will be able to:

• better understand the prevalence of insufficient sleep and sleep disorders and relevance for public health and policy;

• understand the relationship between insufficient sleep and cardiometabolic disease risk and be able to apply this to improve patient care;

• gain a better understanding of the policy implications of insufficient sleep for school children and for other groups, and become better equipped to assist in the development and implementation of these policy initiatives.

This session focuses on some of the most pressing public health concerns regarding sleep health. Sleep is a biological requirement for human life, but insufficient sleep is experienced by approximately 1/3 of U.S. adults and a large portion of U.S. children and adolescents. In addition, sleep disorders are highly prevalent, with up to 10-17% of men and 3-9% of women over 30 having sleep apnea and approximately 5-15% having an insomnia disorder. These issues are associated with cardiometabolic risk, functional deficits, and mortality. These issues need to be addressed and dealt with in the community as well as the associated with cardiometabolic risk, functional deficits, and mortality. These issues need to be addressed and dealt with in the community as well as the clinic. This is a public health problem. This session addresses many of the major public health and public policy issues relevant to population sleep health.

Chairing: M. Grandner, PhD, Tucson, AZ
E. Tasali, MD, Chicago, IL

9:15 Sleep and Health: Are We Getting Enough Sleep?
M. Grandner, PhD, Tucson, AZ

9:40 Sleep and the Public Health Epidemic of Obesity
J. Chaput, PhD, Ottawa, Canada

10:05 Sleep and Health Equity: Implications for Health Disparities and Policy
N. Williams, EdD, New York, NY

10:30 Delayed School Start Times: Impact on Sleep and Public Health
M. Chen, MD, Seattle, WA

10:55 Patient Presentation
Speaker To Be Announced

---

D7 AIR POLLUTION AND PSYCHOSOCIAL STRESS AND THE ORIGINS OF LUNG DISEASE

Assemblies on Environmental, Occupational and Population Health; Behavioral Science and Health Services Research

9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 147 A-B (Middle Building, Street Level)

Target Audience

Basic and clinical pulmonary scientists and behavioral scientists

Objectives

At the conclusion of this session, the participant will be able to:

• improve the quality of life/health status patients by recognizing how psychosocial stressors impact negative health outcomes associated with air pollution exposure;

• integrate new treatment options in discussing how to manage asthma/allergic disease by employing psychosocial stressor reduction strategies such as a diet, exercise, relaxation;

• learn new findings about the importance of psychosocial stressors and how they impact the association between air pollution and lung disease.

Social and psychological stressors may lead directly to poor health outcomes. They may also increase susceptibility to air pollution through alterations in immune function and biological systems (McEwen and Seeman 1999) known to affect specific respiratory diseases like asthma and allergic disorders. Thus, the most pollution-exposed communities may also be more susceptible because of higher prevalence of social stressors (Lipfert 2004). The combination of chemical and non-chemical stressors may be an important factor in asthma and allergy disparities. Disentangling social and physical environmental risks is becoming a priority area of research for NIH Environmental Public Health and EPA policy guided research. This symposium will present current evidence of the interactions and potential synergies between psychosocial and environmental stressors, effects on susceptible populations such as those with pre-existing lung disease, and potential methods of intervention to improve overall population health.

Chairing: N.E. Alexis, PhD, Chapel Hill, NC
R.J. Laumbach, MD, MPH, Piscataway, NJ

9:15 Overview of Evidence for Interactions Between Psychosocial Stress and Air Pollution in Asthma/Allergy
R. Wright, MD, MPH, New York, NY

9:40 Epidemiologic and Epigenetic Evidence of Links Between Air Pollution, Stress and Negative Respiratory Health Outcomes
J. Clougherty, MSc, ScD, Pittsburgh, PA

10:05 Children Cohort Studies of Interaction of Acute Stress and Susceptibility to Air Pollution in Asthma and Allergic Disease
K. Shankardass, PhD, Toronto, Canada

10:30 Stress Response Studies Using Animal Models
U. Kodavanti, PhD, Chapel Hill, NC

10:55 Intervention Studies to Mitigate Effects of Stress Environmental Lung Disease
P. Lehrer, PhD, Piscataway, NJ
D8 THE NEXT NEXT-GENERATION: FUNCTION, MODELING AND MECHANISM AND THE LUNG MICROBIOME

Assemblies on Microbiology, Tuberculosis and Pulmonary Infections; Allergy, Immunology and Inflammation
9:15 a.m. - 11:15 a.m. MARRIOTT MARQUIS WASHINGTON

Independence Ballroom A-D (Level M4)

Target Audience
Clinicians and research scientists interested in innovative approaches that move lung microbiome research from descriptive to mechanistic pathophysiological research

Objectives
At the conclusion of this session, the participant will be able to:

- understand the role of microbial communities in the lung by exploring microbial community function through the integration of complementary ‘omics such as transcriptomics and metabolomics. Audience will understand microbial community function, transcending the antiquated pathogen/commensal paradigm;
- gain understanding how the host responds to complex microbial communities in health and disease. Audience will appreciate the applications of broad molecular techniques beyond 16s rRNA gene sequencing in the characterization of host responses;
- understand the need and utility of in vivo and ex vivo models of disease that combine classical basic science techniques with complex microbial community characterization for investigating mechanisms of disease and therapeutic targets. Audience will be encouraged to prioritize mechanistic approaches to lung microbiome study for future progress.

The lung microbiome field is rapidly evolving beyond mere description of respiratory microbiota into the integrative study of the mechanisms of microbial disease pathogenesis. This scientific symposium will reveal how diverse methodologies can complement microbial community sequencing to unfold the microbiome’s role in the pathogenesis of diverse respiratory diseases. Speakers will demonstrate how multi-omic approaches and animal modeling can elucidate host-microbe and microbe-microbe interactions within the dynamic microbial ecosystem of the diseased respiratory tract.

Chairing: R.P. Dickson, MD, Ann Arbor, MI
L. Segal, MD, New York, NY
A. Morris, MD, MS, Pittsburgh, PA

9:15 Host Immune Response: The Inflammatory Response to the Microbiome in Health and Airway Diseases
L. Segal, MD, New York, NY

D9 SCIENTIFIC PROMISE AND TRANSLATIONAL CHALLENGES IN LUNG REGENERATIVE MEDICINE

Assemblies on Respiratory Cell and Molecular Biology; Behavioral Science and Health Services Research; Clinical Problems; Respiratory Structure and Function
9:15 a.m. - 11:15 a.m. MARRIOTT MARQUIS WASHINGTON

Marquis Ballroom 5 (Level M2)

Target Audience
Basic scientists, clinicians, and trainees with an interest in the role of stem cells in respiratory development and disease; those who set policy for government institutions such as the NIH or FDA

Objectives
At the conclusion of this session, the participant will be able to:

- review the current understanding and provide latest updates in the mechanisms regulating the activation of stem and progenitor cells both in lung repair after injury and from pluripotent stem cells.
- improve knowledge of potential translation of regenerative medical advances for the treatment of lung diseases;
- improve understanding of ethical dilemmas and regulatory challenges posed by advances in biomedical research.

This session will evaluate recent progress made in deciphering the signaling pathways governing the regulation and function of lung stem cells as well as ethical, and policy issues surrounding stem cell biology, stem cell transplantation, and their therapeutic application to lung disease.

Chairing: A.L. Firth, PhD, Los Angeles, CA
A. Wilson, MD, Boston, MA
Z. Borok, MD, Los Angeles, CA

There will be a 5-minute discussion after each talk.

This session and the International Conference are supported by educational grants from Actelion Pharmaceuticals US, Inc., Teva Pharmaceuticals.
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
9:15 Translating Stem Cell Science to the Clinical Arena  
G. Gibbons, MD, Bethesda, MD

9:35 Epithelial-Mesenchymal-Niche Interactions Regulating Alveolar Type II Cells  
C. Barkauskas, MD, Durham, NC

9:55 Dynamics of Lineage Negative Epithelial Cell Notch Signaling in Lung Injury  
H. Chapman, MD, San Francisco, CA

10:15 Hippo/Yap Regulation of Lung Stem Cells and Development  
X. Varelas, PhD, Boston, MA

10:35 Challenges and Controversies in Bringing Regenerative Products to Market: The Japanese Experience  
D. Sipp, BA, Kobe, Japan

CME Credits Available: 2

**D10 ENVIRONMENTAL POLLUTION AND THE GLOBAL RISE IN COPD FOOTPRINT**

**Membership Committee; Assemblies on Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Clinical Problems; Environmental, Occupational and Population Health; Pediatrics; Respiratory Cell and Molecular Biology; Respiratory Structure and Function**

**9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER Room 145 A-B (Middle Building, Street Level)**

**Target Audience**
Early career scientists and physicians, clinician educators, clinician scholars, trainees, nurses, junior and mid-level faculty

**Objectives**
At the conclusion of this session, the participant will be able to:

- define the epidemiology of COPD and environmental risk factors world-wide;
- identify commonalities and differences in environmental hazard exposures and their impact on respiratory symptoms across populations;
- identify major obstacles and opportunities in risk reduction measures to impact on COPD footprint.

This symposium will highlight the epidemiology of environmental exposures and the global rise in COPD footprint. The symposium will provide the perspective of leaders and future leaders within the field of international respiratory health, identify commonalities and differences in modifiable, environmental risk factors, and provide potential strategies for risk reduction in the global community.

**Chairs:**
Y.N. Mageto, MD, MPH, Burlington, VT  
I.P. Lewkowich, PhD, Cincinnati, OH  
D.C. Newcomb, PhD, Nashville, TN

**Oral Presentations**

9:15 The Unfolded Protein Response Is an Essential Regulator of Airway Inflammatory Responses in a Murine Model of Allergic Asthma  

9:30 Role of Clock Genes in Viral Bronchiolitis and Post-Viral Airway Disease  

9:45 IL-4/13 Activated Pericytes License the Recruitment of Eosinophils and Inflammatory Monocytes in Allergic Airway Inflammation  

9:50 Persistent IL-33 in a Preclinical Chronic Asthma Model Underpins Rhinovirus-Induced Exacerbation by Dampening Antiviral Immunity  
S. Phipps, R. Werder, V. Zhang, J. Lynch, K. Spann, Brisbane, Australia, p.A6994

This session and the International Conference are supported by educational grants from AstraZeneca LP, Teva Pharmaceuticals.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

**D12 MECHANISMS OF ALLERGIC AIRWAY INFLAMMATION**

**9:15 a.m. - 11:15 a.m. MARRIOTT MARQUIS WASHINGTON Independence Ballroom E-H (Level M4)**

**Chairs:**
J.L. Cho, MD, Boston, MA  
I.P. Lewkowich, PhD, Cincinnati, OH  
D.C. Newcomb, PhD, Nashville, TN

**Oral Presentations**

9:15 The Unfolded Protein Response Is an Essential Regulator of Airway Inflammatory Responses in a Murine Model of Allergic Asthma  

9:30 IL-4/13 Activated Pericytes License the Recruitment of Eosinophils and Inflammatory Monocytes in Allergic Airway Inflammation  

9:45 Role of Clock Genes in Viral Bronchiolitis and Post-Viral Airway Disease  

10:00 Location Dependent Signals Fine-Tune Dendritic Cell Control of Th2 Responses  

10:15 Persistent IL-33 in a Preclinical Chronic Asthma Model Underpins Rhinovirus-Induced Exacerbation by Dampening Antiviral Immunity  
S. Phipps, R. Werder, V. Zhang, J. Lynch, K. Spann, Brisbane, Australia, p.A6994

The information contained in this program is up to date as of March 9, 2017. For the most current session information, please visit the online program itinerary.

10:45 Regulation of Type 2 Innate Lymphoid Cells by microRNA-155/ M.D. Knolle, A. Englezakis, A. McKenzie, Cambridge, United Kingdom, p.A6996

11:00 The Innate Cytokines IL-25, IL-33 and TSLP Cooperate in the Induction of IL22 Gene Expression and Mucous Metaplasia in RV-Infected Immature Mice/M. Han, C. Rajput, J.K. Bentley, J.Y. Hong, J. Lei, J. Hinde, Q. Wu, M.B. Hershenson, Ann Arbor, MI, p.A6997

MINI SYMPOSIUM

D14 IPF: MOVING FORWARD

9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER

Room 143 A-C (Middle Building, Street Level)

Chairing: J.S. Lee, MD, Aurora, CO
A. Pardo, PhD, Mexico City, Mexico
G.M. Hunninghake, MD, Boston, MA

Oral Presentations


9:45 Multidisciplinary Collaborative Care for Idiopathic Pulmonary Fibrosis Increases Days Spent at Home During the Last 12 Months of Life/J. Moolji, F. Cavaleri, E. Ainsley, M. Haggag, J. Richman-Eisenstat, M. Kalluri, Edmonton, Canada, p.A7008


10:45 Frailty as an Outcome Measure in Idiopathic Pulmonary Fibrosis Patients/T. Luckhardt, M.D.P. Acosta Lara, T. Kulikarni, R. Sharif, V. Desarro, Y.-I. Kim, J.A. De Andrade, Birmingham, AL, p.A7012

D15 CRITICAL CARE: DO WE HAVE A CRYSTAL BALL?
PREDICTING CLINICAL DETERIORATION AND OUTCOME IN CRITICALLY ILL PATIENTS
9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 146 C (Middle Building, Street Level)

Chairing:
M.N. Gong, MD, MS, Bronx, NY
M.M. Churpek, MD, MPH, PhD, Chicago, IL
M. Hu, MD, MSc, New York, NY

Oral Presentations
10:00 The Association Between Pre-Hospital Vulnerability, the Development of ARDS and Mortality Among At-Risk Adults: Results from the LIPS-A Randomized Clinical Trial/A. Hope, Y. Wu, J.-T. Chen, D. Kaufman, D. Talmor, D.J. Kor, O. Gajic, M.N. Gong, Bronx, NY, p.A7017
10:30 Recovery Trajectories of Critically III Patients in a Randomized Controlled Trial of Early Rehabilitation/S. Gandhi, J. Lovato, D. Case, R.N. Bakhru, K. Gibbs, M. Berry, D.C. Files, P.E. Morris, Winston-Salem, NC, p.A7019
10:45 Development and Validation of a Hospital Performance Measure for 30-Day Sepsis Mortality/J. Darby, B. Davis, I. Barbash, J. Kahn, Pittsburgh, PA, p.A7020
11:00 Late Mortality After ARDS: Excess Mortality Is Large Exposed by Hospitalization with ARDS Risk Factors/H.C. Prescott, T.J. Iwashyna, D.F. McAuley, Ann Arbor, MI, p.A7021

D16 CAN CHILDREN SLEEP AND BREATHE AT THE SAME TIME?
9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 202 A (South Building, Level 2)

Chairing:
G.R. Nino, MD, MSc, Washington, DC
E.S. Katz, MD, Boston, MA

Oral Presentations
9:15 Clinical Characteristics of Central Sleep Apnea in Infants and Young Children in the First 2 Years of Life/J.A. Torres Garcia, S. Hantragool, N. Gurbani, N. Simakajornboon, Cincinnati, OH, p.A7022
10:00 Atopy Is Associated with Persistent Sleep Disordered Breathing to 2 Years of Age; A CHILD Birth Cohort Study Project/F. C. Ding, M. Kamal, S. Tamana, L. Smithson, P. Subbarao, A. Becker, S. Turvey, M. Sears, P. Mandhane, Edmonton, Canada, p.A7025

Featured Speaker
10:45 Many Phases of Sleep/D. Gozal, MD, MBA, Chicago, IL,
Oral Presentations


Oral Presentations


9:45 Human Alveolar Epithelial Cells Derived from Gene-Edited Induced Pluripotent Stem Cells for Alpha-1 Antitrypsin Deficiency Lung Disease Modelling/K.J. Hurley, A. Jacob, D.C. Thomas, J. Kaserman, F.J. Hawkins, A. Wilson, D.N. Kotton, Boston, MA, p.A7038

10:00 Inflammatory Response of Lung Recruited Macrophages Is Partly Regulated by Non-Canonical Notch Pathway in Chronic Obstructive Pulmonary Diseases (COPD)/C. Ballester Lopez, T. Conlon, Z. Ertuez, O. Eickelberg, A.O. Yildirim, Munich, Germany, p.A7039


11:00 Loss of Function of the Transcription Factor Miz1 Causes Spontaneous Emphysema and Bronchitis in Mice/J.I. Sznajder, S. Okamori, T. Asami, N. Hasegawa, T. Betsuyaku, Tokyo, Japan, p.A7043
Oral Presentations


10:00 TRPing the Bronchodilator Switch: TRPA1 as a Novel Bronchodilator/B.J. Marsh, A. Fryer, D.B. Jacoby, M.G. Drake, Portland, OR, p.A7046


10:30 Increased Circulating β2-Adrenergic Receptor Autoantibodies Are Associated with Smoking Related Emphysema/J. Hu, B. He, B. Liu, Y. Du, Y. Zhang, M. Xu, Beijing, China, p.A7048

10:45 Chloride Intracellular Channel 1 (CLIC1) Contributes to Modulation of Cyclic AMP-Activated Whole Cell Chloride Currents in Human Bronchial Epithelial Cells/B. Liu, C. Billington, A. Kheirallah, A. Henry, C. Swan, I.P. Hall, Nottingham, United Kingdom, p.A7049

11:00 Identification of a New Pathway Controlling Steroid Activity Involving Casein Kinase 1-Dependent Cofilin1-Phosphorylation and Phospholipase D Activation/A.G. Stewart, M. Li, C. Keenan, Y.C. Xia, S. Langenbach, Melbourne, Australia, p.A7050

Oral Presentations

9:30 Stratification of CT Screening Participants Using a SNP-Based Risk Score Helps Quantify Outcomes in the NLST-ACRIN Sub-Study (N=10,054)/R.P. Young, R.J. Hopkins, F. Duan, E. Greco, C. Chiles, D. Aberle, G.D. Gamble, Auckland, New Zealand, p.A7051


RAPiD: RAPID ABSTRACT POSTER DISCUSSION

D21 IMMUNE PATHWAYS IN ACUTE LUNG INJURY AND FIBROSIS

9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER Room 206 (South Building, Level 2)

Abstract Summaries

9:15-9:45

Poster Viewing/Discussion

9:45-11:15

Chairing: O. Eickelberg, MD, Denver, CO R.M. Tighe, MD, Durham, NC E.S. White, MD, MS, Ann Arbor, MI


The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.
602 Inhibition of Lipolysis In-Vivo Improves Disease Severity and Lung Inflammation in a Mouse Model of Pseudomonas Pneumonia/S. Tunup, P. Jayaguru, A. Desmett, A. Kadi, Charlottesville, VA, p.A7059


604 Functional Role of Lung Recruited Bone Marrow Derived Exudate M2-Polarized Macrophages in Influenza Virus-Induced Lung Injury and Repair/S. Selvakumar, J. Wilhelm, D. Wolff, W. Seeger, J. Lohmeyer, S. Herold, Bad Nauheim, Germany, p.A7061


609 NETosis Mechanism: Transcriptional Firing Is Important to Drive Both Nox-Dependent and -Independent Types of NETosis/N. Palaniyar, M.A. Khan, Toronto, Canada, p.A7065


614 The Role of TLR Signaling in Regulating Macrophage Recruitment and Activation During Bleomycin-Induced Pulmonary Fibrosis/M.N. Ballinger, B. Reader, B.R. Hay, B.B. Moore, J.W. Christman, Columbus, OH, p.A7071


617 Surfactant Protein-D Regulates the Inflammatory Response and Modulates the Transcription Factor Profile of Group 2 Innate Lymphoid Cells in the Lung After Ozone Inhalation/C.H. Flayer, M.O. Ge, P.B. Kovacs, S. Ott, S.S. Killingbeck, A. Haczku, Davis, CA, p.A7074


624 Higher Monocytes in IPF Patients Is a Marker of Worse Transplant-Free Survival/M. Scott, F. Vallania, K. Quinn, S. Poole, N. Shah, P. Khatri, Stanford, CA, p.A7081

625 The Role of TLR Signaling in Regulating Collagen Uptake and Degradation in Macrophages Following Bleomycin-Induced Pulmonary Fibrosis/B.R. Hay, B. Reader, J.W. Christman, J. Leight, M.N. Ballinger, Columbus, OH, p.A7082
D22 THE COURSE OF CRITICAL ILLNESS: ADMISSION TO FOLLOW-UP

9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 150 B (Middle Building, Street Level)

Poster Viewing 9:15-10:00
Discussion 10:00-11:15

Chairing: A.J. Walkey, MD, MSc, Boston, MA
K.R. Courtright, MD, Philadelphia, PA
W.J. Ehlenbach, MD, MSc, Madison, WI

201 Delayed Recognition of Critically Ill ED Patients Admitted to the ICU: Effect on Hospital Outcomes/M. Durst, C. Vargas-Torres, L.D. Richardson, K.S. Mathews, New York, NY, p.A7083


207 Impact of Transitions of Care on Severe Sepsis Outcomes/J. Paralkar, E. Wan, S. Acquah, P. Patrawalla, New York, NY, p.A7089


211 Survey on Barriers to Critical Care and Palliative Care Integration/K. Kyeremanteng, G. D’Egidio, W. Beckerleg, B. Vanderspank, S. Sutherland, C. Wan, A. Sarti, Ottawa, Canada, p.A7093

212 Study of the Relationship of Health Insurance Resources to Goals of Care Discussions, Advance Care and End of Life Planning Requiring Medical Intensive Care in an Inner City Academic Medical Center/S. Easaw, M. Warshawsky, P. Spiro, V. Kaul, New York, NY, p.A7094


215 Experiences and Attitudes with End of Life Care for Pulmonary Patients on an Intermediate Care Unit/A. Frogameani, L. Chiec, S.R. Russell, Chicago, IL, p.A7097


220 Study to Evaluate the Relationship of Advanced Health Care Decision Counselling in Patients Requiring Critical Care with Respect to Survival Outcomes in an Inner City Hospital/V. Kaul, S. Easaw, P. Spiro, M. Warshawsky, Elmhurst, NY, p.A7102

221 Failure to Recover from Anemia Following Hospital Discharge Is Associated with Higher 30-Day Mortality in Intensive Care Unit Patients/N. Roubiniian, E. Murphy, D. Mark, V. Liu, G.J. Escobar, Oakland, CA, p.A7103


—

POSTER DISCUSSION SESSION

D23 AUTOIMMUNE LUNG DISEASE: CLINICAL PRESENTATION, PROGNOSIS, AND TREATMENT

9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 209 A-C (South Building, Level 2)

Poster Viewing
9:15-10:00
Discussion
10:00-11:15

Chairing: M.E. Strek, MD, Chicago, IL
N. Patel, MD, New York, NY
J.M. Oldham, MD, MS, Sacramento, CA

701 Clinical and Radiological Features of 37 Chilean Patients with Interstitial Lung Disease and Antisyntetase Syndrome/M. Florenzano, V. Wolff, A. Rivera, J.C. Maya, M. Salinas, Santiago, Chile, p.A7108

702 The Clinical Significance of Ferritin in Bronchoalveolar Lavage Fluid of Patients with the Anti-Aminoacyl-tRNA Synthetase Antibody-Positive Interstitial Lung Disease/M. Yamasue, M. Ando, H. Matsumoto, S. Uchida, T. Ono, A. Goto, Y. Usagawa, S. Kadoya, Yufu-City, Japan, p.A7109


Clinical Characteristics of Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease in a Danish Cohort/C. Hyldgaard, T. Ellingsen, O. Hilberg, E. Bendstrup, Aarhus, Denmark, p.A7118


Rituximab for Refractory Granulomatosis with Polyangiitis and for Eosinophilic Granulomatosis with Polyangiitis/L. Kawano-Dourado, J.R.B. De Oliveira Filho, R.M. Lima, M.S. Tavares, C.S.V. Barbosa, Sao Paulo, Brazil, p.A7120


Forced Vital Capacity Predicts Outcome in Scleroderma Associated Interstitial Lung Disease with Concomitant Pulmonary Hypertension: Data from the PHAROS Registry/J.S. Lee, J. Gordon, L. Chung, M.R. Lammi, J. Zymonifka, V. Steen, A. Fischer, Aurora, CO, p.A7127

For the most current session information, please visit the online program itinerary.
721 The Effect of Permissive Underfeeding Compared to Standard Initial Trophic Vs. Full Enteral Feeding in Patients with Acute J. Diaz, MD, San Francisco, CA Chairing:
Discussion 10:00-11:15
Poster Viewing 9:15-10:00
9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER Room 151 A (Middle Building, Street Level)
9:15-10:00
10:00-11:15
Chairing: J. Diaz, MD, San Francisco, CA
M.A. Tidswell, MD, Springfield, MA
A.J. Goodwin, MD, MSCR, Charleston, SC
306 Vitamin D Supplementation and Outcomes in Critically Ill Intubated Patients in the Medical Intensive Care Unit/T. Leclair, N.A. Zakai, J. Bunn, R.D. Stapleton, Burlington, VT, p.A7135
311 Fluid Resuscitation in Patients with End-Stage Renal Disease Presenting with Severe Sepsis or Septic Shock/Y. Omar, K. Kaczmarszyk, A.A. El Solh, P.E. Jaoude, Buffalo, NY, p.A7140
312 Fluid Resuscitation Dilemma in Patients with Congestive Heart Failure Presenting with Severe Sepsis in Intensive Care Unit: An Analysis of a Large Clinical Database MIMIC III/Q. Tran, Harrisburg, PA, p.A7141
313 The Incidence and the Risk Factor of Acquired Swallowing Disorders Among Patients After Cardiac Surgery in China/M. Zhou, Beijing, China, p.A7142
103 Aspergillus Muscle Abscess: A Rare Manifestation of Disseminated Infection/H. Poser, S.J. Quinn, Chicago, IL, p.A7157


105 Pulmonary Empyema with Thoracic Compression resulting from Direct Invasion of Xanthogranulomatous Pyleonephritis/R.S. Kadakia, T. Pelleg, M. Wili, Roanoke, VA, p.A7159

106 An Unusual Cause of Tracheitis/B.A. Weiler-Lisowski, B.-C. Tran, P. Bergquist, J. Heath, K.S. Robinett, Baltimore, MD, p.A7160


109 Successful Recovery from Hantavirus Pulmonary Syndrome Via Utilization of Venovenous Extracorporeal Membrane Oxygenation (ECMO)/M. Abidali, N. Shamsid-Deen, T. Whiting, Phoenix, AZ, p.A7163

110 Pneumocystis Pneumonia in a Patient with Hepatitis C and Cirrhosis Without HIV or Other Risk Factors/N. Yee, B. Mann, K.A. Crothers, T. Albert, Seattle, WA, p.A7164


112 Broncho-Esophageal Fistula Secondary to Histoplasmosis that Underwent Spontaneous Healing/A. Attaway, F.J. Jacoone, R. Gilkeson, J. Fares, Cleveland, OH, p.A7166


114 Membranoproliferative Glomerulonephritis Secondary to Disseminated Tuberculosis After Withdrawal of Adalimumab/G. Samuel, D. Storey, D. Singh, J.J. Zhou, Fort Worth, TX, p.A7168


117 A Case of Pulmonary Mycobacterium Tuberculosis and Mycobacterium Abscessus Co-Infection/S. Bhardwaj, S. Khanijao, E. Sharma, K. Kitchloo, M. Hecht, Brooklyn, NY, p.A7171

501 Inflammation and Hyperoxia Lead to Pulmonary Hypertension

Chairing:
R.M. Ryan, MD, Charleston, SC

Poster Viewing 9:15-10:00

9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER

D26 LUNG DEVELOPMENT AND BPD

9:15 a.m. - 11:15 a.m. WALTER E. WASHINGTON CONVENTION CENTER

Room 201 (South Building, Level 2)

Poster Viewing 9:15-10:00
Discussion 10:00-11:15

Chairing:
R.M. Ryan, MD, Charleston, SC
H. Rozycki, MD, Richmond, VA
G.S. Pryhuber, MD, Rochester, NY

501 Inflammation and Hyperoxia Lead to Pulmonary Hypertension in a Mouse Model of Bronchopulmonary Dysplasia but Not Increased Ex Vivo Intrapulmonary Artery Contraction


502 Adrenomedullin-Haploinsufficient Neonatal Mice Display Increased Susceptibility to Hyperoxia-Induced Lung Injury

B. Shivanna, A.K. Shrestha, R.T. Menon, Houston, TX, p.A7180

503 CD103+ Dendritic Cells and CLEC9A Signaling Are Required for Hyperoxia-Induced Hypoalveolarization in a Murine Model of Bronchopulmonary Dysplasia

C.T. Fulton, T.X. Cui, A.P. Popova, Ann Arbor, MI, p.A7181

504 The Thioredoxin Reductase-1 Inhibitor Aurothioglucose Does Not Require Nuclear Factor E2-Related Factor 2 (Nrf2) for the Attenuation of Lung Developmental Deficits in a Murine BPD Model

Q. Li, R. Li, K. Dunigan, S. Wall, T.E. Tipple, Birmingham, AL, p.A7182

505 MSC Extracellular Vessicles Enhance Angiogenesis In Vitro

V. Balasubramaniam, C. Chetty, G. Nelson, R. Braun, Madison, WI, p.A7183

506 Immune Activation Programs Lung Endothelial Cell-Fate Decisions by Inducing Delta-Like 4 (DLL4) in an ERK-FOXC2-Dependent Manner

H. Menden, S. Xia, V. Sampath, Kansas City, MO, p.A7184

507 Lymphocyte Expression Biomarkers of Chronic Lung Diseases Following Preterm Birth


508 Cellular and Molecular Mechanisms of Mononuclear Cell Populations in Acute Neonatal Hyperoxia-Induced Lung Injury


509 Monocyte-Centred Inflammatory Response Driving Pulmonary Injury in Neonatal Chronic Lung Disease


510 Enhanced Vulnerability of the Developing Lungs by Moderate Prenatal Cigarette Smoke Upon Postnatal Injury


511 Bone Marrow-Derived Mesenchymal Stem Cells and Conditioned Media Have Differential Effects in an In Vitro Model of Bronchopulmonary Dysplasia

C.R. Nitkin, T. Bonfield, Cleveland, OH, p.A7189

512 Bone Morphogenetic Protein 9 Protects Against Neonatal Hyperoxia-Induced Lung Injury by Improving Alveolarization and Reducing Pulmonary Inflammation


513 Serum Brain-Derived Neurotrophic Factor (BDNF) Levels Can Predict Bronchopulmonary Dysplasia and Clinical Outcomes in the Neonatal Period


514 High Versus Therapeutic Doses of Caffeine on Biomarkers of Inflammation and Oxidative Stress in the Lungs of Neonatal Rats Exposed to Hyperoxia and Intermittent Hypoxia


515 Effect of Oxygen Saturation Targets on Development of Pulmonary Hypertension in Extremely Premature Infants


516 Effect of Oxygen Saturation Targets on Duration of Respiratory Support and Disposition


520 Quality of Life and Cardiorespiratory Function in Children Born Extremely Preterm Birth/J.E. MacLean, A. Le, K. Dehaan, L. Hendson, D. Nicholas, M. Stickland, Edmonton, Canada, p.A7198


525 Pretreatment with Dexamethasone Steroid Blunts the Effect of Natriuretic Peptide Receptor-C (NPR-C) Inhibition of Terbutaline-Induced Surfactant Secretion in Human Lung Tissue Type II Cells/R.M. Ryan, M.K. Paintlia, D.A. Newton, J.E. Baatz, Charleston, SC, p.A7695


527 MiRNA Cargo in Microvesicles Released from Hypoxic Pulmonary Arterioendothelial Cells Induces Pulmonary Vascular Smooth Muscle Cell Proliferation and Pulmonary Hypertension/T. Chen, M. Sun, R. Ramchandran, J.U. Raj, Chicago, IL, p.A7204

528 SphK1 Deficiency in Smooth Muscle Cells Protects Against Hypoxia- or Hypoxia plus Sugen Mediated Pulmonary Hypertension/J. Chen, S. Zhao, L.S. Huang, Y. Wang, N. Folesena, V. Natarajan, R.F. Machado, Chicago, IL, p.A7205


530 Pulmonary Transfer of Regulatory Macrophages in Experimental Pulmonary Hypertension Ameliorates Vascular Disease by Modulating the Local Inflammatory Response to Hypoxia/A. Fernandez-Gonzalez, A. Mukhia, S.H. Vitali, S.A. Mitsialis, S. Kourembanas, Boston, MA, p.A7207

531 Contribution of Reduced Toll-Like Receptor 3 Expression to Endothelial Dysfunction in Pulmonary Hypertension/D. Farkas, C. Cool, E.A. Goncharova, L. Farkas, Richmond, VA, p.A7208


533 Role of the FOXO3-FOXM1 Axis in Pulmonary Hypertension/O. Felesena, V. Natarajan, R.F. Machado, Chicago, IL, p.A7210


535 Role of Female Sex Hormones in Modulating the Severe Pulmonary Arterial Hypertension Phenotype Induced by VEGFR2 Inhibition in a ‘Hyper-Responsive’ Colony of Sprague Dawley Rats/K.R. Chaudhary, Y. Deng, K. Tyson, D.J. Stewart, Ottawa, Canada, p.A7213


537 Protracted Endothelial Cell Apoptosis Leads to Direct Microvascular Loss as a Major Mechanism of Severe Pulmonary Arterial Hypertension in the Rat SU5416-Hypoxia Model/Y. Deng, K.R. Chaudhary, A. Yang, K.J. Rowe, D.J. Stewart, Ottawa, Canada, p.A7214


Bardoxolone Methyl Inhibits Proliferation of Human Pulmonary Arterial Smooth Muscle Cells Cultured Under Hypoxic Conditions/ C. Wigley, G. Miller, L. McCauley, D. Ferguson, Irving, TX, p.A7219


PPAR3/HUWE1/miR-98 Signaling Axis Regulates Nuclear Factor Kappa-B p65 (NF-κB p65) and Endothelial Dysfunction in Lungs of Sickle Cell Mice and in Hemin-Treated Human Pulmonary Artery Endothelial Cells (HPAECs)/B.-Y. Kang, R.L. Sutliff, D.R. Archer, C.M. Hart, Decatur, GA, p.A7696


Use of Novel DNA Methylation Signatures to Distinguish Between Human Airway Structural Cell Types/P. Rajasekar, R.L. Clifford, J.L. Maaslaak, L.M. McEwen, M. Kobor, A.J. Knox, Nottingham, United Kingdom, p.A7227


Epigenetic Regulation of Runx2 in Epithelial Mesenchymal Transition (ETM) of Non-Small-Cell Lung Cancer Cells A549/A.P. Rojas, A. Canas, A. Herreno, Bogota, Colombia, p.A7231

Function and Epigenetic Regulation of the Large Conductance Potassium Ion Channel Subunit KCNMB1 in Normal and IPF Fibroblasts/A. Scruggs, S. Gravelyn, S.K. Huang, Ann Arbor, MI, p.A7232

Protein Arginine Methyltransferase Enzymes 6 Attenuates Cigarette Smoke-Induced Endothelial Cell Senescences, Oxidative Damage and Dysfunction/T. Li, X. He, H. Zeng, Z. Dai, Y. Cui, J. Xue, Y. Chen, Changsha, China, p.A7233


819 Pharmacometabolomic Characterization of the Polarization of Human Lung Macrophages/F. Fall, N. Fabresse, M. Brollo, I. Etting, E. Naline, J.-C. Alvarez, P. Devillier, S. Grassin-Delyle, Montigny le Bretonneux, France, p.A7239

820 The Alveolar Macrophage Toponome Is Altered by SP-A1 Treatment/D.S. Phelps, J. Floros, Hershey, PA, p.A7240


826 Matrix Metalloproteinase-7 Is a Potential Marker of Early Chronic Lung Allograft Dysfunction/J. Jaffar, G. Westall, Melbourne, Australia, p.A7246


832 Pharmacometabolomic Characterization of the Polarization of Human Lung Macrophages/F. Fall, N. Fabresse, M. Brollo, I. Etting, E. Naline, J.-C. Alvarez, P. Devillier, S. Grassin-Delyle, Montigny le Bretonneux, France, p.A7239

833 The Alveolar Macrophage Toponome Is Altered by SP-A1 Treatment/D.S. Phelps, J. Floros, Hershey, PA, p.A7240


839 Matrix Metalloproteinase-7 Is a Potential Marker of Early Chronic Lung Allograft Dysfunction/J. Jaffar, G. Westall, Melbourne, Australia, p.A7246


Collagen Accumulation in the Rat Lung After Repetitive Instillations of Gastric Contents/G. Borzone, P. Ayala, T. San Martin, M. Meneses, R. Montalva, Santiago, Chile, p.A7259

Comparison of Bleomycin Models of Pulmonary Fibrosis in Rats and Mice/D. Walter, D. Schaudien, K. Sewald, A. Braun, H.-G. Hoymann, Hannover, Germany, p.A7260

PBI-4050 Reduces Expression of Fibrosis Biomarkers in the BioMAP SAEMyoF Primary Human Small Airway Epithelial Cells and Lung Myofibroblasts System/M. Leduc, B. Grouix, P. Laurin, L. Gagnon, Laval, Canada, p.A7261


Role of Collagen Fibers in Modulating the Constriction of an Airway in Response to a Low Dose of Agonist/S.R. Polio, H. Parameswaran, K. Lutchen, Boston, MA, p.A7267


412 Apolipoprotein A2 Confers Independent Risk for Obesity and Breathing Inconsistency in the B6 Mouse/K.P. Strohl, S. Azzam, Cleveland, OH, p.A7279


414 Effects of Fluid Overload on the Genioglossus Activity in Urethane-Anesthetized Rat Model/P. Sabetian, A. Yadollahi, P. Yoo, Toronto, Canada, p.A7281


416 Effects of Tiagabine on Slow Wave Sleep and Arousal Threshold in Patients with Obstructive Sleep Apnea/L. Taranto Montemurro, S.A. Sands, B.A. Edwards, A. Azarbarzin, M. Marques, C. De Melo, D.J. Eckert, D.P. White, A. Wellman, Boston, MA, p.A7283

417 Relationship Between Drug-Induced Sleep Endoscopy (DISE) and Awake Endoscopy Findings in Patients with Obstructive Sleep Apnea/T.D. Rachakonda, A.M. Willis, B. Williams, M.E. Error, K.M. Sundar, Salt Lake City, UT, p.A7284

418 Comparison of Site and Configuration of Upper Airway Collapse Between Natural and Propofol-Induced Sleep Endoscopy - Preliminary Results/A.B. Ordonez, G. Grad, M. Cahali, L.U. Sennes, G. Lorenzi-Filho, P. Genta, Sao Paulo, Brazil, p.A7285


WS7 MOLECULAR DIAGNOSTICS FOR ACUTE PNEUMONIA: PRACTICAL IMPACT AND FUTURE HORIZONS

Registration Fee: $75 (includes box lunch)

Attendance is limited. Pre-registration is required.

Assemblies on Microbiology, Tuberculosis and Pulmonary Infections; Clinical Problems; Critical Care

11:45 a.m. - 1:15 p.m. MARRIOTT MARQUIS WASHINGTON Archives (Level M4)

Target Audience
Pulmonologists, critical care physicians, hospitalists, microbiologists, infectious disease specialists, and infection control specialists seeking to update their knowledge of the latest molecular assays as well as emerging diagnostic technologies for the microbial etiology of acute pneumonia

Objectives
At the conclusion of this session, the participant will be able to:

- learn new findings about novel molecular diagnostic tests for acute pneumonia;
- diagnose patients with acute pneumonia;
- gain new strategies to manage the care of patients with CAP or VAP.

This session will provide attendees with a cutting edge review of novel diagnostic technologies that can be used to facilitate rapid and accurate identification and characterization of the etiology of acute pneumonia. Individual speakers will 1) describe the scientific basis of the latest molecular tests for rapid identification of viral and bacterial pathogens and review the use of automated functional approaches for rapid antimicrobial susceptibility testing; 2) provide a perspective from the clinical microbiology laboratory on the advantages and challenges of implementing and integrating these new and emerging methodologies into clinical practice; and 3) assess the clinical utility of the approved molecular techniques for rapid identification of viral and bacterial pathogens that cause community-acquired pneumonia.
Chairing: R. Nusrat, MD, Princeton, NJ  
S.T. Qureshi, MD, Montreal, Canada

11:45 Molecular Testing for Acute Pneumonia Diagnosis  
M.H. Kollef, MD, St. Louis, MO

12:05 Emerging Diagnostic Technologies for Ventilator-Associated Pneumonia  
I.S. Douglas, MD, Denver, CO

12:25 Novel Pneumonia Diagnostics: View from the Clinical Microbiology Laboratory  
R. Patel, MD, Rochester, MN

12:45 Molecular Diagnosis of Community Acquired Pneumonia  
R.G. Wunderink, MD, Chicago, IL

1:05 Panel Discussion

---

**PREPARING FOR ENTERING THE GRANT SHARK TANK: ATTAINING EARLY CAREER FUNDING**

This Forum is part of the ATS initiative to offer program specifically geared toward the professional development of trainees, fellows and students to aid in the pursuit of successful careers in pulmonary, critical care and sleep medicine.

Pre-registration is required. Attendance is limited. There is no additional fee.

Assembly on Respiratory Structure and Function
11:45 a.m. - 1:15 p.m.  
MARRIOTT MARQUIS WASHINGTON  
Capitol/Congress (Level M4)

**Target Audience**
Graduate students, PhD, MD, post-doctoral/clinical fellows and faculty interested in gaining insight into early career funding mechanisms and learning tips for successful applications. This interactive session is designed to attract grant applicants to understand the funding process in U.S./international agencies or foundations to enhance success in attaining early career funding.

**Objectives**
At the conclusion of this session, the participant will be able to:
- understand the advantages and challenge of seeking federal, industry, or foundation, funding;
- gain a greater understanding of the criteria used to identify innovative and outstanding grant applications;
- discover the most common pitfalls, which can lead to lack of success in obtaining grants.

Early career investigators are faced with a challenging research funding climate. In order to succeed in obtaining support, they must have a clear understanding of funding mechanisms available and how to navigate the application process in order to excel with innovative proposals. A NIH official, a representative from the American Association for the Advancement of Science, two highly experienced, internationally recognized senior scientists, and a recently awardee investigator will review and discuss available career development grant opportunities with particular focus on K-awards, private grant mechanisms and international funding options. This will be followed by Questions and Answers. We will also provide an information booklet with a brief overview of international grant details, deadlines, and resources for locating funding.

Chairing: C.R. Kliment, MD, PhD, Baltimore, MD  
K. Jetmalani, PhD, Sydney, Australia

11:45 NIH Awards  
W. Wang, PhD, Bethesda, MD

12:05 K Awards and Foundation Mechanisms  
L. Smith, MD, Chicago, IL

12:30 International Funding Mechanisms  
A.J. Halayko, PhD, Winnipeg, Canada

12:45 Navigating Early Career Funding  
J. Englert, MD, Columbus, OH

1:00 General Discussion

---

**TOWARDS A FDA COMPREHENSIVE NICOTINE REGULATORY POLICY: HOW DO ELECTRONIC NICOTINE DELIVERY SYSTEMS FIT?**

12:15 p.m. - 1:15 p.m.  
WALTER E. WASHINGTON CONVENTION CENTER  
Room 204 A-C (South Building, Level 2)

**Target Audience**
Clinicians trying to advise patients about nicotine and electronic nicotine delivery systems; Anyone interested in nicotine policy

**Objectives**
At the conclusion of this session, the participant will be able to:
- understand FDA’s Center for Tobacco Products strategic priorities and the need for a comprehensive FDA regulatory nicotine policy;
- evaluate whether electronic nicotine delivery systems have a role in FDA regulatory nicotine policy.

Tobacco harm reduction and the continuum of risk are concepts that have been the subject of ongoing discussion and debate within the tobacco research and public health community. Points of view vary regarding approaches to reduce tobacco-caused morbidity and mortality. One of the five strategic priorities of the Food and Drug Administration’s Center for Tobacco Products is the need for a Comprehensive FDA Regulatory Nicotine Policy. This strategic priority aims to establish an integrated, FDA-wide policy on nicotine containing products that is public health based. This strategic priority has implications for tobacco, drug, and device regulatory policy. This session will provide an overview of tobacco harm reduction and the continuum of risk, a summary of nicotine science, and considerations regarding how electronic nicotine delivery systems (ENDS) fit into a comprehensive nicotine regulatory policy.

Chairing: P. Callahan-Lyon, MD, Silver Spring, MD

12:15 Setting the Stage  
M. Zeller, JD, Silver Spring, MD
12:15 p.m. - 1:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 102 A-B (South Building, Street Level)

Target Audience
Pulmonary health researchers and clinicians interested in needed environmental data on health and Air Quality, wildfires and overview of the NASA Health and Air Quality Applied Sciences Team (H-AQAST); those interested in understanding the geographic, environmental, and meteorological differences in pulmonary disease.

Objectives
At the conclusion of this session, the participant will be able to:
• gain knowledge about ongoing NASA projects related to performance lung and cardiac disease;
• provide a synopsis of a project using observations of earth’s environment and public health applications that are of interest to pulmonary clinicians and researchers;
• provide an overview of the NASA Health and Air Quality Program relating to public health applications that are of interest to pulmonary clinicians and researchers.

Speakers will highlight the newly formed NASA Health and Air Quality Team that is studying environmental health as well as air quality. These researchers will provide an overview of the Health and Air Quality Program and the types of projects that will benefit attendees. They will identify sources for information about the satellite data as well as possibly find new medical resources within the attendees of the American Thoracic Society International Conference.

Chairing: S.M. Estes, MS, Huntsville, AL

12:15 Overview of NASA’s Public Health Program
J.A. Haynes, MS, Washington, DC

12:30 The NASA Health and Air Quality Applied Sciences Team (H-AQAST)
T. Holloway, PhD, Madison, WI

12:45 A Multi-Pollutant, Satellite-Based Health-Air Quality Index
B. Duncan, PhD, Greenbelt, MD

1:00 Air Quality Forecasting and Reanalysis
D. Tong, PhD, Fairfax, VA

L23 PROMOTING ACCESS TO GUIDELINES-BASED CARE FOR PEOPLE WITH ASTHMA
12:15 p.m. - 1:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 143 A-C (Middle Building, Street Level)

Target Audience
Physicians, nurses, respiratory therapists, asthma educators

Objectives
At the conclusion of this session, the participant will be able to:
• improve quality of asthma care provided to patients;
• recognize the role of non-governmental organizations in asthma control.

CDC’s National Asthma Control Program has partnered with national non-governmental organizations (NGOs) to promote access to guidelines-based asthma care using health education and communication strategies that will result in measurable impacts. The NGOs will provide clear and consistent guidance on the delivery of asthma education for people with asthma, health professionals, and on the interactions between these two groups. As a result, audiences will have the knowledge and skills to demand appropriate care (people with asthma) or deliver it (health care providers), and schools and communities will have the capacity to promote policies, systems, and environments that support people with asthma.

Chairing: P.L. Garbe, DVM, MPH, Atlanta, GA

12:15 Reducing the Burden of Asthma in Adults
B. Kaplan, MPH, Washington, DC

12:30 Building Blocks for Better Breathing: A Comprehensive Approach to Promote Quality Care for Asthma According to the NAEPP Guidelines
T. Winders, MBA, Vienna, VA

12:45 Creating Asthma-Friendly Environments and Promoting Access to Guidelines-Based Care for Children with Asthma
T. Bobbitt, MA, MS, Washington, DC

1:00 Developing and Disseminating an Educational Intervention for the Medically Underserved
M. Bloomrosen, MBA, MBI, Landover, GA

L24 PATIENT-CENTERED OUTCOME RESEARCH INSTITUTE (PCORI): PCORNET AND EVIDENCE TO ACTION NETWORKS UPDATE
12:15 p.m. - 1:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 202 B (South Building, Level 2)

Target Audience
Clinicians (physicians, nurses, fellows, residents), researchers, administrators and policymakers: anyone involved in delivery of care and the science of patient-centered research
Objectives
At the conclusion of this session, the participant will be able to:

- understand funding comparative effectiveness research;
- learn from PCORI official what network activities are ongoing.

A PCORI official will introduce summaries of PCORI funded projects in pulmonary, critical care and sleep disorders. The PCORI officials will update the unique evidence to action network activities in asthma and transition of care, and also review activities and collaboration opportunities in PCORnet. At the panel discussion, PCORI officials and PCORI funded researchers will discuss question from audience related to PCORI activities. The purpose of the session will be to raise awareness of PCORI activities relevant to patient centered care for patients with pulmonary, critical care, and sleep disorders.

Chairing: K. Sumino, MD, MPH, St. Louis, MO

12:15 Patient-Centered Comparative Effectiveness Research to Reduce Asthma Disparities and Improve Adherence to Asthma Guidelines
A. Anise, MHS, Washington, DC

12:27 Accessing PCORnet’s Data and Network Resources
R. Fleurence, PhD, Washington, DC

12:39 Transitional Care Evidence to Action Network: Approaches, Accomplishments, Opportunities in Transitional Care Research
C. Parry, PhD, MSW, Washington, DC

12:51 Wrap Up and Panel Discussion
K. Sumino, MD, MPH, St. Louis, MO
A. Anise, MHS, Washington, DC
R. Fleurence, PhD, Washington, DC
C. Parry, PhD, MSW, Washington, DC
C.E. Cox, MD, MPH, Durham, NC
S. Parthasarathy, MD, Tucson, AZ

Chairing: S. Wisniewski, PhD, Pittsburgh, PA
A. Punturieri, MD, PhD, Bethesda, MD

12:15 PTC: NEMO and PLGs
S. Wisniewski, PhD, Pittsburgh, PA

12:27 INSIGHT COPD
D.H. Au, MD, MS, Seattle, WA

12:39 LEEP
R.A. Wise, MD, Baltimore, MD

12:51 RETHINC
M.K. Han, MD, MS, Ann Arbor, MI

1:03 CleanUP IPF
F.J. Martinez, MD, New York, NY

L26 NHLBI-FUNDED RESOURCES FOR IMPROVING LONG-TERM OUTCOMES CLINICAL RESEARCH FOR ACUTE RESPIRATORY FAILURE

12:15 p.m. - 1:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 147 A-B (Middle Building, Street Level)

Target Audience
Practicing critical care clinicians and clinical researchers; fellows, students, nurses, and other medical professionals and others interested in long-term outcomes and clinical research would also benefit from this session

Objectives
At the conclusion of this session, the participant will be able to:

- learn what instruments are recommended and the resources available for assessing acute respiratory failure survivors’ long-term physical, cognitive, and mental health outcomes;
- understand methods and resources available for maximizing cohort retention;
- understand statistical methods and resources available to analyze longitudinal outcomes in the presence of high patient mortality.

This session will provide an overview of NHLBI-funded resources for improving long-term outcomes research in acute respiratory failure clinical studies. This session will cover research and resources in the following areas: 1) instruments for measuring acute respiratory failure survivors’ long-term physical, cognitive, and mental health outcomes; 2) methods for maximizing retention of acute respiratory failure survivors in long-term research studies; and 3) statistical methods for analyzing long-term outcomes in the presence of high patient mortality.

Chairing: D. Needham, MD, Baltimore, MD
L. Reineck, MD, Bethesda, MD

12:15 Outcome Measures for Acute Respiratory Failure Survivors: An Overview
D. Needham, MD, Baltimore, MD

12:27 Understanding Important Outcomes to ICU Survivors Using Qualitative Methods
M.N. Eakin, PhD, Baltimore, MD

L25 THE PULMONARY TRIALS COOPERATIVE (PTC): PURPOSE, STRUCTURE AND CURRENT TRIALS

12:15 p.m. - 1:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 145 A-B (Middle Building, Street Level)

Target Audience
Multiple groups, patients, clinical researchers, pulmonologists, health care providers

Objectives
At the conclusion of this session, the participant will be able to:

- learning new findings and ideas about treatment of COPD and IPF;
- learning new strategies to conduct clinical trials.

The presenters will illustrate what is the NHLBI-funded Pulmonary Trials Cooperative (PTC). They will describe in detail its purpose, structure and functions. The four trials currently undergoing execution will be presented describing for each of the protocols and the background behind them.
ATS 2017 • Washington, DC

The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.

12:39 Reaching International Consensus on Long-Term Outcomes Measures for Acute Respiratory Failure
A.E. Turnbull, DVM, MPH, PhD, Baltimore, MD

12:51 Understanding and Improving Cohort Retention in Long-Term Outcome Studies
V. Dinglas, MPH, Baltimore, MD

1:03 Statistical Methods for Evaluating Patient Outcomes in the Presence of a Competing Risk of Mortality
E. Colantuoni, PhD, Baltimore, MD

1:15 NHLBI Mechanisms to Accelerate Translational Science
P. Noel, PhD, Bethesda, MD

12:15 Overview of ECHO
M.W. Gillman, MD, Bethesda, MD

12:30 Children’s Health Exposure Analysis Resource (CHEAR) for Data Science
S. Teitelbaum, PhD, New York, NY

12:45 Patient Reported Outcomes Research Resource Center Core (ECHO PRO Core)
R. Gershon, MD, Chicago, IL

1:00 Early Exposures and ECHO Asthma Outcomes
J.E. Gern, MD, Madison, WI

For more information, please visit the online program itinerary.
THE LUNG HEALTH COST OF ENERGY: CARING FOR COAL, URANIUM, AND NUCLEAR INDUSTRY WORKERS

12:15 p.m. - 1:15 p.m. WALTER E. WASHINGTON CONVENTION CENTER
Room 202 A (South Building, Level 2)

Target Audience
Clinicians who treat, or are interested in treating, pulmonary disease in coal, uranium, and nuclear weapons workers. This may be of particular interest to clinicians working in areas with large numbers of active and retired coal miners or uranium and nuclear industry workers and areas affected by nuclear weapons testing.

Objectives
At the conclusion of this session, the participant will be able to:

• describe the services and funding available through the Black Lung Clinics Program and the Radiation Exposure Screening and Education Program;

• learn about the unique challenges of caring for coal and uranium workers in a clinical setting;

• better treat and/or refer coal, uranium, and nuclear weapons worker patients suffering from occupational lung disease.

Attendees will learn about the Black Lung and Radiation Exposure Screening and Education Programs administered by the Health Resources and Services Administration (HRSA); the Department of Labor (DOL) and Department of Justice (DOJ) claims processes for coal and uranium and nuclear weapons workers; and the challenges and opportunities providers who treat these populations face.

Attendees will also be able to describe the mission of the Federal Black Lung program, the Energy Employees Occupational Illness Compensation Program Act and the Radiation Exposure Compensation Act; the statutory requirements for conducting a complete pulmonary evaluation to determine disability; and the need for additional diagnostic providers to conduct disability evaluations for the programs.

Chairing: A. Hutchings, MA, MPH, Rockville, MD
M. Chance, JD, Washington, DC

12:15 Overview of HRSA’s Black Lung and Radiation Exposure Screening and Education Programs
M. Lincoln, MSW, Rockville, MD
A. Hutchings, MA, MPH, Rockville, MD

12:25 Overview of DOJ and DOL Claims Processes for Coal, Uranium and Nuclear Industry Workers
M. Chance, JD, Washington, DC
R. Leiton, MPA, Washington, DC
J. Bougere, JD, Washington, DC
L.L. Beg, JD, Washington, DC

12:40 A Physician Perspective on Caring for Coal Workers
R.A. Cohen, MD, Chicago, IL

12:50 A Physician Perspective on Caring for Uranium and Nuclear Industry Workers
A. Sood, MD, MPH, Albuquerque, NM

1:00 Questions and Answers
A. Hutchings, MA, MPH, Rockville, MD
M. Chance, JD, Washington, DC

The information contained in this program is up to date as of March 9, 2017.
For the most current session information, please visit the online program itinerary.
Target Audience
Practicing internists and subspecialists in Pulmonary, Critical Care, and Sleep medicine who work in a clinical setting and are currently engaged in maintenance of certification.

Objectives
At the conclusion of this session, the participant will be able to:
- remain current with medical knowledge relevant to their practice in pulmonary, critical care, and sleep medicine;
- evaluate their understanding of key skills and content areas in pulmonary, critical care and sleep medicine, as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
- support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The ATS Clinical Core Curriculum Symposia focus on a 3-year content cycle of key medical content in the areas of Pulmonary, Critical Care, and Sleep Medicine. The topics are also aligned with corresponding MOC Medical Knowledge modules. This symposium is intended to assist clinicians with staying current with the growth of information relevant to their medical practice, as well as provide an opportunity to evaluate individual knowledge and skills while earning MOC Medical Knowledge points.

Chairing:
T.S. Wang, MD, Los Angeles, CA

1:30 OSA: Diagnosis
M. Kaminska, MD, Montreal, Canada

2:00 OSA: PAP Therapies
L. Wolfe, MD, Chicago, IL

1:30 What Is COPD?
R. Rodriguez-Roisin, MD, PhD, Barcelona, Spain
1:45 The Diagnosis and Assessment of COPD  
C. Vogelmeier, MD, Marburg, Germany

2:00 Overview of Therapeutic Options in COPD  
N. Roche, MD, Paris, France

2:15 Treatment of Stable COPD  
G.J. Criner, MD, Philadelphia, PA

2:30 Definition and Management of Acute Exacerbations  
J.A. Wedzicha, MD, PhD, London, United Kingdom

2:45 Comorbidities and COPD  
L.M. Fabbri, MD, Modena, Italy

3:00 Asthma-COPD Overlap  
B.R. Celli, MD, Boston, MA

3:15 Future Needs and Summary of New Recommendations  
A. Agusti, MD, Barcelona, Spain

---

**D83 INNOVATIVE CLINICAL TRIALS IN PULMONARY FIBROSIS AND BEYOND**

Assemblies on Clinical Problems; Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology  
1:30 p.m. - 3:30 p.m. WALTER E. WASHINGTON CONVENTION CENTER  
Ballroom C (South Building, Level 3)

**Target Audience**  
Clinical researchers, clinicians, basic science researchers

**Objectives**  
At the conclusion of this session, the participant will be able to:

- learn the rationale of different clinical trial designs in IPF;
- learn novel clinical trial designs employed in cancer;
- leverage genomic data in IPF as markers of clinical responsiveness in clinical trials.

FDA-approved therapies are now available for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and are currently being studied in other fibrotic diseases. We are now seeing several clinical trials in fibrosis based on novel rationales or employ innovative outcome measures. This session is designed to introduce some of these novel studies and to introduce the audience to adaptive clinical trial design, which is currently being studied in breast cancer. This design may help leverage the enormous amount of genomic data in pulmonary fibrosis to personalize therapy for patients.

**Chairing:** D. Kass, MD, Pittsburgh, PA  
S.K. Danoff, MD, PhD, Baltimore, MD

1:30 A Patient’s Perspective  
S. Collins, Kirkwood, MO

1:35 A Half Century of ARDS: Progress and Setbacks  
A. Slutsky, MD, Toronto, Canada

1:45 Changing Definitions: Progress?  
G.D. Rubenfeld, MD, MSc, Toronto, Canada

2:05 Mechanical Ventilation in ARDS: Has Anything Changed in 50 Years?  
E. Fan, MD, PhD, Toronto, Canada

D. Brodie, MD, New York, NY

2:45 Shifting to Prevention: PETAL  
R.G. Brower, MD, Baltimore, MD

3:05 Predictions for ARDS 2067: What Will the Future Bring?  
C.S. Cafee, MD, San Francisco, CA

3:25 Panel Discussion
D85  RECOGNITION, DIAGNOSIS AND MANAGEMENT OF INDOLENT LUNG CANCER

Assemblies on Thoracic Oncology; Clinical Problems
1:30 p.m. - 3:30 p.m.  WALTER E. WASHINGTON CONVENTION CENTER
Room 202 A (South Building, Level 2)

Target Audience
Academic and private practice pulmonary specialists and thoracic surgeons evaluating and treating patients with indeterminate persistent sub-solid opacities or pulmonary nodules of the lung adenocarcinoma spectrum. Pulmonary Fellows, medical residents and medical students, PA, NP and nursing providers caring for patients with these lesions.

Objectives
At the conclusion of this session, the participant will be able to:
- recognize “indolent” lung cancers;
- develop an approach to the diagnosis, risk stratification and management of indolent lung cancers;
- understand the potential impact of overtreatment of indolent lung cancers and improve patient communication.

Increasing use of screening and clinical chest CT scans results in increased detection of persistent sub-solid opacities most commonly representing lung adenocarcinomas (AC). Consequently, the number of surgically resected lung adenocarcinomas increased significantly. A subgroup, AIS/MIA, has almost complete (100%) post-surgical disease-free survival. In the NLST cohort 18% of the detected cancers, almost exclusively AC, were “overdiagnosed” and overtreated. Similarly to prostate and breast cancer there is a potentially large subset of “indolent” lung cancers. This concept is not well known. The prospective identification, risk stratification and individualized management of these lesions may significantly decrease treatment-related morbidity, mortality and health care costs. This session will comprehensively address these issues.

Chairing:
G.A. Silvestri, MD, MS, Charleston, SC
F. Maldonado, MD, Nashville, TN

1:30  Population-Based Screening for Cancer: Hope and Hype
L. Esserman, MD, MBA, San Francisco, CA

1:50  Epidemiology of “Indolent” Lung Cancers
P.P. Massion, MD, Nashville, TN

2:10  Risk Stratification of Lung Lesions Prior to Therapy: Where Do We Stand?
T. Peikert, MD, Rochester, MN

2:30  To Treat or Not To Treat “Indolent” Lung Cancers?
F.C. Detterbeck, MD, New Haven, CT

2:50  What’s the Cost of Overtreatment? and How Do I Tell My Patient About Their “Overdiagnosed” Lung Cancer?
G.A. Silvestri, MD, MS, Charleston, SC

3:10  Interactive Case Presentation
F. Maldonado, MD, Nashville, TN

D86  INTERACTIONS BETWEEN FAT AND FLOW

Assemblies on Respiratory Structure and Function; Clinical Problems; Environmental, Occupational and Population Health; Sleep and Respiratory Neurobiology
1:30 p.m. - 3:30 p.m.  MARRIOTT MARQUIS WASHINGTON
Marquis Ballroom 5 (Level M2)

Target Audience
Translational Investigators, clinicians taking care of obese patients.

Objectives
At the conclusion of this session, the participant will be able to:
- understand the effect of obesity on pulmonary physiology and pathophysiology;
- have new strategies for the management of mechanical ventilation in critically ill patients;
- understand the interactions between obesity and air pollutants such as ozone.

Epidemiological data suggest there has been a major shift in the presentation and underlying pathogenesis of many pulmonary diseases in patients with obesity. This session will discuss the pathophysiology of airway disease in obesity, and the implications this has for treatment of obese patients.

Chairing:
A.E. Dixon, MD, Burlington, VT
J.H.T. Bates, DSc, PhD, Burlington, VT

1:30  Fat and Flow: The Effects of the Obesity Epidemic on Lung Disease
A.E. Dixon, MD, Burlington, VT

1:40  Ozone and Obesity
S. Shore, PhD, Boston, MA

2:05  Pathogenesis of Obstructive Sleep Apnea in Obesity
S. Patil, MD, Baltimore, MD

2:25  Effects of Obesity on Airway Function and Ventilation
G. King, MBChB, PhD, St. Leonards, Australia

2:50  Mechanical Ventilation of Obese Patients
L. Berra, MD, Boston, MA

3:10  The Mechanical Consequences of Obesity on Airways Responsiveness
J.H.T. Bates, DSc, PhD, Burlington, VT

There will be a 5-minute discussion after each talk.
OBESITY AND CHRONIC RESPIRATORY DISEASES IN CHILDREN: RECENT ADVANCES AND CLINICAL IMPLICATIONS

Assemblies on Pediatrics; Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Environmental, Occupational and Population Health; Respiratory Cell and Molecular Biology; Sleep and Respiratory Neurobiology

1:30 p.m. - 3:30 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Target Audience
Pediatricians, primary care providers, and pulmonary/sleep specialists taking care of children with chronic respiratory and sleep disorders, as well as providers taking care of these patients as they transition to young adults. Whose main research focus is on the mechanisms and pathophysiology of chronic pediatric respiratory disorders

Objectives
At the conclusion of this session, the participant will be able to:

- understand how obesity affects the risk and severity of chronic respiratory diseases in children;
- understand new findings on the mechanisms that lead from obesity to childhood asthma, sleep disorders, and others diseases of the lung;
- identify these patients and treat them in a personalized manner to improve their quality of life.

Mounting evidence over the past 10-15 years has demonstrated an association between obesity and chronic respiratory conditions in children, including asthma and sleep disorders. In this session, we will review current epidemiological and experimental evidence for these associations. We will then discuss proposed mechanisms including epigenetic regulation, the role of obesity-related metabolic changes, and alterations in the microbiome that may underlie both obesity and childhood respiratory diseases. Next, we will focus on important management considerations for these patients, as well as on the transition to adolescence and adulthood. Finally, we will discuss unanswered questions and propose directions for future research in the field.

Chairing:
E. Forno, MD, MPH, Pittsburgh, PA
I. Narang, MD, Toronto, Canada
S. Saglani, MD, MBChB, London, United Kingdom

1:30 Lung Function in Obese Youth with and Without Asthma
E. Forno, MD, MPH, Pittsburgh, PA

1:50 Obesity-Related Epigenetic Reprogramming of Airway Cells and Remodeling in Lower Airway Disease
R.J. Freishtat, MD, MPH, Washington, DC

2:10 Obesity and Sleep Disorders
H. Jalou, MD, Indianapolis, IN

2:30 Sleep Disorders: Therapeutic Management and Transition to Adulthood
I. Narang, MD, Toronto, Canada

2:50 The Microbiome: A Link Between Obesity and Lung Disease?
N. Ubags, PhD, Epalinges, Switzerland

3:10 Session Summary, Unanswered Questions, and Future Directions
S. Saglani, MD, MBChB, London, United Kingdom

There will be a 5-minute discussion after each talk.

LIFE IN THE FAST LANE: USE OF PLURIPOTENT STEM CELLS IN PULMONARY DISEASE

Assemblies on Pulmonary Circulation; Critical Care; Respiratory Cell and Molecular Biology; Respiratory Structure and Function

1:30 p.m. - 3:30 p.m. MARRIOTT MARQUIS WASHINGTON

Target Audience
Clinicians (especially internists, pulmonologists/intensivists, and cardiologists) interested in personalized medicine and scientists interested in lung and heart development

Objectives
At the conclusion of this session, the participant will be able to:

- improve their knowledge on embryologic development of heart and lung;
- learn new techniques to study lung disease in a dish;
- know the advantages and disadvantages of the use of induced pluripotent stem cells.

This session will focus on the applicability of cell culture model systems to study pathophysiological alterations in pulmonary disease and right heart failure. Because animal models do not fully replicate the clinical phenotypes of pulmonary diseases (e.g. pulmonary hypertension, pulmonary edema, cystic fibrosis), alternative methods have been suggested to use. The most promising new tool is induced pluripotent stem cells. During the session, we will discuss the molecular determinants of heart and lung development, knowledge that is essential for the development of clinical relevant disease models. Subsequently, we will discuss the most practical and efficient substrate for the generation of induced pluripotent stem cells. Finally, the applicability of pluripotent cell technique in modeling pulmonary hypertension, pulmonary edema, cystic fibrosis and right heart failure will be addressed.

Chairing:
E.F. Speierkoetter, MD, Palo Alto, CA
F. De Man, PhD, Amsterdam, Netherlands
J.D. West, PhD, Nashville, TN

1:30 Molecular Determinants of Heart and Lung Development
E. Morrisey, PhD, Philadelphia, PA

1:50 Modeling of Cystic Fibrosis by Lung Organoids
J. Spence, PhD, Ann Arbor, MI

2:10 Pulmonary Hypertension Research in the Era of Pluripotency
M. Rabinovitch, MD, Stanford, CA
D89 OF MICE AND MEN: MECHANISMS OF GRANULOMATOUS INFLAMMATION

Assemblies on Allergy, Immunology and Inflammation; Microbiology, Tuberculosis and Pulmonary Infections

1:30 p.m. - 3:30 p.m. MARRIOTT MARQUIS WASHINGTON
Marquis Ballroom 6 (Level M2)

Target Audience
Physicians and scientists interested in granulomatous lung diseases as well as lung immunology; clinicians who care for patients with infectious and noninfectious granulomatous lung diseases

Objectives
At the conclusion of this session, the participant will be able to:
- understand the generation of the granuloma;
- understand the generation of an adaptive immune response and the consequences of failure to eradicate the stimulating antigen;
- understanding the mechanisms that result in eventual fibrosis development.

Recently, significant advances in our understanding of the formation of granulomas in both infectious and noninfectious granulomatous lung disease have occurred. This symposium brings together world-class immunologists (including those from the NIH) to discuss these advances. The symposium will bring together scientists investigating both infectious and noninfectious granulomatous lung diseases to delineate common themes. In addition, it addresses gene-environment interactions, which is the science core for this ATS meeting.

Chairing: A.I. Sperling, PhD, Chicago, IL
L. Koth, MD, San Francisco, CA

1:30 Macrophage Epithelial Reprogramming in Mycobacterial Granulomas
D.M. Tobin, MD, Durham, NC

1:50 Dynamics of Granuloma Formation in Tuberculosis
J. Flynn, PhD, Pittsburgh, PA

2:10 Gene-Environment Interactions in Chronic Beryllium Disease
A.P. Fontenot, MD, Aurora, CO

2:30 Mechanisms of Granuloma-Induced Fibrosis
T. Wynn, PhD, Bethesda, MD

2:50 Immune Dysfunction in Sarcoidosis
W. Drake, MD, Nashville, TN

3:10 Lessons Learned from Lofgren’s Syndrome
J. Grunewald, MD, PhD, Stockholm, Sweden

This session and the International Conference are supported by an educational grant from Actelion Pharmaceuticals US, Inc. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
1:30 Integrated ICU Team Communications and the Nursing Perspective
D.K. Costa, PhD, RN, Ann Arbor, MI

2:05 ATS/ESICM Guidelines on Liberation from Mechanical Ventilation
J. Truwit, MD, Milwaukee, WI

2:25 ATS/ERS Guidelines on the Treatment of COPD Exacerbations
M. Miravitlles, MD, PhD, Barcelona, Spain

3:05 Guidelines to Performance Measures
C.H. Weiss, MD, Chicago, IL

3:25 Closing
C.C. Thomson, MD, MPH, Cambridge, MA

There will be a 5-minute discussion after each talk.

This session and the International Conference are supported by an educational grant from AstraZeneca LP.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education ( ACCME) and are free of the control of commercial interests.


2:30 Behaviors of Skilled Bronchoscopy Teachers/A.K. Brady, J.A. Town, Seattle, WA, p.A7298


3:00 A Randomized Trial of a Simulated Versus Didactic Educational Intervention to Teach End-of-Life Communication to Internal Medicine Residents in the Intensive Care Unit/D. Miller, A.M. Sullivan, J. McSparron, A. Anandaiah, B. Armstrong, L. Rock, M.M. Hayes, Boston, MA, p.A7300


3:00 Comparison of Nebulized Levofloxacin Inhaled Solution (LIS) and Tobramycin Inhaled Solution (TIS) on Time to Cystic Fibrosis (CF) Exacerbation in Patients Chronically Infected with Pseudomonas Aeruginosaj/Szwarcberg, P. Flume, J.S. Elborn, M. Pecoraro, N. Bhatt, K. Polu, Novato, CA, p.A7308

3:15 The Effect of Perinatal Stem Cells as a Novel Anti-Inflammatory Therapy in Cystic Fibrosis/C.R. Barrios, O. Khouy, S. Murphy, A. Atala, V.E. Ortega, Winston-Salem, NC, p.A7309

3:30 Factors Associated with Growth of Tuberculosis Genotype /R. Almberg, L.H. Go, C.N. Halldin, D.J. Blackley, A.S. Laney, C.N. Halldin, Chicago, IL, p.A7310


MINI SYMPOSIUM

D96 INFECTION AND TRANSMISSION OF TUBERCULOSIS

1:30 p.m. - 3:30 p.m. WALTER E. WASHINGTON CONVENTION CENTER Room 143 A-C (Middle Building, Street Level)

Chairing: K.P. Fennelly, MD, MPH, Bethesda, MD
S.S. Shin, PhD, Los Angeles, CA
M. O’Donnell, MD, MPH, New York, NY

Featured Speaker
1:30 TB Transmission and Progression in Contacts Exposed to MDR-TB/M. Murray, MD, MPH, ScD, Boston, MA

Oral Presentations


The information contained in this program is up to date as of March 9, 2017. For the most current session information, please visit the online program itinerary.
### D97 IMPACT OF INFLAMMATION ON ACUTE LUNG INJURY

1:30 p.m. - 3:30 p.m.  
**MARRIOTT MARQUIS WASHINGTON**  
Independence Ballroom A-D (Level M4)

**Chairing:** C.M. Waters, PhD, Memphis, TN  
J. Liu, PhD, Chicago, IL  
V. Kolliputi, PhD, Tampa, FL

**Oral Presentations**

1:30  
*Inflammasome-Mediated IL-1β Release Drives Lung Ischemia Reperfusion (IR) Injury While Augmenting Bacterial Clearance in a Mouse Model of Lung Infection*  
A. Prakash, X. Tian, S. He, J. Hellman, San Francisco, CA, p.A7325

1:45  
*Being a Good Influence? Alveolar Type 2 Cells Dampen Macrophage Inflammatory Response in Acute Lung Injury Via Glycolysis Driven Mechanism*  

2:00  
*Inflammasome Priming in Alveolar Macrophages Involves Differential Activation of p38 and ERK Through Apoptosis Signal Regulating Kinase 1 (ASK-1)*  
S. Ruwanpura, L. McLeod, G. Anderson, B. Jenkins, Clayton, Australia, p.A7328

2:15  
*Novel Role of Inflammasomes in the Molecular Pathogenesis of Emphysema*  

2:30  
*Uptake of Cell-Free Hemoglobin Impairs Cytokine Production by Macrophages*  

2:45  
*NLRX1 Is Induced by Lipopolysaccharide Through Post-Translational Modification*  
S. Han, Y. Jerome, J. Bednash, R. Mallampalli, Chicago, IL, p.A7330

3:00  
*Resolution of Hyperoxia Induced Acute Lung Injury Is Dependent Upon TLR4*  

3:15  
*Transient Receptor Potential Vanilloid 4 (TRPV4) Mediates the Macrophage Response to Bacterial Pneumonia Through the p38 MAPK-MK2 Pathway*  

---

### D98 INSIGHTS INTO ENVIRONMENTAL EXPOSURES IN ASTHMA, COPD, AND CONSTRUCTIVE BRONCHIOLITIS

1:30 p.m. - 3:30 p.m.  
**WALTER E. WASHINGTON CONVENTION CENTER**  
Room 145 A-B (Middle Building, Street Level)

**Chairing:** A. Lee, MD, MS, New York, NY  
C.J. Baglole, PhD, Montreal, Canada  
Y.S. Prakash, MD, PhD, Rochester, MN

**Oral Presentations**

1:30  
*Maternal E-cigarette Vaping Enhances Development of Allergic Asthma in the Offspring*  

1:45  
*E-cigarette Use and Lung Density on Computed Tomography. Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)*  

2:00  
*5-year Change in Airway Wall Thickness in Cigarette Smokers: Clinically Important Changes Derived from Computed Tomography*  
J.-P. Charbonnier, E. Pompe, C.M. Moore, E. Van Rikxoort, D. Lynch, Nijmegen, Netherlands, p.A7335

2:15  
*Cigarette Smoke Changes CAMP Microdomains in Lung Slices*  

2:30  
*Loss of Multiciliated Epithelium and Impaired Mucosal Immunity in Lungs of Soldiers with Constrictive Bronchiolitis*  

2:45  
*Peroxidation of Phosphatidylcholine: A Signature for Allergen-Induced Airway Responses and Allergen Specificity*  

3:00  
*Rhinovirus Induces Dysmaturity and Unjamming of Normal and Asthmatic Human Bronchial Epithelial Layers*  

3:15  
*Vitamin D Deficiency Alters Airway Smooth Muscle Structure during Allergic Airway Inflammation in Mice*  
M. Thompson, M. Freeman, C. Pabelick, Y.S. Prakash, Rochester, MN, p.A7340
MINI SYMPOSIUM

D99  BEST FROM THE LAB IN SDB: MECHANISMS AND BEYOND
1:30 p.m. - 3:15 p.m.  MARRIOTT MARQUIS WASHINGTON Liberty Ballroom M-P (Level M4)

Chairs: E. Tasali, MD, Chicago, IL
C.P. O'Donnell, PhD, Pittsburgh, PA
C.M. Hoyos, MPH, PhD, Glebe, Australia

Featured Speaker
1:30  Sleep Disordered Breathing: At the Crossroads of Inflammation and Metabolic Dysfunction/C. P. O'Donnell, PhD, Pittsburgh, PA

Oral Presentations
1:45  Obstructive Sleep Apnea Causes Nocturnal Metabolic Dysregulation/J. Jun, S. Chopra, A. Rathore, H. Younas, L. Pham, V.Y. Polotsky, Baltimore, MD, p.A7341
2:15  The Role of Sleep and Circadian Genes on Outcomes of Critical Illness/L. Durairaj, T. Hamieh, J. Barnes, J. Cavanaugh, B.K. Gehlbach, Iowa City, IA, p.A7343
3:00  Von Willebrand Factor Release in Obstructive Sleep Apnea/T. Thoma, M. Emin, R. Shah, S. Jelic, New York, NY, p.A7346

RAPID: RAPID ABSTRACT POSTER DISCUSSION

D101  MECHANISTIC AND TRANSLATIONAL STUDIES IN COPD
1:30 p.m. - 3:30 p.m.  WALTER E. WASHINGTON CONVENTION CENTER Room 151 B (Middle Building, Street Level)

Abstract Summaries
1:30-2:00

Poster Viewing/Discussion
2:00-3:30

Chairs: M.T. Borchers, PhD, Cincinnati, OH
M.R. Stampfl, PhD, Hamilton, Canada
C.M. Freeman, PhD, Ann Arbor, MI

402  Eosinophilic Inflammation in COPD Is Associated with Increased Exacerbations and Unique Blood Transcriptomic Signatures/J.H. Yun, A. Lamb, M. Parker, R.P. Chase, P.J. Castaldi, C.P. Hersh, Boston, MA, p.A7348
405  Loss of SigA Contributes to Activation of Adaptive Immunity in COPD/B. Richmond, R.-H. Du, S. Novitskii, L. Ware, T.S. Blackwell, V.V. Polosukhin, Nashville, TN, p.A7351
409  The Role of T-Bet in Emphysema/S. Hayashi, Y. Matsuno, Y. Tsunoda, H. Sakurai, T. Kiwamoto, M. Kawaguchi, Y. Morishima, Y. Ishii, N. Hizawa, Tsukuba, Japan, p.A7355

The information contained in this program is up to date as of March 9, 2017. For the most current session information, please visit the online program itinerary.

415 COPD Monocyte-Derived and Tissue Macrophages Are Driven by GM-CSF Towards a Pro-Inflammatory Phenotype/J. Tilman, P.J. Barnes, L. Donnelly, London, United Kingdom, p.A7361

416 Short-Term Inhibition of NOTCH Signalling Ablates MUC5AC Production in Human Airway Epithelial Cells from Asthmatic, Non-Asthmatic and COPD Donors/A. Reid, F. Moheimani, K. Nichol, N. Bartlett, P.A. Wark, C. Grainge, P.M. Hансbro, D. Knight, Callaghan, Australia, p.A7362

417 Non-Typeable Haemophilus Influenzae Is Associated with Rapid Lung Function Decline and Poor Macrophage and Neutrophil Phagocytosis in Patients with Alpha-1 Anti-Trypsin Deficiency/G.M. Walton, K.B.R. Belchamber, S.M. Hughes, P.J. Barnes, R.A. Stockley, L. Donnelly, E. Sapey, Birmingham, United Kingdom, p.A7363


421 IL-1 Signaling Imbalance Affects Lung Development and Predisposes to Cigarette Smoke-Induced Emphysema in Mice/J. Radder, A.D. Gregory, Y. Chu, Y. Zhang, S.D. Shapiro, Pittsburgh, PA, p.A7367


424 Cigarette Smoke Impairs Alveolar Macrophage Host Defense via Rac2 Inhibition/J.L. Casey, P.L. Jackson, V.B. Antony, A.B. Carter, Birmingham, AL, p.A7370

511 Vaping Characteristics of Veterans Replacing Tobacco Smoking with Electronic Cigarettes/ A.M. Guerrero, M.D.

512 Weight Gain After Tobacco Cessation/M. Barrueco Ferrero, J.
Perez-Rodriguez, M. Lopez-Zubizarreta, P. Alvarez Vega, E.
Barrueco-Otero, M. Bartol-Sanchez, Salamanca, Spain, p.A7383

513 Development of a Test to Evaluate the Emotional Status of Smokers/J. Baddini-Martinez, M. Monteschi, M.V.O. Castelliano, C.R. Perez, S. Cedano, A.I. De Padua, Ribeirao Preto, Brazil, p.A7384

514 Lung Age with Ex-Smokers and Non-Smokers at Two-Days Medical Checkup/M. Fukakusa, Y. Ichikawa, Y. Ishida, K. Masuda, Tokyo, Japan, p.A7385

515 Duration to Self-Selected Future Quit Date Is Associated with Sustained Smoking Abstinence Rates at 6 Months/G.L. Anesi, K.G.M. Volpp, M.O. Harhay, S.D. Halpern, K. Saulsgiver, Philadelphia, PA, p.A7386


105 Factors Associated with FEV1 Decline in Alpha-1 Antitrypsin Deficient Patients/R. Choate, D.M. Mannino, R. Sandhaus, K. Holm, Lexington, KY, p.A7391

106 Association of Serum Alpha-1 Antitrypsin Levels with Clinical Course of COPD/N. Takei, M. Suzuki, H. Makita, S. Konno, K. Shimizu, H. Kimura, M. Nishimura, Sapporo, Japan, p.A7392

107 Higher C-Reactive Protein Levels Are Associated with Less Symptoms Among a Pi (MZ) Alpha-1 Antitrypsin Phenotype Cohort/H.S. Al Ashry, K. Brown, C. Sanders, J. Kim, G. Blanton, T. Beiko, C.B. Strange, Charleston, SC, p.A7393

108 A Re-Analysis of FEV1 Decline and Augmentation Effects Using Stricter Slope Measurements from the NIH Alpha 1-Antitrypsin Deficiency Registry Study/M.D. Wewers, Columbus, OH, p.A7394


110 Identification of Genetic Variants in the SERPINA1 Gene that Influence A1AT Levels/C. Sanders, J. Kim, Fulton, MD, p.A7396

112 Decline in FEV1 in Patients with PIZZ Alpha-1-Antitrypsin Deficiency Depends on the Exacerbation Rate/S.W. Fahndrich, N. Bernhard, P.M. Lepper, C. Vogelmeier, M. Seibt, S. Wagenpfeil, R. Bals, Homburg/Saar, Germany, p.A7397


117 The Irish National Alpha-1 Antitrypsin Deficiency Targeted Detection Programme/T.P. Carroll, M. Molloy, L. Fee, C. O’Connor, N.G. McElvaney, Dublin, Ireland, p.A7394

WEDNESDAY • MAY 24

POSTER DISCUSSION SESSION

D103 ALPHA-1-ANTITRYPSIN DEFICIENCY: 50 YEARS OF PROGRESS

1:30 p.m. - 3:30 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Room 144 A-C (Middle Building, Street Level)

Poster Viewing

1:30-2:15

Discussion

2:15-3:30

Chairing:
C.B. Strange, MD, Charleston, SC
R. Sandhaus, MD, PhD, Denver, CO
J. Stoller, MD, Cleveland, OH


102 Demographics and Clinical Profiles of Patients with Alpha-1 Antitrypsin Deficiency PiMZ and PiMS Genotypes Started on Augmentation Therapy/N. S. Zaidi, P. Scolum, S. Kearns, L. Kristofek, Pittsburgh, KS, p.A7388

103 Multicomponent Intervention Improves BMI in a Randomized Trial of Alpha-1 Antitrypsin Deficient Patients/R. Choate, D.M. Mannino, K. Holm, R. Sandhaus, Lexington, KY, p.A7389

104 Increase in Exercise Activities in Alpha-1 Antitrypsin Deficient Patients: Results of a Randomized Trial/R. Choate, D.M. Mannino, K. Holm, R. Sandhaus, Lexington, KY, p.A7390

For the most current session information, please visit the online program itinerary.

ATS 2017 • Washington, DC
D104 ADVANCES IN INTERSTITIAL LUNG DISEASE

1:30 p.m. - 3:30 p.m. WALTER E. WASHINGTON CONVENTION CENTER

Room 209 A-C (South Building, Level 2)

Poster Viewing 1:30-2:15

Discussion 2:15-3:30

Chairing: I. Noth, MD, Chicago, IL
R. Bascom, MD, MPH, Hershey, PA
J. Morisset, MD, Montreal, Canada


119 Real Life Treatment Benefit of Intravenous Augmentation Therapy for Severe Alpha-1 Antitrypsin Deficiency/M. Molloy, C. O'Connor, L. Fee, T.P. Carroll, N.G. McElvaney, Dublin, Ireland, p.A7405


POSTER DISCUSSION SESSION


714 Tankyrase Inhibitors: A Potential Novel Therapy for LAM/TSC/M. Orschiolsi, S. Russos, C. Filippakiss, E. Henske, V. de Jesus Perez, Stanford, CA, p.A7422


716 TSC2-Null Cell-Fibroblast Interactions Enhance Protease Activity by Extracellular Acidification in Lymphangioleiomyomatosis (LAM)/A. Dongre, D. Clements, S.R. Johnson, Nottingham, United Kingdom, p.A7424


718 Changes in Lung Function During Pregnancy in Patients with Lymphangioleiomyomatosis/A.M. Taveira-DaSilva, P. Julien-Williams, A. Jones, J. Yao, J. Mose, Bethesda, MD, p.A7426

D105 CRITICAL CARE: FROM CELL TO MICE TO BEDSIDE - TRANSLATIONAL STUDIES IN SEPSIS AND PNEUMONIA

1:30 p.m. - 3:30 p.m.  WALTER E. WASHINGTON CONVENTION CENTER

*** POSTER DISCUSSION SESSION ***

Room 151 A (Middle Building, Street Level)

**Poster Viewing**
1:30-2:15

**Discussion**
2:15-3:30

**Chairing:** I.S. Douglas, MD, Denver, CO

J.P. Reilly, MD, MSCE, Philadelphia, PA

C. Mikacenic, MD, Seattle, WA


302 Sepsis Mediated cAMP Signals Increase Caspase-1 Activation in Pulmonary Microvascular Endothelial Cells During Pseudomonas Aeruginosa Infection/P. Renema, N.A. Housley, J.P. Audia, D.F. Alvarez, Mobile, AL, p.A7429


305 Inhibition of Human Pulmonary Microvascular Endothelial Cell Apoptosis Protects Against Septic Barrier Dysfunction/S.E. Gill, L. Wang, S. Mehta, London, Canada, p.A7432


**310** SS31 Prevents Sepsis Induced Reductions in Diaphragm Strength and Endurance/G.S. Supinski, L. Wang, E.A. Schroder, L.A.P. Callahan, Lexington, KY, p.A7437


**314** Different Expression Profile in Primary Cell Lines Exposed to Septic Plasma of Rats/J. Brungue, R. Guillamat-Prats, M. Camprubi-Rimbias, E. Torrents, M. Martinez, A. Artigas, Sabadell, Spain, p.A7441


**319** Delivery of Human MSC Derived Extracellular Vesicles Directly to the Lung Improves Bacterial Pneumonia Acute Lung Injury/J. Devaney, E. Horan, D. O’Toole, S. Elliman, J. Laffey, R. MacLoughlin, Galway, Ireland, p.A7446

---

**The information contained in this program is up to date as of March 9, 2017. For the most current session information, please visit the online program itinerary.**

Physiologic and Molecular Profiling of Shock Subtypes in Critically Ill Patients with Decompensated Liver Failure/J.E. Prasso, S. Hu, B.J. Garber, T. Young, K. Schwab, T.S. Wang, S. Chang, J.C. Deng, Los Angeles, CA, p.A7448


Adiponectin-Enhancing Drugs Shorten the Time to First J.S. Lee, Pittsburgh, PA, p.A7452


Impact of Physical Activity on Childhood Asthma Symptoms: A Longitudinal Study in Inner City Baltimore, Maryland/B.N. Long, J.E. Lang, E. Mougey, J.J. Lima, Durham, NC, p.A7457


Body Mass Index and Adipose Tissue Within the Airway Wall/U. Elliot, F. Green, P. Noble, A. James, Perth, Australia, p.A7465

Correlation Between Lung Function and Carotid Intima Media Thickness in Indian Patients of Bronchial Asthma/P. Bhadoria, S.G. Nithin, K. Goyal, D.P. Bhadoria, New Delhi, India, p.A7466

Saturated Fatty Acids, but Not n-6 Polyunsaturated Fatty Acids or Carbohydrates, Increase Airway Inflammation in Non-Obese Asthmatics/L.G. Wood, O. Li, H.A. Scott, B.S. Berthon, P.G. Gibson, K.A. Baines, New Lambton Heights, Australia, p.A7467

Fish Intake, Dietary Polyunsaturated Fatty Acids, and Lung Cancer: Systematic Review and Dose-Response Meta-Analysis of Data from 15 Prospective Studies/C. Cao, X. Kong, W. Zhang, X. Huang, Ningbo, China, p.A7468
D107 DIAMONDS AND PEARLS: PULMONARY HYPERTENSION PHENOTYPES

1:30 p.m. - 3:30 p.m.  MARRIOTT MARQUIS WASHINGTON

Marquis Ballroom 9-10 (Level M2)

Poster Viewing 1:30-2:15
Discussion 2:15-3:30

Chairing: S.M. Kawut, MD, MS, Philadelphia, PA
E.S. Klings, MD, Boston, MA
V. De Jesus Perez, MD, Stanford, CA


D108  CELL FATE DECISIONS: SENESCENCE, REPAIR, AND REGENERATION
1:30 p.m. - 3:30 p.m.  MARRIOTT MARQUIS WASHINGTON
Marquis Ballroom 3-4 (Level M2)

Abstract Summaries 1:30-2:00

Poster Viewing/Discussion 2:00-3:30


902 TLR4-Mediated Epigenetic and Senescence Mechanisms in COPD/C. Hwangbo, P. Shan, X. Zhang, P.J. Lee, New Haven, CT, p.A7489

903 Antagonism of MicroRNA-34a Rescues Cellular Senescence in Bronchial Epithelial Cells of COPD Patients/J. Baker, C. Vuppusetty, K. Ito, P.J. Barnes, London, United Kingdom, p.A7490

904 Targeting the Phospholipase A2 Receptor (PLA2R1) and Its Downstream Effectors to Inhibit Lung Cell Senescence in Chronic Obstructive Pulmonary Disease (COPD)/A. Attwe, J. Huang, V. Amsellem, E. Marcos, M. Breau, K. Kebe, A. Houssaini, P. Validire, B. Maitre, D. Vindrieux, D. Bernard, S. Adnot, Creteil, France, p.A7491


910 Age-Dependent Decline in Lung Function in Cigarette Smoke-Induced Cellular Senescence and Airspace Enlargement in Mice/K. Sundar, J. Gerloff, I. Rahman, Rochester, NY, p.A7497

911 Forkhead BOX F1 as a Novel Regulator of Quiescence in Human Lung-Resident Mesenchymal Stem Cells/P. Cao, N. Walker, Y. Aoki, V.N. Lama, Ann Arbor, MI, p.A7498


914 Nintedanib Reduces Ventilation-Augmented Bleomycin-Induced Epithelial-Mesenchymal Transition and Pulmonary Fibrosis Through Suppressing the Src Pathway/L.-F. Li, Taoyuan, Taiwan, p.A7501


917 Mesenchymal Stromal Cells Use Extracellular Vesicle-Mediated Mitochondrial Transfer to Modulate Human Macrophage Phenotype Through Enhancement of Oxidative Phosphorylation in the In Vitro and In Vivo Models of the Acute Respiratory Distress Syndrome/T. Morrison, M. Jackson, D.F. McAuley, A. Kissenpfennig, C.M. O’Kane, A. Krasnodembskaya, Belfast, United Kingdom, p.A7504

918 Human Mesenchymal Stromal Cell Derived Conditioned Medium Delivered Directly to the Lung Ameliorates E.coli Pneumonia Acute Lung Injury in the Rat//J. Devaney, R. MacLoughlin, D. O’Toole, J. Laffey, Galway, Ireland, p.A7505


921 Wnt Activity Marks Lung Progenitors Capable of Forming Spheres In Vitro/J.-P. Ng-Bleichfeldt, C. Ota, J. Stolik, P. Hiemstra, R. Gosen, M. Konigshoff, Groningen, Netherlands, p.A7508
922 Distal Pneumocyte Differentiation of Basal Epithelial Stem Cells by Inhibition of Notch Signaling During Ex Vivo Lung Regeneration/S. E. Gilpin, T. Wu, X. Ren, D. Evangelista-Leite, H. C. Ott, Boston, MA, p.A7509


D109 UNDERSTANDING THE MECHANISMS OF ACUTE LUNG INJURY

1:30 p.m. - 3:30 p.m. MARRIOTT MARQUIS WASHINGTON

Marquis Ballroom 1-2 (Level M2)

Poster Viewing
1:30-2:15

Discussion
2:15-3:30

Chairing: R. A. Oeccker, MD, PhD, Rochester, MN

S. Camhi, MD, Pittsburgh, PA


804 Real-Time Wide Field of View Imaging of Stretch-Induced ATP Release in Rat Alveolar Type I and II Cells/J. J. Tan, F. Boudreault, E. Brochero, R. Grygorczyk, Montreal, Canada, p.A7515


806 The Impact of Alkalizing Agents on Breathing Effort in Lung Injury Model Rabbits/T. Yamashita, A. Uchiyama, Y. Koyama, Y. Fujino, Osaka, Japan, p.A7517

807 THAM Administration Reduces Pulmonary Carbon Dioxide Elimination, Causing Rebound in Arterial Carbon Dioxide Tension. An Experimental Study in Hyperventilated Pigs/G. Perchiazzi, S. Hostman, R. Kawati, A. Larsson, Uppsala, Sweden, p.A7518

808 TNFR1 Inhibition Mitigates Susceptibility to Ventilator-Induced Lung Injury in Mice with Established ARDS/C. M. Oakley, M. Wilson, K. O’Dea, J. Cordy, M. Takata, London, United Kingdom, p.A7519


810 Therapeutic Effects of Mesenchymal Stromal Cells and Extracellular Vesicles with or Without Prior Activation with Serum from Endotoxin-Induced Lung-Injured Mice in Experimental Acute Respiratory Distress Syndrome/J. Silva, C. Braga, G. Oliveira, S. Trevelin, C. Barbosa Junior, M. Morales, C. C. Dos Santos, D. J. Weiss, P. R. Rocco, Rio de Janeiro, Brazil, p.A7521

811 In Situ Alveolar Surface Tension After Exogenous Surfactant Treatment in an Acid Aspiration Acute Respiratory Distress Syndrome Model/T. L. Nguyen, C. E. Perlman, Hoboken, NJ, p.A7522


618 Host-Derived Interleukin-10 Promotes Murine Malignant Pleural Effusion/X.Z. Wu, Y. Wang, X.-Y. Shi, Beijing, China, p.A7553


621 Microsomal Prostaglandin E Synthase-1 Promotes Lung Metastasis by Enhancement of Accumulation of MDSCs from Bone Marrow/R. Takahashi, H. Amano, K. Eshima, A. Shizuo, M. Majima, Sagamihara, Japan, p.A7556


623 MCC950 a Novel Inhibitor of NLRP3 Inflammasome Reduces Migration and Invasion of Lung Adenocarcinoma In-Vitro/M. Siterman, S. Lengier, L. Zadik, N. Ofir, N. Nachmias, M. Rotem, M. Yadgar, Y. Schwarz, A. Bar-Shai, Tel Aviv, Israel, p.A7558

Where today’s science meets tomorrow’s care™

ATS 2017
Where today’s science meets tomorrow’s care™

May 19- May 24, 2017
Washington, DC
conference.thoracic.org